
<html lang="en"     class="pb-page"  data-request-id="95f20d1a-fa8e-4811-9c29-521eb968fb31"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-22;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.8b00294;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction" /></meta><meta name="dc.Creator" content="Lucienne  Juillerat-Jeanneret" /></meta><meta name="dc.Creator" content="John-David  Aubert" /></meta><meta name="dc.Creator" content="Josip  Mikulic" /></meta><meta name="dc.Creator" content="Dela  Golshayan" /></meta><meta name="dc.Description" content="Fibrosis is an inadequate response to tissue stress with very few therapeutic options to prevent its progression to organ dysfunction. There is an urgent need to identify drugs with a therapeutic p..." /></meta><meta name="Description" content="Fibrosis is an inadequate response to tissue stress with very few therapeutic options to prevent its progression to organ dysfunction. There is an urgent need to identify drugs with a therapeutic p..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 3, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00294" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00294" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00294" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00294" /></link>
        
    
    

<title>Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00294" /></meta><meta property="og:title" content="Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0018.jpeg" /></meta><meta property="og:description" content="Fibrosis is an inadequate response to tissue stress with very few therapeutic options to prevent its progression to organ dysfunction. There is an urgent need to identify drugs with a therapeutic potential for fibrosis, either by designing and developing new compounds or by repurposing drugs already in clinical use which were developed for other indications. In this Perspective, we summarize some pathways and biological targets involved in fibrosis development and maintenance, focusing on common mechanisms between organs and diseases. We review the therapeutic agents under experimental development, clinical trials, or in clinical use for the treatment of fibrotic disorders, evaluating the reasons for the discrepancies observed between preclinical and clinical results. We also discuss the improvement that we envision in the development of therapeutic molecules able to achieve improved potential for treatment, including indirect modulators, targeting approaches, or drug combinations." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00294"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00294">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00294&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00294&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00294&amp;href=/doi/10.1021/acs.jmedchem.8b00294" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 9811-9840</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00185" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b00435" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Lucienne Juillerat-Jeanneret</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lucienne Juillerat-Jeanneret</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Transplantation Center and Transplantation Immunopathology Laboratory, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +41 21 314 7214/7117. E-mail: <a href="/cdn-cgi/l/email-protection#f9958c9a909c97979cd7938c9095959c8b988db99a918c8fd79a91"><span class="__cf_email__" data-cfemail="b0dcc5d3d9d5deded59edac5d9dcdcd5c2d1c4f0d3d8c5c69ed3d8">[emailÂ protected]</span></a>. Address: Transplantation Center, CHUV-UNIL, Chemin des Boveresses 155, CH1011 Lausanne, Switzerland.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lucienne++Juillerat-Jeanneret">Lucienne Juillerat-Jeanneret</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8039-7882" title="Orcid link">http://orcid.org/0000-0002-8039-7882</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">John-David Aubert</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John-David Aubert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pneumology Division and Transplantation Center, Centre Hospitalier Universitaire Vaudois (CHUV), CH1011 Lausanne, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John-David++Aubert">John-David Aubert</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Josip Mikulic</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Josip Mikulic</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Transplantation Center and Transplantation Immunopathology Laboratory, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Josip++Mikulic">Josip Mikulic</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Dela Golshayan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dela Golshayan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Transplantation Center and Transplantation Immunopathology Laboratory, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dela++Golshayan">Dela Golshayan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00294&amp;href=/doi/10.1021%2Facs.jmedchem.8b00294" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 9811â9840</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 3, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 February 2018</li><li><span class="item_label"><b>Published</b> online</span>3 July 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 21 November 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00294" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00294</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9811%26pageCount%3D30%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLucienne%2BJuillerat-Jeanneret%252C%2BJohn-David%2BAubert%252C%2BJosip%2BMikulic%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D22%26contentID%3Dacs.jmedchem.8b00294%26title%3DFibrogenic%2BDisorders%2Bin%2BHuman%2BDiseases%253A%2BFrom%2BInflammation%2Bto%2BOrgan%2BDysfunction%26numPages%3D30%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9840%26publicationDate%3DNovember%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00294"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2247</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00294" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Lucienne&quot;,&quot;last_name&quot;:&quot;Juillerat-Jeanneret&quot;},{&quot;first_name&quot;:&quot;John-David&quot;,&quot;last_name&quot;:&quot;Aubert&quot;},{&quot;first_name&quot;:&quot;Josip&quot;,&quot;last_name&quot;:&quot;Mikulic&quot;},{&quot;first_name&quot;:&quot;Dela&quot;,&quot;last_name&quot;:&quot;Golshayan&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;9811-9840&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00294&quot;},&quot;abstract&quot;:&quot;Fibrosis is an inadequate response to tissue stress with very few therapeutic options to prevent its progression to organ dysfunction. There is an urgent need to identify drugs with a therapeutic potential for fibrosis, either by designing and developing new compounds or by repurposing drugs already in clinical use which were developed for other indications. In this Perspective, we summarize some pathways and biological targets involved in fibrosis development and maintenance, focusing on common mechanisms between organs and diseases. We review the therapeutic agents under experimental development, clinical trials, or in clinical use for the treatment of fibrotic disorders, evaluating the reasons for the discrepancies observed between preclinical and clinical results. We also discuss the improvement that we envision in the development of therapeutic molecules able to achieve improved potential for treatment, including indirect modulators, targeting approaches, or drug combinations.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00294&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00294" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00294&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00294" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00294&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00294" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00294&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00294&amp;href=/doi/10.1021/acs.jmedchem.8b00294" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00294" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00294" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00294%26sid%3Dliteratum%253Aachs%26pmid%3D29969256%26genre%3Darticle%26aulast%3DJuillerat-Jeanneret%26date%3D2018%26atitle%3DFibrogenic%2BDisorders%2Bin%2BHuman%2BDiseases%253A%2BFrom%2BInflammation%2Bto%2BOrgan%2BDysfunction%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D22%26spage%3D9811%26epage%3D9840%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292016" title="Therapeutics">Therapeutics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/jmcmar.2018.61.issue-22/20181121/jmcmar.2018.61.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Fibrosis is an inadequate response to tissue stress with very few therapeutic options to prevent its progression to organ dysfunction. There is an urgent need to identify drugs with a therapeutic potential for fibrosis, either by designing and developing new compounds or by repurposing drugs already in clinical use which were developed for other indications. In this Perspective, we summarize some pathways and biological targets involved in fibrosis development and maintenance, focusing on common mechanisms between organs and diseases. We review the therapeutic agents under experimental development, clinical trials, or in clinical use for the treatment of fibrotic disorders, evaluating the reasons for the discrepancies observed between preclinical and clinical results. We also discuss the improvement that we envision in the development of therapeutic molecules able to achieve improved potential for treatment, including indirect modulators, targeting approaches, or drug combinations.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22623" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22623" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">1.1.  Molecular and Cellular Players Mediating Fibrosis</h3><div class="NLM_p">Fibrosis is a maladaptive response to tissue or organ injury such as chronic inflammation or chemical and mechanical insults. These result in metabolic dysregulation, abnormal production of extracellular matrix (ECM), formation of stiff scar tissue, and compromised organ function. Fibrosis can affect any organ of the body. In response to tissue injury, the repair process may result in two distinct phenomena, a <i>normal</i> regenerative process, limited in time, in which injured tissues and cells are replaced by cells of the same type, maintaining tissue homeostasis, and a <i>chronic</i> fibrotic process, noncontrolled, in which connective tissue replaces normal tissues. During the process of normal remodeling, resolution of organ fibrosis includes regeneration of the normal cell and tissue functions and disappearance of myofibroblasts,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> which is a process not observed in chronic fibrotic processes. The mechanisms leading to the development of fibrosis are not completely understood and depend on the underlying diseases and/or local tissue properties. An inflammatory response to an initial injury, whatever the injury, can be postulated in most but not all fibrotic processes. For example, inflammation is involved in liver fibrosis, metabolic disorders and inflammation are involved in heart and kidney diseases, whereas there is no real inflammation in idiopathic pulmonary fibrosis (IPF). The quality of the connective tissue, especially of the collagens, is also important in the maintenance of homeostasis in the different tissue compartments. Pathological fibrotic processes are associated with abnormal and excessive deposition of an altered ECM by activated (myo)fibroblasts, a consequence and a driver of fibrosis,<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> which finally results in the replacement of normal tissue with permanent scar tissue of increased stiffness.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Whereas there has been progress in understanding some of the mechanisms of fibrosis, there is still an urgent need to find new biological targets and therapeutics to control fibrosis development, progression, and resolution. Indeed, there are very few treatment options for this progressive, often fatal condition, which may be responsible of up to 45% of deaths in the industrialized world.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> Current therapeutics are mostly supportive rather than curative, but as ongoing research identifies the molecular pathways that initiate and propagate fibrotic processes, better antifibrotic therapeutic possibilities may become available.</div><div class="NLM_p">Immune cells (T-cells and macrophages), fibroblasts and epithelial cells all contribute to the development of tissue fibrosis. In fibrotic diseases involving inflammation, macrophages and other immune cells are recruited to inflamed/injured tissues to promote diseased tissue clearance, repair, and healing and are crucial in maintaining tissue homeostasis. Profibrotic M1-type macrophages can locally synthesize a variety of growth factors, pro-inflammatory cytokines, enzymes, and ECM proteins, whereas M2-type macrophages produce anti-inflammatory compounds, together influencing fibrogenesis and its resolution. However, activation of resident and/or recruited tissue fibroblasts into activated (myo)fibroblasts is central to the development of fibrosis,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> in conjunction with the transforming growth factor-Î² (TGF-Î²)-associated signaling pathways.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> TGF-Î² is predominantly produced by circulating monocytes, tissue macrophages, and cancer cells. Epithelial damage triggers the production of TGF-Î² and its associated molecules, which in turn activate the epithelial-to-mesenchymal transdifferentiation (EMT) program as well as fibroblasts to become ECM-secreting (myo)fibroblasts. TGF-Î² is synthesized as an inactive latent peptide, needing transconformational and/or proteolytic processing to become active. In addition to TGF-Î², cytokines (such as interleukin (IL)-4, IL-6, IL-13), chemokines (CâC motif chemokine ligand (CCL2)), growth factors (such as platelet-derived growth factor, PDGF), cadherins, and integrins (in particular, the Î±<sub>v</sub>Î²<sub>6</sub> integrin) able to activate latent TGF-Î² via a RGD-binding site also contribute to the fibrotic processes and hence are potential therapeutic targets. Other inducers of fibrosis include the cellular pathways associated with the components of the angiotensin and endothelin systems. Angiotensin and endothelin peptides exhibit profibrotic activity, enhancing the production and signaling of active TGF-Î², ECM deposition, and fibroblast proliferation and differentiation into collagen-producing myofibroblasts via autocrine amplifying loops. During the normal process of tissue remodeling, the final stages include not only reduced synthesis but also increased degradation of collagens. An imbalance between the levels and activities of proteases secreted by myofibroblasts and/or their inhibitors may compromise this regenerative phase and drive a progressive fibrotic process, suggesting that protease inhibitors also are potential therapeutics for controlling fibrosis. Several proteolytic enzymes, such as the matrix metalloproteinases (MMPs) or enzymes of postprolyl-cleaving specificities such as dipeptidyl peptidase IV (DPP IV/CD26) or fibroblast activation protein-Î± (FAP-Î±) are involved in fibrotic processes. Resolution of organ fibrosis can also be envisioned as a biological process under the control of three critical components: (1) eradication of the cause of injury, (2) degradation and removal of the fibrotic ECM, mainly by increasing the activity of specific MMPs and/or decreasing the expression level of MMP inhibitors, and (3) elimination of fibrogenic myofibroblasts, through apoptosis, senescence, dedifferentiation, and reprogramming, according to not well-defined processes.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p last">As stated above, the accumulation of proliferating activated ECM-producing fibroblasts and myofibroblasts in response to an initial inflammatory stress or tissue injury is central to tissue fibrosis across a range of pathologic states. In comparison with their resting counterparts, activated ECM-secreting (myo)fibroblasts express de novo specific molecules;<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> however, all the precise molecular mechanisms are not yet elucidated. Myofibroblasts are activated by a variety of stimuli, including mechanical stress as well as autocrine and paracrine inflammatory and noninflammatory cell-derived factors, in particular from the TGF-Î² pathway. Myofibroblasts are present at very low number in normal tissues but in increased number in healing wounds, fibrotic, and cancerous tissues. The hallmarks of myofibroblasts consist in the expression of Î±-smooth muscle actin (Î±-SMA), comparable to smooth muscle cells, the production of ECM, including several collagens, and of ECM-modifying enzymes. The source of activated fibroblasts and myofibroblasts is believed to be multiple, potentially including tissue-resident fibroblasts, circulating bone-marrow-derived fibrocytes, vascular pericytes and epithelial/endothelial cells via EMT, and endothelial-to-mesenchymal transdifferentiation (EndMT) mechanisms.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10â12)</a> The increased number of (myo)fibroblasts could also originate from excessive proliferation or acquired resistance to physiological apoptosis of tissue-resident cells. Fibroblasts represent a heterogeneous population of cells<a onclick="showRef(event, 'ref7 ref10 ref11 ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref7 ref10 ref11 ref12 ref13 ref14 ref15">(7,10â15)</a> with diverse features between anatomic sites and even within a single tissue. Fibroblasts exhibit considerable functional diversity, but it is not clear whether this is due to intrinsic differentiation properties of these cells or if it is a response to environmental factors. The identification and characterization of distinct lineages of fibroblasts, based on functional roles or with intrinsic fibrogenic potential, suggest that some populations of fibroblasts are more prone than others to induce fibrosis. Recently, in the mouse skin, at least two lineages of fibroblasts with different location, capacities for wound healing, and the production of ECM proteins and to express the Wnt/Î²-catenin pathway could be distinguished.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> DPP IV was shown to be a cell marker of this fibrogenic lineage and exposure to a DPP IV/FAP-Î± inhibitor during wound healing resulted in diminished cutaneous scarring. Fibroblast heterogeneity was stable following transplantation, suggesting tissue origin memory rather than tissue environmental differences. In summary, myofibroblasts producing an altered ECM<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> with increased stiffness<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> are found in fibrotic, metabolic, oncogenic, and inflammatory diseases and in implant-related fibrotic disorders. In this Perspective, we will review what is known about the mechanisms involved in the development and maintenance of fibrotic processes in an organ-specific manner in order to determine potential therapeutic targets which may be common to all organs. We will also discuss some of the drugs developed for therapeutic intervention presently available.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  Organ-Specific Fibrosis and Therapeutic Targets</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30062" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30062" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As stated above, fibrosis, the excessive scarring of tissues, is a nonspecific terminal pathway of many toxic, metabolic, and inflammatory diseases and can develop in almost all organs exposed to chronic injury.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Fibrogenic mechanisms are initially aimed at repairing short-term tissue insults, however, when repetitive, they lead eventually to organ scaring and failure. While fibrosis represents a final common response to injury from ubiquitous processes, the resulting phenotype is tissue-specific and the course of organ failure can be highly variable, dependent on local tissue characteristics,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> thus presenting opportunities for targeted therapeutic intervention.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> However, in all organs, fibrosis has been linked to the activation of the TGF-Î² signaling pathway, which currently represents the main pathway under investigation for the development and evaluation of therapeutic approaches. Below we will discuss for the most commonly affected organs some novel therapeutic options to control fibrosis and organ dysfunction. The chemical structures of the molecules discussed in the following paragraphs are presented in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>â<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a> and some selected clinical trials in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.1.  Liver Fibrosis</h3><div class="NLM_p last">Liver fibrosis leading to cirrhosis results from persistent healing attempts to replace defective/dead hepatocytes in response to injury and is a common consequence of chronic liver disorders. Following liver injury, either toxic or metabolic, hepatic stellate cells, and portal fibroblasts transform into myofibroblasts and with disease progression express the integrin Î±<sub>v</sub>Î²<sub>3</sub>. Hepatic stellate cells are responsible for maintaining the ECM in the liver and activation of these cells leads to excess collagen formation and fibrosis. Controlling the functions of stellate cells may thus represent means of regulating the fibrotic response.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Kupffer cells are an important source of cytokines and are known to stimulate stellate cells to secrete hepatocyte growth factor (HGF). Presently, there is no effective therapy for liver fibrosis. However, as compared to other organs, the liver has some potential for regeneration. Proteolytic digestion of collagens with disappearance of myofibroblasts may resolve fibrosis upon cessation of liver injury.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> Liver fibrosis has been mostly studied in nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH), either in animal models of the disease or human surgical specimens.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> NASH covers a range of diseases that result from fat accumulation in the liver leading to liver inflammation, scarring, irreversible damage, and liver failure. NASH is currently estimated to affect up to 20â30% of the general population in the western world. Patients with type-2 diabetes mellitus and morbid obesity are the most affected. Thus, fatty acid metabolic pathways have been evaluated as therapeutic targets. Peroxisome proliferator-activated receptor (PPAR)-Î³ agonists combined with cholesterol-lowering agents, the âstatinsâ, possibly associated with omega 3 fatty acids, antidiabetic agents, or vitamin E, have been proposed,<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> but only very limited clinical trial data are presently available. Farnesoid X-activated receptor (FXR) agonists are under investigation as potential treatment for multiple metabolic and liver disorders. For example, single agonists to the FXR receptor<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and the PPAR-Î³ receptor<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> or dual PPAR-Î³/FXR agonists<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> are under clinical development for NASH. A liver-directed oral inhibitor of acetyl CoA carboxylase (ACC), an enzyme involved in the metabolism of fatty acids in the liver, has shown beneficial effects in animal models and in a clinical trial in overweight adult male subjects.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In NASH, the protein sterol regulatory element-binding protein 1 (SREBP-1), which regulates fatty acid biosynthesis in the liver, is increased and could represent another therapeutic target.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The reninâangiotensin system (RAS) has also been implicated in NASH. However, trials including angiotensin receptor type 1 (AT<sub>1</sub>R) blockers produced mixed results, while control of obesity, of insulin resistance, and of hypercholesterolemia may be more efficient to reverse fibrosis.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Fibroblast growth factor 21 (FGF21) is a hepatoprotective hormone identified as a substrate of FAP-Î±, a membrane-bound protease expressed at sites of tissue remodeling, inflammation, and fibrosis. Cleavage by FAP-Î± inactivates FGF21, while FAP-Î± inhibition increases endogenous levels of active FGF21, making FAP-Î± an attractive target for liver diseases.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> The lysyloxidase-like 2 (LOXL2) enzyme catalyzes the oxidation of Îµ-amines of lysine residues within collagen, generating reactive aldehydes that condense to form collagen cross-linkages. Dysregulation of this process can lead to fibrosis and LOX(L) inhibitors were shown to significantly reduce fibrosis in mouse models. Following on these experimental results, a phase I trial was completed in healthy volunteers.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Blocking chemokine pathways is also a promising approach, and a dual CâC chemokine receptor (CCR)-2/5 antagonist is under a phase IIb study in adults with NASH and liver fibrosis (CENTAUR study) after promising results in experimental rodent models.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The clinically approved family of DPP IV inhibitors, the âgliptinsâ, and several kinase inhibitors are evaluated in various clinical trials, either completed or ongoing, but no molecule has been presently approved for this indication. In animal models, another promising target, besides TGF-Î², is the sphingosine axis,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> expressed and active in many organs and tissues. Sphigosine-1-phosphate (S1P)/S1PR signaling has both pro- and antifibrotic effects depending on the context and site of action.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In the liver, S1P is involved in profibrotic processes, including the differentiation of resident hepatic stellate cells into activated myofibroblasts.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.2.  Lung Fibrosis</h3><div class="NLM_p last">In the lung, fibrosis encompasses a variety of idiopathic disorders with distinct clinical phenotypes, characterized by progressive replacement of normal alveolar structures by dense connective tissue that prevents normal gas exchange. Idiopathic pulmonary fibrosis (IPF) is the most frequent, progressive, and fatal fibrotic lung disease that eventually leads to respiratory failure and death. Presently, lung transplantation is the sole curative intervention for IPF. The contribution of inflammation is not the main driver of IPF but can orchestrate existing fibrotic responses.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Unfortunately, no animal model truly reproduces the pathogenesis of IPF. The mouse bleomycin model has been nevertheless extensively studied, but bleomycin is associated with a marked influx of inflammatory cells into the lung parenchyma in contrast to IPF in humans. A recent review has described the therapeutic agents of interest in IPF.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> We will not repeat the discussion of the molecules presented in this review with some exceptions for the compounds that we believe are of a broader interest in the development of therapies for fibrotic diseases other than IPF. Currently, no approved treatment can cure this disease, nevertheless, pirfenidone (<b>1</b>, structure in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), a pleiotropic anti-inflammatory, antifibrotic, and antioxidant molecule, and nintedanib (<b>63</b>, structure in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), a multikinase inhibitor, have been shown (ASCEND, CAPACITY, TOMORROW, and IMPULSIS trials) to slow down disease progression and prevent acute exacerbations in patients with IPF and have been recently approved for the treatment of IPF. In lung fibrosis, most mechanisms of disease induction converge toward the TGF-Î² pathway, making this pathway an obvious target for the development of therapy.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> In addition, myofibroblasts are activated by the components of the endothelin axis, another potential therapeutic target.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> TGF-Î² induces endothelin (ET)-1 expression, forming an autocrine amplifying loop. ET-1 is chemotactic and proliferative for fibroblasts, induces Î±-SMA expression, ECM accumulation, and contraction, and the myofibroblast phenotype in human lung fibroblasts, mediated by the ET<sub>A</sub> and ET<sub>B</sub> receptors. ET receptor antagonists are approved for the treatment of pulmonary hypertension. The dual ET-1 receptor antagonist bosentan (<b>40</b>, structure in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) decreases collagen I and III synthesis by fibroblasts, suggesting that ET-1 receptors antagonists may have therapeutic potential in lung fibrosis. However, several phases II or III clinical trials in patients with established pulmonary fibrosis of the dual ET<sub>A/B</sub> antagonists <b>40</b> (Build-1, -2, and -3 trials) and macitentan (<b>41</b>, structure in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) (MUSIC trial), and the ET<sub>A</sub>-selective ambrisentan (<b>43</b>, structure in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) (ARTEMIS trial) produced negative results. Acquisition of an apoptosis-resistant myofibroblast phenotype in the injured lung is mediated, at least in part, by the sustained activation of focal adhesion kinase (FAK) and protein kinase B (PKB/Akt).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> A C-Jun N-terminal kinase (JNK)-1 inhibitor is currently being evaluated in a phase I/II trial. A reversible inhibitor of PI3K/Akt/mammalian target of rapamycin (mTOR), and the approved immunosuppressive drug sirolimus/rapamycin (<b>16</b>, structure in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), also targeting mTOR, are being evaluated in double-blind placebo-controlled trials. A Rho-associated protein kinase (ROCK) II inhibitor is in phase II trials. Compounds with anti-inflammatory and antioxidative properties were shown to attenuate or even reverse fibrosis in several animal and clinical studies.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> A multikinase inhibitor related to the natural antioxidant quercetin (<b>110</b>, structure in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) is presently being evaluated in a phase I trial. Basic fibroblast growth factor (bFGF) is mitogenic for human lung fibroblasts via the plasminogen activator inhibitor type 1 (PAI-1) cascade.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Inhibitors targeting among others platelet-derived growth factor receptor (PDGFR)Î±/Î² and vascular endothelial growth factor receptors (VEGFRs) have been evaluated in several clinical trials with some positive effects.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The protease FAP-Î± is selectively expressed by activated myofibroblasts. FAP-Î±, in concert with MMPs, participates in collagen catabolism and clearance, scar resolution, and restoration of lung homeostasis, displaying protective effects in murine experimental models.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Loss of this protease was associated with fibrosis exacerbation in FAP-Î±-deficient mice exposed to bleomycin. Fatty acid pathways have also been studied. Agonists to the S1P pathways are pro-fibrotic in human lung fibroblasts in a Smad- independent mechanism.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Lysophosphatidic acid (LPA) is a bioactive phospholipid acting on LPA receptors. Results in LPA1 receptor-knockout mice suggested that blocking LPA1 signaling could provide a potential novel approach for the treatment of IPF.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> A selective LPA1 antagonist inhibited proliferation and contraction of normal human lung fibroblasts following LPA stimulation.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> An antagonist to the LPA1 receptor has been tested in a phase II trial, but results are not yet published. An inhibitor of autotaxin (ATX), an enzyme involved in the synthesis of LPA, is evaluated in an ongoing phase II trial. As IPF is characterized by a paucity of inflammatory cells within the lung parenchyma, classical anti-inflammatory treatments such as glucorticosteroids or purine inhibitors have proven ineffective except for acute exacerbation episodes. A small molecule antagonist of the Î±<sub>v</sub>Î²<sub>6</sub> integrin was evaluated in phase I trials.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Drugs modulating the immune system have mostly involved antagonizing antibodies, which we will not discuss in the present Perspective. Stem cell therapies and antisenescence therapies are novel therapeutic approaches to repair damaged tissue. They are too recent and only in early preclinical stage to draw conclusions, but they may be interesting targets to pursue.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.3.  Kidney Fibrosis</h3><div class="NLM_p last">Fibrosis in the kidney is the final common pathway following severe acute and chronic kidney diseases, independent of the type of initial injury. Inflammatory and noninflammatory stresses can affect the structure and physiological function of the glomeruli (the main filtration barrier that determines global kidney function) and/or the tubulointerstitial compartment, leading to progressive renal failure requiring dialysis or renal transplantation.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> Acute kidney injury is an increasing common clinical disorder, in particular in frail and hospitalized patients, due to multiple causes such as ischemic injury and exposure to nephrotoxic substances.<a onclick="showRef(event, 'ref18 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref18 ref54 ref55">(18,54,55)</a> Oxidative stress-mediated injury as well as toxins mainly affect the tubulointerstitial compartment, resulting in an inflammatory response. This process is characterized by fibroblast proliferation near the site of the injury, the appearance of Î±-SMA-positive activated myofibroblasts depositing excessive ECM in the interstitial space, and the activation of an EMT program in tubular epithelial cells.<a onclick="showRef(event, 'ref54 ref56 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref54 ref56 ref57 ref58">(54,56â58)</a> The crosstalk between tubular cells and myofibroblasts in driving fibrosis is not clear but seems to involve the transcription factors Snail and Twist that regulate EMT.<a onclick="showRef(event, 'ref56 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref56 ref59 ref60">(56,59,60)</a> The glomerular compartment can also be damaged by acute or chronic primary glomerulopathies as well as during systemic ongoing diseases such as diabetes. Defaults in the metabolism of fatty acids, driven by TGF-Î²1 and involving PPAR-Î³ pathways, have also been implied. PPAR-Î³ agonists activating the S1P axis are antifibrotic in the kidney.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Activation of PPAR-Î³ by synthetic agonists,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> the âglitazonesâ rosiglitazone (<b>117</b>) or pioglizazone (<b>118</b>, structures in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), approved in the treatment of type-2 diabetes, inhibit TGF-Î² profibrotic effects. These molecules are presently under clinical evaluation for kidney fibrosis. Activation of ET-1 receptors has also been implicated in the pathophysiology of chronic kidney disease and particularly in diabetic nephropathy. Animal models have shown beneficial effects on proteinuria and kidney function of the blockade of the endothelin axis, using either dual ET<sub>A/B</sub>- or ET<sub>A</sub>-selective antagonists.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> For example, an ET<sub>A</sub>-selective antagonist is in phase III for diabetic nephropathy.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Central to the therapy of kidney diseases are antagonists to the RAS, either angiotensin converting enzyme (ACE) inhibitors, AT<sub>1</sub>R antagonists, or antagonists to mineralocorticoids, which have been in clinical use for decades for hypertension and cardiovascular disorders. However, in glomerular fibrosis, RAS blockade only modestly slows down progression. The RAS is a potent inducer of TGF-Î², suggesting that anti-RAS drugs should be associated with TGF-Î² antagonists.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Angiotensin (Ang) II activates the epidermal growth factor receptor (EGFR) pathway, another potential therapeutic target in renal fibrosis.<a onclick="showRef(event, 'ref54 ref64'); return false;" href="javascript:void(0);" class="ref ref54 ref64">(54,64)</a> The bone morphogenic protein (BMP) receptor activin-like kinase 3 (Alk3) has antifibrotic properties in the tubular epithelium, inhibiting TGF-Î²1/Smad3 signaling, epithelial damage, and fibrosis. The peptide AA123/THR123 BMP7 agonist could reverse fibrosis in mouse models of kidney injury and are presently in phase I trials for acute kidney injury.<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a> Combining AA123/THR123 and the approved ACE inhibitor, captopril (<b>35</b>, structure in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), exhibited additive therapeutic benefit in controlling fibrosis. Anti-TGF-Î² therapeutics clinically evaluated include neutralizing antibodies and antisense or silencing nucleotides. Small molecule antagonist of the TGF-Î² receptor 1 have been examined in several clinical trials for diabetic nephropathy and was proposed to be effective in slowing the decline of renal function. Tranilast (<b>17</b>, structure in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), a drug approved for bronchial asthma and hypertrophic scar, as well as new cynnamoylanthranilate analogues,<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> have been shown to inhibit the TGF-Î² and PDGF pathways and are presently under clinical evaluation for the treatment of diabetic nephropathy. Additional pathways such as integrin-linked kinases and Wnt/Î²-catenin, which have a central role in EMT regulation, have been suggested to be potential therapeutic targets for renal fibrosis. Activation of the Wnt/Î²-catenin, pathway, of which the RAS is a target in the kidney, enhances renal fibrotic processes.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Inhibition of the Ca<sup>2+</sup>-activated K<sup>+</sup> channel (KCa3.1) inhibits TGF-Î²-induced upregulation of ECM-associated genes in renal fibroblasts.<a onclick="showRef(event, 'ref54 ref57 ref69'); return false;" href="javascript:void(0);" class="ref ref54 ref57 ref69">(54,57,69)</a> Janus kinase/signal transducers and activators of transcription (JAK/STAT)-3/6 that governs lymphocyte functions has an important role in interstitial fibrosis development which is abolished by a JAK3 inhibitor.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> An antagonist to the CCR2 chemokine is being evaluated in three phase II trials for diabetic nephropathy.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> The kidney is the organ expressing the highest levels of the protease DPP IV which has been associated with cell survival and ECM remodeling, suggesting that beside their glucose-lowering action, DPP IV inhibitors, the âgliptinsâ,<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> may have potential renal protective effects, inhibiting EndMT.<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73,74)</a> Anticholesterol agents, the âstatinsâ, diminish EMT, TGF-Î² signaling, and oxidative stress in glomerular cells.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> An antioxidant NADPH oxidases (NOX1/4) inhibitor is in phase II trials for diabetic nephropathy. A nonselective phosphodiesterase (PDE) inhibitor is under one phase III and two phase IV clinical trials, and the PDE-5-selective PF00489791 (<b>130</b>, structure in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) is in phase II trials, all for diabetic nephropathy.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> It has to be underlined that in the kidney the course of fibrosis progression is heterogeneous between patients, depending on the nature of the injury, continuous activation of the (myo)fibroblasts, and patient-associated environmental and genetic factors.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Facilitating regeneration through the ability of resident progenitor cells to differentiate into new renal cells was shown in experimental models to enhance recovery from acute kidney injury.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.4.  Cardiovascular System-Associated Fibrosis</h3><div class="NLM_p last">Fibrillar collagen-1 is the main protein of the heart structural ECM network, providing a scaffold for and regulating the contraction of cardiomyocytes. This ECM scaffolding is maintained by interstitial fibroblasts. In heart diseases, such as ischemic cardiomyopathy, cardiomyocytes loss is observed but the heart structural integrity is maintained by activated myofibroblasts in a healing response, with formation of a scar tissue involving stiff cross-linked fibrillar collagen-1 and various ECM proteins. With disease progression, this initial reparative process results in an amplification loop of continuous fibrogenesis and general cardiomyocyte dysfunction. The mediators and pathways involved are the RAS, the ET-1 axis, and TGF-Î²-dependent signaling, growth factors, macrophage-derived pro-inflammatory molecules, such as tumor necrosis factor (TNF)-Î±, oxidative stress, and proteases. Candidate proteases include MMP-2 and MMP-9,<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> as well as the serine proteases FAP-Î±<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> and DPP IV expressed by activated fibroblasts and smooth muscle cells.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> The PREMIER clinical trial of a MMP inhibitor was not conclusive of a beneficial effect.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> FAP-Î± is induced by TNF-Î± in activated myofibroblasts and can degrade type-1 collagen.<a onclick="showRef(event, 'ref80 ref83'); return false;" href="javascript:void(0);" class="ref ref80 ref83">(80,83)</a> In vascular diseases, atherosclerotic plaque rupture is facilitated by the protease activity of FAP-Î± able to degrade type-1 collagen.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Antifibrotic therapeutics for heart diseases include antioxidants such as flavonoids, mitochondrial regulators such as cyclosporin A (<b>20</b>, structure in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), Î²-adrenergic receptor antagonists, and inhibitors of the angiotensin and endothelin pathways, such as the âsartanâ family of AT<sub>1</sub>R antagonists or ACE inhibitors (ACEI) and the âsentanâ family of ETRs antagonists. Both activators and antagonists of the fatty acid pathways, such as the S1P/S1PR axis, must also be considered, as well as antagonists to inflammatory mediators, because most chronic heart diseases have an inflammatory component. Antagonizing the binding of stromal cell-derived factor 1 (SDF1, also known as C-X-C motif chemokine 12 (CXCL12)), to its CXCR4 receptor was as efficient in reducing cardiac fibrosis as inhibiting the binding of Ang II to AT<sub>1</sub>R, independently of the level of blood pressure control.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Notch signaling has also been involved in cardiac and other organs fibrotic processes.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Notch activation was shown to be protective by reducing the effects of the profibrotic cytokine TGF-Î² on the differentiation of fibroblasts into myofibroblasts, the production of fibrillary type-1 collagen as well as EMT and EndMT. These data suggest that activating Notch functions, for example, with soluble Notch ligands or Notch pathway activators including the hormone relaxin, may be beneficial in preventing cardiac fibrosis.<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a> Relaxin indeed affects collagen metabolism, inhibiting collagen synthesis and enhancing its breakdown by MMPs. Adenosine and its G-protein coupled receptors (GPCR), in particular the A<sub>2B</sub>AR, are able to modulate fibrosis in the heart following myocardiac damage. In the early stages of the disease, adenosine receptor (AR) agonists seem to be antifibrotic whereas antagonists seem to be of interest for a chronic treatment.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.5.  Wound Healing</h3><div class="NLM_p last">Wound repair involves stages of inflammation, tissue regeneration, and remodeling. In the healing skin, Î±-SMA-positive myofibroblasts contract and exert mechanical tension on the ECM, causing it to be reorganized into a functional connective tissue with the formation of a normal temporary fibrogenic process, the closing of the wound, and the reconstruction of a functional skin. As already stated, discrete skin fibroblast lineages have been described, at least in mice, depending on their embryonic origin and their expression of specific markers, in particular of the Wnt/Î²-catenin pathway, and their capacity to deposit ECM in response to fibrogenis stresses. The subset of fibroblasts contributing mainly to ECM deposition are DPP IV- and likely also FAP-Î±-positive,<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> and express ADAM12,<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> suggesting potential therapeutic intervention targeting these proteases. Two deviations from the normal process of healing may happen in the skin: an over-reaction of the myofibroblasts resulting in scar tissue as observed for example in scleroderma or in cheloid formation, or on the contrary the absence of wound closing and the formation of ulcers. Scleroderma is an autoimmune chronic connective tissue disease that may be limited to the skin of the face and extremities, but it may also affect internal organs (systemic sclerosis) including lungs, heart, gastrointestinal tract, and kidneys. The etiology is not well-defined, and no specific treatment is currently available. The prognosis is determined by the form of the disease and the extent of visceral involvement. The underlying mechanism involves abnormal growth of connective tissue, exaggerated deposition of collagen and ECM, and tissue fibrosis, which is believed to occur as a result of an initial insult by the immune system. Some biological pathways have been implicated, including the TGF-Î² and PDGF signaling pathways, as well as the endothelin axis. The purinergic P2X7 receptor, a nucleotide-gated ionotropic channel primarily involved in inflammatory response, may also play a role.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Therapeutic approaches have been based on the control of myofibroblasts differentiation and recruitment.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> In this regard, the Wnt/Î²-catenin/tankyrase signaling is an important mediator of sustained fibroblast activation in fibrotic diseases, including systemic sclerosis.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Chronic nonhealing wounds are characterized by unresolved inflammation, impaired fibroblast function and ECM deposition, and increased levels of proteolytic activity. To date, approved therapies for chronic cutaneous wounds include human skin substitutes and recombinant human PDGF. Blockade of the endothelin axis by the dual ET<sub>A/B</sub> antagonist <b>40</b> for digital ulcers is presently approved, following the demonstration in phase III and IV trials, of beneficial effects on the development of new ulcers. However, many patients affected with chronic ulcers remain unhealed, suggesting that the design of novel topical therapies is necessary.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">2.6.  Allogeneic Transplant-Associated Fibrosis</h3><div class="NLM_p last">Solid organ, cell, or engineered tissue transplantation are therapies required in the treatment of patients with end-stage organ diseases. Graft-associated fibrosis is a predictor of dysfunction of solid organ transplants and implanted biomaterials.<a onclick="showRef(event, 'ref5 ref57 ref94'); return false;" href="javascript:void(0);" class="ref ref5 ref57 ref94">(5,57,94)</a> While the development of potent immunosuppressive regimens has resulted in improved short-term allograft outcome, long-term survival and functioning of the grafts remain a challenge. Beside alloimmune injuries such as cell- and antibody-mediated rejection, late allograft loss is often due to a conjunction of nonimmune factors, such as local oxidative stress due to ischemic injury, or the toxicity of immunosuppressive drugs used for maintenance therapy, leading to progressive nonspecific inflammation, ECM deposition by tissue (myo)fibroblasts, and fibrosis. Some degree of ischemia-reperfusion injury is unavoidable in the early phase of organ transplantation and influences both short-term and long-term allograft outcome. Carbon monoxide (CO) has attracted attention as a medical gas with anti-inflammatory and antiapoptotic effects. CO decreases oxidative stress and mRNA expression of proinflammatory cytokines. In experimental models of kidney transplantation, CO inhibited inflammation, interstitial fibrosis, tubular apoptosis, and injury.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> By controlling leukocyte trafficking, S1PR agonists produce clinical immunosuppression useful for preventing transplant rejection and treating immune diseases. However, they also cause side effects due to the activation of different S1PRs, suggesting that receptor-specific agonists or antagonists may be preferable. S1PR modulators attenuated myocardial fibrosis following heart transplantation by reducing oxidative stress and apoptosis in a rat experimental model.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> The complement pathway is part of the innate immune system. Inappropriate activation of this system is involved in organ dysfunction in transplantation, in particular in kidney transplantation. The complement cascade may be activated by ischemia/reperfusion injury and other nonspecific inflammatory processes, representing a potential therapeutic target,<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> but to the best of our knowledge, no small molecule has presently been developed able to inhibit complement activation (apart from anti-C3a and C5a antibodies). DPP IV/CD26 is a costimulator of T-cells and a therapeutic target for type-2 diabetes. Following transplantation, type-2 diabetes is a common side effect of immunosuppressive antirejection therapies, which is improved by DPP IV inhibition.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> In a murine model of lung allograft, DPP IV inhibition promoted graft acceptance by reducing T-cell infiltration and modulating cytokine expression.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> The secretion of TGF-Î² by activated fibroblasts together with other cytokines and chemokines, the activation of the mTOR pathway, the release of ET-1, prostacyclins, MMPs, and the activation of the RAS by immunosuppressive drugs are some of the identified culprits of allograft fibrosis and dysfunction. However, no clinically evidence-based regimen has emerged so far. Another form of transplantation and regenerative medicine is represented by the direct transfer of cells, mostly by injecting them in the blood or following encapsulation into a polymeric device. Therapeutic mesenchymal stem cell therapy<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> has raised hopes for new treatments as these cells have high self-renewal capacity and can generate multiple cell lineages. They can be isolated from many tissues such as bone marrow, amniotic fluid, skin, heart, kidneys, liver, and the adipose tissue. Amnion-derived fetal epithelial cells which are nonimmunogenic and have anti-inflammatory and antifibrotic potential<a onclick="showRef(event, 'ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref101 ref102">(101,102)</a> are of potential interest. Autologous or allogeneic mesenchymal stem cells are presently under evaluation in many clinical trials (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a>) for the treatment of organ fibrosis, including after transplantation. As many adult tissues contain stem and progenitor cells able to proliferate, differentiate, and maintain tissue homeostasis and repair, efforts have been made to enhance these cell populations using small molecules.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">2.7.  Medical Biodevice Implants-Associated Fibrosis</h3><div class="NLM_p">Biomedical devices have important applications as orthopedic, dental, and breast implants, pacemakers, vascular grafts, heart valves, intraocular lenses, drug delivery devices, and biosensors. The fate of almost all medical implants is dictated by the biological response at the interface of host tissue and the implanted devices.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> The engineering of safe biomaterials is fundamental because tissue-replacement scaffolds in regenerative medicine provide physical support and deliver biologically active molecules and cells or mobilize endogenous cells to repair, maintain, replace, or enhance the function of a specific tissue or organ.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Medical devices must be biocompatible, not activating the immune system,<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> and functional, displaying properties adapted to the aims of the replacement.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> However, many biomaterials promote local inflammation, the adhesion, proliferation, and activation of (myo)fibroblasts, resulting in abnormal tissue repair and fibrosis, ultimately hindering long-term functioning of the devices. For example, we have shown (LJJ; unpublished results) that human fibroblasts grown in 3-dimensional collagen lattices in which a synthetic surgical implant was incorporated to enwrap the implant in a thick ECM layer (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Implant-induced fibrosis. Three-dimensional culture in collagen gels of human fibroblasts with a surgical mesh. (left) At the initiation of the culture no ECM layer could be detected. (right) After 2 weeks of culture, the fibroblasts adhered to the mesh and secreted a thick ECM layer (brown layer tightly surrounding the mesh).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The mechanisms behind implant-associated fibrosis are postulated to involve an initial, and probably repetitive, injury and tissue stress at the interface of the implant and the receiving tissue.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Manipulating the surface chemistry of biomaterials<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> is a way to modulate protein recognition and biomaterialsâhost contact and, subsequently localize the inflammatory response. Several support systems may be envisioned, natural source-derived, polymer-derived, or tissue-derived following sophisticated processing. To be accepted by the host tissue, a medical implant requires two main properties: first to resist inflammation and subsequent fibrosis development and second to support vascularization, to bring nutriments, growth factors, and oxygen for local physiological needs.<a onclick="showRef(event, 'ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref109 ref110">(109,110)</a> The development of a functional vascular system depends on the response of vascular cells to inflammation and oxidative stress.<a onclick="showRef(event, 'ref111 ref112'); return false;" href="javascript:void(0);" class="ref ref111 ref112">(111,112)</a> Thus, controlling these processes will improve the viability of the bioengineered implants. These issues have been addressed by innovative approaches: the development of tissue-engineered blood vessels for arterial revascularization and the production of nonimmunogenic decellularized 3-D matrix organ scaffolds that can be recellularized with host-derived stem cells, as performed in experimental models and pioneering clinical studies in the respiratory system.<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112,113)</a> Modulating the local cell responses against engineered structures must also involve controlling the release of pro-inflammatory cytokines/chemokines induced by biomaterials. Besides the modification of the physical and chemical properties of biomaterials to minimize inflammatory responses, novel therapies are being developed based on cells with specific anti-inflammatory functions.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Presently, very few studies have aimed at developing antifibrotic strategies in the context of implanted biomaterials. However, there is an urgent need to develop strategies to prolong the physiological life of the implant and prevent implant failure. Up to now, most tissue-engineered products have been used in the clinic for the management of burns and severe wounds as well as for cartilage and bone replacement. We believe that evaluating and comparing what has been developed in several organs as antifibrotic therapy for other situations may allow to define relevant strategies to prevent fibrosis associated with implants. Molecules able to favor medical device implantation are also under development, which includes <b>1</b>,<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> an approved drug for treating IPF.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">2.8.  Cancer-Associated Fibrosis</h3><div class="NLM_p last">Tumors are heterogeneous populations of cells, the tumor cells themselves, inflammatory and immune cells, vascular cells, and cancer-associated (myo)fibroblasts (CAFs) interacting with each other through direct interactions or mediated by secreted factors and their receptors, as well as enzymes, including many kinases, all influenced by inflammation-derived signaling processes.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> The fibrotic tumor stroma has only recently emerged as a potential target for anticancer therapy. Many previous and recent reviews<a onclick="showRef(event, 'ref117 ref118'); return false;" href="javascript:void(0);" class="ref ref117 ref118">(117,118)</a> have discussed the involvement of the stroma in cancer progression, including CAFs, thus we will only summarize the information relevant to our purpose provided in these reviews. CAFs express specific markers and display distinct properties and origin<a onclick="showRef(event, 'ref117 ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref117 ref118 ref119">(117â119)</a> and are resistant to apoptosis. CAFs recruited to the stroma of tumors modulate oncogenic processes and cancer progression. They produce an altered cross-linked ECM<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> of increased stiffness,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> which influences tumor immunity, vascularization, and metastatic behavior as well as the distribution of therapeutics. Collagen cross-linking is dependent on the action of LOX and LOXL enzymes. Inhibitors for these enzymes are under investigation. Collagen cross-linking might be also indirectly targeted with the approved immunosuppressive drug tacrolimus/FK506 (<b>18</b>, structure in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), which inhibits FKBP65 a peptidyl prolyl isomerase that enhances lysine-hydroxylase-2 (LH2) activity.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Classically, CAFs are considered as pro-tumorigenic, however, when in a nonstimulated form, tumor-resident fibroblasts may also display antitumoral functions, promoting antitumor immunity similar to what is known about polarized pro- and antitumor (M1 and M2, respectively) populations of macrophages. From a therapeutic view, selectively promoting antitumor fibroblast populations would be more interesting than eradicating all fibroblast populations. CAFs express and/or secrete TGF-Î², CXCL12/SDF1, and its CXCR4 receptor, Notch, Wnt, and HGF (the cMet ligand expressed on tumor cells and involved in cell scattering and invasion), several cytokines, chemokines, growth factors, proteins, and enzymes. CAFs also express fibroblast-specific protein-1 (FSP-1/S100A4), Î±-SMA, FAP-Î±, and PDGFRÎ². Altogether, this results in the activation of the EMT and the metastasis programs<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> but also provides targets for therapy. In CAFs, the transcriptional regulator heat shock factor 1 (HSF1) is activated and regulates cancer cell growth via TGF-Î² and CXCL12/SDF1 signaling in an autocrine loop.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> CAFs have been involved in promoting cancer stem cell properties via insulin-like growth factor (IGF)1R-Akt signaling, suggesting the applicability of antagonists of IGFR, however, combination therapies will probably be necessary.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> The enzyme FAP-Î± is expressed in the stroma directly surrounding epithelial cancers and in melanoma and sarcoma tumor cells. FAP-Î± inhibition is generally considered a potential therapeutic target for oncologic diseases. The proteolytic activity of FAP-Î± is pro-fibrogenic being involved in remodeling of the ECM, in particular increasing the levels of fibronectin and collagen fibers, an effect mediated by the Î±<sub>9</sub>Î²<sub>1</sub> integrin which contributes to the recruitment of CAFs.<a onclick="showRef(event, 'ref124 ref125 ref126'); return false;" href="javascript:void(0);" class="ref ref124 ref125 ref126">(124â126)</a> Thus antagonists to integrins are also of potential therapeutic value in oncologic contexts. Tumor-associated S1P kinase signaling pathway promotes the differentiation of fibroblasts into myofibroblasts, then myofibroblasts-associated S1P kinase via a S1P receptor promotes tumor cell dissemination,<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> suggesting that the S1P axis is a potential target for controlling CAFs. The enzyme thrombin can directly stimulate ECM deposition, fibroblast proliferation, and differentiation into myofibroblasts. Several thrombin inhibitors have been developed in the context of coagulopathies and may be of therapeutic interest. In normal tissues, epithelial cells create an anti-inflammatory milieu which is lost in cancer and may be an initial signal for fibrotic responses. The combination of <b>1</b> and <b>63</b>, two drugs approved for the treatment of IPF, has demonstrated a survival benefit in cancer.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> A phase II clinical trial combining the approved AT<sub>1</sub>R antagonist losartan (<b>37</b>, structure in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) and FOLFIRINOX regimen is underway in pancreatic cancer. Chemotherapy- and radiotherapy-induced fibrosis in cancer survivors is a common complication of therapeutic cancer regimens.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Targeting tumor stromal cells would be advantageous as these cells are genetically stable and therefore less prone to develop resistance mechanisms. Stromal cells also express specific markers, different from the markers expressed by tumor cells, thus allowing more diversified combination and targeted therapies. In cancer, therapeutic attempts have been mainly, with a few exceptions, directed at blocking the effects in tumor cells of factors secreted by CAFs or to develop drugs aimed at modulating the vascular and immune systems in the stroma. Very few preclinical and clinical attempts have been made (yet) aimed at directly targeting CAFs.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">2.9.  Common Mechanisms and Therapeutic Strategies</h3><div class="NLM_p">In summary, during development and wound healing, physiological fibrogenesis maintains connective tissue integrity and structure through the synthesis of ECM. However, chronic organ stress results in fibrosis, overgrowth, hardening, and scarring of tissues, ultimately progressing to loss of organ function. Currently, there are very few approved antifibrotic therapeutic drugs (<a class="ref internalNav" href="#sec3_1" aria-label="section 3.1">section 3.1</a>), and often these drugs are only slowing disease progression. While the pathology of fibrosis and its functional significance are well described, its molecular regulation and therapeutic targets for preventing and treating fibrosis are less understood. Whereas fibrosis represents a final common pathway to injury, the course of organ failure can be highly variable dependent on local tissue characteristics.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> It seems, however, possible to generalize some findings between organs, as common key contributors to fibrotic diseases have been identified and are as outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The TGF-Î²1 signaling pathway (<a class="ref internalNav" href="#sec3_2" aria-label="section 3.2">section 3.2</a>) is central to fibrosis,<a onclick="showRef(event, 'ref129 ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref129 ref130 ref131">(129â131)</a> and selectively antagonizing it is mandatory in the therapeutic arsenal. An inflammatory stress has been shown to be relevant in the initiation of fibrosis in defined organs, but inflammation seems to be less involved in later stages. Thus, anti-inflammatory strategies (<a class="ref internalNav" href="#sec3_3" aria-label="section 3.3">section 3.3</a>) must be initiated early in the course of the disease. Controlling the bioactive lipid S1P (<a class="ref internalNav" href="#sec3_4" aria-label="section 3.4">section 3.4</a>) is also very relevant in antifibrotic therapies for all organs considered.<a onclick="showRef(event, 'ref37 ref96'); return false;" href="javascript:void(0);" class="ref ref37 ref96">(37,96)</a> Depending on the context, targeting the kinases acting on sphigosine or developing agonists and/or antagonists for the S1PRs is to be considered. Targeting vasoactive peptides, in particular angiotensin and endothelin and their receptors (<a class="ref internalNav" href="#sec3_5" aria-label="section 3.5">section 3.5</a>), also represent common mechanisms in the development and progression of fibrosis. In many organs, RAS blockade is currently the best available antifibrotic therapy.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Activation of AT<sub>1</sub>R by Ang II mediates inflammation and fibrogenesis, whereas activation of the AT<sub>2</sub>R has counter-regulatory anti-inflammatory and antiproliferative effects, suggesting that compounds activating AT<sub>2</sub>R have therapeutic interest.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> The blockade of ET<sub>A/B</sub> receptors by itself was shown to be not sufficient to control fibrosis progression,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> but combination therapies with ET-1 receptor(s) antagonists provided interesting results. Several enzymes, in particular some proteases and the lysyloxidases, have been shown to be involved in fibrotic processes and inhibitors able to control their activity have been developed and evaluated (<a class="ref internalNav" href="#sec3_6" aria-label="section 3.6">section 3.6</a>). Kinases and receptors involved in the differentiation of fibroblasts into activated (myo)fibroblasts have also been the targets of antifibrotic strategies (<a class="ref internalNav" href="#sec3_7" aria-label="section 3.7">section 3.7</a>). Modulators of several metabolic pathways, in particular oxidative stress, PPAR-Î³, FXR ,and the synthesis of fatty acids (<a class="ref internalNav" href="#sec3_8" aria-label="section 3.8">section 3.8</a>), have also been developed and evaluated. Controlling the adenosine pathway, in particular the A<sub>2B</sub>AR,<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> and the Notch1 pathway<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85,86)</a> are also relevant to fibrogenesis therapy. A few natural products have shown interesting properties and may be relevant for developing synthesis programs and optimization (<a class="ref internalNav" href="#sec3_9" aria-label="section 3.9">section 3.9</a>). Finally, cell therapy options must be considered (<a class="ref internalNav" href="#sec3_10" aria-label="section 3.10">section 3.10</a>) to replace organ transplantation in terminal diseases. Stem cell therapies offer opportunity to enhance tissue repair in chronic organ diseases,<a onclick="showRef(event, 'ref101 ref102 ref133'); return false;" href="javascript:void(0);" class="ref ref101 ref102 ref133">(101,102,133)</a> but in this Perspective these therapeutic approaches will only be outlined and not discussed in detail. In conclusion, the recent development of treatment strategies offers the prospect of more efficacious therapies to prevent or even treat fibrosis (see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> for the list of clinical trials). However, as these antifibrotic therapies may target widely expressed and important physiological pathways, it will be mandatory to develop tissue-selective approaches.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0017.jpeg" id="GRAPHIC-d7e926-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Schematic Representation of Cellular Pathways Mediating Fibrosis</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">3.  Antifibrotic Therapeutics</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00873" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00873" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A large amount of potential therapeutics against fibrotic diseases have been designed, prepared, and evaluated in vitro in animal experimental models (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a><b>-</b><a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) and for some of them in clinical trials (summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Several excellent previous review papers have described in detail the molecules that have been designed, prepared, and evaluated.<a onclick="showRef(event, 'ref40 ref134 ref135 ref136 ref137'); return false;" href="javascript:void(0);" class="ref ref40 ref134 ref135 ref136 ref137">(40,134â137)</a> We will not repeat here in depth all this information but only outline the most relevant characteristics of these previously described therapeutics. Therefore, in this chapter, we will discuss a selection of small molecules developed for the prevention and therapy of fibrosis and fibrosis progression, excluding genetic tools, antibodies, and analogues of proteins. We will also not discuss in detail cell-based therapies that were recently reviewed.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> We have chosen to discuss the development of therapeutics according to the physiological pathways targeted rather than the affected organ/tissue in an attempt to extract relevant information of more general interest for antifibrotic therapy in human diseases.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">3.1.  Clinically Approved Drugs for the Prevention and Treatment of Fibrosis</h3><div class="NLM_p">Presently, only very few drugs, in particular <b>1</b> (pirfenidone, trade names Esbriet, Pirespa, Etuary, structure in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) and <b>63</b> (nintedanib/BIBF1120, trade name Ofev, structure in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), have been specifically approved for clinical use as antifibrotic therapeutics. These two drugs have been shown in several clinical trials (the ASCEND, CAPACITY, TOMORROW, and INPULSIS trials) to reduce the decline in lung function in patients with IPF and have been approved for this indication. <b>1</b> is an antifibrotic drug able to suppress fibroblast proliferation and to downregulate the production of growth factors, including TGF-Î², and of procollagens I and II. It is also under evaluation for the treatment of other fibrotic processes, including renal, cardiac, and liver fibrosis and abnormal wound healing.<a onclick="showRef(event, 'ref138 ref139 ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref138 ref139 ref140 ref141">(138â141)</a><b>1</b> was evaluated in the CAPACITY-004 and -006 clinical trials, resulting in its approval by the FDA for IPF in 2014. <b>63</b> is an intracellular inhibitor of multiple receptor-associated tyrosine kinases, including PDGFR. <b>63</b> was evaluated in the INPULSIS-1 and -2 phase III clinical trials as an oral treatment for IPF, resulting in its approval by the FDA for this indication in 2014. In addition, several drugs designed, developed, and clinically approved for other indications have been shown to be clinically interesting for the treatment of fibrotic conditions. <b>17</b> (tranilast, trade name Rizaben, structure in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) is a drug inhibiting IL-6 production, initially approved for allergic bronchial asthma. Therapeutic indication for hypertrophic scars was added later. In vitro it reduces collagen synthesis in fibroblasts<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> and has been shown to also display modest anti-TGF-Î² activity, however, with disappointing results in the PRESTO study.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Roflumilast (<b>127</b>, trade names Daxas, Daliresp, structure in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), an orally active, selective, long-acting inhibitor of the enzyme PDE-4 with anti-inflammatory effects, was approved for the treatment of inflammatory conditions of the lungs.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a><b>1</b> and <b>17</b> have adverse effects on liver function. It has to be noted that these therapeutics can slow down the progression of the disease but cannot reverse it. Therapeutic antifibrotic strategies using approved drugs also include RAS antagonists, either ACEI, such as <b>35</b> (captopril, trade name Capoten) or AT<sub>1</sub>R antagonists such as <b>37</b> (losartan, trade name Cozaar) (structures in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), as well as ET-1 receptor antagonists, such as bosentan (<b>40</b>, trade name Tracleer), macitentan (<b>41</b>, trade name OPSUMIT), or ambrisentan (<b>43</b>, trade names Letairis, Volibris) (structures in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of inhibitors of the TGF-Î² signaling pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Examples of inhibitors of the immune/inflammatory stress.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">3.2.  Inhibitors of TGF-Î² Signaling (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>)</h3><div class="NLM_p">TGF-Î²1â4s are a family of multifunctional cytokines that bind to TGF-Î² receptors, composed of type 1 (TGF-Î²RI) and type 2 (TGF-Î²R2) receptor subunits. After the binding of TGF-Î², TGF-Î²R2 kinase phosphorylates TGF-Î²R1 kinase, inducing a signaling cascade that recruits and activates the Smads proteins. Their translocation to the cell nucleus induces transcription of different effectors of downstream regulatory proteins, which results in differentiation, chemotaxis, proliferation, and activation of target cells. TGF-Î²1 has been the most studied pro-fibrogenic factor. TGF-Î²1 is biosynthesized as an inactive latent peptide needing proteolytic activation by several proteases including MMPs but also by transconformation by integrins, local pH, and reactive oxygen species. TGF-Î²1 key functions include regulation of inflammatory processes, ECM production, and stem cell differentiation as well as T-cell regulation and differentiation. In the context of fibrosis, TGF-Î² signaling promotes the differentiation of quiescent fibroblasts into ECM-secreting myofibroblasts. TGF-Î²-dependent signaling via the Smad-3 pathway is responsible for many of its functions, therefore inhibiting TGF-Î²1 binding to its receptors and the associated Smad3 signaling pathway has been the target of many attempts in fibrosis. The profibrotic effects of TGF-Î²1-Smad 2/3 may also be antagonized by the activation of the BMP7-Smad1/5 axis, but to the best of our knowledge, no synthetic agonists for this axis have been described. Only small peptide analogues of BMP7 (AA123/THR123, Thrasos Therapeutics) have been prepared, presently in phase I clinical trials.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> TGF-Î² antagonists have been examined in several clinical trials for diabetic nephropathy and were proposed to be effective in slowing fibrogenesis. GW 788388 (<b>2</b>), IN 1130 (<b>3</b>), LY 364947 (<b>4</b>), R 268712 (<b>5</b>), RepSox (<b>6</b>), SB 525334 (<b>7</b>), and ITD 1 (<b>8</b>) are potent and selective TGF-Î²RI inhibitors; A 83-01 (<b>9</b>) and SB 431542 (<b>10</b>) inhibit TGF-Î²RI, anaplastic lymphoma kinase (ALK)-4 and ALK-7; D 4476 (<b>11</b>) inhibits TGF-Î²RI and casein kinase-1 (CK1); SD 208 (<b>12</b>) is a potent ATP-competitive TGF-Î²RI inhibitor. SIS3 (<b>13</b>), a selective Smad3 inhibitor, was shown to delay the progression of diabetic nephropathy in experimental models by reducing ECM proteins and antagonizing the effects of C5a receptor activation.<a onclick="showRef(event, 'ref65 ref145'); return false;" href="javascript:void(0);" class="ref ref65 ref145">(65,145)</a> The new cynnamoylanthranilate analogue FT011 (<b>14</b>) inhibits the TGF-Î² and PDGF pathways<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> and is presently under clinical evaluation for the treatment of diabetic nephropathy. Hydronidone (<b>15</b>), a cyclo-oxygenase (COX) and TGF-Î² inhibitor, is in clinical trial for liver fibrosis, whereas PDE inhibitors, also able to decrease TGF-Î², are in trials for diabetic nephropathy.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Relaxin, an endogenous potent vasodilator hormone with pleiotropic effects, controls fibrosis by inhibiting TGF-Î² and Smads, regulating the MMP proteolytic balance and inhibiting local inflammatory response. Relaxin displayed antifibrotic effects in experimental models of cardiovascular diseases, but only when TGF-Î²1 levels were elevated.<a onclick="showRef(event, 'ref147 ref148 ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref147 ref148 ref149 ref150">(147â150)</a></div><div class="NLM_p last">In summary, antagonizing TGF-Î²-associated pathways is necessary to control fibrosis, however, due to the pleiotropic effects of these pathways in normal physiological conditions, it will be necessary to develop disease-targeted and target-addressed therapeutics.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">3.3.  Inhibitors of Inflammation and Immunosuppressive Drugs (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>)</h3><div class="NLM_p">Although the trigger of fibrosis in different organs and clinical situations not always implies an inflammatory stress, the mechanisms leading to fibrosis frequently involve either initial or subsequent inflammation and the secretion of cytokines and chemokines by immune cells. In response to these stimuli, monocytes/macrophages infiltrate the interstitial space, perpetuating inflammation and inducing differentiation and proliferation of myofibroblasts. Then it is generally thought that the fibrotic process progressively becomes independent of inflammation. Therefore, anti-inflammatory drugs targeting cytokine production and their cognate receptors may be relevant to be used early in the fibrogenic process. <b>16</b> and <b>17</b>, approved for bronchial asthma and hypertrophic scar, <b>18</b> and <b>20</b>, as well as <b>127</b>, an inhibitor of PDE-4 approved for chronic obstructive pulmonary disease, have also anti-inflammatory properties. The oral chemokine receptor antagonist cenicriviroc/TAK-652/TBR-652 (<b>19</b>), an inhibitor of CCR2/5 receptors, has been evaluated in the CENTAUR phase IIb study in NASH and liver fibrosis in adults at increased risk of progression to cirrhosis but failed for this indication although it had a significant impact on fibrosis.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a><b>18</b> and <b>20</b> are immunosuppressive drugs used in preventing transplant rejection. They inhibit the activation and effector function of T-cells, including the production of inflammatory cytokines. <b>20</b> forms a complex with cyclophilin to block the phosphatase activity of calcineurin. Thalidomide (<b>21</b>) and pomalidomide (<b>22</b>) are able to inhibit inflammation-induced angiogenesis. PBI-4050 (<b>23</b>) binds to GPR40 and GPR84 receptors, inhibiting collagen I production in epithelial cells and fibroblasts. Bardoxolone (<b>24</b>) inhibits the pro-inflammatory nuclear transcription factor NF-ÎºB. Selective p38 mitogen-activated protein kinase (MAPK) inhibitors blocked the secretion of TNF-Î± and decreased cardiac fibrosis in mice<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> and may represent a new treatment modality in humans. The RENEWAL study<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> examining the effect of the TNF-Î± fusion protein antagonist etanercept in patients with heart failure was negative, and the ATTACH trial was stopped prematurely as the high dose of the anti-TNF-Î± monoclonal antibody infliximab increased mortality in patients with moderate-to-severe chronic heart failure.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Statins are also anti-inflammatory and were shown to attenuate cardiac fibrosis in animal models and in a small clinical study, but the large-scale CORONA and GISSIF-HF trials displayed only a neutral effect.<a onclick="showRef(event, 'ref154 ref155 ref156 ref157'); return false;" href="javascript:void(0);" class="ref ref154 ref155 ref156 ref157">(154â157)</a></div><div class="NLM_p last">In summary, inhibitors of inflammatory pathways are likely to be of therapeutic interest in defined organs in controlling the early phase, but not the late phase, of fibrosis development and progression.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">3.4.  Inhibitors of the Sphingosine Pathway (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>)</h3><div class="NLM_p">The S1P/S1PR axis is expressed and active in many organs and tissues and involved in diverse cellular processes. Sphingosine (2-amino-4-octadecene-1,3-diol) is an unsaturated 18-carbon amino alcohol cell membrane lipid. Sphingosine is phosphorylated in vivo by two kinases, sphingosine kinase-1 (SK1) and SK2, leading to the formation of S1P. S1P exhibits a broad spectrum of biological activities, including cell proliferation, survival, migration, cytoskeletal organization, morphogenesis, and the differentiation of resident hepatic stellate cells into activated myofibroblasts. S1P is active intracellularly and can also bind extracellularly to five distinct GPCRs, S1P<sub>1â5</sub>R, displaying both pro- and antifibrotic effects, depending on the context and site of action.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> S1PR agonists and antagonists and SK inhibitors have been developed and evaluated, in particular in liver fibrosis,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and represent targets for the treatment of fibrosis. Side effects are observed due to the nonselective activation of different S1PRs, suggesting that receptor-specific agonists or antagonists may be preferable. The agonist FTY720/fingolimod (<b>25</b>) following its phosphorylation by SKs binds to S1P<sub>1</sub>R, S1P<sub>3</sub>R, S1P<sub>4</sub>R, and S1P<sub>5</sub>R (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). SEW2871 (<b>26</b>) is a selective S1P<sub>1</sub>R agonist not active on the S1P<sub>2â5</sub>R. KRP203 (<b>27</b>) is a selective S1P<sub>1</sub>R agonist with potential immunosuppressive activity by decreasing the production by lymphocytes of inflammatory cytokines, such as interferon (IFN)-Î³, IL-12, and TNF-Î±. VPC23019 (<b>28</b>) is a dual S1P<sub>1/3</sub>R antagonist. W146 (<b>29</b>) is a S1P<sub>1</sub>R antagonist with no agonist or antagonist activity on S1P<sub>2</sub>R, S1P<sub>3</sub>R, or S1P<sub>5</sub>R. JTE-013 (<b>30</b>) is a potent (IC<sub>50</sub> = 20 nM), selective S1P<sub>2</sub>R antagonist of the human and rat receptors modulating cell migration, contraction, and cyclic AMP accumulation. CAY-10444/BML-241 (<b>31</b>) is a selective antagonist of S1P<sub>3</sub>R, blocking calcium increase in cells. However, the selectivity of several S1P agonists and antagonists currently under development has been questioned.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> For example, <b>30</b> also inhibited the effects of ET-1. PF543 (<b>32</b>) is a cell-permeable hydroxyl methyl pyrrolidine compound that reversibly inhibits SK1-catalyzed sphingosine phosphorylation in a sphingosine-competitive manner (<i>K</i><sub>d</sub> = 5 nM), exhibiting no affinity toward S1PRs, with no effect on cell proliferation and survival. SKI-II (<b>33</b>) is a dual orally active SK1/2 inhibitor (IC<sub>50</sub> = 35 and 20 Î¼M for SK1 and SK2, respectively), which inhibits tumor growth in vivo. <i>N</i>,<i>N</i>-Dimethylsphingosine (<b>34</b>), a natural metabolite of sphingosine inhibiting both SKs, induces apoptosis, decreases airway inflammation, and is cardioprotective. Selectively silencing SKs or S1PRs with siRNAs has also been attempted.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Examples of modulators of the sphingosine pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, S1PR-selective agonists and antagonists and SK inhibitors have the potential to be of therapeutic use in fibrosis. However, their target organs and their optimal molecular structures and timing of therapeutic efficacy in fibrogenesis need to be better defined.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">3.5.  Inhibitors of Vasoactive Peptides: Angiotensin and Endothelin (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>)</h3><div class="NLM_p">Angiotensin (Ang) and endothelin (ET) peptides are pro-fibrotic, enhancing TGF-Î²1 production, fibroblast proliferation, and activation and EMT/EndMT, effects mediated by autocrine amplifying loops. Antagonists of the Ang and ET pathways may represent interesting molecules for antifibrotic therapy because several drugs are already approved for clinical use in the management of cardiovascular and hypertensive diseases.</div><div id="sec3_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">3.5.1.  Angiotensin Pathway Inhibitors (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>)</h4><div class="NLM_p">From the angiotensinogen precursor, the enzyme renin selectively releases an inactive decapeptide Ang I, further activated by ACE to the active octapeptide Ang II which acts on two GPCRs AT<sub>1</sub>R and AT<sub>2</sub>R. AT<sub>1</sub>R activation is pro-fibrogenic, pro-inflammatory, and pro-oxidative,<a onclick="showRef(event, 'ref31 ref159'); return false;" href="javascript:void(0);" class="ref ref31 ref159">(31,159)</a> whereas AT<sub>2</sub>R activation counteracts AT<sub>1</sub>R activation, being protective against fibrosis.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Ang(1â7) produced by the action of ACE2 and acting on the Mas receptor attenuates myofibroblasts activation,<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> hence functioning as a negative regulator of Ang II-mediated fibrosis. Ang II may be released locally by activated macrophages and fibroblasts, activating an inflammatory response, TGF-Î² production and signaling, and fibroblast proliferation and differentiation into ECM-producing myofibroblasts. Inhibition of the conversion of Ang I to Ang II with ACE inhibitors or blockade of AT<sub>1</sub>R by antagonists demonstrated the role of the RAS in fibrosis. Inhibitors of ACE, including <b>35</b> or enalapril (<b>36</b>), as well as antagonists of the AT<sub>1</sub>R, including <b>37</b> or valsartan (<b>38</b>), in clinical use for the treatment of cardiovascular disorders, have been evaluated in the context of fibrosis, showing some benefit (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). For example, <b>37</b> was shown in cancer models to reprogram CAFs, reduce their number and decrease TGF-Î², connective tissue growth factor (CTGF) and ET-1.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Agonists of AT<sub>2</sub>R have been developed, such as the AT<sub>2</sub>R-selective nonpeptidyl molecule C21 (<b>39</b>) (<i>K</i><sub>i</sub> 0.4 nM for AT<sub>2</sub>R and 10 Î¼M for AT<sub>1</sub>R) are antifibrotic in cardiovascular and renal diseases.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Examples of inhibitors of the angiotensin pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">3.5.2.  Endothelin Pathway Inhibitors (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>)</h4><div class="NLM_p">Precursor endothelin polypeptides (ppET1â3) are proteolytically activated in two steps, first by the intracellular serine proteases subtilisin-like convertases/furins, releasing the 38 aa-long pro-ETs/big ETs, then subsequently by the more specific membrane-bound endothelin converting enzyme-1 (ECE-1) to yield the 21aa active ET-1, ET-2, and ET-3 peptides. Following secretion, ET peptides act on two distinct high-affinity GPCRs, ET<sub>A</sub> and ET<sub>B</sub>, located on target cell membranes and signaling through the MAPK pathway. The ET-1 axis plays a fundamental role in the pathogenesis of fibrosis,<a onclick="showRef(event, 'ref162 ref163'); return false;" href="javascript:void(0);" class="ref ref162 ref163">(162,163)</a> mediating the profibrotic effects of TGF-Î². ET-1 is chemotactic for cells and induces fibroblast proliferation, ECM accumulation and contraction, mediated by the two ET-1 receptors. Most cells express both receptors, rendering it difficult to define the culprit receptor in the context of fibrosis. A consensus exists that dual ET<sub>A/B</sub> antagonists are probably to be preferred.<a onclick="showRef(event, 'ref42 ref163'); return false;" href="javascript:void(0);" class="ref ref42 ref163">(42,163)</a> Antagonists for the ET receptors, either dual ET<sub>A/B</sub> or ET<sub>A</sub>-selective, are in clinical use for the treatment of pulmonary hypertension.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Receptors antagonists decrease collagen I and III synthesis by fibroblasts. Several phases II or III clinical trials were performed in patients with fibrosis-associated diseases. The dual ET<sub>A/B</sub> receptor antagonist <b>40</b> was evaluated in the BUILD-1 and -3 trials in lung fibrosis and in the RAPIDS-1 and -2 trials in skin fibrosis (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The dual ET<sub>A/B</sub> receptor antagonists <b>41</b> and enrasentan (<b>42</b>) were evaluated in the MUSIC trial in lung fibrosis and in heart fibrosis, respectively. The ET<sub>A</sub>-selective antagonist <b>43</b> was evaluated in the ARTEMIS trial for lung fibrosis. The ET<sub>A</sub>-selective antagonists avosentan (<b>44</b>), sitaxentan (<b>45</b>), and darusentan (<b>46</b>) were evaluated in the ASCEND trials for kidney fibrosis and in the EARTH trial for heart fibrosis, whereas the ET<sub>B</sub>-selective BQ-788 (<b>47</b>) was evaluated only in liver fibrotic diseases. All trials showed mixed outcomes, mostly being ineffective to reverse fibrosis, with the exception of <b>40</b>, which has received clinical approval for digital ulceration in systemic sclerosis. ET<sub>A</sub>-selective antagonists demonstrated some reduction of proteinuria in kidney fibrosis, but they are associated with side effects when prescribed in combination with RAS blockade.<a onclick="showRef(event, 'ref42 ref163'); return false;" href="javascript:void(0);" class="ref ref42 ref163">(42,163)</a> The dual ET<sub>A</sub>/AT<sub>1</sub>R antagonist, sparsentan/RE-021/retrophin/BMS456567 (<b>48</b>) is presently in a phase II trial for diabetic nephropathy.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Examples of inhibitors of ET-1 receptors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, blockers of the Ang and ET pathways may present interest in the treatment of fibrosis, mainly by their beneficial effects on associated pathologies, such as diabetes or hypertension. In the context of fibrosis, they are likely to be mandatory in combination regimens.</div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">3.6.  Enzyme Inhibitors (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>)</h3><div class="NLM_p">In fibrosis, two families of enzymes have crucial roles in ECM remodeling. Proteases involved in ECM degradation, the Zn-dependent proteases such as MMPs and ADAMs or the prolyl-specific serine-proteases of the DPP IV family, and enzymes involved in ECM stabilization, the lysyloxidases LOX and LOXL1â4.</div><div id="sec3_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24">3.6.1.  Inhibitors of Proteases (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>)</h4><div class="NLM_p">Inhibitors of the proteases. MMPs and ADAMs are implicated in a variety of physiological processes as well as in pathological conditions such as inflammation, cancer, fibrosis, and tissue repair,<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> acting on cytokines, chemokines, adhesion, and signaling molecules and structural proteins.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> MMPs and ADAMs mediate ECM remodeling and release fibrogenic factors including TGF-Î² or TNF-Î±, triggering inflammation, and fibrosis.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> The role of MMPs in fibrogenic diseases has been previously reviewed by several authors.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> The first MMP inhibitors failed in clinical trials due to their low selectivity. Later on, MMP inhibitors with higher affinity and increased selectivity or MMP inhibitors targeting exosites mediating cell surface interactions and activation were designed (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Whereas MMP inhibitors, for instance <b>18</b> (structure in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) and batimastat/BB-94 (<b>49</b>) or marimastat (<b>50</b>), can control the perpetuation of fibrosis induced by MMP overproduction,<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> the PREMIER clinical trial of the MMP inhibitor PG-116800 (<b>51</b>) was not conclusive of a beneficial effect.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Specific inhibitors have been developed against the proteases able to process biologically active prolyl-containing peptides: DPP IV, FAP-Î±, and POP/PREP.<a onclick="showRef(event, 'ref72 ref124'); return false;" href="javascript:void(0);" class="ref ref72 ref124">(72,124)</a> DPP IV/CD26 is a costimulator of T-cells and a therapeutic target for type-2 diabetes. Indeed, DPP IV inhibitors, the âgliptinsâ, are approved in the clinic for the treatment of type 2 diabetes,<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> a condition frequently associated with fibrosis. Diabetic nephropathy is associated with increased expression of DPP IV on endothelial and tubular epithelial cells. The proteolytic activity of FAP-Î± is pro-fibrogenic, but the protein itself is a regulator of cell apoptosis, adhesion, and migration. FAP-Î± protein and/or activity has been associated with fibrosis in many organs.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> FAP-Î± inhibition increases endogenous levels of active FGF21, making FAP-Î± an attractive target for the treatment of liver diseases and NASH.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Synthetic POP inhibitors have been developed and evaluated mainly in the context of neurodegenerative diseases. However, as POP, and possibly also FAP-Î±, have been involved in the activation of the antifibrotic Ac-Ser-Asp-Lys-Pro peptide from thymosin-Î²4,<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> its inhibition in the context of fibrosis would be detrimental. The DPP IV inhibitor linagliptin (<b>52</b>) has incretin-independent antifibrotic effects in diabetic nephropathy, preventing renal fibrosis mediated by TGF-Î². <b>52</b> has the advantage that it can be used in patients with renal dysfunction without dose adjustment because it is not excreted by the kidney. New onset diabetes after transplantation is a common side effect of immunosuppressive therapies, which could be improved by the DPP IV inhibitor vildagliptin (<b>53</b>).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> In a murine model of lung allograft, <b>53</b> promoted graft acceptance by reducing T-cell infiltration and modulating cytokine expression.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> In DPP IV- and likely FAP-Î±-positive fibroblasts, able to deposit ECM in response to fibrogenic stresses, diprotin A/Ile-Pro-Ile (<b>54</b>), a competitive substrate of DPP IV-like proteases could reduce scar formation.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> The only FAP-Î± inhibitor which has been evaluated in clinical trials is the small molecule dual DPP IV/FAP-Î± inhibitor PT-100/ValboroPro/talabostat (<b>55</b>). Clinical trials of <b>55</b> demonstrated positive response in a phase II trial of stage IV melanoma patients.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Dabigatran (<b>56</b>) is in clinical use to inhibit thrombin-induced fibroblast proliferation, presently under consideration for clinical trial.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Examples of protease inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25">3.6.2.  Inhibitors of Lysyloxidases (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>)</h4><div class="NLM_p">LOX and LOXL-1â4 enzymes are a family of lysine-tyrosylquinone-dependent copper amine oxidases which are upregulated by TGF-Î²1 before the appearance of fibrotic lesions. These enzymes catalyze the oxidation of Îµ-amines of lysine residues within collagen, generating reactive aldehydes that condense to form covalent collagen cross-linkages in the ECM.<a onclick="showRef(event, 'ref170 ref171'); return false;" href="javascript:void(0);" class="ref ref170 ref171">(170,171)</a> Cross-linking by LOX and LOXLs not only stabilizes collagen fibers, rendering them more resistant to degradation, but also contribute to myofibroblast activation due to increased stiffness, causing progression of interstitial fibrosis.<a onclick="showRef(event, 'ref172 ref173'); return false;" href="javascript:void(0);" class="ref ref172 ref173">(172,173)</a> Specific LOXL inhibitors could prevent fibrosis (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Î²-Aminopropionitrile (<b>57</b>, BAPN), a small molecule inhibitor of the LOX family, improved the outcome of experimental liver and reversed cardiac fibrosis.<a onclick="showRef(event, 'ref174 ref175 ref176'); return false;" href="javascript:void(0);" class="ref ref174 ref175 ref176">(174â176)</a> On the basis of this lead, LOX(L) inhibitors have been designed. PAT-1251 (<b>58</b>) was identified as a potent, highly selective, irreversible inhibitor of LOXL2, significantly reducing fibrosis in mouse bleomycin-mediated lung injury models. It has completed a healthy volunteer phase I trial.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> CCT365623 (<b>59</b>) successfully disrupted the LOX signaling pathway by decreasing the EGFR pathway in cancer models.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> Out of two series of potent chemical inhibitors for LOXL-2, either para-substituted benzylamines or 2-substituted pyridin-4-ylmethanamines, the most potent and reversible inhibitor was the (2-chloropyridin-4-yl)methanamine (<b>60</b>), selective for LOXL-2 compared to LOX.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Other selective inhibitors under development with wide application from fibrotic disease to cancer include the 3-fluoro-4-aryloxyallylamine inhibitors PXS-S1A (<b>61</b>) able to significantly reduce the activation of CAFs in cancer models,<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> as well as collagen accumulation and cross-linking in CCl<sub>4</sub>-induced liver fibrosis. Gilead Sciences is testing simtuzumab, a recombinant humanized monoclonal antibody against LOXL2 designed as an immunomodulator for the treatment of fibrosis. It is in multiple phase II trials for several organ fibrosis. Tipelukast/MN-001 (<b>62</b>) is an oral dual leukotriene receptor antagonist/LOXL-2 inhibitor, which also inhibits PDE-3 and PDE-4, as well as 5-lipoxygenase. It downregulates collagen type 1, MMP inhibitors, and pro-inflammatory chemokines and is presently being evaluated in a phase II trial.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Examples of LOX and LOXL inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, inhibiting the activity of proteases and lysyloxidases in the early phase of fibrosis development is relevant. However, more information is necessary to ascertain their effect in progression and late phase of fibrosis. Combination therapies would probably be necessary.</div></div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">3.7.  Inhibitors of Kinases and Cellular Signaling Pathways (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>)</h3><div class="NLM_p">Several kinases and cellular signaling pathways participate in the development and progression of fibrotic processes. These include the EGFR-MAPK, IGF1R-Akt, JAK3/STAT6, Wnt/Î²-catenin, and Notch signaling pathways, CXCL12/SDF1 and its CXCR4 receptor, integrins, and cadherins. Thus, controlling activation of these pathways with antagonists and/or inhibitors has been attempted, but reaching selectivity for one pathway over the others is difficult. Moreover, many of these pathways are involved in tissue homeostasis in normal physiological conditions. It is impossible in this Perspective to describe all pathways and molecules; thus, we present a selection that we hope is representative of the attempts made.</div><div id="sec3_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27">3.7.1.  Kinases Inhibitors (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>)</h4><div class="NLM_p">EGFR (ErbB-1; HER1 in humans) belongs to a family of receptors for members of the EGF protein ligands. Overexpression of EGFR signaling is associated with the development of a wide variety of diseases. Upon activation by its growth factor ligands, EGFR dimerizes which stimulates its intrinsic intracellular protein-tyrosine kinase activity. The resulting autophosphorylation initiates signal transduction cascades, principally the MAPK-ERK, PI3K-Akt-mTOR, and STAT/JNK pathways, leading to cell activation, proliferation, and migration. Interruption of EGFR signaling can be achieved either by blocking EGFR binding sites on the extracellular domain of the receptor or by inhibiting intracellular tyrosine kinase activity. Therapeutics directed against EGFR include small molecule kinase inhibitors or antibodies, targeting the ligand binding site or the downstream signaling pathways (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). CAFs have also been shown to activate the insulin-like growth factor 1 receptor (IGF1R)-Akt signaling,<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> raising interest for antagonists of these receptors. However, due to the similarity of IGF-1R and the insulin receptor structures, especially in the ATP binding site and tyrosine kinase domain, side effects can be expected. Selectivity of inhibitors for specific kinases has been generally difficult to achieve and several small molecule drugs display multikinase inhibition, suggesting that the design of targeted analogues will be necessary. <b>16</b> (structure in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), an immunosuppressive drug targeting mTOR, is being evaluated in a double-blind placebo-controlled trial. <b>63</b>, clinically approved for IPF, is a tyrosine kinase inhibitor of VEGFR, FGFR, and PDGFR. Dasatinib/BMS-483525 (<b>64</b>), a multikinase inhibitor, in association with the natural antioxidant <b>110</b> (structure in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) is presently being evaluated in a phase I trial. Suramin (<b>65</b>) is a polysulfonated naphthylurea with potential antitumor activity, able to block the binding of various growth factors, including IGF-I, EGF, PDGF, and TGF-Î² to their receptors, thereby inhibiting cell proliferation and migration. Sunitinib (<b>66</b>), a multikinase inhibitor, was developed as a kidney-targeted therapeutic by conjugating the analogue 17864 (<b>67</b>) to the kidney-specific enzyme lysozyme, but this did not result in antifibrotic effects.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Cabozantinib (<b>68</b>) is a small molecule inhibitor of the tyrosine kinases c-Met, VEGFR2, AXL, and RET. Omipalisib/GSK2126458 (<b>69</b>) is a highly selective and potent inhibitor of p110Î±/Î²/Î´/Î³ and mTORC1/2 with <i>K</i><sub>i</sub> in the low nM range, able to decrease mitogenic fibroblast responses through inhibition of the PI3K/Akt/mTOR pathway. It has been already tested in a completed phase I trial. KD025/Slx-2119 (<b>70</b>) is an orally available selective ROCK2 versus ROCK1 inhibitor, with IC<sub>50</sub> and <i>K</i><sub>i</sub> of 100 and 40 nM, respectively, able to reduce the secretion of the IL-21 and IL-17 proinflammatory cytokines by leukocytes. It is presently evaluated in an ongoing phase II trial. Tanzisertib/CC930 (<b>71</b>), a potent, selective, and orally active antifibrotic inhibitor of the MAPK/JNK pathway (IC<sub>50</sub> values 61, 7, 6, 480, and 3400 nM for JNK1, JNK2, JNK3, ERK1, and p38Î±, respectively) was evaluated in a phase II trial for the treatment of IPF. CC90001 (<b>72</b>), a second-generation JNK inhibitor, selective for JNK1, has completed phase I and is presently evaluated in a phase II trial.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Several EGFR kinase inhibitors have been approved for clinical use, mostly in the context of cancer. Gefitinib/ZD1839 (<b>73</b>) was the first selective antagonist of EGFR, inhibiting the ATP-binding site of the enzyme and the antiapoptotic Ras signal transduction cascade. Erlotinib (<b>74</b>), the second approved EGFR inhibitor, reversibly binds to the ATP site of the receptor. Afatinib (<b>75</b>), is an irreversible covalent inhibitor of EGFR and ErbB-2/HER2. Lapatinib (<b>76</b>), is an orally active dual HER2/EGFR inhibitor of the ATP-binding pocket of the kinase domains. Brigatinib/AP26113 (<b>77</b>) is a dual ALK/EGFR inhibitor, able to overcome resistance conferred by the EGFR C797S mutation when combined with an anti-EGFR antibody. Icotinib/BPI-2009H (<b>78</b>) is a highly selective, first generation EGFR tyrosine kinase inhibitor, solely approved and marketed in China. Osimertinib/AZD9291 (<b>79</b>) is a third-generation irreversible and specific inhibitor of T790 M or L858R mutated EGFR or of EGFR with exon 19 deletion. Imatinib (<b>80</b>, Glivec) and sorafenib/BAY43â9006 (<b>81</b>) are active on PDGFR and VEGFR. Synthesizing selective inhibitors of IGF-1R is difficult but includes ChEBI:75252 (<b>82</b>), BMS-754807 (<b>83</b>), and NVP-AEW541 (<b>84</b>). The tyrphostins AG538 (<b>85</b>) and AG1024 (<b>86</b>) are in early preclinical testing. They do not appear to be ATP-competitive and show some selectivity toward IGF-1R. K252a (<b>87</b>), a staurosporine analogue, is a cell permeable inhibitor of CaM kinase and phosphorylase kinase (IC<sub>50</sub> = 1.8 and 1.7 nM, respectively). Monoclonal antibodies, such as figitumumab, are probably the most specific and promising therapeutic compounds currently undergoing trials.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Examples of kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28">3.7.2.  Inhibitors of cellular signaling pathways (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>)</h4><div class="NLM_p"><named-content content-type="anchor" rid="fig10" type="simple"></named-content>Activation of fibroblasts depends on the profibrotic cytokines IL-4 and IL-13, resulting in activation of JAK3 and phosphorylation of STAT6, which translocates to the nucleus and promotes responsive gene transcription, production of ECM proteins (fibronectin and collagen I), and fibrosis. These effects can be antagonized by JAK3 inhibition.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Tofacitinib/CP-690550 (<b>88</b>) is a selective JAK3 inhibitor with an IC<sub>50</sub> of 1 nM that governs lymphocyte survival, proliferation, differentiation, cytokine and chemokine production, and apoptosis. Treatment with <b>88</b> was shown to significantly reduce myofibroblast transformation and fibrosis development in a murine model of kidney fibrosis.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> ZM 39923 (<b>89</b>) is a dual JAK1/3 inhibitor. WHI-P154 (<b>90</b>) is a JAK3 inhibitor with an IC<sub>50</sub> of only 1.8 Î¼M, but selective versus JAK1 or JAK2, preventing STAT3, but not STAT5 phosphorylation, and also inhibiting EGFR, VEGFR, and MAPK. Cerdulatinib/PRT-062070 (<b>91</b>) is an orally active nonspecific kinase inhibitor with an IC<sub>50</sub> of 12, 6, or 8 nM for JAK1, JAK2, or JAK3, respectively. The Wnt/Î²-catenin-TCF signaling pathways are a group of highly conserved cell surface receptors and <i>signal transduction</i> pathways, mediating sustained fibroblast activation in fibrotic diseases, including systemic sclerosis. The binding of a Wntâprotein ligand to a receptor of the Frizzled family activates downstream signaling to the Dishevelled protein, which leads to gene transcription, cytoskeleton reorganization, intracellular calcium regulation, and cell proliferation and migration. The Wnt-dependent pathways are necessary in embryo development, tissue regeneration, and cancer progression, making interferences with these pathways prone to side effects. PKF118-310 (<b>92</b>) disrupts the TCF4/Î²-catenin complex and inhibits the expression of TCF4-responsive genes and of survivin. ICG-001/PRI-724 (<b>93</b>) antagonizes Wnt/Î²-catenin/TCF-mediated transcription by specifically binding to CREB-binding protein (CBP) with an IC<sub>50</sub> of 3 Î¼M, and it is presently in phase II clinical trials.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> XAV-939 (<b>94</b>) selectively inhibits Wnt/Î²-catenin-mediated transcription through tankyrase1/2 inhibition with an IC<sub>50</sub> of 11 nM, and it does not affect NF-ÎºB or TGF-Î².<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Lectin antagonism has also been examined. TD139 (<b>95</b>) is a high-affinity inhibitor of galectin-3 carbohydrate binding domain with a <i>K</i><sub>d</sub> of 14 nM able to decrease TGF-Î²1-induced Î²-catenin phosphorylation and translocation to the nucleus, reducing fibrosis. In a completed phase Ib/IIa clinical trial for IPF, it was shown that inhaled <b>95</b> is effective, safe, and well-tolerated. The Notch signaling pathway is a highly conserved cell signaling system. The single-pass transmembrane receptor Notch is activated by direct cellâcell contact. Binding of protein ligands to the extracellular domain induce sequential proteolytic cleavage, in particular involving Î³-secretase, releasing the intracellular domain, which migrates to the cell nucleus to modify gene expression. We have previously reviewed in detail Notch inhibition and the associated therapeutics.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Notch antagonism is mainly based on the use of Î³-secretase inhibitors such as MK-0752 (<b>96</b>, IC<sub>50</sub> = 5 nM, LY411575 (<b>97</b>, IC<sub>50</sub> = 0.39 nM), RO4929097 (<b>98</b>, IC<sub>50</sub> = 5 nM), avagacestat/BMS-708163 (<b>99</b>, IC<sub>50</sub> = 58 nM), semagacestat/LY450139 (<b>100</b>, IC<sub>50</sub> = 14 nM), and LY-900009 (<b>101</b>, IC<sub>50</sub> = 27 nM). Inflammatory signaling has also been targeted. The CXCR4 and CCR2 receptors are inhibited, respectively, by plerixafor/AMD3100 (<b>102</b>), recently approved for hematopoietic stem cell mobilization, and CCX140B (<b>103</b>). Antagonists have been developed for the c-Met/hepatocytes growth factor receptor/scatter factor (HGFR/SF). HGFR/SF tyrosine kinase is essential for wound healing and angiogenesis, and the cMet ligand expressed on tumor cells is involved in tissue invasion and metastasis. SU11274 (<b>104</b>) is a selective c-Met inhibitor with an IC<sub>50</sub> of 10 nM inactive on PDGFRÎ², EGFR, and Tie2. PHA665752 (<b>105</b>) is a potent, selective ATP-competitive c-Met inhibitor with an IC<sub>50</sub> of 9 nM. Antagonists to the prostacyclin receptor, such as the PGI2 analogue treprostinil (<b>106</b>), to the purinergic P2X2/3 receptor, such as gefaxinant/AF219/MK7264 (<b>107</b>), or to Hedghog, such as vismodegrib (<b>108</b>), are in clinical trials. Controlling the integrins and cadherins-associated pathways is also of interest in fibrotic therapies<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> as the integrin Î±3Î²1 and the cadherin-11 adhesion molecule are mediators of tissue fibrosis and the integrin Î±<sub>v</sub>Î²<sub>6</sub> activates latent TGF-Î². Naphthyridine derivatives, such as GSK3008348 (<b>109</b>), have been developed for the treatment of fibrotic diseases as antagonists of the integrin Î±<sub><i>v</i></sub>Î²<sub>6</sub>.</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0010.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Examples of inhibitors of cell signaling pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, inhibitors of kinases and antagonists to cellular pathways are likely to play an indirect role by modifying the functions of activated myofibroblasts as well as fibrosis-associated cells other than fibroblasts. More information from the outcome of clinical trials is needed to define the most relevant pathway(s).</div></div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">3.8.  Inhibitors of Metabolic Pathways (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>â<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>)</h3><div class="NLM_p">Several metabolic pathways, including oxidative stress, FXR, and PPAR receptors and fatty acid synthesis have been targeted with small molecules in the aim to achieve treatment of fibrosis and able to modulate the level of activity of these pathways.</div><div id="sec3_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30">3.8.1.  Inhibitors of Oxidative Stress (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>)</h4><div class="NLM_p">In humans, oxidative stress is involved in the development of many diseases, including fibrosis. Oxidative stress reflects an imbalance between the production of reactive oxygen species (ROS) and detoxification mechanisms. Oxidative stress disrupts normal mechanisms of cellular signaling and damages all components of the cell, including proteins, lipids, and nucleic acids. Oxidative stress plays a role in the inflammatory cascade in ischemic-reperfusion injury, an important problem in solid organ transplantation procedures. But some ROS also act as cellular messengers in redox signaling, and the immune system uses the lethal effects of oxidants in its mechanism of killing pathogens. ROS under normal conditions in humans are produced by the mitochondria during oxidative phosphorylation as well as by various oxidases. Some organic compounds, such as quinones cycling with their conjugate semiquinones and hydroquinones, in addition to metal redox catalysts, can produce ROS. Cellular antioxidant enzymes encompass superoxide dismutase, catalase, glutathione peroxidase, glutathione-S transferases, and various aldehyde dehydrogenases. Several physiological pathways, such as TGF-Î² signaling and the RAS, as well as some pathologic conditions, such as type-2 diabetes, have been associated with oxidative stress. Therefore, drugs developed to control these pathways are of interest in controlling oxidative stress. In addition, small molecules have been developed as more specific antioxidative therapeutics (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). The natural anti-inflammatory and antifibrotic compounds <b>110</b> and curcumin (<b>111</b>) are antioxidant, protecting DNA and regulating the immune system. Melatonin/<i>N</i>-acetyl-5-methoxytryptamine (<b>112</b>), a regulator of circadian rhythm, <i>S</i>-nitroso-<i>N</i>-acetylcysteine (<b>113</b>), a nitric oxide donor and antioxidant, regulates proteolytic balance, collagen deposition, and TGF-Î² activation.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> Î±-Lipoic acid (<b>114</b>) is a mitochondrial fatty acid organosulfur compound essential for aerobic metabolism. As a dietary supplement it is an antioxidant, with protective effects in inflammatory diseases. The approved antioxidant and free-radical scavenger compounds edaravone (<b>115</b>) can reduce cardiac fibrosis by decreasing TGF-Î²1/Smad2/3 signaling, collagen I synthesis, and AT<sub>1</sub>R signaling while up-regulating AT<sub>2</sub>R. They also decrease the recruitment of macrophages and myofibroblasts to the myocardium,<a onclick="showRef(event, 'ref183 ref184'); return false;" href="javascript:void(0);" class="ref ref183 ref184">(183,184)</a> attenuating or even reversing fibrosis as shown in animal and clinical studies. The antioxidant NOX1/4 inhibitor GKT137831 (<b>116</b>) is in phase II for diabetic nephropathy.</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0011.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Examples of inhibitors of oxidative stress.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">3.8.2.  PPAR and FXR Agonists (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>)</h4><div class="NLM_p">FXR is a nuclear receptor that, when activated, translocates to the cell nucleus, where it forms a heterodimer with retinoid X receptor (RXR) and binds to hormone response elements on DNA. This regulates gene expression, in particular cholesterol 7Î± hydroxylase, the rate-limiting enzyme in bile acid synthesis and hepatic triglycerides. FXR agonists are under investigation in early clinical and preclinical trials as potential therapeutics for NASH. Several FXR agonists are presently in phase I or II development for NASH such as <b>117</b> and <b>118</b> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). The synthetically modified bile acid obeticholic acid/ocaliva (<b>119</b>) is a potent agonist of FXR used to treat liver diseases. The FXR agonists EDP-305 (structure not disclosed) and tropifexor/LJN452 (<b>120</b>) were shown to perturb FXR-dependent gene expression and reduce hepatocyte ballooning and liver fibrosis in animal models. <b>120</b> was successfully tested in the phase II FLINT trial, showing a reduction of fibrosis and scaring. Several other FXR agonists are presently in phase I or II development for NASH, such as GS-9674 (<b>121</b>)  or pioglitazone (<b>118</b>, brand name Actos), an oral antidiabetic agent belonging to the thiazolidinediones class. FXR can interact with PPAR-Î³ coactivator 1-Î±. The PPAR subfamily of nuclear receptors can form heterodimers which regulate transcription of various genes. The nuclear PPAR-Î³/glitazone receptor regulates fatty acid storage and glucose metabolism and is implicated in the pathology of numerous diseases. Many naturally occurring agents directly bind with and activate PPAR-Î³, including various polyunsaturated fatty acids like arachidonic acid. PPAR-Î³ agonists decrease the inflammatory response. Many insulin-sensitizing drugs, the âthiazolidinedionesâ, used in the treatment of diabetes activate PPAR-Î³. Compounds that more weakly activate PPAR-Î³ as partial agonists, such as the medium-chain triglyceride decanoic acid, are currently under study. <b>118</b> is also a PPAR-Î³ agonist, acting on adipocytes, hepatocytes, and muscle cells to inhibit TGF-Î² profibrotic effects. Its combination with anticholesterol agents, the âstatinsâ, and omega 3 fatty acids or vitamin E has been proposed,<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> but only limited clinical trial data are presently available. <b>117</b> is another antidiabetic drug of the thiazolidinedione class that works as an insulin sensitizer by binding to PPAR-Î³ in fat cells. Elafibranor/GFT505 (<b>122</b>), a dual PPAR-Î±/Î´ agonist,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> developed for the treatment of metabolic disorders, and in particular NASH, produced mixed results in phase II trials.</div><figure id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0012.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Examples of FXR and PPAR-Î³ modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32">3.8.3.  Fatty Acid Synthesis and Phosphodiesterases (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>)</h4><div class="NLM_p">Lysophospholipids (LPs), which include S1P and lysophosphatidic acid (LPA), are bioactive phospholipids that transduce signals through their specific cell-surface GPCRs, S1P<sub>1â5</sub>R, and LPA<sub>1â6</sub>R, respectively. LPs and their receptors have been implicated in both physiological and pathological processes, including fibrosis. S1P has been discussed separately in section <a class="ref internalNav" href="#sec3_4" aria-label="3.4">3.4</a>. Targeting the biosynthesis of fatty acids has been attempted, mostly in the liver, using either inhibitors of ACC and of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase or antagonists to the LPARs-MAPK signaling pathways, involved in the production of pro-inflammatory cytokines (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). NDI-010976/ND630 (<b>123</b>) is a potent liver-directed inhibitor of ACC in NASH. Pyrazole- and triazole-derived carbamates, such as RO6842262 (<b>124</b>), are selective antagonists for LPA<sub>1</sub>R (IC<sub>50</sub> 25 nM) versus LPA<sub>3</sub>R. They inhibit the proliferation and contraction of normal human lung fibroblasts following LPA stimulation, suggesting a potential novel approach for the treatment of IPF.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The clinically approved cholesterol lowering agents, the âstatinsâ family, diminish EMT, TGF-Î² signaling, and oxidative stress in glomerular cells.<a onclick="showRef(event, 'ref75 ref154 ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref75 ref154 ref155 ref156">(75,154â156)</a> GLPG1690 (<b>125</b>), an ATX inhibitor, the major enzyme generating the LPA, is presently in a phase II clinical trial. BMS-986020/AM152 (<b>126</b>) is a LPAR antagonist presently tested in a completed phase II trial. Inhibitors of PDEs have also attracted interest as potential antifibrotic therapeutics. As already stated, <b>127</b>, an orally active, selective, long-acting inhibitor of the enzyme PDE-4 with anti-inflammatory effects, was approved for the treatment of inflammatory conditions of the lungs.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Pentoxifylline (<b>128</b>), a methylxanthine nonspecific PDE inhibitor developed for vascular diseases, displaying also anti-inflammatory and antioxidative properties, is under one phase III and two phase IV clinical trials. The cyclic GMP-specific PDE5A-selective inhibitors sildenafil (<b>129</b>) and PF00489791 (<b>130</b>), in phase II for diabetic nephropathy and the PDE4-selective inhibitor <b>127</b>, approved for chronic obstructive pulmonary disease, are less potent therapeutics for fibrotic disorders. In the first proof-of-concept human study, <b>129</b> was shown to reduce TGF-Î² in IPF;<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> however, fibrosis parameters were not measured.</div><figure id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0013.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Inhibitors of fatty acid synthesis and phosphodiesterases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33">3.8.4.  Others (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>)</h4><div class="NLM_p">Therapeutic attempts have also included targeting histone H4 acetylation, inhibition of the Ca<sup>2+</sup>-activated K<sup>+</sup> channel (KCa3.1), the mineralocorticoid/aldosterone receptors, or the vitamin D-dependent pathways. TGF-Î²1- or PDGF-mediated profibrotic and inflammatory responses in lung fibroblasts of patients with IPF were attenuated by the bromodomain 4 (Brd4) inhibitor JQ1 (<b>131</b>) (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> Inhibition of KCa3.1 channel by TRAM34 (<b>132</b>) suppresses TGF-Î²-induced upregulation of ECM-associated genes in renal fibroblasts.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Inhibitors of the mineralocorticoid/aldosterone receptor, such as spironolactone (<b>133</b>) tested in the RALES trial, finerenone/BAY-94-8862 (<b>134</b>) in a phase III trial, esaxerenone/CS-3150 (<b>135</b>), or PF-03882845 (<b>136</b>), can suppress fibrosis development in the heart and the kidney.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Stimulation of the adenosine A<sub>2B</sub>R has antifibrotic properties, mediated by antagonizing ET-1 effects on fibroblasts.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Adenosine receptor antagonists include caffeine, theophylline, or theobromine and the pharmaceutical drug regadenoson (<b>137</b>).</div><figure id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0014.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Examples of various pathways modulators of potential interest in fibrosis treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, modulators of metabolic pathways and FXR and PPAR-Î³ agonists display antifibrotic properties and anti-inflammatory properties. They may be of therapeutic interest in combination therapy regimens, but they are likely to act in the early phase of fibrosis.</div></div></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">3.9.  Natural Products (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>)</h3><div class="NLM_p">Several natural products with antioxidant properties as well as immunomodulatory and anti-inflammatory activities, such as <b>110</b>, <b>111</b>, or <b>112</b> (structures in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>), have been evaluated as antifibrotic therapeutics. Schisandrin B (<b>138</b>) reduces ROS formation, inhibits the apoptotic mitochondrial pathway, and is a regulator of TGF-Î² signaling (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> Astragaloside IV (<b>139</b>), a glycoside of cycloartane-type triperpene, protects against fibrosis development in several organs by attenuating ECM deposition.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> Echinacoside (<b>140</b>) was demonstrated to inhibit the TGF-Î² signaling pathway.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a></div><figure id="fig15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0015.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Examples of natural products of potential interest in fibrosis treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, natural products display antifibrosis properties and may be of therapeutic interest as potential leads for the development of antifibrotic therapeutics.</div></div><div id="sec3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">3.10.  Regenerative Cell Therapeutics for Fibrosis Treatment (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>)</h3><div class="NLM_p">Healing from tissue injury depends on the regeneration of damaged tissue cells through dedifferentiation of surviving cells and/or the ability of resident progenitor cells to proliferate and differentiate into new organ-specific cells. Because, for end-stage fibrotic diseases, the only treatment is organ transplantation and as donor organs are in very short supply, facilitating tissue regeneration is a key component to treating both acute and chronic organ diseases. Besides fetal-derived tissues,<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> many adult tissues contain stem and progenitor cells able to proliferate and differentiate and to maintain tissue homeostasis and repair. In the kidney, mesenchymal stromal cells (MSCs, also called mesenchymal progenitor/stem cells) have been shown to have beneficial paracrine-mediated effects, both on the initial acute recovery from ischemia-reperfusion injury and in preventing the development of further chronic kidney disease.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> This demonstrates that effective treatment may be possible, either through adoptive cell therapy or through stimulation of paracrine responses from resident MSCs after injury.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Direct transfer of autologous or allogeneic MSCs, mostly by injecting them in the blood or following encapsulation into a polymeric device, is presently under evaluation in a large amount of clinical trials, mainly, but not only, for the treatment of acute liver injury and chronic fibrosis. Thus, efforts have been made to enhance these regenerative cell populations using small molecules (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>). <b>102</b> (structure in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), a CXCR4 antagonist, SB497115/eltrombopag (<b>141</b>), a thrombopoietin mimetic, FT1050/16,16-dimethyl prostaglandin E2 (<b>142</b>), a PGE2 analogue, and Isx-9 (<b>143</b>), a GPR68 agonist,<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> are under evaluation to enhance proliferation and differentiation of stem and progenitor cells.</div><figure id="fig16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0016.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Examples of small molecules of potential interest in regenerative cell therapy for fibrosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, recent progress in regenerative medicine has opened new therapeutic perspectives in the treatment of fibrosis, in particular the possibility to induce the repair of diseased tissues rather than reverse progression.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">4.  Lessons from Clinical Trials for the Treatment of Fibrosis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00004" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00004" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Several hundreds of molecules able to interfere with the fibrotic process at each of its phases of progression have been designed, prepared, and evaluated in preclinical models. The most promising of them have been evaluated in human clinical trials for possible therapy of fibrosis. Again, hundreds of trials, either phase I, II, III, or IV trials, have been performed, way too many to discuss all of them in this Perspective. In this part, we will focus the discussion on clinical trials, either terminated or ongoing, which have the potential to provide therapeutics for the prevention and treatment of fibrosis. We will concentrate on small molecule drugs, excluding antibodies, fusion proteins, modified proteins or protein fragments, or genetic tools. Toward this aim, we have compiled the US clinical trials registry (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a>), published reviews and original manuscripts describing and discussing the outcomes of these trials.<a onclick="showRef(event, 'ref5 ref6 ref42 ref63 ref82 ref124 ref135 ref136 ref163'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref42 ref63 ref82 ref124 ref135 ref136 ref163">(5,6,42,63,82,124,135,136,163)</a> The information obtained is summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Selected Clinical Trials for Small Molecule Modulators of Fibrotic Pathways<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug/target</th><th class="colsep0 rowsep0" align="center">trial code</th><th class="colsep0 rowsep0" align="center">organ</th><th class="colsep0 rowsep0" align="center">phase/status/outcome</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b>/TGF-Î²</td><td class="colsep0 rowsep0" align="left">NCT00287729</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">III, positive results</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/CAPACITY</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT01366209</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT00001959</td><td class="colsep0 rowsep0" align="left">kidney GS</td><td class="colsep0 rowsep0" align="left">II, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT00063583</td><td class="colsep0 rowsep0" align="left">kidney DN</td><td class="colsep0 rowsep0" align="left">I/II, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b>/COX</td><td class="colsep0 rowsep0" align="left">NCT02499562</td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="left">II, no information</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b>/mTOR</td><td class="colsep0 rowsep0" align="left">NCT01462006</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II,Â worsening,Â unpublished</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b>/CCR2/5</td><td class="colsep0 rowsep0" align="left">NCT02217475</td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="left">II, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/CENTAUR</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT03028740</td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="left">III, ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/AURORA</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b>/inflammation</td><td class="colsep0 rowsep0" align="left">NCT00162760</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II, completed, unpublished</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b>/inflammation</td><td class="colsep0 rowsep0" align="left">NCT01135199</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II, withdrawn</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b>/CTGF</td><td class="colsep0 rowsep0" align="left">NCT02538536</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II, open, completed, no results</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b>/NFÎºB</td><td class="colsep0 rowsep0" align="left">NCT01351675</td><td class="colsep0 rowsep0" align="left">kidney</td><td class="colsep0 rowsep0" align="left">III, terminated for safety concerns</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b>/AT<sub>1</sub>R</td><td class="colsep0 rowsep0" align="left">NCT00298714</td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="left">IV, completed, improvement</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT00879879</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">pilot, stabilized lung function</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT01150461</td><td class="colsep0 rowsep0" align="left">heart</td><td class="colsep0 rowsep0" align="left">II, completed, lower progression</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT01051219</td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="left">III, no information</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/FELINE</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b>/ET<sub>A/B</sub></td><td class="colsep0 rowsep0" align="left">NCT00070590</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II, completed, no improvement</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/Build2</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT00631475</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">open label, failed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/Build3</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT00319696</td><td class="colsep0 rowsep0" align="left">digital ulcers</td><td class="colsep0 rowsep0" align="left">III, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/RAPIDS-1</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT01395732</td><td class="colsep0 rowsep0" align="left">digital ulcers</td><td class="colsep0 rowsep0" align="left">IV, completed, approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/RAPIDS-2</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b>/ET<sub>A/B</sub></td><td class="colsep0 rowsep0" align="left">NCT00903331</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II, completed, no improvement</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/MUSIC</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b>/ET<sub>A</sub></td><td class="colsep0 rowsep0" align="left">NCT00879229</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">III, fail</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/ARTEMIS-PH</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT01051960</td><td class="colsep0 rowsep0" align="left">Ssc</td><td class="colsep0 rowsep0" align="left">IV, terminated, unknown</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT00768300</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">III, ineffective, halted</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/ARTEMIS-IPF</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b>/ET<sub>A</sub></td><td class="colsep0 rowsep0" align="left">NCT00120328/</td><td class="colsep0 rowsep0" align="left">kidney</td><td class="colsep0 rowsep0" align="left">III,Â lowerÂ proteinuria,Â halted</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">ASCEND</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b>/ET<sub>A</sub></td><td class="colsep0 rowsep0" align="left">EARTH</td><td class="colsep0 rowsep0" align="left">heart</td><td class="colsep0 rowsep0" align="left">ineffective</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b>/AT<sub>1</sub>R/ET<sub>A</sub></td><td class="colsep0 rowsep0" align="left">NCT01613118</td><td class="colsep0 rowsep0" align="left">kidney</td><td class="colsep0 rowsep0" align="left">II, active</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b>/ LOXL2</td><td class="colsep0 rowsep0" align="left">NCT02852551</td><td class="colsep0 rowsep0" align="left">several organs</td><td class="colsep0 rowsep0" align="left">I,Â safetyÂ inÂ volunteers,Â completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b>/PDE3/LO/LTR</td><td class="colsep0 rowsep0" align="left">NCT02503657</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II, ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b>/PDGFR/VEGFR</td><td class="colsep0 rowsep0" align="left">NCT00514683</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II, positive results</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/INPULSIS</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT01335464</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">III, completed, approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/INPULSIS</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT 01335477</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">III, completed, approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT02597933</td><td class="colsep0 rowsep0" align="left">Ssc</td><td class="colsep0 rowsep0" align="left">III, ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/SENCSIS</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b>/PDGFR</td><td class="colsep0 rowsep0" align="left">NCT00764309</td><td class="colsep0 rowsep0" align="left">lung (Ssc)</td><td class="colsep0 rowsep0" align="left">II, completed, ineffective</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69</b>/PI3K/mTOR</td><td class="colsep0 rowsep0" align="left">NCT01725139</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">I, completed, no published data</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b>/ROCK2</td><td class="colsep0 rowsep0" align="left">NCT02688647</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II, open label, ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71</b>/JNK</td><td class="colsep0 rowsep0" align="left">NCT01203943</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II, discontinued for side effects</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>80</b>/PDGFR</td><td class="colsep0 rowsep0" align="left">NCT00131274</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II/III, failed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT006677092</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>81</b>/PDGFR/VEGFR</td><td class="colsep0 rowsep0" align="left">NCT01425216</td><td class="colsep0 rowsep0" align="left">keloids</td><td class="colsep0 rowsep0" align="left">II, terminated; approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>95</b>/galectin-3</td><td class="colsep0 rowsep0" align="left">NCT02257177</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">I/II, completed, no information</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>103</b>/CCR2</td><td class="colsep0 rowsep0" align="left">NCT01028963</td><td class="colsep0 rowsep0" align="left">kidney</td><td class="colsep0 rowsep0" align="left">II, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT01440257</td><td class="colsep0 rowsep0" align="left">kidney</td><td class="colsep0 rowsep0" align="left">II, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT01447145</td><td class="colsep0 rowsep0" align="left">kidney</td><td class="colsep0 rowsep0" align="left">II, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>109</b>/integrin Î±vÎ²6</td><td class="colsep0 rowsep0" align="left">NCT02612051</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II, safety and tolerability</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>106</b>/prostacyclin R</td><td class="colsep0 rowsep0" align="left">NCT00703339</td><td class="colsep0 rowsep0" align="left">lung/PH, IPF</td><td class="colsep0 rowsep0" align="left">II, completed, early termination</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>107</b>/purinergic R</td><td class="colsep0 rowsep0" align="left">NCT02502097</td><td class="colsep0 rowsep0" align="left">lung/cough</td><td class="colsep0 rowsep0" align="left">II, completed, unpublished</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>116</b>/NOX1/4</td><td class="colsep0 rowsep0" align="left">NCT02010242</td><td class="colsep0 rowsep0" align="left">kidney DN</td><td class="colsep0 rowsep0" align="left">II, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>119</b>/FXR</td><td class="colsep0 rowsep0" align="left">NCT01265498/</td><td class="colsep0 rowsep0" align="left">liver NASH</td><td class="colsep0 rowsep0" align="left">II, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">FLINT</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT02548351</td><td class="colsep0 rowsep0" align="left">liver NASH</td><td class="colsep0 rowsep0" align="left">III, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">/REGENERATE</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>120</b>/FXR</td><td class="colsep0 rowsep0" align="left">NCT02855164</td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="left">II, recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>122</b>/PPARÎ±/Î´</td><td class="colsep0 rowsep0" align="left">NCT01694849.</td><td class="colsep0 rowsep0" align="left">liver NASH</td><td class="colsep0 rowsep0" align="left">II, resolution no fibrosis worsening</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>123</b>/ACC</td><td class="colsep0 rowsep0" align="left">NCT02876796</td><td class="colsep0 rowsep0" align="left">liver</td><td class="colsep0 rowsep0" align="left">I, safety, overweight volunteers</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>125</b>/ATX</td><td class="colsep0 rowsep0" align="left">NCT02738801</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II, partial report, stabilization</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>126</b>/LPAR</td><td class="colsep0 rowsep0" align="left">NCT02588625</td><td class="colsep0 rowsep0" align="left">Ssc</td><td class="colsep0 rowsep0" align="left">II, completed, no results</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT01766817</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">II, withdrawn</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>128</b>/PDEs</td><td class="colsep0 rowsep0" align="left">NCT00285298</td><td class="colsep0 rowsep0" align="left">kidney DN</td><td class="colsep0 rowsep0" align="left">III, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT01382303</td><td class="colsep0 rowsep0" align="left">kidney DN</td><td class="colsep0 rowsep0" align="left">IV, ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT01377285</td><td class="colsep0 rowsep0" align="left">kidney DN</td><td class="colsep0 rowsep0" align="left">IV, ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>130</b>/PDE5</td><td class="colsep0 rowsep0" align="left">NCT01200394</td><td class="colsep0 rowsep0" align="left">kidney DN</td><td class="colsep0 rowsep0" align="left">II, ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">Drug Combinations</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1Â +Â 63</b>/TGF-Î²Â +Â PDGF/VEGF</td><td class="colsep0 rowsep0" align="left">NCT02598193</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">IV, tolerability, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NCT02579603</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">IV, tolerability, completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1Â +Â 108</b>/Â TGF-Î²+Â Hedgehog</td><td class="colsep0 rowsep0" align="left">NCT02648048</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">I, completed, no results</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b>+FOLFIRINOX</td><td class="colsep0 rowsep0" align="left">NCT01821729</td><td class="colsep0 rowsep0" align="left">cancer</td><td class="colsep0 rowsep0" align="left">II, ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">/AT<sub>1</sub>R+therapyÂ regimen</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44Â +Â 37</b>/ET<sub>A</sub>+AT<sub>1</sub>R</td><td class="colsep0 rowsep0" align="left">ASCEND follow-up</td><td class="colsep0 rowsep0" align="left">kidney</td><td class="colsep0 rowsep0" align="left">tolerability, no information</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>110Â +Â 64</b>/antiox+PDGF</td><td class="colsep0 rowsep0" align="left">NCT02874989</td><td class="colsep0 rowsep0" align="left">lung</td><td class="colsep0 rowsep0" align="left">I, open label, ongoing</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">ACC, acetyl-CoA carboxylase; AT<sub>1</sub>R, angiotensin receptor 1; ATX, autotaxin; CCR,: CâC chemokine receptor; COX,: cyclooxygenase; CTGF,: connective tissue growth factor; DN, diabetic nephropathy; ET<sub>A</sub>, endothelin receptor A; ET<sub>A/B</sub>, endothelin receptors A and B; GS, glomerulosclerosis; IPF, idiopathic pulmonary fibrosis; LO, lipoxygenase; LOX-L, lysyloxidase-like; LPAR, lysophosphatidic acid receptor; LTR, leukotriene receptor; PDE, phosphodiesterase; PH, pulmonary hypertension; PPAR,: peroxisome proliferator activated receptor; ROCK, Rho-associated protein kinase; Ssc, systemic scleroderma.</p></div></div></div><div class="NLM_p last">In summary, most completed and published clinical trials were rather disappointing, showing only limited efficacy to reverse established fibrotic diseases. The majority of recent and previous trials were performed using drug monotherapy and were aimed at the treatment of IPF, many with not yet published results. Trials of combination therapies and new antifibrotic agents are underway.<a onclick="showRef(event, 'ref51 ref137'); return false;" href="javascript:void(0);" class="ref ref51 ref137">(51,137)</a> Two very recent clinical reviews have analyzed clinical trials performed for IPF;<a onclick="showRef(event, 'ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref135 ref136">(135,136)</a> both reviews concluded that compounds that have shown efficacy in preclinical studies failed to demonstrate positive effects when translated into humans due to the limitations of animal models. TGF-Î² is central to fibrosis development, and small molecules able to decrease TGF-Î² production and inhibitors of the kinase activity of the TGF-Î² receptors or the intracellular signaling proteins Smads have been evaluated in clinical trials. However, they were associated with adverse cardiovascular and hepatic side effects.<a onclick="showRef(event, 'ref191 ref192'); return false;" href="javascript:void(0);" class="ref ref191 ref192">(191,192)</a> Only <b>1</b>, which decreases TGF-Î² production, and <b>63</b>, a multikinase inhibitor, have been approved for the treatment of IPF in humans; <b>1</b> is under trials for fibrosis therapy in other organs. The endothelin and angiotensin systems are also central to fibrosis development, promoting the myofibroblast phenotype and the production of TGF-Î². Drugs able to control the endothelin and angiotensin pathways are in clinical use for many years for cardiovascular and hypertensive diseases. Clinical trials have evaluated ET<sub>A</sub>-selective, ET<sub>B</sub>-selective or dual ET<sub>A/B</sub> antagonists in disorders of the lung, liver, heart, kidney, and the skin.<a onclick="showRef(event, 'ref42 ref154'); return false;" href="javascript:void(0);" class="ref ref42 ref154">(42,154)</a> The primary objective of reducing mortality/morbidity was generally not achieved, with, however, a positive trend. In the context of digital skin ulcer, even if <b>40</b> was not able to shorten the time to healing, it was effective in preventing the formation of new ulcers, suggesting that dual ET<sub>A/B</sub> antagonists may be interesting tools to <i>prevent</i> fibrosis in medical situations. Ang II interaction with AT<sub>1</sub>R stimulates fibroblast proliferation and collagen synthesis. To the best of our knowledge, only very few dedicated clinical trials have been performed to test per se antagonism of the RAS to treat fibrosis. Most of the trials evaluated antifibrotic drugs in patients already on RAS inhibition for cardiovascular or diabetic disorders. Ang II receptor blockers, ACEI, or mineralo-corticoid receptor antagonists demonstrated, however, some potential to improve fibrotic processes by controlling the underlying diseases. Inflammatory mediators are involved in the initiation and progression of fibrosis, in some clinical situation like kidney fibrosis, but not in IPF, for example. Clinical trials attempting to decrease cytokine and chemokine secretion using kinase inhibitors or antagonists to their cognate receptors were performed. To date, mainly fusion proteins or blocking antibodies were used; the RENEWAL study<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> examined the effect of the TNF-Î± fusion protein antagonist etanercept and in the ATTACH trial the anti-TNF-Î± monoclonal antibody infliximab was tested. These trials were halted for inefficacy regarding the primary outcome or for side effects. The cholesterol-lowering agents statins are also anti-inflammatory. Two large-scale clinical trials, the CORONA and GISSIF-HF trials,<a onclick="showRef(event, 'ref155 ref156 ref157'); return false;" href="javascript:void(0);" class="ref ref155 ref156 ref157">(155â157)</a> demonstrated only a neutral effect of statins. PPAR agonists have anti-inflammatory properties, however, their cardiac safety profile is controversial.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> Overall, there is yet a lack of effective fibrosis inhibitors in patients.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">5.  Conclusion and Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48076" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48076" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Fibrosis proceeds in three steps: an initial phase of injury, an inflammatory phase in most clinical situations, and a remodeling phase. Then, in normal situations, the third phase is followed by a fourth phase of resolution, which does not happen in the context of progressive fibrosis. Antifibrotic treatments under development and (pre)clinical evaluation include small molecules, antibodies, genetic tools, peptides, protein analogues, and receptor decoys. Progression to fibrosis is mediated by the activation of TGF-Î²-associated signaling pathways, and the appearance of myofibroblasts producing an altered ECM. Thus, blockade of the TGF-Î² pathways is an obvious target for the treatment of fibrotic diseases. However, due to the ubiquitous and pleiotropic physiological functions of TGF-Î², depending on the local microenvironment and the organ, a challenge to be addressed will be to achieve its targeted inhibition. Therefore, despite its critical importance in fibrosis, systemic and nonselective inhibition of TGF-Î² may not be the best approach to treat fibrosis. The same consideration applies for inhibition of other important signaling pathways such as the Wnt or Notch pathways. Thus, one major challenge in antifibrotic therapy is selectivity and specificity of the drugs aimed at controlling fibrosis.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> Functionalized therapeutics with tissue- and/or cell-selective molecules must be designed. For example, in a recent approach,<a onclick="showRef(event, 'ref85 ref195'); return false;" href="javascript:void(0);" class="ref ref85 ref195">(85,195)</a> we used experimental rodent models of acute inflammatory and profibrotic kidney diseases to selectively target Notch1 signaling activation. We developed Î³-secretase inhibitor-based prodrug strategies for enzymatic activities specifically expressed in injured kidneys. Using these functionalized prodrugs, we could demonstrate a nephroprotective effect without systemic toxicity. Drug-delivering nanoparticles displaying at their surface reconnaissance molecules for overexpressed targets in fibrosis-associated cells may represent another approach to solve some of the problems of off-target side effects, as shown in a rat model of pulmonary fibrosis.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a></div><div class="NLM_p">Drugs able to modulate physiological pathways other than the TGF-Î², such as oxidative stress, lipids, enzymes, kinases, or peptide receptors, have been evaluated. Most clinical trials were disappointing, although the molecules had shown efficacy in preclinical animal models of the diseases. The majority of the therapeutics evaluated in preclinical models were selected to prevent the development of the fibrotic process. Novel compounds are often tested in patients with diseases that did not respond to established therapies, meaning that many compounds are tested at the later refractory stages of disease. Animal models do not recapitulate the complex nature of human fibrotic diseases because in these simplified models treatment is initiated in the early phase of the disease. In humans, fibrosis takes decades to develop and has often reached a no-return point when therapeutic intervention is attempted, requiring long-term treatment to diminish its progression. The type of fibrosis, its tissue origin, its stage of progression, the exact cells involved, and the level of heterogeneity between organs and diseases must be also considered, but this is generally not realistic in the medical context. In addition, young and healthy animals were studied, while patients with fibrosis are generally at a more advanced age and may have other comorbidities, suggesting that drug combination regimens must be considered to achieve optimal therapeutic efficacy with limited toxicity. It remains to be demonstrated, however, which adjuvant drug(s) may be more appropriate and which combined-schedule therapy should be proposed to patients according to their level of risk. To improve clinical translation, it is important in the future to design more clinically relevant research models and to perform clinical trials that include larger cohorts of suitable patients.</div><div class="NLM_p">Presently, end-stage chronic fibrotic diseases of the lung, kidney, liver, heart, and skin require organ/tissue replacement by either autologous or allogeneic transplantation or the implantation of artificial medical devices. In these processes, the time of injury is known but unavoidable, either due to ischemia-reperfusion injury or due to the presence of a foreign body and an accompanying inflammation. Therefore, antifibrotic therapies should ideally be delivered at the time of transplantation/implantation. Recent progress in regenerative medicine to induce the repair of diseased tissues, rather than reverse progression, has open new therapeutic perspectives in the treatment of fibrosis.</div><div class="NLM_p last">In conclusion, to control and possibly reverse fibrosis progression, treatment approaches require the control of key pathways that influence cell functions and the development of a permissive environment, mainly composed of activated (myo)fibroblasts. To achieve clinically meaningful results in human trials, the strategy to treat fibrosis should include the three following challenges: (1) a targeted/addressed delivery of therapeutic drugs to the organ or to the tissue to avoid systemic side effects, (2) an upfront combination therapy with molecules targeting different pathways, and (3) a treatment administered very early in the course of the disease because organ dysfunction is unlikely to regress significantly once present. We believe that selectively blocking the TGF-Î² signaling pathways will be necessary. Blocking the RAS was shown to improve fibrosis therapy. Thus, combining RAS blockade with the approved antifibrotic drugs <b>1</b> or <b>63</b> may be an option. Therapeutics able to modulate the endothelin pathway must also be considered in combination therapeutic regimens. Controlling inflammation and oxidative stress is probably not of interest in the late phase of the fibrotic processes. As several kinases, the PPAR, FXR, and fatty acid pathways such as S1P, mediate a variety of pro-fibrotic effects in many tissues and organs, kinases, and receptor-specific agonists or antagonists may be of interest.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00294" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82267" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82267" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lucienne Juillerat-Jeanneret</span> - <span class="hlFld-Affiliation affiliation">Transplantation
Center and Transplantation Immunopathology Laboratory, Department
of Medicine, Centre Hospitalier Universitaire
Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8039-7882" title="Orcid link">http://orcid.org/0000-0002-8039-7882</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2a465f49434f44444f04405f4346464f584b5e6a49425f5c044942"><span class="__cf_email__" data-cfemail="87ebf2e4eee2e9e9e2a9edf2eeebebe2f5e6f3c7e4eff2f1a9e4ef">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John-David Aubert</span> - <span class="hlFld-Affiliation affiliation">Pneumology
Division and Transplantation Center, Centre
Hospitalier Universitaire Vaudois (CHUV), CH1011 Lausanne, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Josip Mikulic</span> - <span class="hlFld-Affiliation affiliation">Transplantation
Center and Transplantation Immunopathology Laboratory, Department
of Medicine, Centre Hospitalier Universitaire
Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dela Golshayan</span> - <span class="hlFld-Affiliation affiliation">Transplantation
Center and Transplantation Immunopathology Laboratory, Department
of Medicine, Centre Hospitalier Universitaire
Vaudois (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05750" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05750" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Lucienne Juillerat-Jeanneret</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=BIO-d7e3463-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Lucienne Juillerat-Jeanneret</b> obtained her Ph.D. from the University of Geneva, Switzerland. After postdoctoral experiences at the University of Geneva and the University Hospital of Lausanne (CHUV-UNIL), she joined the University Institute of Pathology of Lausanne as a tenured senior lecturer and a teacher at the University of Lausanne (UNIL) and the Swiss Federal Institute of Technology of Lausanne (EPFL). Her main research interests are focused at the interface between biomedicine, chemistry. and biomaterials to design and develop innovative devices or modified drugs to deliver therapeutics as well as therapeutics repurposing. She is also involved in the development of novel approaches for diagnosis and tissue engineering. The strategies investigated include nanotherapeutics and the design and evaluation of targeted chemotherapeutics for the treatment of cancer and degenerative diseases.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="19" class="article__inlineFigure"><h2 class="fig-label">John-David Aubert</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=BIO-d7e3468-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>John-David Aubert</b> graduated from the Faculty of Biology and Medicine of the University of Lausanne (UNIL), Switzerland, and specialized in internal and respiratory medicine, first in Lausanne University Hospital then in UBC Research Laboratory in Vancouver (Prof. J. C. Hogg) as a postdoctoral assistant. Back in Lausanne in 1993, he was involved in the creation of the new lung transplantation program, being presently its medical director and associate professor. He is also leading the pulmonary hypertension clinic and has been president of the Swiss Society for Pulmonary Hypertension. He has been appointed president of the Research Committee of the Swiss Lung League for 2016â2018. His main research interests focus on chronic allograft dysfunction after lung transplantation and clinical aspects of pulmonary hypertension.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Josip Mikulic</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=BIO-d7e3473-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Josip Mikulic</b> graduated from the Faculty of Biology and Medicine of the University of Lausanne (UNIL), Switzerland, obtaining his Masters in Molecular Life Science. He received his Ph.D. from the University of Lausanne in the field of mucosal immunology. He currently works as a research assistant at the Transplantation Center of the University Hospital of Lausanne (CHUV-UNIL) in the Transplantation Immunopathology Laboratory. His research is focusing on the identification of T and B cells signatures associated with graft rejection and outcome after kidney transplantation.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Dela Golshayan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=BIO-d7e3478-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>DÃ©la Golshayan</b> graduated from the Faculty of Biology and Medicine of the University of Lausanne (UNIL), Switzerland, and trained as a specialist clinician in Internal Medicine and Nephrology. She received her MD degree from UNIL and her Ph.D. from Imperial College of London, UK, in the field of transplantation immunology. She currently works as an associate physician at the Transplantation Center and the Division of Nephrology of the University Hospital of Lausanne (CHUV-UNIL) and as head of the Transplantation Immunopathology Laboratory. Her research interests are focusing on immune-mediated diseases, in particular in the field of nephrology and transplantation.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACC</td><td class="NLM_def"><p class="first last">acetyl-CoA carboxylase</p></td></tr><tr><td class="NLM_term">ACE(I)</td><td class="NLM_def"><p class="first last">angiotensin converting enzyme (inhibitor)</p></td></tr><tr><td class="NLM_term">ADAM</td><td class="NLM_def"><p class="first last">a-disintegrin-and-metalloproteinase</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">adenosine receptor</p></td></tr><tr><td class="NLM_term">Ang</td><td class="NLM_def"><p class="first last">angiotensin</p></td></tr><tr><td class="NLM_term">AT<sub>1/2</sub>R</td><td class="NLM_def"><p class="first last">angiotensin receptor 1/2</p></td></tr><tr><td class="NLM_term">ATX</td><td class="NLM_def"><p class="first last">autotaxin</p></td></tr><tr><td class="NLM_term">BMP</td><td class="NLM_def"><p class="first last">bone morphogenic protein</p></td></tr><tr><td class="NLM_term">CAF</td><td class="NLM_def"><p class="first last">cancer-associated fibroblast</p></td></tr><tr><td class="NLM_term">CC/CXC (R/L)</td><td class="NLM_def"><p class="first last">CâC/CâXâC motif chemokine (receptor/ligand)</p></td></tr><tr><td class="NLM_term">COX</td><td class="NLM_def"><p class="first last">cyclooxygenase</p></td></tr><tr><td class="NLM_term">CTGF</td><td class="NLM_def"><p class="first last">connective tissue growth factor</p></td></tr><tr><td class="NLM_term">DPP IV</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase IV</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">EGF(R)</td><td class="NLM_def"><p class="first last">epidermal growth factor (receptor)</p></td></tr><tr><td class="NLM_term">EMT/EndMT</td><td class="NLM_def"><p class="first last">epithelial/endothelial-to-mesenchymal transdifferentiation</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular regulated kinase</p></td></tr><tr><td class="NLM_term">ET</td><td class="NLM_def"><p class="first last">endothelin</p></td></tr><tr><td class="NLM_term">ET<sub>A/B</sub></td><td class="NLM_def"><p class="first last">endothelin receptor A/B</p></td></tr><tr><td class="NLM_term">FAP-Î±</td><td class="NLM_def"><p class="first last">fibroblast activation protein-Î±</p></td></tr><tr><td class="NLM_term">FGF</td><td class="NLM_def"><p class="first last">fibroblast growth factor</p></td></tr><tr><td class="NLM_term">FXR</td><td class="NLM_def"><p class="first last">farnesoid X receptor</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein coupled receptor</p></td></tr><tr><td class="NLM_term">HGF</td><td class="NLM_def"><p class="first last">hepatocyte growth factor</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">IGF</td><td class="NLM_def"><p class="first last">insulin (like) growth factor, interleukin</p></td></tr><tr><td class="NLM_term">JAK/STAT</td><td class="NLM_def"><p class="first last">Janus kinase/signal transducers and activators of transcription</p></td></tr><tr><td class="NLM_term">JNK</td><td class="NLM_def"><p class="first last">C-Jun NH<sub>2</sub>-terminal kinase</p></td></tr><tr><td class="NLM_term">LOX(L)</td><td class="NLM_def"><p class="first last">lysyl(like)oxidase</p></td></tr><tr><td class="NLM_term">LPA(R)</td><td class="NLM_def"><p class="first last">lysophosphatidic acid (receptor)</p></td></tr><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">matrix metalloproteinase</p></td></tr><tr><td class="NLM_term">MSC</td><td class="NLM_def"><p class="first last">mesenchymal stem cells</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">NAFLD/NASH</td><td class="NLM_def"><p class="first last">nonalcoholic fatty liver disease/nonalcoholic steatohepatitis</p></td></tr><tr><td class="NLM_term">NFÎºB</td><td class="NLM_def"><p class="first last">nuclear factor ÎºB</p></td></tr><tr><td class="NLM_term">NOX</td><td class="NLM_def"><p class="first last">NADPH oxidase</p></td></tr><tr><td class="NLM_term">IPF</td><td class="NLM_def"><p class="first last">idiopathic pulmonary fibrosis</p></td></tr><tr><td class="NLM_term">PDGF</td><td class="NLM_def"><p class="first last">platelet-derived growth factor (receptor)</p></td></tr><tr><td class="NLM_term">PDE</td><td class="NLM_def"><p class="first last">phosphodiesterase</p></td></tr><tr><td class="NLM_term">POP/PREP</td><td class="NLM_def"><p class="first last">prolyl-oligopeptidase</p></td></tr><tr><td class="NLM_term">PPAR</td><td class="NLM_def"><p class="first last">peroxisome proliferator activated receptor</p></td></tr><tr><td class="NLM_term">RAS</td><td class="NLM_def"><p class="first last">renin angiotensin (aldosterone) system</p></td></tr><tr><td class="NLM_term">ROCK</td><td class="NLM_def"><p class="first last">Rho-associated protein kinase</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">S1P(R)</td><td class="NLM_def"><p class="first last">sphingosine-1-phosphate (receptor)</p></td></tr><tr><td class="NLM_term">SK</td><td class="NLM_def"><p class="first last">sphingosine kinase</p></td></tr><tr><td class="NLM_term">Î±-SMA</td><td class="NLM_def"><p class="first last">Î±-smooth muscle actin</p></td></tr><tr><td class="NLM_term">Ssc</td><td class="NLM_def"><p class="first last">systemic scleroderma/sclerosis</p></td></tr><tr><td class="NLM_term">TGF-Î²(R)</td><td class="NLM_def"><p class="first last">transforming growth factor-beta (receptor)</p></td></tr><tr><td class="NLM_term">TNF-Î±</td><td class="NLM_def"><p class="first last">tumor necrosis factor-Î±</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32706" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32706" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 196 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jun, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, L. F.</span></span> <span> </span><span class="NLM_article-title">Resolution of organ fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">97</span>â <span class="NLM_lpage">107</span>, <span class="refDoi">Â DOI: 10.1172/JCI93563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29293097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzms1OitQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=97-107&author=J.+I.+Junauthor=L.+F.+Lau&title=Resolution+of+organ+fibrosis&doi=10.1172%2FJCI93563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Resolution of organ fibrosis</span></div><div class="casAuthors">Jun Joon-Il; Lau Lester F</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-107</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fibrosis is the excessive accumulation of extracellular matrix that often occurs as a wound healing response to repeated or chronic tissue injury, and may lead to the disruption of organ architecture and loss of function.  Although fibrosis was previously thought to be irreversible, recent evidence indicates that certain circumstances permit the resolution of fibrosis when the underlying causes of injury are eradicated.  The mechanism of fibrosis resolution encompasses degradation of the fibrotic extracellular matrix as well as elimination of fibrogenic myofibroblasts through their adaptation of various cell fates, including apoptosis, senescence, dedifferentiation, and reprogramming.  In this Review, we discuss the present knowledge and gaps in our understanding of how matrix degradation is regulated and how myofibroblast cell fates can be manipulated, areas that may identify potential therapeutic approaches for fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTs93SFSBVYoK91pGlMMoT5fW6udTcc2eYFGmYv2yGGYLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzms1OitQ%253D%253D&md5=6334bc508b9ac4c632e9ba99bed851c9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1172%2FJCI93563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93563%26sid%3Dliteratum%253Aachs%26aulast%3DJun%26aufirst%3DJ.%2BI.%26aulast%3DLau%26aufirst%3DL.%2BF.%26atitle%3DResolution%2520of%2520organ%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D97%26epage%3D107%26doi%3D10.1172%2FJCI93563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span> <span> </span><span class="NLM_article-title">Extracellular matrix as a driver of progressive fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">45</span>â <span class="NLM_lpage">53</span>, <span class="refDoi">Â DOI: 10.1172/JCI93557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93557" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=45-53&author=J.+Herreraauthor=C.+A.+Henkeauthor=P.+B.+Bitterman&title=Extracellular+matrix+as+a+driver+of+progressive+fibrosis&doi=10.1172%2FJCI93557"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1172%2FJCI93557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93557%26sid%3Dliteratum%253Aachs%26aulast%3DHerrera%26aufirst%3DJ.%26aulast%3DHenke%26aufirst%3DC.%2BA.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26atitle%3DExtracellular%2520matrix%2520as%2520a%2520driver%2520of%2520progressive%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D45%26epage%3D53%26doi%3D10.1172%2FJCI93557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karsdal, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sand, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henriksen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bay-Jensen, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamkewicz, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeming, D. J.</span></span> <span> </span><span class="NLM_article-title">Extracellular remodeling: the common denominator in connective tissue diseases</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">70</span>â <span class="NLM_lpage">92</span>, <span class="refDoi">Â DOI: 10.1089/adt.2012.474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1089%2Fadt.2012.474" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=70-92&author=M.+A.+Karsdalauthor=M.+J.+Nielsenauthor=J.+N.+Sandauthor=K.+Henriksenauthor=F.+Genoveseauthor=A.+C.+Bay-Jensenauthor=V.+Smithauthor=J.+I.+Adamkewiczauthor=C.+Christiansenauthor=D.+J.+Leeming&title=Extracellular+remodeling%3A+the+common+denominator+in+connective+tissue+diseases&doi=10.1089%2Fadt.2012.474"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1089%2Fadt.2012.474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2012.474%26sid%3Dliteratum%253Aachs%26aulast%3DKarsdal%26aufirst%3DM.%2BA.%26aulast%3DNielsen%26aufirst%3DM.%2BJ.%26aulast%3DSand%26aufirst%3DJ.%2BN.%26aulast%3DHenriksen%26aufirst%3DK.%26aulast%3DGenovese%26aufirst%3DF.%26aulast%3DBay-Jensen%26aufirst%3DA.%2BC.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DAdamkewicz%26aufirst%3DJ.%2BI.%26aulast%3DChristiansen%26aufirst%3DC.%26aulast%3DLeeming%26aufirst%3DD.%2BJ.%26atitle%3DExtracellular%2520remodeling%253A%2520the%2520common%2520denominator%2520in%2520connective%2520tissue%2520diseases%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2013%26volume%3D11%26spage%3D70%26epage%3D92%26doi%3D10.1089%2Fadt.2012.474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tschumperlin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilscher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, V. H.</span></span> <span> </span><span class="NLM_article-title">Mechanosensing and fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">74</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1172/JCI93561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93561" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=74-84&author=D.+J.+Tschumperlinauthor=G.+Ligrestiauthor=M.+B.+Hilscherauthor=V.+H.+Shah&title=Mechanosensing+and+fibrosis&doi=10.1172%2FJCI93561"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1172%2FJCI93561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93561%26sid%3Dliteratum%253Aachs%26aulast%3DTschumperlin%26aufirst%3DD.%2BJ.%26aulast%3DLigresti%26aufirst%3DG.%26aulast%3DHilscher%26aufirst%3DM.%2BB.%26aulast%3DShah%26aufirst%3DV.%2BH.%26atitle%3DMechanosensing%2520and%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D74%26epage%3D84%26doi%3D10.1172%2FJCI93561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, T. A.</span></span> <span> </span><span class="NLM_article-title">Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">524</span>â <span class="NLM_lpage">529</span>, <span class="refDoi">Â DOI: 10.1172/JCI31487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI31487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17332879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12hsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=524-529&author=T.+A.+Wynn&title=Common+and+unique+mechanisms+regulate+fibrosis+in+various+fibroproliferative+diseases&doi=10.1172%2FJCI31487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases</span></div><div class="casAuthors">Wynn, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">524-529</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Fibroproliferative diseases, including the pulmonary fibroses, systemic sclerosis, liver cirrhosis, cardiovascular disease, progressive kidney disease, and macular degeneration, are a leading cause of morbidity and mortality and can affect all tissues and organ systems.  Fibrotic tissue remodeling can also influence cancer metastasis and accelerate chronic graft rejection in transplant recipients.  Nevertheless, despite its enormous impact on human health, there are currently no approved treatments that directly target the mechanism(s) of fibrosis.  The primary goals of this Review series on fibrotic diseases are to discuss some of the major fibroproliferative diseases and to identify the common and unique mechanisms of fibrogenesis that might be exploited in the development of effective antifibrotic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiqNOvOKpFz7Vg90H21EOLACvtfcHk0ligTbJwRILd0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12hsbY%253D&md5=405b7386fce6872b460943303b7d8b3c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1172%2FJCI31487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI31487%26sid%3Dliteratum%253Aachs%26aulast%3DWynn%26aufirst%3DT.%2BA.%26atitle%3DCommon%2520and%2520unique%2520mechanisms%2520regulate%2520fibrosis%2520in%2520various%2520fibroproliferative%2520diseases%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D524%26epage%3D529%26doi%3D10.1172%2FJCI31487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span> <span> </span><span class="NLM_article-title">Drugs and targets in fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">855</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29218009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFems77P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=855&author=X.+Liauthor=L.+Zhuauthor=B.+Wangauthor=M.+Yuanauthor=R.+Zhu&title=Drugs+and+targets+in+fibrosis&doi=10.3389%2Ffphar.2017.00855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs and targets in fibrosis</span></div><div class="casAuthors">Li, Xiaoyi; Zhu, Lixin; Wang, Beibei; Yuan, Meifei; Zhu, Ruixin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">855/1-855/21</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Fibrosis contributes to the development of many diseases and many target mols. are involved in fibrosis.  Currently, the majority of fibrosis treatment strategies are limited to specific diseases or organs.  However, accumulating evidence demonstrates great similarities among fibroproliferative diseases, and more and more drugs are proved to be effective anti-fibrotic therapies across different diseases and organs.  Here we comprehensively review the current knowledge on the pathol. mechanisms of fibrosis, and divide factors mediating fibrosis progression into extracellular and intracellular groups.  Furthermore, we systematically summarize both single and multiple component drugs that target fibrosis.  Future directions of fibrosis drug discovery are also proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYWFKoJKIMZ7Vg90H21EOLACvtfcHk0likRMzFS3NJsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFems77P&md5=ce450251ad612e940967fde259549692</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00855%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DR.%26atitle%3DDrugs%2520and%2520targets%2520in%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D855%26doi%3D10.3389%2Ffphar.2017.00855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feghali-Bostwick, C. A.</span></span> <span> </span><span class="NLM_article-title">Fibroblasts in fibrosis: novel roles and mediators</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">123</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24904424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvFKlsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=123&author=R.+T.+Kendallauthor=C.+A.+Feghali-Bostwick&title=Fibroblasts+in+fibrosis%3A+novel+roles+and+mediators&doi=10.3389%2Ffphar.2014.00123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblasts in fibrosis: novel roles and mediators</span></div><div class="casAuthors">Kendall Ryan T; Feghali-Bostwick Carol A</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Fibroblasts are the most common cell type of the connective tissues found throughout the body and the principal source of the extensive extracellular matrix (ECM) characteristic of these tissues.  They are also the central mediators of the pathological fibrotic accumulation of ECM and the cellular proliferation and differentiation that occurs in response to prolonged tissue injury and chronic inflammation.  The transformation of the fibroblast cell lineage involves classical developmental signaling programs and includes a surprisingly diverse range of precursor cell types-most notably, myofibroblasts that are the apex of the fibrotic phenotype.  Myofibroblasts display exaggerated ECM production; constitutively secrete and are hypersensitive to chemical signals such as cytokines, chemokines, and growth factors; and are endowed with a contractile apparatus allowing them to manipulate the ECM fibers physically to close open wounds.  In addition to ECM production, fibroblasts have multiple concomitant biological roles, such as in wound healing, inflammation, and angiogenesis, which are each interwoven with the process of fibrosis.  We now recognize many common fibroblast-related features across various physiological and pathological protracted processes.  Indeed, a new appreciation has emerged for the role of non-cancerous fibroblast interactions with tumors in cancer progression.  Although the predominant current clinical treatments of fibrosis involve non-specific immunosuppressive and anti-proliferative drugs, a variety of potential therapies under investigation specifically target fibroblast biology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCTjHiOSmRmvEeosoOnpOLfW6udTcc2eayxtVCWmE_Vbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvFKlsQ%253D%253D&md5=f4342f5b9eac9e0882255b07162a34a4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00123%26sid%3Dliteratum%253Aachs%26aulast%3DKendall%26aufirst%3DR.%2BT.%26aulast%3DFeghali-Bostwick%26aufirst%3DC.%2BA.%26atitle%3DFibroblasts%2520in%2520fibrosis%253A%2520novel%2520roles%2520and%2520mediators%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D123%26doi%3D10.3389%2Ffphar.2014.00123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gauldie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonniaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sime, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ask, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, M.</span></span> <span> </span><span class="NLM_article-title">TGF-Î², Smad3 and the process of progressive fibrosis</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">661</span>â <span class="NLM_lpage">664</span>, <span class="refDoi">Â DOI: 10.1042/BST0350661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1042%2FBST0350661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17635115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKmt7zO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=661-664&author=J.+Gauldieauthor=P.+Bonniaudauthor=P.+Simeauthor=K.+Askauthor=M.+Kolb&title=TGF-%CE%B2%2C+Smad3+and+the+process+of+progressive+fibrosis&doi=10.1042%2FBST0350661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">TGF-Î², Smad3 and the process of progressive fibrosis</span></div><div class="casAuthors">Gauldie, J.; Bonniaud, P.; Sime, P.; Ask, K.; Kolb, M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">661-664</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Transient adenovirus-mediated gene transfer of active TGF-Î²1 (transforming growth factor-Î²1) induces severe and progressive fibrosis in rodent lung without apparent inflammation.  Alternatively, transfer of IL-1Î² (interleukin 1Î²) induces marked tissue injury and inflammation, which develops into progressive fibrosis, assocd. with an increase in TGF-Î²1 concns. in lung fluid and tissue.  Both vector treatments induce a fibrotic response involving myofibroblasts and progressive matrix deposition starting at the peri-bronchial site of expression and extending over days to involve the entire lung and pleural surface.  Administration of the TGF-Î²1 vector to the pleural space induces progressive pleural fibrosis, which minimally extends into the lung parenchyma.  The mechanisms involved in progressive fibrosis need to account for the limitation of fibrosis to specific organs (lung fibrosis and not liver fibrosis or vice versa) and the lack of effect of anti-inflammatory treatments in regulating progressive fibrosis.  TGF-Î²1 is a key cytokine in the process of fibrogenesis, using intracellular signalling pathways involving the ALK5 receptor and signalling mols. Smad2 and Smad3.  Transient gene transfer of either TGF-Î²1 or IL-1Î² to Smad3-null mouse lung provides little evidence of progressive fibrosis and no fibrogenesis-assocd. genes are induced.  These results suggest that mechanisms of progressive fibrosis involve factors presented within the context of the matrix that define the microenvironment for progressive matrix deposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuRnVzkD7GVLVg90H21EOLACvtfcHk0likRMzFS3NJsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKmt7zO&md5=ca63dcb951042df2e2c5d73d0d12c6b8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1042%2FBST0350661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0350661%26sid%3Dliteratum%253Aachs%26aulast%3DGauldie%26aufirst%3DJ.%26aulast%3DBonniaud%26aufirst%3DP.%26aulast%3DSime%26aufirst%3DP.%26aulast%3DAsk%26aufirst%3DK.%26aulast%3DKolb%26aufirst%3DM.%26atitle%3DTGF-%25CE%25B2%252C%2520Smad3%2520and%2520the%2520process%2520of%2520progressive%2520fibrosis%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2007%26volume%3D35%26spage%3D661%26epage%3D664%26doi%3D10.1042%2FBST0350661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rockey, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. A.</span></span> <span> </span><span class="NLM_article-title">Fibrosis - a common pathway of organ injury and failure</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1138</span>â <span class="NLM_lpage">1149</span>, <span class="refDoi">Â DOI: 10.1056/NEJMra1300575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1056%2FNEJMra1300575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25785971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVaku7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1138-1149&author=D.+C.+Rockeyauthor=P.+D.+Bellauthor=J.+A.+Hill&title=Fibrosis+-+a+common+pathway+of+organ+injury+and+failure&doi=10.1056%2FNEJMra1300575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Fibrosis - a common pathway to organ injury and failure</span></div><div class="casAuthors">Rockey, Don C.; Bell, P. Darwin; Hill, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1138-1149</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  This article describes the cellular and mol. aspects of fibrosis, in lieu of cellular dysfunction and various organ failure and avail pharmacol. therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwApriu_6jarVg90H21EOLACvtfcHk0ljjySxvmsqxgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVaku7o%253D&md5=676a2ea78a319160d668fc882f5fd7c0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1300575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1300575%26sid%3Dliteratum%253Aachs%26aulast%3DRockey%26aufirst%3DD.%2BC.%26aulast%3DBell%26aufirst%3DP.%2BD.%26aulast%3DHill%26aufirst%3DJ.%2BA.%26atitle%3DFibrosis%2520-%2520a%2520common%2520pathway%2520of%2520organ%2520injury%2520and%2520failure%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1138%26epage%3D1149%26doi%3D10.1056%2FNEJMra1300575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiRocco, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, B. D.</span></span> <span> </span><span class="NLM_article-title">Understanding the origin, activation and regulation of matrix-producing myofibroblasts for the treatment of fibrotic diseases</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">273</span>â <span class="NLM_lpage">289</span>, <span class="refDoi">Â DOI: 10.1002/path.4253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1002%2Fpath.4253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24006178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1WntLjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2013&pages=273-289&author=R.+Kramannauthor=D.+P.+DiRoccoauthor=B.+D.+Humphreys&title=Understanding+the+origin%2C+activation+and+regulation+of+matrix-producing+myofibroblasts+for+the+treatment+of+fibrotic+diseases&doi=10.1002%2Fpath.4253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease</span></div><div class="casAuthors">Kramann, Rafael; Di Rocco, Derek P.; Humphreys, Benjamin D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-289</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Fibrosis and scar formation results from chronic progressive injury in virtually every tissue and affects a growing no. of people around the world.  Myofibroblasts drive fibrosis, and recent work has demonstrated that mesenchymal cells, including pericytes and perivascular fibroblasts, are their main progenitors.  Understanding the cellular mechanisms of pericyte/fibroblast-to-myofibroblast transition, myofibroblast proliferation and the key signalling pathways that regulate these processes is essential to develop novel targeted therapeutics for the growing patient population suffering from solid organ fibrosis.  In this review, we summarize the current knowledge about different progenitor cells of myofibroblasts, discuss major pathways that regulate their transdifferentiation and discuss the current status of novel targeted anti-fibrotic therapeutics in development.  Copyright Â© 2013 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAAWbN_PK94rVg90H21EOLACvtfcHk0ljjySxvmsqxgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1WntLjN&md5=7e37d84ada44e021c13c0c07165f85ed</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fpath.4253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4253%26sid%3Dliteratum%253Aachs%26aulast%3DKramann%26aufirst%3DR.%26aulast%3DDiRocco%26aufirst%3DD.%2BP.%26aulast%3DHumphreys%26aufirst%3DB.%2BD.%26atitle%3DUnderstanding%2520the%2520origin%252C%2520activation%2520and%2520regulation%2520of%2520matrix-producing%2520myofibroblasts%2520for%2520the%2520treatment%2520of%2520fibrotic%2520diseases%26jtitle%3DJ.%2520Pathol.%26date%3D2013%26volume%3D231%26spage%3D273%26epage%3D289%26doi%3D10.1002%2Fpath.4253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilkoff, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, E. L.</span></span> <span> </span><span class="NLM_article-title">Fibrocytes: emerging effector cells in chronic inflammation</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">427</span>â <span class="NLM_lpage">435</span>, <span class="refDoi">Â DOI: 10.1038/nri2990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnri2990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=21597472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlemtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=427-435&author=R.+A.+Reilkoffauthor=R.+Bucalaauthor=E.+L.+Herzog&title=Fibrocytes%3A+emerging+effector+cells+in+chronic+inflammation&doi=10.1038%2Fnri2990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fibrocytes: emerging effector cells in chronic inflammation</span></div><div class="casAuthors">Reilkoff, Ronald A.; Bucala, Richard; Herzog, Erica L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">427-435</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibrocytes are mesenchymal cells that arise from monocyte precursors.  They are present in injured organs and have both the inflammatory features of macrophages and the tissue remodelling properties of fibroblasts.  Chronic inflammatory stimuli mediate the differentiation, trafficking and accumulation of these cells in fibrosing conditions assocd. with autoimmunity, cardiovascular disease and asthma.  This Opinion article discusses the immunol. mediators controlling fibrocyte differentiation and recruitment, describes the assocn. of fibrocytes with chronic inflammatory diseases and compares the potential roles of fibrocytes in these disorders with those of macrophages and fibroblasts.  It is hoped that this information prompts new opportunities for the study of these unique cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8QY-QSZ6KlrVg90H21EOLACvtfcHk0lhRKFZWw82IzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlemtLk%253D&md5=ce88c26e651b94212982b09401a1a3f6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnri2990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2990%26sid%3Dliteratum%253Aachs%26aulast%3DReilkoff%26aufirst%3DR.%2BA.%26aulast%3DBucala%26aufirst%3DR.%26aulast%3DHerzog%26aufirst%3DE.%2BL.%26atitle%3DFibrocytes%253A%2520emerging%2520effector%2520cells%2520in%2520chronic%2520inflammation%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2011%26volume%3D11%26spage%3D427%26epage%3D435%26doi%3D10.1038%2Fnri2990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Carlo, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peduto, L.</span></span> <span> </span><span class="NLM_article-title">The perivascular origin of pathological fibroblasts</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">54</span>â <span class="NLM_lpage">63</span>, <span class="refDoi">Â DOI: 10.1172/JCI93558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93558" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=54-63&author=S.+E.+Di%0ACarloauthor=L.+Peduto&title=The+perivascular+origin+of+pathological+fibroblasts&doi=10.1172%2FJCI93558"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1172%2FJCI93558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93558%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BCarlo%26aufirst%3DS.%2BE.%26aulast%3DPeduto%26aufirst%3DL.%26atitle%3DThe%2520perivascular%2520origin%2520of%2520pathological%2520fibroblasts%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D54%26epage%3D63%26doi%3D10.1172%2FJCI93558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, F. M.</span></span> <span> </span><span class="NLM_article-title">Fibroblast heterogeneity: implications for human disease</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">26</span>â <span class="NLM_lpage">35</span>, <span class="refDoi">Â DOI: 10.1172/JCI93555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93555" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=26-35&author=M.+D.+Lynchauthor=F.+M.+Watt&title=Fibroblast+heterogeneity%3A+implications+for+human+disease&doi=10.1172%2FJCI93555"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1172%2FJCI93555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93555%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DM.%2BD.%26aulast%3DWatt%26aufirst%3DF.%2BM.%26atitle%3DFibroblast%2520heterogeneity%253A%2520implications%2520for%2520human%2520disease%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D26%26epage%3D35%26doi%3D10.1172%2FJCI93555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heywood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tourkina, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visconti, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S.</span></span> <span> </span><span class="NLM_article-title">Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">141</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24999331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cbgtFSqtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=141&author=C.+Reeseauthor=R.+Leeauthor=M.+Bonnerauthor=B.+Perryauthor=J.+Heywoodauthor=R.+M.+Silverauthor=R.+P.+Tourkinaauthor=R.+P.+Viscontiauthor=S.+Hoffman&title=Fibrocytes+in+the+fibrotic+lung%3A+altered+phenotype+detected+by+flow+cytometry&doi=10.3389%2Ffphar.2014.00141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry</span></div><div class="casAuthors">Reese Charles; Lee Rebecca; Bonner Michael; Perry Beth; Heywood Jonathan; Silver Richard M; Tourkina Elena; Hoffman Stanley; Visconti Richard P</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">141</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Fibrocytes are bone marrow hematopoietic-derived cells that also express a mesenchymal cell marker (commonly collagen I) and participate in fibrotic diseases of multiple organs.  Given their origin, they or their precursors must be circulating cells before recruitment into target tissues.  While most previous studies focused on circulating fibrocytes, here we focus on the fibrocyte phenotype in fibrotic tissue.  The study's relevance to human disease is heightened by use of a model in which bleomycin is delivered systemically, recapitulating several features of human scleroderma including multi-organ fibrosis not observed when bleomycin is delivered directly into the lungs.  Using flow cytometry, we find in the fibrotic lung a large population of CD45(high) fibrocytes (called Region I) rarely found in vehicle-treated control mice.  A second population of CD45+ fibrocytes (called Region II) is observed in both control and fibrotic lung.  The level of CD45 in circulating fibrocytes is far lower than in either Region I or II lung fibrocytes.  The chemokine receptors CXCR4 and CCR5 are expressed at higher levels in Region I than in Region II and are present at very low levels in all other lung cells including CD45+/collagen I- leucocytes.  The collagen chaperone HSP47 is present at similar high levels in both Regions I and II, but at a higher level in fibrotic lung than in control lung.  There is also a major population of HSP47(high)/CD45- cells in fibrotic lung not present in control lung.  CD44 is present at higher levels in Region I than in Region II and at much lower levels in all other cells including CD45+/collagen I- leucocytes.  When lung fibrosis is inhibited by restoring caveolin-1 activity using a caveolin-1 scaffolding domain peptide (CSD), a strong correlation is observed between fibrocyte number and fibrosis score.  In summary, the distinctive phenotype of fibrotic lung fibrocytes suggests that fibrocyte differentiation occurs primarily within the target organ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQ619baX0m4r9KldV63DuefW6udTcc2eYvXPkDEC3wsrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbgtFSqtg%253D%253D&md5=d87dbf8e62bbc8e0abd30a1b39873ded</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00141%26sid%3Dliteratum%253Aachs%26aulast%3DReese%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DBonner%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DB.%26aulast%3DHeywood%26aufirst%3DJ.%26aulast%3DSilver%26aufirst%3DR.%2BM.%26aulast%3DTourkina%26aufirst%3DR.%2BP.%26aulast%3DVisconti%26aufirst%3DR.%2BP.%26aulast%3DHoffman%26aufirst%3DS.%26atitle%3DFibrocytes%2520in%2520the%2520fibrotic%2520lung%253A%2520altered%2520phenotype%2520detected%2520by%2520flow%2520cytometry%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D141%26doi%3D10.3389%2Ffphar.2014.00141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Habiel, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogaboam, C.</span></span> <span> </span><span class="NLM_article-title">Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24478703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsF2nuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=2&author=D.+M.+Habielauthor=C.+Hogaboam&title=Heterogeneity+in+fibroblast+proliferation+and+survival+in+idiopathic+pulmonary+fibrosis&doi=10.3389%2Ffphar.2014.00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Habiel David M; Hogaboam Cory</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease characterized by the persistence of activated myofibroblasts resulting in excessive deposition of extracellular matrix proteins and profound tissue remodeling.  Myofibroblasts have been shown to arise from interstitial fibroblasts, epithelial to mesenchymal transition of type II alveolar epithelial cells, and the differentiation of recruited fibrocytes.  There are many mechanisms that are utilized by these cells for survival, proliferation, and persistent activation including up-regulation of cytokines [i.e., Interleukin 6 (IL-6) and C-C motif chemokine ligand 21 (CCL21)], cytokine receptors [i.e., Interleukin 6Receptor 1 (IL-6R1), Glycoprotein 130 (gp130) and C-C Chemokine Receptor type 7 (CCR7)], and innate pattern recognition receptors [(PRRs; i.e., Toll Like Receptor 9 (TLR9)].  In this review, we will discuss the role of the cytokines IL-6 and CCL21, their receptors and the PRR, TLR9, in fibroblast recruitment, activation, survival, and differentiation into myofibroblasts in IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAiCiGNKbA0NLIORRPd5lbfW6udTcc2eYvXPkDEC3wsrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsF2nuw%253D%253D&md5=358e8b6635a462016df931d6ea2bd0c1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00002%26sid%3Dliteratum%253Aachs%26aulast%3DHabiel%26aufirst%3DD.%2BM.%26aulast%3DHogaboam%26aufirst%3DC.%26atitle%3DHeterogeneity%2520in%2520fibroblast%2520proliferation%2520and%2520survival%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D2%26doi%3D10.3389%2Ffphar.2014.00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rinkevich, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maan, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drukker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Januszyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krampitz, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurtner, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longaker, M. T.</span></span> <span> </span><span class="NLM_article-title">Identification and isolation of a dermal lineage with intrinsic fibrogenic potential</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">aaa2151</span>, <span class="refDoi">Â DOI: 10.1126/science.aaa2151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1126%2Fscience.aaa2151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25883361" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=aaa2151&author=Y.+Rinkevichauthor=G.+G.+Walmsleyauthor=M.+S.+Huauthor=Z.+N.+Maanauthor=A.+M.+Newmanauthor=M.+Drukkerauthor=M.+Januszykauthor=G.+W.+Krampitzauthor=G.+C.+Gurtnerauthor=H.+P.+Lorenzauthor=I.+L.+Weissmanauthor=M.+T.+Longaker&title=Identification+and+isolation+of+a+dermal+lineage+with+intrinsic+fibrogenic+potential&doi=10.1126%2Fscience.aaa2151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaa2151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaa2151%26sid%3Dliteratum%253Aachs%26aulast%3DRinkevich%26aufirst%3DY.%26aulast%3DWalmsley%26aufirst%3DG.%2BG.%26aulast%3DHu%26aufirst%3DM.%2BS.%26aulast%3DMaan%26aufirst%3DZ.%2BN.%26aulast%3DNewman%26aufirst%3DA.%2BM.%26aulast%3DDrukker%26aufirst%3DM.%26aulast%3DJanuszyk%26aufirst%3DM.%26aulast%3DKrampitz%26aufirst%3DG.%2BW.%26aulast%3DGurtner%26aufirst%3DG.%2BC.%26aulast%3DLorenz%26aufirst%3DH.%2BP.%26aulast%3DWeissman%26aufirst%3DI.%2BL.%26aulast%3DLongaker%26aufirst%3DM.%2BT.%26atitle%3DIdentification%2520and%2520isolation%2520of%2520a%2520dermal%2520lineage%2520with%2520intrinsic%2520fibrogenic%2520potential%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3Daaa2151%26doi%3D10.1126%2Fscience.aaa2151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Driskell, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenberger, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoste, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretzschmar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charalambous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferron, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herault, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlovic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson-Smith, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, F. M.</span></span> <span> </span><span class="NLM_article-title">Distinct fibroblast lineages determine dermal architecture in skin development and repair</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>504</i></span>,  <span class="NLM_fpage">277</span>â <span class="NLM_lpage">281</span>, <span class="refDoi">Â DOI: 10.1038/nature12783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnature12783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24336287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFars7zL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=504&publication_year=2013&pages=277-281&author=R.+R.+Driskellauthor=B.+M.+Lichtenbergerauthor=E.+Hosteauthor=K.+Kretzschmarauthor=B.+D.+Simonsauthor=M.+Charalambousauthor=S.+R.+Ferronauthor=Y.+Heraultauthor=G.+Pavlovicauthor=A.+C.+Ferguson-Smithauthor=F.+M.+Watt&title=Distinct+fibroblast+lineages+determine+dermal+architecture+in+skin+development+and+repair&doi=10.1038%2Fnature12783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct fibroblast lineages determine dermal architecture in skin development and repair</span></div><div class="casAuthors">Driskell, Ryan R.; Lichtenberger, Beate M.; Hoste, Esther; Kretzschmar, Kai; Simons, Ben D.; Charalambous, Marika; Ferron, Sacri R.; Herault, Yann; Pavlovic, Guillaume; Ferguson-Smith, Anne C.; Watt, Fiona M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">504</span>
        (<span class="NLM_cas:issue">7479</span>),
    <span class="NLM_cas:pages">277-281</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Fibroblasts are the major mesenchymal cell type in connective tissue and deposit the collagen and elastic fibers of the extracellular matrix (ECM).  Even within a single tissue, fibroblasts exhibit considerable functional diversity, but it is not known whether this reflects the existence of a differentiation hierarchy or is a response to different environmental factors.  Here we show, using transplantation assays and lineage tracing in mice, that the fibroblasts of skin connective tissue arise from two distinct lineages.  One forms the upper dermis, including the dermal papilla that regulates hair growth and the arrector pili muscle, which controls piloerection.  The other forms the lower dermis, including the reticular fibroblasts that synthesize the bulk of the fibrillar ECM, and the preadipocytes and adipocytes of the hypodermis.  The upper lineage is required for hair follicle formation.  In wounded adult skin, the initial wave of dermal repair is mediated by the lower lineage and upper dermal fibroblasts are recruited only during re-epithelialization.  Epidermal Î²-catenin activation stimulates the expansion of the upper dermal lineage, rendering wounds permissive for hair follicle formation.  Our findings explain why wounding is linked to formation of ECM-rich scar tissue that lacks hair follicles.  They also form a platform for discovering fibroblast lineages in other tissues and for examg. fibroblast changes in ageing and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjaSvqKUhu0rVg90H21EOLACvtfcHk0lgJr8fcu-bh6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFars7zL&md5=9bb443f3349a44966028ac89e32204c9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature12783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12783%26sid%3Dliteratum%253Aachs%26aulast%3DDriskell%26aufirst%3DR.%2BR.%26aulast%3DLichtenberger%26aufirst%3DB.%2BM.%26aulast%3DHoste%26aufirst%3DE.%26aulast%3DKretzschmar%26aufirst%3DK.%26aulast%3DSimons%26aufirst%3DB.%2BD.%26aulast%3DCharalambous%26aufirst%3DM.%26aulast%3DFerron%26aufirst%3DS.%2BR.%26aulast%3DHerault%26aufirst%3DY.%26aulast%3DPavlovic%26aufirst%3DG.%26aulast%3DFerguson-Smith%26aufirst%3DA.%2BC.%26aulast%3DWatt%26aufirst%3DF.%2BM.%26atitle%3DDistinct%2520fibroblast%2520lineages%2520determine%2520dermal%2520architecture%2520in%2520skin%2520development%2520and%2520repair%26jtitle%3DNature%26date%3D2013%26volume%3D504%26spage%3D277%26epage%3D281%26doi%3D10.1038%2Fnature12783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hewitson, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. R.</span></span> <span> </span><span class="NLM_article-title">Progression of tubulointerstitial fibrosis and the chronic kidney disease phenotype- role of risk factors and epigenetics</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">520</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28848437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2nsL3N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=520&author=T.+D.+Hewitsonauthor=S.+G.+Holtauthor=E.+R.+Smith&title=Progression+of+tubulointerstitial+fibrosis+and+the+chronic+kidney+disease+phenotype-+role+of+risk+factors+and+epigenetics&doi=10.3389%2Ffphar.2017.00520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Progression of tubulointerstitial fibrosis and the chronic kidney disease phenotype - role of risk factors and epigenetics</span></div><div class="casAuthors">Hewitson, Timothy D.; Holt, Stephen G.; Smith, Edward R.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">520/1-520/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Although the kidney has capacity to repair after mild injury, ongoing or severe damage results in scarring (fibrosis) and an assocd. progressive loss of kidney function.  However, despite its universal significance, evidence highlights a population based heterogeneity in the trajectory of chronic kidney disease (CKD) in these patients.  To explain the heterogeneity of the CKD phenotype requires an understanding of the relevant risk factors for fibrosis.  These factors include both the extrinsic nature of injury, and intrinsic factors such as age, gender, genetics, and perpetual activation of fibroblasts through priming.  In many cases an addnl. level of regulation is provided by epigenetic mechanisms which integrate the various pro-fibrotic and anti-fibrotic triggers in fibrogenesis.  In this review we therefore examine the various mol. and structural changes of fibrosis, and how they are influenced by extrinsic and intrinsic factors.  Our aim is to provide a unifying hypothesis to help explain the transition from acute to CKD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPa1YhclMiuLVg90H21EOLACvtfcHk0lgJr8fcu-bh6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2nsL3N&md5=1c34dcc38ce96a4c6527c65e25f59c66</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00520%26sid%3Dliteratum%253Aachs%26aulast%3DHewitson%26aufirst%3DT.%2BD.%26aulast%3DHolt%26aufirst%3DS.%2BG.%26aulast%3DSmith%26aufirst%3DE.%2BR.%26atitle%3DProgression%2520of%2520tubulointerstitial%2520fibrosis%2520and%2520the%2520chronic%2520kidney%2520disease%2520phenotype-%2520role%2520of%2520risk%2520factors%2520and%2520epigenetics%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D520%26doi%3D10.3389%2Ffphar.2017.00520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonis, S. T.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24734020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsl2gtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=51&author=M.+L.+Manciniauthor=S.+T.+Sonis&title=Mechanisms+of+cellular+fibrosis+associated+with+cancer+regimen-related+toxicities&doi=10.3389%2Ffphar.2014.00051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities</span></div><div class="casAuthors">Mancini Maria L; Sonis Stephen T</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Fibrosis is a common, persistent and potentially debilitating complication of chemotherapy and radiation regimens used for the treatment of cancer.  The molecular mechanisms underlying fibrosis have been well studied and reveal overall processes that are largely ubiquitous.  However, it is important to note that although the processes are similar, they result in cellular phenotypes that are highly tissue specific.  These tissue specific differences may present opportunities for therapeutic interventions to prevent or treat this often irreversible condition.  Data generated from animal models of cancer therapy-related tissue toxicities have revealed that the signaling pathways involved in fibrosis are the same as those involved in the normal injury response and include the transforming growth factor Î² superfamily and a range of pro-inflammatory cytokines.  The critical difference between normal wound healing and fibrosis development appears to be, that in fibrosis, these signaling pathways escape normal cellular regulation.  As a result, an injury state is maintained and processes involved in normal healing are usurped.  There are a few, if any, therapeutics that effectively prevent or treat fibrosis in patients.  Consequently, cancer survivors may be chronically plagued with a variety of life-altering fibrosis-related symptoms.  Uncovering the signaling pathways that drive cellular fibrosis is paramount to the development of specific therapeutics that will mitigate this potentially devastating condition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYoMsMF_spOi86Js-BCLiifW6udTcc2eapr4FhbQJgIrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsl2gtA%253D%253D&md5=667555e3939a13d23d3d2ae6b3d2286c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00051%26sid%3Dliteratum%253Aachs%26aulast%3DMancini%26aufirst%3DM.%2BL.%26aulast%3DSonis%26aufirst%3DS.%2BT.%26atitle%3DMechanisms%2520of%2520cellular%2520fibrosis%2520associated%2520with%2520cancer%2520regimen-related%2520toxicities%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D51%26doi%3D10.3389%2Ffphar.2014.00051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bataller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, D. A.</span></span> <span> </span><span class="NLM_article-title">Liver fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">209</span>â <span class="NLM_lpage">218</span>, <span class="refDoi">Â DOI: 10.1172/JCI24282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI24282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=15690074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyjs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=209-218&author=R.+Batallerauthor=D.+A.+Brenner&title=Liver+fibrosis&doi=10.1172%2FJCI24282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Liver fibrosis</span></div><div class="casAuthors">Bataller, Ramon; Brenner, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-218</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases.  Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation.  Our knowledge of the cellular and mol. mechanisms of liver fibrosis has greatly advanced.  Activated hepatic stellate cells, portal fibroblasts, and myofibroblasts of bone marrow origin have been identified as major collagen-producing cells in the injured liver.  These cells are activated by fibrogenic cytokines such as TGF-Î²1, angiotensin II, and leptin.  Reversibility of advanced liver fibrosis in patients has been recently documented, which has stimulated researchers to develop antifibrotic drugs.  Emerging antifibrotic therapies are aimed at inhibiting the accumulation of fibrogenic cells and/or preventing the deposition of extracellular matrix proteins.  Although many therapeutic interventions are effective in exptl. models of liver fibrosis, their efficacy and safety in humans is unknown.  This review summarizes recent progress in the study of the pathogenesis and diagnosis of liver fibrosis and discusses current antifibrotic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADNkKCYBJYLVg90H21EOLACvtfcHk0lhU-a0egQK9ZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyjs70%253D&md5=f96b24aca82750b66fc1cb05b4b6216b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1172%2FJCI24282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI24282%26sid%3Dliteratum%253Aachs%26aulast%3DBataller%26aufirst%3DR.%26aulast%3DBrenner%26aufirst%3DD.%2BA.%26atitle%3DLiver%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D209%26epage%3D218%26doi%3D10.1172%2FJCI24282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisseleva, T.</span></span> <span> </span><span class="NLM_article-title">The types of hepatic myelofribroblasts contributing to liver fibrosis of different etiologies</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">167</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25100997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cbpslCrsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=167&author=J.+Xuauthor=X.+Liuauthor=Y.+Koyamaauthor=P.+Wangauthor=T.+Lanauthor=I.+G.+Kimauthor=I.+H.+Kimauthor=H.+Y.+Maauthor=T.+Kisseleva&title=The+types+of+hepatic+myelofribroblasts+contributing+to+liver+fibrosis+of+different+etiologies&doi=10.3389%2Ffphar.2014.00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies</span></div><div class="casAuthors">Xu Jun; Liu Xiao; Koyama Yukinori; Wang Ping; Lan Tian; Kim In-Gyu; Kim In H; Ma Hsiao-Yen; Kisseleva Tatiana</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Liver fibrosis results from dysregulation of normal wound healing, inflammation, activation of myofibroblasts, and deposition of extracellular matrix (ECM).  Chronic liver injury causes death of hepatocytes and formation of apoptotic bodies, which in turn, release factors that recruit inflammatory cells (neutrophils, monocytes, macrophages, and lymphocytes) to the injured liver.  Hepatic macrophages (Kupffer cells) produce TGFÎ²1 and other inflammatory cytokines that activate Collagen Type I producing myofibroblasts, which are not present in the normal liver.  Secretion of TGFÎ²1 and activation of myofibroblasts play a critical role in the pathogenesis of liver fibrosis of different etiologies.  Although the composition of fibrogenic myofibroblasts varies dependent on etiology of liver injury, liver resident hepatic stellate cells and portal fibroblasts are the major source of myofibroblasts in fibrotic liver in both experimental models of liver fibrosis and in patients with liver disease.  Several studies have demonstrated that hepatic fibrosis can reverse upon cessation of liver injury.  Regression of liver fibrosis is accompanied by the disappearance of fibrogenic myofibroblasts followed by resorption of the fibrous scar.  Myofibroblasts either apoptose or inactivate into a quiescent-like state (e.g., stop collagen production and partially restore expression of lipogenic genes).  Resolution of liver fibrosis is associated with recruitment of macrophages that secrete matrix-degrading enzymes (matrix metalloproteinase, collagenases) and are responsible for fibrosis resolution.  However, prolonged/repeated liver injury may cause irreversible crosslinking of ECM and formation of uncleavable collagen fibers.  Advanced fibrosis progresses to cirrhosis and hepatocellular carcinoma.  The current review will summarize the role and contribution of different cell types to populations of fibrogenic myofibroblasts in fibrotic liver.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsz95bn0G8oHELvajU9pjPfW6udTcc2eapr4FhbQJgIrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbpslCrsA%253D%253D&md5=7bb9ff49469844f1887571f746998a75</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00167%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKoyama%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLan%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DI.%2BG.%26aulast%3DKim%26aufirst%3DI.%2BH.%26aulast%3DMa%26aufirst%3DH.%2BY.%26aulast%3DKisseleva%26aufirst%3DT.%26atitle%3DThe%2520types%2520of%2520hepatic%2520myelofribroblasts%2520contributing%2520to%2520liver%2520fibrosis%2520of%2520different%2520etiologies%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D167%26doi%3D10.3389%2Ffphar.2014.00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cordero-Espinoza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huch, M.</span></span> <span> </span><span class="NLM_article-title">The balancing act of the liver: tissue regeneration versus fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">85</span>â <span class="NLM_lpage">96</span>, <span class="refDoi">Â DOI: 10.1172/JCI93562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93562" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=85-96&author=L.+Cordero-Espinozaauthor=M.+Huch&title=The+balancing+act+of+the+liver%3A+tissue+regeneration+versus+fibrosis&doi=10.1172%2FJCI93562"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1172%2FJCI93562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93562%26sid%3Dliteratum%253Aachs%26aulast%3DCordero-Espinoza%26aufirst%3DL.%26aulast%3DHuch%26aufirst%3DM.%26atitle%3DThe%2520balancing%2520act%2520of%2520the%2520liver%253A%2520tissue%2520regeneration%2520versus%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D85%26epage%3D96%26doi%3D10.1172%2FJCI93562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samir, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhyani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halpern, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ©ndez-Navarro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, R. T.</span></span> <span> </span><span class="NLM_article-title">Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement</span>. <i>Radiology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">888</span>â <span class="NLM_lpage">896</span>, <span class="refDoi">Â DOI: 10.1148/radiol.14140839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1148%2Fradiol.14140839" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=2015&pages=888-896&author=A.+E.+Samirauthor=M.+Dhyaniauthor=A.+Vijauthor=A.+K.+Bhanauthor=E.+F.+Halpernauthor=J.+M%C3%A9ndez-Navarroauthor=K.+E.+Coreyauthor=R.+T.+Chung&title=Shear-wave+elastography+for+the+estimation+of+liver+fibrosis+in+chronic+liver+disease%3A+determining+accuracy+and+ideal+site+for+measurement&doi=10.1148%2Fradiol.14140839"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1148%2Fradiol.14140839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1148%252Fradiol.14140839%26sid%3Dliteratum%253Aachs%26aulast%3DSamir%26aufirst%3DA.%2BE.%26aulast%3DDhyani%26aufirst%3DM.%26aulast%3DVij%26aufirst%3DA.%26aulast%3DBhan%26aufirst%3DA.%2BK.%26aulast%3DHalpern%26aufirst%3DE.%2BF.%26aulast%3DM%25C3%25A9ndez-Navarro%26aufirst%3DJ.%26aulast%3DCorey%26aufirst%3DK.%2BE.%26aulast%3DChung%26aufirst%3DR.%2BT.%26atitle%3DShear-wave%2520elastography%2520for%2520the%2520estimation%2520of%2520liver%2520fibrosis%2520in%2520chronic%2520liver%2520disease%253A%2520determining%2520accuracy%2520and%2520ideal%2520site%2520for%2520measurement%26jtitle%3DRadiology%26date%3D2015%26volume%3D274%26spage%3D888%26epage%3D896%26doi%3D10.1148%2Fradiol.14140839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Athyros, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrides, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilianou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholongitas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doumas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganotakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudevenos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elisaf, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germanidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giouleme, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karvounis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsiki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotsis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kountouras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liberopoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitsavos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyzos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rallidis, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsapas, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tselepis, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsioufis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tziomalos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzotzas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasiliadis, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlachopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhailidis, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantzoros, C.</span></span> <span> </span><span class="NLM_article-title">The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement</span>. <i>Metab., Clin. Exp.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">17</span>â <span class="NLM_lpage">32</span>, <span class="refDoi">Â DOI: 10.1016/j.metabol.2017.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.metabol.2017.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28521870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktl2jur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2017&pages=17-32&author=V.+G.+Athyrosauthor=T.+K.+Alexandridesauthor=H.+Bilianouauthor=E.+Cholongitasauthor=M.+Doumasauthor=E.+S.+Ganotakisauthor=J.+Goudevenosauthor=M.+S.+Elisafauthor=G.+Germanidisauthor=O.+Gioulemeauthor=A.+Karagiannisauthor=C.+Karvounisauthor=N.+Katsikiauthor=V.+Kotsisauthor=J.+Kountourasauthor=E.+Liberopoulosauthor=C.+Pitsavosauthor=S.+Polyzosauthor=L.+S.+Rallidisauthor=D.+Richterauthor=A.+G.+Tsapasauthor=A.+D.+Tselepisauthor=K.+Tsioufisauthor=K.+Tziomalosauthor=T.+Tzotzasauthor=T.+G.+Vasiliadisauthor=C.+Vlachopoulosauthor=D.+P.+Mikhailidisauthor=C.+Mantzoros&title=The+use+of+statins+alone%2C+or+in+combination+with+pioglitazone+and+other+drugs%2C+for+the+treatment+of+non-alcoholic+fatty+liver+disease%2Fnon-alcoholic+steatohepatitis+and+related+cardiovascular+risk.+An+expert+panel+statement&doi=10.1016%2Fj.metabol.2017.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement</span></div><div class="casAuthors">Athyros, Vasilios G.; Alexandrides, Theodore K.; Bilianou, Helen; Cholongitas, Evangelos; Doumas, Michael; Ganotakis, Emmanuel S.; Goudevenos, John; Elisaf, Moses S.; Germanidis, Georgios; Giouleme, Olga; Karagiannis, Asterios; Karvounis, Charalambos; Katsiki, Niki; Kotsis, Vasilios; Kountouras, Jannis; Liberopoulos, Evangelos; Pitsavos, Christos; Polyzos, Stergios; Rallidis, Loukianos S.; Richter, Dimitrios; Tsapas, Apostolos G.; Tselepis, Alexandros D.; Tsioufis, Konstantinos; Tziomalos, Konstantinos; Tzotzas, Themistoklis; Vasiliadis, Themistoklis G.; Vlachopoulos, Charalambos; Mikhailidis, Dimitri P.; Mantzoros, Christos</div><div class="citationInfo"><span class="NLM_cas:title">Metabolism, Clinical and Experimental</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-32</span>CODEN:
                <span class="NLM_cas:coden">METAAJ</span>;
        ISSN:<span class="NLM_cas:issn">0026-0495</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Non-alc. fatty liver disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (> 5% of the liver tissue), in the absence of alc. abuse or other chronic liver diseases.  It is closely related to the epidemic of obesity, metabolic syndrome or type 2 diabetes mellitus (T2DM).  NAFLD can cause liver inflammation and progress to non-alc. steatohepatitis (NASH), fibrosis, cirrhosis or hepatocellular cancer (HCC).  Nevertheless, cardiovascular disease (CVD) is the most common cause of death in NAFLD/NASH patients.  Current guidelines suggest the use of pioglitazone both in patients with T2DM and in those without.  The use of statins, though considered safe by the guidelines, have very limited use; only 10% in high CVD risk patients are on statins by tertiary centers in the US.  There are data from several animal studies, 5 post hoc analyses of prospective long-term survival studies, and 5 rather small biopsy proven NASH studies, one at baseline and on at the end of the study.  All these studies provide data for biochem. and histol. improvement of NAFLD/NASH with statins and in the clin. studies large redns. in CVD events in comparison with those also on statins and normal liver.  Ezetimibe was also reported to improve NAFLD.  Drugs currently in clin. trials seem to have potential for slowing down the evolution of NAFLD and for reducing liver- and CVD-related morbidity and mortality, but it will take time before they are ready to be used in everyday clin. practice.  The suggestion of this Expert Panel is that, pending forthcoming randomized clin. trials, physicians should consider using a PPARgamma agonist, such as pioglitazone, or, statin use in those with NAFLD/NASH at high CVD or HCC risk, alone and/or preferably in combination with each other or with ezetimibe, for the primary or secondary prevention of CVD, and the avoidance of cirrhosis, liver transplantation or HCC, bearing in mind that CVD is the main cause of death in NAFLD/NASH patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSr74j-BQ187Vg90H21EOLACvtfcHk0liuCS55K6XmDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktl2jur4%253D&md5=210e5048217d85c04e4e317d0d34dc25</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.metabol.2017.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.metabol.2017.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DAthyros%26aufirst%3DV.%2BG.%26aulast%3DAlexandrides%26aufirst%3DT.%2BK.%26aulast%3DBilianou%26aufirst%3DH.%26aulast%3DCholongitas%26aufirst%3DE.%26aulast%3DDoumas%26aufirst%3DM.%26aulast%3DGanotakis%26aufirst%3DE.%2BS.%26aulast%3DGoudevenos%26aufirst%3DJ.%26aulast%3DElisaf%26aufirst%3DM.%2BS.%26aulast%3DGermanidis%26aufirst%3DG.%26aulast%3DGiouleme%26aufirst%3DO.%26aulast%3DKaragiannis%26aufirst%3DA.%26aulast%3DKarvounis%26aufirst%3DC.%26aulast%3DKatsiki%26aufirst%3DN.%26aulast%3DKotsis%26aufirst%3DV.%26aulast%3DKountouras%26aufirst%3DJ.%26aulast%3DLiberopoulos%26aufirst%3DE.%26aulast%3DPitsavos%26aufirst%3DC.%26aulast%3DPolyzos%26aufirst%3DS.%26aulast%3DRallidis%26aufirst%3DL.%2BS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DTsapas%26aufirst%3DA.%2BG.%26aulast%3DTselepis%26aufirst%3DA.%2BD.%26aulast%3DTsioufis%26aufirst%3DK.%26aulast%3DTziomalos%26aufirst%3DK.%26aulast%3DTzotzas%26aufirst%3DT.%26aulast%3DVasiliadis%26aufirst%3DT.%2BG.%26aulast%3DVlachopoulos%26aufirst%3DC.%26aulast%3DMikhailidis%26aufirst%3DD.%2BP.%26aulast%3DMantzoros%26aufirst%3DC.%26atitle%3DThe%2520use%2520of%2520statins%2520alone%252C%2520or%2520in%2520combination%2520with%2520pioglitazone%2520and%2520other%2520drugs%252C%2520for%2520the%2520treatment%2520of%2520non-alcoholic%2520fatty%2520liver%2520disease%252Fnon-alcoholic%2520steatohepatitis%2520and%2520related%2520cardiovascular%2520risk.%2520An%2520expert%2520panel%2520statement%26jtitle%3DMetab.%252C%2520Clin.%2520Exp.%26date%3D2017%26volume%3D71%26spage%3D17%26epage%3D32%26doi%3D10.1016%2Fj.metabol.2017.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, S.</span></span> <span> </span><span class="NLM_article-title">NASH therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs</span>. <i>Clin. Mol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">103</span>â <span class="NLM_lpage">108</span>, <span class="refDoi">Â DOI: 10.3350/cmh.2017.0103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3350%2Fcmh.2017.0103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28494529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1crmtlWitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=103-108&author=S.+Caldwell&title=NASH+therapy%3A+omega+3+supplementation%2C+vitamin+E%2C+insulin+sensitizers+and+statin+drugs&doi=10.3350%2Fcmh.2017.0103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs</span></div><div class="casAuthors">Caldwell Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and molecular hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Non-alcoholic steatohepatitis (NASH) is the more aggressive form of non-alcoholic fatty liver disease (NAFLD).  NASH can progress to hepatic fibrosis, cirrhosis, portal hypertension and primary liver cancer.  Therapy is evolving with a substantial number of trials of promising new agents now in progress.  In this article however, we will examine data for several older forms of therapy which have been fairly extensively studied over the years: Polyunsaturated Fatty Acid (PUFA) supplements, vitamin E, insulin sensitizing agents with a focus on pioglitazone and statin agents.  Early interest in PUFA derived from their potential benefit in cardio-metabolic disease and the close association of NAFLD/NASH with Metabolic Syndrome.  Results have been variable although most studies show reduction of liver fat without other major effects and their effects are influenced by concomitant weight loss and underlying genetic factors.  Vitamin E has had some efficacy in pediatric NASH but questionable efficacy in even mild NASH among adults.  Pioglitazone has shown significant histological benefit in a number of trials but concern over side-effects (especially weight gain) have dampened enthusiasm.  A newer insulin sensitizer, liraglutide, has also shown promise in a small randomized, controlled trial.  Very limited data exists regarding the histological effects of the statins in NASH and these agents appear to be fairly neutral with neither clear cut benefit nor detriment.  Their use is best guided by cardiovascular risks rather than liver histology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRCC_fJjxR5EEgZCMqtRBifW6udTcc2ebKVDImb04Idrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crmtlWitw%253D%253D&md5=59b2bc8761d7fe3899cbb32bec23b035</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3350%2Fcmh.2017.0103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3350%252Fcmh.2017.0103%26sid%3Dliteratum%253Aachs%26aulast%3DCaldwell%26aufirst%3DS.%26atitle%3DNASH%2520therapy%253A%2520omega%25203%2520supplementation%252C%2520vitamin%2520E%252C%2520insulin%2520sensitizers%2520and%2520statin%2520drugs%26jtitle%3DClin.%2520Mol.%2520Hepatol.%26date%3D2017%26volume%3D23%26spage%3D103%26epage%3D108%26doi%3D10.3350%2Fcmh.2017.0103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholongitas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tziomalos, K.</span></span> <span> </span><span class="NLM_article-title">Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">9039</span>â <span class="NLM_lpage">9043</span>, <span class="refDoi">Â DOI: 10.3748/wjg.v22.i41.9039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3748%2Fwjg.v22.i41.9039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=27895393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2sjht1emug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=9039-9043&author=E.+Makriauthor=E.+Cholongitasauthor=K.+Tziomalos&title=Emerging+role+of+obeticholic+acid+in+the+management+of+nonalcoholic+fatty+liver+disease&doi=10.3748%2Fwjg.v22.i41.9039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease</span></div><div class="casAuthors">Makri Evangelia; Cholongitas Evangelos; Tziomalos Konstantinos</div><div class="citationInfo"><span class="NLM_cas:title">World journal of gastroenterology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">9039-9043</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nonalcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and its prevalence is increasing driven by the pandemic of obesity and type 2 diabetes mellitus.  NAFLD can progress to cirrhosis and is associated with increased risk for cardiovascular disease and hepatocellular cancer.  Diet and exercise are limited by suboptimal long-term adherence in patients with NAFLD.  On the other hand, current pharmacological treatment of NAFLD has limited efficacy and unfavorable safety profile.  In this context, obeticholic acid (OCA), a selective agonist of the farnesoid X receptors, might represent a useful option in these patients.  Preclinical studies suggest that OCA improves hepatic steatosis, inflammation and fibrosis.  A proof-of-concept study and the randomized, placebo-controlled Farnesoid X Receptor Ligand Obeticholic Acid in non-alcoholic steatohepatitis Treatment (FLINT) trial also showed improvements in liver histology in patients with NAFLD who received OCA.  Weight loss and reduction in blood pressure were also observed.  However, the effects of OCA on insulin resistance are conflicting and the lipid profile is adversely affected by this agent.  In addition, pruritus is frequently observed during treatment with OCA and might lead to treatment discontinuation.  However, given the limitations of existing treatments for NAFLD, OCA might represent a useful therapeutic option in selected patients with NAFLD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFQCUUiZpTcFMGsG_HTXYFfW6udTcc2ebKVDImb04Idrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjht1emug%253D%253D&md5=f77eb086a95997b49dabd00303e21a22</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v22.i41.9039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v22.i41.9039%26sid%3Dliteratum%253Aachs%26aulast%3DMakri%26aufirst%3DE.%26aulast%3DCholongitas%26aufirst%3DE.%26aulast%3DTziomalos%26aufirst%3DK.%26atitle%3DEmerging%2520role%2520of%2520obeticholic%2520acid%2520in%2520the%2520management%2520of%2520nonalcoholic%2520fatty%2520liver%2520disease%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2016%26volume%3D22%26spage%3D9039%26epage%3D9043%26doi%3D10.3748%2Fwjg.v22.i41.9039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ratziu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francque, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedossa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serfaty, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Gomez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boursier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelmalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drenth, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anstee, Q. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanf, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roudot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Megnien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanyal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathurin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gournay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Khac, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ledinghen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourliere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard-Muet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asselah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrion, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassiman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geerts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuers, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galle, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spengler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugianesi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craxi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voiculescu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheorghe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preotescu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballeria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callera, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luketic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pockros, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poordad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shores, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moehlen, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satapathy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parekh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vierling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umpierrez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallegos-Orozco, J.</span></span> <span> </span><span class="NLM_article-title">Elafibranor, an agonist of the peroxisome proliferator-activated receptor-Î± and -Î´, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">1147</span>â <span class="NLM_lpage">1159</span>, <span class="refDoi">Â DOI: 10.1053/j.gastro.2016.01.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1053%2Fj.gastro.2016.01.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26874076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Klu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2016&pages=1147-1159&author=V.+Ratziuauthor=S.+A.+Harrisonauthor=S.+Francqueauthor=P.+Bedossaauthor=P.+Lehertauthor=L.+Serfatyauthor=M.+Romero-Gomezauthor=J.+Boursierauthor=M.+Abdelmalekauthor=S.+Caldwellauthor=I.+Drenthauthor=Q.+M.+Ansteeauthor=D.+Humauthor=R.+Hanfauthor=A.+Roudotauthor=S.+Megnienauthor=B.+Staelsauthor=A.+Sanyalauthor=P.+Mathurinauthor=J.+Gournayauthor=E.+Nguyen-Khacauthor=V.+De+Ledinghenauthor=D.+Larreyauthor=A.+Tranauthor=M.+Bourliereauthor=M.+Maynard-Muetauthor=T.+Asselahauthor=J.+Henrionauthor=F.+Nevensauthor=D.+Cassimanauthor=A.+Geertsauthor=C.+Morenoauthor=U.+H.+Beuersauthor=P.+R.+Galleauthor=U.+Spenglerauthor=E.+Bugianesiauthor=A.+Craxiauthor=M.+Angelicoauthor=S.+Fargionauthor=M.+Voiculescuauthor=L.+Gheorgheauthor=L.+Preotescuauthor=J.+Caballeriaauthor=R.+J.+Andradeauthor=J.+Crespoauthor=J.+L.+Calleraauthor=A.+Alaauthor=G.+Aithalauthor=G.+Aboudaauthor=V.+Luketicauthor=M.+A.+Huangauthor=S.+Gordonauthor=P.+Pockrosauthor=F.+Poordadauthor=N.+Shoresauthor=M.+W.+Moehlenauthor=K.+Bambhaauthor=V.+Clarkauthor=S.+Satapathyauthor=S.+Parekhauthor=R.+K.+Reddyauthor=M.+Y.+Sheikhauthor=G.+Szaboauthor=J.+Vierlingauthor=T.+Fosterauthor=G.+Umpierrezauthor=C.+Changauthor=T.+Boxauthor=J.+Gallegos-Orozco&title=Elafibranor%2C+an+agonist+of+the+peroxisome+proliferator-activated+receptor-%CE%B1+and+-%CE%B4%2C+induces+resolution+of+nonalcoholic+steatohepatitis+without+fibrosis+worsening&doi=10.1053%2Fj.gastro.2016.01.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-Î± and -Î´, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening</span></div><div class="casAuthors">Ratziu, Vlad; Harrison, Stephen A.; Francque, Sven; Bedossa, Pierre; Lehert, Philippe; Serfaty, Lawrence; Romero-Gomez, Manuel; Boursier, Jerome; Abdelmalek, Manal; Caldwell, Steve; Drenth, Joost; Anstee, Quentin M.; Hum, Dean; Hanf, Remy; Roudot, Alice; Megnien, Sophie; Staels, Bart; Sanyal, Arun</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1147-1159.e5</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Elafibranor is an agonist of the peroxisome proliferator-activated receptor-Î± and peroxisome proliferator-activated receptor-Î´.  Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metab. and reduces inflammation.  We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).  Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 wk at sites in Europe and the United States.  Clin. and lab. evaluations were performed every 2 mo during this 1-yr period.  Liver biopsies were then collected and patients were assessed 3 mo later.  The primary outcome was resoln. of NASH without fibrosis worsening, using protocol-defined and modified definitions.  Data from the groups given the different doses of elafibranor were compared with those from the placebo group using step-down logistic regression, adjusting for baseline nonalcoholic fatty liver disease activity score.  In intention-to-treat anal., there was no significant difference between the elafibranor and placebo groups in the protocol-defined primary outcome.  However, NASH resolved without fibrosis worsening in a higher proportion of patients in the 120-mg elafibranor group vs the placebo group (19% vs 12%; odds ratio = 2.31; 95% confidence interval: 1.02-5.24; P = .045), based on a post-hoc anal. for the modified definition.  In post-hoc analyses of patients with nonalcoholic fatty liver disease activity score â¥4 (n = 234), elafibranor 120 mg resolved NASH in larger proportions of patients than placebo based on the protocol definition (20% vs 11%; odds ratio = 3.16; 95% confidence interval: 1.22-8.13; P = .018) and the modified definitions (19% vs 9%; odds ratio = 3.52; 95% confidence interval: 1.32-9.40; P = .013).  Patients with NASH resoln. after receiving elafibranor 120 mg had reduced liver fibrosis stages compared with those without NASH resoln. (mean redn. of 0.65 Â± 0.61 in responders for the primary outcome vs an increase of 0.10 Â± 0.98 in nonresponders; P < .001).  Liver enzymes, lipids, glucose profiles, and markers of systemic inflammation were significantly reduced in the elafibranor 120-mg group vs the placebo group.  Elafibranor was well tolerated and did not cause wt. gain or cardiac events, but did produce a mild, reversible increase in serum creatinine (effect size vs placebo: increase of 4.31 Â± 1.19 Î¼mol/L; P < .001).  A post-hoc anal. of data from trial of patients with NASH showed that elafibranor (120 mg/d for 1 yr) resolved NASH without fibrosis worsening, based on a modified definition, in the intention-to-treat anal. and in patients with moderate or severe NASH.  However, the predefined end point was not met in the intention to treat population.  Elafibranor was well tolerated and improved patients' cardiometabolic risk profile.  ClinicalTrials.gov no.: NCT01694849.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2XAE5YwAQt7Vg90H21EOLACvtfcHk0lgl6Dwf2svXiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Klu7g%253D&md5=cee5c53be700bd0a9eadb455390a222c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2016.01.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2016.01.038%26sid%3Dliteratum%253Aachs%26aulast%3DRatziu%26aufirst%3DV.%26aulast%3DHarrison%26aufirst%3DS.%2BA.%26aulast%3DFrancque%26aufirst%3DS.%26aulast%3DBedossa%26aufirst%3DP.%26aulast%3DLehert%26aufirst%3DP.%26aulast%3DSerfaty%26aufirst%3DL.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DBoursier%26aufirst%3DJ.%26aulast%3DAbdelmalek%26aufirst%3DM.%26aulast%3DCaldwell%26aufirst%3DS.%26aulast%3DDrenth%26aufirst%3DI.%26aulast%3DAnstee%26aufirst%3DQ.%2BM.%26aulast%3DHum%26aufirst%3DD.%26aulast%3DHanf%26aufirst%3DR.%26aulast%3DRoudot%26aufirst%3DA.%26aulast%3DMegnien%26aufirst%3DS.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DSanyal%26aufirst%3DA.%26aulast%3DMathurin%26aufirst%3DP.%26aulast%3DGournay%26aufirst%3DJ.%26aulast%3DNguyen-Khac%26aufirst%3DE.%26aulast%3DDe%2BLedinghen%26aufirst%3DV.%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DTran%26aufirst%3DA.%26aulast%3DBourliere%26aufirst%3DM.%26aulast%3DMaynard-Muet%26aufirst%3DM.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DHenrion%26aufirst%3DJ.%26aulast%3DNevens%26aufirst%3DF.%26aulast%3DCassiman%26aufirst%3DD.%26aulast%3DGeerts%26aufirst%3DA.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DBeuers%26aufirst%3DU.%2BH.%26aulast%3DGalle%26aufirst%3DP.%2BR.%26aulast%3DSpengler%26aufirst%3DU.%26aulast%3DBugianesi%26aufirst%3DE.%26aulast%3DCraxi%26aufirst%3DA.%26aulast%3DAngelico%26aufirst%3DM.%26aulast%3DFargion%26aufirst%3DS.%26aulast%3DVoiculescu%26aufirst%3DM.%26aulast%3DGheorghe%26aufirst%3DL.%26aulast%3DPreotescu%26aufirst%3DL.%26aulast%3DCaballeria%26aufirst%3DJ.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DCrespo%26aufirst%3DJ.%26aulast%3DCallera%26aufirst%3DJ.%2BL.%26aulast%3DAla%26aufirst%3DA.%26aulast%3DAithal%26aufirst%3DG.%26aulast%3DAbouda%26aufirst%3DG.%26aulast%3DLuketic%26aufirst%3DV.%26aulast%3DHuang%26aufirst%3DM.%2BA.%26aulast%3DGordon%26aufirst%3DS.%26aulast%3DPockros%26aufirst%3DP.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DShores%26aufirst%3DN.%26aulast%3DMoehlen%26aufirst%3DM.%2BW.%26aulast%3DBambha%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DV.%26aulast%3DSatapathy%26aufirst%3DS.%26aulast%3DParekh%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DR.%2BK.%26aulast%3DSheikh%26aufirst%3DM.%2BY.%26aulast%3DSzabo%26aufirst%3DG.%26aulast%3DVierling%26aufirst%3DJ.%26aulast%3DFoster%26aufirst%3DT.%26aulast%3DUmpierrez%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DBox%26aufirst%3DT.%26aulast%3DGallegos-Orozco%26aufirst%3DJ.%26atitle%3DElafibranor%252C%2520an%2520agonist%2520of%2520the%2520peroxisome%2520proliferator-activated%2520receptor-%25CE%25B1%2520and%2520-%25CE%25B4%252C%2520induces%2520resolution%2520of%2520nonalcoholic%2520steatohepatitis%2520without%2520fibrosis%2520worsening%26jtitle%3DGastroenterology%26date%3D2016%26volume%3D150%26spage%3D1147%26epage%3D1159%26doi%3D10.1053%2Fj.gastro.2016.01.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flesch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span> <span> </span><span class="NLM_article-title">Anthranilic acid derivatives as nuclear receptor modulators - Development of novel PPAR selective and dual PPAR/FXR ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">499</span>â <span class="NLM_lpage">514</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2014.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.bmc.2014.12.013" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=499-514&author=D.+Merkauthor=C.+Lamersauthor=J.+Weberauthor=D.+Fleschauthor=M.+Gablerauthor=E.+Proschakauthor=M.+Schubert-Zsilavecz&title=Anthranilic+acid+derivatives+as+nuclear+receptor+modulators+-+Development+of+novel+PPAR+selective+and+dual+PPAR%2FFXR+ligands&doi=10.1016%2Fj.bmc.2014.12.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DLamers%26aufirst%3DC.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DFlesch%26aufirst%3DD.%26aulast%3DGabler%26aufirst%3DM.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DSchubert-Zsilavecz%26aufirst%3DM.%26atitle%3DAnthranilic%2520acid%2520derivatives%2520as%2520nuclear%2520receptor%2520modulators%2520-%2520Development%2520of%2520novel%2520PPAR%2520selective%2520and%2520dual%2520PPAR%252FFXR%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D499%26epage%3D514%26doi%3D10.1016%2Fj.bmc.2014.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stiede, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchette, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beysen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harriman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harwood, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapeller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmalbach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">324</span>â <span class="NLM_lpage">334</span>, <span class="refDoi">Â DOI: 10.1002/hep.29246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1002%2Fhep.29246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28470676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtF2qs7jI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=324-334&author=K.+Stiedeauthor=W.+Miaoauthor=H.+S.+Blanchetteauthor=C.+Beysenauthor=G.+Harrimanauthor=H.+J.+Harwoodauthor=H.+Kelleyauthor=R.+Kapellerauthor=T.+Schmalbachauthor=W.+F.+Westlin&title=Acetyl-coenzyme+A+carboxylase+inhibition+reduces+de+novo+lipogenesis+in+overweight+male+subjects%3A+A+randomized%2C+double-blind%2C+crossover+study&doi=10.1002%2Fhep.29246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Acetyl-coenzyme a carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double-blind, crossover study</span></div><div class="casAuthors">Stiede, Kathryn; Miao, Wenyan; Blanchette, Heather S.; Beysen, Carine; Harriman, Geraldine; Harwood, H. James, Jr.; Kelley, Heather; Kapeller, Rosana; Schmalbach, Tess; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-334</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">NDI-010976, an allosteric inhibitor of acetyl-CoA carboxylases (ACC) ACC1 and ACC2, reduces hepatic de novo lipogenesis (DNL) and favorably affects steatosis, inflammation, and fibrosis in animal models of fatty liver disease.  This study was a randomized, double-blind, placebo-controlled, crossover trial evaluating the pharmacodynamic effects of a single oral dose of NDI-010976 on hepatic DNL in overweight and/or obese but otherwise healthy adult male subjects.  Subjects were randomized to receive either NDI-010976 (20, 50, or 200 mg) or matching placebo in period 1, followed by the alternate treatment in period 2; and hepatic lipogenesis was stimulated with oral fructose administration.  Fractional DNL was quantified by infusing a stable isotope tracer, [1-13C]acetate, and monitoring 13C incorporation into palmitate of circulating very low-d. lipoprotein triglyceride.  Single-dose administration of NDI-010976 was well tolerated at doses up to and including 200 mg.  Fructose administration over a 10-h period stimulated hepatic fractional DNL an av. of 30.9 Â± 6.7% (mean Â± std. deviation) above fasting DNL values in placebo-treated subjects.  Subjects administered single doses of NDI-010976 at 20, 50, or 200 mg had significant inhibition of DNL compared to placebo (mean inhibition relative to placebo was 70%, 85%, and 104%, resp.).  An inverse relationship between fractional DNL and NDI-010976 exposure was obsd. with >90% inhibition of fractional DNL assocd. with plasma concns. of NDI-010976 >4 ng/mL.  Conclusion: ACC inhibition with a single dose of NDI-010976 is well tolerated and results in a profound dose-dependent inhibition of hepatic DNL in overweight adult male subjects.  Therefore, NDI-010976 could contribute considerable value to the treatment algorithm of metabolic disorders characterized by dysregulated fatty acid metab., including nonalcoholic steatohepatitis. (Hepatol. 2017;66:324-334).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT9388eyXnR7Vg90H21EOLACvtfcHk0lgl6Dwf2svXiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtF2qs7jI&md5=e6d5240fb6dfd9fc71be7c9a008b3659</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fhep.29246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.29246%26sid%3Dliteratum%253Aachs%26aulast%3DStiede%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DW.%26aulast%3DBlanchette%26aufirst%3DH.%2BS.%26aulast%3DBeysen%26aufirst%3DC.%26aulast%3DHarriman%26aufirst%3DG.%26aulast%3DHarwood%26aufirst%3DH.%2BJ.%26aulast%3DKelley%26aufirst%3DH.%26aulast%3DKapeller%26aufirst%3DR.%26aulast%3DSchmalbach%26aufirst%3DT.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DAcetyl-coenzyme%2520A%2520carboxylase%2520inhibition%2520reduces%2520de%2520novo%2520lipogenesis%2520in%2520overweight%2520male%2520subjects%253A%2520A%2520randomized%252C%2520double-blind%252C%2520crossover%2520study%26jtitle%3DHepatology%26date%3D2017%26volume%3D66%26spage%3D324%26epage%3D334%26doi%3D10.1002%2Fhep.29246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demagny, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ¼scher, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oosterveer, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoonjans, K.</span></span> <span> </span><span class="NLM_article-title">Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">583</span>â <span class="NLM_lpage">592</span>, <span class="refDoi">Â DOI: 10.1172/JCI85499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI85499" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=583-592&author=S.+Steinauthor=V.+Lemosauthor=P.+Xuauthor=H.+Demagnyauthor=X.+Wangauthor=D.+Ryuauthor=V.+Jimenezauthor=F.+Boschauthor=T.+F.+L%C3%BCscherauthor=M.+H.+Oosterveerauthor=K.+Schoonjans&title=Impaired+SUMOylation+of+nuclear+receptor+LRH-1+promotes+nonalcoholic+fatty+liver+disease&doi=10.1172%2FJCI85499"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1172%2FJCI85499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI85499%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DS.%26aulast%3DLemos%26aufirst%3DV.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DDemagny%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRyu%26aufirst%3DD.%26aulast%3DJimenez%26aufirst%3DV.%26aulast%3DBosch%26aufirst%3DF.%26aulast%3DL%25C3%25BCscher%26aufirst%3DT.%2BF.%26aulast%3DOosterveer%26aufirst%3DM.%2BH.%26aulast%3DSchoonjans%26aufirst%3DK.%26atitle%3DImpaired%2520SUMOylation%2520of%2520nuclear%2520receptor%2520LRH-1%2520promotes%2520nonalcoholic%2520fatty%2520liver%2520disease%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D583%26epage%3D592%26doi%3D10.1172%2FJCI85499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbeek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spincemaille, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhorebeek, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Berghe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Elst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windmolders, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Pelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Merwe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedossa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thevissen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassiman, D.</span></span> <span> </span><span class="NLM_article-title">Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice</span>. <i>Lipids Health Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">46</span>, <span class="refDoi">Â DOI: 10.1186/s12944-017-0432-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1186%2Fs12944-017-0432-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28231800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVSjsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=46&author=J.+Verbeekauthor=P.+Spincemailleauthor=I.+Vanhorebeekauthor=G.+Van+den+Bergheauthor=I.+Van+der+Elstauthor=P.+Windmoldersauthor=J.+van+Peltauthor=S.+van+der%0AMerweauthor=P.+Bedossaauthor=F.+Nevensauthor=B.+Cammueauthor=K.+Thevissenauthor=D.+Cassiman&title=Dietary+intervention%2C+but+not+losartan%2C+completely+reverses+non-alcoholic+steatohepatitis+in+obese+and+insulin+resistant+mice&doi=10.1186%2Fs12944-017-0432-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice</span></div><div class="casAuthors">Verbeek, Jef; Spincemaille, Pieter; Vanhorebeek, Ilse; Van den Berghe, Greet; Vander Elst, Ingrid; Windmolders, Petra; van Pelt, Jos; van der Merwe, Schalk; Bedossa, Pierre; Nevens, Frederik; Cammue, Bruno; Thevissen, Karin; Cassiman, David</div><div class="citationInfo"><span class="NLM_cas:title">Lipids in Health and Disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46/1-46/10</span>CODEN:
                <span class="NLM_cas:coden">LHDIA7</span>;
        ISSN:<span class="NLM_cas:issn">1476-511X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Dietary intervention is the cornerstone of non-alc. steatohepatitis (NASH) treatment.  However, histol. evidence of its efficacy is limited and its impact on hepatic pathways involved in NASH is underreported.  The efficacy of the angiotensin receptor type 1 blocker losartan is controversial because of varying results in a few animal and human studies.  We evaluated the effect of dietary intervention vs. losartan on NASH and assocd. systemic metabolic features in a representative mouse model.  Methods: Male C57BL/6 J mice with high fat-high sucrose diet (HF-HSD) induced NASH, obesity, insulin resistance and hypercholesterolemia were subjected to dietary intervention (switch from HF-HSD to normal chow diet (NCD)) (n = 9), continuation HF-HSD together with losartan (30 mg/kg/day) (n = 9) or continuation HF-HSD only (n = 9) for 8 wk. 9 mice received NCD during the entire expt. (20 wk).  We assessed the systemic metabolic effects and performed a detailed hepatic histol. and mol. profiling.  A P-value of < 0.05, using the group with continuation of HF-HSD only as control, was considered as statistically significant.  Results: Dietary intervention normalized obesity, insulin resistance, and hypercholesterolemia (for all P < 0.001), and remarkably, completely reversed all histol. features of pre-existent NASH (for all P < 0.001), including fibrosis measured by quantification of collagen proportional area (P < 0.01).  At the hepatic mol. level, dietary intervention targeted fibrogenesis with a normalization of collagen type I alpha 1, transforming growth factor Î²1, tissue inhibitor of metalloproteinase 1 mRNA levels (for all P < 0.01), lipid metab. with a normalization of fatty acid translocase/CD36, fatty acid transport protein 5, fatty acid synthase mRNA levels (P < 0.05) and markers related to mitochondrial function with a normalization of hepatic ATP content (P < 0.05) together with sirtuin1 and uncoupling protein 2 mRNA levels (for both P < 0.001).  Dietary intervention abolished p62 accumulation (P < 0.01), suggesting a restoration of autophagic flux.  Losartan did not significantly affect obesity, insulin resistance, hypercholesterolemia or any histol. NASH feature.  Conclusions: Dietary intervention, and not losartan, completely restores the metabolic phenotype in a representative mouse model with pre-existent NASH, obesity, insulin resistance and hypercholesterolemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJxJHF21qk67Vg90H21EOLACvtfcHk0lhJloG70A76_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVSjsLc%253D&md5=02e8d1394c4c37a16e20313b87df4e2f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2Fs12944-017-0432-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12944-017-0432-7%26sid%3Dliteratum%253Aachs%26aulast%3DVerbeek%26aufirst%3DJ.%26aulast%3DSpincemaille%26aufirst%3DP.%26aulast%3DVanhorebeek%26aufirst%3DI.%26aulast%3DVan%2Bden%2BBerghe%26aufirst%3DG.%26aulast%3DVan%2Bder%2BElst%26aufirst%3DI.%26aulast%3DWindmolders%26aufirst%3DP.%26aulast%3Dvan%2BPelt%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BMerwe%26aufirst%3DS.%26aulast%3DBedossa%26aufirst%3DP.%26aulast%3DNevens%26aufirst%3DF.%26aulast%3DCammue%26aufirst%3DB.%26aulast%3DThevissen%26aufirst%3DK.%26aulast%3DCassiman%26aufirst%3DD.%26atitle%3DDietary%2520intervention%252C%2520but%2520not%2520losartan%252C%2520completely%2520reverses%2520non-alcoholic%2520steatohepatitis%2520in%2520obese%2520and%2520insulin%2520resistant%2520mice%26jtitle%3DLipids%2520Health%2520Dis.%26date%3D2017%26volume%3D16%26spage%3D46%26doi%3D10.1186%2Fs12944-017-0432-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coppage, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heard, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMare, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, W. W.</span></span> <span> </span><span class="NLM_article-title">Human FGF21 is a substrate of fibroblast activation protein</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0151269</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0151269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1371%2Fjournal.pone.0151269" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0151269&author=A.+L.+Coppageauthor=K.+R.+Heardauthor=M.+T.+DiMareauthor=Y.+Liuauthor=W.+Wuauthor=J.+H.+Laiauthor=W.+W.+Bachovchin&title=Human+FGF21+is+a+substrate+of+fibroblast+activation+protein&doi=10.1371%2Fjournal.pone.0151269"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0151269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0151269%26sid%3Dliteratum%253Aachs%26aulast%3DCoppage%26aufirst%3DA.%2BL.%26aulast%3DHeard%26aufirst%3DK.%2BR.%26aulast%3DDiMare%26aufirst%3DM.%2BT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DLai%26aufirst%3DJ.%2BH.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26atitle%3DHuman%2520FGF21%2520is%2520a%2520substrate%2520of%2520fibroblast%2520activation%2520protein%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0151269%26doi%3D10.1371%2Fjournal.pone.0151269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunshee, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bainbridge, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kljavin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavala-Solorio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corpuz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, J.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">5986</span>â <span class="NLM_lpage">5996</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M115.710582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1074%2Fjbc.M115.710582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26797127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvFKhsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=5986-5996&author=D.+R.+Dunsheeauthor=T.+W.+Bainbridgeauthor=N.+M.+Kljavinauthor=J.+Zavala-Solorioauthor=A.+C.+Schroederauthor=R.+Chanauthor=R.+Corpuzauthor=M.+Wongauthor=W.+Zhouauthor=G.+Deshmukhauthor=J.+Lyauthor=D.+P.+Sutherlinauthor=J.+A.+Ernstauthor=J.+Sonoda&title=Fibroblast+activation+protein+cleaves+and+inactivates+fibroblast+growth+factor+21&doi=10.1074%2Fjbc.M115.710582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21</span></div><div class="casAuthors">Dunshee, Diana Ronai; Bainbridge, Travis W.; Kljavin, Noelyn M.; Zavala-Solorio, Jose; Schroeder, Amy C.; Chan, Ruby; Corpuz, Racquel; Wong, Manda; Zhou, Wei; Deshmukh, Gauri; Ly, Justin; Sutherlin, Daniel P.; Ernst, James A.; Sonoda, Junichiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5986-5996</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">FGF21 is a stress-induced hormone with potent anti-obesity, insulin-sensitizing, and hepatoprotective properties.  Although proteolytic cleavage of recombinant human FGF21 in preclin. species has been obsd. previously, the regulation of endogenously produced FGF21 is not well understood.  Here we identify fibroblast activation protein (FAP) as the enzyme that cleaves and inactivates human FGF21.  A selective chem. inhibitor, immunodepletion, or genetic deletion of Fap stabilized recombinant human FGF21 in serum.  In addn., administration of a selective FAP inhibitor acutely increased circulating intact FGF21 levels in cynomolgus monkeys.  On the basis of our findings, we propose selective FAP inhibition as a potential therapeutic approach to increase endogenous FGF21 activity for the treatment of obesity, type 2 diabetes, non-alc. steatohepatitis, and related metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqblF1sLi2N5LVg90H21EOLACvtfcHk0lhJloG70A76_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvFKhsrs%253D&md5=a5f4f63ef8d94c2ba0bd50f2bebac075</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.710582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.710582%26sid%3Dliteratum%253Aachs%26aulast%3DDunshee%26aufirst%3DD.%2BR.%26aulast%3DBainbridge%26aufirst%3DT.%2BW.%26aulast%3DKljavin%26aufirst%3DN.%2BM.%26aulast%3DZavala-Solorio%26aufirst%3DJ.%26aulast%3DSchroeder%26aufirst%3DA.%2BC.%26aulast%3DChan%26aufirst%3DR.%26aulast%3DCorpuz%26aufirst%3DR.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DErnst%26aufirst%3DJ.%2BA.%26aulast%3DSonoda%26aufirst%3DJ.%26atitle%3DFibroblast%2520activation%2520protein%2520cleaves%2520and%2520inactivates%2520fibroblast%2520growth%2520factor%252021%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D5986%26epage%3D5996%26doi%3D10.1074%2Fjbc.M115.710582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonergan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darlington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodanovich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span> <span> </span><span class="NLM_article-title">Small molecule lysyloxidase-like 2 (LOXL2) inhibitors: the identification of an inhibitor selective for LOXL2 over LOX</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">423</span>â <span class="NLM_lpage">427</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.7b00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=423-427&author=J.+H.+Hutchinsonauthor=M.+W.+Rowbottomauthor=D.+Lonerganauthor=J.+Darlingtonauthor=P.+Prodanovichauthor=C.+D.+Kingauthor=J.+F.+Evansauthor=G.+Bain&title=Small+molecule+lysyloxidase-like+2+%28LOXL2%29+inhibitors%3A+the+identification+of+an+inhibitor+selective+for+LOXL2+over+LOX&doi=10.1021%2Facsmedchemlett.7b00014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00014%26sid%3Dliteratum%253Aachs%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DLonergan%26aufirst%3DD.%26aulast%3DDarlington%26aufirst%3DJ.%26aulast%3DProdanovich%26aufirst%3DP.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DBain%26aufirst%3DG.%26atitle%3DSmall%2520molecule%2520lysyloxidase-like%25202%2520%2528LOXL2%2529%2520inhibitors%253A%2520the%2520identification%2520of%2520an%2520inhibitor%2520selective%2520for%2520LOXL2%2520over%2520LOX%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D423%26epage%3D427%26doi%3D10.1021%2Facsmedchemlett.7b00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratziu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelmalek, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballeria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francque, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craxi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchor-Khan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vest, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiens, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seyedkazemi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loomba, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tacke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanyal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, E.</span></span> <span> </span><span class="NLM_article-title">A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1754</span>â <span class="NLM_lpage">1767</span>, <span class="refDoi">Â DOI: 10.1002/hep.29477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1002%2Fhep.29477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28833331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlCms7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2018&pages=1754-1767&author=S.+L.+Friedmanauthor=V.+Ratziuauthor=S.+A.+Harrisonauthor=M.+F.+Abdelmalekauthor=G.+P.+Aithalauthor=J.+Caballeriaauthor=S.+Francqueauthor=G.+Farrellauthor=K.+V.+Kowdleyauthor=A.+Craxiauthor=K.+Simonauthor=L.+Fischerauthor=L.+Melchor-Khanauthor=J.+Vestauthor=B.+L.+Wiensauthor=P.+Vigauthor=S.+Seyedkazemiauthor=Z.+Goodmanauthor=V.+W.+Wongauthor=R.+Loombaauthor=F.+Tackeauthor=A.+Sanyalauthor=E.+Lefebvre&title=A+randomized%2C+placebo-controlled+trial+of+cenicriviroc+for+treatment+of+nonalcoholic+steatohepatitis+with+fibrosis&doi=10.1002%2Fhep.29477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis</span></div><div class="casAuthors">Friedman, Scott L.; Ratziu, Vlad; Harrison, Stephen A.; Abdelmalek, Manal F.; Aithal, Guruprasad P.; Caballeria, Juan; Francque, Sven; Farrell, Geoffrey; Kowdley, Kris V.; Craxi, Antonio; Simon, Krzysztof; Fischer, Laurent; Melchor-Khan, Liza; Vest, Jeffrey; Wiens, Brian L.; Vig, Pamela; Seyedkazemi, Star; Goodman, Zachary; Wong, Vincent Wai-Sun; Loomba, Rohit; Tacke, Frank; Sanyal, Arun; Lefebvre, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1754-1767</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C-C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis (LF).  A randomized, double-blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fatty liver disease activity score (NAS) â¥4, and LF (stages 1-3, NASH Clin. Research Network) at 81 clin. sites.  Subjects (N = 289) were randomly assigned CVC 150 mg or placebo.  Primary outcome was â¥2-point improvement in NAS and no worsening of fibrosis at year 1.  Key secondary outcomes were: resoln. of steatohepatitis (SH) and no worsening of fibrosis; improvement in fibrosis by â¥1 stage and no worsening of SH.  Biomarkers of inflammation and adverse events were assessed.  Full study recruitment was achieved.  The primary endpoint of NAS improvement in the intent-to-treat population and resoln. of SH was achieved in a similar proportion of subjects on CVC (N = 145) and placebo (N = 144; 16% vs. 19%, P = 0.52 and 8% vs. 6%, P = 0.49, resp.).  However, the fibrosis endpoint was met in significantly more subjects on CVC than placebo (20% vs. 10%; P = 0.02).  Treatment benefits were greater in those with higher disease activity and fibrosis stage at baseline.  Biomarkers of systemic inflammation were reduced with CVC.  Safety and tolerability of CVC were comparable to placebo.  Conclusion: After 1 yr of CVC treatment, twice as many subjects achieved improvement in fibrosis and no worsening of SH compared with placebo.  Given the urgent need to develop antifibrotic therapies in NASH, these findings warrant phase 3 evaluation. (Hepatol. 2018;67:1754-1767).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg_4ETuDf9irVg90H21EOLACvtfcHk0lg2MHRQO5ZtAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlCms7g%253D&md5=a712985806b627b992895637d9f59b58</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fhep.29477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.29477%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DS.%2BL.%26aulast%3DRatziu%26aufirst%3DV.%26aulast%3DHarrison%26aufirst%3DS.%2BA.%26aulast%3DAbdelmalek%26aufirst%3DM.%2BF.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DCaballeria%26aufirst%3DJ.%26aulast%3DFrancque%26aufirst%3DS.%26aulast%3DFarrell%26aufirst%3DG.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DCraxi%26aufirst%3DA.%26aulast%3DSimon%26aufirst%3DK.%26aulast%3DFischer%26aufirst%3DL.%26aulast%3DMelchor-Khan%26aufirst%3DL.%26aulast%3DVest%26aufirst%3DJ.%26aulast%3DWiens%26aufirst%3DB.%2BL.%26aulast%3DVig%26aufirst%3DP.%26aulast%3DSeyedkazemi%26aufirst%3DS.%26aulast%3DGoodman%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DV.%2BW.%26aulast%3DLoomba%26aufirst%3DR.%26aulast%3DTacke%26aufirst%3DF.%26aulast%3DSanyal%26aufirst%3DA.%26aulast%3DLefebvre%26aufirst%3DE.%26atitle%3DA%2520randomized%252C%2520placebo-controlled%2520trial%2520of%2520cenicriviroc%2520for%2520treatment%2520of%2520nonalcoholic%2520steatohepatitis%2520with%2520fibrosis%26jtitle%3DHepatology%26date%3D2018%26volume%3D67%26spage%3D1754%26epage%3D1767%26doi%3D10.1002%2Fhep.29477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swendeman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christoffersen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafii, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span> <span> </span><span class="NLM_article-title">HDL activation of endothelial sphingosine-1-phosphate receptor-1 (S1P<sub>1</sub>) promotes regeneration and suppresses fibrosis in the liver</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e87058</span>, <span class="refDoi">Â DOI: 10.1172/jci.insight.87058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2Fjci.insight.87058" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=e87058&author=B.+S.+Dingauthor=C.+H.+Liuauthor=Y.+Sunauthor=Y.+Chenauthor=S.+L.+Swendemanauthor=B.+Jungauthor=D.+Chavezauthor=Z.+Caoauthor=C.+Christoffersenauthor=L.+B.+Nielsenauthor=S.+R.+Schwabauthor=S.+Rafiiauthor=T.+Hla&title=HDL+activation+of+endothelial+sphingosine-1-phosphate+receptor-1+%28S1P1%29+promotes+regeneration+and+suppresses+fibrosis+in+the+liver&doi=10.1172%2Fjci.insight.87058"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.87058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.87058%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DB.%2BS.%26aulast%3DLiu%26aufirst%3DC.%2BH.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSwendeman%26aufirst%3DS.%2BL.%26aulast%3DJung%26aufirst%3DB.%26aulast%3DChavez%26aufirst%3DD.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DChristoffersen%26aufirst%3DC.%26aulast%3DNielsen%26aufirst%3DL.%2BB.%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26aulast%3DRafii%26aufirst%3DS.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DHDL%2520activation%2520of%2520endothelial%2520sphingosine-1-phosphate%2520receptor-1%2520%2528S1P1%2529%2520promotes%2520regeneration%2520and%2520suppresses%2520fibrosis%2520in%2520the%2520liver%26jtitle%3DJCI%2520Insight%26date%3D2016%26volume%3D1%26spage%3De87058%26doi%3D10.1172%2Fjci.insight.87058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vestri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierucci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meacci, E.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate receptors: do they have a therapeutic potential in cardiac fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">298</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28588497" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=298&author=A.+Vestriauthor=F.+Pierucciauthor=A.+Fratiauthor=L.+Monacoauthor=E.+Meacci&title=Sphingosine-1-phosphate+receptors%3A+do+they+have+a+therapeutic+potential+in+cardiac+fibrosis&doi=10.3389%2Ffphar.2017.00296"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00296%26sid%3Dliteratum%253Aachs%26aulast%3DVestri%26aufirst%3DA.%26aulast%3DPierucci%26aufirst%3DF.%26aulast%3DFrati%26aufirst%3DA.%26aulast%3DMonaco%26aufirst%3DL.%26aulast%3DMeacci%26aufirst%3DE.%26atitle%3DSphingosine-1-phosphate%2520receptors%253A%2520do%2520they%2520have%2520a%2520therapeutic%2520potential%2520in%2520cardiac%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D298%26doi%3D10.3389%2Ffphar.2017.00296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Fernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Gallego, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunon, M. J.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate signaling as a target in hepatic fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">579</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28890699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2nsLrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=579&author=B.+Gonzalez-Fernandezauthor=D.+I.+Sanchezauthor=J.+Gonzalez-Gallegoauthor=M.+J.+Tunon&title=Sphingosine-1-phosphate+signaling+as+a+target+in+hepatic+fibrosis&doi=10.3389%2Ffphar.2017.00579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate signaling as a target in hepatic fibrosis therapy</span></div><div class="casAuthors">Gonzalez-Fernandez, Barbara; Sanchez, Diana I.; Gonzalez-Gallego, Javier; Tunon, Maria J.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">579/1-579/15</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Liver fibrosis is an excess prodn. of extracellular matrix proteins as a result of chronic liver disease which leads to cell death and organ dysfunction.  The key cells involved in fibrogenesis are resident hepatic stellate cells (HSCs) which are termed myofibroblasts after activation, acquiring contractile, proliferative, migratory and secretory capability.  Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid with well-established effects on angiogenesis, carcinogenesis and immunity.  Accumulating evidence demonstrates that this metabolite is involved in the profibrotic inflammatory process through the regulation of pleiotropic cell responses, such as vascular permeability, leukocyte infiltration, cell survival, migration, proliferation and HSCs differentiation to myofibroblasts.  S1P is synthesized by sphingosine kinases (SphKs) and many of its actions are mediated by S1P specific cell surface receptors (S1P1-5), although different intracellular targets of S1P have been identified.  Modulation of SphKs/S1P/S1P receptors signaling is known to result in beneficial effects on various in vivo and in vitro models of liver fibrosis.  Thus, a better knowledge of the mol. mechanisms involved in the modulation of the S1P pathway could help to improve liver fibrosis therapy.  In this review, we analyze the effects of the S1P axis on the fibrogenic process, and the involvement of a range of inhibitors or approaches targeting enzymes related to S1P in the abrogation of pathol. fibrogenesis.  All in all, targeting this pathway offers therapeutic potential in the treatment of hepatic fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2MtTJWyqUCLVg90H21EOLACvtfcHk0liq6JV1IcltiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2nsLrN&md5=e18ac82c856baa9a1b2c40e19afbfaaa</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00579%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Fernandez%26aufirst%3DB.%26aulast%3DSanchez%26aufirst%3DD.%2BI.%26aulast%3DGonzalez-Gallego%26aufirst%3DJ.%26aulast%3DTunon%26aufirst%3DM.%2BJ.%26atitle%3DSphingosine-1-phosphate%2520signaling%2520as%2520a%2520target%2520in%2520hepatic%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D579%26doi%3D10.3389%2Ffphar.2017.00579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minasyan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, E. L.</span></span> <span> </span><span class="NLM_article-title">The role of immune and inflammatory cells in idiopathic pulmonary fibrosis</span>. <i>Front. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">43</span>, <span class="refDoi">Â DOI: 10.3389/fmed.2018.00043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffmed.2018.00043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1Mnosl2ksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=43&author=O.+Desaiauthor=J.+Winklerauthor=M.+Minasyanauthor=E.+L.+Herzog&title=The+role+of+immune+and+inflammatory+cells+in+idiopathic+pulmonary+fibrosis&doi=10.3389%2Ffmed.2018.00043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis</span></div><div class="casAuthors">Desai Omkar; Winkler Julia; Minasyan Maksym; Herzog Erica L</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43</span>
        ISSN:<span class="NLM_cas:issn">2296-858X</span>.
    </div><div class="casAbstract">The contribution of the immune system to idiopathic pulmonary fibrosis (IPF) remains poorly understood.  While most sources agree that IPF does not result from a primary immunopathogenic mechanism, evidence gleaned from animal modeling and human studies suggests that innate and adaptive immune processes can orchestrate existing fibrotic responses.  This review will synthesize the available data regarding the complex role of professional immune cells in IPF.  The role of innate immune populations such as monocytes, macrophages, myeloid suppressor cells, and innate lymphoid cells will be discussed, as will the activation of these cells via pathogen-associated molecular patterns derived from invading or commensural microbes, and danger-associated molecular patterns derived from injured cells and tissues.  The contribution of adaptive immune responses driven by T-helper cells and B cells will be reviewed as well.  Each form of immune activation will be discussed in the context of its relationship to environmental and genetic factors, disease outcomes, and potential therapies.  We conclude with discussion of unanswered questions and opportunities for future study in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTp_tzP210nszK395ZObgVfW6udTcc2ebP04VE4u6xu7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mnosl2ksg%253D%253D&md5=82ee170bfe6a824071c52b618faec2b9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3389%2Ffmed.2018.00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmed.2018.00043%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DO.%26aulast%3DWinkler%26aufirst%3DJ.%26aulast%3DMinasyan%26aufirst%3DM.%26aulast%3DHerzog%26aufirst%3DE.%2BL.%26atitle%3DThe%2520role%2520of%2520immune%2520and%2520inflammatory%2520cells%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DFront.%2520Med.%26date%3D2018%26volume%3D5%26spage%3D43%26doi%3D10.3389%2Ffmed.2018.00043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: current status, recent progress, and emerging targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">527</span>â <span class="NLM_lpage">553</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00935</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00935" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCjsLjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=527-553&author=Y.+M.+Liuauthor=K.+Nepaliauthor=J.+P.+Liou&title=Idiopathic+pulmonary+fibrosis%3A+current+status%2C+recent+progress%2C+and+emerging+targets&doi=10.1021%2Facs.jmedchem.6b00935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets</span></div><div class="casAuthors">Liu, Yi-Min; Nepali, Kunal; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">527-553</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial pneumonia is a fatal lung disease with a median survival time of 3-5 years.  Problems in accurate diagnosis, poor prognosis, limited clin. therapy and high mortality rate together demonstrate that the development of efficient therapeutic strategies for IPF is an important future endeavor.  Deeper understanding of pathogenesis and identification of biomarkers and pathways involved might lead in the future to the emergence of some agents as novel therapeutics for IPF.  This review article presents the pathogenesis, therapeutic interventions, treatment approaches, and strategies employed for the design of antifibrotic agents for the treatment of IPF along with the patent literature from the last 10 years.  With a dozen antifibrotic agents with exciting preclin. potential in the armory, it seems certain that some of them will advance to clin. stage investigations.  The results of clin. trials for some of the new agents are also awaited, to assess their benefits in terms of efficacy and survival benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqizofQCxRDlrVg90H21EOLACvtfcHk0liq6JV1IcltiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCjsLjK&md5=9c6f4f3ebde53b7d2afa625b8de4cf4d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00935%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BM.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520current%2520status%252C%2520recent%2520progress%252C%2520and%2520emerging%2520targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D527%26epage%3D553%26doi%3D10.1021%2Facs.jmedchem.6b00935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Araya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S. L.</span></span> <span> </span><span class="NLM_article-title">Fibrogenic reactions in lung disease</span>. <i>Annu. Rev. Pathol.: Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">77</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1146/annurev.pathol.4.110807.092217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1146%2Fannurev.pathol.4.110807.092217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=20078216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFekt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=77-98&author=J.+Arayaauthor=S.+L.+Nishimura&title=Fibrogenic+reactions+in+lung+disease&doi=10.1146%2Fannurev.pathol.4.110807.092217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Fibrogenic reactions in lung disease</span></div><div class="casAuthors">Araya, Jun; Nishimura, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77-98</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Fibrogenic lung reactions occur as a common phenotype shared among disorders of heterogeneous etiologies.  Even with a common etiol., the extent and pattern of fibrosis vary greatly among individuals, even within families, suggesting complex gene-environment interactions.  The search for mechanisms shared among all fibrotic lung diseases would represent a major advance in the identification of therapeutic targets that could have a broad impact on lung health.  Although it is difficult to grasp all of the complexities of the varied cell types and cytokine networks involved in lung fibrogenic responses, and to predict the biol. responses to the overexpression or deficiency of individual cytokines, a large body of evidence converges on a single common theme: the central importance of the transforming growth factor beÎ²ta (TGF-Î²) pathway.  Therapies that act upstream or downstream of TGF-Î² activation have the therapeutic potential to treat all fibrogenic responses in the lung.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9JN7xNQMZt7Vg90H21EOLACvtfcHk0liCSrQY_Sf-tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFekt7w%253D&md5=1883ae9d3a397d4768750cdf9249f978</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathol.4.110807.092217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathol.4.110807.092217%26sid%3Dliteratum%253Aachs%26aulast%3DAraya%26aufirst%3DJ.%26aulast%3DNishimura%26aufirst%3DS.%2BL.%26atitle%3DFibrogenic%2520reactions%2520in%2520lung%2520disease%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2010%26volume%3D5%26spage%3D77%26epage%3D98%26doi%3D10.1146%2Fannurev.pathol.4.110807.092217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aubert, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span> <span> </span><span class="NLM_article-title">Endothelin-receptor antagonists beyond pulmonary arterial hypertension: cancer and fibrosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8168</span>â <span class="NLM_lpage">8188</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01781</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01781" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVClsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8168-8188&author=J.+D.+Aubertauthor=L.+Juillerat-Jeanneret&title=Endothelin-receptor+antagonists+beyond+pulmonary+arterial+hypertension%3A+cancer+and+fibrosis&doi=10.1021%2Facs.jmedchem.5b01781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis</span></div><div class="casAuthors">Aubert, John-David; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8168-8188</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for therapeutic intervention in human diseases.  Endothelin-receptor antagonists are in clin. use to treat pulmonary arterial hypertension and have been under clin. investigation for the treatment of several other diseases, such as systemic hypertension, cancer, vasospasm, and fibrogenic diseases.  In this Perspective, we review the mols. that have been evaluated in human clin. trials for the treatment of pulmonary arterial hypertension, as well as other cardiovascular diseases, cancer, and fibrosis.  We will also discuss the therapeutic consequences of receptor selectivity with regard to ETA-selective, ETB-selective, or dual ETA/ETB antagonists.  We will also consider which chem. characteristics are relevant to clin. use and the properties of mols. necessary for efficacy in treating diseases against which known mols. displayed suboptimal efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKfhFfiImWNbVg90H21EOLACvtfcHk0liCSrQY_Sf-tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVClsrs%253D&md5=b6f008d678c7e4ff5ded1db5f4a940c5</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01781%26sid%3Dliteratum%253Aachs%26aulast%3DAubert%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DEndothelin-receptor%2520antagonists%2520beyond%2520pulmonary%2520arterial%2520hypertension%253A%2520cancer%2520and%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8168%26epage%3D8188%26doi%3D10.1021%2Facs.jmedchem.5b01781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garneau-Tsodikova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thannickal, V. J.</span></span> <span> </span><span class="NLM_article-title">Protein kinase inhibitors in the treatment of pulmonary fibrosis</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2632</span>â <span class="NLM_lpage">2640</span>, <span class="refDoi">Â DOI: 10.2174/092986708785908969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2174%2F092986708785908969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18855683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1SgtbfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=2632-2640&author=S.+Garneau-Tsodikovaauthor=V.+J.+Thannickal&title=Protein+kinase+inhibitors+in+the+treatment+of+pulmonary+fibrosis&doi=10.2174%2F092986708785908969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase inhibitors in the treatment of pulmonary fibrosis</span></div><div class="casAuthors">Garneau-Tsodikova, Sylvie; Thannickal, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2632-2640</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Fibrosis of the lung and other organ systems is an increasing cause of morbidity and mortality worldwide.  Effective anti-fibrotic agents for such disorders are currently lacking.  Injury to epithelium-lined tissues in mammals is typically assocd. with a mesenchymal response, including the activation of myofibroblasts.  Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease that results from effacement of the normal alveolar architecture of the lung.  Loss of lung capacity for gas-exchange and increased work of breathing eventually leads to respiratory failure and death.  In cutaneous wound models, apoptosis of myofibroblasts are essential to scar-less wound healing.  Recent studies indicate that acquisition of an apoptosis-resistant myofibroblast phenotype in the injured lung is assocd. with non-resolving and persistent fibrosis.  The acquired resistance to apoptosis in myofibroblasts is mediated, at least in part, by the sustained activation of two crit. pro-survival protein kinases, focal adhesion kinase (FAK) and protein kinase B (PKB/AKT).  Therapeutic interventions that modulate the activity of these protein kinases with resultant alterations in the phenotype of myofibroblasts may prove to be effective anti-fibrotic therapeutic strategies.  We discuss the potential roles for protein kinase inhibitors as novel drugs for fibrotic disorders.  Progress in pre-clin. and clin. development of small mol. inhibitors targeting pro-survival protein kinases is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriAW2A7_uv37Vg90H21EOLACvtfcHk0liCSrQY_Sf-tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1SgtbfN&md5=030118de5dbd67f6ba3cedb95b872d52</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F092986708785908969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785908969%26sid%3Dliteratum%253Aachs%26aulast%3DGarneau-Tsodikova%26aufirst%3DS.%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26atitle%3DProtein%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520pulmonary%2520fibrosis%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D2632%26epage%3D2640%26doi%3D10.2174%2F092986708785908969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, W. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, R. Y.</span></span> <span> </span><span class="NLM_article-title">Repurposing pentoxifylline for the treatment of fibrosis: an overview</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1245</span>â <span class="NLM_lpage">1269</span>, <span class="refDoi">Â DOI: 10.1007/s12325-017-0547-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1007%2Fs12325-017-0547-2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=1245-1269&author=W.+X.+Wenauthor=S.+Y.+Leeauthor=R.+Siangauthor=R.+Y.+Koh&title=Repurposing+pentoxifylline+for+the+treatment+of+fibrosis%3A+an+overview&doi=10.1007%2Fs12325-017-0547-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs12325-017-0547-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-017-0547-2%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DW.%2BX.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DSiang%26aufirst%3DR.%26aulast%3DKoh%26aufirst%3DR.%2BY.%26atitle%3DRepurposing%2520pentoxifylline%2520for%2520the%2520treatment%2520of%2520fibrosis%253A%2520an%2520overview%26jtitle%3DAdv.%2520Ther.%26date%3D2017%26volume%3D34%26spage%3D1245%26epage%3D1269%26doi%3D10.1007%2Fs12325-017-0547-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, C. H.</span></span> <span> </span><span class="NLM_article-title">ERK5 regulates basic fibroblast growth factor-induced type 1 plasminogen activator inhibitor expression and cell proliferation in lung fibroblasts</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">8</span>, <span class="refDoi">Â DOI: 10.1016/j.lfs.2015.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.lfs.2015.05.006" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=1-8&author=J.+H.+Hanauthor=A.+R.+Hwangauthor=D.+H.+Namauthor=S.+Kimauthor=H.+C.+Choiauthor=J.+H.+Limauthor=C.+H.+Woo&title=ERK5+regulates+basic+fibroblast+growth+factor-induced+type+1+plasminogen+activator+inhibitor+expression+and+cell+proliferation+in+lung+fibroblasts&doi=10.1016%2Fj.lfs.2015.05.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2015.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2015.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%2BH.%26aulast%3DHwang%26aufirst%3DA.%2BR.%26aulast%3DNam%26aufirst%3DD.%2BH.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DH.%2BC.%26aulast%3DLim%26aufirst%3DJ.%2BH.%26aulast%3DWoo%26aufirst%3DC.%2BH.%26atitle%3DERK5%2520regulates%2520basic%2520fibroblast%2520growth%2520factor-induced%2520type%25201%2520plasminogen%2520activator%2520inhibitor%2520expression%2520and%2520cell%2520proliferation%2520in%2520lung%2520fibroblasts%26jtitle%3DLife%2520Sci.%26date%3D2015%26volume%3D135%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.lfs.2015.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonella, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stowasser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollin, L.</span></span> <span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">6407</span>â <span class="NLM_lpage">6419</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S76648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S76648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26715838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVekur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=6407-6419&author=F.+Bonellaauthor=S.+Stowasserauthor=L.+Wollin&title=Idiopathic+pulmonary+fibrosis%3A+current+treatment+options+and+critical+appraisal+of+nintedanib&doi=10.2147%2FDDDT.S76648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic pulmonary fibrosis: Current treatment options and critical appraisal of nintedanib</span></div><div class="casAuthors">Bonella, Francesco; Stowasser, Susanne; Wollin, Lutz</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6407-6419</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial pneumonia and is characterized by a poor prognosis, with an estd. 5-yr survival of approx. 20%.  Progressive and irreversible lung functional impairment leads to chronic respiratory insufficiency with a severely impaired quality of life.  In the last 2 decades, novel treatments for IPF have been developed as a consequence of an increasing understanding of disease pathogenesis and pathobiol.  In IPF, injured dysfunctional alveolar epithelial cells promote fibroblast recruitment and proliferation, resulting in scarring of the lung tissue.  Recently, pirfenidone and nintedanib have been approved for the treatment of IPF, having shown efficacy to slow functional decline and disease progression.  This article focuses on the pharmacol. characteristics and clin. evidence supporting the use of nintedanib, a potent small-mol. tyrosine kinase inhibitor, as therapy for IPF.  After introducing the mechanism of action and pharmacokinetics, an overview of the safety and efficacy results from the most recent clin. trials of nintedanib in IPF is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfjUsaFPn0erVg90H21EOLACvtfcHk0liMT66Fdxwcow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVekur8%253D&md5=ad6fa39dba483ae329daf63d5e38cc5a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S76648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S76648%26sid%3Dliteratum%253Aachs%26aulast%3DBonella%26aufirst%3DF.%26aulast%3DStowasser%26aufirst%3DS.%26aulast%3DWollin%26aufirst%3DL.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520current%2520treatment%2520options%2520and%2520critical%2520appraisal%2520of%2520nintedanib%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D6407%26epage%3D6419%26doi%3D10.2147%2FDDDT.S76648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ra, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulick, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerome, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofidou-Solomidou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speicher, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feghali-Bostwick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PurÃ©, E.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein (FAP) accelerates collagen degradation and clearance from lungs in mice</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">8070</span>â <span class="NLM_lpage">8089</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M115.701433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1074%2Fjbc.M115.701433" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=8070-8089&author=M.+H.+Fanauthor=Q.+Zhuauthor=H.+H.+Liauthor=H.+J.+Raauthor=S.+Majumdarauthor=D.+L.+Gulickauthor=J.+A.+Jeromeauthor=D.+H.+Madsenauthor=M.+Christofidou-Solomidouauthor=D.+W.+Speicherauthor=W.+W.+Bachovchinauthor=C.+Feghali-Bostwickauthor=E.+Pur%C3%A9&title=Fibroblast+activation+protein+%28FAP%29+accelerates+collagen+degradation+and+clearance+from+lungs+in+mice&doi=10.1074%2Fjbc.M115.701433"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.701433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.701433%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DM.%2BH.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DH.%2BH.%26aulast%3DRa%26aufirst%3DH.%2BJ.%26aulast%3DMajumdar%26aufirst%3DS.%26aulast%3DGulick%26aufirst%3DD.%2BL.%26aulast%3DJerome%26aufirst%3DJ.%2BA.%26aulast%3DMadsen%26aufirst%3DD.%2BH.%26aulast%3DChristofidou-Solomidou%26aufirst%3DM.%26aulast%3DSpeicher%26aufirst%3DD.%2BW.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DFeghali-Bostwick%26aufirst%3DC.%26aulast%3DPur%25C3%25A9%26aufirst%3DE.%26atitle%3DFibroblast%2520activation%2520protein%2520%2528FAP%2529%2520accelerates%2520collagen%2520degradation%2520and%2520clearance%2520from%2520lungs%2520in%2520mice%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D8070%26epage%3D8089%26doi%3D10.1074%2Fjbc.M115.701433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menyhart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Killer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renault, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolli, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatfield, J.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate (S1P) receptor agonists mediate pro-fibrotic response in normal human lung fibroblasts via S1P<sub>2</sub> and S1P<sub>3</sub> receptors and Smad-independent mechanisms</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">14839</span>â <span class="NLM_lpage">14851</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M112.426726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1074%2Fjbc.M112.426726" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=14839-14851&author=K.+Sobelauthor=K.+Menyhartauthor=N.+Killerauthor=B.+Renaultauthor=Y.+Bauerauthor=R.+Studerauthor=B.+Steinerauthor=M.+H.+Bolliauthor=O.+Naylerauthor=J.+Gatfield&title=Sphingosine-1-phosphate+%28S1P%29+receptor+agonists+mediate+pro-fibrotic+response+in+normal+human+lung+fibroblasts+via+S1P2+and+S1P3+receptors+and+Smad-independent+mechanisms&doi=10.1074%2Fjbc.M112.426726"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.426726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.426726%26sid%3Dliteratum%253Aachs%26aulast%3DSobel%26aufirst%3DK.%26aulast%3DMenyhart%26aufirst%3DK.%26aulast%3DKiller%26aufirst%3DN.%26aulast%3DRenault%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DY.%26aulast%3DStuder%26aufirst%3DR.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DGatfield%26aufirst%3DJ.%26atitle%3DSphingosine-1-phosphate%2520%2528S1P%2529%2520receptor%2520agonists%2520mediate%2520pro-fibrotic%2520response%2520in%2520normal%2520human%2520lung%2520fibroblasts%2520via%2520S1P2%2520and%2520S1P3%2520receptors%2520and%2520Smad-independent%2520mechanisms%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D14839%26epage%3D14851%26doi%3D10.1074%2Fjbc.M112.426726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tager, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCamera, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shea, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campanella, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polosukhin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karimi-Shah, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackwell, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luster, A. D.</span></span> <span> </span><span class="NLM_article-title">The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">45</span>â <span class="NLM_lpage">54</span>, <span class="refDoi">Â DOI: 10.1038/nm1685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm1685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18066075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVWisQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=45-54&author=A.+M.+Tagerauthor=P.+LaCameraauthor=B.+S.+Sheaauthor=G.+S.+Campanellaauthor=M.+Selmanauthor=Z.+Zhaoauthor=V.+Polosukhinauthor=J.+Wainauthor=B.+A.+Karimi-Shahauthor=N.+D.+Kimauthor=W.+K.+Hartauthor=A.+Pardoauthor=T.+S.+Blackwellauthor=Y.+Xuauthor=J.+Chunauthor=A.+D.+Luster&title=The+lysophosphatidic+acid+receptor+LPA1+links+pulmonary+fibrosis+to+lung+injury+by+mediating+fibroblast+recruitment+and+vascular+leak&doi=10.1038%2Fnm1685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak</span></div><div class="casAuthors">Tager, Andrew M.; LaCamera, Peter; Shea, Barry S.; Campanella, Gabriele S.; Selman, Moises; Zhao, Zhenwen; Polosukhin, Vasiliy; Wain, John; Karimi-Shah, Banu A.; Kim, Nancy D.; Hart, William K.; Pardo, Annie; Blackwell, Timothy S.; Xu, Yan; Chun, Jerold; Luster, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-54</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathol. responses have yet to be fully identified.  We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model.  The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury.  In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid.  LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8pk5JY4qBbLVg90H21EOLACvtfcHk0lh2fc3Ozjt8EQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVWisQ%253D%253D&md5=1a7e86264154df8960699d18a7ef2407</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnm1685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1685%26sid%3Dliteratum%253Aachs%26aulast%3DTager%26aufirst%3DA.%2BM.%26aulast%3DLaCamera%26aufirst%3DP.%26aulast%3DShea%26aufirst%3DB.%2BS.%26aulast%3DCampanella%26aufirst%3DG.%2BS.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DPolosukhin%26aufirst%3DV.%26aulast%3DWain%26aufirst%3DJ.%26aulast%3DKarimi-Shah%26aufirst%3DB.%2BA.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DHart%26aufirst%3DW.%2BK.%26aulast%3DPardo%26aufirst%3DA.%26aulast%3DBlackwell%26aufirst%3DT.%2BS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26atitle%3DThe%2520lysophosphatidic%2520acid%2520receptor%2520LPA1%2520links%2520pulmonary%2520fibrosis%2520to%2520lung%2520injury%2520by%2520mediating%2520fibroblast%2520recruitment%2520and%2520vascular%2520leak%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D45%26epage%3D54%26doi%3D10.1038%2Fnm1685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidduri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truitt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fretland, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budd, D. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7920</span>â <span class="NLM_lpage">7939</span>, <span class="refDoi">Â DOI: 10.1021/jm301022v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301022v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7920-7939&author=Y.+Qianauthor=M.+Hamiltonauthor=A.+Sidduriauthor=S.+Gabrielauthor=Y.+Renauthor=R.+Pengauthor=R.+Kondruauthor=A.+Narayananauthor=T.+Truittauthor=R.+Hamidauthor=Y.+Chenauthor=L.+Zhangauthor=A.+J.+Fretlandauthor=R.+Alvarez+Sanchezauthor=K.+C.+Changauthor=M.+Lucasauthor=R.+C.+Schoenfeldauthor=D.+Laineauthor=M.+E.+Fuentesauthor=C.+S.+Stevensonauthor=D.+C.+Budd&title=Discovery+of+highly+selective+and+orally+active+lysophosphatidic+acid+receptor-1+antagonists+with+potent+activity+on+human+lung+fibroblasts&doi=10.1021%2Fjm301022v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm301022v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301022v%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DY.%26aulast%3DHamilton%26aufirst%3DM.%26aulast%3DSidduri%26aufirst%3DA.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DNarayanan%26aufirst%3DA.%26aulast%3DTruitt%26aufirst%3DT.%26aulast%3DHamid%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFretland%26aufirst%3DA.%2BJ.%26aulast%3DAlvarez%2BSanchez%26aufirst%3DR.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DLucas%26aufirst%3DM.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DLaine%26aufirst%3DD.%26aulast%3DFuentes%26aufirst%3DM.%2BE.%26aulast%3DStevenson%26aufirst%3DC.%2BS.%26aulast%3DBudd%26aufirst%3DD.%2BC.%26atitle%3DDiscovery%2520of%2520highly%2520selective%2520and%2520orally%2520active%2520lysophosphatidic%2520acid%2520receptor-1%2520antagonists%2520with%2520potent%2520activity%2520on%2520human%2520lung%2520fibroblasts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7920%26epage%3D7939%26doi%3D10.1021%2Fjm301022v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richeldi, L.</span></span> <span> </span><span class="NLM_article-title">Current approaches to the management of idiopathic pulmonary fibrosis</span>. <i>Resp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">24</span>â <span class="NLM_lpage">30</span>, <span class="refDoi">Â DOI: 10.1016/j.rmed.2017.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.rmed.2017.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28732832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1cfgtVGmtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=24-30&author=G.+Raghuauthor=L.+Richeldi&title=Current+approaches+to+the+management+of+idiopathic+pulmonary+fibrosis&doi=10.1016%2Fj.rmed.2017.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Current approaches to the management of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Raghu Ganesh; Richeldi Luca</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease associated with dyspnoea, cough and impaired quality of life.  Currently, the aims of patient care are to improve outcomes for patients by slowing the progression of the disease, extending life, and improving quality of life.  A prompt, accurate diagnosis is important to enable patients to receive treatment early in the course of the disease and to be considered for lung transplantation.  Two anti-fibrotic drugs, nintedanib and pirfenidone, have been shown to reduce decline in lung function in patients with IPF.  In addition to pharmacological therapy, optimal management of IPF includes treatment of comorbidities, symptom relief, pulmonary rehabilitation, and palliative care.  Patient education is important to enable patients to make decisions about their care and to help them manage their disease and the side-effects of anti-fibrotic drugs.  Research continues into new treatments and combinations of treatments that may improve outcomes for patients with this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDPrPp1yCsHpSWdIdmEou5fW6udTcc2eaKdD-HFA7z4rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfgtVGmtw%253D%253D&md5=4e0d042f92f1c57f906dd1fe61f73224</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2017.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2017.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DRicheldi%26aufirst%3DL.%26atitle%3DCurrent%2520approaches%2520to%2520the%2520management%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DResp.%2520Med.%26date%3D2017%26volume%3D129%26spage%3D24%26epage%3D30%26doi%3D10.1016%2Fj.rmed.2017.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, J. S.</span></span> <span> </span><span class="NLM_article-title">Cellular and molecular mechanisms in kidney fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2299</span>â <span class="NLM_lpage">2306</span>, <span class="refDoi">Â DOI: 10.1172/JCI72267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI72267" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=2299-2306&author=J.+S.+Duffield&title=Cellular+and+molecular+mechanisms+in+kidney+fibrosis&doi=10.1172%2FJCI72267"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1172%2FJCI72267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI72267%26sid%3Dliteratum%253Aachs%26aulast%3DDuffield%26aufirst%3DJ.%2BS.%26atitle%3DCellular%2520and%2520molecular%2520mechanisms%2520in%2520kidney%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D2299%26epage%3D2306%26doi%3D10.1172%2FJCI72267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violette, S.</span></span> <span> </span><span class="NLM_article-title">Therapy for fibrotic diseases: nearing the starting line</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">167sr1</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3004700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1126%2Fscitranslmed.3004700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23303606" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=167sr1&author=S.+L.+Friedmanauthor=D.+Sheppardauthor=J.+S.+Duffieldauthor=S.+Violette&title=Therapy+for+fibrotic+diseases%3A+nearing+the+starting+line&doi=10.1126%2Fscitranslmed.3004700"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3004700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3004700%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DS.%2BL.%26aulast%3DSheppard%26aufirst%3DD.%26aulast%3DDuffield%26aufirst%3DJ.%2BS.%26aulast%3DViolette%26aufirst%3DS.%26atitle%3DTherapy%2520for%2520fibrotic%2520diseases%253A%2520nearing%2520the%2520starting%2520line%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26spage%3D167sr1%26doi%3D10.1126%2Fscitranslmed.3004700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plieth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Threadgill, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neilson, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R. C.</span></span> <span> </span><span class="NLM_article-title">EGFR signaling promotes TGFÎ²-dependent renal fibrosis</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">215</span>â <span class="NLM_lpage">224</span>, <span class="refDoi">Â DOI: 10.1681/ASN.2011070645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1681%2FASN.2011070645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22095949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjslamtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=215-224&author=J.+Chenauthor=J.+K.+Chenauthor=K.+Nagaiauthor=D.+Pliethauthor=M.+Tanauthor=T.+C.+Leeauthor=D.+W.+Threadgillauthor=E.+G.+Neilsonauthor=R.+C.+Harris&title=EGFR+signaling+promotes+TGF%CE%B2-dependent+renal+fibrosis&doi=10.1681%2FASN.2011070645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR signaling promotes TGFÎ²-dependent renal fibrosis</span></div><div class="casAuthors">Chen, Jianchun; Chen, Jian-Kang; Nagai, Kojiro; Plieth, David; Tan, Mingqi; Lee, Tang-Cheng; Threadgill, David W.; Neilson, Eric G.; Harris, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-224</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">The mechanisms by which angiotensin II (Ang II) promotes renal fibrosis remain incompletely understood.  Ang II both stimulates TGFÎ² signaling and activates the EGF receptor (EGFR), but the relative contribution of these pathways to renal fibrogenesis is unknown.  Using a murine model with EGFR-deficient proximal tubules, we demonstrate that upstream activation of EGFR-dependent ERK signaling is crit. for mediating sustained TGFÎ² expression in renal fibrosis.  Persistent activation of the Ang II receptor stimulated ROS-dependent phosphorylation of Src, leading to sustained EGFR-dependent signaling for TGFÎ² expression.  Either genetic or pharmacol. inhibition of EGFR significantly decreased TGFÎ²-mediated fibrogenesis.  We conclude that TGFÎ²-mediated tissue fibrosis relies on a persistent feed-forward mechanism of EGFR/ERK activation through an unexpected signaling pathway, highlighting EGFR as a potential therapeutic target for modulating tissue fibrogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3mTaG1FkGTrVg90H21EOLACvtfcHk0lg1W9rEx3J5ew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjslamtb8%253D&md5=bd4a76b4371d21ae732b07925e43b077</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1681%2FASN.2011070645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2011070645%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%2BK.%26aulast%3DNagai%26aufirst%3DK.%26aulast%3DPlieth%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DT.%2BC.%26aulast%3DThreadgill%26aufirst%3DD.%2BW.%26aulast%3DNeilson%26aufirst%3DE.%2BG.%26aulast%3DHarris%26aufirst%3DR.%2BC.%26atitle%3DEGFR%2520signaling%2520promotes%2520TGF%25CE%25B2-dependent%2520renal%2520fibrosis%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2012%26volume%3D23%26spage%3D215%26epage%3D224%26doi%3D10.1681%2FASN.2011070645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span> <span> </span><span class="NLM_article-title">Renal interstitial fibrosis induced by high doses mesoporous silica nanoparticles via the NF-ÎºB signaling pathway</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">22</span>, <span class="refDoi">Â DOI: 10.2147/IJN.S73538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FIJN.S73538" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1-22&author=C.+Xiauthor=Z.+Wangauthor=J.+Zhouauthor=X.+Fuauthor=J.+Liangauthor=Y.+Qiuauthor=Z.+Huang&title=Renal+interstitial+fibrosis+induced+by+high+doses+mesoporous+silica+nanoparticles+via+the+NF-%CE%BAB+signaling+pathway&doi=10.2147%2FIJN.S73538"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2147%2FIJN.S73538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S73538%26sid%3Dliteratum%253Aachs%26aulast%3DXi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26atitle%3DRenal%2520interstitial%2520fibrosis%2520induced%2520by%2520high%2520doses%2520mesoporous%2520silica%2520nanoparticles%2520via%2520the%2520NF-%25CE%25BAB%2520signaling%2520pathway%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2015%26volume%3D10%26spage%3D1%26epage%3D22%26doi%3D10.2147%2FIJN.S73538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovisa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBleu, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tampe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadnagara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carstens, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagos, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burckhardt, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pentcheva-Hoang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nischal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeisberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalluri, R.</span></span> <span> </span><span class="NLM_article-title">Epithelial to mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">998</span>â <span class="NLM_lpage">1009</span>, <span class="refDoi">Â DOI: 10.1038/nm.3902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm.3902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26236991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCksL7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=998-1009&author=S.+Lovisaauthor=V.+S.+LeBleuauthor=B.+Tampeauthor=H.+Sugimotoauthor=K.+Vadnagaraauthor=J.+L.+Carstensauthor=C.+C.+Wuauthor=Y.+Hagosauthor=B.+C.+Burckhardtauthor=T.+Pentcheva-Hoangauthor=H.+Nischalauthor=J.+P.+Allisonauthor=M.+Zeisbergauthor=R.+Kalluri&title=Epithelial+to+mesenchymal+transition+induces+cell+cycle+arrest+and+parenchymal+damage+in+renal+fibrosis&doi=10.1038%2Fnm.3902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis</span></div><div class="casAuthors">Lovisa, Sara; Le Bleu, Valerie S.; Tampe, Bjorn; Sugimoto, Hikaru; Vadnagara, Komal; Carstens, Julienne L.; Wu, Chia-Chin; Hagos, Yohannes; Burckhardt, Birgitta C.; Pentcheva-Hoang, Tsvetelina; Nischal, Hersharan; Allison, James P.; Zeisberg, Michael; Kalluri, Raghu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">998-1009</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kidney fibrosis is marked by an epithelial-to-mesenchymal transition (EMT) of tubular epithelial cells (TECs).  Here we find that, during renal fibrosis, TECs acquire a partial EMT program during which they remain assocd. with their basement membrane and express markers of both epithelial and mesenchymal cells.  The functional consequence of the EMT program during fibrotic injury is an arrest in the G2 phase of the cell cycle and lower expression of several solute and solvent transporters in TECs.  We also found that transgenic expression of either Twist1 (encoding twist family bHLH transcription factor 1, known as Twist) or Snai1 (encoding snail family zinc finger 1, known as Snail) expression is sufficient to promote prolonged TGF-Î²1-induced G2 arrest of TECs, limiting the cells' potential for repair and regeneration.  In mouse models of exptl. induced renal fibrosis, conditional deletion of Twist1 or Snai1 in proximal TECs resulted in inhibition of the EMT program and the maintenance of TEC integrity, while also restoring cell proliferation, dedifferentiation-assocd. repair and regeneration of the kidney parenchyma and attenuating interstitial fibrosis.  Thus, inhibition of the EMT program in TECs during chronic renal injury represents a potential anti-fibrosis therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIWzh92Cy4rbVg90H21EOLACvtfcHk0lg1W9rEx3J5ew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCksL7N&md5=54a4949f76e6f9fcc845f262c4c50344</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnm.3902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3902%26sid%3Dliteratum%253Aachs%26aulast%3DLovisa%26aufirst%3DS.%26aulast%3DLeBleu%26aufirst%3DV.%2BS.%26aulast%3DTampe%26aufirst%3DB.%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DVadnagara%26aufirst%3DK.%26aulast%3DCarstens%26aufirst%3DJ.%2BL.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DHagos%26aufirst%3DY.%26aulast%3DBurckhardt%26aufirst%3DB.%2BC.%26aulast%3DPentcheva-Hoang%26aufirst%3DT.%26aulast%3DNischal%26aufirst%3DH.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DZeisberg%26aufirst%3DM.%26aulast%3DKalluri%26aufirst%3DR.%26atitle%3DEpithelial%2520to%2520mesenchymal%2520transition%2520induces%2520cell%2520cycle%2520arrest%2520and%2520parenchymal%2520damage%2520in%2520renal%2520fibrosis%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D998%26epage%3D1009%26doi%3D10.1038%2Fnm.3902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eddy, A. A.</span></span> <span> </span><span class="NLM_article-title">Overview of the cellular and molecular basis of kidney fibrosis</span>. <i>Kidney Int. Suppl.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2</span>â <span class="NLM_lpage">8</span>, <span class="refDoi">Â DOI: 10.1038/kisup.2014.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fkisup.2014.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVKmtb3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=2-8&author=A.+A.+Eddy&title=Overview+of+the+cellular+and+molecular+basis+of+kidney+fibrosis&doi=10.1038%2Fkisup.2014.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the cellular and molecular basis of kidney fibrosis</span></div><div class="casAuthors">Eddy, Allison A.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International Supplements</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-8</span>CODEN:
                <span class="NLM_cas:coden">KISIAA</span>;
        ISSN:<span class="NLM_cas:issn">2157-1716</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The common pathogenetic pathway of progressive injury in patients with chronic kidney disease (CKD) is epitomized as normal kidney parenchymal destruction due to scarring (fibrosis).  Understanding the fundamental pathways that lead to renal fibrosis is essential in order to develop better therapeutic options for human CKD.  Although complex, four cellular responses are pivotal. (1) An interstitial inflammatory response that has multiple consequences-some harmful and others healing. (2) The appearance of a unique interstitial cell population of myofibroblasts, primarily derived from kidney stromal cells (fibroblasts and pericytes), that are the primary source of the various extracellular matrix proteins that form interstitial scars. (3) Tubular epithelial cells that have variable and time-dependent roles as early responders to injury and later as victims of fibrosis due to the loss of their regenerative abilities. (4) Loss of interstitial capillary integrity that compromises oxygen delivery and leads to a vicious cascade of hypoxia-oxidant stress that accentuates injury and fibrosis.  In the absence of adequate angiogenic responses, a healthy interstitial capillary network is not maintained.  The fibrotic 'scar' that typifies CKD is an interesting consortium of multifunctional macromols. that not only change in compn. and structure over time, but can be degraded via extracellular and intracellular proteases.  Although transforming growth factor beta appears to be the primary driver of kidney fibrosis, a vast array of addnl. mols. may have modulating roles.  The importance of genetic and epigenetic factors is increasingly appreciated.  An intriguing but incompletely understood cardiorenal syndrome underlies the high morbidity and mortality rates that develop in assocn. with progressive kidney fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQbMRehR4jqrVg90H21EOLACvtfcHk0lgONxvkP8G8bQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVKmtb3J&md5=dc65f7c53ed78530c8f2e76a9da8716a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fkisup.2014.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fkisup.2014.2%26sid%3Dliteratum%253Aachs%26aulast%3DEddy%26aufirst%3DA.%2BA.%26atitle%3DOverview%2520of%2520the%2520cellular%2520and%2520molecular%2520basis%2520of%2520kidney%2520fibrosis%26jtitle%3DKidney%2520Int.%2520Suppl.%26date%3D2014%26volume%3D4%26spage%3D2%26epage%3D8%26doi%3D10.1038%2Fkisup.2014.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanasaki, K.</span></span> <span> </span><span class="NLM_article-title">Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease</span>. <i>Clin. Exp. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">488</span>â <span class="NLM_lpage">497</span>, <span class="refDoi">Â DOI: 10.1007/s10157-013-0781-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1007%2Fs10157-013-0781-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23430391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGmt7rI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=488-497&author=J.+Heauthor=Y.+Xuauthor=D.+Koyaauthor=K.+Kanasaki&title=Role+of+the+endothelial-to-mesenchymal+transition+in+renal+fibrosis+of+chronic+kidney+disease&doi=10.1007%2Fs10157-013-0781-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease</span></div><div class="casAuthors">He, Jianhua; Xu, Yong; Koya, Daisuke; Kanasaki, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Nephrology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">488-497</span>CODEN:
                <span class="NLM_cas:coden">CENPFV</span>;
        ISSN:<span class="NLM_cas:issn">1342-1751</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">A review.  All types of progressive chronic kidney disease (CKD) inevitably induce renal fibrosis, the hallmark of which is the activation and accumulation of a large no. of matrix-producing fibroblasts or myofibroblasts.  The activated fibroblasts or myofibroblasts are derived from diverse origins, such as residential fibroblasts, vascular pericytes, epithelial-to-mesenchymal transition (EMT), and bone marrow (circulating fibrocytes).  Recently, endothelial-to-mesenchymal transition (EndMT) or endothelial-to-myofibroblast transition has also been suggested to promote fibrosis and is recognized as a novel mechanism for the generation of myofibroblasts.  Similar to EMT, during EndMT, endothelial cells lose their adhesion and apical-basal polarity to form highly invasive, migratory, spindle-shaped, elongated mesenchymal cells.  More importantly, biochem. changes accompany these distinct changes in cell polarity and morphol., including the decreased expression of endothelial markers and the acquisition of mesenchymal markers.  This review highlights evidence supporting the important role of EndMT in the development of renal fibrosis in CKD and its underlying mechanisms, including novel biol. significance of microRNA regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrByO0uthLHtrVg90H21EOLACvtfcHk0lgONxvkP8G8bQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGmt7rI&md5=7c758f89478cc01cff93db82bf2025f5</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1007%2Fs10157-013-0781-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10157-013-0781-0%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DKoya%26aufirst%3DD.%26aulast%3DKanasaki%26aufirst%3DK.%26atitle%3DRole%2520of%2520the%2520endothelial-to-mesenchymal%2520transition%2520in%2520renal%2520fibrosis%2520of%2520chronic%2520kidney%2520disease%26jtitle%3DClin.%2520Exp.%2520Nephrol.%26date%3D2013%26volume%3D17%26spage%3D488%26epage%3D497%26doi%3D10.1007%2Fs10157-013-0781-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grande, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¡nchez-Laorden, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ³pez-Blau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Frutos, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ArÃ©valo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ³pez-Novoa, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, M. A.</span></span> <span> </span><span class="NLM_article-title">Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">989</span>â <span class="NLM_lpage">997</span>, <span class="refDoi">Â DOI: 10.1038/nm.3901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm.3901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26236989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCksL7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=989-997&author=T.+M.+Grandeauthor=B.+S%C3%A1nchez-Laordenauthor=C.+L%C3%B3pez-Blauauthor=C.+A.+De+Frutosauthor=A.+Boutetauthor=M.+Ar%C3%A9valoauthor=R.+G.+Roweauthor=S.+J.+Weissauthor=J.+M.+L%C3%B3pez-Novoaauthor=M.+A.+Nieto&title=Snail1-induced+partial+epithelial-to-mesenchymal+transition+drives+renal+fibrosis+in+mice+and+can+be+targeted+to+reverse+established+disease&doi=10.1038%2Fnm.3901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease</span></div><div class="casAuthors">Grande, M. Teresa; Sanchez-Laorden, Berta; Lopez-Blau, Cristina; De Frutos, Cristina A.; Boutet, Agnes; Arevalo, Miguel; Rowe, R. Grant; Weiss, Stephen J.; Lopez-Novoa, Jose M.; Nieto, M. Angela</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">989-997</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Progressive kidney fibrosis contributes greatly to end-stage renal failure, and no specific treatment is available to preserve organ function.  During renal fibrosis, myofibroblasts accumulate in the interstitium of the kidney, leading to massive deposition of extracellular matrix and organ dysfunction.  The origin of myofibroblasts is manifold, but the contribution of an epithelial-to-mesenchymal transition (EMT) undergone by renal epithelial cells during kidney fibrosis is still debated.  We show that the reactivation of Snai1 (encoding snail family zinc finger 1, known as Snail1) in mouse renal epithelial cells is required for the development of fibrosis in the kidney.  Damage-mediated Snail1 reactivation induces a partial EMT in tubular epithelial cells that, without directly contributing to the myofibroblast population, relays signals to the interstitium to promote myofibroblast differentiation and fibrogenesis and to sustain inflammation.  We also show that Snail1-induced fibrosis can be reversed in vivo and that obstructive nephropathy can be therapeutically ameliorated in mice by genetically targeting Snail1 expression.  These results reconcile conflicting data on the role of the EMT in renal fibrosis and provide avenues for the design of novel anti-fibrotic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0A_c4no3Q27Vg90H21EOLACvtfcHk0lgONxvkP8G8bQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCksL7I&md5=691983f25e28ebf2a325dd59d6680c44</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fnm.3901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3901%26sid%3Dliteratum%253Aachs%26aulast%3DGrande%26aufirst%3DT.%2BM.%26aulast%3DS%25C3%25A1nchez-Laorden%26aufirst%3DB.%26aulast%3DL%25C3%25B3pez-Blau%26aufirst%3DC.%26aulast%3DDe%2BFrutos%26aufirst%3DC.%2BA.%26aulast%3DBoutet%26aufirst%3DA.%26aulast%3DAr%25C3%25A9valo%26aufirst%3DM.%26aulast%3DRowe%26aufirst%3DR.%2BG.%26aulast%3DWeiss%26aufirst%3DS.%2BJ.%26aulast%3DL%25C3%25B3pez-Novoa%26aufirst%3DJ.%2BM.%26aulast%3DNieto%26aufirst%3DM.%2BA.%26atitle%3DSnail1-induced%2520partial%2520epithelial-to-mesenchymal%2520transition%2520drives%2520renal%2520fibrosis%2520in%2520mice%2520and%2520can%2520be%2520targeted%2520to%2520reverse%2520established%2520disease%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D989%26epage%3D997%26doi%3D10.1038%2Fnm.3901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ovadya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krizhanovsky, V.</span></span> <span> </span><span class="NLM_article-title">A new Twist in kidney fibrosis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">975</span>â <span class="NLM_lpage">977</span>, <span class="refDoi">Â DOI: 10.1038/nm.3938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm.3938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26340117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7vF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=975-977&author=Y.+Ovadyaauthor=V.+Krizhanovsky&title=A+new+Twist+in+kidney+fibrosis&doi=10.1038%2Fnm.3938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">A new Twist in kidney fibrosis</span></div><div class="casAuthors">Ovadya, Yossi; Krizhanovsky, Valery</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">975-977</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kidney fibrosis is a main pathol. component of chronic kidney disease.  Two new studies pinpoint a partial epithelial-to-mesenchymal transition as a mechanism driving the development of kidney fibrosis, thus paving the way for novel treatments of fibrosis-assocd. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0BqbbOvScsrVg90H21EOLACvtfcHk0lgONxvkP8G8bQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7vF&md5=dc56e8509c6b6ac385d6e742dad414da</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnm.3938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3938%26sid%3Dliteratum%253Aachs%26aulast%3DOvadya%26aufirst%3DY.%26aulast%3DKrizhanovsky%26aufirst%3DV.%26atitle%3DA%2520new%2520Twist%2520in%2520kidney%2520fibrosis%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D975%26epage%3D977%26doi%3D10.1038%2Fnm.3938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VÃ¶lzke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ¼nsche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer zu Heringdorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwiler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeilschifter, J.</span></span> <span> </span><span class="NLM_article-title">Thiazolidinedione-dependent activation of sphingosine kinase 1 causes an anti-fibrotic effect in renal mesangial cells</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">1018</span>â <span class="NLM_lpage">1032</span>, <span class="refDoi">Â DOI: 10.1111/j.1476-5381.2012.01824.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1111%2Fj.1476-5381.2012.01824.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22221312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlWmsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2012&pages=1018-1032&author=A.+Kochauthor=A.+V%C3%B6lzkeauthor=C.+W%C3%BCnscheauthor=D.+Meyer+zu+Heringdorfauthor=A.+Huwilerauthor=J.+Pfeilschifter&title=Thiazolidinedione-dependent+activation+of+sphingosine+kinase+1+causes+an+anti-fibrotic+effect+in+renal+mesangial+cells&doi=10.1111%2Fj.1476-5381.2012.01824.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazolidinedione-dependent activation of sphingosine kinase 1 causes an anti-fibrotic effect in renal mesangial cells</span></div><div class="casAuthors">Koch, A.; Voelzke, A.; Wuensche, C.; Meyer zu Heringdorf, D.; Huwiler, A.; Pfeilschifter, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1018-1032</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose PPARÎ³ agonists [thiazolidinediones (TZDs)] are known to exert anti-fibrotic effects in the kidney.  In addn., we previously demonstrated that sphingosine kinase 1 (SK-1) and intracellular sphingosine-1-phosphate (S1P), by reducing the expression of connective tissue growth factor (CTGF), have a protective role in the fibrotic process.  Exptl. Approach Here, we investigated the effect of TZDs on intracellular sphingolipid levels and the transcriptional regulation of SK-1 in mesangial cells to evaluate potential novel aspects of the anti-fibrotic capacity of TZDs.  Key Results Stimulation with the TZDs, troglitazone and rosiglitazone, led to increased S1P levels in rat mesangial cells.  This was paralleled by increased SK-1 activity as a consequence of direct effects of the TZDs on SK-1 expression.  GW-9662, a PPARÎ³ antagonist, inhibited the stimulating effect of TZDs on SK-1 mRNA and activity levels and intracellular S1P concns.  Furthermore, SK-1 up-regulation by TZDs was functionally coupled with lower amts. of pro-fibrotic CTGF.  SK-1 inhibition with SKI II almost completely abolished this effect in a dose-dependent manner.  Moreover, the CTGF lowering effect of TZDs was fully blocked in MC isolated from SK-1 deficient mice (SK-1-/-) as well as in glomeruli of SK-1-/- mice compared with wild-type mice treated with TRO and RSG.  Conclusion and Implications These data show that TZD-induced SK-1 up-regulation results in lower amts. of CTGF, demonstrating novel facets for the anti-fibrotic effects of this class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXiojwdx-qZbVg90H21EOLACvtfcHk0lgibFV88pHH6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlWmsbo%253D&md5=2acbeb8f8b093a837cf96b15b69186bc</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.01824.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.01824.x%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%26aulast%3DV%25C3%25B6lzke%26aufirst%3DA.%26aulast%3DW%25C3%25BCnsche%26aufirst%3DC.%26aulast%3DMeyer%2Bzu%2BHeringdorf%26aufirst%3DD.%26aulast%3DHuwiler%26aufirst%3DA.%26aulast%3DPfeilschifter%26aufirst%3DJ.%26atitle%3DThiazolidinedione-dependent%2520activation%2520of%2520sphingosine%2520kinase%25201%2520causes%2520an%2520anti-fibrotic%2520effect%2520in%2520renal%2520mesangial%2520cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D166%26spage%3D1018%26epage%3D1032%26doi%3D10.1111%2Fj.1476-5381.2012.01824.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span> <span> </span><span class="NLM_article-title">Pioglitazone improves mitochondrial function in the remnant kidney and protects against renal fibrosis in 5/6 nephrectomized rats</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">545</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28860994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2gurbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=545&author=L.+Sunauthor=Q.+Yuanauthor=T.+Xuauthor=L.+Yaoauthor=J.+Fengauthor=J.+Maauthor=L.+Wangauthor=C.+Luauthor=D.+Wang&title=Pioglitazone+improves+mitochondrial+function+in+the+remnant+kidney+and+protects+against+renal+fibrosis+in+5%2F6+nephrectomized+rats&doi=10.3389%2Ffphar.2017.00545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Pioglitazone improves mitochondrial function in the remnant kidney and protects against renal fibrosis in 5/6 nephrectomized rats</span></div><div class="casAuthors">Sun, Li; Yuan, Quan; Xu, Tianhua; Yao, Li; Feng, Jiangmin; Ma, Jianfei; Wang, Lining; Lu, Changlong; Wang, Danan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">545/1-545/10</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Pioglitazone is a type of peroxisome proliferator-activated receptor Î³ (PPARÎ³) agonist and has been demonstrated to be effective in chronic kidney diseases (CKD) treatment.  However, the underlying mechanism involved in the renoprotection of pioglitazone has not been fully revealed.  In the present study, the renoprotective mechanism of pioglitazone was investigated in 5/6 nephrectomized (Nx) rats and TGF-Î²1-exposed HK- 2 cells.  Pioglitazone attenuated renal injury and improved renal function, as examd. by 24 h urinary protein, blood urea nitrogen and plasma creatinine in Nx rats.  Renal fibrosis and enhanced expressions of profibrotic proteins TGF-Î²1, fibronectin and collagen I caused by Nx were significantly alleviated by pioglitazone.  In addn., pioglitazone protected mitochondrial functions by stabilizing the mitochondrial membrane potential, inhibiting ROS generation, maintaining ATP prodn. and the activities of complexes I and III, and preventing cytochrome C leakage from mitochondria.  Pioglitazone also upregulated the expression levels of ATP synthase Î², COX I and NDUFB8, which were downregulated in the kidney of Nx rats and TGF-Î²1-exposed HK-2 cells.  Furthermore, pioglitazone increased fusion proteins Opa-1 and Mfn2 expressions and decreased fission protein Drp1 expression.  The results imply that pioglitazone may exert the renoprotective effects through modulating mitochondrial electron transport chain and mitochondrial dynamics in CKD.  Finally, these recoveries were completely or partly inhibited by GW9662, which suggests that these effects at least partly PPARg dependent.  This study provides evidence for the pharmacol. mechanism of pioglitazone in the treatment of CKD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4c61AWf-jbbVg90H21EOLACvtfcHk0lgibFV88pHH6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2gurbI&md5=9cacf04e6d432a1bf1c7c41c28379c8a</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00545%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DD.%26atitle%3DPioglitazone%2520improves%2520mitochondrial%2520function%2520in%2520the%2520remnant%2520kidney%2520and%2520protects%2520against%2520renal%2520fibrosis%2520in%25205%252F6%2520nephrectomized%2520rats%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D545%26doi%3D10.3389%2Ffphar.2017.00545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, M. E.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targets for treating fibrotic kidney diseases</span>. <i>Translat. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">512</span>â <span class="NLM_lpage">530</span>, <span class="refDoi">Â DOI: 10.1016/j.trsl.2014.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.trsl.2014.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25176603" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2015&pages=512-530&author=S.+Y.+Leeauthor=S.+I.+Kimauthor=M.+E.+Choi&title=Therapeutic+targets+for+treating+fibrotic+kidney+diseases&doi=10.1016%2Fj.trsl.2014.07.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.trsl.2014.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trsl.2014.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DS.%2BI.%26aulast%3DChoi%26aufirst%3DM.%2BE.%26atitle%3DTherapeutic%2520targets%2520for%2520treating%2520fibrotic%2520kidney%2520diseases%26jtitle%3DTranslat.%2520Res.%26date%3D2015%26volume%3D165%26spage%3D512%26epage%3D530%26doi%3D10.1016%2Fj.trsl.2014.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolbert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponnusamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworkin, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, S.</span></span> <span> </span><span class="NLM_article-title">Genetic and pharmacologic blockade of EGFR inhibits renal fibrosis</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">854</span>â <span class="NLM_lpage">867</span>, <span class="refDoi">Â DOI: 10.1681/ASN.2011050493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1681%2FASN.2011050493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22362908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns12isbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=854-867&author=N.+Liuauthor=J.+K.+Guoauthor=M.+Pangauthor=E.+Tolbertauthor=M.+Ponnusamyauthor=R.+Gongauthor=G.+Baylissauthor=L.+D.+Dworkinauthor=H.+Yanauthor=S.+Zhuang&title=Genetic+and+pharmacologic+blockade+of+EGFR+inhibits+renal+fibrosis&doi=10.1681%2FASN.2011050493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis</span></div><div class="casAuthors">Liu, Na; Guo, Jian-Kan; Pang, Maoyin; Tolbert, Evelyn; Ponnusamy, Murugavel; Gong, Rujun; Bayliss, George; Dworkin, Lance D.; Yan, Haidong; Zhuang, Shougang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">854-867</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">Although enhanced activation of the EGF receptor (EGFR) assocs. with the development and progression of renal fibrosis, the mechanisms linking these observations are not completely understood.  Here, after unilateral ureteral obstruction (UUO), wild-type mice exhibited sustained EGFR phosphorylation in the kidney and developed renal fibrosis that was more severe than the renal fibrosis obsd. in waved-2 mice, which have reduced EGFR tyrosine kinase activity.  Waved-2 mice also showed fewer renal tubular cells arrested at G2/M, reduced expression of Î±-smooth muscle actin (Î±-SMA), downregulation of multiple genes encoding profibrogenic cytokines, including TGF-Î²1, and dephosphorylation of Smad3, STAT3, and ERK1/2.  Administration of the specific EGFR inhibitor gefitinib recapitulated this phenotype in wild-type mice after UUO.  Furthermore, inactivation of either EGFR or STAT3 reduced UUO-induced expression of lipocalin-2, a mol. assocd. with the pathogenesis of CKD.  In cultured renal interstitial fibroblasts, inhibition of EGFR also abrogated TGF-Î²1- or serum-induced phosphorylation of EGFR, STAT3, ERK1/2, and Smad3 as well as expression of Î±-SMA and extracelluar matrix proteins.  Taken together, these data suggest that EGFR may mediate renal fibrogenesis by promoting transition of renal epithelial cells to a profibrotic phenotype, increased prodn. of inflammatory factors, and activation of renal interstitial fibroblasts.  Inhibition of EGFR may have therapeutic potential for fibrotic kidney disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN8RUUw0GKybVg90H21EOLACvtfcHk0lgibFV88pHH6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns12isbo%253D&md5=012740de2ce38f4ed7c317173147d2ce</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1681%2FASN.2011050493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2011050493%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DJ.%2BK.%26aulast%3DPang%26aufirst%3DM.%26aulast%3DTolbert%26aufirst%3DE.%26aulast%3DPonnusamy%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DR.%26aulast%3DBayliss%26aufirst%3DG.%26aulast%3DDworkin%26aufirst%3DL.%2BD.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhuang%26aufirst%3DS.%26atitle%3DGenetic%2520and%2520pharmacologic%2520blockade%2520of%2520EGFR%2520inhibits%2520renal%2520fibrosis%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2012%26volume%3D23%26spage%3D854%26epage%3D867%26doi%3D10.1681%2FASN.2011050493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walton, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. A.</span></span> <span> </span><span class="NLM_article-title">Targeting TGF-Î² mediated SMAD signaling for the prevention of fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">461</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28769795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2nsr3M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=461&author=K.+L.+Waltonauthor=K.+E.+Johnsonauthor=C.+A.+Harrison&title=Targeting+TGF-%CE%B2+mediated+SMAD+signaling+for+the+prevention+of+fibrosis&doi=10.3389%2Ffphar.2017.00461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting TGF-Î² mediated SMAD signaling for the prevention of fibrosis</span></div><div class="casAuthors">Walton, Kelly L.; Johnson, Katharine E.; Harrison, Craig A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">461/1-461/11</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Fibrosis occurs when there is an imbalance in extracellular matrix (ECM) deposition and degrdn.  Excessive ECM deposition results in scarring and thickening of the affected tissue, and interferes with tissue and organ homeostasis - mimicking an exaggerated "wound healing" response.  Many transforming growth factor-Î² (TGF-Î²) ligands are potent drivers of ECM deposition, and addnl., have a natural affinity for the ECM, creating a concd. pool of pro-fibrotic factors at the site of injury.  Consequently, TGF-Î² ligands are upregulated in many human fibrotic conditions and, as such, are attractive targets for fibrosis therapy.  Here, we will discuss the contribution of TGF-Î² proteins in the pathogenesis of fibrosis, and promising anti-fibrotic approaches that target TGF-Î² ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5ECKO8MIXQrVg90H21EOLACvtfcHk0liEFg6Qu7za9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2nsr3M&md5=313823330d5d45a7a2aee6d67c90b640</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00461%26sid%3Dliteratum%253Aachs%26aulast%3DWalton%26aufirst%3DK.%2BL.%26aulast%3DJohnson%26aufirst%3DK.%2BE.%26aulast%3DHarrison%26aufirst%3DC.%2BA.%26atitle%3DTargeting%2520TGF-%25CE%25B2%2520mediated%2520SMAD%2520signaling%2520for%2520the%2520prevention%2520of%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D461%26doi%3D10.3389%2Ffphar.2017.00461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBleu, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosukonda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taduri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechtel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusckowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tampe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tampe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeisberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalluri, P.</span></span> <span> </span><span class="NLM_article-title">Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">396</span>â <span class="NLM_lpage">404</span>, <span class="refDoi">Â DOI: 10.1038/nm.2629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm.2629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22306733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslGktLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=396-404&author=H.+Sugimotoauthor=V.+S.+LeBleuauthor=D.+Bosukondaauthor=P.+Keckauthor=G.+Taduriauthor=W.+Bechtelauthor=H.+Okadaauthor=W.+Carlsonauthor=P.+Beyauthor=M.+Rusckowskiauthor=B.+Tampeauthor=D.+Tampeauthor=K.+Kanasakiauthor=M.+Zeisbergauthor=P.+Kalluri&title=Activin-like+kinase+3+is+important+for+kidney+regeneration+and+reversal+of+fibrosis&doi=10.1038%2Fnm.2629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis</span></div><div class="casAuthors">Sugimoto, Hikaru; LeBleu, Valerie S.; Bosukonda, Dattatreyamurty; Keck, Peter; Taduri, Gangadhar; Bechtel, Wibke; Okada, Hirokazu; Carlson, William; Bey, Philippe; Rusckowski, Mary; Tampe, Bjoern; Tampe, Desiree; Kanasaki, Keizo; Zeisberg, Michael; Kalluri, Raghu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">396-404</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mols. assocd. with the transforming growth factor Î² (TGF-Î²) superfamily, such as bone morphogenic proteins (BMPs) and TGF-Î², are key regulators of inflammation, apoptosis, and cellular transitions.  Here we show that the BMP receptor activin-like kinase 3 (Alk3) is elevated early in diseased kidneys after injury.  We also found that its deletion in the tubular epithelium leads to enhanced TGF-Î²1-Smad family member 3 (Smad3) signaling, epithelial damage, and fibrosis, suggesting a protective role for Alk3-mediated signaling in the kidney.  A structure-function anal. of the BMP-Alk3-BMP receptor, type 2 (BMPR2) ligand-receptor complex, along with synthetic org. chem., led us to construct a library of small peptide agonists of BMP signaling that function through the Alk3 receptor.  One such peptide agonist, THR-123, suppressed inflammation, apoptosis and the epithelial-to-mesenchymal transition program and reversed established fibrosis in 5 mouse models of acute and chronic renal injury.  THR-123 acts specifically through Alk3 signaling, as mice with a targeted deletion for Alk3 in their tubular epithelium did not respond to therapy with THR-123.  Combining THR-123 and the angiotensin-converting enzyme inhibitor captopril had an additive therapeutic benefit in controlling renal fibrosis.  Our studies show that BMP signaling agonists constitute a new line of therapeutic agents with potential utility in the clinic to induce regeneration, repair and reverse established fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXFd239-5fm7Vg90H21EOLACvtfcHk0lgEhHUZySMxQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslGktLs%253D&md5=db8ecebab61dc74ca3411b1d628b8203</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fnm.2629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2629%26sid%3Dliteratum%253Aachs%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DLeBleu%26aufirst%3DV.%2BS.%26aulast%3DBosukonda%26aufirst%3DD.%26aulast%3DKeck%26aufirst%3DP.%26aulast%3DTaduri%26aufirst%3DG.%26aulast%3DBechtel%26aufirst%3DW.%26aulast%3DOkada%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DW.%26aulast%3DBey%26aufirst%3DP.%26aulast%3DRusckowski%26aufirst%3DM.%26aulast%3DTampe%26aufirst%3DB.%26aulast%3DTampe%26aufirst%3DD.%26aulast%3DKanasaki%26aufirst%3DK.%26aulast%3DZeisberg%26aufirst%3DM.%26aulast%3DKalluri%26aufirst%3DP.%26atitle%3DActivin-like%2520kinase%25203%2520is%2520important%2520for%2520kidney%2520regeneration%2520and%2520reversal%2520of%2520fibrosis%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D396%26epage%3D404%26doi%3D10.1038%2Fnm.2629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, R.
E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zammit, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stapleton, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, D. J.</span></span> <span> </span><span class="NLM_article-title">A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e47160</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0047160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1371%2Fjournal.pone.0047160" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e47160&author=R.%0AE.+Gilbertauthor=Y.+Zhangauthor=S.+J.+Williamsauthor=S.+C.+Zammitauthor=D.+I.+Stapletonauthor=A.+J.+Coxauthor=H.+Krumauthor=R.+Langhamauthor=D.+J.+Kelly&title=A+purpose-synthesised+anti-fibrotic+agent+attenuates+experimental+kidney+diseases+in+the+rat&doi=10.1371%2Fjournal.pone.0047160"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0047160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0047160%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DR.%2BE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWilliams%26aufirst%3DS.%2BJ.%26aulast%3DZammit%26aufirst%3DS.%2BC.%26aulast%3DStapleton%26aufirst%3DD.%2BI.%26aulast%3DCox%26aufirst%3DA.%2BJ.%26aulast%3DKrum%26aufirst%3DH.%26aulast%3DLangham%26aufirst%3DR.%26aulast%3DKelly%26aufirst%3DD.%2BJ.%26atitle%3DA%2520purpose-synthesised%2520anti-fibrotic%2520agent%2520attenuates%2520experimental%2520kidney%2520diseases%2520in%2520the%2520rat%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De47160%26doi%3D10.1371%2Fjournal.pone.0047160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Renal fibrosis in 2015: Understanding the mechanisms of kidney fibrosis</span>. <i>Nat. Rev. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">68</span>â <span class="NLM_lpage">70</span>, <span class="refDoi">Â DOI: 10.1038/nrneph.2015.215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnrneph.2015.215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26714578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs12qtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=68-70&author=D.+Zhouauthor=Y.+Liu&title=Renal+fibrosis+in+2015%3A+Understanding+the+mechanisms+of+kidney+fibrosis&doi=10.1038%2Fnrneph.2015.215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Renal fibrosis in 2015 understanding the mechanisms of kidney fibrosis</span></div><div class="casAuthors">Zhou, Dong; Liu, Youhua</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Nephrology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">68-70</span>CODEN:
                <span class="NLM_cas:coden">NRNABO</span>;
        ISSN:<span class="NLM_cas:issn">1759-5061</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The year 2015 has seen great progress in the renal fibrosis field, as key studies began to build a consensus on the importance of epithelial-to-mesenchymal transition, cell cycle arrest, and defective metab. in the pathogenesis of kidney fibrosis.  New findings also point to a role of developmental signalling in renal fibrogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkJ8zl1sTVc7Vg90H21EOLACvtfcHk0lgEhHUZySMxQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs12qtw%253D%253D&md5=f6cf020b7c94e29f2e71ca8d4ececbc1</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnrneph.2015.215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneph.2015.215%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DRenal%2520fibrosis%2520in%25202015%253A%2520Understanding%2520the%2520mechanisms%2520of%2520kidney%2520fibrosis%26jtitle%3DNat.%2520Rev.%2520Nephrol.%26date%3D2016%26volume%3D12%26spage%3D68%26epage%3D70%26doi%3D10.1038%2Fnrneph.2015.215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. M.</span></span> <span> </span><span class="NLM_article-title">KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis</span>. <i>Nephrol., Dial., Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">313</span>â <span class="NLM_lpage">324</span>, <span class="refDoi">Â DOI: 10.1093/ndt/gft431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1093%2Fndt%2Fgft431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24166472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslyguro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=313-324&author=C.+Huangauthor=S.+Shenauthor=Q.+Maauthor=A.+Gillauthor=C.+A.+Pollockauthor=X.+M.+Chen&title=KCa3.1+mediates+activation+of+fibroblasts+in+diabetic+renal+interstitial+fibrosis&doi=10.1093%2Fndt%2Fgft431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis</span></div><div class="casAuthors">Huang, Chunling; Shen, Sylvie; Ma, Qing; Gill, Anthony; Pollock, Carol A.; Chen, Xin-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology, Dialysis, Transplantation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">313-324</span>CODEN:
                <span class="NLM_cas:coden">NDTREA</span>;
        ISSN:<span class="NLM_cas:issn">0931-0509</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background Fibroblast activation plays a crit. role in diabetic nephropathy (DN).  The Ca2+-activated K+ channel KCa3.1 mediates cellular proliferation of many cell types including fibroblasts.  KCa3.1 has been reported to be a potential mol. target for pharmacol. intervention in a diverse array of clin. conditions.  However, the role of KCa3.1 in the activation of myofibroblasts in DN is unknown.  These studies assessed the effect of KCa3.1 blockade on renal injury in exptl. diabetes.  Methods As TGF-Î²1 plays a central role in the activation of fibroblasts to myofibroblasts in renal interstitial fibrosis, human primary renal interstitial fibroblasts were incubated with TGF-Î²1 +/- the selective inhibitor of KCa3.1, TRAM34, for 48 h.  Two streptozotocin-induced diabetic mouse models were used in this study: wild-type KCa3.1+/+ and KCa3.1-/- mice, and secondly eNOS-/- mice treated with or without a selective inhibitor of KCa3.1 (TRAM34).  Then, markers of fibroblast activation and fibrosis were detd.  Results Blockade of KCa3.1 inhibited the upregulation of type I collagen, fibronectin, Î±-smooth muscle actin, vimentin and fibroblast-specific protein-1 in renal fibroblasts exposed to TGF-Î²1 and in kidneys from diabetic mice.  TRAM34 reduced TGF-Î²1-induced phosphorylation of Smad2/3 and ERK1/2 but not P38 and JNK MAPK in interstitial fibroblasts.  Conclusions These results suggest that blockade of KCa3.1 attenuates diabetic renal interstitial fibrogenesis through inhibiting activation of fibroblasts and phosphorylation of Smad2/3 and ERK1/2.  Therefore, therapeutic interventions to prevent or ameliorate DN through targeted inhibition of KCa3.1 deserve further consideration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyjWbmiONuerVg90H21EOLACvtfcHk0lgEhHUZySMxQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslyguro%253D&md5=d7b7a5d23d0d4dbb97406cfdd7d9aac2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgft431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgft431%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DGill%26aufirst%3DA.%26aulast%3DPollock%26aufirst%3DC.%2BA.%26aulast%3DChen%26aufirst%3DX.%2BM.%26atitle%3DKCa3.1%2520mediates%2520activation%2520of%2520fibroblasts%2520in%2520diabetic%2520renal%2520interstitial%2520fibrosis%26jtitle%3DNephrol.%252C%2520Dial.%252C%2520Transplant.%26date%3D2014%26volume%3D29%26spage%3D313%26epage%3D324%26doi%3D10.1093%2Fndt%2Fgft431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitch, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">JAK3/STAT6 stimulates bone-marrow-derived fibroblast activation in renal fibrosis</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3060</span>â <span class="NLM_lpage">3071</span>, <span class="refDoi">Â DOI: 10.1681/ASN.2014070717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1681%2FASN.2014070717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26032813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFGnsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=3060-3071&author=J.+Yanauthor=Z.+Zhangauthor=J.+Yangauthor=W.+E.+Mitchauthor=Y.+Wang&title=JAK3%2FSTAT6+stimulates+bone-marrow-derived+fibroblast+activation+in+renal+fibrosis&doi=10.1681%2FASN.2014070717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">JAK3/STAT6 stimulates bone marrow-derived fibroblast activation in renal fibrosis</span></div><div class="casAuthors">Yan, Jingyin; Zhang, Zhengmao; Yang, Jun; Mitch, William E.; Wang, Yanlin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3060-3071</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">Renal fibrosis is a final common manifestation of CKD resulting in progressive loss of kidney function.  Bone marrow-derived fibroblast precursors contribute significantly to the pathogenesis of renal fibrosis.  However, the signaling mechanisms underlying the activation of bone marrow-derived fibroblast precursors in the kidney are not fully understood.  In this study, we investigated the role of the Janus kinase 3 (JAK3)/signal transducer and activator of transcription (STAT6) signaling pathway in the activation of bone marrow-derived fibroblasts.  In cultured mouse monocytes, IL-4 or IL-13 activated STAT6 and induced expression of Î±-smooth muscle actin and extracellular matrix proteins (fibronectin and collagen I), which was abolished by a JAK3 inhibitor (CP690,550) in a dose-dependent manner or blocked in the absence of STAT6.  In vivo, STAT6 was activated in interstitial cells of the obstructed kidney, an effect that was abolished by CP690,550.  Mice treated with CP690,550 accumulated fewer bone marrow-derived fibroblasts in the obstructed kidneys compared with vehicle-treated mice.  Treatment with CP690,550 also significantly reduced myofibroblast transformation, matrix protein expression, fibrosis development, and apoptosis in obstructed kidneys.  Furthermore, STAT6-deficient mice accumulated fewer bone marrow-derived fibroblasts in the obstructed kidneys, produced less extracellular matrix protein, and developed much less fibrosis.  Finally, wild-type mice engrafted with STAT6-/- bone marrow cells displayed fewer bone marrow-derived fibroblasts in the obstructed kidneys and showed less severe renal fibrosis compared with wild-type mice engrafted with STAT6+/+ bone marrow cells.  Our results demonstrate that JAK3/STAT6 has an important role in bone marrow-derived fibroblast activation, extracellular matrix prodn., and interstitial fibrosis development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLBszkirUxgrVg90H21EOLACvtfcHk0lg9RDwml6kxBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFGnsro%253D&md5=7c55c38e56ac3744db0935656aff38f6</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1681%2FASN.2014070717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2014070717%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMitch%26aufirst%3DW.%2BE.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DJAK3%252FSTAT6%2520stimulates%2520bone-marrow-derived%2520fibroblast%2520activation%2520in%2520renal%2520fibrosis%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2015%26volume%3D26%26spage%3D3060%26epage%3D3071%26doi%3D10.1681%2FASN.2014070717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Zeeuw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasslacher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouni-Berthold, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potarca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerspink, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schall, T. J.</span></span> <span> </span><span class="NLM_article-title">CCX140-B Diabetic Nephropathy Study Group. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial</span>. <i>Lancet Diabetes Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">687</span>â <span class="NLM_lpage">696</span>, <span class="refDoi">Â DOI: 10.1016/S2213-8587(15)00261-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2FS2213-8587%2815%2900261-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26268910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCisbrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=687-696&author=D.+de%0AZeeuwauthor=P.+Bekkerauthor=E.+Henkelauthor=C.+Hasslacherauthor=I.+Gouni-Bertholdauthor=H.+Mehlingauthor=A.+Potarcaauthor=V.+Tesarauthor=H.+J.+Heerspinkauthor=T.+J.+Schall&title=CCX140-B+Diabetic+Nephropathy+Study+Group.+The+effect+of+CCR2+inhibitor+CCX140-B+on+residual+albuminuria+in+patients+with+type+2+diabetes+and+nephropathy%3A+a+randomised+trial&doi=10.1016%2FS2213-8587%2815%2900261-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial</span></div><div class="casAuthors">de Zeeuw, Dick; Bekker, Pirow; Henkel, Elena; Hasslacher, Christopher; Gouni-Berthold, Ioanna; Mehling, Heidrun; Potarca, Antonia; Tesar, Vladimir; Heerspink, Hiddo J. Lambers; Schall, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Diabetes & Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">687-696</span>CODEN:
                <span class="NLM_cas:coden">LDEAAS</span>;
        ISSN:<span class="NLM_cas:issn">2213-8587</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with type 2 diabetes and nephropathy have high cardiorenal morbidity and mortality despite optimum treatment including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).  Residual risk is related to residual albuminuria.  We assessed whether CCX140-B, a selective inhibitor of C-C chemokine receptor type 2 (CCR2), could further reduce albuminuria when given in addn. to std. care, including ACE inhibitors or ARBs.  In this randomised, double-blind, placebo-controlled clin. trial, we recruited patients from 78 research centers in Belgium, Czech Republic, Germany, Hungary, Poland, and the UK.  We enrolled patients with type 2 diabetes aged 18-75 years with proteinuria (first morning void urinary albumin to creatinine ratio [UACR] 100-3000 mg/g), estd. glomerular filtration rate of 25 mL/min per 1Â·73 m2 or higher, and taking stable antidiabetic treatment and ACE inhibitors or ARBs, for at least 8 wk before study entry.  Patients were stratified based on baseline UACR and renal function (estd. glomerular filtration rate), and then randomly assigned (1:1:1) via an interactive web response system with a minimisation algorithm to oral placebo, 5 mg CCX140-B, or 10 mg CCX140-B once a day.  The 12-wk dosing period in the initial protocol was extended to 52 wk by protocol amendment.  The primary efficacy measure was change from baseline in UACR during 52 wk in the modified intention-to-treat population (all patients with uninterrupted dosing, excluding patients who stopped dosing at week 12 either permanently under the original protocol, or temporarily because of delay in approval of the protocol amendment).  We did safety analyses on all randomly assigned patients who received at least one dose of study drug.  According to a prespecified anal. plan, we analyzed the primary endpoint with one-sided statistical testing with calcn. of upper 95% confidence limits of the differences between active and control.  This trial is registered with ClinicalTrials.gov, no. NCT01447147.  The study ran from Dec 7, 2011 (first patient enrolled), until Aug 4, 2014.  We enrolled 332 patients: 111 were assigned to receive placebo, 110 to 5 mg CCX140-B, and 111 to 10 mg CCX140-B.  Of these, 192 were included in the modified intention-to-treat population.  UACR changes from baseline during 52 wk were -2% for placebo (95% CI -11% to 9%), -18% for 5 mg CCX140-B (-26% to -8%), and -11% for 10 mg CCX140-B (-20% to -1%).  We recorded a -16% difference between 5 mg CCX140-B and placebo (one-sided upper 95% confidence limit -5%; p=0Â·01) and a -10% difference between 10 mg CCX140-B and placebo (upper 95% confidence limit 2%; p=0Â·08).  Adverse events occurred in 81 (73%) of 111 patients in the placebo group vs. 71 (65%) of 110 patients in the CCX140-B 5 mg group and 68 (61%) of 111 patients in the CCX140-B 10 mg group; there were no renal events during the study.  Our data suggest that CCR2 inhibition with CCX140-B has renoprotective effects on top of current std. of care in patients with type 2 diabetes and nephropathy.ChemoCentryx.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqarqWvXCzPfLVg90H21EOLACvtfcHk0lg9RDwml6kxBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCisbrF&md5=6eb7cea04fe6b0312c360a487b6cffbf</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS2213-8587%2815%2900261-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-8587%252815%252900261-2%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BZeeuw%26aufirst%3DD.%26aulast%3DBekker%26aufirst%3DP.%26aulast%3DHenkel%26aufirst%3DE.%26aulast%3DHasslacher%26aufirst%3DC.%26aulast%3DGouni-Berthold%26aufirst%3DI.%26aulast%3DMehling%26aufirst%3DH.%26aulast%3DPotarca%26aufirst%3DA.%26aulast%3DTesar%26aufirst%3DV.%26aulast%3DHeerspink%26aufirst%3DH.%2BJ.%26aulast%3DSchall%26aufirst%3DT.%2BJ.%26atitle%3DCCX140-B%2520Diabetic%2520Nephropathy%2520Study%2520Group.%2520The%2520effect%2520of%2520CCR2%2520inhibitor%2520CCX140-B%2520on%2520residual%2520albuminuria%2520in%2520patients%2520with%2520type%25202%2520diabetes%2520and%2520nephropathy%253A%2520a%2520randomised%2520trial%26jtitle%3DLancet%2520Diabetes%2520Endocrinol.%26date%3D2015%26volume%3D3%26spage%3D687%26epage%3D696%26doi%3D10.1016%2FS2213-8587%2815%2900261-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span> <span> </span><span class="NLM_article-title">Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2197</span>â <span class="NLM_lpage">2212</span>, <span class="refDoi">Â DOI: 10.1021/jm400658e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400658e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFynsrvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2197-2212&author=L.+Juillerat-Jeanneret&title=Dipeptidyl+peptidase+IV+and+its+inhibitors%3A+therapeutics+for+type+2+diabetes+and+what+else%3F&doi=10.1021%2Fjm400658e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Dipeptidyl Peptidase IV and Its Inhibitors: Therapeutics for Type 2 Diabetes and What Else?</span></div><div class="casAuthors">Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2197-2212</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The proline-specific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26), widely expressed in mammalians, releases X-Pro/Ala dipeptides from the N-terminus of peptides.  DPP IV is responsible of the degrdn. of the incretin peptide hormones regulating blood glucose levels.  Several families of DPP IV inhibitors have been synthesized and evaluated.  Their pos. effects on the degrdn. of the incretins and the control of blood glucose levels have been demonstrated in biol. models and in clin. trials.  Presently, several DPP IV inhibitors, the "gliptins", are approved for type 2 diabetes or are under clin. evaluation.  However, the gliptins may also be of therapeutic interest for other diseases beyond the inhibition of incretin degrdn.  In this Perspective, the biol. functions and potential substrates of DPP IV enzymes are reviewed and the characteristics of the DPP IV inhibitors are discussed in view of type 2 diabetes and further therapeutic interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWd_YPU84lhrVg90H21EOLACvtfcHk0lg9RDwml6kxBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFynsrvK&md5=f7ff160773940e307ddc3dc1495053b6</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm400658e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400658e%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DDipeptidyl%2520peptidase%2520IV%2520and%2520its%2520inhibitors%253A%2520therapeutics%2520for%2520type%25202%2520diabetes%2520and%2520what%2520else%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2197%26epage%3D2212%26doi%3D10.1021%2Fjm400658e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, D.</span></span> <span> </span><span class="NLM_article-title">N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">70</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24782774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvVeqtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=70&author=K.+Kanasakiauthor=T.+Nagaiauthor=K.+Nittaauthor=M.+Kitadaauthor=D.+Koya&title=N-acetyl-seryl-aspartyl-lysyl-proline%3A+a+valuable+endogenous+anti-fibrotic+peptide+for+combating+kidney+fibrosis+in+diabetes&doi=10.3389%2Ffphar.2014.00070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes</span></div><div class="casAuthors">Kanasaki Keizo; Nagai Takako; Nitta Kyoko; Kitada Munehiro; Koya Daisuke</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">70</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Fibroproliferative diseases are responsible for 45% of deaths in the developed world.  Curing organ fibrosis is essential for fibroproliferative diseases.  Diabetic nephropathy is a common fibroproliferative disease of the kidney and is associated with multiorgan dysfunction.  However, therapy to combat diabetic nephropathy has not yet been established.  In this review, we discuss the novel therapeutic possibilities for kidney fibrosis in diabetes focusing on the endogenous anti-fibrotic peptide, N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), which is the substrate for angiotensin-converting enzyme and exhibits meaningful anti-fibrotic effects in various experimental models of fibrotic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZfmq9ctleGs25P7XSLhESfW6udTcc2eYNRcowN9cS6bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvVeqtQ%253D%253D&md5=910d0627fe05257c118d9f528d9a5333</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00070%26sid%3Dliteratum%253Aachs%26aulast%3DKanasaki%26aufirst%3DK.%26aulast%3DNagai%26aufirst%3DT.%26aulast%3DNitta%26aufirst%3DK.%26aulast%3DKitada%26aufirst%3DM.%26aulast%3DKoya%26aufirst%3DD.%26atitle%3DN-acetyl-seryl-aspartyl-lysyl-proline%253A%2520a%2520valuable%2520endogenous%2520anti-fibrotic%2520peptide%2520for%2520combating%2520kidney%2520fibrosis%2520in%2520diabetes%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D70%26doi%3D10.3389%2Ffphar.2014.00070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boutet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Frutos, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayol, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, M. A.</span></span> <span> </span><span class="NLM_article-title">Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5603</span>â <span class="NLM_lpage">5613</span>, <span class="refDoi">Â DOI: 10.1038/sj.emboj.7601421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fsj.emboj.7601421" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=5603-5613&author=A.+Boutetauthor=C.+A.+De+Frutosauthor=P.+H.+Maxwellauthor=M.+J.+Mayolauthor=J.+Romeroauthor=M.+A.+Nieto&title=Snail+activation+disrupts+tissue+homeostasis+and+induces+fibrosis+in+the+adult+kidney&doi=10.1038%2Fsj.emboj.7601421"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601421%26sid%3Dliteratum%253Aachs%26aulast%3DBoutet%26aufirst%3DA.%26aulast%3DDe%2BFrutos%26aufirst%3DC.%2BA.%26aulast%3DMaxwell%26aufirst%3DP.%2BH.%26aulast%3DMayol%26aufirst%3DM.%2BJ.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DNieto%26aufirst%3DM.%2BA.%26atitle%3DSnail%2520activation%2520disrupts%2520tissue%2520homeostasis%2520and%2520induces%2520fibrosis%2520in%2520the%2520adult%2520kidney%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26spage%3D5603%26epage%3D5613%26doi%3D10.1038%2Fsj.emboj.7601421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span> <span> </span><span class="NLM_article-title">Lovastatin alleviates endothelial-to-mesenchymal transition in glomeruli via suppression of oxidative stress and TGF-Î²1 signaling</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">473</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28769803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2ns7bK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=473&author=Z.+Maauthor=L.+Zhuauthor=Y.+Liuauthor=Z.+Wangauthor=Y.+Yangauthor=L.+Chenauthor=Q.+Lu&title=Lovastatin+alleviates+endothelial-to-mesenchymal+transition+in+glomeruli+via+suppression+of+oxidative+stress+and+TGF-%CE%B21+signaling&doi=10.3389%2Ffphar.2017.00473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Lovastatin alleviates endothelial-to-mesenchymal transition in glomeruli via suppression of oxidative stress and TGF-Î²1 signaling</span></div><div class="casAuthors">Ma, Zejun; Zhu, Lili; Liu, Yan; Wang, Zhida; Yang, Yang; Chen, Liming; Lu, Qiulun</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">473/1-473/10</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Statins may decrease chronic kidney diseases (CKDs) risk, but their underlying mol. mechanisms are not completely understood.  Recent studies indicate Endothelial-to-mesenchymal transition (EndMT) plays an important role contributing to renal interstitial fibrosis.  In the present study, we first investigated whether lovastatin could ameliorate renal fibrosis via suppression of EndMT and its possible mechanism.  In vitro expts., lovastatin significantly ameliorated microalbuminuria and pathol. changes in diabetic rats.  Double labeling immunofluorescence showed lovastatin could inhibit EndMT in glomeruli.  Furthermore, lovastatin could inhibit oxidative stress and down-regulate TGF-Î²1-Smad signaling.  Consistent alterations were obsd. in vivo that lovastatin substantially suppressed EndMT and TGF-Î²1 signaling induced by high glucose in glomerular endothelial cells (GEnCs).  These data indicated that lovastatin could ameliorate EndMT in glomeruli in diabetic nephropathy, the mechanism of which might be at least partly through suppression of oxidative stress and TGF-Î²1/Smad signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoeubp74PzJLVg90H21EOLACvtfcHk0lh9dvDINpAacg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2ns7bK&md5=e17d2579fe481902e60a43c322d6d2b9</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00473%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DQ.%26atitle%3DLovastatin%2520alleviates%2520endothelial-to-mesenchymal%2520transition%2520in%2520glomeruli%2520via%2520suppression%2520of%2520oxidative%2520stress%2520and%2520TGF-%25CE%25B21%2520signaling%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D473%26doi%3D10.3389%2Ffphar.2017.00473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheele, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clerin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamimi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grover-PÃ¡ez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros-Huguet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolph, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Nahas, M.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3459</span>â <span class="NLM_lpage">3468</span>, <span class="refDoi">Â DOI: 10.1681/ASN.2015050473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1681%2FASN.2015050473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=27113485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOru7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=3459-3468&author=W.+Scheeleauthor=S.+Diamondauthor=J.+Galeauthor=V.+Clerinauthor=N.+Tamimiauthor=V.+Leauthor=R.+Walleyauthor=F.+Grover-P%C3%A1ezauthor=C.+Perros-Huguetauthor=T.+Rolphauthor=M.+El+Nahas&title=Phosphodiesterase+type+5+inhibition+reduces+albuminuria+in+subjects+with+overt+diabetic+nephropathy&doi=10.1681%2FASN.2015050473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy</span></div><div class="casAuthors">Scheele, Wim; Diamond, Susan; Gale, Jeremy; Clerin, Valerie; Tamimi, Nihad; Le, Vu; Walley, Rosalind; Grover-Paez, Fernando; Perros-Huguet, Christelle; Rolph, Timothy; El Nahas, Meguid</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3459-3468</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">Diabetic nephropathy (DN) is the leading cause of ESRD worldwide.  Reduced bioavailability or uncoupling of nitric oxide in the kidney, leading to decreased intracellular levels of the nitric oxide pathway effector mol. cyclic guanosine monophosphate (cGMP), has been implicated in the progression of DN.  Preclin. studies suggest that elevating the cGMP intracellular pool through inhibition of the cGMP-hydrolyzing enzyme phosphodiesterase type 5 (PDE5) might exert renoprotective effects in DN.  To test this hypothesis, the novel, highly specific, and long-acting PDE5 inhibitor, PF-00489791, was assessed in a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group trial of subjects with type 2 diabetes mellitus and overt nephropathy receiving angiotensin converting enzyme inhibitor or angiotensin receptor blocker background therapy.  In total, 256 subjects with an eGFR between 25 and 60 mL/min per 1.73 m2 and macroalbuminuria defined by a urinary albumin-to-creatinine ratio >300 mg/g, were randomly assigned 3:1, resp., to receive PF-00489791 (20 mg) or placebo orally, once daily for 12 wk.  Using the predefined primary assessment of efficacy (Bayesian anal. with informative prior), we obsd. a significant redn. in urinary albumin-to-creatinine ratio of 15.7% (ratio 0.843; 95% credible interval 0.73 to 0.98) in response to the 12-wk treatment with PF-00489791 compared with placebo.  PF-00489791 was safe and generally well tolerated in this patient population.  Most common adverse events were mild in severity and included headache and upper gastrointestinal events.  In conclusion, the safety and efficacy profile of PDE5 inhibitor PF-00489791 supports further investigation as a novel therapy to improve renal outcomes in DN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuWrAOhY1Dj7Vg90H21EOLACvtfcHk0lh6Y_4PBzxalQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOru7o%253D&md5=386d1c840e15e0184c7b5f64f1fb9894</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1681%2FASN.2015050473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2015050473%26sid%3Dliteratum%253Aachs%26aulast%3DScheele%26aufirst%3DW.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DGale%26aufirst%3DJ.%26aulast%3DClerin%26aufirst%3DV.%26aulast%3DTamimi%26aufirst%3DN.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DWalley%26aufirst%3DR.%26aulast%3DGrover-P%25C3%25A1ez%26aufirst%3DF.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DRolph%26aufirst%3DT.%26aulast%3DEl%2BNahas%26aufirst%3DM.%26atitle%3DPhosphodiesterase%2520type%25205%2520inhibition%2520reduces%2520albuminuria%2520in%2520subjects%2520with%2520overt%2520diabetic%2520nephropathy%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2016%26volume%3D27%26spage%3D3459%26epage%3D3468%26doi%3D10.1681%2FASN.2015050473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thannickal, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, S. R.</span></span> <span> </span><span class="NLM_article-title">Fibrosis: ultimate and proximate causes</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">4673</span>â <span class="NLM_lpage">4677</span>, <span class="refDoi">Â DOI: 10.1172/JCI74368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI74368" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=4673-4677&author=V.+J.+Thannickalauthor=Y.+Zhouauthor=A.+Gaggarauthor=S.+R.+Duncan&title=Fibrosis%3A+ultimate+and+proximate+causes&doi=10.1172%2FJCI74368"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1172%2FJCI74368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI74368%26sid%3Dliteratum%253Aachs%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DGaggar%26aufirst%3DA.%26aulast%3DDuncan%26aufirst%3DS.%2BR.%26atitle%3DFibrosis%253A%2520ultimate%2520and%2520proximate%2520causes%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D4673%26epage%3D4677%26doi%3D10.1172%2FJCI74368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranghino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussolati, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moggio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimuccio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapparo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biancone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gontero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frea, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camussi, G.</span></span> <span> </span><span class="NLM_article-title">The effects of glomerular and tubular renal progenitors and derived extracellular vesicles on recovery from acute kidney injury</span>. <i>Stem Cell Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi">Â DOI: 10.1186/s13287-017-0478-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1186%2Fs13287-017-0478-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28173878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVahurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=24&author=A.+Ranghinoauthor=S.+Brunoauthor=B.+Bussolatiauthor=A.+Moggioauthor=V.+Dimuccioauthor=M.+Tapparoauthor=L.+Bianconeauthor=P.+Gonteroauthor=B.+Freaauthor=G.+Camussi&title=The+effects+of+glomerular+and+tubular+renal+progenitors+and+derived+extracellular+vesicles+on+recovery+from+acute+kidney+injury&doi=10.1186%2Fs13287-017-0478-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of glomerular and tubular renal progenitors and derived extracellular vesicles on recovery from acute kidney injury</span></div><div class="casAuthors">Ranghino, Andrea; Bruno, Stefania; Bussolati, Benedetta; Moggio, Aldo; Dimuccio, Veronica; Tapparo, Marta; Biancone, Luigi; Gontero, Paolo; Frea, Bruno; Camussi, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Research & Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24/1-24/15</span>CODEN:
                <span class="NLM_cas:coden">SCRTEK</span>;
        ISSN:<span class="NLM_cas:issn">1757-6512</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Mesenchymal stromal cells (MSCs) and renal stem/progenitors improve the recovery of acute kidney injury (AKI) mainly through the release of paracrine mediators including the extracellular vesicles (EVs).  Several studies have reported the existence of a resident population of MSCs within the glomeruli (Gl-MSCs).  However, their contribution towards kidney repair still remains to be elucidated.  The aimof the present study was to evaluate whether Gl-MSCs and Gl-MSC-EVs promote the recovery of AKI induced by ischemia-reperfusion injury (IRI) in SCID mice.  Moreover, the effects of Gl-MSCs and Gl-MSC-EVs were compared with those of CD133+ progenitor cells isolated from human tubules of the renal cortical tissue (T-CD133+ cells) and their EVs (T-CD133+-EVs).  Methods: IRI was performed in mice by clamping the left renal pedicle for 35 min together with a right nephrectomy.  Immediately after reperfusion, the animals were divided in different groups to be treated with: Gl-MSCs, T-CD133+ cells, Gl-MSC-EVs, T-CD133+-EVs or vehicle.  To assess the role of vesicular RNA, EVs were either isolated by floating to avoid contamination of non-vesicles-assocd. RNA or treated with a high dose of RNase.  Mice were sacrificed 48 h after surgery.  Results: Gl-MSCs, and Gl-MSC-EVs both ameliorate kidney function and reduce the ischemic damage post IRI by activating tubular epithelial cell proliferation.  Furthermore, T-CD133+ cells, but not their EVs, also significantly contributed to the renal recovery after IRI compared to the controls.  Floating EVs were effective while RNase-inactivated EVs were ineffective.  Anal. of the EV miRnome revealed that Gl-MSC-EVs selectively expressed a group of miRNAs, compared to EVs derived from fibroblasts, which were biol. ineffective in IRI.  Conclusions: In this study, we demonstrate that Gl-MSCs may contribute in the recovery of mice with AKI induced by IRI primarily through the release of EVs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1TgkCExYuDLVg90H21EOLACvtfcHk0lh6Y_4PBzxalQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVahurw%253D&md5=5878116d772b15c228cef4727135c6d2</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1186%2Fs13287-017-0478-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13287-017-0478-5%26sid%3Dliteratum%253Aachs%26aulast%3DRanghino%26aufirst%3DA.%26aulast%3DBruno%26aufirst%3DS.%26aulast%3DBussolati%26aufirst%3DB.%26aulast%3DMoggio%26aufirst%3DA.%26aulast%3DDimuccio%26aufirst%3DV.%26aulast%3DTapparo%26aufirst%3DM.%26aulast%3DBiancone%26aufirst%3DL.%26aulast%3DGontero%26aufirst%3DP.%26aulast%3DFrea%26aufirst%3DB.%26aulast%3DCamussi%26aufirst%3DG.%26atitle%3DThe%2520effects%2520of%2520glomerular%2520and%2520tubular%2520renal%2520progenitors%2520and%2520derived%2520extracellular%2520vesicles%2520on%2520recovery%2520from%2520acute%2520kidney%2520injury%26jtitle%3DStem%2520Cell%2520Res.%2520Ther.%26date%3D2017%26volume%3D8%26spage%3D24%26doi%3D10.1186%2Fs13287-017-0478-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahokas, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerling, I. C.</span></span> <span> </span><span class="NLM_article-title">Myofibroblast-mediated mechanisms of pathological remodeling of the heart</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">15</span>â <span class="NLM_lpage">26</span>, <span class="refDoi">Â DOI: 10.1038/nrcardio.2012.158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnrcardio.2012.158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23207731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvV2gtrfO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=15-26&author=K.+T.+Weberauthor=Y.+Sunauthor=S.+K.+Bhattacharyaauthor=R.+A.+Ahokasauthor=I.+C.+Gerling&title=Myofibroblast-mediated+mechanisms+of+pathological+remodeling+of+the+heart&doi=10.1038%2Fnrcardio.2012.158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Myofibroblast-mediated mechanisms of pathological remodelling of the heart</span></div><div class="casAuthors">Weber, Karl T.; Sun, Yao; Bhattacharya, Syamal K.; Ahokas, Robert A.; Gerling, Ivan C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-26</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The syncytium of cardiomyocytes in the heart is tethered within a matrix composed principally of type I fibrillar collagen.  The matrix has diverse mech. functions that ensure the optimal contractile efficiency of this muscular pump.  In the diseased heart, cardiomyocytes are lost to necrotic cell death, and phenotypically transformed fibroblast-like cells-termed 'myofibroblasts'-are activated to initiate a 'reparative' fibrosis.  The structural integrity of the myocardium is preserved by this scar tissue, although at the expense of its remodelled architecture, which has increased tissue stiffness and propensity to arrhythmias.  A persisting population of activated myofibroblasts turns this fibrous tissue into a living 'secretome' that generates angiotensin II and its type 1 receptor, and fibrogenic growth factors (such as transforming growth factor-Î²), all of which collectively act as a signal-transducer-effector signalling pathway to type I collagen synthesis and, therefore, fibrosis.  Persistent myofibroblasts, and the resultant fibrous tissue they produce, cause progressive adverse myocardial remodelling, a pathol. hallmark of the failing heart irresp. of its etiol. origin.  Herein, we review relevant cellular, subcellular, and mol. mechanisms integral to cardiac fibrosis and consequent remodelling of atria and ventricles with a heterogeneity in cardiomyocyte size.  Signalling pathways that antagonize collagen fibrillogenesis provide novel strategies for cardioprotection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVeP8kxRg0zrVg90H21EOLACvtfcHk0lhRVLbaMNPn5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvV2gtrfO&md5=61bbe8d33f74ca318772709b734408fd</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2012.158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2012.158%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DK.%2BT.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26aulast%3DAhokas%26aufirst%3DR.%2BA.%26aulast%3DGerling%26aufirst%3DI.%2BC.%26atitle%3DMyofibroblast-mediated%2520mechanisms%2520of%2520pathological%2520remodeling%2520of%2520the%2520heart%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2013%26volume%3D10%26spage%3D15%26epage%3D26%26doi%3D10.1038%2Fnrcardio.2012.158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tillmanns, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habbaba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitto, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedding, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraccarollo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galuppo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauersachs, J.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardiac infarction</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">194</span>â <span class="NLM_lpage">203</span>, <span class="refDoi">Â DOI: 10.1016/j.yjmcc.2015.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.yjmcc.2015.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26319660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFeht7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=194-203&author=J.+Tillmannsauthor=D.+Hoffmannauthor=Y.+Habbabaauthor=J.+D.+Schmittoauthor=D.+Seddingauthor=D.+Fraccarolloauthor=P.+Galuppoauthor=J.+Bauersachs&title=Fibroblast+activation+protein+alpha+expression+identifies+activated+fibroblasts+after+myocardiac+infarction&doi=10.1016%2Fj.yjmcc.2015.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction</span></div><div class="casAuthors">Tillmanns, Jochen; Hoffmann, Daniel; Habbaba, Yasmin; Schmitto, Jan D.; Sedding, Daniel; Fraccarollo, Daniela; Galuppo, Paolo; Bauersachs, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">194-203</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fibroblast activation protein Î± (FAP) is a membrane-bound serine protease expressed by activated fibroblasts during wound healing in the skin.  Expression of FAP after myocardial infarction (MI) and potential effects on cardiac wound healing are largely unknown.  MI was induced in rats and FAP expression was analyzed at 3, 7 and 28 days post-MI by microarray, Western blot and immunohistochem.  In human hearts after MI, a FAP+ fibroblast population was identified, and characterized by immunohistochem. for prolyl-4-hydroxylase Î², Î±-smooth muscle actin, Thy-1 and vimentin.  Signaling pathways leading to FAP expression were studied in human cardiac fibroblasts by Western blot and ELISA using TGFÎ²1, TGF-beta type I-receptor (TGFbR1)-inhibitor SB431542 or the MAPK-inhibitor U0126 as well as siRNA targeting SMAD2 and SMAD3.  Finally, fibroblasts were assayed for FAP-dependent migration (modified Boyden-chamber), proliferation (BrdU-assay) and gelatinolytic activity by gelatin zymog.  In rats, FAP expression was increased after MI esp. in the peri-infarct area peaking at 7 days post-MI.  Co-localization anal. identified the majority of FAP+ cells as activated proto-myofibroblasts and myofibroblasts.  Concordantly, FAP+ fibroblasts were abundant in ischemic tissue of human hearts after MI, but not in healthy control hearts.  In vitro, FAP was induced by TGFÎ²1 via the canonical SMAD2/SMAD3 pathway.  Depletion of FAP in fibroblasts reduced migratory capacity, while proliferation was not affected.  Gelatin zymog. revealed gelatinase activity by fibroblast-derived FAP.  In this study, we show for the first time the expression of FAP in activated fibroblasts after MI and its activation by TGFÎ²1.  Effects of FAP on fibroblast migration and gelatinolytic activity indicate a potential role in cardiac wound healing and remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkduzibIcGTLVg90H21EOLACvtfcHk0lhRVLbaMNPn5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFeht7zP&md5=979deaf019af45915ad8192b352a7b88</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2015.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2015.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DTillmanns%26aufirst%3DJ.%26aulast%3DHoffmann%26aufirst%3DD.%26aulast%3DHabbaba%26aufirst%3DY.%26aulast%3DSchmitto%26aufirst%3DJ.%2BD.%26aulast%3DSedding%26aufirst%3DD.%26aulast%3DFraccarollo%26aufirst%3DD.%26aulast%3DGaluppo%26aufirst%3DP.%26aulast%3DBauersachs%26aufirst%3DJ.%26atitle%3DFibroblast%2520activation%2520protein%2520alpha%2520expression%2520identifies%2520activated%2520fibroblasts%2520after%2520myocardiac%2520infarction%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2015%26volume%3D87%26spage%3D194%26epage%3D203%26doi%3D10.1016%2Fj.yjmcc.2015.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. S.</span></span> <span> </span><span class="NLM_article-title">Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e35007</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0035007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1371%2Fjournal.pone.0035007" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e35007&author=S.+Limauthor=S.+H.+Choiauthor=H.+Shinauthor=B.+J.+Choauthor=H.+S.+Parkauthor=B.+Y.+Ahnauthor=S.+M.+Kangauthor=J.+W.+Yoonauthor=H.+C.+Jangauthor=Y.+B.+Kimauthor=K.+S.+Park&title=Effect+of+a+dipeptidyl+peptidase-IV+inhibitor%2C+des-fluoro-sitagliptin%2C+on+neointimal+formation+after+balloon+injury+in+rats&doi=10.1371%2Fjournal.pone.0035007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0035007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0035007%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DShin%26aufirst%3DH.%26aulast%3DCho%26aufirst%3DB.%2BJ.%26aulast%3DPark%26aufirst%3DH.%2BS.%26aulast%3DAhn%26aufirst%3DB.%2BY.%26aulast%3DKang%26aufirst%3DS.%2BM.%26aulast%3DYoon%26aufirst%3DJ.%2BW.%26aulast%3DJang%26aufirst%3DH.%2BC.%26aulast%3DKim%26aufirst%3DY.%2BB.%26aulast%3DPark%26aufirst%3DK.%2BS.%26atitle%3DEffect%2520of%2520a%2520dipeptidyl%2520peptidase-IV%2520inhibitor%252C%2520des-fluoro-sitagliptin%252C%2520on%2520neointimal%2520formation%2520after%2520balloon%2520injury%2520in%2520rats%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De35007%26doi%3D10.1371%2Fjournal.pone.0035007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, A. M.</span></span> <span> </span><span class="NLM_article-title">A clinical perspective of anti-fibrotic therapies for cardiovascular diseases</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">186</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28428753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvFWjtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=186&author=L.+Fangauthor=A.+J.+Murphyauthor=A.+M.+Dart&title=A+clinical+perspective+of+anti-fibrotic+therapies+for+cardiovascular+diseases&doi=10.3389%2Ffphar.2017.00186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">A clinical perspective of anti-fibrotic therapies for cardiovascular disease</span></div><div class="casAuthors">Fang, Lu; Murphy, Andrew J.; Dart, Anthony M.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">186/1-186/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Cardiac fibrosis are central to various cardiovascular diseases.  Research on the mechanisms and therapeutic targets for cardiac fibrosis has advanced greatly in recent years.  However, while many anti-fibrotic treatments have been studied in animal models and seem promising, translation of exptl. findings into human patients has been rather limited.  Thus, several potential new treatments which have shown to reduce cardiac fibrosis in animal models have either not been tested in humans or proved to be disappointing in clin. trials.  A majority of clin. studies are of small size or have not been maintained for long enough periods.  In addn., although some conventional therapies, such as renin-angiotensin-aldosterone system (RAAS) inhibitors, have been shown to reduce cardiac fibrosis in humans, cardiac fibrosis persists in patients with heart failure even when treated with these conventional therapies, indicating a need to develop novel and effective anti-fibrotic therapies in cardiovascular disease.  In this review article, we summarize anti-fibrotic therapies for cardiovascular disease in humans, discuss the limitations of currently used therapies, along with possible reasons for the failure of so many anti-fibrotic drugs at the clin. level.  We will then explore the future directions of anti-fibrotic therapies on cardiovascular disease, and this will include emerging anti-fibrotics that show promise, such as relaxin.  A better understanding of the differences between animal models and human pathol., and improved insight into carefully designed trials on appropriate end-points and appropriate dosing need to be considered to identify more effective anti-fibrotics for treating cardiovascular fibrosis in human patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn2yH71JqfzLVg90H21EOLACvtfcHk0lhK0UYvk8uSLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvFWjtrY%253D&md5=0296828eb268e985bf2d6acedfab457d</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00186%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DL.%26aulast%3DMurphy%26aufirst%3DA.%2BJ.%26aulast%3DDart%26aufirst%3DA.%2BM.%26atitle%3DA%2520clinical%2520perspective%2520of%2520anti-fibrotic%2520therapies%2520for%2520cardiovascular%2520diseases%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D186%26doi%3D10.3389%2Ffphar.2017.00186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brokopp, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmert, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aikawa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ¼scher, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoerstrup, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, C. M.</span></span> <span> </span><span class="NLM_article-title">Fibroblasts activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2713</span>â <span class="NLM_lpage">2722</span>, <span class="refDoi">Â DOI: 10.1093/eurheartj/ehq519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1093%2Feurheartj%2Fehq519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=21292680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGnu7nO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=2713-2722&author=C.+E.+Brokoppauthor=R.+Schoenauerauthor=P.+Richardsauthor=S.+Bauerauthor=C.+Lohmannauthor=M.+Y.+Emmertauthor=B.+Weberauthor=S.+Winnikauthor=E.+Aikawaauthor=K.+Gravesauthor=M.+Genoniauthor=P.+Vogtauthor=T.+F.+L%C3%BCscherauthor=C.+Rennerauthor=S.+P.+Hoerstrupauthor=C.+M.+Matter&title=Fibroblasts+activation+protein+is+induced+by+inflammation+and+degrades+type+I+collagen+in+thin-cap+fibroatheromata&doi=10.1093%2Feurheartj%2Fehq519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata</span></div><div class="casAuthors">Brokopp, Chad E.; Schoenauer, Roman; Richards, Peter; Bauer, Stefan; Lohmann, Christine; Emmert, Maximilian Y.; Weber, Benedikt; Winnik, Stephan; Aikawa, Elena; Graves, Kirk; Genoni, Michele; Vogt, Peter; Luescher, Thomas F.; Renner, Christoph; Hoerstrup, Simon P.; Matter, Christian M.</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2713-2722</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims Collagen degrdn. in atherosclerotic plaques with thin fibrous caps renders them more prone to rupture.  Fibroblast activation protein (FAP) plays a role in arthritis and tumor formation through its collagenase activity.  However, the significance of FAP in thin-cap human fibroatheromata remains unknown.  Methods and results We detected enhanced FAP expression in type IV-V human aortic atheromata (n = 12), compared with type II-III lesions (n = 9; P < 0.01) and healthy aortae (n = 8; P < 0.01) by immunostaining and western blot analyses.  Fibroblast activation protein was also increased in thin-cap (<65 Î¼m) vs. thick-cap (â¥65 Î¼m) human coronary fibroatheromata (n = 12; P < 0.01).  Fibroblast activation protein was expressed by human aortic smooth muscle cells (HASMC) as shown by colocalization on immunofluorescent aortic plaque stainings (n = 10; P < 0.01) and by flow cytometry in cell culture.  Although macrophages did not express FAP, macrophage burden in human aortic plaques correlated with FAP expression (n = 12; R2= 0.763; P < 0.05).  Enzyme-linked immunosorbent assays showed a time- and dose-dependent up-regulation of FAP in response to human tumor necrosis factor Î± (TNFÎ±) in HASMC (n = 6; P < 0.01).  Moreover, supernatants from peripheral blood-derived macrophages induced FAP expression in cultured HASMC (n = 6; P < 0.01), an effect abolished by blocking TNFÎ± (n = 6; P < 0.01).  Fibroblast activation protein assocd. with collagen-poor regions in human coronary fibrous caps and digested type I collagen and gelatin in vitro (n = 6; P < 0.01).  Zymog. revealed that FAP-mediated collagenase activity was neutralized by an antibody directed against the FAP catalytic domain both in HASMC (n = 6; P < 0.01) and in fibrous caps of atherosclerotic plaques (n = 10; P < 0.01).  Conclusion Fibroblast activation protein expression in HASMC is induced by macrophage-derived TNFÎ±.  Fibroblast activation protein assocs. with thin-cap human coronary fibroatheromata and contributes to type I collagen breakdown in fibrous caps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4eDr7Cnj1c7Vg90H21EOLACvtfcHk0lhK0UYvk8uSLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGnu7nO&md5=585eb7eb395d15ac6c5bb83f625da5b6</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehq519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehq519%26sid%3Dliteratum%253Aachs%26aulast%3DBrokopp%26aufirst%3DC.%2BE.%26aulast%3DSchoenauer%26aufirst%3DR.%26aulast%3DRichards%26aufirst%3DP.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DLohmann%26aufirst%3DC.%26aulast%3DEmmert%26aufirst%3DM.%2BY.%26aulast%3DWeber%26aufirst%3DB.%26aulast%3DWinnik%26aufirst%3DS.%26aulast%3DAikawa%26aufirst%3DE.%26aulast%3DGraves%26aufirst%3DK.%26aulast%3DGenoni%26aufirst%3DM.%26aulast%3DVogt%26aufirst%3DP.%26aulast%3DL%25C3%25BCscher%26aufirst%3DT.%2BF.%26aulast%3DRenner%26aufirst%3DC.%26aulast%3DHoerstrup%26aufirst%3DS.%2BP.%26aulast%3DMatter%26aufirst%3DC.%2BM.%26atitle%3DFibroblasts%2520activation%2520protein%2520is%2520induced%2520by%2520inflammation%2520and%2520degrades%2520type%2520I%2520collagen%2520in%2520thin-cap%2520fibroatheromata%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2011%26volume%3D32%26spage%3D2713%26epage%3D2722%26doi%3D10.1093%2Feurheartj%2Fehq519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horlock, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jandeleit-Dahm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, D. M.</span></span> <span> </span><span class="NLM_article-title">CXCR4 antagonism attenuates the development of diabetic cardiac fibrosis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0133616</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0133616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1371%2Fjournal.pone.0133616" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0133616&author=P.+Y.+Chuauthor=K.+Walderauthor=D.+Horlockauthor=D.+Williamsauthor=E.+Nelsonauthor=M.+Byrneauthor=K.+Jandeleit-Dahmauthor=P.+Zimmetauthor=D.+M.+Kaye&title=CXCR4+antagonism+attenuates+the+development+of+diabetic+cardiac+fibrosis&doi=10.1371%2Fjournal.pone.0133616"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0133616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0133616%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DP.%2BY.%26aulast%3DWalder%26aufirst%3DK.%26aulast%3DHorlock%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%26aulast%3DNelson%26aufirst%3DE.%26aulast%3DByrne%26aufirst%3DM.%26aulast%3DJandeleit-Dahm%26aufirst%3DK.%26aulast%3DZimmet%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DD.%2BM.%26atitle%3DCXCR4%2520antagonism%2520attenuates%2520the%2520development%2520of%2520diabetic%2520cardiac%2520fibrosis%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0133616%26doi%3D10.1371%2Fjournal.pone.0133616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span> <span> </span><span class="NLM_article-title">Notch antagonists: potential modulators of cancer and inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7719</span>â <span class="NLM_lpage">7737</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01516</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01516" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7719-7737&author=R.+Kumarauthor=L.+Juillerat-Jeanneretauthor=D.+Golshayan&title=Notch+antagonists%3A+potential+modulators+of+cancer+and+inflammatory+diseases&doi=10.1021%2Facs.jmedchem.5b01516"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01516%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DGolshayan%26aufirst%3DD.%26atitle%3DNotch%2520antagonists%253A%2520potential%2520modulators%2520of%2520cancer%2520and%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7719%26epage%3D7737%26doi%3D10.1021%2Facs.jmedchem.5b01516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nistri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bani, D.</span></span> <span> </span><span class="NLM_article-title">Notch signaling in ischemic damage and fibrosis: evidence and clues from the heart</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">187</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28424623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVKmsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=187&author=S.+Nistriauthor=C.+Sassoliauthor=D.+Bani&title=Notch+signaling+in+ischemic+damage+and+fibrosis%3A+evidence+and+clues+from+the+heart&doi=10.3389%2Ffphar.2017.00187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Notch signaling in ischemic damage and fibrosis: evidence and clues from the heart</span></div><div class="casAuthors">Nistri, Silvia; Sassoli, Chiara; Bani, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">187/1-187/6</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Notch signaling is a major intercellular coordination mechanism highly conserved throughout evolution.  In vertebrates, Notch signaling is physiol. involved in embryo development, including mesenchymal cell commitment, formation of heart tissues and angiogenesis.  In post-natal life, Notch signaling is maintained as a key mechanism of cell-cell communication and its dysregulations have been found in pathol. conditions such as ischemic and fibrotic diseases.  In the heart, Notch takes part in the protective response to ischemia, being involved in pre- and post-conditioning, redn. of reperfusion-induced oxidative stress and myocardial damage, and cardiomyogenesis.  Conceivably, the cardioprotective effects of Notch may depend on neo-angiogenesis, thus blunting lethal myocardial ischemia, as well as on direct stimulation of cardiac cells to increase their resistance to injury.  Another post-developmental adaptation of Notch signaling is fibrosis: being involved in the orientation of mesenchymal cell fate, Notch can modulate the differentiation of profibrotic myofibroblasts, e.g., by reducing the effects of the profibrotic cytokine TGF-Î².  In conclusion, Notch can regulate the interactions between heart muscle and stromal cells and switch cardiac repair from a pro-fibrotic default pathway to a pro-cardiogenic one.  These features make Notch signaling a suitable target for new cardiotropic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Pma0PnG-jrVg90H21EOLACvtfcHk0lg7RK0wr0VuIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVKmsrY%253D&md5=ea35dd67d811b4f1055e9638bb742cda</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00187%26sid%3Dliteratum%253Aachs%26aulast%3DNistri%26aufirst%3DS.%26aulast%3DSassoli%26aufirst%3DC.%26aulast%3DBani%26aufirst%3DD.%26atitle%3DNotch%2520signaling%2520in%2520ischemic%2520damage%2520and%2520fibrosis%253A%2520evidence%2520and%2520clues%2520from%2520the%2520heart%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D187%26doi%3D10.3389%2Ffphar.2017.00187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span> <span> </span><span class="NLM_article-title">Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4599</span>â <span class="NLM_lpage">4611</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S85399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S85399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26316699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVOgsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=4599-4611&author=X.+Zhouauthor=X.+Chenauthor=J.+J.+Caiauthor=L.+Z.+Chenauthor=Y.+S.+Gongauthor=L.+X.+Wangauthor=Z.+Gaoauthor=H.+Q.+Zhangauthor=W.+J.+Huangauthor=H.+Zhou&title=Relaxin+inhibits+cardiac+fibrosis+and+endothelial-mesenchymal+transition+via+the+Notch+pathway&doi=10.2147%2FDDDT.S85399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway</span></div><div class="casAuthors">Zhou, X.; Chen, X.; Cai, J. J.; Chen, L. Z.; Gong, Y. S.; Wang, L. X.; Gao, Z.; Zhang, H. Q.; Huang, W. J.; Zhou, H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4599-4611</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Relaxin (RLX) can prevent cardiac fibrosis.  We aimed to investigate the possible mechanism and signal transduction pathway of RLX inhibiting cardiac fibrosis Methods: Isoproterenol (5 mgÂ·kg-1Â·d-1) was used to establish the cardiac fibrosis model in rats, which were administered RLX.  The cardiac function, related targets of cardiac fibrosis, and endothelial-mesenchymal transition (EndMT) were measured.  Transforming growth factor Î² (TGF-Î²) was used to induce EndMT in human umbilical vein endothelial cells, which were pretreated with RLX, 200 ngÂ·mL-1, then with the inhibitor of Notch.  Transwell cell migration was used to evaluate cell migration.  CD31 and vimentin content was detd. by immunofluorescence staining and Western blot anal.  Notch protein level was examd. by Western blot anal. Results: RLX improved cardiac function in rats with cardiac fibrosis;it reduced the content of collagen I and III, increased the microvascular d. of the myocardium,and suppressed the EndMT in heart tissue.  In vitro,RLX decreased the mobility of human umbilical vein endothelial cells induced by TGF-Î²,increased the expression of endothelial CD31, and decreased vimentin content.  Compared to TGF-Î² and RLX co-culture alone,TGF-Î² + RLX + Notch inhibitor increased cell mobility and the EndMT, but decreased the levels of Notch-1, HES-1, and Jagged-1 proteins Conclusion: RLX may inhibit the cardiac fibrosis via EndMT by Notch-mediated signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYPR5yurBlHrVg90H21EOLACvtfcHk0lg7RK0wr0VuIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVOgsbw%253D&md5=240a8b1bf3c18e6844de3ca06adfb60d</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S85399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S85399%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DJ.%2BJ.%26aulast%3DChen%26aufirst%3DL.%2BZ.%26aulast%3DGong%26aufirst%3DY.%2BS.%26aulast%3DWang%26aufirst%3DL.%2BX.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%2BQ.%26aulast%3DHuang%26aufirst%3DW.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26atitle%3DRelaxin%2520inhibits%2520cardiac%2520fibrosis%2520and%2520endothelial-mesenchymal%2520transition%2520via%2520the%2520Notch%2520pathway%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D4599%26epage%3D4611%26doi%3D10.2147%2FDDDT.S85399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vecchio, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, L. T.</span></span> <span> </span><span class="NLM_article-title">Targeting adenosine receptors for the treatment of cardiac fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">243</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28529484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFentbrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=243&author=E.+A.+Vecchioauthor=P.+J.+Whiteauthor=L.+T.+May&title=Targeting+adenosine+receptors+for+the+treatment+of+cardiac+fibrosis&doi=10.3389%2Ffphar.2017.00243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting adenosine receptors for the treatment of cardiac fibrosis</span></div><div class="casAuthors">Vecchio, Elizabeth A.; White, Paul J.; May, Lauren T.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">243/1-243/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Adenosine is a ubiquitous mol. with key regulatory and cytoprotective mechanisms at times of metabolic imbalance in the body.  Among a plethora of physiol. actions, adenosine has an important role in attenuating ischemia-reperfusion injury and modulating the ensuing fibrosis and tissue remodeling following myocardial damage.  Adenosine exerts these actions through interaction with four adenosine G protein-coupled receptors expressed in the heart.  The adenosine A2B receptor (A2BAR) is the most abundant adenosine receptor (AR) in cardiac fibroblasts and is largely responsible for the influence of adenosine on cardiac fibrosis.  In vitroand in vivo studies demonstrate that acute A2BAR stimulation can decrease fibrosis through the inhibition of fibroblast proliferation and redn. in collagen synthesis.  However, in contrast, there is also evidence that chronic A2BAR antagonism reduces tissue fibrosis.  This review explores the opposing pro- and anti-fibrotic activity attributed to the activation of cardiac ARs and investigates the therapeutic potential of targeting ARs for the treatment of cardiac fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3KFPvl-g-rrVg90H21EOLACvtfcHk0lg7RK0wr0VuIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFentbrN&md5=d196d5cc0362cc0ee2cf728503cbd761</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00243%26sid%3Dliteratum%253Aachs%26aulast%3DVecchio%26aufirst%3DE.%2BA.%26aulast%3DWhite%26aufirst%3DP.%2BJ.%26aulast%3DMay%26aufirst%3DL.%2BT.%26atitle%3DTargeting%2520adenosine%2520receptors%2520for%2520the%2520treatment%2520of%2520cardiac%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D243%26doi%3D10.3389%2Ffphar.2017.00243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dulauroy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Carlo, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peduto, L.</span></span> <span> </span><span class="NLM_article-title">Lineage tracing and genetic ablation of ADAM12+ perivascular cells identify a major source of profibrotic cells during acute tissue injury</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1262</span>â <span class="NLM_lpage">1270</span>, <span class="refDoi">Â DOI: 10.1038/nm.2848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm.2848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22842476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1262-1270&author=S.+Dulauroyauthor=S.+E.+Di+Carloauthor=F.+Langaauthor=G.+Eberlauthor=L.+Peduto&title=Lineage+tracing+and+genetic+ablation+of+ADAM12%2B+perivascular+cells+identify+a+major+source+of+profibrotic+cells+during+acute+tissue+injury&doi=10.1038%2Fnm.2848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Lineage tracing and genetic ablation of ADAM12+ perivascular cells identify a major source of profibrotic cells during acute tissue injury</span></div><div class="casAuthors">Dulauroy, Sophie; Di Carlo, Selene E.; Langa, Francina; Eberl, Gerard; Peduto, Lucie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1262-1270</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Profibrotic cells that develop upon injury generate permanent scar tissue and impair organ recovery, though their origin and fate are unclear.  Here we show that transient expression of ADAM12 (a disintegrin and metalloprotease 12) identifies a distinct proinflammatory subset of platelet-derived growth factor receptor-Î±-pos. stromal cells that are activated upon acute injury in the muscle and dermis.  By inducible genetic fate mapping, we demonstrate in vivo that injury-induced ADAM12+ cells are specific progenitors of a major fraction of collagen-overproducing cells generated during scarring, which are progressively eliminated during healing.  Genetic ablation of ADAM12+ cells, or knockdown of ADAM12, is sufficient to limit generation of profibrotic cells and interstitial collagen accumulation.  ADAM12+ cells induced upon injury are developmentally distinct from muscle and skin lineage cells and are derived from fetal ADAM12+ cells programmed during vascular wall development.  Thus, our data identify injury-activated profibrotic progenitors residing in the perivascular space that can be targeted through ADAM12 to limit tissue scarring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo32-rtcfFTSrVg90H21EOLACvtfcHk0lhxAC3b5oE--w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73I&md5=28b13b4d88a2e9c43e9ffc0b1b5a0766</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fnm.2848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2848%26sid%3Dliteratum%253Aachs%26aulast%3DDulauroy%26aufirst%3DS.%26aulast%3DDi%2BCarlo%26aufirst%3DS.%2BE.%26aulast%3DLanga%26aufirst%3DF.%26aulast%3DEberl%26aufirst%3DG.%26aulast%3DPeduto%26aufirst%3DL.%26atitle%3DLineage%2520tracing%2520and%2520genetic%2520ablation%2520of%2520ADAM12%252B%2520perivascular%2520cells%2520identify%2520a%2520major%2520source%2520of%2520profibrotic%2520cells%2520during%2520acute%2520tissue%2520injury%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D1262%26epage%3D1270%26doi%3D10.1038%2Fnm.2848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzerini, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamberucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlÃ¬, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taddeucci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del-Ry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabiati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della-Latta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulceri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laghi-Pasini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capecchi, P. L.</span></span> <span> </span><span class="NLM_article-title">Searching novel therapeutic targets for scleroderma: P2 Ã 7-receptor is up-regulated and promotes a fibrogenic phenotype in systemic sclerosis fibroblasts</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">638</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28955239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegs7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=638&author=D.+Gentileauthor=P.+E.+Lazzeriniauthor=A.+Gamberucciauthor=M.+Nataleauthor=E.+Selviauthor=F.+Vanniauthor=A.+Al%C3%ACauthor=P.+Taddeucciauthor=S.+Del-Ryauthor=M.+Cabiatiauthor=V.+Della-Lattaauthor=D.+J.+Abrahamauthor=M.+A.+Moralesauthor=R.+Fulceriauthor=F.+Laghi-Pasiniauthor=P.+L.+Capecchi&title=Searching+novel+therapeutic+targets+for+scleroderma%3A+P2+%C3%97+7-receptor+is+up-regulated+and+promotes+a+fibrogenic+phenotype+in+systemic+sclerosis+fibroblasts&doi=10.3389%2Ffphar.2017.00638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Searching novel therapeutic targets for scleroderma: P2X7-receptor is up-regulated and promotes a fibrogenic phenotype in systemic sclerosis fibroblasts</span></div><div class="casAuthors">Gentile, Daniela; Lazzerini, Pietro E.; Gamberucci, Alessandra; Natale, Mariarita; Selvi, Enrico; Vanni, Francesca; Ali, Alessandra; Taddeucci, Paolo; Del-Ry, Silvia; Cabiati, Manuela; Della-Latta, Veronica; Abraham, David J.; Morales, Maria A.; Fulceri, Rosella; Laghi-Pasini, Franco; Capecchi, Pier L.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">638/1-638/13</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Objectives: Systemic sclerosis (SSc) is a connective tissue disorder presenting fibrosis of the skin and internal organs, for which no effective treatments are currently available.  Increasing evidence indicates that the P2X7 receptor (P2X7R), a nucleotide-gated ionotropic channel primarily involved in the inflammatory response, may also have a key role in the development of tissue fibrosis in different body districts.  This study was aimed at investigating P2X7R expression and function in promoting a fibrogenic phenotype in dermal fibroblasts from SSc patients, also analyzing putative underlying mechanistic pathways.  Methods: Fibroblasts were isolated by skin biopsy from 9 SSc patients and 8 healthy controls.  P2X7R expression, and function (cytosolic free Ca2+ fluxes, Î±-smooth muscle actin [Î±-SMA] expression, cell migration, and collagen release) were studied.  Moreover, the role of cytokine (interleukin-1Î², interleukin-6) and connective tissue growth factor (CTGF) prodn., and extracellular signal-regulated kinases (ERK) activation in mediating P2X7R-dependent pro-fibrotic effects in SSc fibroblasts was evaluated.  Results: P2X7R expression and Ca2+ permeability induced by the selective P2X7R agonist 2'-3'-O-(4-benzoylbenzoyl)ATP (BzATP) weremarkedly higher in SSc than control fibroblasts.  Moreover, increased Î±SMA expression, cell migration, CTGF, and collagen release were obsd. in lipopolysaccharides-primed SSc fibroblasts after BzATP stimulation.  While P2X7-induced cytokine changes did not affect collagen prodn., it was completely abrogated by inhibition of the ERK pathway.  Conclusion: In SSc fibroblasts, P2X7R is overexpressed and its stimulation induces Ca2+-signaling activation and a fibrogenic phenotype characterized by increased migration and collagen prodn.  These data point to the P2X7R as a potential, novel therapeutic target for controlling exaggerated collagen deposition and tissue fibrosis in patients with SSc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1qa9_QLCuprVg90H21EOLACvtfcHk0lhxAC3b5oE--w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegs7rN&md5=734dd4a1baaf01b6dfdcc81c76c18143</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00638%26sid%3Dliteratum%253Aachs%26aulast%3DGentile%26aufirst%3DD.%26aulast%3DLazzerini%26aufirst%3DP.%2BE.%26aulast%3DGamberucci%26aufirst%3DA.%26aulast%3DNatale%26aufirst%3DM.%26aulast%3DSelvi%26aufirst%3DE.%26aulast%3DVanni%26aufirst%3DF.%26aulast%3DAl%25C3%25AC%26aufirst%3DA.%26aulast%3DTaddeucci%26aufirst%3DP.%26aulast%3DDel-Ry%26aufirst%3DS.%26aulast%3DCabiati%26aufirst%3DM.%26aulast%3DDella-Latta%26aufirst%3DV.%26aulast%3DAbraham%26aufirst%3DD.%2BJ.%26aulast%3DMorales%26aufirst%3DM.%2BA.%26aulast%3DFulceri%26aufirst%3DR.%26aulast%3DLaghi-Pasini%26aufirst%3DF.%26aulast%3DCapecchi%26aufirst%3DP.%2BL.%26atitle%3DSearching%2520novel%2520therapeutic%2520targets%2520for%2520scleroderma%253A%2520P2%2520%25C3%2597%25207-receptor%2520is%2520up-regulated%2520and%2520promotes%2520a%2520fibrogenic%2520phenotype%2520in%2520systemic%2520sclerosis%2520fibroblasts%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D638%26doi%3D10.3389%2Ffphar.2017.00638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leask, A.</span></span> <span> </span><span class="NLM_article-title">Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment</span>. <i>Fibrog. Tissue Repair</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi">Â DOI: 10.1186/1755-1536-3-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1186%2F1755-1536-3-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=20507556" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=8&author=A.+Leask&title=Towards+an+anti-fibrotic+therapy+for+scleroderma%3A+targeting+myofibroblast+differentiation+and+recruitment&doi=10.1186%2F1755-1536-3-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-3-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-3-8%26sid%3Dliteratum%253Aachs%26aulast%3DLeask%26aufirst%3DA.%26atitle%3DTowards%2520an%2520anti-fibrotic%2520therapy%2520for%2520scleroderma%253A%2520targeting%2520myofibroblast%2520differentiation%2520and%2520recruitment%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2010%26volume%3D3%26spage%3D8%26doi%3D10.1186%2F1755-1536-3-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distler, J. H. W.</span></span> <span> </span><span class="NLM_article-title">Canonical Wnt signaling in systemic sclerosis</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">151</span>â <span class="NLM_lpage">155</span>, <span class="refDoi">Â DOI: 10.1038/labinvest.2015.154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Flabinvest.2015.154" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2016&pages=151-155&author=C.+Bergmannauthor=J.+H.+W.+Distler&title=Canonical+Wnt+signaling+in+systemic+sclerosis&doi=10.1038%2Flabinvest.2015.154"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2015.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2015.154%26sid%3Dliteratum%253Aachs%26aulast%3DBergmann%26aufirst%3DC.%26aulast%3DDistler%26aufirst%3DJ.%2BH.%2BW.%26atitle%3DCanonical%2520Wnt%2520signaling%2520in%2520systemic%2520sclerosis%26jtitle%3DLab.%2520Invest.%26date%3D2016%26volume%3D96%26spage%3D151%26epage%3D155%26doi%3D10.1038%2Flabinvest.2015.154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamdan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drakulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikici, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomic-Canic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daunert, S.</span></span> <span> </span><span class="NLM_article-title">Nanotechnology-driven therapeutic interventions in wound healing: potential uses and applications</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">163</span>â <span class="NLM_lpage">175</span>, <span class="refDoi">Â DOI: 10.1021/acscentsci.6b00371</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.6b00371" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtlCjt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=163-175&author=S.+Hamdanauthor=I.+Pastarauthor=S.+Drakulichauthor=E.+Dikiciauthor=M.+Tomic-Canicauthor=S.+Deoauthor=S.+Daunert&title=Nanotechnology-driven+therapeutic+interventions+in+wound+healing%3A+potential+uses+and+applications&doi=10.1021%2Facscentsci.6b00371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Nanotechnology-Driven Therapeutic Interventions in Wound Healing: Potential Uses and Applications</span></div><div class="casAuthors">Hamdan, Suzana; Pastar, Irena; Drakulich, Stefan; Dikici, Emre; Tomic-Canic, Marjana; Deo, Sapna; Daunert, Sylvia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">163-175</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The chronic nature and assocd. complications of nonhealing wounds have led to the emergence of nanotechnol.-based therapies that aim at facilitating the healing process and ultimately repairing the injured tissue.  A no. of engineered nanotechnologies have been proposed demonstrating unique properties and multiple functions that address specific problems assocd. with wound repair mechanisms.  In this outlook, we highlight the most recently developed nanotechnol.-based therapeutic agents and assess the viability and efficacy of each treatment, with emphasis on chronic cutaneous wounds.  Herein we explore the unmet needs and future directions of current technologies, while discussing promising strategies that can advance the wound healing field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1UHLlQ5pa0LVg90H21EOLACvtfcHk0lgBIAIZ2PLBNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtlCjt78%253D&md5=8d062dc44d44c7b028f9ebdd8d44e5c3</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.6b00371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.6b00371%26sid%3Dliteratum%253Aachs%26aulast%3DHamdan%26aufirst%3DS.%26aulast%3DPastar%26aufirst%3DI.%26aulast%3DDrakulich%26aufirst%3DS.%26aulast%3DDikici%26aufirst%3DE.%26aulast%3DTomic-Canic%26aufirst%3DM.%26aulast%3DDeo%26aufirst%3DS.%26aulast%3DDaunert%26aufirst%3DS.%26atitle%3DNanotechnology-driven%2520therapeutic%2520interventions%2520in%2520wound%2520healing%253A%2520potential%2520uses%2520and%2520applications%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2017%26volume%3D3%26spage%3D163%26epage%3D175%26doi%3D10.1021%2Facscentsci.6b00371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajanayake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olariu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeclÃ¨re, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhayani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bongoni, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banz, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar Vemula, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieben, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VÃ¶gelin, E.</span></span> <span> </span><span class="NLM_article-title">A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">249ra110</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3008778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1126%2Fscitranslmed.3008778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25122638" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=249ra110&author=T.+Gajanayakeauthor=R.+Olariuauthor=F.+M.+Lecl%C3%A8reauthor=A.+Dhayaniauthor=Z.+Yangauthor=A.+K.+Bongoniauthor=Y.+Banzauthor=M.+A.+Constantinescuauthor=J.+M.+Karpauthor=P.+Kumar+Vemulaauthor=R.+Riebenauthor=E.+V%C3%B6gelin&title=A+single+localized+dose+of+enzyme-responsive+hydrogel+improves+long-term+survival+of+a+vascularized+composite+allograft&doi=10.1126%2Fscitranslmed.3008778"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3008778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3008778%26sid%3Dliteratum%253Aachs%26aulast%3DGajanayake%26aufirst%3DT.%26aulast%3DOlariu%26aufirst%3DR.%26aulast%3DLecl%25C3%25A8re%26aufirst%3DF.%2BM.%26aulast%3DDhayani%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DBongoni%26aufirst%3DA.%2BK.%26aulast%3DBanz%26aufirst%3DY.%26aulast%3DConstantinescu%26aufirst%3DM.%2BA.%26aulast%3DKarp%26aufirst%3DJ.%2BM.%26aulast%3DKumar%2BVemula%26aufirst%3DP.%26aulast%3DRieben%26aufirst%3DR.%26aulast%3DV%25C3%25B6gelin%26aufirst%3DE.%26atitle%3DA%2520single%2520localized%2520dose%2520of%2520enzyme-responsive%2520hydrogel%2520improves%2520long-term%2520survival%2520of%2520a%2520vascularized%2520composite%2520allograft%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D249ra110%26doi%3D10.1126%2Fscitranslmed.3008778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatayama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsutahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichimaru, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaimori, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomura, N.</span></span> <span> </span><span class="NLM_article-title">High-pressure carbon monoxide preserves rat kidney grafts from apoptosis and inflammation</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">468</span>â <span class="NLM_lpage">477</span>, <span class="refDoi">Â DOI: 10.1038/labinvest.2016.157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Flabinvest.2016.157" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2017&pages=468-477&author=T.+Abeauthor=K.+Yazawaauthor=M.+Fujinoauthor=R.+Imamuraauthor=N.+Hatayamaauthor=Y.+Kakutaauthor=K.+Tsutaharaauthor=M.+Okumiauthor=N.+Ichimaruauthor=J.+Y.+Kaimoriauthor=Y.+Isakaauthor=K.+Sekiauthor=S.+Takaharaauthor=X.+K.+Liauthor=N.+Nonomura&title=High-pressure+carbon+monoxide+preserves+rat+kidney+grafts+from+apoptosis+and+inflammation&doi=10.1038%2Flabinvest.2016.157"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2016.157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2016.157%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DT.%26aulast%3DYazawa%26aufirst%3DK.%26aulast%3DFujino%26aufirst%3DM.%26aulast%3DImamura%26aufirst%3DR.%26aulast%3DHatayama%26aufirst%3DN.%26aulast%3DKakuta%26aufirst%3DY.%26aulast%3DTsutahara%26aufirst%3DK.%26aulast%3DOkumi%26aufirst%3DM.%26aulast%3DIchimaru%26aufirst%3DN.%26aulast%3DKaimori%26aufirst%3DJ.%2BY.%26aulast%3DIsaka%26aufirst%3DY.%26aulast%3DSeki%26aufirst%3DK.%26aulast%3DTakahara%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%2BK.%26aulast%3DNonomura%26aufirst%3DN.%26atitle%3DHigh-pressure%2520carbon%2520monoxide%2520preserves%2520rat%2520kidney%2520grafts%2520from%2520apoptosis%2520and%2520inflammation%26jtitle%3DLab.%2520Invest.%26date%3D2017%26volume%3D97%26spage%3D468%26epage%3D477%26doi%3D10.1038%2Flabinvest.2016.157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linardi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiamulera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumagalli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Biagio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebrie, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luciani, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faggian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rungatscher, A.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate receptor modulator fingolimod (FTY720) attenuates myocardial fibrosis in post-heterotropic heart transplantation</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">645</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28966593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegsb7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=645&author=N.+Ahmedauthor=D.+Linardiauthor=N.+Muhammadauthor=C.+Chiamuleraauthor=G.+Fumagalliauthor=L.+San+Biagioauthor=M.+A.+Gebrieauthor=M.+Aslamauthor=G.+B.+Lucianiauthor=G.+Faggianauthor=A.+Rungatscher&title=Sphingosine-1-phosphate+receptor+modulator+fingolimod+%28FTY720%29+attenuates+myocardial+fibrosis+in+post-heterotropic+heart+transplantation&doi=10.3389%2Ffphar.2017.00645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) attenuates myocardial fibrosis in post-heterotopic heart transplantation</span></div><div class="casAuthors">Ahmed, Naseer; Linardi, Daniele; Muhammad, Nazeer; Chiamulera, Cristiano; Fumagalli, Guido; San Biagio, Livio; Gebrie, Mebratu A.; Aslam, Muhammad; Luciani, Giovanni Battista; Faggian, Giuseppe; Rungatscher, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">645/1-645/10</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Background and Objective: Sphingosine 1-phosphate (S1P), and S1P receptor modulator fingolimod have been suggested to play important cardioprotective role in animal models of myocardial ischemia/reperfusion injuries.  To understand the cardioprotective function of S1P and its mechanism in vivo, we analyzed apoptotic, inflammatory biomarkers, and myocardial fibrosis in an in vivo heterotopic rat heart transplantation model.  Methods: Heterotopic heart transplantation is performed in 60 Sprague-Dawley (SD) rats (350-400 g).  The heart transplant recipients (n = 60) are categorized into Group A (control) and Group B (fingolimod treated 1 mg/kg i.v.).  At baseline with 24 h after heart transplantation, blood and myocardial tissue are collected for anal. of myocardial biomarkers, apoptosis, inflammatory markers, oxidative stress, and phosphorylation of Akt/Erk/STAT-3 signaling pathways.  Myocardial fibrosis was investigated using Masson's trichrome staining and L-hydroxyline.  Results: Fingolimod treatment activates both Reperfusion Injury Salvage Kinase (RISK) and Survivor Activating Factor Enhancement (SAFE) pathways as evident from activation of anti-apoptotic and anti-inflammatory pathways.  Fingolimod treatment caused a redn. in myocardial oxidative stress and hence cardiomyocyte apoptosis resulting in a decrease in myocardial reperfusion injury.  Moreover, a significant (p < 0.001) redn. in collagen staining and hydroxyproline content was obsd. in fingolimod treated animals 30 days after transplantation demonstrating a redn. in cardiac fibrosis.  Conclusion: S1P receptor activation with fingolimod activates anti-apoptotic and antiinflammatory pathways, leading to improved myocardial salvage causing a redn. in cardiac fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGongOy-7Mf4RbVg90H21EOLACvtfcHk0lgBIAIZ2PLBNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegsb7O&md5=aa78e1a5c883558d2f969e7225092c20</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00645%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DN.%26aulast%3DLinardi%26aufirst%3DD.%26aulast%3DMuhammad%26aufirst%3DN.%26aulast%3DChiamulera%26aufirst%3DC.%26aulast%3DFumagalli%26aufirst%3DG.%26aulast%3DSan%2BBiagio%26aufirst%3DL.%26aulast%3DGebrie%26aufirst%3DM.%2BA.%26aulast%3DAslam%26aufirst%3DM.%26aulast%3DLuciani%26aufirst%3DG.%2BB.%26aulast%3DFaggian%26aufirst%3DG.%26aulast%3DRungatscher%26aufirst%3DA.%26atitle%3DSphingosine-1-phosphate%2520receptor%2520modulator%2520fingolimod%2520%2528FTY720%2529%2520attenuates%2520myocardial%2520fibrosis%2520in%2520post-heterotropic%2520heart%2520transplantation%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D645%26doi%3D10.3389%2Ffphar.2017.00645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cernoch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viklicky, O.</span></span> <span> </span><span class="NLM_article-title">Complement in kidney transplantation</span>. <i>Front. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">66</span>, <span class="refDoi">Â DOI: 10.3389/fmed.2017.00066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffmed.2017.00066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1cnotVGisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=66&author=M.+Cernochauthor=O.+Viklicky&title=Complement+in+kidney+transplantation&doi=10.3389%2Ffmed.2017.00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Complement in Kidney Transplantation</span></div><div class="casAuthors">Cernoch Marek; Viklicky Ondrej; Viklicky Ondrej</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">66</span>
        ISSN:<span class="NLM_cas:issn">2296-858X</span>.
    </div><div class="casAbstract">The complement system is considered to be an important part of innate immune system with a significant role in inflammation processes.  The activation can occur through classical, alternative, or lectin pathway, resulting in the creation of anaphylatoxins C3a and C5a, possessing a vast spectrum of immune functions, and the assembly of terminal complement cascade, capable of direct cell lysis.  The activation processes are tightly regulated; inappropriate activation of the complement cascade plays a significant role in many renal diseases including organ transplantation.  Moreover, complement cascade is activated during ischemia/reperfusion injury processes and influences delayed graft function of kidney allografts.  Interestingly, complement system has been found to play a role in both acute cellular and antibody-mediated rejections and thrombotic microangiopathy.  Therefore, complement system may represent an interesting therapeutical target in kidney transplant pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3msm3K93O7BBrI9DTGjC0fW6udTcc2eYTP1KA3J3vPLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnotVGisA%253D%253D&md5=d65996d8dd178c8ee5e483481efefc53</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.3389%2Ffmed.2017.00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmed.2017.00066%26sid%3Dliteratum%253Aachs%26aulast%3DCernoch%26aufirst%3DM.%26aulast%3DViklicky%26aufirst%3DO.%26atitle%3DComplement%2520in%2520kidney%2520transplantation%26jtitle%3DFront.%2520Med.%26date%3D2017%26volume%3D4%26spage%3D66%26doi%3D10.3389%2Ffmed.2017.00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gueler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmschrott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeing, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankenstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleissner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruhparwar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlermann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katus, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doesch, A. O.</span></span> <span> </span><span class="NLM_article-title">Effects of vildagliptin (Galvus<sup>R</sup>) therapy in patients with type 2 diabetes mellitus after heart transplantation</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">297</span>â <span class="NLM_lpage">303</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S43092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S43092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23630415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVSntLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=297-303&author=I.+Guelerauthor=S.+Muellerauthor=M.+Helmschrottauthor=C.+U.+Oeingauthor=C.+Erbelauthor=L.+Frankensteinauthor=C.+Gleissnerauthor=A.+Ruhparwarauthor=P.+Ehlermannauthor=T.+J.+Denglerauthor=H.+A.+Katusauthor=A.+O.+Doesch&title=Effects+of+vildagliptin+%28GalvusR%29+therapy+in+patients+with+type+2+diabetes+mellitus+after+heart+transplantation&doi=10.2147%2FDDDT.S43092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of vildagliptin (Galvus) therapy in patients with type 2 diabetes mellitus after heart transplantation</span></div><div class="casAuthors">Gueler, Ibrahim; Mueller, Susanne; Helmschrott, Matthias; Oeing, Christian U.; Erbel, Christian; Frankenstein, Lutz; Gleissner, Christian; Ruhparwar, Arjang; Ehlermann, Philipp; Dengler, Thomas J.; Katus, Hugo A.; Doesch, Andreas O.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">297-303</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Type 2 Diabetes mellitus (T2DM) is a common comorbidity in patients after heart transplantation (HTx) and is assocd. with adverse long-term outcomes.  Methods: The retrospective study reported here analyzed the effects of vildagliptin therapy in stable patients post-HTx with T2DM and compared these with control patients for matched-pairs anal.  A total of 30 stable patients post-HTx with T2DM were included in the study.  Fifteen patients (mean age 58.6 Â± 6.0 years, mean time post-HTx 4.9 Â± 5.3 years, twelve male and three female) were included in the vildagliptin group (VG) and 15 patients were included in the control group (CG) (mean age 61.2 Â± 8.3 years, mean time post-HTx 7.2 Â± 6.6 years, all male).  Results: Mean glycated Hb (HbA1c) in the VG was 7.4% Â± 0.7% before vs. 6.8% Â± 0.8% after 8 mo of vildagliptin therapy (P = 0.002 vs. baseline).  In the CG, HbA1c was 7.0% Â± 0.7% vs. 7.3% Â± 1.2% at follow-up (P = 0.21).  Addnl., there was a significant redn. in mean blood glucose in the VG, from 165.0 Â± 18.8 mg/dL to 147.9 Â± 22.7 mg/dL (P = 0.002 vs. baseline), whereas mean blood glucose increased slightly in the CG from 154.7 Â± 19.7 mg/dL to 162.6 Â± 35.0 mg/dL (P = 0.21).  No statistically significant changes in body wt. (from 83.3 Â± 10.8 kg to 82.0 Â± 10.9 kg, P = 0.20), total cholesterol (1.5%, P = 0.68), or triglyceride levels (8.0%, P = 0.65) were seen in the VG.  No significant changes in immunosuppressive drug levels or dosages were obsd. in either group.  Conclusion: Vildagliptin therapy significantly reduced HbA1c and mean blood glucose levels in post-HTx patients in this study with T2DM and did not have any neg. effects on lipid profile or body wt.  Thus, vildagliptin therapy presented an interesting therapeutic approach for this selected patient cohort.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAIk48pts7FLVg90H21EOLACvtfcHk0lgkWW82lE4Q-g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVSntLo%253D&md5=b0a4aa610c5d9cad1aaa897a5f4d7e4e</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S43092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S43092%26sid%3Dliteratum%253Aachs%26aulast%3DGueler%26aufirst%3DI.%26aulast%3DMueller%26aufirst%3DS.%26aulast%3DHelmschrott%26aufirst%3DM.%26aulast%3DOeing%26aufirst%3DC.%2BU.%26aulast%3DErbel%26aufirst%3DC.%26aulast%3DFrankenstein%26aufirst%3DL.%26aulast%3DGleissner%26aufirst%3DC.%26aulast%3DRuhparwar%26aufirst%3DA.%26aulast%3DEhlermann%26aufirst%3DP.%26aulast%3DDengler%26aufirst%3DT.%2BJ.%26aulast%3DKatus%26aufirst%3DH.%2BA.%26aulast%3DDoesch%26aufirst%3DA.%2BO.%26atitle%3DEffects%2520of%2520vildagliptin%2520%2528GalvusR%2529%2520therapy%2520in%2520patients%2520with%2520type%25202%2520diabetes%2520mellitus%2520after%2520heart%2520transplantation%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2013%26volume%3D7%26spage%3D297%26epage%3D303%26doi%3D10.2147%2FDDDT.S43092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Meester, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baerts, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vliegen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inci, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weder, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jungraithmayr, W.</span></span> <span> </span><span class="NLM_article-title">CD26 costimulation blockade improves lung allograft rejection and is associated with enhanced interleukin-10 expression</span>. <i>J. Heart Lung Transl.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">508</span>â <span class="NLM_lpage">517</span>, <span class="refDoi">Â DOI: 10.1016/j.healun.2015.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.healun.2015.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26755203" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=508-517&author=Y.+Yamadaauthor=J.+H.+Jangauthor=I.+De+Meesterauthor=L.+Baertsauthor=G.+Vliegenauthor=I.+Inciauthor=I.+Yoshinoauthor=W.+Wederauthor=W.+Jungraithmayr&title=CD26+costimulation+blockade+improves+lung+allograft+rejection+and+is+associated+with+enhanced+interleukin-10+expression&doi=10.1016%2Fj.healun.2015.11.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.healun.2015.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.healun.2015.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DJang%26aufirst%3DJ.%2BH.%26aulast%3DDe%2BMeester%26aufirst%3DI.%26aulast%3DBaerts%26aufirst%3DL.%26aulast%3DVliegen%26aufirst%3DG.%26aulast%3DInci%26aufirst%3DI.%26aulast%3DYoshino%26aufirst%3DI.%26aulast%3DWeder%26aufirst%3DW.%26aulast%3DJungraithmayr%26aufirst%3DW.%26atitle%3DCD26%2520costimulation%2520blockade%2520improves%2520lung%2520allograft%2520rejection%2520and%2520is%2520associated%2520with%2520enhanced%2520interleukin-10%2520expression%26jtitle%3DJ.%2520Heart%2520Lung%2520Transl.%26date%3D2016%26volume%3D35%26spage%3D508%26epage%3D517%26doi%3D10.1016%2Fj.healun.2015.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, S.</span></span> <span> </span><span class="NLM_article-title">Recent advances in renal interstitial fibrosis and tubular atrophy after kidney transplantation</span>. <i>Fibrog. Tissue Repair</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">15</span>, <span class="refDoi">Â DOI: 10.1186/1755-1536-7-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1186%2F1755-1536-7-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25285155" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=15&author=X.+Liauthor=S.+Zhuang&title=Recent+advances+in+renal+interstitial+fibrosis+and+tubular+atrophy+after+kidney+transplantation&doi=10.1186%2F1755-1536-7-15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-7-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-7-15%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhuang%26aufirst%3DS.%26atitle%3DRecent%2520advances%2520in%2520renal%2520interstitial%2520fibrosis%2520and%2520tubular%2520atrophy%2520after%2520kidney%2520transplantation%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2014%26volume%3D7%26spage%3D15%26doi%3D10.1186%2F1755-1536-7-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievert, W.</span></span> <span> </span><span class="NLM_article-title">A pilot study evaluating the safety of intravenously administrated human amnion epithelial cells for the treatment of hepatic fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">549</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28878671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2ns7jL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=549&author=R.+Limauthor=A.+Hodgeauthor=G.+Mooreauthor=E.+M.+Wallaceauthor=W.+Sievert&title=A+pilot+study+evaluating+the+safety+of+intravenously+administrated+human+amnion+epithelial+cells+for+the+treatment+of+hepatic+fibrosis&doi=10.3389%2Ffphar.2017.00549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">A pilot study evaluating the safety of intravenously administered human amnion epithelial cells for the treatment of hepatic fibrosis</span></div><div class="casAuthors">Lim, Rebecca; Hodge, Alexander; Moore, Gregory; Wallace, Euan M.; Sievert, William</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">549/1-549/9</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Liver cirrhosis is the 6th leading cause of death in adults aged 15-59 years in high-income countries.  For many who progress to cirrhosis, the only prospect for survival is liver transplantation.  While there is some indication that mesenchymal stem cells may be useful in reversing established liver fibrosis, there are limitations to their widespread use - namely their rarity, the need for extensive serial passaging and the assocd. potential for genomic instability and cellular senescence.  To this end, we propose the use of allogeneic amnion epithelial cells.  This clin. trial will assess the safety of i.v. delivered allogeneic human amnion epithelial cells (hAECs) in patients with compensated liver cirrhosis.  This will also provide clin. data that will inform phases 2 and 3 clin. trials with the ultimate goal of developing hAECs as a therapeutic option for patients with cirrhosis who are at significant risk of disease progression.  We will recruit 12 patients with compensated cirrhosis, based on their hepatic venous pressure gradient, for a dose escalation study.  Patients will be closely monitored in the first 24 h post-infusion, then via daily telephone interviews until clin. assessment on day 5.  Long term follow up will include std. liver tests, transient elastog. and hepatic ultrasound.  Ethics approval was obtained from Monash Health for this trial 16052A, "A Pilot Study Evaluating the Safety of I.v. Administered Human Amnion Epithelial Cells for the Treatment of Liver Fibrosis, A First in Adult Human Study." The trial will be conducted in accordance to Monash Health Human Ethics guidelines.  Outcomes from this study will be disseminated in the form of conference presentations and submission to a peer reviewed journal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMgemCyYmmWLVg90H21EOLACvtfcHk0ljBYwqf12ZuRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2ns7jL&md5=98eb6eea483f6508b0461f67fa44cb01</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00549%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DR.%26aulast%3DHodge%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DG.%26aulast%3DWallace%26aufirst%3DE.%2BM.%26aulast%3DSievert%26aufirst%3DW.%26atitle%3DA%2520pilot%2520study%2520evaluating%2520the%2520safety%2520of%2520intravenously%2520administrated%2520human%2520amnion%2520epithelial%2520cells%2520for%2520the%2520treatment%2520of%2520hepatic%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D549%26doi%3D10.3389%2Ffphar.2017.00549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricardo, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievert, W.</span></span> <span> </span><span class="NLM_article-title">Cell-based therapies for tissue fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">633</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29033833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegs7fJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=633&author=R.+Limauthor=S.+D.+Ricardoauthor=W.+Sievert&title=Cell-based+therapies+for+tissue+fibrosis&doi=10.3389%2Ffphar.2017.00633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-based therapies for tissue fibrosis</span></div><div class="casAuthors">Lim, Rebecca; Ricardo, Sharon D.; Sievert, William</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">633/1-633/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The development of tissue fibrosis in the context of a wound-healing response to injury is common to many chronic diseases.  Unregulated or persistent fibrogenesis may lead to structural and functional changes in organs that increase the risk of significant morbidity and mortality.  We will explore the natural history, epidemiol., and pathogenesis of fibrotic disease affecting the lungs, kidneys, and liver as dysfunction of these organs is responsible for a substantial proportion of global mortality.  For many patients with end-stage disease, organ transplantation is the only effective therapy to prolong life.  However, not all patients are candidates for the major surgical interventions and life-long immunosuppression required for a successful outcome and donor organs may not be available to meet the clin. need.  We will provide an overview of the latest treatment strategies for these conditions and will focus on stem or progenitor cell-based therapies for which there is substantial pre-clin. evidence based on animal models as well as early phase clin. trials of cell-based therapy in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBNGfSdTptErVg90H21EOLACvtfcHk0ljBYwqf12ZuRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegs7fJ&md5=5686439cda982717c1c765dd3ad0828c</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00633%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DR.%26aulast%3DRicardo%26aufirst%3DS.%2BD.%26aulast%3DSievert%26aufirst%3DW.%26atitle%3DCell-based%2520therapies%2520for%2520tissue%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D633%26doi%3D10.3389%2Ffphar.2017.00633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russell, A. J.</span></span> <span> </span><span class="NLM_article-title">Regenerative medicinal chemistry: the in situ control of stem cells</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">365</span>â <span class="NLM_lpage">368</span>, <span class="refDoi">Â DOI: 10.1021/ml400110b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400110b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkslahu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=365-368&author=A.+J.+Russell&title=Regenerative+medicinal+chemistry%3A+the+in+situ+control+of+stem+cells&doi=10.1021%2Fml400110b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Regenerative Medicinal Chemistry: The in Situ Control of Stem Cells</span></div><div class="casAuthors">Russell, Angela J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">365-368</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In recent years, there has been mounting evidence to support the presence of stem and progenitor cells within many adult tissues that retain the capacity to proliferate and differentiate, thereby contributing to tissue homeostasis and repair.  In line with these discoveries, there have been increasing efforts to develop new agents that target these resident stem and progenitor cell populations in situ to augment or to stimulate repair and regeneration processes.  Two such agents are approved drugs, and several more are currently in clin. and preclin. development.  Through this emerging therapeutic paradigm there is enormous scope for medicinal chem. to play a pivotal role in regenerative medicine.  The potential impact of regenerative medicinal chem. is profound, and future studies will reveal which tissue types or disease states will prove most readily tractable through this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcSsyW6-vi6LVg90H21EOLACvtfcHk0ljBYwqf12ZuRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkslahu7g%253D&md5=b47be3ceb0d356268f8972a380323e72</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fml400110b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400110b%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DA.%2BJ.%26atitle%3DRegenerative%2520medicinal%2520chemistry%253A%2520the%2520in%2520situ%2520control%2520of%2520stem%2520cells%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D365%26epage%3D368%26doi%3D10.1021%2Fml400110b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thevenot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span> <span> </span><span class="NLM_article-title">Surface chemistry influences implant biocompatibility</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">270</span>â <span class="NLM_lpage">280</span>, <span class="refDoi">Â DOI: 10.2174/156802608783790901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2174%2F156802608783790901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18393890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsFyjtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=270-280&author=L.+Tangauthor=P.+Thevenotauthor=W.+Hu&title=Surface+chemistry+influences+implant+biocompatibility&doi=10.2174%2F156802608783790901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Surface chemistry influences implant biocompatibility</span></div><div class="casAuthors">Thevenot, Paul; Hu, Wenjing; Tang, Liping</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">270-280</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Implantable medical devices are increasingly important in the practice of modern medicine.  Unfortunately, almost all medical devices suffer to a different extent from adverse reactions, including inflammation, fibrosis, thrombosis and infection.  To improve the safety and function of many types of medical implants, a major need exists for development of materials that evoked desired tissue responses.  Because implant-assocd. protein adsorption and conformational changes thereafter have been shown to promote immune reactions, rigorous research efforts have been emphasized on the engineering of surface property (phys. and chem. characteristics) to reduce protein adsorption and cell interactions and subsequently improve implant biocompatibility.  This brief review is aimed to summarize the past efforts and our recent knowledge about the influence of surface functionality on protein:cell:biomaterial interactions.  It is our belief that detailed understandings of bioactivity of surface functionality provide an easy, economic, and specific approach for the future rational design of implantable medical devices with desired tissue reactivity and, hopefully, wound healing capability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0qBMRoM-27Vg90H21EOLACvtfcHk0lhPWPSmWTEFXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsFyjtbw%253D&md5=214eb8c68652a06868b190192f8d0287</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.2174%2F156802608783790901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608783790901%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DL.%26aulast%3DThevenot%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DW.%26atitle%3DSurface%2520chemistry%2520influences%2520implant%2520biocompatibility%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D270%26epage%3D280%26doi%3D10.2174%2F156802608783790901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nerem, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambanis, A.</span></span> <span> </span><span class="NLM_article-title">Tissue engineering: from biology to biological substitutes</span>. <i>Tissue Eng.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">13</span>, <span class="refDoi">Â DOI: 10.1089/ten.1995.1.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1089%2Ften.1995.1.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=19877911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BD1MjjtVegtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1995&pages=3-13&author=R.+M.+Neremauthor=A.+Sambanis&title=Tissue+engineering%3A+from+biology+to+biological+substitutes&doi=10.1089%2Ften.1995.1.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue engineering: from biology to biological substitutes</span></div><div class="casAuthors">Nerem R M; Sambanis A</div><div class="citationInfo"><span class="NLM_cas:title">Tissue engineering</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-13</span>
        ISSN:<span class="NLM_cas:issn">1076-3279</span>.
    </div><div class="casAbstract">Tissue engineering is an emerging multidisciplinary and interdisciplinary field involving the development of bioartificial implants and/or the fostering of tissue remodeling with the purpose of repairing or enhancing tissue or organ function.  Bioartificial constructs generally consist of cells and biomaterials, so tissue engineering draws from both cell and biomaterials science and technology.  Successful applications require a thorough understanding of the environment experienced by cells in normal tissues and by cells in bioartificial devices before and after implantation.  This paper reviews these topics, as well as the current status and future possibilities in the development of different bioartificial constructs, including bioartificial skin, cardiovascular implants, bioartificial pancreas, and encapsulated secretory cells.  Issues that need to be addressed in the future are also discussed.  These include, but are not limited to, the development of new cell lines and biomaterials, the evaluation of the optimal construct architecture, and the reproducible manufacture and preservation of bioartificial devices until ready for use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmwWIRoKhvqa69lAbTj9rGfW6udTcc2eZ3g6g0F96cXrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjjtVegtQ%253D%253D&md5=755262ffccfc3b7c519d5b931ded7c97</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1089%2Ften.1995.1.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Ften.1995.1.3%26sid%3Dliteratum%253Aachs%26aulast%3DNerem%26aufirst%3DR.%2BM.%26aulast%3DSambanis%26aufirst%3DA.%26atitle%3DTissue%2520engineering%253A%2520from%2520biology%2520to%2520biological%2520substitutes%26jtitle%3DTissue%2520Eng.%26date%3D1995%26volume%3D1%26spage%3D3%26epage%3D13%26doi%3D10.1089%2Ften.1995.1.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadtler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrellas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Housseau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elisseeff, J. H.</span></span> <span> </span><span class="NLM_article-title">Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">366</span>â <span class="NLM_lpage">370</span>, <span class="refDoi">Â DOI: 10.1126/science.aad9272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1126%2Fscience.aad9272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=27081073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2isbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2016&pages=366-370&author=K.+Sadtlerauthor=K.+Estrellasauthor=B.+W.+Allenauthor=M.+T.+Wolfauthor=H.+Fanauthor=A.+J.+Tamauthor=C.+H.+Patelauthor=B.+Luberauthor=H.+Wangauthor=K.+R.+Wagnerauthor=J.+D.+Powellauthor=F.+Housseauauthor=D.+M.+Pardollauthor=J.+H.+Elisseeff&title=Developing+a+pro-regenerative+biomaterial+scaffold+microenvironment+requires+T+helper+2+cells&doi=10.1126%2Fscience.aad9272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells</span></div><div class="casAuthors">Sadtler, Kaitlyn; Estrellas, Kenneth; Allen, Brian W.; Wolf, Matthew T.; Fan, Hongni; Tam, Ada J.; Patel, Chirag H.; Luber, Brandon S.; Wang, Hao; Wagner, Kathryn R.; Powell, Jonathan D.; Housseau, Franck; Pardoll, Drew M.; Elisseeff, Jennifer H.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">6283</span>),
    <span class="NLM_cas:pages">366-370</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Immune-mediated tissue regeneration driven by a biomaterial scaffold is emerging as an innovative regenerative strategy to repair damaged tissues.  The authors investigated how biomaterial scaffolds shape the immune microenvironment in traumatic muscle wounds to improve tissue regeneration.  The scaffolds induced a pro-regenerative response, characterized by an mTOR/Rictor-dependent T helper 2 pathway that guides interleukin-4-dependent macrophage polarization, which is crit. for functional muscle recovery.  Manipulating the adaptive immune system using biomaterials engineering may support the development of therapies that promote both systemic and local pro-regenerative immune responses, ultimately stimulating tissue repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKgZIM1DC6HLVg90H21EOLACvtfcHk0lhPWPSmWTEFXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2isbs%253D&md5=190e9c20fc5c18d91ff4570c4d980e5c</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad9272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad9272%26sid%3Dliteratum%253Aachs%26aulast%3DSadtler%26aufirst%3DK.%26aulast%3DEstrellas%26aufirst%3DK.%26aulast%3DAllen%26aufirst%3DB.%2BW.%26aulast%3DWolf%26aufirst%3DM.%2BT.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DTam%26aufirst%3DA.%2BJ.%26aulast%3DPatel%26aufirst%3DC.%2BH.%26aulast%3DLuber%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWagner%26aufirst%3DK.%2BR.%26aulast%3DPowell%26aufirst%3DJ.%2BD.%26aulast%3DHousseau%26aufirst%3DF.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DElisseeff%26aufirst%3DJ.%2BH.%26atitle%3DDeveloping%2520a%2520pro-regenerative%2520biomaterial%2520scaffold%2520microenvironment%2520requires%2520T%2520helper%25202%2520cells%26jtitle%3DScience%26date%3D2016%26volume%3D352%26spage%3D366%26epage%3D370%26doi%3D10.1126%2Fscience.aad9272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadtler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elisseeff, J. H.</span></span> <span> </span><span class="NLM_article-title">Design, clinical translation and immunological response of biomaterials in regenerative medicine</span>. <i>Nat. Rev. Materials</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">16040</span>, <span class="refDoi">Â DOI: 10.1038/natrevmats.2016.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnatrevmats.2016.40" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVeru70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=16040&author=K.+Sadtlerauthor=A.+Singhauthor=M.+T.+Wolfauthor=X.+Wangauthor=D.+M.+Pardollauthor=J.+H.+Elisseeff&title=Design%2C+clinical+translation+and+immunological+response+of+biomaterials+in+regenerative+medicine&doi=10.1038%2Fnatrevmats.2016.40"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Design, clinical translation and immunological response of biomaterials in regenerative medicine</span></div><div class="casAuthors">Sadtler, Kaitlyn; Singh, Anirudha; Wolf, Matthew T.; Wang, Xiaokun; Pardoll, Drew M.; Elisseeff, Jennifer H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Materials</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">16040</span>CODEN:
                <span class="NLM_cas:coden">NRMADL</span>;
        ISSN:<span class="NLM_cas:issn">2058-8437</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The field of regenerative medicine aims to replace tissues lost as a consequence of disease, trauma or congenital abnormalities.  Biomaterials serve as scaffolds for regenerative medicine to deliver cells, provide biol. signals and phys. support, and mobilize endogenous cells to repair tissues.  Sophisticated chemistries are used to synthesize materials that mimic and modulate native tissue microenvironments, to replace form and to elucidate structure-function relationships of cell-material interactions.  The therapeutic relevance of these biomaterial properties can only be studied after clin. translation, whereby key parameters for efficacy can be defined and then used for future design.  In this Review, we present the development and translation of biomaterials for two tissue engineering targets, cartilage and cornea, both of which lack the ability to self-repair.  Finally, looking to the future, we discuss the role of the immune system in regeneration and the potential for biomaterial scaffolds to modulate immune signalling to create a pro-regenerative environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWEUcW7pDiArVg90H21EOLACvtfcHk0ljb0JCjwNC3fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVeru70%253D&md5=31da0789b8d8931cb8d7cbfa44a9bc2b</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fnatrevmats.2016.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnatrevmats.2016.40%26sid%3Dliteratum%253Aachs%26aulast%3DSadtler%26aufirst%3DK.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DWolf%26aufirst%3DM.%2BT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DElisseeff%26aufirst%3DJ.%2BH.%26atitle%3DDesign%252C%2520clinical%2520translation%2520and%2520immunological%2520response%2520of%2520biomaterials%2520in%2520regenerative%2520medicine%26jtitle%3DNat.%2520Rev.%2520Materials%26date%3D2016%26volume%3D1%26spage%3D16040%26doi%3D10.1038%2Fnatrevmats.2016.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eming, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, J. M.</span></span> <span> </span><span class="NLM_article-title">Inflammation in wound repair: molecular and cellular mechanisms</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">514</span>â <span class="NLM_lpage">525</span>, <span class="refDoi">Â DOI: 10.1038/sj.jid.5700701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fsj.jid.5700701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17299434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhs1CrtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2007&pages=514-525&author=S.+A.+Emingauthor=T.+Kriegauthor=J.+M.+Davidson&title=Inflammation+in+wound+repair%3A+molecular+and+cellular+mechanisms&doi=10.1038%2Fsj.jid.5700701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation in Wound Repair: Molecular and Cellular Mechanisms</span></div><div class="casAuthors">Eming, Sabine A.; Krieg, Thomas; Davidson, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">514-525</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In post-natal life the inflammatory response is an inevitable consequence of tissue injury.  Exptl. studies established the dogma that inflammation is essential to the establishment of cutaneous homeostasis following injury, and in recent years information about specific subsets of inflammatory cell lineages and the cytokine network orchestrating inflammation assocd. with tissue repair has increased.  Recently, this dogma has been challenged, and reports have raised questions on the validity of the essential prerequisite of inflammation for efficient tissue repair.  Indeed, in exptl. models of repair, inflammation has been shown to delay healing and to result in increased scarring.  Furthermore, chronic inflammation, a hallmark of the non-healing wound, predisposes tissue to cancer development.  Thus, a more detailed understanding in mechanisms controlling the inflammatory response during repair and how inflammation directs the outcome of the healing process will serve as a significant milestone in the therapy of pathol. tissue repair.  Here, the authors review cellular and mol. mechanisms controlling inflammation in cutaneous tissue repair and provide a rationale for targeting the inflammatory phase to modulate the outcome of the healing response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Hbzwd2DTdbVg90H21EOLACvtfcHk0ljb0JCjwNC3fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhs1CrtL0%253D&md5=4e5422d628b2d71d755ea6138052cf5c</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fsj.jid.5700701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.jid.5700701%26sid%3Dliteratum%253Aachs%26aulast%3DEming%26aufirst%3DS.%2BA.%26aulast%3DKrieg%26aufirst%3DT.%26aulast%3DDavidson%26aufirst%3DJ.%2BM.%26atitle%3DInflammation%2520in%2520wound%2520repair%253A%2520molecular%2520and%2520cellular%2520mechanisms%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2007%26volume%3D127%26spage%3D514%26epage%3D525%26doi%3D10.1038%2Fsj.jid.5700701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermette, P.</span></span> <span> </span><span class="NLM_article-title">Endothelial cell response towards low-fouling surfaces bearing RGD in a three-dimensional environment</span>. <i>Exp. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">1994</span>â <span class="NLM_lpage">2006</span>, <span class="refDoi">Â DOI: 10.1016/j.yexcr.2011.05.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.yexcr.2011.05.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=21679704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1ykt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2011&pages=1994-2006&author=G.+Sabraauthor=P.+Vermette&title=Endothelial+cell+response+towards+low-fouling+surfaces+bearing+RGD+in+a+three-dimensional+environment&doi=10.1016%2Fj.yexcr.2011.05.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelial cell responses towards low-fouling surfaces bearing RGD in a three-dimensional environment</span></div><div class="casAuthors">Sabra, Georges; Vermette, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1994-2006</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study reveals that it is possible to obtain a specific cell response towards low-fouling carboxymethyl dextran (CMD) surfaces bearing the RGD adhesive peptide in fibrin.  To avoid cell sedimentation on surfaces obsd. in traditional cell culture systems, CMD surfaces bearing RGD were vertically embedded in fibrin contg. human umbilical vein endothelial cells (HUVEC) and their effect over cells was investigated.  Compared to the CMD surfaces and to CMD layers bearing the neg. control RGE, RGD coatings promoted cell adhesion, induced focal contact formation indicated by co-localization of vinculin and actin fibers, and presented a significant effect over HUVEC net growth during the first 24 h of the culture, as revealed by Ki67 staining and cell counting.  The intracellular localization of caveolin-1 combined with the expression of beta 1 integrins was investigated and the orientation of HUVEC towards and on the RGD surfaces was studied.  When compared to the neg. controls, HUVEC responded to the RGD surface in fibrin resulting in acceleration of morphol. changes.  RGD surfaces supported fibrin degrdn. by HUVEC as revealed by fluorescent fibrin expts. as well as multi-cellular structure formation, vacuolation and lumen formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhO-MKiI74TLVg90H21EOLACvtfcHk0ljb0JCjwNC3fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1ykt74%253D&md5=46886ab9246c8d6238ea6dee2b75e325</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2011.05.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2011.05.029%26sid%3Dliteratum%253Aachs%26aulast%3DSabra%26aufirst%3DG.%26aulast%3DVermette%26aufirst%3DP.%26atitle%3DEndothelial%2520cell%2520response%2520towards%2520low-fouling%2520surfaces%2520bearing%2520RGD%2520in%2520a%2520three-dimensional%2520environment%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2011%26volume%3D317%26spage%3D1994%26epage%3D2006%26doi%3D10.1016%2Fj.yexcr.2011.05.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nih, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimatteo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segura, T.</span></span> <span> </span><span class="NLM_article-title">Hydrogels with precisely controlled integrin activation dictate vascular patterning and permeability</span>. <i>Nat. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">953</span>â <span class="NLM_lpage">961</span>, <span class="refDoi">Â DOI: 10.1038/nmat4954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnmat4954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28783156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ylsb3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=953-961&author=S.+Liauthor=L.+R.+Nihauthor=H.+Bachmanauthor=P.+Feiauthor=Y.+Liauthor=E.+Namauthor=R.+Dimatteoauthor=S.+T.+Carmichaelauthor=T.+H.+Barkerauthor=T.+Segura&title=Hydrogels+with+precisely+controlled+integrin+activation+dictate+vascular+patterning+and+permeability&doi=10.1038%2Fnmat4954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrogels with precisely controlled integrin activation dictate vascular patterning and permeability</span></div><div class="casAuthors">Li, Shuoran; Nih, Lina R.; Bachman, Haylee; Fei, Peng; Li, Yilei; Nam, Eunwoo; Dimatteo, Robert; Carmichael, S. Thomas; Barker, Thomas H.; Segura, Tatiana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Materials</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">953-961</span>CODEN:
                <span class="NLM_cas:coden">NMAACR</span>;
        ISSN:<span class="NLM_cas:issn">1476-1122</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Integrin binding to bioengineered hydrogel scaffolds is essential for tissue regrowth and regeneration, yet not all integrin binding can lead to tissue repair.  Here, we show that through engineering hydrogel materials to promote Î±3/Î±5Î²1 integrin binding, we can promote the formation of a space-filling and mature vasculature compared with hydrogel materials that promote Î±vÎ²3 integrin binding.  In vitro, Î±3/Î±5Î²1 scaffolds promoted endothelial cells to sprout and branch, forming organized extensive networks that eventually reached and anastomosed with neighboring branches.  In vivo, Î±3/Î±5Î²1 scaffolds delivering vascular endothelial growth factor (VEGF) promoted non-tortuous blood vessel formation and non-leaky blood vessels by 10 days post-stroke.  In contrast, materials that promote Î±vÎ²3 integrin binding promoted endothelial sprout clumping in vitro and leaky vessels in vivo.  This work shows that precisely controlled integrin activation from a biomaterial can be harnessed to direct therapeutic vessel regeneration and reduce VEGF-induced vascular permeability in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeGpYdULzN47Vg90H21EOLACvtfcHk0lishTaGBfN2Yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ylsb3J&md5=cda5518a4fdceb95686f0a9521f670a3</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fnmat4954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmat4954%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DNih%26aufirst%3DL.%2BR.%26aulast%3DBachman%26aufirst%3DH.%26aulast%3DFei%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DNam%26aufirst%3DE.%26aulast%3DDimatteo%26aufirst%3DR.%26aulast%3DCarmichael%26aufirst%3DS.%2BT.%26aulast%3DBarker%26aufirst%3DT.%2BH.%26aulast%3DSegura%26aufirst%3DT.%26atitle%3DHydrogels%2520with%2520precisely%2520controlled%2520integrin%2520activation%2520dictate%2520vascular%2520patterning%2520and%2520permeability%26jtitle%3DNat.%2520Mater.%26date%3D2017%26volume%3D16%26spage%3D953%26epage%3D961%26doi%3D10.1038%2Fnmat4954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Washington, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashur, C. A.</span></span> <span> </span><span class="NLM_article-title">Delivery of anti-oxidant and anti-inflammatory agents for tissue engineered vascular grafts</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">659</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29033836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegs7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=659&author=K.+S.+Washingtonauthor=C.+A.+Bashur&title=Delivery+of+anti-oxidant+and+anti-inflammatory+agents+for+tissue+engineered+vascular+grafts&doi=10.3389%2Ffphar.2017.00659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Delivery of antioxidant and anti-inflammatory agents for tissue engineered vascular grafts</span></div><div class="casAuthors">Washington, Kenyatta S.; Bashur, Chris A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">659/1-659/18</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The treatment of patients with severe coronary and peripheral artery disease represents a significant clin. need, esp. for those patients that require a bypass graft and do not have viable veins for autologous grafting.  Tissue engineering is being investigated to generate an alternative graft.  While tissue engineering requires surgical intervention, the release of pharmacol. agents is also an important part of many tissue engineering strategies.  Delivery of these agents offers the potential to overcome the major concerns for graft patency and viability.  These concerns are related to an extended inflammatory response and its impact on vascular cells such as endothelial cells.  This review discusses the drugs that have been released from vascular tissue engineering scaffolds and some of the non-traditional ways that the drugs are presented to the cells.  The impact of antioxidant compds. and gasotransmitters, such as nitric oxide and carbon monoxide, are discussed in detail.  The application of tissue engineering and drug delivery principles to biodegradable stents is also briefly discussed.  Overall, there are scaffold-based drug delivery techniques that have shown promise for vascular tissue engineering, but much of this work is in the early stages and there are still opportunities to incorporate addnl. drugs to modulate the inflammatory process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI6U3dDFud67Vg90H21EOLACvtfcHk0lishTaGBfN2Yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegs7zP&md5=037861f5e933a61120b39f6485287325</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00659%26sid%3Dliteratum%253Aachs%26aulast%3DWashington%26aufirst%3DK.%2BS.%26aulast%3DBashur%26aufirst%3DC.%2BA.%26atitle%3DDelivery%2520of%2520anti-oxidant%2520and%2520anti-inflammatory%2520agents%2520for%2520tissue%2520engineered%2520vascular%2520grafts%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D659%26doi%3D10.3389%2Ffphar.2017.00659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorrello, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenthart, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biscotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wobma, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchetta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vunjak-Novakovic, G.</span></span> <span> </span><span class="NLM_article-title">Functional vascularized lung grafts for lung bioengineering</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e1700521</span>, <span class="refDoi">Â DOI: 10.1126/sciadv.1700521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1126%2Fsciadv.1700521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28875163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls1Gmtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=e1700521&author=N.+V.+Dorrelloauthor=B.+A.+Guenthartauthor=J.+D.+O%E2%80%99Neillauthor=J.+Kimauthor=K.+Cunninghamauthor=Y.+W.+Chenauthor=M.+Biscottiauthor=T.+Swayneauthor=H.+M.+Wobmaauthor=S.+X.+L.+Huangauthor=H.+W.+Snoeckauthor=M.+Bacchettaauthor=G.+Vunjak-Novakovic&title=Functional+vascularized+lung+grafts+for+lung+bioengineering&doi=10.1126%2Fsciadv.1700521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Functional vascularized lung grafts for lung bioengineering</span></div><div class="casAuthors">Dorrello, N. Valerio; Guenthart, Brandon A.; O'Neill, John D.; Kim, Jinho; Cunningham, Katherine; Chen, Ya-Wen; Biscotti, Mauer; Swayne, Theresa; Wobma, Holly M.; Huang, Sarah X. L.; Snoeck, Hans-Willem; Bacchetta, Matthew; Vunjak-Novakovic, Gordana</div><div class="citationInfo"><span class="NLM_cas:title">Science Advances</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1700521/1-e1700521/14</span>CODEN:
                <span class="NLM_cas:coden">SACDAF</span>;
        ISSN:<span class="NLM_cas:issn">2375-2548</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">End-stage lung disease is the third leading cause of death worldwide, accounting for 400,000 deaths per yr in the United States alone.  To reduce the morbidity and mortality assocd. with lung disease, new therapeutic strategies aimed at promoting lung repair and increasing the no. of donor lungs available for transplantation are being explored.  Because of the extreme complexity of this organ, previous attempts at bioengineering functional lungs from fully decellularized or synthetic scaffolds lacking functional vasculature have been largely unsuccessful.  An intact vascular network is crit. not only for maintaining the blood-gas barrier and allowing for proper graft function but also for supporting the regenerative cells.  We therefore developed an airway-specific approach to removing the pulmonary epithelium, while maintaining the viability and function of the vascular endothelium, using a rat model.  The resulting vascularized lung grafts supported the attachment and growth of human adult pulmonary cells and stem cell-derived lung-specified epithelial cells.  We propose that de-epithelialization of the lung with preservation of intact vasculature could facilitate cell therapy of pulmonary epithelium and enable bioengineering of functional lungs for transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ZUT3lWVYEbVg90H21EOLACvtfcHk0lishTaGBfN2Yg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls1Gmtbc%253D&md5=c835f710667dca537f9d20bb32d4758c</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.1700521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.1700521%26sid%3Dliteratum%253Aachs%26aulast%3DDorrello%26aufirst%3DN.%2BV.%26aulast%3DGuenthart%26aufirst%3DB.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DJ.%2BD.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DY.%2BW.%26aulast%3DBiscotti%26aufirst%3DM.%26aulast%3DSwayne%26aufirst%3DT.%26aulast%3DWobma%26aufirst%3DH.%2BM.%26aulast%3DHuang%26aufirst%3DS.%2BX.%2BL.%26aulast%3DSnoeck%26aufirst%3DH.%2BW.%26aulast%3DBacchetta%26aufirst%3DM.%26aulast%3DVunjak-Novakovic%26aufirst%3DG.%26atitle%3DFunctional%2520vascularized%2520lung%2520grafts%2520for%2520lung%2520bioengineering%26jtitle%3DSci.%2520Adv.%26date%3D2017%26volume%3D3%26spage%3De1700521%26doi%3D10.1126%2Fsciadv.1700521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthiesen, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kren, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netoff, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. A.</span></span> <span> </span><span class="NLM_article-title">Perfusion-decellularized matrix: using natureâs platform to engineer a bioartificial heart</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">213</span>â <span class="NLM_lpage">221</span>, <span class="refDoi">Â DOI: 10.1038/nm1684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm1684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18193059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1Khsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=213-221&author=H.+C.+Ottauthor=T.+S.+Matthiesenauthor=S.+K.+Gohauthor=L.+D.+Blackauthor=S.+M.+Krenauthor=T.+I.+Netoffauthor=D.+A.+Taylor&title=Perfusion-decellularized+matrix%3A+using+nature%E2%80%99s+platform+to+engineer+a+bioartificial+heart&doi=10.1038%2Fnm1684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart</span></div><div class="casAuthors">Ott, Harald C.; Matthiesen, Thomas S.; Goh, Saik-Kia; Black, Lauren D.; Kren, Stefan M.; Netoff, Theoden I.; Taylor, Doris A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">About 3,000 individuals in the United States are awaiting a donor heart; worldwide, 22 million individuals are living with heart failure.  A bioartificial heart is a theor. alternative to transplantation or mech. left ventricular support.  Generating a bioartificial heart requires engineering of cardiac architecture, appropriate cellular constituents and pump function.  We decellularized hearts by coronary perfusion with detergents, preserved the underlying extracellular matrix, and produced an acellular, perfusable vascular architecture, competent acellular valves and intact chamber geometry.  To mimic cardiac cell compn., we reseeded these constructs with cardiac or endothelial cells.  To establish function, we maintained eight constructs for up to 28 d by coronary perfusion in a bioreactor that simulated cardiac physiol.  By day 4, we obsd. macroscopic contractions.  By day 8, under physiol. load and elec. stimulation, constructs could generate pump function (equiv. to about 2% of adult or 25% of 16-wk fetal heart function) in a modified working heart prepn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDxMjft9JY6bVg90H21EOLACvtfcHk0ljQRK5vmAp9hQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1Khsb0%253D&md5=a7e728c7751a88a9b13d1d96364ea8e8</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fnm1684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1684%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DH.%2BC.%26aulast%3DMatthiesen%26aufirst%3DT.%2BS.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DBlack%26aufirst%3DL.%2BD.%26aulast%3DKren%26aufirst%3DS.%2BM.%26aulast%3DNetoff%26aufirst%3DT.%2BI.%26aulast%3DTaylor%26aufirst%3DD.%2BA.%26atitle%3DPerfusion-decellularized%2520matrix%253A%2520using%2520nature%25E2%2580%2599s%2520platform%2520to%2520engineer%2520a%2520bioartificial%2520heart%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D213%26epage%3D221%26doi%3D10.1038%2Fnm1684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakarma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhise, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelista, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouwkema, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokmeci, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghaemmaghami, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrana, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khademhosseini, A.</span></span> <span> </span><span class="NLM_article-title">Engineering immunomodulatory biomaterials to tune the inflammatory response</span>. <i>Trends Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">470</span>â <span class="NLM_lpage">482</span>, <span class="refDoi">Â DOI: 10.1016/j.tibtech.2016.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.tibtech.2016.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=27138899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtValtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=470-482&author=A.+Vishwakarmaauthor=N.+S.+Bhiseauthor=M.+B.+Evangelistaauthor=J.+Rouwkemaauthor=M.+R.+Dokmeciauthor=A.+M.+Ghaemmaghamiauthor=N.+E.+Vranaauthor=A.+Khademhosseini&title=Engineering+immunomodulatory+biomaterials+to+tune+the+inflammatory+response&doi=10.1016%2Fj.tibtech.2016.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering Immunomodulatory Biomaterials To Tune the Inflammatory Response</span></div><div class="casAuthors">Vishwakarma, Ajaykumar; Bhise, Nupura S.; Evangelista, Marta B.; Rouwkema, Jeroen; Dokmeci, Mehmet R.; Ghaemmaghami, Amir M.; Vrana, Nihal Engin; Khademhosseini, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biotechnology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">470-482</span>CODEN:
                <span class="NLM_cas:coden">TRBIDM</span>;
        ISSN:<span class="NLM_cas:issn">0167-7799</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Current state-of-the-art biomedical implants and tissue engineering methods promise technologies to improve or even restore the function of diseased organs.  However, one of the biggest challenges to clin. success is the lack of functional integration.  A series of cellular and mol. events following biomaterial implantation poses an important bottleneck for developing breakthrough solns.  With inflammation increasingly recognized as a crucial component influencing regeneration, immunomodulation or immuno-engineering has emerged as a potential soln. to overcome this key challenge in regenerative medicine.  We postulate possibilities to utilize biomaterial physicochem. modifications to modulate the host inflammatory response and develop strategies for effective biomaterial integration.  Biomaterial-based immunomodulation strategies can significantly ameliorate the outcomes of medical implants and tissue engineering therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOZPzYj8mSZLVg90H21EOLACvtfcHk0ljQRK5vmAp9hQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtValtbY%253D&md5=dafb6701a987b7cbfcd7fc675ff9e1bc</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.tibtech.2016.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibtech.2016.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DVishwakarma%26aufirst%3DA.%26aulast%3DBhise%26aufirst%3DN.%2BS.%26aulast%3DEvangelista%26aufirst%3DM.%2BB.%26aulast%3DRouwkema%26aufirst%3DJ.%26aulast%3DDokmeci%26aufirst%3DM.%2BR.%26aulast%3DGhaemmaghami%26aufirst%3DA.%2BM.%26aulast%3DVrana%26aufirst%3DN.%2BE.%26aulast%3DKhademhosseini%26aufirst%3DA.%26atitle%3DEngineering%2520immunomodulatory%2520biomaterials%2520to%2520tune%2520the%2520inflammatory%2520response%26jtitle%3DTrends%2520Biotechnol.%26date%3D2016%26volume%3D34%26spage%3D470%26epage%3D482%26doi%3D10.1016%2Fj.tibtech.2016.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. K.</span></span> <span> </span><span class="NLM_article-title">Pirfenidone inhibits fibrosis in foreign body reaction after glaucoma drainage device</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1477</span>â <span class="NLM_lpage">1488</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S99957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S99957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=27143855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtFOltLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=1477-1488&author=K.+I.+Jungauthor=C.+K.+Park&title=Pirfenidone+inhibits+fibrosis+in+foreign+body+reaction+after+glaucoma+drainage+device&doi=10.2147%2FDDDT.S99957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone inhibits fibrosis in foreign body reaction after glaucoma drainage device implantation</span></div><div class="casAuthors">Jung, Kyoung In; Park, Chan Kee</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1477-1488</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: The aim of this study was to investigate the antiscarring effects of pirfenidone on foreign body reaction in a rabbit model of glaucoma drainage implant surgery.  Methods: Adult New Zealand White rabbits had glaucoma drainage device implantation using Model FP8 Ahmed glaucoma valves.  One eye was randomly assigned to receive postoperative intrableb injection of pirfenidone followed by topical treatment.  The other eye underwent the same procedure but without the addn. of pirfenidone.  Histochem. staining and immuno histochem. for blebs were performed.  Results: The degree of cellularity was smaller in the pirfenidone group than in the control group at 2 wk post operation (P=0.005).  A few foreign body giant cells were detected in the inner border of the capsule, and their nos. were similar in the control and pirfenidone groups (P >0.05).  Using Masson's trichrome stain, the inner collagen-rich layer was found to be thinner in the pirfenidone group than the control group at 4 wk (P=0.031) and 8 wk (P=0.022) post operation.  The percentage of proliferating cell nuclear antigen-pos. cells was lower in the pirfenidone group than in the control group at 2 wk post operation (total bleb, P=0.022; inner bleb, P=0.036).  Pirfenidone treatment decreased the immunoreactiv ity of connective tissue growth factor at 2 wk post operation (total bleb, P=0.029; inner bleb, P=0.018).  The height and area of Î±-smooth muscle actin expression were lower in the pirfenidone group than the control group at 2 wk, 4 wk, and 8 wk post operation (all P <0.05).  Conclusion: Postoperative intrableb injection of pirfenidone followed by topical administra tion reduced fibrosis following glaucoma drainage device implantation.  These findings sug gest that pirfenidone may function as an antiscarring treatment in foreign body reaction after tube-shunt surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_VXroKAd5cLVg90H21EOLACvtfcHk0ljQRK5vmAp9hQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtFOltLc%253D&md5=26f30e5d68013049914820a86f1e7a99</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S99957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S99957%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DK.%2BI.%26aulast%3DPark%26aufirst%3DC.%2BK.%26atitle%3DPirfenidone%2520inhibits%2520fibrosis%2520in%2520foreign%2520body%2520reaction%2520after%2520glaucoma%2520drainage%2520device%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D1477%26epage%3D1488%26doi%3D10.2147%2FDDDT.S99957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tlsty, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coussens, L. M.</span></span> <span> </span><span class="NLM_article-title">Tumor stroma and regulation of cancer development</span>. <i>Annu. Rev. Pathol.: Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">119</span>â <span class="NLM_lpage">150</span>, <span class="refDoi">Â DOI: 10.1146/annurev.pathol.1.110304.100224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1146%2Fannurev.pathol.1.110304.100224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18039110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVOitb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=119-150&author=T.+D.+Tlstyauthor=L.+M.+Coussens&title=Tumor+stroma+and+regulation+of+cancer+development&doi=10.1146%2Fannurev.pathol.1.110304.100224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor stroma and regulation of cancer development</span></div><div class="casAuthors">Tlsty, Thea D.; Coussens, Lisa M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">119-150</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  In the past 25 years, a majority of cancer studies have focused on examg. functional consequences of activating and/or inactivating mutations in crit. genes implicated in cell cycle control.  These studies have taught us a great deal about the functions of oncogenes and tumor suppressor genes and the signaling pathways regulating cell proliferation and/or cell death.  However, such studies have largely ignored the fact that cancers are heterogeneous cellular entities whose growth is dependent upon reciprocal interactions between genetically altered "initiated" cells and the dynamic microenvironment in which they live.  This review highlights the aspects of cancer development that, like organogenesis during embryonic development and tissue repair in adult mammals, are regulated by interactions between epithelial cells, activated stromal cells, and sol. and insol. components of the extracellular matrix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZHCYEcFMcsrVg90H21EOLACvtfcHk0ljpg6a7iivnfA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVOitb0%253D&md5=6140a30a9a1b09ad067ebdb0b6ae0eff</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathol.1.110304.100224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathol.1.110304.100224%26sid%3Dliteratum%253Aachs%26aulast%3DTlsty%26aufirst%3DT.%2BD.%26aulast%3DCoussens%26aufirst%3DL.%2BM.%26atitle%3DTumor%2520stroma%2520and%2520regulation%2520of%2520cancer%2520development%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2006%26volume%3D1%26spage%3D119%26epage%3D150%26doi%3D10.1146%2Fannurev.pathol.1.110304.100224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orimo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Stromal fibroblasts in cancer. A novel tumor-promoting cell type</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1597</span>â <span class="NLM_lpage">1601</span>, <span class="refDoi">Â DOI: 10.4161/cc.5.15.3112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.4161%2Fcc.5.15.3112" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1597-1601&author=A.+Orimoauthor=R.+A.+Weinberg&title=Stromal+fibroblasts+in+cancer.+A+novel+tumor-promoting+cell+type&doi=10.4161%2Fcc.5.15.3112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.4161%2Fcc.5.15.3112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.5.15.3112%26sid%3Dliteratum%253Aachs%26aulast%3DOrimo%26aufirst%3DA.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DStromal%2520fibroblasts%2520in%2520cancer.%2520A%2520novel%2520tumor-promoting%2520cell%2520type%26jtitle%3DCell%2520Cycle%26date%3D2006%26volume%3D5%26spage%3D1597%26epage%3D1601%26doi%3D10.4161%2Fcc.5.15.3112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamauchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurie, J. M.</span></span> <span> </span><span class="NLM_article-title">The fibrotic tumor stroma</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">16</span>â <span class="NLM_lpage">25</span>, <span class="refDoi">Â DOI: 10.1172/JCI93554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93554" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=16-25&author=M.+Yamauchiauthor=T.+H.+Barkerauthor=D.+L.+Gibbonsauthor=J.+M.+Kurie&title=The+fibrotic+tumor+stroma&doi=10.1172%2FJCI93554"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1172%2FJCI93554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93554%26sid%3Dliteratum%253Aachs%26aulast%3DYamauchi%26aufirst%3DM.%26aulast%3DBarker%26aufirst%3DT.%2BH.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DKurie%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520fibrotic%2520tumor%2520stroma%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D16%26epage%3D25%26doi%3D10.1172%2FJCI93554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Augsten, M.</span></span> <span> </span><span class="NLM_article-title">Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">62</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2014.00062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffonc.2014.00062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24734219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsl2mtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=62&author=M.+Augsten&title=Cancer-associated+fibroblasts+as+another+polarized+cell+type+of+the+tumor+microenvironment&doi=10.3389%2Ffonc.2014.00062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment</span></div><div class="casAuthors">Augsten Martin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">62</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Tumor- or cancer-associated fibroblasts (CAFs) are one of the most abundant stromal cell types in different carcinomas and comprise a heterogeneous cell population.  Classically, CAFs are assigned with pro-tumorigenic effects stimulating tumor growth and progression.  More recent studies demonstrated also tumor-inhibitory effects of CAFs suggesting that tumor-residing fibroblasts exhibit a similar degree of plasticity as other stromal cell types.  Reciprocal interactions with the tumor milieu and different sources of origin are emerging as two important factors underlying CAF heterogeneity.  This review highlights recent advances in our understanding of CAF biology and proposes to expand the term of cellular "polarization," previously introduced to describe different activation states of various immune cells, onto CAFs to reflect their phenotypic diversity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYoMsMF_spOohLSh9fo81bfW6udTcc2eaZMs3pAmmRy7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsl2mtQ%253D%253D&md5=f9f948b6990677005a727651ef53654b</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2014.00062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2014.00062%26sid%3Dliteratum%253Aachs%26aulast%3DAugsten%26aufirst%3DM.%26atitle%3DCancer-associated%2520fibroblasts%2520as%2520another%2520polarized%2520cell%2520type%2520of%2520the%2520tumor%2520microenvironment%26jtitle%3DFront.%2520Oncol.%26date%3D2014%26volume%3D4%26spage%3D62%26doi%3D10.3389%2Ffonc.2014.00062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamauchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurie, J.</span></span> <span> </span><span class="NLM_article-title">MFKBP65-dependent peptidyl-prolyl isomerase activity potentiates the lysyl hydroxylase 2-driven collagen cross-link switch</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46021</span>, <span class="refDoi">Â DOI: 10.1038/srep46021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fsrep46021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28378777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVeksrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=46021&author=Y.+Chenauthor=M.+Terajimaauthor=P.+Banerjeeauthor=H.+Guoauthor=X.+Liuauthor=J.+Yuauthor=M.+Yamauchiauthor=J.+Kurie&title=MFKBP65-dependent+peptidyl-prolyl+isomerase+activity+potentiates+the+lysyl+hydroxylase+2-driven+collagen+cross-link+switch&doi=10.1038%2Fsrep46021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">FKBP65-dependent peptidyl-prolyl isomerase activity potentiates the lysyl hydroxylase 2-driven collagen cross-link switch</span></div><div class="casAuthors">Chen, Yulong; Terajima, Masahiko; Banerjee, Priyam; Guo, Houfu; Liu, Xin; Yu, Jiang; Yamauchi, Mitsuo; Kurie, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46021</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruck Syndrome is a connective tissue disease assocd. with inactivating mutations in lysyl hydroxylase 2 (LH2/PLOD2) or FK506 binding protein 65 (FKBP65/FKBP10).  However, the functional relationship between LH2 and FKBP65 remains unclear.  Here, we postulated that peptidyl prolyl isomerase (PPIase) activity of FKBP65 pos. modulates LH2 enzymic activity and is crit. for the formation of hydroxylysine-aldehyde derived intermol. collagen cross-links (HLCCs).  To test this hypothesis, we analyzed collagen cross-links in Fkbp10-null and -wild-type murine embryonic fibroblasts.  Although LH2 protein levels did not change, FKBP65 deficiency significantly diminished HLCCs and increased the non-hydroxylated lysine-aldehyde-derived collagen cross-links (LCCs), a pattern consistent with loss of LH2 enzymic activity.  The HLCC-to-LCC ratio was rescued in FKBP65-deficient murine embryonic fibroblasts by reconstitution with wild-type but not mutant FKBP65 that lacks intact PPIase domains.  Findings from co-immunopptn., protein-fragment complementation, and co-immunofluorescence assays showed that LH2 and FKBP65 are part of a common protein complex.  We conclude that FKBP65 regulates LH2-mediated collagen crosslinking.  Because LH2 promotes fibrosis and cancer metastasis, our findings suggest that pharmacol. strategies to target FKBP65 and LH2 may have complementary therapeutic activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrojTNo3vnJkbVg90H21EOLACvtfcHk0ljStz20x6npEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVeksrk%253D&md5=01e4ccef57b455d6803fd6b6f5018181</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fsrep46021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep46021%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTerajima%26aufirst%3DM.%26aulast%3DBanerjee%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYamauchi%26aufirst%3DM.%26aulast%3DKurie%26aufirst%3DJ.%26atitle%3DMFKBP65-dependent%2520peptidyl-prolyl%2520isomerase%2520activity%2520potentiates%2520the%2520lysyl%2520hydroxylase%25202-driven%2520collagen%2520cross-link%2520switch%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D46021%26doi%3D10.1038%2Fsrep46021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tommelein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verset, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boterberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wever, O.</span></span> <span> </span><span class="NLM_article-title">Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">63</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2015.00063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffonc.2015.00063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25853091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjit1WrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=63&author=J.+Tommeleinauthor=L.+Versetauthor=T.+Boterbergauthor=P.+Demetterauthor=M.+Brackeauthor=O.+De+Wever&title=Cancer-associated+fibroblasts+connect+metastasis-promoting+communication+in+colorectal+cancer&doi=10.3389%2Ffonc.2015.00063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer</span></div><div class="casAuthors">Tommelein Joke; Boterberg Tom; Bracke Marc; De Wever Olivier; Verset Laurine; Demetter Pieter</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Colorectal cancer (CRC) progression and eventually metastasis is directed in many aspects by a circuitous ecosystem consisting of an extracellular matrix scaffold populated by cancer-associated fibroblasts (CAFs), endothelial cells, and diverse immune cells.  CAFs are recruited from local tissue-resident fibroblasts or pericryptal fibroblasts and distant fibroblast precursors.  CAFs are highly abundant in CRC.  In this review, we apply the metastasis-promoting communication of colorectal CAFs to 10 cancer hallmarks described by Hanahan and Weinberg.  CAFs influence innate and adaptive tumor immune responses.  Using datasets from previously published work, we re-explore the potential messages implicated in this process.  Fibroblasts present in metastasis (metastasis-associated fibroblasts) from CRC may have other characteristics and functional roles than CAFs in the primary tumor.  Since CAFs connect metastasis-promoting communication, CAF markers are potential prognostic biomarkers.  CAFs and their products are possible targets for novel therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZvHVQAn27d5cXNb62YGmbfW6udTcc2eYLIvilWo7nRLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjit1WrtA%253D%253D&md5=38d11271526ef0ba95352cb5ad8f1349</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2015.00063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2015.00063%26sid%3Dliteratum%253Aachs%26aulast%3DTommelein%26aufirst%3DJ.%26aulast%3DVerset%26aufirst%3DL.%26aulast%3DBoterberg%26aufirst%3DT.%26aulast%3DDemetter%26aufirst%3DP.%26aulast%3DBracke%26aufirst%3DM.%26aulast%3DDe%2BWever%26aufirst%3DO.%26atitle%3DCancer-associated%2520fibroblasts%2520connect%2520metastasis-promoting%2520communication%2520in%2520colorectal%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2015%26volume%3D5%26spage%3D63%26doi%3D10.3389%2Ffonc.2015.00063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scherz-Shouval, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santagata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendillo, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sholl, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Aharon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span> <span> </span><span class="NLM_article-title">The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">564</span>â <span class="NLM_lpage">578</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2014.05.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.cell.2014.05.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25083868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ymtLrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2014&pages=564-578&author=R.+Scherz-Shouvalauthor=S.+Santagataauthor=M.+L.+Mendilloauthor=L.+M.+Shollauthor=I.+Ben-Aharonauthor=A.+H.+Beckauthor=D.+Dias-Santagataauthor=M.+Koevaauthor=S.+M.+Stemmerauthor=L.+Whitesellauthor=S.+Lindquist&title=The+reprogramming+of+tumor+stroma+by+HSF1+is+a+potent+enabler+of+malignancy&doi=10.1016%2Fj.cell.2014.05.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy</span></div><div class="casAuthors">Scherz-Shouval, Ruth; Santagata, Sandro; Mendillo, Marc L.; Sholl, Lynette M.; Ben-Aharon, Irit; Beck, Andrew H.; Dias-Santagata, Dora; Koeva, Martina; Stemmer, Salomon M.; Whitesell, Luke; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">564-578</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Stromal cells within the tumor microenvironment are essential for tumor progression and metastasis.  Surprisingly little is known about the factors that drive the transcriptional reprogramming of stromal cells within tumors.  We report that the transcriptional regulator heat shock factor 1 (HSF1) is frequently activated in cancer-assocd. fibroblasts (CAFs), where it is a potent enabler of malignancy.  HSF1 drives a transcriptional program in CAFs that complements, yet is completely different from, the program it drives in adjacent cancer cells.  This CAF program is uniquely structured to support malignancy in a non-cell-autonomous way.  Two central stromal signaling mols.-TGF-Î² and SDF1-play a crit. role.  In early-stage breast and lung cancer, high stromal HSF1 activation is strongly assocd. with poor patient outcome.  Thus, tumors co-opt the ancient survival functions of HSF1 to orchestrate malignancy in both cell-autonomous and non-cell-autonomous ways, with far-reaching therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCiHlbkoEibVg90H21EOLACvtfcHk0ljStz20x6npEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ymtLrE&md5=a01f61fa9ef05c97681dc52386741332</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.05.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.05.045%26sid%3Dliteratum%253Aachs%26aulast%3DScherz-Shouval%26aufirst%3DR.%26aulast%3DSantagata%26aufirst%3DS.%26aulast%3DMendillo%26aufirst%3DM.%2BL.%26aulast%3DSholl%26aufirst%3DL.%2BM.%26aulast%3DBen-Aharon%26aufirst%3DI.%26aulast%3DBeck%26aufirst%3DA.%2BH.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DKoeva%26aufirst%3DM.%26aulast%3DStemmer%26aufirst%3DS.%2BM.%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DThe%2520reprogramming%2520of%2520tumor%2520stroma%2520by%2520HSF1%2520is%2520a%2520potent%2520enabler%2520of%2520malignancy%26jtitle%3DCell%26date%3D2014%26volume%3D158%26spage%3D564%26epage%3D578%26doi%3D10.1016%2Fj.cell.2014.05.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, H. Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. C.</span></span> <span> </span><span class="NLM_article-title">Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signaling</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3472</span>, <span class="refDoi">Â DOI: 10.1038/ncomms4472</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fncomms4472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24668028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2crnt12rsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3472&author=W.+J.+Chenauthor=C.+C.+Hoauthor=Y.+L.+Changauthor=H.+Y.+Chenauthor=C.+A.+Linauthor=T.+Y.+Lingauthor=S.+L.+Yuauthor=S.+S.+Yuanauthor=Y.+J.+L.+Chenauthor=C.+Y.+Linauthor=S.+H.+Panauthor=H.+Y.+E.+Chouauthor=Y.+J.+Chenauthor=G.+C.+Changauthor=W.+C.+Chuauthor=Y.+M.+Leeauthor=J.+Y.+Leeauthor=P.+J.+Leeauthor=K.+C.+Liauthor=H.+W.+Chenauthor=P.+C.+Yang&title=Cancer-associated+fibroblasts+regulate+the+plasticity+of+lung+cancer+stemness+via+paracrine+signaling&doi=10.1038%2Fncomms4472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling</span></div><div class="casAuthors">Chen Wan-Jiun; Ho Chao-Chi; Chang Yih-Leong; Chen Hsuan-Yu; Yuan Shin-Sheng; Chen Yu-Ju Louisa; Lin Chien-Yu; Lin Chih-An; Yu Sung-Liang; Ling Thai-Yen; Pan Szu-Hua; Chou Han-Yi Elizabeth; Chen Yu-Ju; Chang Gee-Chen; Chu Wen-Cheng; Lee Yee-Ming; Lee Jen-Yi; Lee Pei-Jung; Li Ker-Chau; Chen Huei-Wen; Yang Pan-Chyr</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3472</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer stem cells (CSCs) are a promising target for treating cancer, yet how CSC plasticity is maintained in vivo is unclear and is difficult to study in vitro.  Here we establish a sustainable primary culture of Oct3/4(+)/Nanog(+) lung CSCs fed with CD90(+) cancer-associated fibroblasts (CAFs) to further advance our knowledge of preserving stem cells in the tumour microenvironment.  Using transcriptomics we identify the paracrine network by which CAFs enrich CSCs through de-differentiation and reacquisition of stem cell-like properties.  Specifically, we find that IGF1R signalling activation in cancer cells in the presence of CAFs expressing IGF-II can induce Nanog expression and promote stemness.  Moreover, this paracrine signalling predicts overall and relapse-free survival in stage I non-small cell lung cancer (NSCLC) patients.  IGF-II/IGF1R signalling blockade inhibits Nanog expression and attenuates cancer stem cell features.  Our data demonstrate that CAFs constitute a supporting niche for cancer stemness, and targeting this paracrine signalling may present a new therapeutic strategy for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTm3hC1BFRecNy3lHz94U-GfW6udTcc2eb-TpKnn0YhFbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crnt12rsQ%253D%253D&md5=361b9cb8eee2a5a5b521f2d8a7ae7992</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fncomms4472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4472%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%2BJ.%26aulast%3DHo%26aufirst%3DC.%2BC.%26aulast%3DChang%26aufirst%3DY.%2BL.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DLin%26aufirst%3DC.%2BA.%26aulast%3DLing%26aufirst%3DT.%2BY.%26aulast%3DYu%26aufirst%3DS.%2BL.%26aulast%3DYuan%26aufirst%3DS.%2BS.%26aulast%3DChen%26aufirst%3DY.%2BJ.%2BL.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DPan%26aufirst%3DS.%2BH.%26aulast%3DChou%26aufirst%3DH.%2BY.%2BE.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26aulast%3DChang%26aufirst%3DG.%2BC.%26aulast%3DChu%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DY.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DP.%2BJ.%26aulast%3DLi%26aufirst%3DK.%2BC.%26aulast%3DChen%26aufirst%3DH.%2BW.%26aulast%3DYang%26aufirst%3DP.%2BC.%26atitle%3DCancer-associated%2520fibroblasts%2520regulate%2520the%2520plasticity%2520of%2520lung%2520cancer%2520stemness%2520via%2520paracrine%2520signaling%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3472%26doi%3D10.1038%2Fncomms4472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tafelmeyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein-Î± in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">977</span>â <span class="NLM_lpage">991</span>, <span class="refDoi">Â DOI: 10.1080/14728222.2017.1370455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1080%2F14728222.2017.1370455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28829211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVarsLvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=977-991&author=L.+Juillerat-Jeanneretauthor=P.+Tafelmeyerauthor=D.+Golshayan&title=Fibroblast+activation+protein-%CE%B1+in+fibrogenic+disorders+and+cancer%3A+more+than+a+prolyl-specific+peptidase%3F&doi=10.1080%2F14728222.2017.1370455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein-Î± in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?</span></div><div class="casAuthors">Juillerat-Jeanneret, Lucienne; Tafelmeyer, Petra; Golshayan, Dela</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">977-991</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Fibroblast activation protein-Î± (FAP-Î±) belongs to the family of prolyl-specific serine proteases.  FAP-Î± displays both exopeptidase and endopeptidase/gelatinase/collagenase activities.  FAP-Î± protein and/or activity have been assocd. with fibrosis, inflammation and cancer, but the protein is undetectable in most normal tissues.  FAP-Î± is selectively expressed at sites of tissue remodeling and repair and enhances tumor progression, suggesting that this protease may be a therapeutic target to treat human disorders assocd. with fibrotic dysregulation.  In this review, we summarize the mechanisms driving tissue fibrosis and describe some of the enzymes involved in fibrosis, concg. on FAP-Î±.  We describe its enzymic properties, discuss the tools developed to control its activity and the problem of selectivity toward the other proteases of the family and outline its potential biol. substrates.  We also consider non-enzymic functions of this protein and suggest that repression of FAP-Î± expression may represent therapeutic options.  Questions remain regarding the biol. functions of FAP-Î±, either dependent or independent of its enzyme activity.  However, as progress is underway to develop FAP-Î±-specific inhibitors and therapeutic antibodies, its role in diseases assocd. with fibrosis is starting to emerge, ultimately leading to novel therapeutic options for inflammatory and oncol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcbPSAqAMjn7Vg90H21EOLACvtfcHk0ljNZxKU59gS3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVarsLvJ&md5=596669985733b4eb79e68a66031f7e7a</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1080%2F14728222.2017.1370455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728222.2017.1370455%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DTafelmeyer%26aufirst%3DP.%26aulast%3DGolshayan%26aufirst%3DD.%26atitle%3DFibroblast%2520activation%2520protein-%25CE%25B1%2520in%2520fibrogenic%2520disorders%2520and%2520cancer%253A%2520more%2520than%2520a%2520prolyl-specific%2520peptidase%253F%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2017%26volume%3D21%26spage%3D977%26epage%3D991%26doi%3D10.1080%2F14728222.2017.1370455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ota, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutomi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torigoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morimoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uede, T.</span></span> <span> </span><span class="NLM_article-title">Tumor-Î±9Î²1 integrin-mediated signaling induces breast cancer growth and lymphatic metastasis via the recruitment of cancer-associated fibroblasts</span>. <i>J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1271</span>â <span class="NLM_lpage">1281</span>, <span class="refDoi">Â DOI: 10.1007/s00109-014-1183-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1007%2Fs00109-014-1183-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25099519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlanu7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2014&pages=1271-1281&author=D.+Otaauthor=M.+Kanayamaauthor=Y.+Matsuiauthor=K.+Itoauthor=N.+Maedaauthor=G.+Kutomiauthor=K.+Hirataauthor=T.+Torigoeauthor=N.+Satoauthor=A.+Takaokaauthor=A.+F.+Chambersauthor=J.+Morimotoauthor=T.+Uede&title=Tumor-%CE%B19%CE%B21+integrin-mediated+signaling+induces+breast+cancer+growth+and+lymphatic+metastasis+via+the+recruitment+of+cancer-associated+fibroblasts&doi=10.1007%2Fs00109-014-1183-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-Î±9Î²1 integrin-mediated signaling induces breast cancer growth and lymphatic metastasis via the recruitment of cancer-associated fibroblasts</span></div><div class="casAuthors">Ota, Daichi; Kanayama, Masashi; Matsui, Yutaka; Ito, Koyu; Maeda, Naoyoshi; Kutomi, Goro; Hirata, Koichi; Torigoe, Toshihiko; Sato, Noriyuki; Takaoka, Akinori; Chambers, Ann F.; Morimoto, Junko; Uede, Toshimitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1271-1281</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Tumor-derived matricellular proteins such as osteopontin (OPN) and tenascin-C (TN-C) have been implicated in tumor growth and metastasis.  However, the mol. basis of how these proteins contribute to tumor progression remains to be elucidated.  Importantly, these matricellular proteins are known to interact with Î±9Î²1 integrin.  Therefore, we hypothesized that tumor-derived Î±9Î²1 integrin may contribute to tumor progression.  To clarify the roles of Î±9Î²1 integrin in tumor growth and lymphatic metastasis, we used an inhibitory anti-human Î±9Î²1 integrin antibody (anti-hÎ±9Î²1 antibody) and a Î±9Î²1 integrin-pos. human breast cancer cell line, MDA-MB-231 luc-D3H2LN (D3H2LN), in vitro functional assays, and an in vivo orthotopic xenotransplantation model.  In this study, we demonstrated that tumor, but not host Î±9Î²1 integrin, contributes to tumor growth, lymphatic metastasis, recruitment of cancer-assocd. fibroblasts (CAFs), and host-derived OPN prodn.  We also found that CAFs contributed to tumor growth, lymphatic metastasis, and host-derived OPN levels.  Consistent with those findings, tumor vol. was well-correlated with nos. of CAFs and levels of host-derived OPN.  Furthermore, it was shown that the inoculation of D3H2LN cells into mammary fat pads with mouse embryonic fibroblasts (MEFs), obtained from wild type, but not OPN knock-out mice, resulted in enhancement of tumor growth, thus indicating that CAF-derived OPN enhanced tumor growth.  These results suggested that tumor Î±9Î²1-mediated signaling plays a pivotal role in generating unique primary tumor tissue microenvironments, which favor lymphatic metastasis and tumor growth.  Key messages: Tumor Î±9Î²1 integrin promotes lymphatic metastasis through enhancing invasion.  Tumor Î±9Î²1 integrin promotes tumor growth through CAFs.  Tumor Î±9Î²1 integrin enhances the recruitment of CAFs into the primary tumor.  Tumor cells induce the prodn. of OPN by CAFs in the primary tumor.  CAF-derived OPN promotes tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOoyL5xlQxNLVg90H21EOLACvtfcHk0ljNZxKU59gS3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlanu7rN&md5=614df7c0e6a9e25620d8486acc618dc4</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1007%2Fs00109-014-1183-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-014-1183-9%26sid%3Dliteratum%253Aachs%26aulast%3DOta%26aufirst%3DD.%26aulast%3DKanayama%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DMaeda%26aufirst%3DN.%26aulast%3DKutomi%26aufirst%3DG.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DTorigoe%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DN.%26aulast%3DTakaoka%26aufirst%3DA.%26aulast%3DChambers%26aufirst%3DA.%2BF.%26aulast%3DMorimoto%26aufirst%3DJ.%26aulast%3DUede%26aufirst%3DT.%26atitle%3DTumor-%25CE%25B19%25CE%25B21%2520integrin-mediated%2520signaling%2520induces%2520breast%2520cancer%2520growth%2520and%2520lymphatic%2520metastasis%2520via%2520the%2520recruitment%2520of%2520cancer-associated%2520fibroblasts%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2014%26volume%3D92%26spage%3D1271%26epage%3D1281%26doi%3D10.1007%2Fs00109-014-1183-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco-Barraza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valianou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cukierman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span> <span> </span><span class="NLM_article-title">FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">245</span>, <span class="refDoi">Â DOI: 10.1186/1471-2407-11-245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1186%2F1471-2407-11-245" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=245&author=H.+O.+Leeauthor=S.+R.+Mullinsauthor=J.+Franco-Barrazaauthor=M.+Valianouauthor=E.+Cukiermanauthor=J.+D.+Cheng&title=FAP-overexpressing+fibroblasts+produce+an+extracellular+matrix+that+enhances+invasive+velocity+and+directionality+of+pancreatic+cancer+cells&doi=10.1186%2F1471-2407-11-245"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-11-245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-11-245%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BO.%26aulast%3DMullins%26aufirst%3DS.%2BR.%26aulast%3DFranco-Barraza%26aufirst%3DJ.%26aulast%3DValianou%26aufirst%3DM.%26aulast%3DCukierman%26aufirst%3DE.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26atitle%3DFAP-overexpressing%2520fibroblasts%2520produce%2520an%2520extracellular%2520matrix%2520that%2520enhances%2520invasive%2520velocity%2520and%2520directionality%2520of%2520pancreatic%2520cancer%2520cells%26jtitle%3DBMC%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D245%26doi%3D10.1186%2F1471-2407-11-245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine kinas 1 enables communication between melanoma cells and fibroblasts that provides a new link to metastasis</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">3361</span>â <span class="NLM_lpage">3363</span>, <span class="refDoi">Â DOI: 10.1038/onc.2013.292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fonc.2013.292" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=3361-3363&author=N.+J.+Pyneauthor=S.+Pyne&title=Sphingosine+kinas+1+enables+communication+between+melanoma+cells+and+fibroblasts+that+provides+a+new+link+to+metastasis&doi=10.1038%2Fonc.2013.292"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.292%26sid%3Dliteratum%253Aachs%26aulast%3DPyne%26aufirst%3DN.%2BJ.%26aulast%3DPyne%26aufirst%3DS.%26atitle%3DSphingosine%2520kinas%25201%2520enables%2520communication%2520between%2520melanoma%2520cells%2520and%2520fibroblasts%2520that%2520provides%2520a%2520new%2520link%2520to%2520metastasis%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D3361%26epage%3D3363%26doi%3D10.1038%2Fonc.2013.292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, H.</span></span> <span> </span><span class="NLM_article-title">Strategies targeting angiogenesis in advanced non-small cell lung cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">53854</span>â <span class="NLM_lpage">53872</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.17957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.18632%2Foncotarget.17957" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=53854-53872&author=J.+Wangauthor=J.+Chenauthor=Y.+Guoauthor=B.+Wangauthor=H.+Chu&title=Strategies+targeting+angiogenesis+in+advanced+non-small+cell+lung+cancer&doi=10.18632%2Foncotarget.17957"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17957%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DH.%26atitle%3DStrategies%2520targeting%2520angiogenesis%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D53854%26epage%3D53872%26doi%3D10.18632%2Foncotarget.17957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic-Paterson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, H. Y.</span></span> <span> </span><span class="NLM_article-title">TGFbeta: the master regulator of fibrosis</span>. <i>Nat. Rev. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">325</span>â <span class="NLM_lpage">338</span>, <span class="refDoi">Â DOI: 10.1038/nrneph.2016.48</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnrneph.2016.48" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=27108839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFChu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=325-338&author=X.+M.+Mengauthor=D.+J.+Nikolic-Patersonauthor=H.+Y.+Lan&title=TGFbeta%3A+the+master+regulator+of+fibrosis&doi=10.1038%2Fnrneph.2016.48"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">TGF-Î²: the master regulator of fibrosis</span></div><div class="casAuthors">Meng, Xiao-ming; Nikolic-Paterson, David J.; Lan, Hui Yao</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Nephrology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">325-338</span>CODEN:
                <span class="NLM_cas:coden">NRNABO</span>;
        ISSN:<span class="NLM_cas:issn">1759-5061</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Transforming growth factor-Î² (TGF-Î²) is the primary factor that drives fibrosis in most, if not all, forms of chronic kidney disease (CKD).  Inhibition of the TGF-Î² isoform, TGF-Î²1, or its downstream signalling pathways substantially limits renal fibrosis in a wide range of disease models whereas overexpression of TGF-Î²1 induces renal fibrosis.  TGF-Î²1 can induce renal fibrosis via activation of both canonical (Smad-based) and non-canonical (non-Smad-based) signalling pathways, which result in activation of myofibroblasts, excessive prodn. of extracellular matrix (ECM) and inhibition of ECM degrdn.  The role of Smad proteins in the regulation of fibrosis is complex, with competing profibrotic and antifibrotic actions (including in the regulation of mesenchymal transitioning), and with complex interplay between TGF-Î²/Smads and other signalling pathways.  Studies over the past 5 years have identified addnl. mechanisms that regulate the action of TGF-Î²1/Smad signalling in fibrosis, including short and long noncoding RNA mols. and epigenetic modifications of DNA and histone proteins.  Although direct targeting of TGF-Î²1 is unlikely to yield a viable antifibrotic therapy due to the involvement of TGF-Î²1 in other processes, greater understanding of the various pathways by which TGF-Î²1 controls fibrosis has identified alternative targets for the development of novel therapeutics to halt this most damaging process in CKD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEipbykM1nFLVg90H21EOLACvtfcHk0lj6KDvOgNWLKg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFChu70%253D&md5=7df4db39b64b6137ec52b744d34b9c12</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fnrneph.2016.48&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneph.2016.48%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DX.%2BM.%26aulast%3DNikolic-Paterson%26aufirst%3DD.%2BJ.%26aulast%3DLan%26aufirst%3DH.%2BY.%26atitle%3DTGFbeta%253A%2520the%2520master%2520regulator%2520of%2520fibrosis%26jtitle%3DNat.%2520Rev.%2520Nephrol.%26date%3D2016%26volume%3D12%26spage%3D325%26epage%3D338%26doi%3D10.1038%2Fnrneph.2016.48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Transforming growth factor beta (TGF-beta) mediates cardiac fibrosis and induces diabetic cardiomyopathy</span>. <i>Diabetes Res. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">124</span>â <span class="NLM_lpage">130</span>, <span class="refDoi">Â DOI: 10.1016/j.diabres.2017.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.diabres.2017.08.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28934669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVeqsrrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2017&pages=124-130&author=Y.+Yueauthor=K.+Mengauthor=Y.+Puauthor=X.+Zhang&title=Transforming+growth+factor+beta+%28TGF-beta%29+mediates+cardiac+fibrosis+and+induces+diabetic+cardiomyopathy&doi=10.1016%2Fj.diabres.2017.08.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Transforming growth factor beta (TGF-Î²) mediates cardiac fibrosis and induces diabetic cardiomyopathy</span></div><div class="casAuthors">Yue, Yiyang; Meng, Ke; Pu, Yuejie; Zhang, Xiaoming</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Research and Clinical Practice</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">124-130</span>CODEN:
                <span class="NLM_cas:coden">DRCPE9</span>;
        ISSN:<span class="NLM_cas:issn">0168-8227</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Cardiovascular diseases account for the major cause of morbidity and mortality among individuals with diabetes.  The diabetic cardiomyopathy (DCM) is a type of diabetic cardiovascular disease, which further directs to the heart failure.  The researchers found that diabetes induced cardiac fibrosis plays a vital role in several of the pathol. changes that assocd. with DCM, causing left ventricular hypertrophy (LVH), diastolic dysfunction and systolic dysfunction.  However, the mechanisms involved in the pathogenesis of DCM are still elusive.  Many studies have demonstrated that the transforming growth factor beta (TGF-Î²) is one of the mol. mediators implicated in the progression of fibrogenesis.  In diabetes, hyperglycemia causes the expression changes of microRNAs (miRNAs), long non-coding RNAs (lncRNAs), TGF-Î² genes, TGF-Î² proteins and their receptors.  Activated TGF-Î² further leads to cardiac fibrosis, which in turn inducing DCM through the SMAD-dependent and independent pathways.  Here, we reviewed the the mol. pathways that activate TGF-Î² then leading to cardiac fibrosis, which induced the pathol. changes of DCM.  Illustrating the pathways of TGF-ss would propose an efficient way for the management of diabetic cardiomyopathy (see Fig. 1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7RQaoyUnOKLVg90H21EOLACvtfcHk0lj6KDvOgNWLKg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVeqsrrI&md5=88b8a72ac881b38ef898f6d39805dbcf</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.diabres.2017.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.diabres.2017.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DK.%26aulast%3DPu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DTransforming%2520growth%2520factor%2520beta%2520%2528TGF-beta%2529%2520mediates%2520cardiac%2520fibrosis%2520and%2520induces%2520diabetic%2520cardiomyopathy%26jtitle%3DDiabetes%2520Res.%2520Clin.%2520Pract.%26date%3D2017%26volume%3D133%26spage%3D124%26epage%3D130%26doi%3D10.1016%2Fj.diabres.2017.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shihata, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putra, M. R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin-Dusting, J. P. F.</span></span> <span> </span><span class="NLM_article-title">Is there a potential therapeutic role for caveolin-1 in fibrosis?</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">587</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28900397" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=587&author=W.+A.+Shihataauthor=M.+R.+A.+Putraauthor=J.+P.+F.+Chin-Dusting&title=Is+there+a+potential+therapeutic+role+for+caveolin-1+in+fibrosis%3F&doi=10.3389%2Ffphar.2017.00567"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00567%26sid%3Dliteratum%253Aachs%26aulast%3DShihata%26aufirst%3DW.%2BA.%26aulast%3DPutra%26aufirst%3DM.%2BR.%2BA.%26aulast%3DChin-Dusting%26aufirst%3DJ.%2BP.%2BF.%26atitle%3DIs%2520there%2520a%2520potential%2520therapeutic%2520role%2520for%2520caveolin-1%2520in%2520fibrosis%253F%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D587%26doi%3D10.3389%2Ffphar.2017.00567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Borgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirmiz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspari, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span> <span> </span><span class="NLM_article-title">Anti-fibrotic potential of AT<sub>2</sub> receptor agonists</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">564</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28912715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2nsrfP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=564&author=Y.+Wangauthor=M.+Del+Borgoauthor=H.+W.+Leeauthor=D.+Baraldiauthor=B.+Hirmizauthor=T.+A.+Gaspariauthor=K.+M.+Dentonauthor=M.+I.+Aguilarauthor=C.+S.+Samuelauthor=R.+E.+Widdop&title=Anti-fibrotic+potential+of+AT2+receptor+agonists&doi=10.3389%2Ffphar.2017.00564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-fibrotic potential of AT2 receptor agonists</span></div><div class="casAuthors">Wang, Yan; Del Borgo, Mark; Lee, Huey W.; Baraldi, Dhaniel; Hirmiz, Baydaa; Gaspari, Tracey A.; Denton, Kate M.; Aguilar, Marie-Isabel; Samuel, Chrishan S.; Widdop, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">564/1-564/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">There are a no. of therapeutic targets to treat organ fibrosis that are under investigation in preclin. models.  There is increasing evidence that stimulation of the angiotensin II type 2 receptor (AT2R) is a novel anti-fibrotic strategy and we have reviewed the published in vivo preclin. data relating to the effects of compd. 21 (C21), which is the only nonpeptide AT2R agonist that is currently available for use in chronic preclin. studies.  In particular, the differential influence of AT2R on extracellular matrix status in various preclin. fibrotic models is discussed.  Collectively, these studies demonstrate that pharmacol. AT2R stimulation using C21 decreases organ fibrosis, which has been most studied in the setting of cardiovascular and renal disease.  In addn., AT2R-mediated anti-inflammatory effects may contribute to the beneficial AT2R-mediated anti-fibrotic effects seen in preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXQrEmlGvVi7Vg90H21EOLACvtfcHk0lgzv9ADp17DNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2nsrfP&md5=616e2c23a2a6d046dd5bb0cd2c3733ed</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00564%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDel%2BBorgo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DBaraldi%26aufirst%3DD.%26aulast%3DHirmiz%26aufirst%3DB.%26aulast%3DGaspari%26aufirst%3DT.%2BA.%26aulast%3DDenton%26aufirst%3DK.%2BM.%26aulast%3DAguilar%26aufirst%3DM.%2BI.%26aulast%3DSamuel%26aufirst%3DC.%2BS.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26atitle%3DAnti-fibrotic%2520potential%2520of%2520AT2%2520receptor%2520agonists%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D564%26doi%3D10.3389%2Ffphar.2017.00564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alhomrani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leaw, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greening, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievert, W.</span></span> <span> </span><span class="NLM_article-title">The human amnion epithelial cell secretome decreases hepatic fibrosis in mice with chronic liver ibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">748</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29114223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegs7%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=748&author=M.+Alhomraniauthor=J.+Correiaauthor=M.+Zavouauthor=B.+Leawauthor=N.+Kukauthor=R.+Xuauthor=M.+I.+Saadauthor=A.+Hodgeauthor=D.+W.+Greeningauthor=R.+Limauthor=W.+Sievert&title=The+human+amnion+epithelial+cell+secretome+decreases+hepatic+fibrosis+in+mice+with+chronic+liver+ibrosis&doi=10.3389%2Ffphar.2017.00748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">The human amnion epithelial cell secretome decreases hepatic fibrosis in mice with chronic liver fibrosis</span></div><div class="casAuthors">Alhomrani, Majid; Correia, Jeanne; Zavou, Marcus; Leaw, Bryan; Kuk, Nathan; Xu, Rong; Saad, Mohamed I.; Hodge, Alexander; Greening, David W.; Lim, Rebecca; Sievert, William</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">748/1-748/13</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Background: Hepatic stellate cells (HSCs) are the primary collagen-secreting cells in the liver.  While HSCs are the major cell type involved in the pathogenesis of liver fibrosis, hepatic macrophages also play an important role in mediating fibrogenesis and fibrosis resoln.  Previously, we obsd. a redn. in HSC activation, proliferation, and collagen synthesis following exposure to human amnion epithelial cells (hAEC) and hAEC-conditioned media (hAEC-CM).  This suggested that specific factors secreted by hAEC might be effective in ameliorating liver fibrosis. hAEC-derived extracellular vesicles (hAEC-EVs), which are nanosized (40-100 nm) membrane bound vesicles, may act as novel cell-cell communicators.  Accordingly, we evaluated the efficacy of hAEC-EV in modulating liver fibrosis in a mouse model of chronic liver fibrosis and in human HSC.  Methods: The hAEC-EVs were isolated and characterized.  C57BL/6 mice with CCl4-induced liver fibrosis were administered hAEC-EV, hAEC-CM, or hAEC-EV depleted medium (hAEC-EVDM).  LX2 cells, a human HSC line, and bone marrow-derived mouse macrophages were exposed to hAEC-EV, hAEC-CM, and hAEC-EVDM.  Mass spectrometry was used to examine the proteome profile of each prepn.  Results: The extent of liver fibrosis and no. of activated HSCs were reduced significantly in CCl4-treated mice given hAEC-EVs, hAEC-CM, and hAEC EVDM compared to untreated controls.  Hepatic macrophages were significantly decreased in all treatment groups, where a predominant M2 phenotype was obsd.  Human HSCs cultured with hAEC-EV and hAEC-CM displayed a significant redn. in collagen synthesis and hAEC-EV, hAEC-CM, and hAEC-EVDM altered macrophage polarization in bone marrow-derived mouse macrophages.  Proteome anal. showed that 164 proteins were unique to hAEC-EV in comparison to hAEC-CM and hAEC-EVDM, and 51 proteins were co-identified components with the hAEC-EV fraction.  Conclusion: This study provides novel data showing that hAEC-derived EVs significantly reduced liver fibrosis and macrophage infiltration to an extent similar to hAEC-EVDM and hAEC-CM. hAEC-EV-based therapy may be a potential therapeutic option for liver fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO-RyBjuNS0LVg90H21EOLACvtfcHk0lgzv9ADp17DNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegs7%252FP&md5=2c75fa4216ac03827cf754930609ab31</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00748%26sid%3Dliteratum%253Aachs%26aulast%3DAlhomrani%26aufirst%3DM.%26aulast%3DCorreia%26aufirst%3DJ.%26aulast%3DZavou%26aufirst%3DM.%26aulast%3DLeaw%26aufirst%3DB.%26aulast%3DKuk%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DSaad%26aufirst%3DM.%2BI.%26aulast%3DHodge%26aufirst%3DA.%26aulast%3DGreening%26aufirst%3DD.%2BW.%26aulast%3DLim%26aufirst%3DR.%26aulast%3DSievert%26aufirst%3DW.%26atitle%3DThe%2520human%2520amnion%2520epithelial%2520cell%2520secretome%2520decreases%2520hepatic%2520fibrosis%2520in%2520mice%2520with%2520chronic%2520liver%2520ibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D748%26doi%3D10.3389%2Ffphar.2017.00748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nanthakumar, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatley, R. J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauldie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">Dissecting fibrosis: therapeutic insights from the small-molecule toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">693</span>â <span class="NLM_lpage">720</span>, <span class="refDoi">Â DOI: 10.1038/nrd4592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnrd4592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26338155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7rJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=693-720&author=C.+B.+Nanthakumarauthor=R.+J.+D.+Hatleyauthor=S.+Lemmaauthor=J.+Gauldieauthor=R.+P.+Marshallauthor=S.+J.+F.+Macdonald&title=Dissecting+fibrosis%3A+therapeutic+insights+from+the+small-molecule+toolbox&doi=10.1038%2Fnrd4592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting fibrosis: therapeutic insights from the small-molecule toolbox</span></div><div class="casAuthors">Nanthakumar, Carmel B.; Hatley, Richard J. D.; Lemma, Seble; Gauldie, Jack; Marshall, Richard P.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">693-720</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibrosis, which leads to progressive loss of tissue function and eventual organ failure, has been estd. to contribute to â¼45% of deaths in the developed world, and so new therapeutics to modulate fibrosis are urgently needed.  Major advances in our understanding of the mechanisms underlying pathol. fibrosis are supporting the search for such therapeutics, and the recent approval of two anti-fibrotic drugs for idiopathic pulmonary fibrosis has demonstrated the tractability of this area for drug discovery.  This Review examines the pharmacol. and structural information for small mols. being evaluated for lung, liver, kidney and skin fibrosis.  In particular, we discuss the insights gained from the use of these pharmacol. tools, and how these entities can inform, and probe, emerging insights into disease mechanisms, including the potential for future drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk6pfSk3gsCrVg90H21EOLACvtfcHk0ljaDlefw8vyFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7rJ&md5=b05a37db6ede2acc0f5c65826aa344f3</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnrd4592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4592%26sid%3Dliteratum%253Aachs%26aulast%3DNanthakumar%26aufirst%3DC.%2BB.%26aulast%3DHatley%26aufirst%3DR.%2BJ.%2BD.%26aulast%3DLemma%26aufirst%3DS.%26aulast%3DGauldie%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DR.%2BP.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DDissecting%2520fibrosis%253A%2520therapeutic%2520insights%2520from%2520the%2520small-molecule%2520toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D693%26epage%3D720%26doi%3D10.1038%2Fnrd4592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mora, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selman, M.</span></span> <span> </span><span class="NLM_article-title">Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">755</span>â <span class="NLM_lpage">772</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2017.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnrd.2017.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28983101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7nM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=755-772&author=A.+L.+Moraauthor=M.+Rojasauthor=A.+Pardoauthor=M.+Selman&title=Emerging+therapies+for+idiopathic+pulmonary+fibrosis%2C+a+progressive+age-related+disease&doi=10.1038%2Fnrd.2017.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease</span></div><div class="casAuthors">Mora, Ana L.; Rojas, Mauricio; Pardo, Annie; Selman, Moises</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">755-772</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a fatal age-assocd. disease that is characterized by progressive and irreversible scarring of the lung.  The pathogenesis of IPF is not completely understood and current therapies are limited to those that reduce the rate of functional decline in patients with mild-to-moderate disease.  In this context, new therapeutic approaches that substantially improve the survival time and quality of life of these patients are urgently needed.  Our incomplete understanding of the pathogenic mechanisms of IPF and the lack of appropriate exptl. models that reproduce the key characteristics of the human disease are major challenges.  As ageing is a major risk factor for IPF, age-related cell perturbations such as telomere attrition, senescence, epigenetic drift, stem cell exhaustion, loss of proteostasis and mitochondrial dysfunction are becoming targets of interest for IPF therapy.  In this Review, we discuss current and emerging therapies for IPF, particularly those targeting age-related mechanisms, and discuss future therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhctsz_uEsn7Vg90H21EOLACvtfcHk0liDKZNnpm_2Kw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7nM&md5=47cc6f5e332c9cfe77271cf6d351d233</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.170%26sid%3Dliteratum%253Aachs%26aulast%3DMora%26aufirst%3DA.%2BL.%26aulast%3DRojas%26aufirst%3DM.%26aulast%3DPardo%26aufirst%3DA.%26aulast%3DSelman%26aufirst%3DM.%26atitle%3DEmerging%2520therapies%2520for%2520idiopathic%2520pulmonary%2520fibrosis%252C%2520a%2520progressive%2520age-related%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D755%26epage%3D772%26doi%3D10.1038%2Fnrd.2017.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montemurro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iovene, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mari, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richeldi, L.</span></span> <span> </span><span class="NLM_article-title">Investigational drugs for idiopathic pulmonary fibrosis</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1019</span>â <span class="NLM_lpage">1031</span>, <span class="refDoi">Â DOI: 10.1080/13543784.2017.1364361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1080%2F13543784.2017.1364361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28777013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSlt7rO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=1019-1031&author=F.+Varoneauthor=G.+Montemurroauthor=F.+Macagnoauthor=M.+Calvelloauthor=E.+Conteauthor=E.+Intiniauthor=B.+Ioveneauthor=P.+M.+Leoneauthor=P.+V.+Mariauthor=L.+Richeldi&title=Investigational+drugs+for+idiopathic+pulmonary+fibrosis&doi=10.1080%2F13543784.2017.1364361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational drugs for idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Varone, Francesco; Montemurro, Giuliano; Macagno, Francesco; Calvello, Mariarosaria; Conte, Emanuele; Intini, Enrica; Iovene, Bruno; Leone, Paolo Maria; Mari, Pier-Valerio; Richeldi, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1019-1031</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">IPF is a specific form of chronic fibrosing interstitial pneumonia of unknown cause, characterized by progressive worsening in lung function and an unfavorable prognosis.  Current concepts on IPF pathogenesis are based on a dysregulated wound healing response, leading to an over prodn. of extracellular matrix.  Based on recent research however, several other mechanisms are now proposed as potential targets for novel therapeutic strategies.: This review analyzes the current investigational strategies targeting extracellular matrix deposition, tyrosine-kinase antagonism, immune and autoimmune response, and cell-based therapy.  A description of the pathogenic rationale implied in each novel therapeutic approach is summarized.: New IPF drugs are being evaluated in the context of phase 1 and 2 clin. trials.  Nevertheless, many drugs that have shown efficacy in preclin. studies, failed to exhibit the same pos. effect when translated to humans.  A possible explanation for these failures might be related to the known limitations of animal models of the disease.  The recent development of 3D systems composed of cells from individual patients that recreate an ex-vivo model of IPF, could lead to significant improvements in disease pathogenesis and treatment.  New drugs could be tested on more genuine models and clinicians could tailor therapy based on patient's response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlsdftkwJpvrVg90H21EOLACvtfcHk0liDKZNnpm_2Kw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSlt7rO&md5=928cc7b97e53659c8e4e2e61289afed5</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1364361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1364361%26sid%3Dliteratum%253Aachs%26aulast%3DVarone%26aufirst%3DF.%26aulast%3DMontemurro%26aufirst%3DG.%26aulast%3DMacagno%26aufirst%3DF.%26aulast%3DCalvello%26aufirst%3DM.%26aulast%3DConte%26aufirst%3DE.%26aulast%3DIntini%26aufirst%3DE.%26aulast%3DIovene%26aufirst%3DB.%26aulast%3DLeone%26aufirst%3DP.%2BM.%26aulast%3DMari%26aufirst%3DP.%2BV.%26aulast%3DRicheldi%26aufirst%3DL.%26atitle%3DInvestigational%2520drugs%2520for%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D1019%26epage%3D1031%26doi%3D10.1080%2F13543784.2017.1364361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghu, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential</span>. <i>Eur. Resp. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">170071</span>, <span class="refDoi">Â DOI: 10.1183/16000617.0071-2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1183%2F16000617.0071-2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28954769" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=170071&author=G.+Raghu&title=Pharmacotherapy+for+idiopathic+pulmonary+fibrosis%3A+current+landscape+and+future+potential&doi=10.1183%2F16000617.0071-2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1183%2F16000617.0071-2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F16000617.0071-2017%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26atitle%3DPharmacotherapy%2520for%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520current%2520landscape%2520and%2520future%2520potential%26jtitle%3DEur.%2520Resp.%2520Rev.%26date%3D2017%26volume%3D26%26spage%3D170071%26doi%3D10.1183%2F16000617.0071-2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hewitson, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelynack, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tait, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, G. J.</span></span> <span> </span><span class="NLM_article-title">Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis</span>. <i>J. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">453</span>â <span class="NLM_lpage">460</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=11783601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BD38%252FlvVGisQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=453-460&author=T.+D.+Hewitsonauthor=K.+J.+Kelynackauthor=M.+G.+Taitauthor=M.+Marticauthor=C.+L.+Jonesauthor=S.+B.+Margolinauthor=G.+J.+Becker&title=Pirfenidone+reduces+in+vitro+rat+renal+fibroblast+activation+and+mitogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis</span></div><div class="casAuthors">Hewitson T D; Kelynack K J; Tait M G; Martic M; Jones C L; Margolin S B; Becker G J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nephrology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">453-60</span>
        ISSN:<span class="NLM_cas:issn">1121-8428</span>.
    </div><div class="casAbstract">BACKGROUND:  Fibroblasts have been universally recognised in tubulointerstitial injury, where their presence has been shown to be a marker of disease progression.  Recently, pirfenidone (PF) has been shown to both ameliorate progressive fibrosis and reduce established scarring after ureteric obstruction (UUO) in the rat, suggesting that it is a novel anti-fibrotic agent.  The objective of this study was therefore to determine if these effects include down-regulation of fibroblast function.  METHODS:  Cortical fibroblasts were obtained from outgrowth cultures of renal tissue isolated from kidneys 3 days after UUO and constituted 100% of cells studied.  Functional studies examined the effects of 20 and 200 microg/ml PF on basal serum stimulated activity.  Activation was examined by western blotting for alpha smooth muscle actin (alphaSMA) and connective tissue growth factor (CTGF).  Cell proliferation, collagenase activity and collagen production were determined from kinetic studies, zymography for MMP2 and [3H] proline incorporation in collagenous proteins respectively.  RESULTS:  Proliferation, as measured by [3H] thymidine incorporation, was reduced in dose dependent manner by 20 and 200 microg/ml PF (p<0.05; 200 vs 0 microg/ml).  Likewise, 200 microg/ml PF reduced cell population growth over 5 days of culture (p<0.05 vs 0 microg/ml).  PF (200 microg/ml) decreased alphaSMA and CTGF protein expression to 66+/-13 and 37+/-26% of basal levels respectively (both p<0.05 vs 0 microg/ml).  Synthesis of collagen was unaffected by PF.  Maximal dose of PF produced a modest reduction in MMP2 lytic activity (p=0.05).  Effects of PF were independent of cell toxicity.  CONCLUSIONS:  Down-regulation of renal fibroblast activation and proliferation are specific actions of PF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS5amtT9efKZJ6KlWarZTAzfW6udTcc2eb-UPQ9YcmHpLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38%252FlvVGisQ%253D%253D&md5=afd776d80b9b75917caada6b4792c4db</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHewitson%26aufirst%3DT.%2BD.%26aulast%3DKelynack%26aufirst%3DK.%2BJ.%26aulast%3DTait%26aufirst%3DM.%2BG.%26aulast%3DMartic%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DC.%2BL.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26aulast%3DBecker%26aufirst%3DG.%2BJ.%26atitle%3DPirfenidone%2520reduces%2520in%2520vitro%2520rat%2520renal%2520fibroblast%2520activation%2520and%2520mitogenesis%26jtitle%3DJ.%2520Nephrol.%26date%3D2001%26volume%3D14%26spage%3D453%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grattendick, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giri, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolin, S. B.</span></span> <span> </span><span class="NLM_article-title">Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro</span>. <i>Int. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">679</span>â <span class="NLM_lpage">687</span>, <span class="refDoi">Â DOI: 10.1016/j.intimp.2008.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.intimp.2008.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18387510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlCqurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=679-687&author=K.+J.+Grattendickauthor=J.+M.+Nakashimaauthor=L.+Fengauthor=S.+N.+Giriauthor=S.+B.+Margolin&title=Effects+of+three+anti-TNF-alpha+drugs%3A+etanercept%2C+infliximab+and+pirfenidone+on+release+of+TNF-alpha+in+medium+and+TNF-alpha+associated+with+the+cell+in+vitro&doi=10.1016%2Fj.intimp.2008.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of three anti-TNF-Î± drugs: Etanercept, infliximab and pirfenidone on release of TNF-Î± in medium and TNF-Î± associated with the cell in vitro</span></div><div class="casAuthors">Grattendick, K. J.; Nakashima, J. M.; Feng, L.; Giri, S. N.; Margolin, S. B.</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-687</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tumor necrosis factor-alpha (TNF-Î±) is a vital component of the inflammatory process and its aberrant over-expression has been linked to numerous disease states.  New treatment strategies have sought to reduce circulating TNF-Î±, either with neutralizing anti-TNF-Î± binding proteins such as etanercept or via drugs that inhibit de novo TNF-Î± synthesis like pirfenidone.  In the present study, we examd. the effects of both classes of drugs on secreted and cell-assocd. TNF-Î± produced by THP-1 cells.  All of the tested drugs significantly reduced secreted levels of bioactive TNF-Î± following stimulation with LPS as measured by bioassay.  However, etanercept-treated cells had approx. six-fold higher levels of cell-assocd. TNF-Î± compared with that of the LPS-alone treatment group.  Surprisingly, LPS + infliximab treated cells did not increase cell-assocd. TNF-Î± relative to the LPS-alone treatment.  Pirfenidone significantly reduced both secreted and cell-assocd. TNF-Î± levels.  These drug-related differences in cell-assocd. TNF-Î± may have broad implications in the future for the therapeutic uses of anti-TNF-Î± drugs in the management of TNF-Î± diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFjtVozp1Ru7Vg90H21EOLACvtfcHk0ljHLLWCOcncNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlCqurs%253D&md5=091be3ebb4b611acde0c97fad6d2e9f4</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2008.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2008.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DGrattendick%26aufirst%3DK.%2BJ.%26aulast%3DNakashima%26aufirst%3DJ.%2BM.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DGiri%26aufirst%3DS.%2BN.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26atitle%3DEffects%2520of%2520three%2520anti-TNF-alpha%2520drugs%253A%2520etanercept%252C%2520infliximab%2520and%2520pirfenidone%2520on%2520release%2520of%2520TNF-alpha%2520in%2520medium%2520and%2520TNF-alpha%2520associated%2520with%2520the%2520cell%2520in%2520vitro%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2008%26volume%3D8%26spage%3D679%26epage%3D687%26doi%3D10.1016%2Fj.intimp.2008.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurokawa, K.</span></span> <span> </span><span class="NLM_article-title">Pirfenidone improves renal function and fibrosis in the post-obstructed kidney</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">99</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1046/j.1523-1755.1998.00962.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1046%2Fj.1523-1755.1998.00962.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=9648068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADyaK1cXksVyhs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=99-109&author=T.+Shimizuauthor=T.+Kurodaauthor=S.+Hataauthor=M.+Fukagawaauthor=S.+B.+Margolinauthor=K.+Kurokawa&title=Pirfenidone+improves+renal+function+and+fibrosis+in+the+post-obstructed+kidney&doi=10.1046%2Fj.1523-1755.1998.00962.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone improves renal function and fibrosis in the post-obstructed kidney</span></div><div class="casAuthors">Shimizu, Toshikatsu; Kuroda, Takayuki; Hata, Satoshi; Fukagawa, Masafumi; Margolin, Solomon B.; Kurokawa, Kiyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-109</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">Pirfenidone (PFD) is a novel anti-fibrotic agent that can prevent and even reverse extracellular matrix accumulation in several organs, as shown by exptl. and clin. studies.  Unilateral ureteral obstruction (UUO) is a well-characterized model of exptl. renal disease culminating in tubulointerstitial fibrosis.  UUO or sham-operated rats were administered PFD (500 mg/kg/day) in their food for 21 days to examine the effect on collagen prodn.  The renal function was measured in the kidney after release of obstruction which had been maintained for one week to examine the effects of PFD on restoration after renal dysfunction.  The collagen content detected by hydroxyproline progressively increased in kidney with UUO for 21 days.  These increases were significantly suppressed by administration of PFD.  PFD had no effect on collagen prodn. in sham-operated rats.  Expression of mRNA for type IV and I collagen and matrix metalloproteinase-2 in the cortex increased with UUO, but was inhibited by PFD treatment.  The levels of cortical transforming growth factor-Î² (TGF-Î²) mRNA progressively rose with UUO for 21 days, but this increase also could be suppressed by PFD.  Inulin clearance of the obstructed kidney was markedly depressed and remained low at five weeks after release.  A progressive increase in hydroxyproline content was also obsd. in the post-obstructed kidney despite the release of obstruction.  Administration of PFD following the release not only attenuated collagen accumulation, but also induced recovery of the impaired renal function.  These results demonstrate that PFD can attenuate both renal fibrosis and renal damage in this model, and suggest that PFD can be clin. useful for preventing progressive, irreversible renal failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr01Lihr_mS2bVg90H21EOLACvtfcHk0ljHLLWCOcncNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksVyhs7s%253D&md5=6d2c506191da06ef8af90d3021464139</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1046%2Fj.1523-1755.1998.00962.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1523-1755.1998.00962.x%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DKuroda%26aufirst%3DT.%26aulast%3DHata%26aufirst%3DS.%26aulast%3DFukagawa%26aufirst%3DM.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26aulast%3DKurokawa%26aufirst%3DK.%26atitle%3DPirfenidone%2520improves%2520renal%2520function%2520and%2520fibrosis%2520in%2520the%2520post-obstructed%2520kidney%26jtitle%3DKidney%2520Int.%26date%3D1998%26volume%3D54%26spage%3D99%26epage%3D109%26doi%3D10.1046%2Fj.1523-1755.1998.00962.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costabel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glassberg, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kardatzke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancaster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szwarcberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeyre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">du Bois, R. M.</span></span> <span> </span><span class="NLM_article-title">Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1760</span>â <span class="NLM_lpage">1769</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(11)60405-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2FS0140-6736%2811%2960405-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=21571362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtl2ktrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2011&pages=1760-1769&author=P.+W.+Nobleauthor=C.+Alberaauthor=W.+Z.+Bradfordauthor=U.+Costabelauthor=M.+K.+Glassbergauthor=D.+Kardatzkeauthor=T.+E.+Kingauthor=L.+Lancasterauthor=S.+A.+Sahnauthor=J.+Szwarcbergauthor=D.+Valeyreauthor=R.+M.+du+Bois&title=Pirfenidone+in+patients+with+idiopathic+pulmonary+fibrosis+%28CAPACITY%29%3A+two+randomised+trials&doi=10.1016%2FS0140-6736%2811%2960405-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials</span></div><div class="casAuthors">Noble, Paul W.; Albera, Carlo; Bradford, Williamson Z.; Costabel, Ulrich; Glassberg, Marilyn K.; Kardatzke, David; King, Talmadge E., Jr.; Lancaster, Lisa; Sahn, Steven A.; Szwarcberg, Javier; Valeyre, Dominique; du Bois, Roland M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9779</span>),
    <span class="NLM_cas:pages">1760-1769</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function.  The CAPACITY program (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis.  In two concurrent trials (004 and 006), patients (aged 40-80 years) with idiopathic pulmonary fibrosis were randomly assigned to oral pirfenidone or placebo for a min. of 72 wk in 110 centers in Australia, Europe, and North America.  In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo.  The randomization code (permuted block design) was computer generated and stratified by region.  All study personnel were masked to treatment group assignment until after final database lock.  Treatments were administered orally, 801 mg or 399 mg three times a day.  The primary endpoint was change in percentage predicted forced vital capacity (FVC) at week 72.  Anal. was by intention to treat.  The studies are registered with ClinicalTrials.gov, nos. NCT00287729 and NCT00287716.  In study 004, 174 of 435 patients were assigned to pirfenidone 2403 mg/day, 87 to pirfenidone 1197 mg/day, and 174 to placebo.  In study 006, 171 of 344 patients were assigned to pirfenidone 2403 mg/day, and 173 to placebo.  All patients in both studies were analyzed.  In study 004, pirfenidone reduced decline in FVC (p = 0.001).  Mean FVC change at week 72 was -8.0% (SD 16.5) in the pirfenidone 2403 mg/day group and -12.4% (18.5) in the placebo group (difference 4.4%, 95% CI 0.7 to 9.1); 35 (20%) of 174 vs. 60 (35%) of 174 patients, resp., had a decline of at least 10%.  A significant treatment effect was noted at all timepoints from week 24 and in an anal. over all study timepoints (p = 0.0007).  Mean change in percentage FVC in the pirfenidone 1197 mg/day group was intermediate to that in the pirfenidone 2403 mg/day and placebo groups.  In study 006, the difference between groups in FVC change at week 72 was not significant (p = 0.501).  Mean change in FVC at week 72 was -9.0% (SD 19.6) in the pirfenidone group and -9.6% (19.1) in the placebo group, and the difference between groups in predicted FVC change at week 72 was not significant (0.6%, -3.5 to 4.7); however, a consistent pirfenidone effect was apparent until week 48 (p = 0.005) and in an anal. of all study timepoints (p = 0.007).  Patients in the pirfenidone 2403 mg/day group had higher incidences of nausea (125 [36%] of 345 vs 60 [17%] of 347), dyspepsia (66 [19%] vs 26 [7%]), vomiting (47 [14%] vs 15 [4%]), anorexia (37 [11%] vs 13 [4%]), photosensitivity (42 [12%] vs 6 [2%]), rash (111 [32%] vs 40 [12%]), and dizziness (63 [18%] vs 35 [10%]) than did those in the placebo group.  Fewer overall deaths (19 [6%] vs 29 [8%]) and fewer deaths related to idiopathic pulmonary fibrosis (12 [3%] vs 25 [7%]) occurred in the pirfenidone 2403 mg/day groups than in the placebo groups.  The data show pirfenidone has a favorable benefit risk profile and represents an appropriate treatment option for patients with idiopathic pulmonary fibrosis.  Funding: InterMune.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKu0rjQ2oNaLVg90H21EOLACvtfcHk0ljHLLWCOcncNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtl2ktrg%253D&md5=b32d8b1f0b3b1f8401d3744fc18c662a</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960405-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960405-4%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DAlbera%26aufirst%3DC.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DKardatzke%26aufirst%3DD.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DSahn%26aufirst%3DS.%2BA.%26aulast%3DSzwarcberg%26aufirst%3DJ.%26aulast%3DValeyre%26aufirst%3DD.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26atitle%3DPirfenidone%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%2520%2528CAPACITY%2529%253A%2520two%2520randomised%2520trials%26jtitle%3DLancet%26date%3D2011%26volume%3D377%26spage%3D1760%26epage%3D1769%26doi%3D10.1016%2FS0140-6736%2811%2960405-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohshio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanaoka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teramoto, K.</span></span> <span> </span><span class="NLM_article-title">Tranilast inhibits the function of cancer-associated fibroblasts responsible for the induction of immune suppressor cell types</span>. <i>Scand. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">408</span>â <span class="NLM_lpage">416</span>, <span class="refDoi">Â DOI: 10.1111/sji.12242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1111%2Fsji.12242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25224016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCjtLnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=408-416&author=Y.+Ohshioauthor=J.+Hanaokaauthor=K.+Kontaniauthor=K.+Teramoto&title=Tranilast+inhibits+the+function+of+cancer-associated+fibroblasts+responsible+for+the+induction+of+immune+suppressor+cell+types&doi=10.1111%2Fsji.12242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Tranilast Inhibits the Function of Cancer-Associated Fibroblasts Responsible for the Induction of Immune Suppressor Cell Types</span></div><div class="casAuthors">Ohshio, Y.; Hanaoka, J.; Kontani, K.; Teramoto, K.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">408-416</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cancer-assocd. fibroblasts (CAFs) are the dominant stromal component in the tumor microenvironment (TME), playing crit. roles in generation of pro-tumorigenic TME; however, their contribution to suppression of antitumor immune responses has not been fully understood.  To elucidate the interaction between CAFs and immune suppressor cells, we examd. whether inhibition of CAFs function would impair the induction of immune suppressor cell types in vitro.  In this study, we applied an anti-allergic and antifibrotic agent tranilast, which is used clin., and evaluated a potential of tranilast to serve as a CAFs inhibitor.  CAFs that had been isolated from E.G7 or LLC1 tumor-bearing mice were cultured in the presence of tranilast, and thereafter, CAFs functions on the secretion of some sol. factors as well as the induction of immune suppressor cells were evaluated.  As a result, tranilast inhibited the proliferation of CAFs and reduced the levels of stromal cell-derived factor-1, prostaglandin E2 and transforming growth factor-Î²1 from CAFs in a dose-dependent manner.  On the other hand, tranilast exerted no inhibitory effects on immune cells at doses under 100 Î¼m.  The induction of regulatory T cells and myeloid-derived suppressor cells from their progenitor cells was suppressed in the medium that CAFs had been cultured in the presence of tranilast; however, these findings were not obsd. when those progenitor cells were cultured in the medium contg. tranilast alone.  These data demonstrate that tranilast inhibits CAFs function, which is responsible for the induction of immune suppressor cells, and possesses a potential to serve as a specific CAFs inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaTutpezSASbVg90H21EOLACvtfcHk0lg2PSmR026fuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCjtLnJ&md5=c2b90bd44a4b07a1a49db0c53ae91516</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1111%2Fsji.12242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fsji.12242%26sid%3Dliteratum%253Aachs%26aulast%3DOhshio%26aufirst%3DY.%26aulast%3DHanaoka%26aufirst%3DJ.%26aulast%3DKontani%26aufirst%3DK.%26aulast%3DTeramoto%26aufirst%3DK.%26atitle%3DTranilast%2520inhibits%2520the%2520function%2520of%2520cancer-associated%2520fibroblasts%2520responsible%2520for%2520the%2520induction%2520of%2520immune%2520suppressor%2520cell%2520types%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D2014%26volume%3D80%26spage%3D408%26epage%3D416%26doi%3D10.1111%2Fsji.12242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBlanche, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grip, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serruys, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willerson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lincoff, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tcheng, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poland, M.</span></span> <span> </span><span class="NLM_article-title">Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1243</span>â <span class="NLM_lpage">1250</span>, <span class="refDoi">Â DOI: 10.1161/01.CIR.0000028335.31300.DA</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2F01.CIR.0000028335.31300.DA" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2002&pages=1243-1250&author=D.+R.+Holmesauthor=M.+Savageauthor=J.+M.+LaBlancheauthor=L.+Gripauthor=P.+W.+Serruysauthor=P.+Fitzgeraldauthor=D.+Fischmanauthor=S.+Goldbergauthor=J.+A.+Brinkerauthor=A.+M.+Zeiherauthor=L.+M.+Shapiroauthor=J.+Willersonauthor=B.+R.+Davisauthor=J.+J.+Fergusonauthor=J.+Popmaauthor=S.+B.+Kingauthor=A.+M.+Lincoffauthor=J.+E.+Tchengauthor=R.+Chanauthor=J.+R.+Granettauthor=M.+Poland&title=Results+of+Prevention+of+REStenosis+with+Tranilast+and+its+Outcomes+%28PRESTO%29+trial&doi=10.1161%2F01.CIR.0000028335.31300.DA"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000028335.31300.DA&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000028335.31300.DA%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DD.%2BR.%26aulast%3DSavage%26aufirst%3DM.%26aulast%3DLaBlanche%26aufirst%3DJ.%2BM.%26aulast%3DGrip%26aufirst%3DL.%26aulast%3DSerruys%26aufirst%3DP.%2BW.%26aulast%3DFitzgerald%26aufirst%3DP.%26aulast%3DFischman%26aufirst%3DD.%26aulast%3DGoldberg%26aufirst%3DS.%26aulast%3DBrinker%26aufirst%3DJ.%2BA.%26aulast%3DZeiher%26aufirst%3DA.%2BM.%26aulast%3DShapiro%26aufirst%3DL.%2BM.%26aulast%3DWillerson%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DB.%2BR.%26aulast%3DFerguson%26aufirst%3DJ.%2BJ.%26aulast%3DPopma%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DS.%2BB.%26aulast%3DLincoff%26aufirst%3DA.%2BM.%26aulast%3DTcheng%26aufirst%3DJ.%2BE.%26aulast%3DChan%26aufirst%3DR.%26aulast%3DGranett%26aufirst%3DJ.%2BR.%26aulast%3DPoland%26aufirst%3DM.%26atitle%3DResults%2520of%2520Prevention%2520of%2520REStenosis%2520with%2520Tranilast%2520and%2520its%2520Outcomes%2520%2528PRESTO%2529%2520trial%26jtitle%3DCirculation%26date%3D2002%26volume%3D106%26spage%3D1243%26epage%3D1250%26doi%3D10.1161%2F01.CIR.0000028335.31300.DA" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, S. K.</span></span> <span> </span><span class="NLM_article-title">Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">811</span>â <span class="NLM_lpage">818</span>, <span class="refDoi">Â DOI: 10.1517/13543784.17.5.811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1517%2F13543784.17.5.811" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=811-818&author=S.+K.+Field&title=Roflumilast%3A+an+oral%2C+once-daily+selective+PDE-4+inhibitor+for+the+management+of+COPD+and+asthma&doi=10.1517%2F13543784.17.5.811"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1517%2F13543784.17.5.811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.17.5.811%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DS.%2BK.%26atitle%3DRoflumilast%253A%2520an%2520oral%252C%2520once-daily%2520selective%2520PDE-4%2520inhibitor%2520for%2520the%2520management%2520of%2520COPD%2520and%2520asthma%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D811%26epage%3D818%26doi%3D10.1517%2F13543784.17.5.811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span> <span> </span><span class="NLM_article-title">C3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-Î²/smad3 and IKBÎ± pathway</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e113639</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0113639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1371%2Fjournal.pone.0113639" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e113639&author=J.+Liauthor=Q.+Yinauthor=X.+Tangauthor=L.+Baiauthor=J.+Zhangauthor=S.+Gouauthor=H.+Zhuauthor=J.+Chengauthor=P.+Fuauthor=F.+Liu&title=C3a+receptor+antagonist+ameliorates+inflammatory+and+fibrotic+signals+in+type+2+diabetic+nephropathy+by+suppressing+the+activation+of+TGF-%CE%B2%2Fsmad3+and+IKB%CE%B1+pathway&doi=10.1371%2Fjournal.pone.0113639"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0113639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0113639%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DQ.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DF.%26atitle%3DC3a%2520receptor%2520antagonist%2520ameliorates%2520inflammatory%2520and%2520fibrotic%2520signals%2520in%2520type%25202%2520diabetic%2520nephropathy%2520by%2520suppressing%2520the%2520activation%2520of%2520TGF-%25CE%25B2%252Fsmad3%2520and%2520IKB%25CE%25B1%2520pathway%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De113639%26doi%3D10.1371%2Fjournal.pone.0113639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giannetta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isidori, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galea, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandosi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizza, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenzi, A.</span></span> <span> </span><span class="NLM_article-title">Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2323</span>â <span class="NLM_lpage">2333</span>, <span class="refDoi">Â DOI: 10.1161/CIRCULATIONAHA.111.063412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2FCIRCULATIONAHA.111.063412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22496161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1arsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=2323-2333&author=E.+Giannettaauthor=A.+M.+Isidoriauthor=N.+Galeaauthor=I.+Carboneauthor=E.+Mandosiauthor=C.+D.+Vizzaauthor=F.+Naroauthor=S.+Moranoauthor=F.+Fedeleauthor=A.+Lenzi&title=Chronic+Inhibition+of+cGMP+phosphodiesterase+5A+improves+diabetic+cardiomyopathy%3A+a+randomized%2C+controlled+clinical+trial+using+magnetic+resonance+imaging+with+myocardial+tagging&doi=10.1161%2FCIRCULATIONAHA.111.063412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy: A Randomized, Controlled Clinical Trial Using Magnetic Resonance Imaging With Myocardial Tagging</span></div><div class="casAuthors">Giannetta, Elisa; Isidori, Andrea M.; Galea, Nicola; Carbone, Iacopo; Mandosi, Elisabetta; Vizza, Carmine D.; Naro, Fabio; Morano, Susanna; Fedele, Francesco; Lenzi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2323-2333</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND-: cGMP phosphodiesterase type 5 protein is upregulated in myocardial hypertrophy.  However, it has never been ascertained whether phosphodiesterase type 5 inhibition exerts an antiremodeling effect in nonischemic heart disease in humans.  We explored the cardioreparative properties of a selective phosphodiesterase type 5 inhibitor, sildenafil, in a model of diabetic cardiomyopathy.  METHODS AND RESULTS-: Fifty-nine diabetic men (60.3Â±7.4 years) with cardiac magnetic resonance imaging consistent with nonischemic, nonfailing diabetic cardiomyopathy (reduced circumferential strain [Ï], -12.6Â±3.1; increased left ventricular [LV] torsion [Î¸], 18.4Â±4.6Â°; and increased ratio of LV mass to vol., 2.1Â±0.5 g/mL) were randomized to receive sildenafil or placebo (100 mg/d).  At baseline, the metabolic indexes were correlated with torsion, strain, N-terminal pro-B-type natriuretic peptide, vascular endothelial growth factor, monocyte chemotactic protein-1, and blood pressure.  After 3 mo, sildenafil produced a significant improvement compared with placebo in LV torsion (ÎÎ¸: sildenafil, -3.89Â±3.11Â° vs. placebo, 2.13Â±2.35Â°; P<0.001) and strain (ÎÏ: sildenafil, -3.30Â±1.86 vs. placebo, 1.22Â±1.84; P<0.001).  Sildenafil-induced improvement of LV contraction was accompanied by consistent changes in chamber geometry and performance, with a 6.5Â±11 improvement in mass-to-vol. ratio over placebo (P=0.021).  Monocyte chemotactic protein-1 and transforming growth factor-Î² were the only markers affected by active treatment (Îmonocyte chemotactic protein-1: -75.30Â±159.28 pg/mL, P=0.032; Îtransforming growth factor-Î²: 5.26Â±9.67 ng/mL, P=0.009).  No changes were found in endothelial function, afterload, or metab.  CONCLUSIONS-: The early features of diabetic cardiomyopathy are LV concentric hypertrophy assocd. with altered myocardial contraction dynamics.  Chronic phosphodiesterase type 5 inhibition, at this stage, has an antiremodeling effect, resulting in improved cardiac kinetics and circulating markers.  This effect is independent of any other vasodilatory or endothelial effects and is apparently exerted through a direct intramyocardial action.  Clin. TRIAL REGISTRATION-: URL: http://www.clinicaltrials.gov.  Unique identifier: NCT00692237.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5mdsU_dHU7LVg90H21EOLACvtfcHk0lhotGLNeYfWWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1arsrY%253D&md5=7b9bccb98c10f0a024d8c2713792b3bd</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.063412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.063412%26sid%3Dliteratum%253Aachs%26aulast%3DGiannetta%26aufirst%3DE.%26aulast%3DIsidori%26aufirst%3DA.%2BM.%26aulast%3DGalea%26aufirst%3DN.%26aulast%3DCarbone%26aufirst%3DI.%26aulast%3DMandosi%26aufirst%3DE.%26aulast%3DVizza%26aufirst%3DC.%2BD.%26aulast%3DNaro%26aufirst%3DF.%26aulast%3DMorano%26aufirst%3DS.%26aulast%3DFedele%26aufirst%3DF.%26aulast%3DLenzi%26aufirst%3DA.%26atitle%3DChronic%2520Inhibition%2520of%2520cGMP%2520phosphodiesterase%25205A%2520improves%2520diabetic%2520cardiomyopathy%253A%2520a%2520randomized%252C%2520controlled%2520clinical%2520trial%2520using%2520magnetic%2520resonance%2520imaging%2520with%2520myocardial%2520tagging%26jtitle%3DCirculation%26date%3D2012%26volume%3D125%26spage%3D2323%26epage%3D2333%26doi%3D10.1161%2FCIRCULATIONAHA.111.063412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodaragama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royce, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitson, T. D.</span></span> <span> </span><span class="NLM_article-title">Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">315</span>â <span class="NLM_lpage">322</span>, <span class="refDoi">Â DOI: 10.1161/HYPERTENSIONAHA.114.03594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2FHYPERTENSIONAHA.114.03594" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2014&pages=315-322&author=C.+S.+Samuelauthor=H.+Bodaragamaauthor=J.+Y.+Chewauthor=R.+E.+Widdopauthor=S.+G.+Royceauthor=T.+D.+Hewitson&title=Serelaxin+is+a+more+efficacious+antifibrotic+than+enalapril+in+an+experimental+model+of+heart+disease&doi=10.1161%2FHYPERTENSIONAHA.114.03594"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.114.03594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.114.03594%26sid%3Dliteratum%253Aachs%26aulast%3DSamuel%26aufirst%3DC.%2BS.%26aulast%3DBodaragama%26aufirst%3DH.%26aulast%3DChew%26aufirst%3DJ.%2BY.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DRoyce%26aufirst%3DS.%2BG.%26aulast%3DHewitson%26aufirst%3DT.%2BD.%26atitle%3DSerelaxin%2520is%2520a%2520more%2520efficacious%2520antifibrotic%2520than%2520enalapril%2520in%2520an%2520experimental%2520model%2520of%2520heart%2520disease%26jtitle%3DHypertension%26date%3D2014%26volume%3D64%26spage%3D315%26epage%3D322%26doi%3D10.1161%2FHYPERTENSIONAHA.114.03594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lekgabe, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiriazis, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathgate, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, C. S.</span></span> <span> </span><span class="NLM_article-title">Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">412</span>â <span class="NLM_lpage">418</span>, <span class="refDoi">Â DOI: 10.1161/01.HYP.0000171930.00697.2f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2F01.HYP.0000171930.00697.2f" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=412-418&author=E.+D.+Lekgabeauthor=H.+Kiriazisauthor=C.+Zhaoauthor=Q.+Xuauthor=X.+L.+Mooreauthor=Y.+Suauthor=R.+A.+D.+Bathgateauthor=X.+J.+Duauthor=C.+S.+Samuel&title=Relaxin+reverses+cardiac+and+renal+fibrosis+in+spontaneously+hypertensive+rats&doi=10.1161%2F01.HYP.0000171930.00697.2f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000171930.00697.2f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000171930.00697.2f%26sid%3Dliteratum%253Aachs%26aulast%3DLekgabe%26aufirst%3DE.%2BD.%26aulast%3DKiriazis%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoore%26aufirst%3DX.%2BL.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DBathgate%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDu%26aufirst%3DX.%2BJ.%26aulast%3DSamuel%26aufirst%3DC.%2BS.%26atitle%3DRelaxin%2520reverses%2520cardiac%2520and%2520renal%2520fibrosis%2520in%2520spontaneously%2520hypertensive%2520rats%26jtitle%3DHypertension%26date%3D2005%26volume%3D46%26spage%3D412%26epage%3D418%26doi%3D10.1161%2F01.HYP.0000171930.00697.2f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henry, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabris, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shroff, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salama, G.</span></span> <span> </span><span class="NLM_article-title">Relaxin suppresses atrial fibrillation in aged rats by reversing fibrosis and upregulating Na+ channels</span>. <i>Heart Rhythm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">983</span>â <span class="NLM_lpage">991</span>, <span class="refDoi">Â DOI: 10.1016/j.hrthm.2015.12.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.hrthm.2015.12.030" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=983-991&author=B.+L.+Henryauthor=B.+Gabrisauthor=Q.+Liauthor=B.+Martinauthor=M.+Gianniniauthor=A.+Parikhauthor=D.+Patelauthor=J.+Haneyauthor=D.+S.+Schwartzmanauthor=S.+G.+Shroffauthor=G.+Salama&title=Relaxin+suppresses+atrial+fibrillation+in+aged+rats+by+reversing+fibrosis+and+upregulating+Na%2B+channels&doi=10.1016%2Fj.hrthm.2015.12.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.hrthm.2015.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hrthm.2015.12.030%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DB.%2BL.%26aulast%3DGabris%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMartin%26aufirst%3DB.%26aulast%3DGiannini%26aufirst%3DM.%26aulast%3DParikh%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DHaney%26aufirst%3DJ.%26aulast%3DSchwartzman%26aufirst%3DD.%2BS.%26aulast%3DShroff%26aufirst%3DS.%2BG.%26aulast%3DSalama%26aufirst%3DG.%26atitle%3DRelaxin%2520suppresses%2520atrial%2520fibrillation%2520in%2520aged%2520rats%2520by%2520reversing%2520fibrosis%2520and%2520upregulating%2520Na%252B%2520channels%26jtitle%3DHeart%2520Rhythm%26date%3D2016%26volume%3D13%26spage%3D983%26epage%3D991%26doi%3D10.1016%2Fj.hrthm.2015.12.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekgabe, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tregear, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathgate, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X. J.</span></span> <span> </span><span class="NLM_article-title">Endogenous relaxin does not affect chronic pressure overload-induced cardiac hypertrophy and fibrosis</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">476</span>â <span class="NLM_lpage">482</span>, <span class="refDoi">Â DOI: 10.1210/en.2007-1220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1210%2Fen.2007-1220" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2008&pages=476-482&author=Q.+Xuauthor=E.+D.+Lekgabeauthor=X.+M.+Gaoauthor=Z.+Mingauthor=G.+W.+Tregearauthor=A.+M.+Dartauthor=R.+A.+D.+Bathgateauthor=C.+S.+Samuelauthor=X.+J.+Du&title=Endogenous+relaxin+does+not+affect+chronic+pressure+overload-induced+cardiac+hypertrophy+and+fibrosis&doi=10.1210%2Fen.2007-1220"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1210%2Fen.2007-1220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2007-1220%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLekgabe%26aufirst%3DE.%2BD.%26aulast%3DGao%26aufirst%3DX.%2BM.%26aulast%3DMing%26aufirst%3DZ.%26aulast%3DTregear%26aufirst%3DG.%2BW.%26aulast%3DDart%26aufirst%3DA.%2BM.%26aulast%3DBathgate%26aufirst%3DR.%2BA.%2BD.%26aulast%3DSamuel%26aufirst%3DC.%2BS.%26aulast%3DDu%26aufirst%3DX.%2BJ.%26atitle%3DEndogenous%2520relaxin%2520does%2520not%2520affect%2520chronic%2520pressure%2520overload-induced%2520cardiac%2520hypertrophy%2520and%2520fibrosis%26jtitle%3DEndocrinology%26date%3D2008%26volume%3D149%26spage%3D476%26epage%3D482%26doi%3D10.1210%2Fen.2007-1220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westermann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutschow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Linthout, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linderer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¼cker-GÃ¤rtner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobirey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauschinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultheiss, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TschÃ¶pe, G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2507</span>â <span class="NLM_lpage">2513</span>, <span class="refDoi">Â DOI: 10.1007/s00125-006-0385-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1007%2Fs00125-006-0385-2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2507-2513&author=D.+Westermannauthor=S.+Rutschowauthor=S.+Van+Linthoutauthor=A.+Lindererauthor=C.+B%C3%BCcker-G%C3%A4rtnerauthor=M.+Sobireyauthor=A.+Riadauthor=M.+Pauschingerauthor=H.+P.+Schultheissauthor=G.+Tsch%C3%B6pe&title=Inhibition+of+p38+mitogen-activated+protein+kinase+attenuates+left+ventricular+dysfunction+by+mediating+pro-inflammatory+cardiac+cytokine+levels+in+a+mouse+model+of+diabetes+mellitus&doi=10.1007%2Fs00125-006-0385-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1007%2Fs00125-006-0385-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-006-0385-2%26sid%3Dliteratum%253Aachs%26aulast%3DWestermann%26aufirst%3DD.%26aulast%3DRutschow%26aufirst%3DS.%26aulast%3DVan%2BLinthout%26aufirst%3DS.%26aulast%3DLinderer%26aufirst%3DA.%26aulast%3DB%25C3%25BCcker-G%25C3%25A4rtner%26aufirst%3DC.%26aulast%3DSobirey%26aufirst%3DM.%26aulast%3DRiad%26aufirst%3DA.%26aulast%3DPauschinger%26aufirst%3DM.%26aulast%3DSchultheiss%26aufirst%3DH.%2BP.%26aulast%3DTsch%25C3%25B6pe%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520attenuates%2520left%2520ventricular%2520dysfunction%2520by%2520mediating%2520pro-inflammatory%2520cardiac%2520cytokine%2520levels%2520in%2520a%2520mouse%2520model%2520of%2520diabetes%2520mellitus%26jtitle%3DDiabetologia%26date%3D2006%26volume%3D49%26spage%3D2507%26epage%3D2513%26doi%3D10.1007%2Fs00125-006-0385-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mann, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swedberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borer, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kober, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieminen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavazzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veldhuisen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldenstrom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westheim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zannad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, T.</span></span> <span> </span><span class="NLM_article-title">Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1594</span>â <span class="NLM_lpage">1602</span>, <span class="refDoi">Â DOI: 10.1161/01.CIR.0000124490.27666.B2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2F01.CIR.0000124490.27666.B2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2004&pages=1594-1602&author=D.+L.+Mannauthor=J.+J.+McMurrayauthor=M.+Packerauthor=K.+Swedbergauthor=J.+S.+Borerauthor=W.+S.+Colucciauthor=J.+Djianauthor=H.+Drexlerauthor=A.+Feldmanauthor=L.+Koberauthor=H.+Krumauthor=P.+Liuauthor=M.+Nieminenauthor=L.+Tavazziauthor=D.+J.+van+Veldhuisenauthor=A.+Waldenstromauthor=M.+Warrenauthor=A.+Westheimauthor=F.+Zannadauthor=T.+Fleming&title=Targeted+anticytokine+therapy+in+patients+with+chronic+heart+failure%3A+results+of+the+Randomized+Etanercept+Worldwide+Evaluation+%28RENEWAL%29&doi=10.1161%2F01.CIR.0000124490.27666.B2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000124490.27666.B2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000124490.27666.B2%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DD.%2BL.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26aulast%3DPacker%26aufirst%3DM.%26aulast%3DSwedberg%26aufirst%3DK.%26aulast%3DBorer%26aufirst%3DJ.%2BS.%26aulast%3DColucci%26aufirst%3DW.%2BS.%26aulast%3DDjian%26aufirst%3DJ.%26aulast%3DDrexler%26aufirst%3DH.%26aulast%3DFeldman%26aufirst%3DA.%26aulast%3DKober%26aufirst%3DL.%26aulast%3DKrum%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DNieminen%26aufirst%3DM.%26aulast%3DTavazzi%26aufirst%3DL.%26aulast%3Dvan%2BVeldhuisen%26aufirst%3DD.%2BJ.%26aulast%3DWaldenstrom%26aufirst%3DA.%26aulast%3DWarren%26aufirst%3DM.%26aulast%3DWestheim%26aufirst%3DA.%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DFleming%26aufirst%3DT.%26atitle%3DTargeted%2520anticytokine%2520therapy%2520in%2520patients%2520with%2520chronic%2520heart%2520failure%253A%2520results%2520of%2520the%2520Randomized%2520Etanercept%2520Worldwide%2520Evaluation%2520%2528RENEWAL%2529%26jtitle%3DCirculation%26date%3D2004%26volume%3D109%26spage%3D1594%26epage%3D1602%26doi%3D10.1161%2F01.CIR.0000124490.27666.B2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasanmade, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willerson, J. T.</span></span> <span> </span><span class="NLM_article-title">and the anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">3133</span>â <span class="NLM_lpage">3140</span>, <span class="refDoi">Â DOI: 10.1161/01.CIR.0000077913.60364.D2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2F01.CIR.0000077913.60364.D2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2003&pages=3133-3140&author=E.+S.+Chungauthor=M.+Packerauthor=K.+H.+Loauthor=A.+A.+Fasanmadeauthor=J.+T.+Willerson&title=and+the+anti-TNF+therapy+against+congestive+heart+failure+investigators.+Randomized%2C+double-blind%2C+placebo-controlled%2C+pilot+trial+of+infliximab%2C+a+chimeric+monoclonal+antibody+to+tumor+necrosis+factor-alpha%2C+in+patients+with+moderate-to-severe+heart+failure%3A+results+of+the+anti-TNF+therapy+against+congestive+heart+failure+%28ATTACH%29+trial&doi=10.1161%2F01.CIR.0000077913.60364.D2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000077913.60364.D2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000077913.60364.D2%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DE.%2BS.%26aulast%3DPacker%26aufirst%3DM.%26aulast%3DLo%26aufirst%3DK.%2BH.%26aulast%3DFasanmade%26aufirst%3DA.%2BA.%26aulast%3DWillerson%26aufirst%3DJ.%2BT.%26atitle%3Dand%2520the%2520anti-TNF%2520therapy%2520against%2520congestive%2520heart%2520failure%2520investigators.%2520Randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520pilot%2520trial%2520of%2520infliximab%252C%2520a%2520chimeric%2520monoclonal%2520antibody%2520to%2520tumor%2520necrosis%2520factor-alpha%252C%2520in%2520patients%2520with%2520moderate-to-severe%2520heart%2520failure%253A%2520results%2520of%2520the%2520anti-TNF%2520therapy%2520against%2520congestive%2520heart%2520failure%2520%2528ATTACH%2529%2520trial%26jtitle%3DCirculation%26date%3D2003%26volume%3D107%26spage%3D3133%26epage%3D3140%26doi%3D10.1161%2F01.CIR.0000077913.60364.D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. B.</span></span> <span> </span><span class="NLM_article-title">Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">591</span>â <span class="NLM_lpage">597</span>, <span class="refDoi">Â DOI: 10.1161/HYPERTENSIONAHA.109.131243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2FHYPERTENSIONAHA.109.131243" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=591-597&author=S.+A.+Changauthor=Y.+J.+Kimauthor=H.+W.+Leeauthor=D.+H.+Kimauthor=H.+K.+Kimauthor=H.+J.+Changauthor=D.+W.+Sohnauthor=B.+H.+Ohauthor=Y.+B.+Park&title=Effect+of+rosuvastatin+on+cardiac+remodeling%2C+function%2C+and+progression+to+heart+failure+in+hypertensive+heart+with+established+left+ventricular+hypertrophy&doi=10.1161%2FHYPERTENSIONAHA.109.131243"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.109.131243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.109.131243%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BA.%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BK.%26aulast%3DChang%26aufirst%3DH.%2BJ.%26aulast%3DSohn%26aufirst%3DD.%2BW.%26aulast%3DOh%26aufirst%3DB.%2BH.%26aulast%3DPark%26aufirst%3DY.%2BB.%26atitle%3DEffect%2520of%2520rosuvastatin%2520on%2520cardiac%2520remodeling%252C%2520function%252C%2520and%2520progression%2520to%2520heart%2520failure%2520in%2520hypertensive%2520heart%2520with%2520established%2520left%2520ventricular%2520hypertrophy%26jtitle%3DHypertension%26date%3D2009%26volume%3D54%26spage%3D591%26epage%3D597%26doi%3D10.1161%2FHYPERTENSIONAHA.109.131243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kjekshus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apetrei, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¶hm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleland, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunselman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grande, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullestad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjalmarson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hradec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¡nosi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KamenskÃ½, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komajda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korewicki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuusi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mareev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranjith, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaufelberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaecke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veldhuisen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waagstein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrand, J.</span></span> <span> </span><span class="NLM_article-title">Rosuvastatin in older patients with systolic heart failure</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">2248</span>â <span class="NLM_lpage">2261</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa0706201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1056%2FNEJMoa0706201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17984166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSlsLvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=2248-2261&author=J.+Kjekshusauthor=E.+Apetreiauthor=V.+Barriosauthor=M.+B%C3%B6hmauthor=J.+G.+Clelandauthor=J.+H.+Cornelauthor=P.+Dunselmanauthor=C.+Fonsecaauthor=A.+Goudevauthor=P.+Grandeauthor=L.+Gullestadauthor=A.+Hjalmarsonauthor=J.+Hradecauthor=A.+J%C3%A1nosiauthor=G.+Kamensk%C3%BDauthor=M.+Komajdaauthor=J.+Korewickiauthor=T.+Kuusiauthor=F.+Machauthor=V.+Mareevauthor=J.+J.+V.+McMurrayauthor=N.+Ranjithauthor=M.+Schaufelbergerauthor=J.+Vanhaeckeauthor=D.+J.+van+Veldhuisenauthor=F.+Waagsteinauthor=H.+Wedelauthor=J.+Wikstrand&title=Rosuvastatin+in+older+patients+with+systolic+heart+failure&doi=10.1056%2FNEJMoa0706201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Rosuvastatin in older patients with systolic heart failure</span></div><div class="casAuthors">Kjekshus, John; Apetrei, Eduard; Barrios, Vivencio; Bohm, Michael; Cleland, John G. F.; Cornel, Jan H.; Dunselman, Peter; Fonseca, Candida; Goudev, Assen; Grande, Peer; Gullestad, Lars; Hjalmarson, Ake; Hradec, Jaromir; Janosi, Andras; Kamensky, Gabriel; Komajda, Michel; Korewicki, Jerzy; Kuusi, Timo; Mach, Francois; Mareev, Vycheslav; McMurray, John J. V.; Ranjith, Naresh; Schaufelberger, Maria; Vanhaecke, Johan; van Veldhuisen, Dirk J.; Waagstein, Finn; Wedel, Hans; Wikstrand, John; Aires, N.; Janson, L.; Dunselman, P.; Hjalmarson, A.; Waagstein, F.; Kjekshus, J.; McMurray, J.; Wedel, H.; Wikstrand, J.; Dargie, H.; DeMets, D.; Collins, R.; Feyzi, J.; Massie, B.; Fredlund, B.-O.; Holmberg, M.; Saldeen, K.; Swedberg, K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2248-2261</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Patients with systolic heart failure have generally been excluded from statin trials.  Acute coronary events are uncommon in this population, and statins have theor. risks in these patients.  A total of 5011 patients at least 60 years of age with New York Heart Assocn. class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day.  The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.  Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the no. of hospitalizations.  As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-d. lipoprotein cholesterol (difference between groups, 45.0%; P < 0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P < 0.001).  During a median follow-up of 32.8 mo, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P = 0.12), and 728 patients and 759 patients, resp., died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P = 0.31).  There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes.  In a prespecified secondary anal., there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P < 0.001).  No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group.  Rosuvastatin did not reduce the primary outcome or the no. of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the no. of cardiovascular hospitalizations.  The drug did not cause safety problems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXVo6yWc5QT7Vg90H21EOLACvtfcHk0lhL2eZtywqGqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSlsLvI&md5=4f72e238de430c30369ab3ea8548096c</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0706201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0706201%26sid%3Dliteratum%253Aachs%26aulast%3DKjekshus%26aufirst%3DJ.%26aulast%3DApetrei%26aufirst%3DE.%26aulast%3DBarrios%26aufirst%3DV.%26aulast%3DB%25C3%25B6hm%26aufirst%3DM.%26aulast%3DCleland%26aufirst%3DJ.%2BG.%26aulast%3DCornel%26aufirst%3DJ.%2BH.%26aulast%3DDunselman%26aufirst%3DP.%26aulast%3DFonseca%26aufirst%3DC.%26aulast%3DGoudev%26aufirst%3DA.%26aulast%3DGrande%26aufirst%3DP.%26aulast%3DGullestad%26aufirst%3DL.%26aulast%3DHjalmarson%26aufirst%3DA.%26aulast%3DHradec%26aufirst%3DJ.%26aulast%3DJ%25C3%25A1nosi%26aufirst%3DA.%26aulast%3DKamensk%25C3%25BD%26aufirst%3DG.%26aulast%3DKomajda%26aufirst%3DM.%26aulast%3DKorewicki%26aufirst%3DJ.%26aulast%3DKuusi%26aufirst%3DT.%26aulast%3DMach%26aufirst%3DF.%26aulast%3DMareev%26aufirst%3DV.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3DRanjith%26aufirst%3DN.%26aulast%3DSchaufelberger%26aufirst%3DM.%26aulast%3DVanhaecke%26aufirst%3DJ.%26aulast%3Dvan%2BVeldhuisen%26aufirst%3DD.%2BJ.%26aulast%3DWaagstein%26aufirst%3DF.%26aulast%3DWedel%26aufirst%3DH.%26aulast%3DWikstrand%26aufirst%3DJ.%26atitle%3DRosuvastatin%2520in%2520older%2520patients%2520with%2520systolic%2520heart%2520failure%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D2248%26epage%3D2261%26doi%3D10.1056%2FNEJMoa0706201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavazzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggioni, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchioli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzosi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolosi, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognoni, G.</span></span>; <span class="NLM_contrib-group">GISSI-HF Investigators</span> <span> </span><span class="NLM_article-title">Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1231</span>â <span class="NLM_lpage">1239</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(08)61240-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2FS0140-6736%2808%2961240-4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2008&pages=1231-1239&author=L.+Tavazziauthor=A.+P.+Maggioniauthor=R.+Marchioliauthor=S.+Barleraauthor=M.+G.+Franzosiauthor=R.+Latiniauthor=D.+Lucciauthor=G.+L.+Nicolosiauthor=M.+Porcuauthor=G.+Tognoniauthor=GISSI-HF+Investigators&title=Effect+of+rosuvastatin+in+patients+with+chronic+heart+failure+%28the+GISSI-HF+trial%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2FS0140-6736%2808%2961240-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2961240-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252961240-4%26sid%3Dliteratum%253Aachs%26aulast%3DTavazzi%26aufirst%3DL.%26aulast%3DMaggioni%26aufirst%3DA.%2BP.%26aulast%3DMarchioli%26aufirst%3DR.%26aulast%3DBarlera%26aufirst%3DS.%26aulast%3DFranzosi%26aufirst%3DM.%2BG.%26aulast%3DLatini%26aufirst%3DR.%26aulast%3DLucci%26aufirst%3DD.%26aulast%3DNicolosi%26aufirst%3DG.%2BL.%26aulast%3DPorcu%26aufirst%3DM.%26aulast%3DTognoni%26aufirst%3DG.%26aulast%3D%26atitle%3DEffect%2520of%2520rosuvastatin%2520in%2520patients%2520with%2520chronic%2520heart%2520failure%2520%2528the%2520GISSI-HF%2520trial%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%26date%3D2008%26volume%3D372%26spage%3D1231%26epage%3D1239%26doi%3D10.1016%2FS0140-6736%2808%2961240-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalff, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amarena, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonkin, A.</span></span> <span> </span><span class="NLM_article-title">Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure</span>. <i>J. Card. Failure</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">7</span>, <span class="refDoi">Â DOI: 10.1016/j.cardfail.2006.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.cardfail.2006.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17338996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitl2jtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1-7&author=H.+Krumauthor=E.+Ashtonauthor=C.+Reidauthor=V.+Kalffauthor=J.+Rogersauthor=J.+Amarenaauthor=B.+Singhauthor=A.+Tonkin&title=Double-blind%2C+randomized%2C+placebo-controlled+study+of+high-dose+HMG+CoA+reductase+inhibitor+therapy+on+ventricular+remodeling%2C+pro-inflammatory+cytokines+and+neurohormonal+parameters+in+patients+with+chronic+systolic+heart+failure&doi=10.1016%2Fj.cardfail.2006.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Double-Blind, Randomized, Placebo-Controlled Study of High-Dose HMG CoA Reductase Inhibitor Therapy on Ventricular Remodeling, Pro-Inflammatory Cytokines and Neurohormonal Parameters in Patients With Chronic Systolic Heart Failure</span></div><div class="casAuthors">Krum, Henry; Ashton, Emma; Reid, Christopher; Kalff, Victor; Rogers, Jim; Amarena, John; Singh, Bhuwan; Tonkin, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiac Failure</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">JCFAF9</span>;
        ISSN:<span class="NLM_cas:issn">1071-9164</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: Statins decrease mortality in patients with coronary artery disease.  However, chronic heart failure (CHF) patients were often excluded in such trials.  Statins possess pharmacol. properties (independent of cholesterol lowering) that may be beneficial on ventricular remodeling in such patients.  Methods and Results: We conducted a 6-mo randomized placebo (PBO)-controlled study of rosuvastatin (ROS) in patients with systolic (left ventricular ejection fraction [LVEF] <40%) CHF of ischemic or nonischemic etiol.  The primary end point was change in LVEF by radionuclide ventriculogram.  Secondary end points included change in echocardiog. parameters, neurohormonal and inflammatory markers, Packer composite score, death, and heart failure hospitalization.  Patients were well matched for baseline values.  Compared with PBO (n = 46), ROS patients (n = 40) had a decrease in low-d. lipoprotein cholesterol (PBO +3, ROS -54%, P < .001).  There was no significant change in LVEF by radionuclide ventriculogram (PBO +5.3, ROS +3.2%), fractional shortening by echocardiog. (PBO +2.7, ROS +1.8%), left ventricular end-diastolic diam. (PBO -1.7, ROS +0.8 mm), left ventricular end-systolic diam. (PBO -1.9, ROS +0.1 mm).  Plasma norepinephrine, endothelin-1, brain natriuretic peptide, hsCRP, tumor necrosis factor-Î± and interleukin-6, patient global assessment, Packer composite, death/heart failure hospitalization, and adverse events were similar between PBO and ROS.  Conclusions: Despite being safe and effective at decreasing plasma cholesterol, high-dose ROS did not beneficially alter parameters of LV remodeling.  Reasons for absence of benefit are uncertain, but may include patient population studied, high dose of ROS used or high use of effective background CHF medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbh9jEbKtaEbVg90H21EOLACvtfcHk0liHMhafq2zQ5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitl2jtbw%253D&md5=786f1803c3291366fd8a39e3abefe85b</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.cardfail.2006.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardfail.2006.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DKrum%26aufirst%3DH.%26aulast%3DAshton%26aufirst%3DE.%26aulast%3DReid%26aufirst%3DC.%26aulast%3DKalff%26aufirst%3DV.%26aulast%3DRogers%26aufirst%3DJ.%26aulast%3DAmarena%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DTonkin%26aufirst%3DA.%26atitle%3DDouble-blind%252C%2520randomized%252C%2520placebo-controlled%2520study%2520of%2520high-dose%2520HMG%2520CoA%2520reductase%2520inhibitor%2520therapy%2520on%2520ventricular%2520remodeling%252C%2520pro-inflammatory%2520cytokines%2520and%2520neurohormonal%2520parameters%2520in%2520patients%2520with%2520chronic%2520systolic%2520heart%2520failure%26jtitle%3DJ.%2520Card.%2520Failure%26date%3D2007%26volume%3D13%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.cardfail.2006.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salomone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeber, C.</span></span> <span> </span><span class="NLM_article-title">Selectivity and specificity of sphingosine-1-phosphate receptor ligands: cavats and critical thinking in characterizing receptor-mediated effects</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">9</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2011.00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2011.00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=21687504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC3MnhvV2qsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=9&author=S.+Salomoneauthor=C.+Waeber&title=Selectivity+and+specificity+of+sphingosine-1-phosphate+receptor+ligands%3A+cavats+and+critical+thinking+in+characterizing+receptor-mediated+effects&doi=10.3389%2Ffphar.2011.00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects</span></div><div class="casAuthors">Salomone Salvatore; Waeber Christian</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Receptors for sphingosine-1-phosphate (S1P) have been identified only recently.  Their medicinal chemistry is therefore still in its infancy, and few selective agonists or antagonists are available.  Furthermore, the selectivity of S1P receptor agonists or antagonists is not well established.  JTE-013 and BML-241 (also known as CAY10444), used extensively as specific S1P(2) and S1P(3) receptors antagonists respectively, are cases in point.  When analyzing S1P-induced vasoconstriction in mouse basilar artery, we observed that JTE-013 inhibited not only the effect of S1P, but also the effect of U46619, endothelin-1 or high KCl; JTE-013 strongly inhibited responses to S1P in S1P(2) receptor knockout mice.  Similarly, BML-241 has been shown to inhibit increases in intracellular Ca(2+) concentration via P(2) receptor or Î±(1A)-adrenoceptor stimulation and Î±(1A)-adrenoceptor-mediated contraction of rat mesenteric artery, while it did not affect S1P(3)-mediated decrease of forskolin-induced cyclic AMP accumulation.  Another putative S1P(1/3) receptor antagonist, VPC23019, does not inhibit S1P(3)-mediated vasoconstriction.  With these examples in mind, we discuss caveats about relying on available pharmacological tools to characterize receptor subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStGLeNXz9auf9pSBfyDvp7fW6udTcc2eYfzKevpIB73bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnhvV2qsg%253D%253D&md5=287e62b7cf54d8bc5a73b2ca0abd79a1</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2011.00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2011.00009%26sid%3Dliteratum%253Aachs%26aulast%3DSalomone%26aufirst%3DS.%26aulast%3DWaeber%26aufirst%3DC.%26atitle%3DSelectivity%2520and%2520specificity%2520of%2520sphingosine-1-phosphate%2520receptor%2520ligands%253A%2520cavats%2520and%2520critical%2520thinking%2520in%2520characterizing%2520receptor-mediated%2520effects%26jtitle%3DFront.%2520Pharmacol.%26date%3D2011%26volume%3D2%26spage%3D9%26doi%3D10.3389%2Ffphar.2011.00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezuhly, M.</span></span> <span> </span><span class="NLM_article-title">Modulation of angiotensin II signaling in the prevention of fibrosis</span>. <i>Fibrog. Tissue Repair</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">7</span>, <span class="refDoi">Â DOI: 10.1186/s13069-015-0023-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1186%2Fs13069-015-0023-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25949522" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=7&author=A.+M.+Murphyauthor=A.+L.+Wongauthor=M.+Bezuhly&title=Modulation+of+angiotensin+II+signaling+in+the+prevention+of+fibrosis&doi=10.1186%2Fs13069-015-0023-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1186%2Fs13069-015-0023-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13069-015-0023-z%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DA.%2BM.%26aulast%3DWong%26aufirst%3DA.%2BL.%26aulast%3DBezuhly%26aufirst%3DM.%26atitle%3DModulation%2520of%2520angiotensin%2520II%2520signaling%2520in%2520the%2520prevention%2520of%2520fibrosis%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2015%26volume%3D8%26spage%3D7%26doi%3D10.1186%2Fs13069-015-0023-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alzayadneh, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, M. C.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-(1â7) abolishes AGE-induced cellular hypertrophy and myofibroblasts transformation via inhibition of ERK1/2</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3027</span>â <span class="NLM_lpage">3035</span>, <span class="refDoi">Â DOI: 10.1016/j.cellsig.2014.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.cellsig.2014.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25246357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2gsr7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=3027-3035&author=E.+M.+Alzayadnehauthor=M.+C.+Chappell&title=Angiotensin-%281%E2%80%937%29+abolishes+AGE-induced+cellular+hypertrophy+and+myofibroblasts+transformation+via+inhibition+of+ERK1%2F2&doi=10.1016%2Fj.cellsig.2014.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-(1-7) abolishes AGE-induced cellular hypertrophy and myofibroblast transformation via inhibition of ERK1/2</span></div><div class="casAuthors">Alzayadneh, Ebaa M.; Chappell, Mark C.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3027-3035</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Angiotensin-(1-7) (Ang-(1-7))/AT7-Mas receptor axis is an alternative pathway within the renin-angiotensin system (RAS) that generally opposes the actions of Ang II/AT1 receptor pathway.  Advanced glycated end product (AGEs) including glucose- and methylglyoxal-modified albumin (MGA) may contribute to the development and progression of diabetic nephropathy in part through activation of the Ang II/AT1 receptor system; however, the influence of AGE on the Ang-(1-7) arm of the RAS within the kidney is unclear.  The present study assessed the impact of AGE on the Ang-(1-7) axis in NRK-52E renal epithelial cells.  MGA exposure for 48 h significantly reduced the intracellular levels of Ang-(1-7) approx. 50%; however, Ang I or Ang II expression was not altered.  The reduced cellular content of Ang-(1-7) was assocd. with increased metab. of the peptide to the inactive metabolite Ang-(1-4) [MGA: 175 Â± 9 vs. Control: 115 Â± 11 fmol/min/mg protein, p < 0.05, n = 3] but no change in the processing of Ang I to Ang-(1-7).  Treatment with Ang-(1-7) reversed MGA-induced cellular hypertrophy and myofibroblast transition evidenced by reduced immunostaining and protein expression of Î±-smooth muscle actin (Î±-SMA) [0.4 Â± 0.1 vs. 1.0 Â± 0.1, resp., n = 3, p < 0.05].  Ang-(1-7) abolished AGE-induced activation of the MAP kinase ERK1/2 to a similar extent as the TGF-Î² receptor kinase inhibitor SB58059; however, Ang-(1-7) did not attenuate the MGA-stimulated release of TGF-Î².  The AT7-Mas receptor antagonist D-Ala7-Ang-(1-7) abolished the inhibitory actions of Ang-(1-7).  In contrast, AT1 receptor antagonist losartan did not attenuate the MGA-induced effects.  We conclude that Ang-(1-7) may provide an addnl. therapeutic approach to the conventional RAS blockade regimen to attenuate AGE-dependent renal injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyQEG6vwy6GLVg90H21EOLACvtfcHk0lhP3ymRya-Tag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2gsr7O&md5=f8bd3ee5b505c236324ed75757b6f554</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2014.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2014.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DAlzayadneh%26aufirst%3DE.%2BM.%26aulast%3DChappell%26aufirst%3DM.%2BC.%26atitle%3DAngiotensin-%25281%25E2%2580%25937%2529%2520abolishes%2520AGE-induced%2520cellular%2520hypertrophy%2520and%2520myofibroblasts%2520transformation%2520via%2520inhibition%2520of%2520ERK1%252F2%26jtitle%3DCell.%2520Signalling%26date%3D2014%26volume%3D26%26spage%3D3027%26epage%3D3035%26doi%3D10.1016%2Fj.cellsig.2014.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacorre, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozin, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stylianopoulos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adstamongkonkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PopoviÄ, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bawendi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span> <span> </span><span class="NLM_article-title">Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2516</span>, <span class="refDoi">Â DOI: 10.1038/ncomms3516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fncomms3516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24084631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252Fls1amsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=2516&author=V.+P.+Chauhanauthor=J.+D.+Martinauthor=H.+Liuauthor=D.+A.+Lacorreauthor=S.+R.+Jainauthor=S.+V.+Kozinauthor=T.+Stylianopoulosauthor=A.+S.+Mousaauthor=X.+Hanauthor=P.+Adstamongkonkulauthor=Z.+Popovi%C4%87author=P.+Huangauthor=M.+G.+Bawendiauthor=Y.+Boucherauthor=R.+K.+Jain&title=Angiotensin+inhibition+enhances+drug+delivery+and+potentiates+chemotherapy+by+decompressing+tumour+blood+vessels&doi=10.1038%2Fncomms3516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels</span></div><div class="casAuthors">Chauhan Vikash P; Martin John D; Liu Hao; Lacorre Delphine A; Jain Saloni R; Kozin Sergey V; Stylianopoulos Triantafyllos; Mousa Ahmed S; Han Xiaoxing; Adstamongkonkul Pichet; Popovic Zoran; Huang Peigen; Bawendi Moungi G; Boucher Yves; Jain Rakesh K</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2516</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion.  Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour.  Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels.  We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-Î²1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition.  Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion.  Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models.  Thus, angiotensin inhibitors -inexpensive drugs with decades of safe use - could be rapidly repurposed as cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCTkmoIT3ohZotVjB3IRIyfW6udTcc2eZ78rwwV9F-Brntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252Fls1amsw%253D%253D&md5=c2a7c9d6615a44bd06ab6201a3bc57a2</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fncomms3516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms3516%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DV.%2BP.%26aulast%3DMartin%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLacorre%26aufirst%3DD.%2BA.%26aulast%3DJain%26aufirst%3DS.%2BR.%26aulast%3DKozin%26aufirst%3DS.%2BV.%26aulast%3DStylianopoulos%26aufirst%3DT.%26aulast%3DMousa%26aufirst%3DA.%2BS.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DAdstamongkonkul%26aufirst%3DP.%26aulast%3DPopovi%25C4%2587%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DBawendi%26aufirst%3DM.%2BG.%26aulast%3DBoucher%26aufirst%3DY.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DAngiotensin%2520inhibition%2520enhances%2520drug%2520delivery%2520and%2520potentiates%2520chemotherapy%2520by%2520decompressing%2520tumour%2520blood%2520vessels%26jtitle%3DNat.%2520Commun.%26date%3D2013%26volume%3D4%26spage%3D2516%26doi%3D10.1038%2Fncomms3516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clozel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloukh, H.</span></span> <span> </span><span class="NLM_article-title">Role of endothelin in fibrosis and anti-fibrotic potential of bosentan</span>. <i>Ann. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2</span>â <span class="NLM_lpage">12</span>, <span class="refDoi">Â DOI: 10.1080/07853890410018925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1080%2F07853890410018925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=15902842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslenurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2005&pages=2-12&author=M.+Clozelauthor=H.+Salloukh&title=Role+of+endothelin+in+fibrosis+and+anti-fibrotic+potential+of+bosentan&doi=10.1080%2F07853890410018925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Role of endothelin in fibrosis and anti-fibrotic potential of bosentan</span></div><div class="casAuthors">Clozel, Martine; Salloukh, Hashem</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Medicine (Basingstoke, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">ANMDEU</span>;
        ISSN:<span class="NLM_cas:issn">0785-3890</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent data demonstrate the fundamental role of endothelin in the pathogenesis of fibrosis, and the anti-fibrotic potential of dual endothelin receptor antagonists such as bosentan.  Although transforming growth factor-beta, aldosterone and connective tissue growth factor, have already been established as contributors to the process of fibrosis, endothelin now emerges as a key player, which may have a role both in the initiation and in maintenance of fibrosis, and may mediate the pro-fibrotic effects of the other agents.  Bosentan is an orally active, dual endothelin receptor antagonist, which competitively antagonizes the binding of endothelin to both endothelin receptors ETA and ETB.  Bosentan prevents endothelin-induced fibroblast proliferation and extracellular matrix deposition and contraction, and reduces cardiac, hepatic, pulmonary and renal fibrosis in different disease models characterized by the activation of the endothelin system.  Bosentan even reverses existing fibrosis, possibly by its effect of stimulating matrix metalloproteinase type 1 (collagenase) expression.  The anti-fibrotic effects of bosentan extend to fibrosis induced by mediators other than endothelin such as transforming growth factor-beta, angiotensin II and aldosterone, indicating a central role of endothelin and endothelin receptors in fibrotic processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOmwjYBPr9mbVg90H21EOLACvtfcHk0liOL0ptQvvT5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslenurk%253D&md5=76966435b0243748c07b0cc8fd77960c</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1080%2F07853890410018925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07853890410018925%26sid%3Dliteratum%253Aachs%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DSalloukh%26aufirst%3DH.%26atitle%3DRole%2520of%2520endothelin%2520in%2520fibrosis%2520and%2520anti-fibrotic%2520potential%2520of%2520bosentan%26jtitle%3DAnn.%2520Med.%26date%3D2005%26volume%3D37%26spage%3D2%26epage%3D12%26doi%3D10.1080%2F07853890410018925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Pascual, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busnadiego, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Santamaria, J.</span></span> <span> </span><span class="NLM_article-title">The profibrotic role of endothelin-1: is the door still open for the treatment od fibrotic diseases</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">156</span>â <span class="NLM_lpage">164</span>, <span class="refDoi">Â DOI: 10.1016/j.lfs.2013.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.lfs.2013.12.024" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2014&pages=156-164&author=F.+Rodriguez-Pascualauthor=O.+Busnadiegoauthor=J.+Gonzalez-Santamaria&title=The+profibrotic+role+of+endothelin-1%3A+is+the+door+still+open+for+the+treatment+od+fibrotic+diseases&doi=10.1016%2Fj.lfs.2013.12.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2013.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2013.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez-Pascual%26aufirst%3DF.%26aulast%3DBusnadiego%26aufirst%3DO.%26aulast%3DGonzalez-Santamaria%26aufirst%3DJ.%26atitle%3DThe%2520profibrotic%2520role%2520of%2520endothelin-1%253A%2520is%2520the%2520door%2520still%2520open%2520for%2520the%2520treatment%2520od%2520fibrotic%2520diseases%26jtitle%3DLife%2520Sci.%26date%3D2014%26volume%3D118%26spage%3D156%26epage%3D164%26doi%3D10.1016%2Fj.lfs.2013.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yong, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabad, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves
Dasilva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, L. M.</span></span> <span> </span><span class="NLM_article-title">Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>259</i></span>,  <span class="NLM_fpage">79</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1016/j.jns.2006.11.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.jns.2006.11.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17382965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWrsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=259&publication_year=2007&pages=79-84&author=V.+W.+Yongauthor=R.+K.+Zabadauthor=S.+Agrawalauthor=A.+Goncalves%0ADasilvaauthor=L.+M.+Metz&title=Elevation+of+matrix+metalloproteinases+%28MMPs%29+in+multiple+sclerosis+and+impact+of+immunomodulators&doi=10.1016%2Fj.jns.2006.11.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators</span></div><div class="casAuthors">Yong, V. Wee; Zabad, Rana K.; Agrawal, Smriti; Goncalves Da Silva, Angelika; Metz, Luanne M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Neurological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">259</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">79-84</span>CODEN:
                <span class="NLM_cas:coden">JNSCAG</span>;
        ISSN:<span class="NLM_cas:issn">0022-510X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The matrix metalloproteinases (MMPs) are implicated in the pathol. of multiple sclerosis (MS).  This review summarizes the consequences of upregulation of MMP members in MS as well as in an animal model of the disease, exptl. autoimmune encephalomyelitis (EAE).  The pathogenic roles of MMPs are considered, esp. in the transmigration of leukocytes into the CNS.  We review the evidence that interferon-beta, an immunomodulator that is commonly used in MS, affects MMP expression in the disease.  The potential of minocycline as a therapy in MS, based on its activity as an MMP inhibitor, is discussed.  Besides affecting MMPs, minocycline may have other actions that help account for its possible utility in MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph1mzvbhnbD7Vg90H21EOLACvtfcHk0ljTHuqsidzPuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWrsLc%253D&md5=5b87d04cd4c62500f9d9a084962e0cc9</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2006.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2006.11.021%26sid%3Dliteratum%253Aachs%26aulast%3DYong%26aufirst%3DV.%2BW.%26aulast%3DZabad%26aufirst%3DR.%2BK.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DGoncalves%2BDasilva%26aufirst%3DA.%26aulast%3DMetz%26aufirst%3DL.%2BM.%26atitle%3DElevation%2520of%2520matrix%2520metalloproteinases%2520%2528MMPs%2529%2520in%2520multiple%2520sclerosis%2520and%2520impact%2520of%2520immunomodulators%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2007%26volume%3D259%26spage%3D79%26epage%3D84%26doi%3D10.1016%2Fj.jns.2006.11.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Lint, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libert, C.</span></span> <span> </span><span class="NLM_article-title">Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">1375</span>â <span class="NLM_lpage">1381</span>, <span class="refDoi">Â DOI: 10.1189/jlb.0607338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1189%2Fjlb.0607338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17709402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsValtbfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2007&pages=1375-1381&author=P.+Van+Lintauthor=C.+Libert&title=Chemokine+and+cytokine+processing+by+matrix+metalloproteinases+and+its+effect+on+leukocyte+migration+and+inflammation&doi=10.1189%2Fjlb.0607338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation</span></div><div class="casAuthors">Van Lint, Philippe; Libert, Claude</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1375-1381</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review.  The action of matrix metalloproteinases (MMPs) was originally believed to be restricted to degrdn. of the extracellular matrix; however, in recent years, it has become evident that these proteases can modify many nonmatrix substrates, such as cytokines and chemokines.  The use of MMP-deficient animals has revealed that these proteases can indeed influence the progression of various inflammatory processes.  This review aims to provide the reader with a concise overview of these novel MMP functions in relation to leukocyte migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT2xGqSmyTQbVg90H21EOLACvtfcHk0ljTHuqsidzPuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsValtbfN&md5=65c34da9f3dc5ba1d4ddcdde2a70f0b7</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1189%2Fjlb.0607338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.0607338%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BLint%26aufirst%3DP.%26aulast%3DLibert%26aufirst%3DC.%26atitle%3DChemokine%2520and%2520cytokine%2520processing%2520by%2520matrix%2520metalloproteinases%2520and%2520its%2520effect%2520on%2520leukocyte%2520migration%2520and%2520inflammation%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2007%26volume%3D82%26spage%3D1375%26epage%3D1381%26doi%3D10.1189%2Fjlb.0607338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kefaloyianni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthu, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaeppler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbisetti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalaris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose-John, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waikar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rennke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonventre, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrlich, A.</span></span> <span> </span><span class="NLM_article-title">ADAM17 substrate release in proximal tubule drives kidney fibrosis</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e87023</span>, <span class="refDoi">Â DOI: 10.1172/jci.insight.87023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2Fjci.insight.87023" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=e87023&author=E.+Kefaloyianniauthor=M.+L.+Muthuauthor=K.+Kaepplerauthor=X.+Sunauthor=V.+Sabbisettiauthor=A.+Chalarisauthor=S.+Rose-Johnauthor=E.+Wongauthor=I.+Sagiauthor=S.+S.+Waikarauthor=H.+Rennkeauthor=B.+D.+Humphreysauthor=J.+V.+Bonventreauthor=A.+Herrlich&title=ADAM17+substrate+release+in+proximal+tubule+drives+kidney+fibrosis&doi=10.1172%2Fjci.insight.87023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.87023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.87023%26sid%3Dliteratum%253Aachs%26aulast%3DKefaloyianni%26aufirst%3DE.%26aulast%3DMuthu%26aufirst%3DM.%2BL.%26aulast%3DKaeppler%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DSabbisetti%26aufirst%3DV.%26aulast%3DChalaris%26aufirst%3DA.%26aulast%3DRose-John%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DSagi%26aufirst%3DI.%26aulast%3DWaikar%26aufirst%3DS.%2BS.%26aulast%3DRennke%26aufirst%3DH.%26aulast%3DHumphreys%26aufirst%3DB.%2BD.%26aulast%3DBonventre%26aufirst%3DJ.%2BV.%26aulast%3DHerrlich%26aufirst%3DA.%26atitle%3DADAM17%2520substrate%2520release%2520in%2520proximal%2520tubule%2520drives%2520kidney%2520fibrosis%26jtitle%3DJCI%2520Insight%26date%3D2016%26volume%3D1%26spage%3De87023%26doi%3D10.1172%2Fjci.insight.87023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giannandrea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, W. C.</span></span> <span> </span><span class="NLM_article-title">Diverse functions of matrix metalloproteinases during fibrosis</span>. <i>Disease Models Mech.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">193</span>â <span class="NLM_lpage">203</span>, <span class="refDoi">Â DOI: 10.1242/dmm.012062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1242%2Fdmm.012062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24713275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlGqsLjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=193-203&author=M.+Giannandreaauthor=W.+C.+Parks&title=Diverse+functions+of+matrix+metalloproteinases+during+fibrosis&doi=10.1242%2Fdmm.012062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse functions of matrix metalloproteinases during fibrosis</span></div><div class="casAuthors">Giannandrea, Matthew; Parks, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Disease Models & Mechanisms</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">193-203, 11</span>CODEN:
                <span class="NLM_cas:coden">DMMIAX</span>;
        ISSN:<span class="NLM_cas:issn">1754-8403</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Fibrosis - a debilitating condition that can occur in most organs - is characterized by excess deposition of a collagen-rich extracellular matrix (ECM).  At first sight, the activities of proteinases that can degrade matrix, such as matrix metalloproteinases (MMPs), might be expected to be under-expressed in fibrosis or, if present, could function to resolve the excess matrix.  However, as we review here, some MMPs are indeed anti-fibrotic, whereas others can have profibrotic functions.  MMPs modulate a range of biol. processes, esp. processes related to immunity and tissue repair and/or remodeling.  Although we do not yet know precisely how MMPs function during fibrosis - i.e., the protein substrate or substrates that an individual MMP acts on to effect a specific process - expts. in mouse models demonstrate that MMP-dependent functions during fibrosis are not limited to effects on ECM turnover.  Rather, data from diverse models indicate that these proteinases influence cellular activities as varied as proliferation and survival, gene expression, and multiple aspects of inflammation that, in turn, impact outcomes related to fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGrxTCIFB0KrVg90H21EOLACvtfcHk0ljTHuqsidzPuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlGqsLjL&md5=88d15b1adbf7047a564eebb999463769</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1242%2Fdmm.012062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdmm.012062%26sid%3Dliteratum%253Aachs%26aulast%3DGiannandrea%26aufirst%3DM.%26aulast%3DParks%26aufirst%3DW.%2BC.%26atitle%3DDiverse%2520functions%2520of%2520matrix%2520metalloproteinases%2520during%2520fibrosis%26jtitle%3DDisease%2520Models%2520Mech.%26date%3D2014%26volume%3D7%26spage%3D193%26epage%3D203%26doi%3D10.1242%2Fdmm.012062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzyllo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusmano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzeski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theroux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydlowski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaber, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, W. D.</span></span> <span> </span><span class="NLM_article-title">Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">15</span>â <span class="NLM_lpage">20</span>, <span class="refDoi">Â DOI: 10.1016/j.jacc.2006.02.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.jacc.2006.02.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=16814643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtlGms70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2006&pages=15-20&author=M.+P.+Hudsonauthor=P.+W.+Armstrongauthor=W.+Ruzylloauthor=J.+Brumauthor=L.+Cusmanoauthor=P.+Krzeskiauthor=R.+Lyonauthor=M.+Quinonesauthor=P.+Therouxauthor=D.+Sydlowskiauthor=H.+E.+Kimauthor=M.+J.+Garciaauthor=W.+A.+Jaberauthor=W.+D.+Weaver&title=Effects+of+selective+matrix+metalloproteinase+inhibitor+%28PG-116800%29+to+prevent+ventricular+remodeling+after+myocardial+infarction%3A+results+of+the+PREMIER+%28Prevention+of+Myocardial+Infarction+Early+Remodeling%29+trial&doi=10.1016%2Fj.jacc.2006.02.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial Infarction</span></div><div class="casAuthors">Hudson, Michael P.; Armstrong, Paul W.; Ruzyllo, Witold; Brum, Jose; Cusmano, Lisa; Krzeski, Piotr; Lyon, Robert; Quinones, Miguel; Theroux, Pierre; Sydlowski, Diana; Kim, Henry E.; Garcia, Mario J.; Jaber, Wael A.; Weaver, W. Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-20</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objectives: We sought to det. whether matrix metalloproteinase (MMP) inhibitor, PG-116800, reduced left ventricular (LV) remodeling after myocardial infarction (MI).  Background: PG-116800 is an oral MMP inhibitor with significant antiremodeling effects in animal models of MI and ischemic heart failure.  Methods: In an international, randomized, double-blind, placebo-controlled study, 253 patients with first ST-segment elevation MI and ejection fraction between 15% and 40% were enrolled 48 Â± 24 h after MI and treated with placebo or PG-116800 for 90 days.  Major efficacy end points were changes in LV vols. as detd. by serial echocardiog., and clin. and safety outcomes were also collected.  Results: In total, 203 patients (80%) completed 90 days of treatment and had evaluable baseline and 90-day echo cardiograms.  The proportion of patients with anterior MI (78% vs. 81%) and primary percutaneous coronary intervention (90% vs. 91%) along with baseline LV ejection fraction (35.5% vs. 36.8%) did not differ between PG-116800-treated and placebo-treated patients.  There was no difference in the change in LV end-diastolic vol. index from days 0 to 90 with PG-116800 vs. placebo (5.09 Â± 1.45 mL/m2 vs. 5.48 Â± 1.41 mL/m2, p = 0.42).  Changes in LV diastolic vol., LV systolic vol., LV ejection fraction, sphericity index, plus rates of death or reinfarction were not significantly improved with PG-116800.  PG-116800 was well tolerated; however, there was increased incidence of arthralgia and joint stiffness without significant increase in overall musculoskeletal adverse events (21% vs. 15%, p = 0.33).  Conclusions: Matrix metalloproteinase inhibition with PG-116800 failed to reduce LV remodeling or improve clin. outcomes after MI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqceUkFd2YuhLVg90H21EOLACvtfcHk0lhZ3yfedaigWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtlGms70%253D&md5=ed973718f404cbd7207321dec8f1b4b6</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2006.02.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2006.02.055%26sid%3Dliteratum%253Aachs%26aulast%3DHudson%26aufirst%3DM.%2BP.%26aulast%3DArmstrong%26aufirst%3DP.%2BW.%26aulast%3DRuzyllo%26aufirst%3DW.%26aulast%3DBrum%26aufirst%3DJ.%26aulast%3DCusmano%26aufirst%3DL.%26aulast%3DKrzeski%26aufirst%3DP.%26aulast%3DLyon%26aufirst%3DR.%26aulast%3DQuinones%26aufirst%3DM.%26aulast%3DTheroux%26aufirst%3DP.%26aulast%3DSydlowski%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DH.%2BE.%26aulast%3DGarcia%26aufirst%3DM.%2BJ.%26aulast%3DJaber%26aufirst%3DW.%2BA.%26aulast%3DWeaver%26aufirst%3DW.%2BD.%26atitle%3DEffects%2520of%2520selective%2520matrix%2520metalloproteinase%2520inhibitor%2520%2528PG-116800%2529%2520to%2520prevent%2520ventricular%2520remodeling%2520after%2520myocardial%2520infarction%253A%2520results%2520of%2520the%2520PREMIER%2520%2528Prevention%2520of%2520Myocardial%2520Infarction%2520Early%2520Remodeling%2529%2520trial%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2006%26volume%3D48%26spage%3D15%26epage%3D20%26doi%3D10.1016%2Fj.jacc.2006.02.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Migita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abiru, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatsuhashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibashi, H.</span></span> <span> </span><span class="NLM_article-title">Immunosuppressant FK506 inhibits matrix metalloproteinase-9 induction in TNF-Î±-stimulated human hepatic stellate cells</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">2510</span>â <span class="NLM_lpage">2515</span>, <span class="refDoi">Â DOI: 10.1016/j.lfs.2005.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.lfs.2005.10.003" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2006&pages=2510-2515&author=K.+Migitaauthor=Y.+Maedaauthor=S.+Abiruauthor=M.+Nakamuraauthor=A.+Komoriauthor=T.+Yokoyamaauthor=Y.+Takiiauthor=T.+Moriauthor=H.+Yatsuhashiauthor=K.+Eguchiauthor=H.+Ishibashi&title=Immunosuppressant+FK506+inhibits+matrix+metalloproteinase-9+induction+in+TNF-%CE%B1-stimulated+human+hepatic+stellate+cells&doi=10.1016%2Fj.lfs.2005.10.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2005.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2005.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMigita%26aufirst%3DK.%26aulast%3DMaeda%26aufirst%3DY.%26aulast%3DAbiru%26aufirst%3DS.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DKomori%26aufirst%3DA.%26aulast%3DYokoyama%26aufirst%3DT.%26aulast%3DTakii%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DYatsuhashi%26aufirst%3DH.%26aulast%3DEguchi%26aufirst%3DK.%26aulast%3DIshibashi%26aufirst%3DH.%26atitle%3DImmunosuppressant%2520FK506%2520inhibits%2520matrix%2520metalloproteinase-9%2520induction%2520in%2520TNF-%25CE%25B1-stimulated%2520human%2520hepatic%2520stellate%2520cells%26jtitle%3DLife%2520Sci.%26date%3D2006%26volume%3D78%26spage%3D2510%26epage%3D2515%26doi%3D10.1016%2Fj.lfs.2005.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Donato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiggeri, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Duca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jivotenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acinni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginevri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusmano, R.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase expression and collagen cross-linking during chronic Adriamycin nephropathy</span>. <i>Nephron</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">192</span>â <span class="NLM_lpage">200</span>, <span class="refDoi">Â DOI: 10.1159/000190168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1159%2F000190168" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1997&pages=192-200&author=A.+Di+Donatoauthor=G.+M.+Ghiggeriauthor=M.+Di+Ducaauthor=E.+Jivotenkoauthor=R.+Acinniauthor=J.+Campoloauthor=F.+Ginevriauthor=R.+Gusmano&title=Lysyl+oxidase+expression+and+collagen+cross-linking+during+chronic+Adriamycin+nephropathy&doi=10.1159%2F000190168"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1159%2F000190168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000190168%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BDonato%26aufirst%3DA.%26aulast%3DGhiggeri%26aufirst%3DG.%2BM.%26aulast%3DDi%2BDuca%26aufirst%3DM.%26aulast%3DJivotenko%26aufirst%3DE.%26aulast%3DAcinni%26aufirst%3DR.%26aulast%3DCampolo%26aufirst%3DJ.%26aulast%3DGinevri%26aufirst%3DF.%26aulast%3DGusmano%26aufirst%3DR.%26atitle%3DLysyl%2520oxidase%2520expression%2520and%2520collagen%2520cross-linking%2520during%2520chronic%2520Adriamycin%2520nephropathy%26jtitle%3DNephron%26date%3D1997%26volume%3D76%26spage%3D192%26epage%3D200%26doi%3D10.1159%2F000190168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barker, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erler, J. T.</span></span> <span> </span><span class="NLM_article-title">The rationale for targeting the LOX family in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">540</span>â <span class="NLM_lpage">552</span>, <span class="refDoi">Â DOI: 10.1038/nrc3319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnrc3319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22810810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCltLfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=540-552&author=H.+E.+Barkerauthor=T.+R.+Coxauthor=J.+T.+Erler&title=The+rationale+for+targeting+the+LOX+family+in+cancer&doi=10.1038%2Fnrc3319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">The rationale for targeting the LOX family in cancer</span></div><div class="casAuthors">Barker, Holly E.; Cox, Thomas R.; Erler, Janine T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">540-552</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The therapeutic targeting of extracellular proteins is becoming hugely attractive in light of evidence implicating the tumor microenvironment as pivotal in all aspects of tumor initiation and progression.  Members of the lysyl oxidase (LOX) family of proteins are secreted by tumors and are the subject of much effort to understand their roles in cancer.  In this Review we discuss the roles of members of this family in the remodelling of the tumor microenvironment and their paradoxical roles in tumorigenesis and metastasis.  We also discuss how targeting this family of proteins might lead to a new avenue of cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZcLr3Y7rPKLVg90H21EOLACvtfcHk0lhZ3yfedaigWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCltLfE&md5=455064ea8d5332b43fa6490a1aaa0c8f</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1038%2Fnrc3319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3319%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DH.%2BE.%26aulast%3DCox%26aufirst%3DT.%2BR.%26aulast%3DErler%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520rationale%2520for%2520targeting%2520the%2520LOX%2520family%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D540%26epage%3D552%26doi%3D10.1038%2Fnrc3319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Georges, P.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gombos, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janmey, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furth, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, R. G.</span></span> <span> </span><span class="NLM_article-title">Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis</span>. <i>Am. J. Physiol., Gastrointest. Liver Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">G1147</span>â <span class="NLM_lpage">1154</span>, <span class="refDoi">Â DOI: 10.1152/ajpgi.00032.2007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1152%2Fajpgi.00032.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17932231" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2007&pages=G1147-1154&author=P.%0AC.+Georgesauthor=J.+J.+Huiauthor=Z.+Gombosauthor=M.+E.+McCormickauthor=A.+Y.+Wangauthor=M.+Uemuraauthor=R.+Mickauthor=P.+A.+Janmeyauthor=E.+E.+Furthauthor=R.+G.+Wells&title=Increased+stiffness+of+the+rat+liver+precedes+matrix+deposition%3A+implications+for+fibrosis&doi=10.1152%2Fajpgi.00032.2007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.00032.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.00032.2007%26sid%3Dliteratum%253Aachs%26aulast%3DGeorges%26aufirst%3DP.%2BC.%26aulast%3DHui%26aufirst%3DJ.%2BJ.%26aulast%3DGombos%26aufirst%3DZ.%26aulast%3DMcCormick%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DA.%2BY.%26aulast%3DUemura%26aufirst%3DM.%26aulast%3DMick%26aufirst%3DR.%26aulast%3DJanmey%26aufirst%3DP.%2BA.%26aulast%3DFurth%26aufirst%3DE.%2BE.%26aulast%3DWells%26aufirst%3DR.%2BG.%26atitle%3DIncreased%2520stiffness%2520of%2520the%2520rat%2520liver%2520precedes%2520matrix%2520deposition%253A%2520implications%2520for%2520fibrosis%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Gastrointest.%2520Liver%2520Physiol.%26date%3D2007%26volume%3D293%26spage%3DG1147%26epage%3D1154%26doi%3D10.1152%2Fajpgi.00032.2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchio-Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manabe, N.</span></span> <span> </span><span class="NLM_article-title">Transforming growth factor-beta1 mediated up-regulation of lysyl oxidase in the kidneys of hereditary nephrotic mouse with chronic renal fibrosis</span>. <i>Virchows Arch.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>447</i></span>,  <span class="NLM_fpage">859</span>â <span class="NLM_lpage">868</span>, <span class="refDoi">Â DOI: 10.1007/s00428-005-0001-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1007%2Fs00428-005-0001-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=16086153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1KnsLbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2005&pages=859-868&author=Y.+Gotoauthor=K.+Uchio-Yamadaauthor=S.+Ananauthor=Y.+Yamamotoauthor=A.+Oguraauthor=N.+Manabe&title=Transforming+growth+factor-beta1+mediated+up-regulation+of+lysyl+oxidase+in+the+kidneys+of+hereditary+nephrotic+mouse+with+chronic+renal+fibrosis&doi=10.1007%2Fs00428-005-0001-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Transforming growth factor-Î²1 mediated up-regulation of lysyl oxidase in the kidneys of hereditary nephrotic mouse with chronic renal fibrosis</span></div><div class="casAuthors">Goto, Yasufumi; Uchio-Yamada, Kozue; Anan, Sayuri; Yamamoto, Yoshie; Ogura, Atsuo; Manabe, Noboru</div><div class="citationInfo"><span class="NLM_cas:title">Virchows Archiv</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">859-868</span>CODEN:
                <span class="NLM_cas:coden">VARCEM</span>;
        ISSN:<span class="NLM_cas:issn">0945-6317</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Lysyl oxidase (LOX), an extracellular enzyme, plays a key role in the post-translational modification of collagens and elastin, catalyzing inter- and intra-crosslinking reactions.  Because the crosslinked extracellular matrixes (ECMs) are highly resistant to degradative enzymes, it is considered that the over-expression of LOX may cause severe fibrotic degeneration.  In the present study, we addressed the role of LOX-mediated crosslinking in chronic renal tubulointerstitial fibrosis using an animal model of hereditary nephrotic syndrome, the Institute of Cancer Research (ICR)-derived glomerulonephritis (ICGN) mouse.  RNase protection assay (RPA) revealed that LOX mRNA expression was up-regulated in the kidneys of ICGN mice as compared with control ICR mice.  High-level expression of LOX and transforming growth factor (TGF)-Î²1 (an up-regulator of LOX) mRNA was detected in tubular epithelial cells of ICGN mouse kidneys by in situ hybridization.  Type-I and -III collagens, major substrates for LOX, were accumulated in tubulointerstitium of ICGN mouse kidneys.  The present findings imply that TGF-Î²1 up-regulates the prodn. of LOX in tubular epithelial cells of ICGN mouse kidneys, and the excessive LOX acts on interstitial collagens and catalyzes crosslinking reactions.  As a result, the highly crosslinked collagens induce an irreversible progression of chronic renal tubulointerstitial fibrosis in the kidneys of ICGN mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWwjlWxHOJfbVg90H21EOLACvtfcHk0lhmR-Yx4dwxhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1KnsLbF&md5=a61ad20761ecd209a8fdd0cf2b38c9cc</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1007%2Fs00428-005-0001-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00428-005-0001-8%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DUchio-Yamada%26aufirst%3DK.%26aulast%3DAnan%26aufirst%3DS.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DOgura%26aufirst%3DA.%26aulast%3DManabe%26aufirst%3DN.%26atitle%3DTransforming%2520growth%2520factor-beta1%2520mediated%2520up-regulation%2520of%2520lysyl%2520oxidase%2520in%2520the%2520kidneys%2520of%2520hereditary%2520nephrotic%2520mouse%2520with%2520chronic%2520renal%2520fibrosis%26jtitle%3DVirchows%2520Arch.%26date%3D2005%26volume%3D447%26spage%3D859%26epage%3D868%26doi%3D10.1007%2Fs00428-005-0001-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barry-Hamilton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyasu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikels, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaysberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghermazien, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velayo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biermann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaffryar-Eilot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neufeld, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Vlasselaer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1009</span>â <span class="NLM_lpage">1017</span>, <span class="refDoi">Â DOI: 10.1038/nm.2208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm.2208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=20818376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFWksrvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1009-1017&author=V.+Barry-Hamiltonauthor=R.+Spanglerauthor=D.+Marshallauthor=S.+McCauleyauthor=H.+M.+Rodriguezauthor=M.+Oyasuauthor=A.+Mikelsauthor=M.+Vaysbergauthor=H.+Ghermazienauthor=C.+Waiauthor=C.+A.+Garciaauthor=A.+C.+Velayoauthor=B.+Jorgensenauthor=D.+Biermannauthor=D.+Tsaiauthor=J.+Greenauthor=S.+Zaffryar-Eilotauthor=A.+Holzerauthor=S.+Oggauthor=D.+Thaiauthor=G.+Neufeldauthor=P.+Van+Vlasselaerauthor=V.+Smith&title=Allosteric+inhibition+of+lysyl+oxidase-like-2+impedes+the+development+of+a+pathologic+microenvironment&doi=10.1038%2Fnm.2208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment</span></div><div class="casAuthors">Barry-Hamilton, Vivian; Spangler, Rhyannon; Marshall, Derek; McCauley, Scott; Rodriguez, Hector M.; Oyasu, Miho; Mikels, Amanda; Vaysberg, Maria; Ghermazien, Haben; Wai, Carol; Garcia, Carlos A.; Velayo, Arleene C.; Jorgensen, Brett; Biermann, Donna; Tsai, Daniel; Green, Jennifer; Zaffryar-Eilot, Shelly; Holzer, Alison; Ogg, Scott; Thai, Dung; Neufeld, Gera; Van Vlasselaer, Peter; Smith, Victoria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1009-1017</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have identified a new role for the matrix enzyme lysyl oxidase-like-2 (LOXL2) in the creation and maintenance of the pathol. microenvironment of cancer and fibrotic disease.  Our anal. of biopsies from human tumors and fibrotic lung and liver tissues revealed an increase in LOXL2 in disease-assocd. stroma and limited expression in healthy tissues.  Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models.  Inhibition of LOXL2 resulted in a marked redn. in activated fibroblasts, desmoplasia and endothelial cells, decreased prodn. of growth factors and cytokines and decreased transforming growth factor-Î² (TGF-Î²) pathway signaling.  AB0023 outperformed the small-mol. lysyl oxidase inhibitor Î²-aminopropionitrile.  The efficacy and safety of LOXL2-specific AB0023 represents a new therapeutic approach with broad applicability in oncol. and fibrotic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkE52VQCvcZrVg90H21EOLACvtfcHk0liGR4g-7DDeag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFWksrvF&md5=7e69cbf26c2985ad03fbb620538a5f04</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fnm.2208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2208%26sid%3Dliteratum%253Aachs%26aulast%3DBarry-Hamilton%26aufirst%3DV.%26aulast%3DSpangler%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DD.%26aulast%3DMcCauley%26aufirst%3DS.%26aulast%3DRodriguez%26aufirst%3DH.%2BM.%26aulast%3DOyasu%26aufirst%3DM.%26aulast%3DMikels%26aufirst%3DA.%26aulast%3DVaysberg%26aufirst%3DM.%26aulast%3DGhermazien%26aufirst%3DH.%26aulast%3DWai%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DC.%2BA.%26aulast%3DVelayo%26aufirst%3DA.%2BC.%26aulast%3DJorgensen%26aufirst%3DB.%26aulast%3DBiermann%26aufirst%3DD.%26aulast%3DTsai%26aufirst%3DD.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DZaffryar-Eilot%26aufirst%3DS.%26aulast%3DHolzer%26aufirst%3DA.%26aulast%3DOgg%26aufirst%3DS.%26aulast%3DThai%26aufirst%3DD.%26aulast%3DNeufeld%26aufirst%3DG.%26aulast%3DVan%2BVlasselaer%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DV.%26atitle%3DAllosteric%2520inhibition%2520of%2520lysyl%2520oxidase-like-2%2520impedes%2520the%2520development%2520of%2520a%2520pathologic%2520microenvironment%26jtitle%3DNat.%2520Med.%26date%3D2010%26volume%3D16%26spage%3D1009%26epage%3D1017%26doi%3D10.1038%2Fnm.2208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikenaga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sverdlov, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuppan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, Y.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1599</span>â <span class="NLM_lpage">1609</span>, <span class="refDoi">Â DOI: 10.1096/fj.14-268425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1096%2Ffj.14-268425" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1599-1609&author=S.+B.+Liuauthor=N.+Ikenagaauthor=Z.+W.+Pengauthor=D.+Y.+Sverdlovauthor=A.+Greensteinauthor=V.+Smithauthor=D.+Schuppanauthor=Y.+Popov&title=Lysyl+oxidase+activity+contributes+to+collagen+stabilization+during+liver+fibrosis+progression+and+limits+spontaneous+fibrosis+reversal+in+mice&doi=10.1096%2Ffj.14-268425"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1096%2Ffj.14-268425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.14-268425%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%2BB.%26aulast%3DIkenaga%26aufirst%3DN.%26aulast%3DPeng%26aufirst%3DZ.%2BW.%26aulast%3DSverdlov%26aufirst%3DD.%2BY.%26aulast%3DGreenstein%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DSchuppan%26aufirst%3DD.%26aulast%3DPopov%26aufirst%3DY.%26atitle%3DLysyl%2520oxidase%2520activity%2520contributes%2520to%2520collagen%2520stabilization%2520during%2520liver%2520fibrosis%2520progression%2520and%2520limits%2520spontaneous%2520fibrosis%2520reversal%2520in%2520mice%26jtitle%3DFASEB%2520J.%26date%3D2016%26volume%3D30%26spage%3D1599%26epage%3D1609%26doi%3D10.1096%2Ffj.14-268425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keene, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasumura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism responsible for fibronectin-controlled alterations in matrix stiffness in advanced chronic liver fibrogenesis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">72</span>â <span class="NLM_lpage">88</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M115.691519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1074%2Fjbc.M115.691519" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=72-88&author=A.+Iwasakiauthor=K.+Sakaiauthor=K.+Moriyaauthor=T.+Sasakiauthor=D.+R.+Keeneauthor=R.+Akhtarauthor=T.+Miyazonoauthor=S.+Yasumuraauthor=M.+Watanabeauthor=S.+Morishitaauthor=T.+Sakai&title=Molecular+mechanism+responsible+for+fibronectin-controlled+alterations+in+matrix+stiffness+in+advanced+chronic+liver+fibrogenesis&doi=10.1074%2Fjbc.M115.691519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.691519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.691519%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DA.%26aulast%3DSakai%26aufirst%3DK.%26aulast%3DMoriya%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DKeene%26aufirst%3DD.%2BR.%26aulast%3DAkhtar%26aufirst%3DR.%26aulast%3DMiyazono%26aufirst%3DT.%26aulast%3DYasumura%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DMorishita%26aufirst%3DS.%26aulast%3DSakai%26aufirst%3DT.%26atitle%3DMolecular%2520mechanism%2520responsible%2520for%2520fibronectin-controlled%2520alterations%2520in%2520matrix%2520stiffness%2520in%2520advanced%2520chronic%2520liver%2520fibrogenesis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D72%26epage%3D88%26doi%3D10.1074%2Fjbc.M115.691519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14909</span>, <span class="refDoi">Â DOI: 10.1038/ncomms14909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fncomms14909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28416796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFKgtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14909&author=H.+Tangauthor=L.+Leungauthor=G.+Saturnoauthor=A.+Virosauthor=D.+Smithauthor=G.+Di+Levaauthor=E.+Morrisonauthor=D.+Niculescu-Duvazauthor=F.+Lopesauthor=L.+Johnsonauthor=N.+Dhomenauthor=C.+Springerauthor=R.+Marais&title=Lysyl+oxidase+drives+tumour+progression+by+trapping+EGF+receptors+at+the+cell+surface&doi=10.1038%2Fncomms14909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface</span></div><div class="casAuthors">Tang, Hao Ran; Leung, Leo; Saturno, Grazia; Viros, Amaya; Smith, Duncan; Di Leva, Gianpiero; Morrison, Eamonn; Niculescu-Duvaz, Dan; Lopes, Filipa; Johnson, Louise; Dhomen, Nathalie; Springer, Caroline; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14909</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lysyl oxidase (LOX) remodels the tumor microenvironment by crosslinking the extracellular matrix.  LOX overexpression is assocd. with poor cancer outcomes.  Here, we find that LOX regulates the epidermal growth factor receptor (EGFR) to drive tumor progression.  We show that LOX regulates EGFR by suppressing TGFÎ²1 signalling through the secreted protease HTRA1.  This increases the expression of Matrilin2 (MATN2), an EGF-like domain-contg. protein that traps EGFR at the cell surface to facilitate its activation by EGF.  We describe a pharmacol. inhibitor of LOX, CCT365623, which disrupts EGFR cell surface retention and delays the growth of primary and metastatic tumor cells in vivo.  Thus, we show that LOX regulates EGFR cell surface retention to drive tumor progression, and we validate the therapeutic potential of inhibiting this pathway with the small mol. inhibitor CCT365623.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjI8odBCa4OLVg90H21EOLACvtfcHk0ljIJnFhbMno3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFKgtbw%253D&md5=d0db599dc8344c8685196f6d289fd3cf</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1038%2Fncomms14909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14909%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DDi%2BLeva%26aufirst%3DG.%26aulast%3DMorrison%26aufirst%3DE.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DLysyl%2520oxidase%2520drives%2520tumour%2520progression%2520by%2520trapping%2520EGF%2520receptors%2520at%2520the%2520cell%2520surface%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14909%26doi%3D10.1038%2Fncomms14909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonte, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Montolio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deodhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timpson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erler, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, T. R.</span></span> <span> </span><span class="NLM_article-title">Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">26066</span>â <span class="NLM_lpage">26078</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.15257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.18632%2Foncotarget.15257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28199967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1c3mvFOnsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=26066-26078&author=J.+Changauthor=M.+C.+Lucasauthor=L.+E.+Leonteauthor=M.+Garcia-Montolioauthor=L.+B.+Singhauthor=A.+D.+Findlayauthor=M.+Deodharauthor=J.+S.+Footauthor=W.+Jarolimekauthor=P.+Timpsonauthor=J.+T.+Erlerauthor=T.+R.+Cox&title=Pre-clinical+evaluation+of+small+molecule+LOXL2+inhibitors+in+breast+cancer&doi=10.18632%2Foncotarget.15257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer</span></div><div class="casAuthors">Chang Joan; Leonte Lidia E; Garcia-Montolio Marc; Singh Lukram Babloo; Erler Janine T; Cox Thomas R; Lucas Morghan C; Timpson Paul; Cox Thomas R; Findlay Alison D; Deodhar Mandar; Foot Jonathan S; Jarolimek Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">26066-26078</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lysyl Oxidase-like 2 (LOXL2), a member of the lysyl oxidase family of amine oxidases is known to be important in normal tissue development and homeostasis, as well as the onset and progression of solid tumors.  Here we tested the anti-tumor properties of two generations of novel small molecule LOXL2 inhibitor in the MDA-MB-231 human model of breast cancer.  We confirmed a functional role for LOXL2 activity in the progression of primary breast cancer.  Inhibition of LOXL2 activity inhibited the growth of primary tumors and reduced primary tumor angiogenesis.  Dual inhibition of LOXL2 and LOX showed a greater effect and also led to a lower overall metastatic burden in the lung and liver.  Our data provides the first evidence to support a role for LOXL2 specific small molecule inhibitors as a potential therapy in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOpqvFkfAy6suCWE5mhx1RfW6udTcc2ebZIvPz-DEbTLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3mvFOnsQ%253D%253D&md5=eda7044a327ae1746d7ae3ab2c2386fc</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.15257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.15257%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLeonte%26aufirst%3DL.%2BE.%26aulast%3DGarcia-Montolio%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DL.%2BB.%26aulast%3DFindlay%26aufirst%3DA.%2BD.%26aulast%3DDeodhar%26aufirst%3DM.%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DTimpson%26aufirst%3DP.%26aulast%3DErler%26aufirst%3DJ.%2BT.%26aulast%3DCox%26aufirst%3DT.%2BR.%26atitle%3DPre-clinical%2520evaluation%2520of%2520small%2520molecule%2520LOXL2%2520inhibitors%2520in%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D26066%26epage%3D26078%26doi%3D10.18632%2Foncotarget.15257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolman, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, E. H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparidans, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szokol, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ãrfi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storm, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennink, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, R. C.</span></span> <span> </span><span class="NLM_article-title">Targeting of a oral platinum-bound sunitinib analog to renal proximal tubular cells</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">417</span>â <span class="NLM_lpage">433</span>, <span class="refDoi">Â DOI: 10.2147/IJN.S26485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FIJN.S26485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22334775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFaksbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=417-433&author=E.+M.+Dolmanauthor=S.+Harmsenauthor=E.+H.+E.+Pietersauthor=R.+W.+Sparidansauthor=M.+Lacombeauthor=B.+Szokolauthor=L.+%C3%96rfiauthor=G.+Keriauthor=G.+Stormauthor=W.+E.+Henninkauthor=R.+C.+Kok&title=Targeting+of+a+oral+platinum-bound+sunitinib+analog+to+renal+proximal+tubular+cells&doi=10.2147%2FIJN.S26485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells</span></div><div class="casAuthors">Dolman, M. E. M.; Harmsen, Stefan; Pieters, Ebel H. E.; Sparidans, Rolf W.; Lacombe, Marie; Szokol, Balint; Orfi, Laszlo; Keri, Gyorgy; Storm, Gert; Hennink, Wim E.; Kok, Robbert J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">417-433</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Activated proximal tubular cells play an important role in renal fibrosis.  We investigated whether sunitinib and a kidney-targeted conjugate of sunitinib were capable of attenuating fibrogenic events in tubulointerstitial fibrosis.  Methods: A kidney-targeted conjugate was prepd. by linkage of a sunitinib analog (named 17864) via a platinum-based linker to the kidney-specific carrier lysozyme.  Pharmacol. activity of 17864-lysozyme was evaluated in human kidney proximal tubular cells (HK-2); the capability of the kidney-directed conjugate to accumulate in the kidneys was studied in mice.  Potential antifibrotic effects of a single-dose treatment were evaluated in the unilateral ureteral obstruction (UUO) model in mice.  Results: The 17864-lysozyme conjugate and its metabolites strongly inhibited tyrosine kinase activity.  Upon i.v. injection, 17864-lysozyme rapidly accumulated in the kidneys and provided sustained renal drug levels for up to 3 days after a single dose.  Renal drug level area under the curve was increased 28-fold vs. an equimolar dose of sunitinib malate.  Daily treatment of UUO mice with a high dose of sunitinib malate (50 mg/kg) resulted in antifibrotic responses, but also induced drug-related toxicity.  A single dose of 17864-lysozyme (equiv. to 1.8 mg/kg sunitinib) was safe but showed no antifibrotic effects.  Conclusion: Multikinase inhibitors like sunitinib can be of benefit in the treatment of fibrotic diseases, provided that their safety can be improved by strategies as presented in this paper, and sustained renal levels can be achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDvQxFI8JqnbVg90H21EOLACvtfcHk0ljIJnFhbMno3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFaksbg%253D&md5=5c1e9dc5bb759c3b4478d1f0885943dd</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.2147%2FIJN.S26485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S26485%26sid%3Dliteratum%253Aachs%26aulast%3DDolman%26aufirst%3DE.%2BM.%26aulast%3DHarmsen%26aufirst%3DS.%26aulast%3DPieters%26aufirst%3DE.%2BH.%2BE.%26aulast%3DSparidans%26aufirst%3DR.%2BW.%26aulast%3DLacombe%26aufirst%3DM.%26aulast%3DSzokol%26aufirst%3DB.%26aulast%3D%25C3%2596rfi%26aufirst%3DL.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DStorm%26aufirst%3DG.%26aulast%3DHennink%26aufirst%3DW.%2BE.%26aulast%3DKok%26aufirst%3DR.%2BC.%26atitle%3DTargeting%2520of%2520a%2520oral%2520platinum-bound%2520sunitinib%2520analog%2520to%2520renal%2520proximal%2520tubular%2520cells%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2012%26volume%3D7%26spage%3D417%26epage%3D433%26doi%3D10.2147%2FIJN.S26485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blease, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azaryan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez-Valle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceres, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Velden, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen-Heininger, Y.
M. W.</span></span> <span> </span><span class="NLM_article-title">CC-90001, a second generation Jun N-terminal kinase (JNK) inhibitor for the treatment of idiopathic pulmonary fibrosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">A5409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2017&pages=A5409&author=B.+Bennettauthor=K.+Bleaseauthor=Y.+Yeauthor=A.+Azaryanauthor=F.+Ramirez-Valleauthor=R.+Ceresauthor=G.+Horanauthor=P.+Schaferauthor=J.+L.+Van+Der+Veldenauthor=Y.%0AM.+W.+Janssen-Heininger&title=CC-90001%2C+a+second+generation+Jun+N-terminal+kinase+%28JNK%29+inhibitor+for+the+treatment+of+idiopathic+pulmonary+fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DB.%26aulast%3DBlease%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DAzaryan%26aufirst%3DA.%26aulast%3DRamirez-Valle%26aufirst%3DF.%26aulast%3DCeres%26aufirst%3DR.%26aulast%3DHoran%26aufirst%3DG.%26aulast%3DSchafer%26aufirst%3DP.%26aulast%3DVan%2BDer%2BVelden%26aufirst%3DJ.%2BL.%26aulast%3DJanssen-Heininger%26aufirst%3DY.%2BM.%2BW.%26atitle%3DCC-90001%252C%2520a%2520second%2520generation%2520Jun%2520N-terminal%2520kinase%2520%2528JNK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2017%26volume%3D195%26spage%3DA5409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.
K.</span></span> <span> </span><span class="NLM_article-title">Integrins and cadherins as therapeutic targets in fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">131</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24917820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvFygsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=131&author=S.%0AK.+Agarwal&title=Integrins+and+cadherins+as+therapeutic+targets+in+fibrosis&doi=10.3389%2Ffphar.2014.00131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Integrins and cadherins as therapeutic targets in fibrosis</span></div><div class="casAuthors">Agarwal Sandeep K</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">131</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Fibrosis is the excessive deposition of extracellular matrix proteins into tissues leading to scar formation, disruption of normal tissue architecture and organ failure.  Despite the large clinical impact of fibrosis, treatment options are limited.  Adhesion molecules, in particular Î±vÎ²6 and Î±3Î²1 integrins and cadherin-11, have been demonstrated to be important mediators of tissue fibrosis.  These data are reviewed here and provide the foundation for these molecules to be potential therapeutic targets for patients with fibrotic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQeWflPetSDUHdcurJClFcfW6udTcc2eZxRsptgfER6Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvFygsA%253D%253D&md5=74ef04f4406ee98ba1eead9bbeb266c1</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00131%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DS.%2BK.%26atitle%3DIntegrins%2520and%2520cadherins%2520as%2520therapeutic%2520targets%2520in%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D131%26doi%3D10.3389%2Ffphar.2014.00131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mazo, D. F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, I. V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogliati, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefano, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, G. F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabelo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira Alves, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrilho, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, C. P. M.
S.</span></span> <span> </span><span class="NLM_article-title">S-nitroso, N acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">553</span>â <span class="NLM_lpage">563</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S43930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S43930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23843692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCntrrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=553-563&author=D.+F.+C.+Mazoauthor=M.+G.+de+Oliveiraauthor=I.+V.+A.+Pereiraauthor=B.+Cogliatiauthor=J.+T.+Stefanoauthor=G.+F.+P.+de+Souzaauthor=F.+Rabeloauthor=F.+R.+Limaauthor=V.+A.+Ferreira+Alvesauthor=F.+J.+Carrilhoauthor=C.+P.+M.%0AS.+de+Oliveira&title=S-nitroso%2C+N+acetylcysteine+attenuates+liver+fibrosis+in+experimental+nonalcoholic+steatohepatitis&doi=10.2147%2FDDDT.S43930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis</span></div><div class="casAuthors">Mazo, Daniel F. C.; de Oliveira, Marcelo G.; Pereira, Isabel V. A.; Cogliati, Bruno; Stefano, Jose T.; de Souza, Gabriela F. P.; Rabelo, Fabiola; Lima, Fabiana R.; Alves Ferreira, Venancio A.; Carrilho, Flair J.; de Oliveira, Claudia P. M. S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">553-563</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">S-nitroso-N-acetylcysteine (SNAC) is a water sol. primary S-nitrosothiol capable of transferring and releasing nitric oxide and inducing several biochem. activities, including modulation of hepatic stellate cell activation.  In this study, we evaluated the antifibrotic activity of SNAC in an animal model of nonalcoholic steatohepatitis (NASH) induced in Sprague-Dawley rats fed with a choline-deficient, high trans fat diet and exposed to diethylnitrosamine for 8 wk.  The rats were divided into three groups: SNAC, which received oral SNAC soln. daily; NASH, which received the vehicle; and control, which received std. diet and vehicle.  Genes related to fibrosis (matrix metalloproteinases [MMP]-13, -9, and -2), transforming growth factor Î²-1 [TGFÎ²-1], collagen-1Î±, and tissue inhibitors of metalloproteinase [TIMP-1 and -2] and oxidative stress (heat-shock proteins [HSP]-60 and -90) were evaluated.  SNAC led to a 34.4% redn. in the collagen occupied area assocd. with upregulation of MMP-13 and -9 and downregulation of HSP-60, TIMP-2, TGFÎ²-1, and collagen-1Î±.  These results indicate that oral SNAC administration may represent a potential antifibrotic treatment for NASH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZfIstyEKqr7Vg90H21EOLACvtfcHk0ljNY9WmKfhLHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCntrrP&md5=23b53e42317a5b8d3d11992f7f77a2d7</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S43930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S43930%26sid%3Dliteratum%253Aachs%26aulast%3DMazo%26aufirst%3DD.%2BF.%2BC.%26aulast%3Dde%2BOliveira%26aufirst%3DM.%2BG.%26aulast%3DPereira%26aufirst%3DI.%2BV.%2BA.%26aulast%3DCogliati%26aufirst%3DB.%26aulast%3DStefano%26aufirst%3DJ.%2BT.%26aulast%3Dde%2BSouza%26aufirst%3DG.%2BF.%2BP.%26aulast%3DRabelo%26aufirst%3DF.%26aulast%3DLima%26aufirst%3DF.%2BR.%26aulast%3DFerreira%2BAlves%26aufirst%3DV.%2BA.%26aulast%3DCarrilho%26aufirst%3DF.%2BJ.%26aulast%3Dde%2BOliveira%26aufirst%3DC.%2BP.%2BM.%2BS.%26atitle%3DS-nitroso%252C%2520N%2520acetylcysteine%2520attenuates%2520liver%2520fibrosis%2520in%2520experimental%2520nonalcoholic%2520steatohepatitis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2013%26volume%3D7%26spage%3D553%26epage%3D563%26doi%3D10.2147%2FDDDT.S43930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. Q.</span></span> <span> </span><span class="NLM_article-title">Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3019</span>â <span class="NLM_lpage">3033</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S144807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S144807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29081650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSkt7nE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=3019-3033&author=W.+W.+Zhangauthor=F.+Baiauthor=J.+Wangauthor=R.+H.+Zhengauthor=L.+W.+Yangauthor=E.+Jamesauthor=Z.+Q.+Zhao&title=Edaravone+inhibits+pressure+overload-induced+cardiac+fibrosis+and+dysfunction+by+reducing+expression+of+angiotensin+II+AT1+receptor&doi=10.2147%2FDDDT.S144807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor</span></div><div class="casAuthors">Zhang, Wei-Wei; Bai, Feng; Wang, Jin; Zheng, Rong-Hua; Yang, Li-Wang; James, Erskine A.; Zhao, Zhi-Qing</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3019-3033</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Angiotensin II (Ang II) is known to be involved in the progression of ventricular dysfunction and heart failure by eliciting cardiac fibrosis.  The purpose of this study was to demonstrate whether treatment with an antioxidant compd., edaravone, reduces cardiac fibrosis and improves ventricular function by inhibiting Ang II AT1 receptor.  The study was conducted in a rat model of transverse aortic constriction (TAC).  In control, rats were subjected to 8 wk of TAC.  In treated rats, edaravone (10 mg/kg/day) or Ang II AT1 receptor blocker, telmisartan (10 mg/kg/day) was administered by i.p. injection or gastric gavage, resp., during TAC.  Relative to the animals with TAC, edaravone reduced myocardial malonaldehyde level and increased superoxide dismutase activity.  Protein level of the AT1 receptor was reduced and the AT2 receptor was upregulated, as evidenced by the reduced ratio of AT1 over AT2 receptor (0.57Â±0.2 vs 3.16Â±0.39, p<0.05) and less locally expressed AT1 receptor in the myocardium.  Furthermore, the protein level of angiotensin converting enzyme 2 was upregulated.  In coincidence with these changes, edaravone significantly decreased the populations of macrophages and myofibroblasts in the myocardium, which were accompanied by reduced levels of transforming growth factor beta 1 and Smad2/3.  Collagen I synthesis was inhibited and collagen-rich fibrosis was attenuated.  Relative to the TAC group, cardiac systolic function was preserved, as shown by increased left ventricular systolic pressure (204Â±51 vs 110Â±19 mmHg, p<0.05) and ejection fraction (82%Â±3% vs 60%Â±5%, p<0.05).  Treatment with telmisartan provided a comparable level of protection as compared with edaravone in all the parameters measured.  Taken together, edaravone treatment ameliorates cardiac fibrosis and improves left ventricular function in the pressure overload rat model, potentially via suppressing the AT1 receptor-mediated signaling pathways.  These data indicate that edaravone might be selected in combination with other existing drugs in preventing progression of cardiac dysfunction in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdgiWC1QUkDLVg90H21EOLACvtfcHk0liJhyxaiZ4EhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSkt7nE&md5=b869850a0f306239e13dcc3ae3991cb9</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S144807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S144807%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%2BW.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DR.%2BH.%26aulast%3DYang%26aufirst%3DL.%2BW.%26aulast%3DJames%26aufirst%3DE.%26aulast%3DZhao%26aufirst%3DZ.%2BQ.%26atitle%3DEdaravone%2520inhibits%2520pressure%2520overload-induced%2520cardiac%2520fibrosis%2520and%2520dysfunction%2520by%2520reducing%2520expression%2520of%2520angiotensin%2520II%2520AT1%2520receptor%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D3019%26epage%3D3033%26doi%3D10.2147%2FDDDT.S144807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKallip, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. Q.</span></span> <span> </span><span class="NLM_article-title">Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT<sub>1</sub>/AT<sub>2</sub> receptors and ACE2 in rats</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">6043</span>â <span class="NLM_lpage">6054</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S95333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S95333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26648693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls1Sjtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=6043-6054&author=X.+F.+Pangauthor=L.+H.+Zhangauthor=F.+Baiauthor=N.+P.+Wangauthor=R.+E.+Garnerauthor=R.+J.+McKallipauthor=Z.+Q.+Zhao&title=Attenuation+of+myocardial+fibrosis+with+curcumin+is+mediated+by+modulating+expression+of+angiotensin+II+AT1%2FAT2+receptors+and+ACE2+in+rats&doi=10.2147%2FDDDT.S95333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats</span></div><div class="casAuthors">Pang, Xue-Fen; Zhang, Li-Hui; Bai, Feng; Wang, Ning-Ping; Garner, Ron E.; McKallip, Robert J.; Zhao, Zhi-Qing</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6043-6054</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Curcumin is known to improve cardiac function by balancing degrdn. and synthesis of collagens after myocardial infarction.  This study tested the hypothesis that inhibition of myocardial fibrosis by curcumin is assocd. with modulating expression of angiotensin II (Ang II) receptors and angiotensin-converting enzyme 2 (ACE2).  Male Sprague Dawley rats were subjected to Ang II infusion (500 ng/kg/min) using osmotic minipumps for 2 and 4 wk, resp., and curcumin (150 mg/kg/day) was fed by gastric gavage during Ang II infusion.  Compared to the animals with Ang II infusion, curcumin significantly decreased the mean arterial blood pressure during the course of the observation.  The protein level of the Ang II type 1 (AT1) receptor was reduced, and the Ang II type 2 (AT2) receptor was up-regulated, evidenced by an increased ratio of the AT2 receptor over the AT1 receptor in the curcumin group (1.2Â±0.02%) vs in the Ang II group (0.7Â±0.03%, P<0.05).  These changes were coincident with less locally expressed AT1 receptor and enhanced AT2 receptor in the intracardiac vessels and intermyocardium.  Along with these modulations, curcumin significantly decreased the populations of macrophages and alpha smooth muscle actin-expressing myofibroblasts, which were accompanied by reduced expression of transforming growth factor beta 1 and phosphorylated-Smad2/3.  Collagen I synthesis was inhibited, and tissue fibrosis was attenuated, as demonstrated by less extensive collagen-rich fibrosis.  Furthermore, curcumin increased protein level of ACE2 and enhanced its expression in the intermyocardium relative to the Ang II group.  These results suggest that curcumin could be considered as an add-on therapeutic agent in the treatment of fibrosis-derived heart failure patient who is intolerant of ACE inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhKyEygGyjVLVg90H21EOLACvtfcHk0liJhyxaiZ4EhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls1Sjtr4%253D&md5=87d58358354203eb8ebb40422a86fb5f</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S95333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S95333%26sid%3Dliteratum%253Aachs%26aulast%3DPang%26aufirst%3DX.%2BF.%26aulast%3DZhang%26aufirst%3DL.%2BH.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DN.%2BP.%26aulast%3DGarner%26aufirst%3DR.%2BE.%26aulast%3DMcKallip%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DZ.%2BQ.%26atitle%3DAttenuation%2520of%2520myocardial%2520fibrosis%2520with%2520curcumin%2520is%2520mediated%2520by%2520modulating%2520expression%2520of%2520angiotensin%2520II%2520AT1%252FAT2%2520receptors%2520and%2520ACE2%2520in%2520rats%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D6043%26epage%3D6054%26doi%3D10.2147%2FDDDT.S95333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deguzman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apparsundaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogaboam, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budd, D. C.</span></span> <span> </span><span class="NLM_article-title">Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis in lung fibroblasts and in vivo models of lung fibrosis</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">470</span>â <span class="NLM_lpage">479</span>, <span class="refDoi">Â DOI: 10.1016/j.ajpath.2013.04.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.ajpath.2013.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23759512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFynur7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2013&pages=470-479&author=X.+Tangauthor=R.+Pengauthor=J.+E.+Phillipsauthor=J.+Deguzmanauthor=Y.+Renauthor=S.+Apparsundaramauthor=Q.+Luoauthor=C.+M.+Bauerauthor=M.+E.+Fuentesauthor=J.+A.+DeMartinoauthor=G.+Tyagiauthor=R.+Garridoauthor=C.+M.+Hogaboamauthor=C.+P.+Dentonauthor=A.+M.+Holmesauthor=C.+Kitsonauthor=C.+S.+Stevensonauthor=D.+C.+Budd&title=Assessment+of+Brd4+inhibition+in+idiopathic+pulmonary+fibrosis+in+lung+fibroblasts+and+in+vivo+models+of+lung+fibrosis&doi=10.1016%2Fj.ajpath.2013.04.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Brd4 Inhibition in Idiopathic Pulmonary Fibrosis Lung Fibroblasts and in Vivo Models of Lung Fibrosis</span></div><div class="casAuthors">Tang, Xiaoyan; Peng, Ruoqi; Phillips, Jonathan E.; Deguzman, Jeremy; Ren, Yonglin; Apparsundaram, Subramanium; Luo, Qi; Bauer, Carla M.; Fuentes, Maria E.; DeMartino, Julie A.; Tyagi, Gaurav; Garrido, Rosario; Hogaboam, Cory M.; Denton, Christopher P.; Holmes, Alan M.; Kitson, Christopher; Stevenson, Christopher S.; Budd, David C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">470-479</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of high unmet medical need.  Although bromodomain (Brd) and extra terminal domain isoforms have recently been implicated in mediating inflammatory and oncol. indications, their roles in lung fibrosis have not been comprehensively assessed.  We investigated the role of Brd on the profibrotic responses of lung fibroblasts (LFs) in patients with rapidly progressing IPF and a mouse bleomycin model of lung fibrosis.  The enhanced migration, proliferation, and IL-6 release obsd. in LFs from patients with rapidly progressing IPF are attenuated by pharmacol. inhibition of Brd4.  These changes are accompanied by enhanced histone H4 lysine5 acetylation and assocn. of Brd4 with genes involved in the profibrotic responses in IPF LFs as demonstrated using chromatin immunopptn. and quant. PCR.  Oral administration of 200 mg/kg per day Brd4 inhibitor JQ1 in a therapeutic dosing regimen substantially attenuated lung fibrosis induced by bleomycin in C57BL/6 mice.  In conclusion, this study shows that the Brd4 inhibitor JQ1, administered in a therapeutic dosage, is capable of inhibiting the profibrotic effects of IPF LFs and attenuates bleomycin-induced lung fibrosis in mice.  These results suggest that Brd4 inhibitors may represent a novel therapy for the treatment of rapidly progressing IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeyA6Tfi6PObVg90H21EOLACvtfcHk0liJhyxaiZ4EhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFynur7I&md5=8a7b094630ce44df6cd1b2b9de6cc6ec</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2013.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2013.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DX.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DDeguzman%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DApparsundaram%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DBauer%26aufirst%3DC.%2BM.%26aulast%3DFuentes%26aufirst%3DM.%2BE.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26aulast%3DTyagi%26aufirst%3DG.%26aulast%3DGarrido%26aufirst%3DR.%26aulast%3DHogaboam%26aufirst%3DC.%2BM.%26aulast%3DDenton%26aufirst%3DC.%2BP.%26aulast%3DHolmes%26aufirst%3DA.%2BM.%26aulast%3DKitson%26aufirst%3DC.%26aulast%3DStevenson%26aufirst%3DC.%2BS.%26aulast%3DBudd%26aufirst%3DD.%2BC.%26atitle%3DAssessment%2520of%2520Brd4%2520inhibition%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520in%2520lung%2520fibroblasts%2520and%2520in%2520vivo%2520models%2520of%2520lung%2520fibrosis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2013%26volume%3D183%26spage%3D470%26epage%3D479%26doi%3D10.1016%2Fj.ajpath.2013.04.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tesch, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. J.</span></span> <span> </span><span class="NLM_article-title">Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">313</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28611666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFentbrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=313&author=G.+H.+Teschauthor=M.+J.+Young&title=Mineralocorticoid+receptor+signaling+as+a+therapeutic+target+for+renal+and+cardiac+fibrosis&doi=10.3389%2Ffphar.2017.00313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis</span></div><div class="casAuthors">Tesch, Greg H.; Young, Morag J.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">313/1-313/9</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Activation of the mineralocorticoid receptor (MR) plays important roles in both physiol. and pathol. events.  Blockade of MR signaling with MR antagonists (MRAs) has been used clin. to treat kidney and cardiac disease assocd. with hypertension and other chronic diseases, resulting in suppression of fibrosis in these organs.  However, the current use of steroidal MRAs has been limited by off target effects on other hormone receptors or adverse effects on kidney tubular function.  In this review, we summarize recent insights into the profibrotic roles of MR signaling in kidney and cardiovascular disease.  We review exptl. in vitro data identifying the pathol. mechanisms assocd. with MR signaling in cell types found in the kidney (mesangial cells, podocytes, tubular cells, macrophages, interstitial fibroblasts) and heart (cardiomyocytes, endothelial cells, vascular smooth muscle cells, macrophages).  In addn., we demonstrate the in vivo importance of MR signaling in specific kidney and cardiac cell types by reporting the outcomes of cell type selective MR gene deletion in animal models of kidney and cardiac disease and comparing these findings to those obtained with MRAs treatment.  This review also includes a discussion of the potential benefits of novel non-steroidal MRAs for targeting kidney and cardiac fibrosis compared to existing steroidal MRAs, as well as the possibility of novel combination therapies and cell selective delivery of MRAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIN6hW9Qou5rVg90H21EOLACvtfcHk0lhUIj3gyVSgsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFentbrO&md5=612c08613391192e75b704a32470abe7</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00313%26sid%3Dliteratum%253Aachs%26aulast%3DTesch%26aufirst%3DG.%2BH.%26aulast%3DYoung%26aufirst%3DM.%2BJ.%26atitle%3DMineralocorticoid%2520receptor%2520signaling%2520as%2520a%2520therapeutic%2520target%2520for%2520renal%2520and%2520cardiac%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D313%26doi%3D10.3389%2Ffphar.2017.00313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phosri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arieyawong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunrukchai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parichatikanond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangmool, S.</span></span> <span> </span><span class="NLM_article-title">Stimulation of adenosine A<sub>2B</sub> receptor inhibits endothelin-1-induced cardiac fibroblast proliferation and Î±-smooth muscle actin synthesis through the Camp/Epac/PI3K/Akt signaling pathway</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">428</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28713274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2nsL3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=428&author=S.+Phosriauthor=A.+Arieyawongauthor=K.+Bunrukchaiauthor=W.+Parichatikanondauthor=A.+Nishimuraauthor=M.+Nishidaauthor=S.+Mangmool&title=Stimulation+of+adenosine+A2B+receptor+inhibits+endothelin-1-induced+cardiac+fibroblast+proliferation+and+%CE%B1-smooth+muscle+actin+synthesis+through+the+Camp%2FEpac%2FPI3K%2FAkt+signaling+pathway&doi=10.3389%2Ffphar.2017.00428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of adenosine A2B receptor inhibits endothelin-1-Induced cardiac fibroblast proliferation and Î±-smooth muscle actin synthesis through the cAMP/Epac/PI3K/Akt-signaling pathway</span></div><div class="casAuthors">Phosri, Sarawuth; Arieyawong, Ajaree; Bunrukchai, Kwanchai; Parichatikanond, Warisara; Nishimura, Akiyuki; Nishida, Motohiro; Mangmool, Supachoke</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">428/1-428/15</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Background and Purpose: Cardiac fibrosis is characterized by an increase in fibroblast proliferation, overprodn. of extracellular matrix proteins, and the formation of myofibroblast that express a-smooth muscle actin (Î±-SMA).  Endothelin-1 (ET-1) is involved in the pathogenesis of cardiac fibrosis.  Overstimulation of endothelin receptors induced cell proliferation, collagen synthesis, and Î±-SMA expression in cardiac fibroblasts.  Although adenosine was shown to have cardioprotective effects, the mol. mechanisms by which adenosine A2 receptor inhibit ET-1-induced fibroblast proliferation and Î±-SMA expression in cardiac fibroblasts are not clearly identified.  Exptl. Approach: This study aimed at evaluating the mechanisms of cardioprotective effects of adenosine receptor agonist in rat cardiac fibroblast by measurement of cell proliferation, and mRNA and protein levels of a-SMA.  Key results: Stimulation of adenosine subtype 2B (A2B) receptor resulted in the inhibition of ET-1-induced fibroblast proliferation, and a redn. of ET-1-induced a-SMA expression that is dependent on cAMP/Epac/PI3K/Akt signaling pathways in cardiac fibroblasts.  The data in this study confirm a crit. role for Epac signaling on A2B receptor-mediated inhibition of ET-1-induced cardiac fibrosis via PI3K and Akt activation.  Conclusion and Implications: This is the first work reporting a novel signaling pathway for the inhibition of ET-1-induced cardiac fibrosis mediated through the A2B receptor.  Thus, A2B receptor agonists represent a promising perspective as therapeutic targets for the prevention of cardiac fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrepPFsvzd3trVg90H21EOLACvtfcHk0lhUIj3gyVSgsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2nsL3I&md5=f4a525a71a833f009775a00ef95e80bc</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00428%26sid%3Dliteratum%253Aachs%26aulast%3DPhosri%26aufirst%3DS.%26aulast%3DArieyawong%26aufirst%3DA.%26aulast%3DBunrukchai%26aufirst%3DK.%26aulast%3DParichatikanond%26aufirst%3DW.%26aulast%3DNishimura%26aufirst%3DA.%26aulast%3DNishida%26aufirst%3DM.%26aulast%3DMangmool%26aufirst%3DS.%26atitle%3DStimulation%2520of%2520adenosine%2520A2B%2520receptor%2520inhibits%2520endothelin-1-induced%2520cardiac%2520fibroblast%2520proliferation%2520and%2520%25CE%25B1-smooth%2520muscle%2520actin%2520synthesis%2520through%2520the%2520Camp%252FEpac%252FPI3K%252FAkt%2520signaling%2520pathway%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D428%26doi%3D10.3389%2Ffphar.2017.00428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Schisandrin B atteneuates CCl4-induced liver fibrosis in rats by regulation of Nrf2-ARE and TGF-Î²/Smad signaling pathways</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2179</span>â <span class="NLM_lpage">2191</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S137507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S137507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28794616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1cfmt1aluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=2179-2191&author=Q.+Chenauthor=H.+Zhangauthor=Y.+Caoauthor=Y.+Liauthor=S.+Sunauthor=I.+Zhangauthor=G.+Zhang&title=Schisandrin+B+atteneuates+CCl4-induced+liver+fibrosis+in+rats+by+regulation+of+Nrf2-ARE+and+TGF-%CE%B2%2FSmad+signaling+pathways&doi=10.2147%2FDDDT.S137507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Schisandrin B attenuates CCl4-induced liver fibrosis in rats by regulation of Nrf2-ARE and TGF-Î²/Smad signaling pathways</span></div><div class="casAuthors">Chen Qingshan; Li Ying; Sun Sen; Zhang Guoqing; Zhang Hai; Cao Yan; Zhang Junping</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2179-2191</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Liver fibrosis is a major pathological feature of chronic liver diseases and there is no effective therapy program at present.  Schisandrin B (Sch B) is the major bioactive ingredient of Schisandra chinensis, with antioxidative, anti-inflammatory, antitumor, and hepatoprotective properties.  This study aimed to investigate the protective effect and related molecular mechanism of Sch B against carbon tetrachloride (CCl4)-induced liver fibrosis in rats.  The in vivo therapeutic effect of Sch B on liver fibrosis induced by CCl4 was examined in rats.  In vitro, rat hepatic stellate cells (HSC-T6) were used to assess the effect of Sch B on the activation of HSCs.  Sch B effectively attenuated liver damage and progression of liver fibrosis in rats, as evidenced by improved liver function and decreased collagen deposition.  The effects of Sch B were associated with attenuating oxidative stress by activating nuclear factor-erythroid 2-related factor 2 (Nrf2)-mediated antioxidant signaling and suppressing HSC activation by inhibiting the transforming growth factor-Î² (TGF-Î²)/Smad signaling pathway.  In an in vitro study, it was shown that Sch B inhibited TGF-Î²-induced HSC activation.  Finally, Sch B significantly inhibited TGF-Î²1-stimulated phosphorylation of Smad and signaling of mitogen-activated protein kinases.  This study demonstrates that Sch B prevents the progression of liver fibrosis by the regulation of Nrf2-ARE and TGF-Î²/Smad signaling pathways, and indicates that Sch B can be used for the treatment of liver fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVahJUex_0f8ScOqQTSkOffW6udTcc2eadYvahD-6U_bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfmt1aluw%253D%253D&md5=12677f2fe533b05b1570fad64b1fc1f2</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S137507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S137507%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSchisandrin%2520B%2520atteneuates%2520CCl4-induced%2520liver%2520fibrosis%2520in%2520rats%2520by%2520regulation%2520of%2520Nrf2-ARE%2520and%2520TGF-%25CE%25B2%252FSmad%2520signaling%2520pathways%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D2179%26epage%3D2191%26doi%3D10.2147%2FDDDT.S137507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, L. D.</span></span> <span> </span><span class="NLM_article-title">Astragaloside IV improves bleomycin-induced pulmonary fibrosis in rats by attenuating extracellular matrix deposition</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">513</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28848434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2ns7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=513&author=L.+C.+Liauthor=L.+Xuauthor=Y.+Huauthor=W.+J.+Cuiauthor=W.+H.+Cuiauthor=W.+C.+Zhouauthor=L.+D.+Kan&title=Astragaloside+IV+improves+bleomycin-induced+pulmonary+fibrosis+in+rats+by+attenuating+extracellular+matrix+deposition&doi=10.3389%2Ffphar.2017.00513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Astragaloside IV improves bleomycin-induced pulmonary fibrosis in rats by attenuating extracellular matrix deposition</span></div><div class="casAuthors">Li, Liu-Cheng; Xu, Liang; Hu, Yan; Cui, Wen-Jie; Cui, Wen-Hui; Zhou, Wen-Cheng; Kan, Lian-Di</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">513/1-513/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Pulmonary fibrosis is a devastating lung disorder with mysterious pathogenesis and limited treatment options.  It is well-recognized that the uncontrolled proliferation of lung fibroblasts and differentiation of fibroblasts into myofibroblasts excessively produce extracellular matrix (ECM) proteins which contribute to the fibrosis change of the lungs.  Thus, blocking ECM accumulation would delay fibrosis progression.  In this study, we obsd. the effects of astragaloside IV (ASV) (10 mg/kg/d) on ECM proteins in bleomycin (BLM, 5 mg/kg)-treated rats.  Our results showed that ASV not only ameliorated BLM-induced body wt. loss, lung coeff. increase, histol. changes and collagen secretion, but also reduced the levels of type III collagen (Col-III) in lung homogenate, laminin (LN) and hyaluronic acid (HA) in serum, as well as hydroxyproline (HYP) in lung tissue.  Besides, ASV significantly down-regulated the levels of high-mobility group box1 (HMGB1) in serum and lung tissue, and inhibited the up-regulated expression of Î±-SMA (marker of myofibroblasts) in the lungs.  Taken together, these findings indicate that ASV attenuates BLM-induced ECM deposition, supporting its use as a promising candidate to treat lung fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCoGCZUWiux7Vg90H21EOLACvtfcHk0ljWzUzc3pvE0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2ns7nI&md5=f420d79e2304bde70029d6ca0584ea8c</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00513%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%2BC.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DW.%2BJ.%26aulast%3DCui%26aufirst%3DW.%2BH.%26aulast%3DZhou%26aufirst%3DW.%2BC.%26aulast%3DKan%26aufirst%3DL.%2BD.%26atitle%3DAstragaloside%2520IV%2520improves%2520bleomycin-induced%2520pulmonary%2520fibrosis%2520in%2520rats%2520by%2520attenuating%2520extracellular%2520matrix%2520deposition%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D513%26doi%3D10.3389%2Ffphar.2017.00513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span> <span> </span><span class="NLM_article-title">Effect of echinacoside on kidney fibrosis by inhibition of TGFÎ²1/Smads signaling pathway in the db/db mice model of diabetic nephropathy</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2813</span>â <span class="NLM_lpage">2826</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S143805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S143805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29033543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1M7gvVCruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=2813-2826&author=F.+Tangauthor=Y.+Haoauthor=X.+Zhangauthor=J.+Qin&title=Effect+of+echinacoside+on+kidney+fibrosis+by+inhibition+of+TGF%CE%B21%2FSmads+signaling+pathway+in+the+db%2Fdb+mice+model+of+diabetic+nephropathy&doi=10.2147%2FDDDT.S143805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of echinacoside on kidney fibrosis by inhibition of TGF-Î²1/Smads signaling pathway in the db/db mice model of diabetic nephropathy</span></div><div class="casAuthors">Tang Fengjuan; Hao Yarong; Zhang Xue; Qin Jian</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2813-2826</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Kidney fibrosis and renal tubular epithelial-to-mesenchymal transition (EMT) are the main pathological changes of diabetic nephropathy (DN), which eventually leads to end-stage renal disease.  Previous studies have suggested that echinacoside (ECH) is antifibrotic in the liver.  However, the effect of ECH on kidney fibrosis in DN and its mechanisms are unknown.  This study was performed to explore the effect of ECH on kidney fibrosis and also the molecular mechanisms of ECH in a db/db mice model of DN.  Our results showed that, relative to db/db mice, the mice in the ECH group had an improved general state and reduced blood glucose and 24-hour urinary protein levels.  The deterioration of renal function was delayed due to treatment with ECH.  We also observed that ECH can improve histopathological findings in the kidneys of db/db mice, including collagen deposition, mesangial cell and mesangial matrix hyperplasia, basement membrane thickening, and podocyte reduction.  Moreover, ECH inhibited the TGF-Î²1/Smads signaling pathway, downregulated fibronectin (FN), collagen IV, and alpha-smooth muscle actin (Î±-SMA) levels, and upregulated E-cadherin level in the db/db mice model of DN.  Our findings indicate that ECH has a therapeutic effect on DN, including the inhibition of renal tubular EMT and kidney fibrosis.  Furthermore, ECH inhibits kidney fibrosis through regulation of the TGF-Î²1/Smads signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8dgSWTE02UJagfuraLLzSfW6udTcc2eaZLHrTHYVBnrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7gvVCruw%253D%253D&md5=ef72ed99d7e258df9bc11c82a3a18b29</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S143805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S143805%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DF.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DQin%26aufirst%3DJ.%26atitle%3DEffect%2520of%2520echinacoside%2520on%2520kidney%2520fibrosis%2520by%2520inhibition%2520of%2520TGF%25CE%25B21%252FSmads%2520signaling%2520pathway%2520in%2520the%2520db%252Fdb%2520mice%2520model%2520of%2520diabetic%2520nephropathy%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D2813%26epage%3D2826%26doi%3D10.2147%2FDDDT.S143805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, S. K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauersachs, J.</span></span> <span> </span><span class="NLM_article-title">Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction</span>. <i>Basic Res. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">485</span>â <span class="NLM_lpage">492</span>, <span class="refDoi">Â DOI: 10.1007/s00395-008-0739-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1007%2Fs00395-008-0739-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18651091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOgu7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2008&pages=485-492&author=S.+Frantzauthor=K.+Huauthor=A.+Adamekauthor=J.+Wolfauthor=A.+Sallamauthor=S.+K.+G.+Maierauthor=S.+Lonningauthor=H.+Lingauthor=G.+Ertlauthor=J.+Bauersachs&title=Transforming+growth+factor+beta+inhibition+increases+mortality+and+left+ventricular+dilatation+after+myocardial+infarction&doi=10.1007%2Fs00395-008-0739-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction</span></div><div class="casAuthors">Frantz, Stefan; Hu, Kai; Adamek, Anna; Wolf, Juergen; Sallam, Abed; Maier, Sebastian K. G.; Lonning, Scott; Ling, Hong; Ertl, Georg; Bauersachs, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Basic Research in Cardiology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-492</span>CODEN:
                <span class="NLM_cas:coden">BRCAB7</span>;
        ISSN:<span class="NLM_cas:issn">0300-8428</span>.
    
            (<span class="NLM_cas:orgname">Steinkopff Verlag</span>)
        </div><div class="casAbstract">Transforming growth factor (TGF)-Î² is a locally generated cytokine involved in healing processes and tissue fibrosis, all relevant for cardiac remodeling and the development of heart failure after myocardial infarction (MI).  However, data regarding the function of TGF-Î² after ischemic injury are inconclusive.  We tested the effect of TGF-Î² inhibition by application of a blocking antibody in mice with MI.  Starting 1 wk before or 5 days after coronary artery ligation mice were treated with i.p. injections of an anti-TGF-Î² (5 mg/kg bodyweight 1D11, Genzyme) or control antibody.  Mortality over 8 wk was significantly higher in the groups treated with the anti-TGF-Î² antibody.  Both, pre or post MI treatments were assocd. with increased left ventricular dilatation after MI as detd. by serial echocardiog.  In anti-TGF-Î² treated mice collagen prodn. decreased and matrix-metalloproteinase expression increased.  However, the expression of TGF pro-inflammatory cytokine TNF-Î± was not altered by the treatment.  Anti-TGF-Î² treatment before or after coronary artery ligation increases mortality and worsens left ventricular remodeling in mice with non-reperfused MI.  The detrimental effects of TGF-Î² inhibition may be mediated by alterations in extracellular matrix remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4J94onD-yV7Vg90H21EOLACvtfcHk0ljWzUzc3pvE0w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOgu7jM&md5=d010e346d1b277d104fa0daa0cb06026</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1007%2Fs00395-008-0739-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00395-008-0739-7%26sid%3Dliteratum%253Aachs%26aulast%3DFrantz%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DAdamek%26aufirst%3DA.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DSallam%26aufirst%3DA.%26aulast%3DMaier%26aufirst%3DS.%2BK.%2BG.%26aulast%3DLonning%26aufirst%3DS.%26aulast%3DLing%26aufirst%3DH.%26aulast%3DErtl%26aufirst%3DG.%26aulast%3DBauersachs%26aufirst%3DJ.%26atitle%3DTransforming%2520growth%2520factor%2520beta%2520inhibition%2520increases%2520mortality%2520and%2520left%2520ventricular%2520dilatation%2520after%2520myocardial%2520infarction%26jtitle%3DBasic%2520Res.%2520Cardiol.%26date%3D2008%26volume%3D103%26spage%3D485%26epage%3D492%26doi%3D10.1007%2Fs00395-008-0739-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engebretsen, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SkÃ¥rdal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BjÃ¸rnstad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marstein, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrbic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjaastad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BjÃ¸rnstad, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TÃ¸nnessen, T.</span></span> <span> </span><span class="NLM_article-title">Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">148</span>â <span class="NLM_lpage">157</span>, <span class="refDoi">Â DOI: 10.1016/j.yjmcc.2014.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.yjmcc.2014.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25169971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOhsbzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2014&pages=148-157&author=K.+V.+Engebretsenauthor=K.+Sk%C3%A5rdalauthor=S.+Bj%C3%B8rnstadauthor=H.+S.+Marsteinauthor=B.+Skrbicauthor=I.+Sjaastadauthor=G.+Christensenauthor=J.+J.+Bj%C3%B8rnstadauthor=T.+T%C3%B8nnessen&title=Attenuated+development+of+cardiac+fibrosis+in+left+ventricular+pressure+overload+by+SM16%2C+an+orally+active+inhibitor+of+ALK5&doi=10.1016%2Fj.yjmcc.2014.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5</span></div><div class="casAuthors">Engebretsen, Kristin V. T.; Skaardal, Kristine; Bjoernstad, Sigrid; Marstein, Henriette S.; Skrbic, Biljana; Sjaastad, Ivar; Christensen, Geir; Bjoernstad, Johannes L.; Toennessen, Theis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">148-157</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Pressure overload-induced TGF-Î² signaling activates cardiac fibroblasts (CFB) and leads to increased extracellular matrix (ECM) protein synthesis including fibrosis.  Excessive ECM accumulation may in turn affect cardiac function contributing to development of heart failure.  The aim of this study was to examine the effects of SM16, an orally active small mol. inhibitor of ALK5, on pressure overload-induced cardiac fibrosis.  One week after aortic banding (AB), C57Bl/6J mice were randomized to std. chow or chow with SM16.  Sham operated animals served as controls.  Following 4 wk AB, mice were characterized by echocardiog. and cardiovascular magnetic resonance before sacrifice.  SM16 abolished phosphorylation of SMAD2 induced by AB in vivo and by TGF-Î² in CFB in vitro.  Interestingly, Masson Trichrome and Picrosirius Red stained myocardial left ventricular tissue revealed reduced development of fibrosis and collagen crosslinking following AB in the SM16 treated group, which was confirmed by reduced hydroxyproline incorporation.  Furthermore, treatment with SM16 attenuated mRNA expression following induction of AB in vivo and stimulation with TGF-Î² in CFB in vitro of Col1a2, the crosslinking enzyme LOX, and the pro-fibrotic glycoproteins SPARC and osteopontin.  Reduced ECM synthesis by CFB and a redn. in myocardial stiffness due to attenuated development of fibrosis and collagen crosslinking might have contributed to the improved diastolic function and cardiac output seen in vivo, in combination with reduced lung wt. and ANP expression by treatment with SM16.  Despite these beneficial effects on cardiac function and development of heart failure, mice treated with SM16 exhibited increased mortality, increased LV dilatation and inflammatory heart valve lesions that may limit the use of SM16 and possibly also other small mol. inhibitors of ALK5, as future therapeutic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMNwlO3Nci2LVg90H21EOLACvtfcHk0lhpT3p5OzIXcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOhsbzK&md5=8b1362da806694f28ca846437ba1b1b8</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2014.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2014.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DEngebretsen%26aufirst%3DK.%2BV.%26aulast%3DSk%25C3%25A5rdal%26aufirst%3DK.%26aulast%3DBj%25C3%25B8rnstad%26aufirst%3DS.%26aulast%3DMarstein%26aufirst%3DH.%2BS.%26aulast%3DSkrbic%26aufirst%3DB.%26aulast%3DSjaastad%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DG.%26aulast%3DBj%25C3%25B8rnstad%26aufirst%3DJ.%2BJ.%26aulast%3DT%25C3%25B8nnessen%26aufirst%3DT.%26atitle%3DAttenuated%2520development%2520of%2520cardiac%2520fibrosis%2520in%2520left%2520ventricular%2520pressure%2520overload%2520by%2520SM16%252C%2520an%2520orally%2520active%2520inhibitor%2520of%2520ALK5%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2014%26volume%3D76%26spage%3D148%26epage%3D157%26doi%3D10.1016%2Fj.yjmcc.2014.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, S.</span></span> <span> </span><span class="NLM_article-title">Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits?</span>. <i>Curr. Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">255</span>â <span class="NLM_lpage">263</span>, <span class="refDoi">Â DOI: 10.2174/1874467211205020255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2174%2F1874467211205020255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22122455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVeqsLzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=255-263&author=S.+Sarma&title=Use+of+clinically+available+PPAR+agonists+for+heart+failure%3B+do+the+risks+outweigh+the+potential+benefits%3F&doi=10.2174%2F1874467211205020255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits?</span></div><div class="casAuthors">Sarma, Satyam</div><div class="citationInfo"><span class="NLM_cas:title">Current Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255-263</span>CODEN:
                <span class="NLM_cas:coden">CMPUB6</span>;
        ISSN:<span class="NLM_cas:issn">1874-4672</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  PPAR agonists represent a heterogeneous group of compds. that were used in the treatment of cardiovascular and metabolic diseases for over thirty years.  While the primary indications for PPAR agonist therapy focus on hyperlipidemia and diabetes, there is a growing body of pre-clin. data that suggests they may be beneficial in the treatment of heart failure; a disease marked by abnormal myocardial metab., fibrosis and insulin insensitivity.  PPAR agonist treatment in numerous animal models of systolic heart failure have demonstrated improvement in cardiac function with decreased fibrosis, improved contractility and endothelial function.  However, considerable controversy exists on the cardiac safety profile of PPAR agonists, particularly concern for inducing lipotoxicity and pptg. or worsening heart failure.  In addn. during pre-clin. testing, many compds. have been assocd. with increased death and adverse cardiovascular outcomes casting a pall over their future use for treating disorders of myocardial function.  This article will review cardiac pathways involved in PPAR activation and their potential regulation of maladaptive pathways involved in heart failure and highlight mol. mechanisms that may contribute to adverse events and raise safety concerns.  Specific attention will be focused on PPAR alpha and gamma, subtypes for which com. available PPAR agonists are currently available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoAtL0tkza-7Vg90H21EOLACvtfcHk0lhpT3p5OzIXcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVeqsLzL&md5=ac89552ac28bbe582b34285357a0fb43</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.2174%2F1874467211205020255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874467211205020255%26sid%3Dliteratum%253Aachs%26aulast%3DSarma%26aufirst%3DS.%26atitle%3DUse%2520of%2520clinically%2520available%2520PPAR%2520agonists%2520for%2520heart%2520failure%253B%2520do%2520the%2520risks%2520outweigh%2520the%2520potential%2520benefits%253F%26jtitle%3DCurr.%2520Mol.%2520Pharmacol.%26date%3D2012%26volume%3D5%26spage%3D255%26epage%3D263%26doi%3D10.2174%2F1874467211205020255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poelstra, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beljaars, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melgert, B. N.</span></span> <span> </span><span class="NLM_article-title">Cell-specific delivery of biologicals; problems, pitfals and possibilities of antifibrotic compounds in the liver</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1237</span>â <span class="NLM_lpage">1242</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2013.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.drudis.2013.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23732178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslGjsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=1237-1242&author=K.+Poelstraauthor=L.+Beljaarsauthor=B.+N.+Melgert&title=Cell-specific+delivery+of+biologicals%3B+problems%2C+pitfals+and+possibilities+of+antifibrotic+compounds+in+the+liver&doi=10.1016%2Fj.drudis.2013.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-specific delivery of biologicals: problems, pitfalls and possibilities of antifibrotic compounds in the liver</span></div><div class="casAuthors">Poelstra, Klaas; Beljaars, Leonie; Melgert, Barbro N.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">1237-1242</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Liver fibrosis is a complex disease affecting millions of people world-wide.  It involves the activation of several cell types whose activities are tightly controlled by endogenous mediators.  No pharmacotherapy is available for this disease, despite the fact that many exptl. drugs are very effective in vitro and the liver is easily accessible for most drugs.  Our review provides arguments showing that cell-selectivity is essential for most antifibrotics.  Several cell-specific drug carriers targeting the key pathogenic liver cells are discussed with special focus on hepatic stellate cells and fibroblast-like cells.  Since endogenous mediators represent a powerful set of tools to modify the pathogenic process, this review focuses on these mediators as therapeutics and the problems and pitfalls assocd. with the use of such biologicals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6U6QdUnfw6LVg90H21EOLACvtfcHk0lhpT3p5OzIXcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslGjsro%253D&md5=483b1ffdb897c6e9aebe213233aee286</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DPoelstra%26aufirst%3DK.%26aulast%3DBeljaars%26aufirst%3DL.%26aulast%3DMelgert%26aufirst%3DB.%2BN.%26atitle%3DCell-specific%2520delivery%2520of%2520biologicals%253B%2520problems%252C%2520pitfals%2520and%2520possibilities%2520of%2520antifibrotic%2520compounds%2520in%2520the%2520liver%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D1237%26epage%3D1242%26doi%3D10.1016%2Fj.drudis.2013.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, j. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span> <span> </span><span class="NLM_article-title">Targeted gamma-secretase inhibition of Notch signaling activation in acute renal injury</span>. <i>Am. J. Physiol., Renal Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">F736</span>â <span class="NLM_lpage">F746</span>, <span class="refDoi">Â DOI: 10.1152/ajprenal.00414.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1152%2Fajprenal.00414.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28971991" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2018&pages=F736-F746&author=J.+C.+Wyssauthor=R.+Kumarauthor=J.+Mikulicauthor=M.+Schneiderauthor=j.+D.+Aebiauthor=L.+Juillerat-Jeanneretauthor=D.+Golshayan&title=Targeted+gamma-secretase+inhibition+of+Notch+signaling+activation+in+acute+renal+injury&doi=10.1152%2Fajprenal.00414.2016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.00414.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.00414.2016%26sid%3Dliteratum%253Aachs%26aulast%3DWyss%26aufirst%3DJ.%2BC.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DMikulic%26aufirst%3DJ.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DAebi%26aufirst%3Dj.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DGolshayan%26aufirst%3DD.%26atitle%3DTargeted%2520gamma-secretase%2520inhibition%2520of%2520Notch%2520signaling%2520activation%2520in%2520acute%2520renal%2520injury%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Renal%2520Physiol.%26date%3D2018%26volume%3D314%26spage%3DF736%26epage%3DF746%26doi%3D10.1152%2Fajprenal.00414.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span> <span> </span><span class="NLM_article-title">Spermidine-mediated poly(laxtic-co-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">6687</span>â <span class="NLM_lpage">6704</span>, <span class="refDoi">Â DOI: 10.2147/IJN.S140569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FIJN.S140569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28932114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2gtrzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=6687-6704&author=J.+Tangauthor=J.+Liauthor=G.+Liauthor=H.+Zhangauthor=L.+Wangauthor=D.+Liauthor=J.+Ding&title=Spermidine-mediated+poly%28laxtic-co-glycolic+acid%29+nanoparticles+containing+fluorofenidone+for+the+treatment+of+idiopathic+pulmonary+fibrosis&doi=10.2147%2FIJN.S140569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Spermidine-mediated poly(lactic-co-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Tang, Jing; Li, Jianming; Li, Guo; Zhang, Haitao; Wang, Ling; Li, Dai; Ding, Jinsong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6687/1-6687/18</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive, fatal lung disease with poor survival.  The advances made in deciphering this disease have led to the approval of different antifibrotic mols., such as pirfenidone and nintedanib.  An increasing no. of studies with particles (liposomes, nanoparticles [NPs], microspheres, nanopolymersomes, and nanoliposomes) modified with different functional groups have demonstrated improvement in lung-targeted drug delivery.  In the present study, we prepd., characterized, and evaluated spermidine (Spd)-modified poly(lactic-co-glycolic acid) (PLGA) NPs as carriers for fluorofenidone (AKF) to improve the antifibrotic efficacy of this drug in the lung.  Spd-AKF-PLGA NPs were prepd. and functionalized by modified solvent evapn. with Spd and polyethylene glycol (PEG)-PLGA groups.  The size of Spd-AKF-PLGA NPs was 172.5 Â± 4.3 nm.  AKF release from NPs was shown to fit the Higuchi model.  A549 cellular uptake of an Spd-coumarin (Cou)-6-PLGA NP group was found to be almost twice as high as that of the Cou-6-PLGA NP group.  Free Spd and difluoromethylornithine (DFMO) were preincubated in A549 cells to prove uptake of Spd-Cou-6-PLGA NPs via a polyamine-transport system.  As a result, the uptake of Spd-Cou-6-PLGA NPs significantly decreased with increased Spd concns. in incubation.  At higher Spd concns. of 50 and 500 Î¼M, uptake of Spd-Cou-6-PLGA NPs reduced 0.34- and 0.49-fold from that without Spd pretreatment.  After pretreatment with DFMO for 36 h, cellular uptake of Spd-Cou-6-PLGA NPs reached 1.26-fold compared to the untreated DFMO group.  In a biodistribution study, the drug-targeting index of Spd-AKF-PLGA NPs in the lung was 3.62- and 4.66-fold that of AKF-PLGA NPs and AKF soln., resp.  This suggested that Spd-AKF-PLGA NPs accumulated effectively in the lung.  Lung-histopathol. changes and collagen deposition were obsd. by H&E staining and Masson staining in an efficacy study.  In the Spd-AKF-PLGA NP group, damage was further improved compared to the AKF-PLGA NP group and AKF-soln. group.  The results indicated that Spd-AKF-PLGA NPs are able to be effective nanocarriers for anti-pulmonary fibrosis therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP5HsGu54A3LVg90H21EOLACvtfcHk0lg1066ohlKjbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2gtrzF&md5=68cb89c65f5557a2cffe6fa28a8a5e3e</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.2147%2FIJN.S140569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S140569%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DJ.%26atitle%3DSpermidine-mediated%2520poly%2528laxtic-co-glycolic%2520acid%2529%2520nanoparticles%2520containing%2520fluorofenidone%2520for%2520the%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2017%26volume%3D12%26spage%3D6687%26epage%3D6704%26doi%3D10.2147%2FIJN.S140569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Nicholas G. Welch, Shayanti Mukherjee, Mohammed A. Hossain, Praveen Praveen, Jerome A. Werkmeister, John D. Wade, Ross A. D. Bathgate, David A. Winkler, <span class="NLM_string-name hlFld-ContribAuthor">Helmut Thissen</span>. </span><span class="cited-content_cbyCitation_article-title">Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Materials & Interfaces</span><span> <strong>2019,</strong> <em>11 </em>
                                    (49)
                                     , 45511-45519. <a href="https://doi.org/10.1021/acsami.9b17859" title="DOI URL">https://doi.org/10.1021/acsami.9b17859</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsami.9b17859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsami.9b17859%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Materials%2520%2526%2520Interfaces%26atitle%3DCoatings%252BReleasing%252Bthe%252BRelaxin%252BPeptide%252BAnalogue%252BB7-33%252BReduce%252BFibrotic%252BEncapsulation%26aulast%3DWelch%26aufirst%3DNicholas%2BG.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D01102019%26date%3D12112019%26date%3D02122019%26date%3D12112019%26volume%3D11%26issue%3D49%26spage%3D45511%26epage%3D45519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramya  Ramadoss</span>, <span class="hlFld-ContribAuthor ">Rajkumar  Krishnan</span>, <span class="hlFld-ContribAuthor ">V  Vasanthi</span>, <span class="hlFld-ContribAuthor ">Divya  Bose</span>, <span class="hlFld-ContribAuthor ">R  Vijayalakshmi</span>, <span class="hlFld-ContribAuthor ">Rajashree  Padmanabhan</span>, <span class="hlFld-ContribAuthor ">Balakumar  Subramanian</span>. </span><span class="cited-content_cbyCitation_article-title">New insights for consummate diagnosis and management of oral submucous fibrosis using reactive and reparative fibrotic parameter derived algorithm. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacy And Bioallied Sciences</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 323. <a href="https://doi.org/10.4103/jpbs.JPBS_822_20" title="DOI URL">https://doi.org/10.4103/jpbs.JPBS_822_20</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4103/jpbs.JPBS_822_20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4103%2Fjpbs.JPBS_822_20%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacy%2520And%2520Bioallied%2520Sciences%26atitle%3DNew%252Binsights%252Bfor%252Bconsummate%252Bdiagnosis%252Band%252Bmanagement%252Bof%252Boral%252Bsubmucous%252Bfibrosis%252Busing%252Breactive%252Band%252Breparative%252Bfibrotic%252Bparameter%252Bderived%252Balgorithm%26aulast%3DRamadoss%26aufirst%3DRamya%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas G.  Welch</span>, <span class="hlFld-ContribAuthor ">David A.  Winkler</span>, <span class="hlFld-ContribAuthor ">Helmut  Thissen</span>. </span><span class="cited-content_cbyCitation_article-title">Antifibrotic strategies for medical devices. </span><span class="cited-content_cbyCitation_journal-name">Advanced Drug Delivery Reviews</span><span> <strong>2020,</strong> <em>167 </em>, 109-120. <a href="https://doi.org/10.1016/j.addr.2020.06.008" title="DOI URL">https://doi.org/10.1016/j.addr.2020.06.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.addr.2020.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.addr.2020.06.008%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Drug%2520Delivery%2520Reviews%26atitle%3DAntifibrotic%252Bstrategies%252Bfor%252Bmedical%252Bdevices%26aulast%3DWelch%26aufirst%3DNicholas%2BG.%26date%3D2020%26volume%3D167%26spage%3D109%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Youke  Wang</span>, <span class="hlFld-ContribAuthor ">Yuting  Wang</span>, <span class="hlFld-ContribAuthor ">Fengming  You</span>, <span class="hlFld-ContribAuthor ">Jianxin  Xue</span>. </span><span class="cited-content_cbyCitation_article-title">Novel use for old drugs: The emerging role of artemisinin and its derivatives in fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2020,</strong> <em>157 </em>, 104829. <a href="https://doi.org/10.1016/j.phrs.2020.104829" title="DOI URL">https://doi.org/10.1016/j.phrs.2020.104829</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2020.104829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2020.104829%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DNovel%252Buse%252Bfor%252Bold%252Bdrugs%25253A%252BThe%252Bemerging%252Brole%252Bof%252Bartemisinin%252Band%252Bits%252Bderivatives%252Bin%252Bfibrosis%26aulast%3DWang%26aufirst%3DYouke%26date%3D2020%26volume%3D157%26spage%3D104829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nan  Jiang</span>, <span class="hlFld-ContribAuthor ">Yuhong  Zhou</span>, <span class="hlFld-ContribAuthor ">Minglin  Zhu</span>, <span class="hlFld-ContribAuthor ">Junlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Meng  Cao</span>, <span class="hlFld-ContribAuthor ">Hongrui  Lei</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Guangyue  Su</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>187 </em>, 111904. <a href="https://doi.org/10.1016/j.ejmech.2019.111904" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111904%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Band%252Bevaluation%252Bof%252Bnovel%252Btetrahydropyrido%25255B4%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252BATX%252Binhibitors%252Bfor%252Bcardiac%252Band%252Bhepatic%252Bfibrosis%26aulast%3DJiang%26aufirst%3DNan%26date%3D2020%26volume%3D187%26spage%3D111904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dexin  Deng</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Tingxuan  Lan</span>, <span class="hlFld-ContribAuthor ">Jiali  Zhu</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Linlin  Xue</span>, <span class="hlFld-ContribAuthor ">Zhuang  Yang</span>, <span class="hlFld-ContribAuthor ">Shoujun  Zheng</span>, <span class="hlFld-ContribAuthor ">Haoyu  Ye</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>185 </em>, 111790. <a href="https://doi.org/10.1016/j.ejmech.2019.111790" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111790%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bdiscovery%252Bof%252Bnew%252Bcompounds%252Bbearing%252Bcoumarin%252Bscaffold%252Bfor%252Bthe%252Btreatment%252Bof%252Bpulmonary%252Bfibrosis%26aulast%3DDeng%26aufirst%3DDexin%26date%3D2020%26volume%3D185%26spage%3D111790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashish  Dhayani</span>, <span class="hlFld-ContribAuthor ">Sanjeeb  Kalita</span>, <span class="hlFld-ContribAuthor ">Manohar  Mahato</span>, <span class="hlFld-ContribAuthor ">Preethem  Srinath</span>, <span class="hlFld-ContribAuthor ">Praveen K  Vemula</span>. </span><span class="cited-content_cbyCitation_article-title">Biomaterials for topical and transdermal drug delivery in reconstructive transplantation. </span><span class="cited-content_cbyCitation_journal-name">Nanomedicine</span><span> <strong>2019,</strong> <em>14 </em>
                                    (20)
                                     , 2713-2733. <a href="https://doi.org/10.2217/nnm-2019-0137" title="DOI URL">https://doi.org/10.2217/nnm-2019-0137</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/nnm-2019-0137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Fnnm-2019-0137%26sid%3Dliteratum%253Aachs%26jtitle%3DNanomedicine%26atitle%3DBiomaterials%252Bfor%252Btopical%252Band%252Btransdermal%252Bdrug%252Bdelivery%252Bin%252Breconstructive%252Btransplantation%26aulast%3DDhayani%26aufirst%3DAshish%26date%3D2019%26volume%3D14%26issue%3D20%26spage%3D2713%26epage%3D2733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Implant-induced fibrosis. Three-dimensional culture in collagen gels of human fibroblasts with a surgical mesh. (left) At the initiation of the culture no ECM layer could be detected. (right) After 2 weeks of culture, the fibroblasts adhered to the mesh and secreted a thick ECM layer (brown layer tightly surrounding the mesh).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0017.jpeg" id="rightTab-GRAPHIC-d7e926-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Schematic Representation of Cellular Pathways Mediating Fibrosis</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Examples of inhibitors of the TGF-Î² signaling pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Examples of inhibitors of the immune/inflammatory stress.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Examples of modulators of the sphingosine pathway.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Examples of inhibitors of the angiotensin pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Examples of inhibitors of ET-1 receptors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Examples of protease inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Examples of LOX and LOXL inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Examples of kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0010.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Examples of inhibitors of cell signaling pathways.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0011.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Examples of inhibitors of oxidative stress.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0012.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Examples of FXR and PPAR-Î³ modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0013.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Inhibitors of fatty acid synthesis and phosphodiesterases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0014.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Examples of various pathways modulators of potential interest in fibrosis treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0015.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Examples of natural products of potential interest in fibrosis treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/medium/jm-2018-00294e_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0016.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Examples of small molecules of potential interest in regenerative cell therapy for fibrosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b00294/20181119/images/large/jm-2018-00294e_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00294&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85565" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85565" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 196 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jun, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, L. F.</span></span> <span> </span><span class="NLM_article-title">Resolution of organ fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">97</span>â <span class="NLM_lpage">107</span>, <span class="refDoi">Â DOI: 10.1172/JCI93563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29293097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1Mzms1OitQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=97-107&author=J.+I.+Junauthor=L.+F.+Lau&title=Resolution+of+organ+fibrosis&doi=10.1172%2FJCI93563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Resolution of organ fibrosis</span></div><div class="casAuthors">Jun Joon-Il; Lau Lester F</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-107</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fibrosis is the excessive accumulation of extracellular matrix that often occurs as a wound healing response to repeated or chronic tissue injury, and may lead to the disruption of organ architecture and loss of function.  Although fibrosis was previously thought to be irreversible, recent evidence indicates that certain circumstances permit the resolution of fibrosis when the underlying causes of injury are eradicated.  The mechanism of fibrosis resolution encompasses degradation of the fibrotic extracellular matrix as well as elimination of fibrogenic myofibroblasts through their adaptation of various cell fates, including apoptosis, senescence, dedifferentiation, and reprogramming.  In this Review, we discuss the present knowledge and gaps in our understanding of how matrix degradation is regulated and how myofibroblast cell fates can be manipulated, areas that may identify potential therapeutic approaches for fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTs93SFSBVYoK91pGlMMoT5fW6udTcc2eY3JzfqpG1zabntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mzms1OitQ%253D%253D&md5=6334bc508b9ac4c632e9ba99bed851c9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1172%2FJCI93563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93563%26sid%3Dliteratum%253Aachs%26aulast%3DJun%26aufirst%3DJ.%2BI.%26aulast%3DLau%26aufirst%3DL.%2BF.%26atitle%3DResolution%2520of%2520organ%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D97%26epage%3D107%26doi%3D10.1172%2FJCI93563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span> <span> </span><span class="NLM_article-title">Extracellular matrix as a driver of progressive fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">45</span>â <span class="NLM_lpage">53</span>, <span class="refDoi">Â DOI: 10.1172/JCI93557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93557" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=45-53&author=J.+Herreraauthor=C.+A.+Henkeauthor=P.+B.+Bitterman&title=Extracellular+matrix+as+a+driver+of+progressive+fibrosis&doi=10.1172%2FJCI93557"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1172%2FJCI93557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93557%26sid%3Dliteratum%253Aachs%26aulast%3DHerrera%26aufirst%3DJ.%26aulast%3DHenke%26aufirst%3DC.%2BA.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26atitle%3DExtracellular%2520matrix%2520as%2520a%2520driver%2520of%2520progressive%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D45%26epage%3D53%26doi%3D10.1172%2FJCI93557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karsdal, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sand, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henriksen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bay-Jensen, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamkewicz, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeming, D. J.</span></span> <span> </span><span class="NLM_article-title">Extracellular remodeling: the common denominator in connective tissue diseases</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">70</span>â <span class="NLM_lpage">92</span>, <span class="refDoi">Â DOI: 10.1089/adt.2012.474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1089%2Fadt.2012.474" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=70-92&author=M.+A.+Karsdalauthor=M.+J.+Nielsenauthor=J.+N.+Sandauthor=K.+Henriksenauthor=F.+Genoveseauthor=A.+C.+Bay-Jensenauthor=V.+Smithauthor=J.+I.+Adamkewiczauthor=C.+Christiansenauthor=D.+J.+Leeming&title=Extracellular+remodeling%3A+the+common+denominator+in+connective+tissue+diseases&doi=10.1089%2Fadt.2012.474"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1089%2Fadt.2012.474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2012.474%26sid%3Dliteratum%253Aachs%26aulast%3DKarsdal%26aufirst%3DM.%2BA.%26aulast%3DNielsen%26aufirst%3DM.%2BJ.%26aulast%3DSand%26aufirst%3DJ.%2BN.%26aulast%3DHenriksen%26aufirst%3DK.%26aulast%3DGenovese%26aufirst%3DF.%26aulast%3DBay-Jensen%26aufirst%3DA.%2BC.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DAdamkewicz%26aufirst%3DJ.%2BI.%26aulast%3DChristiansen%26aufirst%3DC.%26aulast%3DLeeming%26aufirst%3DD.%2BJ.%26atitle%3DExtracellular%2520remodeling%253A%2520the%2520common%2520denominator%2520in%2520connective%2520tissue%2520diseases%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2013%26volume%3D11%26spage%3D70%26epage%3D92%26doi%3D10.1089%2Fadt.2012.474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tschumperlin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilscher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, V. H.</span></span> <span> </span><span class="NLM_article-title">Mechanosensing and fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">74</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1172/JCI93561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93561" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=74-84&author=D.+J.+Tschumperlinauthor=G.+Ligrestiauthor=M.+B.+Hilscherauthor=V.+H.+Shah&title=Mechanosensing+and+fibrosis&doi=10.1172%2FJCI93561"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1172%2FJCI93561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93561%26sid%3Dliteratum%253Aachs%26aulast%3DTschumperlin%26aufirst%3DD.%2BJ.%26aulast%3DLigresti%26aufirst%3DG.%26aulast%3DHilscher%26aufirst%3DM.%2BB.%26aulast%3DShah%26aufirst%3DV.%2BH.%26atitle%3DMechanosensing%2520and%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D74%26epage%3D84%26doi%3D10.1172%2FJCI93561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, T. A.</span></span> <span> </span><span class="NLM_article-title">Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">524</span>â <span class="NLM_lpage">529</span>, <span class="refDoi">Â DOI: 10.1172/JCI31487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI31487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17332879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12hsbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=524-529&author=T.+A.+Wynn&title=Common+and+unique+mechanisms+regulate+fibrosis+in+various+fibroproliferative+diseases&doi=10.1172%2FJCI31487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases</span></div><div class="casAuthors">Wynn, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">524-529</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Fibroproliferative diseases, including the pulmonary fibroses, systemic sclerosis, liver cirrhosis, cardiovascular disease, progressive kidney disease, and macular degeneration, are a leading cause of morbidity and mortality and can affect all tissues and organ systems.  Fibrotic tissue remodeling can also influence cancer metastasis and accelerate chronic graft rejection in transplant recipients.  Nevertheless, despite its enormous impact on human health, there are currently no approved treatments that directly target the mechanism(s) of fibrosis.  The primary goals of this Review series on fibrotic diseases are to discuss some of the major fibroproliferative diseases and to identify the common and unique mechanisms of fibrogenesis that might be exploited in the development of effective antifibrotic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiqNOvOKpFz7Vg90H21EOLACvtfcHk0ljXJUNK1KRong"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12hsbY%253D&md5=405b7386fce6872b460943303b7d8b3c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1172%2FJCI31487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI31487%26sid%3Dliteratum%253Aachs%26aulast%3DWynn%26aufirst%3DT.%2BA.%26atitle%3DCommon%2520and%2520unique%2520mechanisms%2520regulate%2520fibrosis%2520in%2520various%2520fibroproliferative%2520diseases%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D524%26epage%3D529%26doi%3D10.1172%2FJCI31487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span> <span> </span><span class="NLM_article-title">Drugs and targets in fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">855</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29218009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFems77P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=855&author=X.+Liauthor=L.+Zhuauthor=B.+Wangauthor=M.+Yuanauthor=R.+Zhu&title=Drugs+and+targets+in+fibrosis&doi=10.3389%2Ffphar.2017.00855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs and targets in fibrosis</span></div><div class="casAuthors">Li, Xiaoyi; Zhu, Lixin; Wang, Beibei; Yuan, Meifei; Zhu, Ruixin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">855/1-855/21</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Fibrosis contributes to the development of many diseases and many target mols. are involved in fibrosis.  Currently, the majority of fibrosis treatment strategies are limited to specific diseases or organs.  However, accumulating evidence demonstrates great similarities among fibroproliferative diseases, and more and more drugs are proved to be effective anti-fibrotic therapies across different diseases and organs.  Here we comprehensively review the current knowledge on the pathol. mechanisms of fibrosis, and divide factors mediating fibrosis progression into extracellular and intracellular groups.  Furthermore, we systematically summarize both single and multiple component drugs that target fibrosis.  Future directions of fibrosis drug discovery are also proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYWFKoJKIMZ7Vg90H21EOLACvtfcHk0lgyZgFcRMD4gg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFems77P&md5=ce450251ad612e940967fde259549692</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00855%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DR.%26atitle%3DDrugs%2520and%2520targets%2520in%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D855%26doi%3D10.3389%2Ffphar.2017.00855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feghali-Bostwick, C. A.</span></span> <span> </span><span class="NLM_article-title">Fibroblasts in fibrosis: novel roles and mediators</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">123</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24904424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvFKlsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=123&author=R.+T.+Kendallauthor=C.+A.+Feghali-Bostwick&title=Fibroblasts+in+fibrosis%3A+novel+roles+and+mediators&doi=10.3389%2Ffphar.2014.00123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblasts in fibrosis: novel roles and mediators</span></div><div class="casAuthors">Kendall Ryan T; Feghali-Bostwick Carol A</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">123</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Fibroblasts are the most common cell type of the connective tissues found throughout the body and the principal source of the extensive extracellular matrix (ECM) characteristic of these tissues.  They are also the central mediators of the pathological fibrotic accumulation of ECM and the cellular proliferation and differentiation that occurs in response to prolonged tissue injury and chronic inflammation.  The transformation of the fibroblast cell lineage involves classical developmental signaling programs and includes a surprisingly diverse range of precursor cell types-most notably, myofibroblasts that are the apex of the fibrotic phenotype.  Myofibroblasts display exaggerated ECM production; constitutively secrete and are hypersensitive to chemical signals such as cytokines, chemokines, and growth factors; and are endowed with a contractile apparatus allowing them to manipulate the ECM fibers physically to close open wounds.  In addition to ECM production, fibroblasts have multiple concomitant biological roles, such as in wound healing, inflammation, and angiogenesis, which are each interwoven with the process of fibrosis.  We now recognize many common fibroblast-related features across various physiological and pathological protracted processes.  Indeed, a new appreciation has emerged for the role of non-cancerous fibroblast interactions with tumors in cancer progression.  Although the predominant current clinical treatments of fibrosis involve non-specific immunosuppressive and anti-proliferative drugs, a variety of potential therapies under investigation specifically target fibroblast biology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCTjHiOSmRmvEeosoOnpOLfW6udTcc2eby_VrhOkDs6Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvFKlsQ%253D%253D&md5=f4342f5b9eac9e0882255b07162a34a4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00123%26sid%3Dliteratum%253Aachs%26aulast%3DKendall%26aufirst%3DR.%2BT.%26aulast%3DFeghali-Bostwick%26aufirst%3DC.%2BA.%26atitle%3DFibroblasts%2520in%2520fibrosis%253A%2520novel%2520roles%2520and%2520mediators%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D123%26doi%3D10.3389%2Ffphar.2014.00123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gauldie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonniaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sime, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ask, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, M.</span></span> <span> </span><span class="NLM_article-title">TGF-Î², Smad3 and the process of progressive fibrosis</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">661</span>â <span class="NLM_lpage">664</span>, <span class="refDoi">Â DOI: 10.1042/BST0350661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1042%2FBST0350661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17635115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVKmt7zO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=661-664&author=J.+Gauldieauthor=P.+Bonniaudauthor=P.+Simeauthor=K.+Askauthor=M.+Kolb&title=TGF-%CE%B2%2C+Smad3+and+the+process+of+progressive+fibrosis&doi=10.1042%2FBST0350661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">TGF-Î², Smad3 and the process of progressive fibrosis</span></div><div class="casAuthors">Gauldie, J.; Bonniaud, P.; Sime, P.; Ask, K.; Kolb, M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">661-664</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Transient adenovirus-mediated gene transfer of active TGF-Î²1 (transforming growth factor-Î²1) induces severe and progressive fibrosis in rodent lung without apparent inflammation.  Alternatively, transfer of IL-1Î² (interleukin 1Î²) induces marked tissue injury and inflammation, which develops into progressive fibrosis, assocd. with an increase in TGF-Î²1 concns. in lung fluid and tissue.  Both vector treatments induce a fibrotic response involving myofibroblasts and progressive matrix deposition starting at the peri-bronchial site of expression and extending over days to involve the entire lung and pleural surface.  Administration of the TGF-Î²1 vector to the pleural space induces progressive pleural fibrosis, which minimally extends into the lung parenchyma.  The mechanisms involved in progressive fibrosis need to account for the limitation of fibrosis to specific organs (lung fibrosis and not liver fibrosis or vice versa) and the lack of effect of anti-inflammatory treatments in regulating progressive fibrosis.  TGF-Î²1 is a key cytokine in the process of fibrogenesis, using intracellular signalling pathways involving the ALK5 receptor and signalling mols. Smad2 and Smad3.  Transient gene transfer of either TGF-Î²1 or IL-1Î² to Smad3-null mouse lung provides little evidence of progressive fibrosis and no fibrogenesis-assocd. genes are induced.  These results suggest that mechanisms of progressive fibrosis involve factors presented within the context of the matrix that define the microenvironment for progressive matrix deposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuRnVzkD7GVLVg90H21EOLACvtfcHk0lgtYf6TP49_HA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVKmt7zO&md5=ca63dcb951042df2e2c5d73d0d12c6b8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1042%2FBST0350661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0350661%26sid%3Dliteratum%253Aachs%26aulast%3DGauldie%26aufirst%3DJ.%26aulast%3DBonniaud%26aufirst%3DP.%26aulast%3DSime%26aufirst%3DP.%26aulast%3DAsk%26aufirst%3DK.%26aulast%3DKolb%26aufirst%3DM.%26atitle%3DTGF-%25CE%25B2%252C%2520Smad3%2520and%2520the%2520process%2520of%2520progressive%2520fibrosis%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2007%26volume%3D35%26spage%3D661%26epage%3D664%26doi%3D10.1042%2FBST0350661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rockey, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. A.</span></span> <span> </span><span class="NLM_article-title">Fibrosis - a common pathway of organ injury and failure</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1138</span>â <span class="NLM_lpage">1149</span>, <span class="refDoi">Â DOI: 10.1056/NEJMra1300575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1056%2FNEJMra1300575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25785971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVaku7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1138-1149&author=D.+C.+Rockeyauthor=P.+D.+Bellauthor=J.+A.+Hill&title=Fibrosis+-+a+common+pathway+of+organ+injury+and+failure&doi=10.1056%2FNEJMra1300575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Fibrosis - a common pathway to organ injury and failure</span></div><div class="casAuthors">Rockey, Don C.; Bell, P. Darwin; Hill, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1138-1149</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  This article describes the cellular and mol. aspects of fibrosis, in lieu of cellular dysfunction and various organ failure and avail pharmacol. therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwApriu_6jarVg90H21EOLACvtfcHk0lhjxyVAMOpOcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVaku7o%253D&md5=676a2ea78a319160d668fc882f5fd7c0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1300575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1300575%26sid%3Dliteratum%253Aachs%26aulast%3DRockey%26aufirst%3DD.%2BC.%26aulast%3DBell%26aufirst%3DP.%2BD.%26aulast%3DHill%26aufirst%3DJ.%2BA.%26atitle%3DFibrosis%2520-%2520a%2520common%2520pathway%2520of%2520organ%2520injury%2520and%2520failure%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1138%26epage%3D1149%26doi%3D10.1056%2FNEJMra1300575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiRocco, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, B. D.</span></span> <span> </span><span class="NLM_article-title">Understanding the origin, activation and regulation of matrix-producing myofibroblasts for the treatment of fibrotic diseases</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">273</span>â <span class="NLM_lpage">289</span>, <span class="refDoi">Â DOI: 10.1002/path.4253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1002%2Fpath.4253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24006178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1WntLjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2013&pages=273-289&author=R.+Kramannauthor=D.+P.+DiRoccoauthor=B.+D.+Humphreys&title=Understanding+the+origin%2C+activation+and+regulation+of+matrix-producing+myofibroblasts+for+the+treatment+of+fibrotic+diseases&doi=10.1002%2Fpath.4253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease</span></div><div class="casAuthors">Kramann, Rafael; Di Rocco, Derek P.; Humphreys, Benjamin D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-289</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Fibrosis and scar formation results from chronic progressive injury in virtually every tissue and affects a growing no. of people around the world.  Myofibroblasts drive fibrosis, and recent work has demonstrated that mesenchymal cells, including pericytes and perivascular fibroblasts, are their main progenitors.  Understanding the cellular mechanisms of pericyte/fibroblast-to-myofibroblast transition, myofibroblast proliferation and the key signalling pathways that regulate these processes is essential to develop novel targeted therapeutics for the growing patient population suffering from solid organ fibrosis.  In this review, we summarize the current knowledge about different progenitor cells of myofibroblasts, discuss major pathways that regulate their transdifferentiation and discuss the current status of novel targeted anti-fibrotic therapeutics in development.  Copyright Â© 2013 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAAWbN_PK94rVg90H21EOLACvtfcHk0lgK9U-jnDD5SA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1WntLjN&md5=7e37d84ada44e021c13c0c07165f85ed</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fpath.4253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4253%26sid%3Dliteratum%253Aachs%26aulast%3DKramann%26aufirst%3DR.%26aulast%3DDiRocco%26aufirst%3DD.%2BP.%26aulast%3DHumphreys%26aufirst%3DB.%2BD.%26atitle%3DUnderstanding%2520the%2520origin%252C%2520activation%2520and%2520regulation%2520of%2520matrix-producing%2520myofibroblasts%2520for%2520the%2520treatment%2520of%2520fibrotic%2520diseases%26jtitle%3DJ.%2520Pathol.%26date%3D2013%26volume%3D231%26spage%3D273%26epage%3D289%26doi%3D10.1002%2Fpath.4253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reilkoff, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bucala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, E. L.</span></span> <span> </span><span class="NLM_article-title">Fibrocytes: emerging effector cells in chronic inflammation</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">427</span>â <span class="NLM_lpage">435</span>, <span class="refDoi">Â DOI: 10.1038/nri2990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnri2990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=21597472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlemtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=427-435&author=R.+A.+Reilkoffauthor=R.+Bucalaauthor=E.+L.+Herzog&title=Fibrocytes%3A+emerging+effector+cells+in+chronic+inflammation&doi=10.1038%2Fnri2990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fibrocytes: emerging effector cells in chronic inflammation</span></div><div class="casAuthors">Reilkoff, Ronald A.; Bucala, Richard; Herzog, Erica L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">427-435</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibrocytes are mesenchymal cells that arise from monocyte precursors.  They are present in injured organs and have both the inflammatory features of macrophages and the tissue remodelling properties of fibroblasts.  Chronic inflammatory stimuli mediate the differentiation, trafficking and accumulation of these cells in fibrosing conditions assocd. with autoimmunity, cardiovascular disease and asthma.  This Opinion article discusses the immunol. mediators controlling fibrocyte differentiation and recruitment, describes the assocn. of fibrocytes with chronic inflammatory diseases and compares the potential roles of fibrocytes in these disorders with those of macrophages and fibroblasts.  It is hoped that this information prompts new opportunities for the study of these unique cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8QY-QSZ6KlrVg90H21EOLACvtfcHk0lgK9U-jnDD5SA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlemtLk%253D&md5=ce88c26e651b94212982b09401a1a3f6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnri2990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2990%26sid%3Dliteratum%253Aachs%26aulast%3DReilkoff%26aufirst%3DR.%2BA.%26aulast%3DBucala%26aufirst%3DR.%26aulast%3DHerzog%26aufirst%3DE.%2BL.%26atitle%3DFibrocytes%253A%2520emerging%2520effector%2520cells%2520in%2520chronic%2520inflammation%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2011%26volume%3D11%26spage%3D427%26epage%3D435%26doi%3D10.1038%2Fnri2990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Carlo, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peduto, L.</span></span> <span> </span><span class="NLM_article-title">The perivascular origin of pathological fibroblasts</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">54</span>â <span class="NLM_lpage">63</span>, <span class="refDoi">Â DOI: 10.1172/JCI93558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93558" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=54-63&author=S.+E.+Di%0ACarloauthor=L.+Peduto&title=The+perivascular+origin+of+pathological+fibroblasts&doi=10.1172%2FJCI93558"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1172%2FJCI93558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93558%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BCarlo%26aufirst%3DS.%2BE.%26aulast%3DPeduto%26aufirst%3DL.%26atitle%3DThe%2520perivascular%2520origin%2520of%2520pathological%2520fibroblasts%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D54%26epage%3D63%26doi%3D10.1172%2FJCI93558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, F. M.</span></span> <span> </span><span class="NLM_article-title">Fibroblast heterogeneity: implications for human disease</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">26</span>â <span class="NLM_lpage">35</span>, <span class="refDoi">Â DOI: 10.1172/JCI93555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93555" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=26-35&author=M.+D.+Lynchauthor=F.+M.+Watt&title=Fibroblast+heterogeneity%3A+implications+for+human+disease&doi=10.1172%2FJCI93555"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1172%2FJCI93555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93555%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DM.%2BD.%26aulast%3DWatt%26aufirst%3DF.%2BM.%26atitle%3DFibroblast%2520heterogeneity%253A%2520implications%2520for%2520human%2520disease%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D26%26epage%3D35%26doi%3D10.1172%2FJCI93555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heywood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tourkina, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visconti, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, S.</span></span> <span> </span><span class="NLM_article-title">Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">141</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24999331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cbgtFSqtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=141&author=C.+Reeseauthor=R.+Leeauthor=M.+Bonnerauthor=B.+Perryauthor=J.+Heywoodauthor=R.+M.+Silverauthor=R.+P.+Tourkinaauthor=R.+P.+Viscontiauthor=S.+Hoffman&title=Fibrocytes+in+the+fibrotic+lung%3A+altered+phenotype+detected+by+flow+cytometry&doi=10.3389%2Ffphar.2014.00141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry</span></div><div class="casAuthors">Reese Charles; Lee Rebecca; Bonner Michael; Perry Beth; Heywood Jonathan; Silver Richard M; Tourkina Elena; Hoffman Stanley; Visconti Richard P</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">141</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Fibrocytes are bone marrow hematopoietic-derived cells that also express a mesenchymal cell marker (commonly collagen I) and participate in fibrotic diseases of multiple organs.  Given their origin, they or their precursors must be circulating cells before recruitment into target tissues.  While most previous studies focused on circulating fibrocytes, here we focus on the fibrocyte phenotype in fibrotic tissue.  The study's relevance to human disease is heightened by use of a model in which bleomycin is delivered systemically, recapitulating several features of human scleroderma including multi-organ fibrosis not observed when bleomycin is delivered directly into the lungs.  Using flow cytometry, we find in the fibrotic lung a large population of CD45(high) fibrocytes (called Region I) rarely found in vehicle-treated control mice.  A second population of CD45+ fibrocytes (called Region II) is observed in both control and fibrotic lung.  The level of CD45 in circulating fibrocytes is far lower than in either Region I or II lung fibrocytes.  The chemokine receptors CXCR4 and CCR5 are expressed at higher levels in Region I than in Region II and are present at very low levels in all other lung cells including CD45+/collagen I- leucocytes.  The collagen chaperone HSP47 is present at similar high levels in both Regions I and II, but at a higher level in fibrotic lung than in control lung.  There is also a major population of HSP47(high)/CD45- cells in fibrotic lung not present in control lung.  CD44 is present at higher levels in Region I than in Region II and at much lower levels in all other cells including CD45+/collagen I- leucocytes.  When lung fibrosis is inhibited by restoring caveolin-1 activity using a caveolin-1 scaffolding domain peptide (CSD), a strong correlation is observed between fibrocyte number and fibrosis score.  In summary, the distinctive phenotype of fibrotic lung fibrocytes suggests that fibrocyte differentiation occurs primarily within the target organ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQ619baX0m4r9KldV63DuefW6udTcc2eaHSvPSm9ps_Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbgtFSqtg%253D%253D&md5=d87dbf8e62bbc8e0abd30a1b39873ded</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00141%26sid%3Dliteratum%253Aachs%26aulast%3DReese%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DR.%26aulast%3DBonner%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DB.%26aulast%3DHeywood%26aufirst%3DJ.%26aulast%3DSilver%26aufirst%3DR.%2BM.%26aulast%3DTourkina%26aufirst%3DR.%2BP.%26aulast%3DVisconti%26aufirst%3DR.%2BP.%26aulast%3DHoffman%26aufirst%3DS.%26atitle%3DFibrocytes%2520in%2520the%2520fibrotic%2520lung%253A%2520altered%2520phenotype%2520detected%2520by%2520flow%2520cytometry%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D141%26doi%3D10.3389%2Ffphar.2014.00141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Habiel, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogaboam, C.</span></span> <span> </span><span class="NLM_article-title">Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24478703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsF2nuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=2&author=D.+M.+Habielauthor=C.+Hogaboam&title=Heterogeneity+in+fibroblast+proliferation+and+survival+in+idiopathic+pulmonary+fibrosis&doi=10.3389%2Ffphar.2014.00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Habiel David M; Hogaboam Cory</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease characterized by the persistence of activated myofibroblasts resulting in excessive deposition of extracellular matrix proteins and profound tissue remodeling.  Myofibroblasts have been shown to arise from interstitial fibroblasts, epithelial to mesenchymal transition of type II alveolar epithelial cells, and the differentiation of recruited fibrocytes.  There are many mechanisms that are utilized by these cells for survival, proliferation, and persistent activation including up-regulation of cytokines [i.e., Interleukin 6 (IL-6) and C-C motif chemokine ligand 21 (CCL21)], cytokine receptors [i.e., Interleukin 6Receptor 1 (IL-6R1), Glycoprotein 130 (gp130) and C-C Chemokine Receptor type 7 (CCR7)], and innate pattern recognition receptors [(PRRs; i.e., Toll Like Receptor 9 (TLR9)].  In this review, we will discuss the role of the cytokines IL-6 and CCL21, their receptors and the PRR, TLR9, in fibroblast recruitment, activation, survival, and differentiation into myofibroblasts in IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAiCiGNKbA0NLIORRPd5lbfW6udTcc2eaeUQK6l2Lcmbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsF2nuw%253D%253D&md5=358e8b6635a462016df931d6ea2bd0c1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00002%26sid%3Dliteratum%253Aachs%26aulast%3DHabiel%26aufirst%3DD.%2BM.%26aulast%3DHogaboam%26aufirst%3DC.%26atitle%3DHeterogeneity%2520in%2520fibroblast%2520proliferation%2520and%2520survival%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D2%26doi%3D10.3389%2Ffphar.2014.00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rinkevich, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maan, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drukker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Januszyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krampitz, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurtner, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longaker, M. T.</span></span> <span> </span><span class="NLM_article-title">Identification and isolation of a dermal lineage with intrinsic fibrogenic potential</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">aaa2151</span>, <span class="refDoi">Â DOI: 10.1126/science.aaa2151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1126%2Fscience.aaa2151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25883361" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=aaa2151&author=Y.+Rinkevichauthor=G.+G.+Walmsleyauthor=M.+S.+Huauthor=Z.+N.+Maanauthor=A.+M.+Newmanauthor=M.+Drukkerauthor=M.+Januszykauthor=G.+W.+Krampitzauthor=G.+C.+Gurtnerauthor=H.+P.+Lorenzauthor=I.+L.+Weissmanauthor=M.+T.+Longaker&title=Identification+and+isolation+of+a+dermal+lineage+with+intrinsic+fibrogenic+potential&doi=10.1126%2Fscience.aaa2151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaa2151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaa2151%26sid%3Dliteratum%253Aachs%26aulast%3DRinkevich%26aufirst%3DY.%26aulast%3DWalmsley%26aufirst%3DG.%2BG.%26aulast%3DHu%26aufirst%3DM.%2BS.%26aulast%3DMaan%26aufirst%3DZ.%2BN.%26aulast%3DNewman%26aufirst%3DA.%2BM.%26aulast%3DDrukker%26aufirst%3DM.%26aulast%3DJanuszyk%26aufirst%3DM.%26aulast%3DKrampitz%26aufirst%3DG.%2BW.%26aulast%3DGurtner%26aufirst%3DG.%2BC.%26aulast%3DLorenz%26aufirst%3DH.%2BP.%26aulast%3DWeissman%26aufirst%3DI.%2BL.%26aulast%3DLongaker%26aufirst%3DM.%2BT.%26atitle%3DIdentification%2520and%2520isolation%2520of%2520a%2520dermal%2520lineage%2520with%2520intrinsic%2520fibrogenic%2520potential%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3Daaa2151%26doi%3D10.1126%2Fscience.aaa2151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Driskell, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenberger, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoste, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretzschmar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charalambous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferron, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herault, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlovic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson-Smith, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, F. M.</span></span> <span> </span><span class="NLM_article-title">Distinct fibroblast lineages determine dermal architecture in skin development and repair</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>504</i></span>,  <span class="NLM_fpage">277</span>â <span class="NLM_lpage">281</span>, <span class="refDoi">Â DOI: 10.1038/nature12783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnature12783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24336287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFars7zL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=504&publication_year=2013&pages=277-281&author=R.+R.+Driskellauthor=B.+M.+Lichtenbergerauthor=E.+Hosteauthor=K.+Kretzschmarauthor=B.+D.+Simonsauthor=M.+Charalambousauthor=S.+R.+Ferronauthor=Y.+Heraultauthor=G.+Pavlovicauthor=A.+C.+Ferguson-Smithauthor=F.+M.+Watt&title=Distinct+fibroblast+lineages+determine+dermal+architecture+in+skin+development+and+repair&doi=10.1038%2Fnature12783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct fibroblast lineages determine dermal architecture in skin development and repair</span></div><div class="casAuthors">Driskell, Ryan R.; Lichtenberger, Beate M.; Hoste, Esther; Kretzschmar, Kai; Simons, Ben D.; Charalambous, Marika; Ferron, Sacri R.; Herault, Yann; Pavlovic, Guillaume; Ferguson-Smith, Anne C.; Watt, Fiona M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">504</span>
        (<span class="NLM_cas:issue">7479</span>),
    <span class="NLM_cas:pages">277-281</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Fibroblasts are the major mesenchymal cell type in connective tissue and deposit the collagen and elastic fibers of the extracellular matrix (ECM).  Even within a single tissue, fibroblasts exhibit considerable functional diversity, but it is not known whether this reflects the existence of a differentiation hierarchy or is a response to different environmental factors.  Here we show, using transplantation assays and lineage tracing in mice, that the fibroblasts of skin connective tissue arise from two distinct lineages.  One forms the upper dermis, including the dermal papilla that regulates hair growth and the arrector pili muscle, which controls piloerection.  The other forms the lower dermis, including the reticular fibroblasts that synthesize the bulk of the fibrillar ECM, and the preadipocytes and adipocytes of the hypodermis.  The upper lineage is required for hair follicle formation.  In wounded adult skin, the initial wave of dermal repair is mediated by the lower lineage and upper dermal fibroblasts are recruited only during re-epithelialization.  Epidermal Î²-catenin activation stimulates the expansion of the upper dermal lineage, rendering wounds permissive for hair follicle formation.  Our findings explain why wounding is linked to formation of ECM-rich scar tissue that lacks hair follicles.  They also form a platform for discovering fibroblast lineages in other tissues and for examg. fibroblast changes in ageing and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjaSvqKUhu0rVg90H21EOLACvtfcHk0limot6k4CFS6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFars7zL&md5=9bb443f3349a44966028ac89e32204c9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature12783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12783%26sid%3Dliteratum%253Aachs%26aulast%3DDriskell%26aufirst%3DR.%2BR.%26aulast%3DLichtenberger%26aufirst%3DB.%2BM.%26aulast%3DHoste%26aufirst%3DE.%26aulast%3DKretzschmar%26aufirst%3DK.%26aulast%3DSimons%26aufirst%3DB.%2BD.%26aulast%3DCharalambous%26aufirst%3DM.%26aulast%3DFerron%26aufirst%3DS.%2BR.%26aulast%3DHerault%26aufirst%3DY.%26aulast%3DPavlovic%26aufirst%3DG.%26aulast%3DFerguson-Smith%26aufirst%3DA.%2BC.%26aulast%3DWatt%26aufirst%3DF.%2BM.%26atitle%3DDistinct%2520fibroblast%2520lineages%2520determine%2520dermal%2520architecture%2520in%2520skin%2520development%2520and%2520repair%26jtitle%3DNature%26date%3D2013%26volume%3D504%26spage%3D277%26epage%3D281%26doi%3D10.1038%2Fnature12783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hewitson, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. R.</span></span> <span> </span><span class="NLM_article-title">Progression of tubulointerstitial fibrosis and the chronic kidney disease phenotype- role of risk factors and epigenetics</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">520</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28848437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2nsL3N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=520&author=T.+D.+Hewitsonauthor=S.+G.+Holtauthor=E.+R.+Smith&title=Progression+of+tubulointerstitial+fibrosis+and+the+chronic+kidney+disease+phenotype-+role+of+risk+factors+and+epigenetics&doi=10.3389%2Ffphar.2017.00520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Progression of tubulointerstitial fibrosis and the chronic kidney disease phenotype - role of risk factors and epigenetics</span></div><div class="casAuthors">Hewitson, Timothy D.; Holt, Stephen G.; Smith, Edward R.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">520/1-520/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Although the kidney has capacity to repair after mild injury, ongoing or severe damage results in scarring (fibrosis) and an assocd. progressive loss of kidney function.  However, despite its universal significance, evidence highlights a population based heterogeneity in the trajectory of chronic kidney disease (CKD) in these patients.  To explain the heterogeneity of the CKD phenotype requires an understanding of the relevant risk factors for fibrosis.  These factors include both the extrinsic nature of injury, and intrinsic factors such as age, gender, genetics, and perpetual activation of fibroblasts through priming.  In many cases an addnl. level of regulation is provided by epigenetic mechanisms which integrate the various pro-fibrotic and anti-fibrotic triggers in fibrogenesis.  In this review we therefore examine the various mol. and structural changes of fibrosis, and how they are influenced by extrinsic and intrinsic factors.  Our aim is to provide a unifying hypothesis to help explain the transition from acute to CKD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPa1YhclMiuLVg90H21EOLACvtfcHk0lgRCyR2gHWfkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2nsL3N&md5=1c34dcc38ce96a4c6527c65e25f59c66</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00520%26sid%3Dliteratum%253Aachs%26aulast%3DHewitson%26aufirst%3DT.%2BD.%26aulast%3DHolt%26aufirst%3DS.%2BG.%26aulast%3DSmith%26aufirst%3DE.%2BR.%26atitle%3DProgression%2520of%2520tubulointerstitial%2520fibrosis%2520and%2520the%2520chronic%2520kidney%2520disease%2520phenotype-%2520role%2520of%2520risk%2520factors%2520and%2520epigenetics%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D520%26doi%3D10.3389%2Ffphar.2017.00520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonis, S. T.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24734020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsl2gtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=51&author=M.+L.+Manciniauthor=S.+T.+Sonis&title=Mechanisms+of+cellular+fibrosis+associated+with+cancer+regimen-related+toxicities&doi=10.3389%2Ffphar.2014.00051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities</span></div><div class="casAuthors">Mancini Maria L; Sonis Stephen T</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Fibrosis is a common, persistent and potentially debilitating complication of chemotherapy and radiation regimens used for the treatment of cancer.  The molecular mechanisms underlying fibrosis have been well studied and reveal overall processes that are largely ubiquitous.  However, it is important to note that although the processes are similar, they result in cellular phenotypes that are highly tissue specific.  These tissue specific differences may present opportunities for therapeutic interventions to prevent or treat this often irreversible condition.  Data generated from animal models of cancer therapy-related tissue toxicities have revealed that the signaling pathways involved in fibrosis are the same as those involved in the normal injury response and include the transforming growth factor Î² superfamily and a range of pro-inflammatory cytokines.  The critical difference between normal wound healing and fibrosis development appears to be, that in fibrosis, these signaling pathways escape normal cellular regulation.  As a result, an injury state is maintained and processes involved in normal healing are usurped.  There are a few, if any, therapeutics that effectively prevent or treat fibrosis in patients.  Consequently, cancer survivors may be chronically plagued with a variety of life-altering fibrosis-related symptoms.  Uncovering the signaling pathways that drive cellular fibrosis is paramount to the development of specific therapeutics that will mitigate this potentially devastating condition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYoMsMF_spOi86Js-BCLiifW6udTcc2eb1ffzyx7fCVLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsl2gtA%253D%253D&md5=667555e3939a13d23d3d2ae6b3d2286c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00051%26sid%3Dliteratum%253Aachs%26aulast%3DMancini%26aufirst%3DM.%2BL.%26aulast%3DSonis%26aufirst%3DS.%2BT.%26atitle%3DMechanisms%2520of%2520cellular%2520fibrosis%2520associated%2520with%2520cancer%2520regimen-related%2520toxicities%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D51%26doi%3D10.3389%2Ffphar.2014.00051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bataller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, D. A.</span></span> <span> </span><span class="NLM_article-title">Liver fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">209</span>â <span class="NLM_lpage">218</span>, <span class="refDoi">Â DOI: 10.1172/JCI24282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI24282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=15690074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyjs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=209-218&author=R.+Batallerauthor=D.+A.+Brenner&title=Liver+fibrosis&doi=10.1172%2FJCI24282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Liver fibrosis</span></div><div class="casAuthors">Bataller, Ramon; Brenner, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-218</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases.  Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation.  Our knowledge of the cellular and mol. mechanisms of liver fibrosis has greatly advanced.  Activated hepatic stellate cells, portal fibroblasts, and myofibroblasts of bone marrow origin have been identified as major collagen-producing cells in the injured liver.  These cells are activated by fibrogenic cytokines such as TGF-Î²1, angiotensin II, and leptin.  Reversibility of advanced liver fibrosis in patients has been recently documented, which has stimulated researchers to develop antifibrotic drugs.  Emerging antifibrotic therapies are aimed at inhibiting the accumulation of fibrogenic cells and/or preventing the deposition of extracellular matrix proteins.  Although many therapeutic interventions are effective in exptl. models of liver fibrosis, their efficacy and safety in humans is unknown.  This review summarizes recent progress in the study of the pathogenesis and diagnosis of liver fibrosis and discusses current antifibrotic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADNkKCYBJYLVg90H21EOLACvtfcHk0lj_3N86YVqM3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyjs70%253D&md5=f96b24aca82750b66fc1cb05b4b6216b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1172%2FJCI24282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI24282%26sid%3Dliteratum%253Aachs%26aulast%3DBataller%26aufirst%3DR.%26aulast%3DBrenner%26aufirst%3DD.%2BA.%26atitle%3DLiver%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D209%26epage%3D218%26doi%3D10.1172%2FJCI24282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisseleva, T.</span></span> <span> </span><span class="NLM_article-title">The types of hepatic myelofribroblasts contributing to liver fibrosis of different etiologies</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">167</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25100997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cbpslCrsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=167&author=J.+Xuauthor=X.+Liuauthor=Y.+Koyamaauthor=P.+Wangauthor=T.+Lanauthor=I.+G.+Kimauthor=I.+H.+Kimauthor=H.+Y.+Maauthor=T.+Kisseleva&title=The+types+of+hepatic+myelofribroblasts+contributing+to+liver+fibrosis+of+different+etiologies&doi=10.3389%2Ffphar.2014.00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies</span></div><div class="casAuthors">Xu Jun; Liu Xiao; Koyama Yukinori; Wang Ping; Lan Tian; Kim In-Gyu; Kim In H; Ma Hsiao-Yen; Kisseleva Tatiana</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Liver fibrosis results from dysregulation of normal wound healing, inflammation, activation of myofibroblasts, and deposition of extracellular matrix (ECM).  Chronic liver injury causes death of hepatocytes and formation of apoptotic bodies, which in turn, release factors that recruit inflammatory cells (neutrophils, monocytes, macrophages, and lymphocytes) to the injured liver.  Hepatic macrophages (Kupffer cells) produce TGFÎ²1 and other inflammatory cytokines that activate Collagen Type I producing myofibroblasts, which are not present in the normal liver.  Secretion of TGFÎ²1 and activation of myofibroblasts play a critical role in the pathogenesis of liver fibrosis of different etiologies.  Although the composition of fibrogenic myofibroblasts varies dependent on etiology of liver injury, liver resident hepatic stellate cells and portal fibroblasts are the major source of myofibroblasts in fibrotic liver in both experimental models of liver fibrosis and in patients with liver disease.  Several studies have demonstrated that hepatic fibrosis can reverse upon cessation of liver injury.  Regression of liver fibrosis is accompanied by the disappearance of fibrogenic myofibroblasts followed by resorption of the fibrous scar.  Myofibroblasts either apoptose or inactivate into a quiescent-like state (e.g., stop collagen production and partially restore expression of lipogenic genes).  Resolution of liver fibrosis is associated with recruitment of macrophages that secrete matrix-degrading enzymes (matrix metalloproteinase, collagenases) and are responsible for fibrosis resolution.  However, prolonged/repeated liver injury may cause irreversible crosslinking of ECM and formation of uncleavable collagen fibers.  Advanced fibrosis progresses to cirrhosis and hepatocellular carcinoma.  The current review will summarize the role and contribution of different cell types to populations of fibrogenic myofibroblasts in fibrotic liver.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsz95bn0G8oHELvajU9pjPfW6udTcc2eaOt9nHl8LS9rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbpslCrsA%253D%253D&md5=7bb9ff49469844f1887571f746998a75</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00167%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKoyama%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLan%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DI.%2BG.%26aulast%3DKim%26aufirst%3DI.%2BH.%26aulast%3DMa%26aufirst%3DH.%2BY.%26aulast%3DKisseleva%26aufirst%3DT.%26atitle%3DThe%2520types%2520of%2520hepatic%2520myelofribroblasts%2520contributing%2520to%2520liver%2520fibrosis%2520of%2520different%2520etiologies%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D167%26doi%3D10.3389%2Ffphar.2014.00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cordero-Espinoza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huch, M.</span></span> <span> </span><span class="NLM_article-title">The balancing act of the liver: tissue regeneration versus fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">85</span>â <span class="NLM_lpage">96</span>, <span class="refDoi">Â DOI: 10.1172/JCI93562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93562" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=85-96&author=L.+Cordero-Espinozaauthor=M.+Huch&title=The+balancing+act+of+the+liver%3A+tissue+regeneration+versus+fibrosis&doi=10.1172%2FJCI93562"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1172%2FJCI93562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93562%26sid%3Dliteratum%253Aachs%26aulast%3DCordero-Espinoza%26aufirst%3DL.%26aulast%3DHuch%26aufirst%3DM.%26atitle%3DThe%2520balancing%2520act%2520of%2520the%2520liver%253A%2520tissue%2520regeneration%2520versus%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D85%26epage%3D96%26doi%3D10.1172%2FJCI93562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samir, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhyani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhan, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halpern, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ©ndez-Navarro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, R. T.</span></span> <span> </span><span class="NLM_article-title">Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement</span>. <i>Radiology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">888</span>â <span class="NLM_lpage">896</span>, <span class="refDoi">Â DOI: 10.1148/radiol.14140839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1148%2Fradiol.14140839" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=2015&pages=888-896&author=A.+E.+Samirauthor=M.+Dhyaniauthor=A.+Vijauthor=A.+K.+Bhanauthor=E.+F.+Halpernauthor=J.+M%C3%A9ndez-Navarroauthor=K.+E.+Coreyauthor=R.+T.+Chung&title=Shear-wave+elastography+for+the+estimation+of+liver+fibrosis+in+chronic+liver+disease%3A+determining+accuracy+and+ideal+site+for+measurement&doi=10.1148%2Fradiol.14140839"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1148%2Fradiol.14140839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1148%252Fradiol.14140839%26sid%3Dliteratum%253Aachs%26aulast%3DSamir%26aufirst%3DA.%2BE.%26aulast%3DDhyani%26aufirst%3DM.%26aulast%3DVij%26aufirst%3DA.%26aulast%3DBhan%26aufirst%3DA.%2BK.%26aulast%3DHalpern%26aufirst%3DE.%2BF.%26aulast%3DM%25C3%25A9ndez-Navarro%26aufirst%3DJ.%26aulast%3DCorey%26aufirst%3DK.%2BE.%26aulast%3DChung%26aufirst%3DR.%2BT.%26atitle%3DShear-wave%2520elastography%2520for%2520the%2520estimation%2520of%2520liver%2520fibrosis%2520in%2520chronic%2520liver%2520disease%253A%2520determining%2520accuracy%2520and%2520ideal%2520site%2520for%2520measurement%26jtitle%3DRadiology%26date%3D2015%26volume%3D274%26spage%3D888%26epage%3D896%26doi%3D10.1148%2Fradiol.14140839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Athyros, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexandrides, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilianou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholongitas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doumas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganotakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudevenos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elisaf, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germanidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giouleme, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karvounis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsiki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotsis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kountouras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liberopoulos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitsavos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyzos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rallidis, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsapas, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tselepis, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsioufis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tziomalos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzotzas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasiliadis, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlachopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhailidis, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantzoros, C.</span></span> <span> </span><span class="NLM_article-title">The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement</span>. <i>Metab., Clin. Exp.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">17</span>â <span class="NLM_lpage">32</span>, <span class="refDoi">Â DOI: 10.1016/j.metabol.2017.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.metabol.2017.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28521870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktl2jur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2017&pages=17-32&author=V.+G.+Athyrosauthor=T.+K.+Alexandridesauthor=H.+Bilianouauthor=E.+Cholongitasauthor=M.+Doumasauthor=E.+S.+Ganotakisauthor=J.+Goudevenosauthor=M.+S.+Elisafauthor=G.+Germanidisauthor=O.+Gioulemeauthor=A.+Karagiannisauthor=C.+Karvounisauthor=N.+Katsikiauthor=V.+Kotsisauthor=J.+Kountourasauthor=E.+Liberopoulosauthor=C.+Pitsavosauthor=S.+Polyzosauthor=L.+S.+Rallidisauthor=D.+Richterauthor=A.+G.+Tsapasauthor=A.+D.+Tselepisauthor=K.+Tsioufisauthor=K.+Tziomalosauthor=T.+Tzotzasauthor=T.+G.+Vasiliadisauthor=C.+Vlachopoulosauthor=D.+P.+Mikhailidisauthor=C.+Mantzoros&title=The+use+of+statins+alone%2C+or+in+combination+with+pioglitazone+and+other+drugs%2C+for+the+treatment+of+non-alcoholic+fatty+liver+disease%2Fnon-alcoholic+steatohepatitis+and+related+cardiovascular+risk.+An+expert+panel+statement&doi=10.1016%2Fj.metabol.2017.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement</span></div><div class="casAuthors">Athyros, Vasilios G.; Alexandrides, Theodore K.; Bilianou, Helen; Cholongitas, Evangelos; Doumas, Michael; Ganotakis, Emmanuel S.; Goudevenos, John; Elisaf, Moses S.; Germanidis, Georgios; Giouleme, Olga; Karagiannis, Asterios; Karvounis, Charalambos; Katsiki, Niki; Kotsis, Vasilios; Kountouras, Jannis; Liberopoulos, Evangelos; Pitsavos, Christos; Polyzos, Stergios; Rallidis, Loukianos S.; Richter, Dimitrios; Tsapas, Apostolos G.; Tselepis, Alexandros D.; Tsioufis, Konstantinos; Tziomalos, Konstantinos; Tzotzas, Themistoklis; Vasiliadis, Themistoklis G.; Vlachopoulos, Charalambos; Mikhailidis, Dimitri P.; Mantzoros, Christos</div><div class="citationInfo"><span class="NLM_cas:title">Metabolism, Clinical and Experimental</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-32</span>CODEN:
                <span class="NLM_cas:coden">METAAJ</span>;
        ISSN:<span class="NLM_cas:issn">0026-0495</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Non-alc. fatty liver disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (> 5% of the liver tissue), in the absence of alc. abuse or other chronic liver diseases.  It is closely related to the epidemic of obesity, metabolic syndrome or type 2 diabetes mellitus (T2DM).  NAFLD can cause liver inflammation and progress to non-alc. steatohepatitis (NASH), fibrosis, cirrhosis or hepatocellular cancer (HCC).  Nevertheless, cardiovascular disease (CVD) is the most common cause of death in NAFLD/NASH patients.  Current guidelines suggest the use of pioglitazone both in patients with T2DM and in those without.  The use of statins, though considered safe by the guidelines, have very limited use; only 10% in high CVD risk patients are on statins by tertiary centers in the US.  There are data from several animal studies, 5 post hoc analyses of prospective long-term survival studies, and 5 rather small biopsy proven NASH studies, one at baseline and on at the end of the study.  All these studies provide data for biochem. and histol. improvement of NAFLD/NASH with statins and in the clin. studies large redns. in CVD events in comparison with those also on statins and normal liver.  Ezetimibe was also reported to improve NAFLD.  Drugs currently in clin. trials seem to have potential for slowing down the evolution of NAFLD and for reducing liver- and CVD-related morbidity and mortality, but it will take time before they are ready to be used in everyday clin. practice.  The suggestion of this Expert Panel is that, pending forthcoming randomized clin. trials, physicians should consider using a PPARgamma agonist, such as pioglitazone, or, statin use in those with NAFLD/NASH at high CVD or HCC risk, alone and/or preferably in combination with each other or with ezetimibe, for the primary or secondary prevention of CVD, and the avoidance of cirrhosis, liver transplantation or HCC, bearing in mind that CVD is the main cause of death in NAFLD/NASH patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSr74j-BQ187Vg90H21EOLACvtfcHk0lgmK0S0ys5nkQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktl2jur4%253D&md5=210e5048217d85c04e4e317d0d34dc25</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.metabol.2017.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.metabol.2017.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DAthyros%26aufirst%3DV.%2BG.%26aulast%3DAlexandrides%26aufirst%3DT.%2BK.%26aulast%3DBilianou%26aufirst%3DH.%26aulast%3DCholongitas%26aufirst%3DE.%26aulast%3DDoumas%26aufirst%3DM.%26aulast%3DGanotakis%26aufirst%3DE.%2BS.%26aulast%3DGoudevenos%26aufirst%3DJ.%26aulast%3DElisaf%26aufirst%3DM.%2BS.%26aulast%3DGermanidis%26aufirst%3DG.%26aulast%3DGiouleme%26aufirst%3DO.%26aulast%3DKaragiannis%26aufirst%3DA.%26aulast%3DKarvounis%26aufirst%3DC.%26aulast%3DKatsiki%26aufirst%3DN.%26aulast%3DKotsis%26aufirst%3DV.%26aulast%3DKountouras%26aufirst%3DJ.%26aulast%3DLiberopoulos%26aufirst%3DE.%26aulast%3DPitsavos%26aufirst%3DC.%26aulast%3DPolyzos%26aufirst%3DS.%26aulast%3DRallidis%26aufirst%3DL.%2BS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DTsapas%26aufirst%3DA.%2BG.%26aulast%3DTselepis%26aufirst%3DA.%2BD.%26aulast%3DTsioufis%26aufirst%3DK.%26aulast%3DTziomalos%26aufirst%3DK.%26aulast%3DTzotzas%26aufirst%3DT.%26aulast%3DVasiliadis%26aufirst%3DT.%2BG.%26aulast%3DVlachopoulos%26aufirst%3DC.%26aulast%3DMikhailidis%26aufirst%3DD.%2BP.%26aulast%3DMantzoros%26aufirst%3DC.%26atitle%3DThe%2520use%2520of%2520statins%2520alone%252C%2520or%2520in%2520combination%2520with%2520pioglitazone%2520and%2520other%2520drugs%252C%2520for%2520the%2520treatment%2520of%2520non-alcoholic%2520fatty%2520liver%2520disease%252Fnon-alcoholic%2520steatohepatitis%2520and%2520related%2520cardiovascular%2520risk.%2520An%2520expert%2520panel%2520statement%26jtitle%3DMetab.%252C%2520Clin.%2520Exp.%26date%3D2017%26volume%3D71%26spage%3D17%26epage%3D32%26doi%3D10.1016%2Fj.metabol.2017.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, S.</span></span> <span> </span><span class="NLM_article-title">NASH therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs</span>. <i>Clin. Mol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">103</span>â <span class="NLM_lpage">108</span>, <span class="refDoi">Â DOI: 10.3350/cmh.2017.0103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3350%2Fcmh.2017.0103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28494529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1crmtlWitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=103-108&author=S.+Caldwell&title=NASH+therapy%3A+omega+3+supplementation%2C+vitamin+E%2C+insulin+sensitizers+and+statin+drugs&doi=10.3350%2Fcmh.2017.0103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs</span></div><div class="casAuthors">Caldwell Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and molecular hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Non-alcoholic steatohepatitis (NASH) is the more aggressive form of non-alcoholic fatty liver disease (NAFLD).  NASH can progress to hepatic fibrosis, cirrhosis, portal hypertension and primary liver cancer.  Therapy is evolving with a substantial number of trials of promising new agents now in progress.  In this article however, we will examine data for several older forms of therapy which have been fairly extensively studied over the years: Polyunsaturated Fatty Acid (PUFA) supplements, vitamin E, insulin sensitizing agents with a focus on pioglitazone and statin agents.  Early interest in PUFA derived from their potential benefit in cardio-metabolic disease and the close association of NAFLD/NASH with Metabolic Syndrome.  Results have been variable although most studies show reduction of liver fat without other major effects and their effects are influenced by concomitant weight loss and underlying genetic factors.  Vitamin E has had some efficacy in pediatric NASH but questionable efficacy in even mild NASH among adults.  Pioglitazone has shown significant histological benefit in a number of trials but concern over side-effects (especially weight gain) have dampened enthusiasm.  A newer insulin sensitizer, liraglutide, has also shown promise in a small randomized, controlled trial.  Very limited data exists regarding the histological effects of the statins in NASH and these agents appear to be fairly neutral with neither clear cut benefit nor detriment.  Their use is best guided by cardiovascular risks rather than liver histology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRCC_fJjxR5EEgZCMqtRBifW6udTcc2eaPbyuGl21Xebntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crmtlWitw%253D%253D&md5=59b2bc8761d7fe3899cbb32bec23b035</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3350%2Fcmh.2017.0103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3350%252Fcmh.2017.0103%26sid%3Dliteratum%253Aachs%26aulast%3DCaldwell%26aufirst%3DS.%26atitle%3DNASH%2520therapy%253A%2520omega%25203%2520supplementation%252C%2520vitamin%2520E%252C%2520insulin%2520sensitizers%2520and%2520statin%2520drugs%26jtitle%3DClin.%2520Mol.%2520Hepatol.%26date%3D2017%26volume%3D23%26spage%3D103%26epage%3D108%26doi%3D10.3350%2Fcmh.2017.0103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholongitas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tziomalos, K.</span></span> <span> </span><span class="NLM_article-title">Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease</span>. <i>World J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">9039</span>â <span class="NLM_lpage">9043</span>, <span class="refDoi">Â DOI: 10.3748/wjg.v22.i41.9039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3748%2Fwjg.v22.i41.9039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=27895393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2sjht1emug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=9039-9043&author=E.+Makriauthor=E.+Cholongitasauthor=K.+Tziomalos&title=Emerging+role+of+obeticholic+acid+in+the+management+of+nonalcoholic+fatty+liver+disease&doi=10.3748%2Fwjg.v22.i41.9039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease</span></div><div class="casAuthors">Makri Evangelia; Cholongitas Evangelos; Tziomalos Konstantinos</div><div class="citationInfo"><span class="NLM_cas:title">World journal of gastroenterology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">9039-9043</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nonalcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and its prevalence is increasing driven by the pandemic of obesity and type 2 diabetes mellitus.  NAFLD can progress to cirrhosis and is associated with increased risk for cardiovascular disease and hepatocellular cancer.  Diet and exercise are limited by suboptimal long-term adherence in patients with NAFLD.  On the other hand, current pharmacological treatment of NAFLD has limited efficacy and unfavorable safety profile.  In this context, obeticholic acid (OCA), a selective agonist of the farnesoid X receptors, might represent a useful option in these patients.  Preclinical studies suggest that OCA improves hepatic steatosis, inflammation and fibrosis.  A proof-of-concept study and the randomized, placebo-controlled Farnesoid X Receptor Ligand Obeticholic Acid in non-alcoholic steatohepatitis Treatment (FLINT) trial also showed improvements in liver histology in patients with NAFLD who received OCA.  Weight loss and reduction in blood pressure were also observed.  However, the effects of OCA on insulin resistance are conflicting and the lipid profile is adversely affected by this agent.  In addition, pruritus is frequently observed during treatment with OCA and might lead to treatment discontinuation.  However, given the limitations of existing treatments for NAFLD, OCA might represent a useful therapeutic option in selected patients with NAFLD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFQCUUiZpTcFMGsG_HTXYFfW6udTcc2ebINrSEVKwSYLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjht1emug%253D%253D&md5=f77eb086a95997b49dabd00303e21a22</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v22.i41.9039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v22.i41.9039%26sid%3Dliteratum%253Aachs%26aulast%3DMakri%26aufirst%3DE.%26aulast%3DCholongitas%26aufirst%3DE.%26aulast%3DTziomalos%26aufirst%3DK.%26atitle%3DEmerging%2520role%2520of%2520obeticholic%2520acid%2520in%2520the%2520management%2520of%2520nonalcoholic%2520fatty%2520liver%2520disease%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2016%26volume%3D22%26spage%3D9039%26epage%3D9043%26doi%3D10.3748%2Fwjg.v22.i41.9039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ratziu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francque, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedossa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serfaty, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Gomez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boursier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelmalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drenth, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anstee, Q. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanf, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roudot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Megnien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanyal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathurin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gournay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Khac, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ledinghen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourliere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard-Muet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asselah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrion, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassiman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geerts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuers, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galle, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spengler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugianesi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craxi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voiculescu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheorghe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preotescu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballeria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callera, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luketic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pockros, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poordad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shores, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moehlen, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satapathy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parekh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vierling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umpierrez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallegos-Orozco, J.</span></span> <span> </span><span class="NLM_article-title">Elafibranor, an agonist of the peroxisome proliferator-activated receptor-Î± and -Î´, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">1147</span>â <span class="NLM_lpage">1159</span>, <span class="refDoi">Â DOI: 10.1053/j.gastro.2016.01.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1053%2Fj.gastro.2016.01.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26874076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Klu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2016&pages=1147-1159&author=V.+Ratziuauthor=S.+A.+Harrisonauthor=S.+Francqueauthor=P.+Bedossaauthor=P.+Lehertauthor=L.+Serfatyauthor=M.+Romero-Gomezauthor=J.+Boursierauthor=M.+Abdelmalekauthor=S.+Caldwellauthor=I.+Drenthauthor=Q.+M.+Ansteeauthor=D.+Humauthor=R.+Hanfauthor=A.+Roudotauthor=S.+Megnienauthor=B.+Staelsauthor=A.+Sanyalauthor=P.+Mathurinauthor=J.+Gournayauthor=E.+Nguyen-Khacauthor=V.+De+Ledinghenauthor=D.+Larreyauthor=A.+Tranauthor=M.+Bourliereauthor=M.+Maynard-Muetauthor=T.+Asselahauthor=J.+Henrionauthor=F.+Nevensauthor=D.+Cassimanauthor=A.+Geertsauthor=C.+Morenoauthor=U.+H.+Beuersauthor=P.+R.+Galleauthor=U.+Spenglerauthor=E.+Bugianesiauthor=A.+Craxiauthor=M.+Angelicoauthor=S.+Fargionauthor=M.+Voiculescuauthor=L.+Gheorgheauthor=L.+Preotescuauthor=J.+Caballeriaauthor=R.+J.+Andradeauthor=J.+Crespoauthor=J.+L.+Calleraauthor=A.+Alaauthor=G.+Aithalauthor=G.+Aboudaauthor=V.+Luketicauthor=M.+A.+Huangauthor=S.+Gordonauthor=P.+Pockrosauthor=F.+Poordadauthor=N.+Shoresauthor=M.+W.+Moehlenauthor=K.+Bambhaauthor=V.+Clarkauthor=S.+Satapathyauthor=S.+Parekhauthor=R.+K.+Reddyauthor=M.+Y.+Sheikhauthor=G.+Szaboauthor=J.+Vierlingauthor=T.+Fosterauthor=G.+Umpierrezauthor=C.+Changauthor=T.+Boxauthor=J.+Gallegos-Orozco&title=Elafibranor%2C+an+agonist+of+the+peroxisome+proliferator-activated+receptor-%CE%B1+and+-%CE%B4%2C+induces+resolution+of+nonalcoholic+steatohepatitis+without+fibrosis+worsening&doi=10.1053%2Fj.gastro.2016.01.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-Î± and -Î´, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening</span></div><div class="casAuthors">Ratziu, Vlad; Harrison, Stephen A.; Francque, Sven; Bedossa, Pierre; Lehert, Philippe; Serfaty, Lawrence; Romero-Gomez, Manuel; Boursier, Jerome; Abdelmalek, Manal; Caldwell, Steve; Drenth, Joost; Anstee, Quentin M.; Hum, Dean; Hanf, Remy; Roudot, Alice; Megnien, Sophie; Staels, Bart; Sanyal, Arun</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1147-1159.e5</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Elafibranor is an agonist of the peroxisome proliferator-activated receptor-Î± and peroxisome proliferator-activated receptor-Î´.  Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metab. and reduces inflammation.  We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).  Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 wk at sites in Europe and the United States.  Clin. and lab. evaluations were performed every 2 mo during this 1-yr period.  Liver biopsies were then collected and patients were assessed 3 mo later.  The primary outcome was resoln. of NASH without fibrosis worsening, using protocol-defined and modified definitions.  Data from the groups given the different doses of elafibranor were compared with those from the placebo group using step-down logistic regression, adjusting for baseline nonalcoholic fatty liver disease activity score.  In intention-to-treat anal., there was no significant difference between the elafibranor and placebo groups in the protocol-defined primary outcome.  However, NASH resolved without fibrosis worsening in a higher proportion of patients in the 120-mg elafibranor group vs the placebo group (19% vs 12%; odds ratio = 2.31; 95% confidence interval: 1.02-5.24; P = .045), based on a post-hoc anal. for the modified definition.  In post-hoc analyses of patients with nonalcoholic fatty liver disease activity score â¥4 (n = 234), elafibranor 120 mg resolved NASH in larger proportions of patients than placebo based on the protocol definition (20% vs 11%; odds ratio = 3.16; 95% confidence interval: 1.22-8.13; P = .018) and the modified definitions (19% vs 9%; odds ratio = 3.52; 95% confidence interval: 1.32-9.40; P = .013).  Patients with NASH resoln. after receiving elafibranor 120 mg had reduced liver fibrosis stages compared with those without NASH resoln. (mean redn. of 0.65 Â± 0.61 in responders for the primary outcome vs an increase of 0.10 Â± 0.98 in nonresponders; P < .001).  Liver enzymes, lipids, glucose profiles, and markers of systemic inflammation were significantly reduced in the elafibranor 120-mg group vs the placebo group.  Elafibranor was well tolerated and did not cause wt. gain or cardiac events, but did produce a mild, reversible increase in serum creatinine (effect size vs placebo: increase of 4.31 Â± 1.19 Î¼mol/L; P < .001).  A post-hoc anal. of data from trial of patients with NASH showed that elafibranor (120 mg/d for 1 yr) resolved NASH without fibrosis worsening, based on a modified definition, in the intention-to-treat anal. and in patients with moderate or severe NASH.  However, the predefined end point was not met in the intention to treat population.  Elafibranor was well tolerated and improved patients' cardiometabolic risk profile.  ClinicalTrials.gov no.: NCT01694849.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2XAE5YwAQt7Vg90H21EOLACvtfcHk0liMYaG_2Q24_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Klu7g%253D&md5=cee5c53be700bd0a9eadb455390a222c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2016.01.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2016.01.038%26sid%3Dliteratum%253Aachs%26aulast%3DRatziu%26aufirst%3DV.%26aulast%3DHarrison%26aufirst%3DS.%2BA.%26aulast%3DFrancque%26aufirst%3DS.%26aulast%3DBedossa%26aufirst%3DP.%26aulast%3DLehert%26aufirst%3DP.%26aulast%3DSerfaty%26aufirst%3DL.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DBoursier%26aufirst%3DJ.%26aulast%3DAbdelmalek%26aufirst%3DM.%26aulast%3DCaldwell%26aufirst%3DS.%26aulast%3DDrenth%26aufirst%3DI.%26aulast%3DAnstee%26aufirst%3DQ.%2BM.%26aulast%3DHum%26aufirst%3DD.%26aulast%3DHanf%26aufirst%3DR.%26aulast%3DRoudot%26aufirst%3DA.%26aulast%3DMegnien%26aufirst%3DS.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DSanyal%26aufirst%3DA.%26aulast%3DMathurin%26aufirst%3DP.%26aulast%3DGournay%26aufirst%3DJ.%26aulast%3DNguyen-Khac%26aufirst%3DE.%26aulast%3DDe%2BLedinghen%26aufirst%3DV.%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DTran%26aufirst%3DA.%26aulast%3DBourliere%26aufirst%3DM.%26aulast%3DMaynard-Muet%26aufirst%3DM.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DHenrion%26aufirst%3DJ.%26aulast%3DNevens%26aufirst%3DF.%26aulast%3DCassiman%26aufirst%3DD.%26aulast%3DGeerts%26aufirst%3DA.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DBeuers%26aufirst%3DU.%2BH.%26aulast%3DGalle%26aufirst%3DP.%2BR.%26aulast%3DSpengler%26aufirst%3DU.%26aulast%3DBugianesi%26aufirst%3DE.%26aulast%3DCraxi%26aufirst%3DA.%26aulast%3DAngelico%26aufirst%3DM.%26aulast%3DFargion%26aufirst%3DS.%26aulast%3DVoiculescu%26aufirst%3DM.%26aulast%3DGheorghe%26aufirst%3DL.%26aulast%3DPreotescu%26aufirst%3DL.%26aulast%3DCaballeria%26aufirst%3DJ.%26aulast%3DAndrade%26aufirst%3DR.%2BJ.%26aulast%3DCrespo%26aufirst%3DJ.%26aulast%3DCallera%26aufirst%3DJ.%2BL.%26aulast%3DAla%26aufirst%3DA.%26aulast%3DAithal%26aufirst%3DG.%26aulast%3DAbouda%26aufirst%3DG.%26aulast%3DLuketic%26aufirst%3DV.%26aulast%3DHuang%26aufirst%3DM.%2BA.%26aulast%3DGordon%26aufirst%3DS.%26aulast%3DPockros%26aufirst%3DP.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DShores%26aufirst%3DN.%26aulast%3DMoehlen%26aufirst%3DM.%2BW.%26aulast%3DBambha%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DV.%26aulast%3DSatapathy%26aufirst%3DS.%26aulast%3DParekh%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DR.%2BK.%26aulast%3DSheikh%26aufirst%3DM.%2BY.%26aulast%3DSzabo%26aufirst%3DG.%26aulast%3DVierling%26aufirst%3DJ.%26aulast%3DFoster%26aufirst%3DT.%26aulast%3DUmpierrez%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DBox%26aufirst%3DT.%26aulast%3DGallegos-Orozco%26aufirst%3DJ.%26atitle%3DElafibranor%252C%2520an%2520agonist%2520of%2520the%2520peroxisome%2520proliferator-activated%2520receptor-%25CE%25B1%2520and%2520-%25CE%25B4%252C%2520induces%2520resolution%2520of%2520nonalcoholic%2520steatohepatitis%2520without%2520fibrosis%2520worsening%26jtitle%3DGastroenterology%26date%3D2016%26volume%3D150%26spage%3D1147%26epage%3D1159%26doi%3D10.1053%2Fj.gastro.2016.01.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flesch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert-Zsilavecz, M.</span></span> <span> </span><span class="NLM_article-title">Anthranilic acid derivatives as nuclear receptor modulators - Development of novel PPAR selective and dual PPAR/FXR ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">499</span>â <span class="NLM_lpage">514</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2014.12.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.bmc.2014.12.013" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=499-514&author=D.+Merkauthor=C.+Lamersauthor=J.+Weberauthor=D.+Fleschauthor=M.+Gablerauthor=E.+Proschakauthor=M.+Schubert-Zsilavecz&title=Anthranilic+acid+derivatives+as+nuclear+receptor+modulators+-+Development+of+novel+PPAR+selective+and+dual+PPAR%2FFXR+ligands&doi=10.1016%2Fj.bmc.2014.12.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.013%26sid%3Dliteratum%253Aachs%26aulast%3DMerk%26aufirst%3DD.%26aulast%3DLamers%26aufirst%3DC.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DFlesch%26aufirst%3DD.%26aulast%3DGabler%26aufirst%3DM.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DSchubert-Zsilavecz%26aufirst%3DM.%26atitle%3DAnthranilic%2520acid%2520derivatives%2520as%2520nuclear%2520receptor%2520modulators%2520-%2520Development%2520of%2520novel%2520PPAR%2520selective%2520and%2520dual%2520PPAR%252FFXR%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D499%26epage%3D514%26doi%3D10.1016%2Fj.bmc.2014.12.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stiede, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchette, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beysen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harriman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harwood, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapeller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmalbach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">324</span>â <span class="NLM_lpage">334</span>, <span class="refDoi">Â DOI: 10.1002/hep.29246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1002%2Fhep.29246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28470676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtF2qs7jI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=324-334&author=K.+Stiedeauthor=W.+Miaoauthor=H.+S.+Blanchetteauthor=C.+Beysenauthor=G.+Harrimanauthor=H.+J.+Harwoodauthor=H.+Kelleyauthor=R.+Kapellerauthor=T.+Schmalbachauthor=W.+F.+Westlin&title=Acetyl-coenzyme+A+carboxylase+inhibition+reduces+de+novo+lipogenesis+in+overweight+male+subjects%3A+A+randomized%2C+double-blind%2C+crossover+study&doi=10.1002%2Fhep.29246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Acetyl-coenzyme a carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double-blind, crossover study</span></div><div class="casAuthors">Stiede, Kathryn; Miao, Wenyan; Blanchette, Heather S.; Beysen, Carine; Harriman, Geraldine; Harwood, H. James, Jr.; Kelley, Heather; Kapeller, Rosana; Schmalbach, Tess; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-334</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">NDI-010976, an allosteric inhibitor of acetyl-CoA carboxylases (ACC) ACC1 and ACC2, reduces hepatic de novo lipogenesis (DNL) and favorably affects steatosis, inflammation, and fibrosis in animal models of fatty liver disease.  This study was a randomized, double-blind, placebo-controlled, crossover trial evaluating the pharmacodynamic effects of a single oral dose of NDI-010976 on hepatic DNL in overweight and/or obese but otherwise healthy adult male subjects.  Subjects were randomized to receive either NDI-010976 (20, 50, or 200 mg) or matching placebo in period 1, followed by the alternate treatment in period 2; and hepatic lipogenesis was stimulated with oral fructose administration.  Fractional DNL was quantified by infusing a stable isotope tracer, [1-13C]acetate, and monitoring 13C incorporation into palmitate of circulating very low-d. lipoprotein triglyceride.  Single-dose administration of NDI-010976 was well tolerated at doses up to and including 200 mg.  Fructose administration over a 10-h period stimulated hepatic fractional DNL an av. of 30.9 Â± 6.7% (mean Â± std. deviation) above fasting DNL values in placebo-treated subjects.  Subjects administered single doses of NDI-010976 at 20, 50, or 200 mg had significant inhibition of DNL compared to placebo (mean inhibition relative to placebo was 70%, 85%, and 104%, resp.).  An inverse relationship between fractional DNL and NDI-010976 exposure was obsd. with >90% inhibition of fractional DNL assocd. with plasma concns. of NDI-010976 >4 ng/mL.  Conclusion: ACC inhibition with a single dose of NDI-010976 is well tolerated and results in a profound dose-dependent inhibition of hepatic DNL in overweight adult male subjects.  Therefore, NDI-010976 could contribute considerable value to the treatment algorithm of metabolic disorders characterized by dysregulated fatty acid metab., including nonalcoholic steatohepatitis. (Hepatol. 2017;66:324-334).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT9388eyXnR7Vg90H21EOLACvtfcHk0lgInPbb5wcfpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtF2qs7jI&md5=e6d5240fb6dfd9fc71be7c9a008b3659</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fhep.29246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.29246%26sid%3Dliteratum%253Aachs%26aulast%3DStiede%26aufirst%3DK.%26aulast%3DMiao%26aufirst%3DW.%26aulast%3DBlanchette%26aufirst%3DH.%2BS.%26aulast%3DBeysen%26aufirst%3DC.%26aulast%3DHarriman%26aufirst%3DG.%26aulast%3DHarwood%26aufirst%3DH.%2BJ.%26aulast%3DKelley%26aufirst%3DH.%26aulast%3DKapeller%26aufirst%3DR.%26aulast%3DSchmalbach%26aufirst%3DT.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DAcetyl-coenzyme%2520A%2520carboxylase%2520inhibition%2520reduces%2520de%2520novo%2520lipogenesis%2520in%2520overweight%2520male%2520subjects%253A%2520A%2520randomized%252C%2520double-blind%252C%2520crossover%2520study%26jtitle%3DHepatology%26date%3D2017%26volume%3D66%26spage%3D324%26epage%3D334%26doi%3D10.1002%2Fhep.29246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demagny, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ¼scher, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oosterveer, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoonjans, K.</span></span> <span> </span><span class="NLM_article-title">Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">583</span>â <span class="NLM_lpage">592</span>, <span class="refDoi">Â DOI: 10.1172/JCI85499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI85499" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=583-592&author=S.+Steinauthor=V.+Lemosauthor=P.+Xuauthor=H.+Demagnyauthor=X.+Wangauthor=D.+Ryuauthor=V.+Jimenezauthor=F.+Boschauthor=T.+F.+L%C3%BCscherauthor=M.+H.+Oosterveerauthor=K.+Schoonjans&title=Impaired+SUMOylation+of+nuclear+receptor+LRH-1+promotes+nonalcoholic+fatty+liver+disease&doi=10.1172%2FJCI85499"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1172%2FJCI85499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI85499%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DS.%26aulast%3DLemos%26aufirst%3DV.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DDemagny%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRyu%26aufirst%3DD.%26aulast%3DJimenez%26aufirst%3DV.%26aulast%3DBosch%26aufirst%3DF.%26aulast%3DL%25C3%25BCscher%26aufirst%3DT.%2BF.%26aulast%3DOosterveer%26aufirst%3DM.%2BH.%26aulast%3DSchoonjans%26aufirst%3DK.%26atitle%3DImpaired%2520SUMOylation%2520of%2520nuclear%2520receptor%2520LRH-1%2520promotes%2520nonalcoholic%2520fatty%2520liver%2520disease%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D583%26epage%3D592%26doi%3D10.1172%2FJCI85499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbeek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spincemaille, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhorebeek, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Berghe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Elst, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windmolders, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Pelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Merwe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedossa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thevissen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassiman, D.</span></span> <span> </span><span class="NLM_article-title">Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice</span>. <i>Lipids Health Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">46</span>, <span class="refDoi">Â DOI: 10.1186/s12944-017-0432-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1186%2Fs12944-017-0432-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28231800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVSjsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=46&author=J.+Verbeekauthor=P.+Spincemailleauthor=I.+Vanhorebeekauthor=G.+Van+den+Bergheauthor=I.+Van+der+Elstauthor=P.+Windmoldersauthor=J.+van+Peltauthor=S.+van+der%0AMerweauthor=P.+Bedossaauthor=F.+Nevensauthor=B.+Cammueauthor=K.+Thevissenauthor=D.+Cassiman&title=Dietary+intervention%2C+but+not+losartan%2C+completely+reverses+non-alcoholic+steatohepatitis+in+obese+and+insulin+resistant+mice&doi=10.1186%2Fs12944-017-0432-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice</span></div><div class="casAuthors">Verbeek, Jef; Spincemaille, Pieter; Vanhorebeek, Ilse; Van den Berghe, Greet; Vander Elst, Ingrid; Windmolders, Petra; van Pelt, Jos; van der Merwe, Schalk; Bedossa, Pierre; Nevens, Frederik; Cammue, Bruno; Thevissen, Karin; Cassiman, David</div><div class="citationInfo"><span class="NLM_cas:title">Lipids in Health and Disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46/1-46/10</span>CODEN:
                <span class="NLM_cas:coden">LHDIA7</span>;
        ISSN:<span class="NLM_cas:issn">1476-511X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Dietary intervention is the cornerstone of non-alc. steatohepatitis (NASH) treatment.  However, histol. evidence of its efficacy is limited and its impact on hepatic pathways involved in NASH is underreported.  The efficacy of the angiotensin receptor type 1 blocker losartan is controversial because of varying results in a few animal and human studies.  We evaluated the effect of dietary intervention vs. losartan on NASH and assocd. systemic metabolic features in a representative mouse model.  Methods: Male C57BL/6 J mice with high fat-high sucrose diet (HF-HSD) induced NASH, obesity, insulin resistance and hypercholesterolemia were subjected to dietary intervention (switch from HF-HSD to normal chow diet (NCD)) (n = 9), continuation HF-HSD together with losartan (30 mg/kg/day) (n = 9) or continuation HF-HSD only (n = 9) for 8 wk. 9 mice received NCD during the entire expt. (20 wk).  We assessed the systemic metabolic effects and performed a detailed hepatic histol. and mol. profiling.  A P-value of < 0.05, using the group with continuation of HF-HSD only as control, was considered as statistically significant.  Results: Dietary intervention normalized obesity, insulin resistance, and hypercholesterolemia (for all P < 0.001), and remarkably, completely reversed all histol. features of pre-existent NASH (for all P < 0.001), including fibrosis measured by quantification of collagen proportional area (P < 0.01).  At the hepatic mol. level, dietary intervention targeted fibrogenesis with a normalization of collagen type I alpha 1, transforming growth factor Î²1, tissue inhibitor of metalloproteinase 1 mRNA levels (for all P < 0.01), lipid metab. with a normalization of fatty acid translocase/CD36, fatty acid transport protein 5, fatty acid synthase mRNA levels (P < 0.05) and markers related to mitochondrial function with a normalization of hepatic ATP content (P < 0.05) together with sirtuin1 and uncoupling protein 2 mRNA levels (for both P < 0.001).  Dietary intervention abolished p62 accumulation (P < 0.01), suggesting a restoration of autophagic flux.  Losartan did not significantly affect obesity, insulin resistance, hypercholesterolemia or any histol. NASH feature.  Conclusions: Dietary intervention, and not losartan, completely restores the metabolic phenotype in a representative mouse model with pre-existent NASH, obesity, insulin resistance and hypercholesterolemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJxJHF21qk67Vg90H21EOLACvtfcHk0li-AQt1F9KMIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVSjsLc%253D&md5=02e8d1394c4c37a16e20313b87df4e2f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2Fs12944-017-0432-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12944-017-0432-7%26sid%3Dliteratum%253Aachs%26aulast%3DVerbeek%26aufirst%3DJ.%26aulast%3DSpincemaille%26aufirst%3DP.%26aulast%3DVanhorebeek%26aufirst%3DI.%26aulast%3DVan%2Bden%2BBerghe%26aufirst%3DG.%26aulast%3DVan%2Bder%2BElst%26aufirst%3DI.%26aulast%3DWindmolders%26aufirst%3DP.%26aulast%3Dvan%2BPelt%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BMerwe%26aufirst%3DS.%26aulast%3DBedossa%26aufirst%3DP.%26aulast%3DNevens%26aufirst%3DF.%26aulast%3DCammue%26aufirst%3DB.%26aulast%3DThevissen%26aufirst%3DK.%26aulast%3DCassiman%26aufirst%3DD.%26atitle%3DDietary%2520intervention%252C%2520but%2520not%2520losartan%252C%2520completely%2520reverses%2520non-alcoholic%2520steatohepatitis%2520in%2520obese%2520and%2520insulin%2520resistant%2520mice%26jtitle%3DLipids%2520Health%2520Dis.%26date%3D2017%26volume%3D16%26spage%3D46%26doi%3D10.1186%2Fs12944-017-0432-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coppage, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heard, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMare, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, W. W.</span></span> <span> </span><span class="NLM_article-title">Human FGF21 is a substrate of fibroblast activation protein</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0151269</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0151269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1371%2Fjournal.pone.0151269" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0151269&author=A.+L.+Coppageauthor=K.+R.+Heardauthor=M.+T.+DiMareauthor=Y.+Liuauthor=W.+Wuauthor=J.+H.+Laiauthor=W.+W.+Bachovchin&title=Human+FGF21+is+a+substrate+of+fibroblast+activation+protein&doi=10.1371%2Fjournal.pone.0151269"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0151269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0151269%26sid%3Dliteratum%253Aachs%26aulast%3DCoppage%26aufirst%3DA.%2BL.%26aulast%3DHeard%26aufirst%3DK.%2BR.%26aulast%3DDiMare%26aufirst%3DM.%2BT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DLai%26aufirst%3DJ.%2BH.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26atitle%3DHuman%2520FGF21%2520is%2520a%2520substrate%2520of%2520fibroblast%2520activation%2520protein%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0151269%26doi%3D10.1371%2Fjournal.pone.0151269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunshee, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bainbridge, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kljavin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavala-Solorio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corpuz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonoda, J.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">5986</span>â <span class="NLM_lpage">5996</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M115.710582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1074%2Fjbc.M115.710582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26797127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvFKhsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=5986-5996&author=D.+R.+Dunsheeauthor=T.+W.+Bainbridgeauthor=N.+M.+Kljavinauthor=J.+Zavala-Solorioauthor=A.+C.+Schroederauthor=R.+Chanauthor=R.+Corpuzauthor=M.+Wongauthor=W.+Zhouauthor=G.+Deshmukhauthor=J.+Lyauthor=D.+P.+Sutherlinauthor=J.+A.+Ernstauthor=J.+Sonoda&title=Fibroblast+activation+protein+cleaves+and+inactivates+fibroblast+growth+factor+21&doi=10.1074%2Fjbc.M115.710582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21</span></div><div class="casAuthors">Dunshee, Diana Ronai; Bainbridge, Travis W.; Kljavin, Noelyn M.; Zavala-Solorio, Jose; Schroeder, Amy C.; Chan, Ruby; Corpuz, Racquel; Wong, Manda; Zhou, Wei; Deshmukh, Gauri; Ly, Justin; Sutherlin, Daniel P.; Ernst, James A.; Sonoda, Junichiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5986-5996</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">FGF21 is a stress-induced hormone with potent anti-obesity, insulin-sensitizing, and hepatoprotective properties.  Although proteolytic cleavage of recombinant human FGF21 in preclin. species has been obsd. previously, the regulation of endogenously produced FGF21 is not well understood.  Here we identify fibroblast activation protein (FAP) as the enzyme that cleaves and inactivates human FGF21.  A selective chem. inhibitor, immunodepletion, or genetic deletion of Fap stabilized recombinant human FGF21 in serum.  In addn., administration of a selective FAP inhibitor acutely increased circulating intact FGF21 levels in cynomolgus monkeys.  On the basis of our findings, we propose selective FAP inhibition as a potential therapeutic approach to increase endogenous FGF21 activity for the treatment of obesity, type 2 diabetes, non-alc. steatohepatitis, and related metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqblF1sLi2N5LVg90H21EOLACvtfcHk0lgy0eu9ssUnYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvFKhsrs%253D&md5=a5f4f63ef8d94c2ba0bd50f2bebac075</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.710582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.710582%26sid%3Dliteratum%253Aachs%26aulast%3DDunshee%26aufirst%3DD.%2BR.%26aulast%3DBainbridge%26aufirst%3DT.%2BW.%26aulast%3DKljavin%26aufirst%3DN.%2BM.%26aulast%3DZavala-Solorio%26aufirst%3DJ.%26aulast%3DSchroeder%26aufirst%3DA.%2BC.%26aulast%3DChan%26aufirst%3DR.%26aulast%3DCorpuz%26aufirst%3DR.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DErnst%26aufirst%3DJ.%2BA.%26aulast%3DSonoda%26aufirst%3DJ.%26atitle%3DFibroblast%2520activation%2520protein%2520cleaves%2520and%2520inactivates%2520fibroblast%2520growth%2520factor%252021%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D5986%26epage%3D5996%26doi%3D10.1074%2Fjbc.M115.710582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonergan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darlington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodanovich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span> <span> </span><span class="NLM_article-title">Small molecule lysyloxidase-like 2 (LOXL2) inhibitors: the identification of an inhibitor selective for LOXL2 over LOX</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">423</span>â <span class="NLM_lpage">427</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.7b00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=423-427&author=J.+H.+Hutchinsonauthor=M.+W.+Rowbottomauthor=D.+Lonerganauthor=J.+Darlingtonauthor=P.+Prodanovichauthor=C.+D.+Kingauthor=J.+F.+Evansauthor=G.+Bain&title=Small+molecule+lysyloxidase-like+2+%28LOXL2%29+inhibitors%3A+the+identification+of+an+inhibitor+selective+for+LOXL2+over+LOX&doi=10.1021%2Facsmedchemlett.7b00014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00014%26sid%3Dliteratum%253Aachs%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DLonergan%26aufirst%3DD.%26aulast%3DDarlington%26aufirst%3DJ.%26aulast%3DProdanovich%26aufirst%3DP.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DBain%26aufirst%3DG.%26atitle%3DSmall%2520molecule%2520lysyloxidase-like%25202%2520%2528LOXL2%2529%2520inhibitors%253A%2520the%2520identification%2520of%2520an%2520inhibitor%2520selective%2520for%2520LOXL2%2520over%2520LOX%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D423%26epage%3D427%26doi%3D10.1021%2Facsmedchemlett.7b00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratziu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelmalek, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aithal, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caballeria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francque, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craxi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchor-Khan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vest, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiens, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seyedkazemi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loomba, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tacke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanyal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, E.</span></span> <span> </span><span class="NLM_article-title">A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1754</span>â <span class="NLM_lpage">1767</span>, <span class="refDoi">Â DOI: 10.1002/hep.29477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1002%2Fhep.29477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28833331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlCms7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2018&pages=1754-1767&author=S.+L.+Friedmanauthor=V.+Ratziuauthor=S.+A.+Harrisonauthor=M.+F.+Abdelmalekauthor=G.+P.+Aithalauthor=J.+Caballeriaauthor=S.+Francqueauthor=G.+Farrellauthor=K.+V.+Kowdleyauthor=A.+Craxiauthor=K.+Simonauthor=L.+Fischerauthor=L.+Melchor-Khanauthor=J.+Vestauthor=B.+L.+Wiensauthor=P.+Vigauthor=S.+Seyedkazemiauthor=Z.+Goodmanauthor=V.+W.+Wongauthor=R.+Loombaauthor=F.+Tackeauthor=A.+Sanyalauthor=E.+Lefebvre&title=A+randomized%2C+placebo-controlled+trial+of+cenicriviroc+for+treatment+of+nonalcoholic+steatohepatitis+with+fibrosis&doi=10.1002%2Fhep.29477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis</span></div><div class="casAuthors">Friedman, Scott L.; Ratziu, Vlad; Harrison, Stephen A.; Abdelmalek, Manal F.; Aithal, Guruprasad P.; Caballeria, Juan; Francque, Sven; Farrell, Geoffrey; Kowdley, Kris V.; Craxi, Antonio; Simon, Krzysztof; Fischer, Laurent; Melchor-Khan, Liza; Vest, Jeffrey; Wiens, Brian L.; Vig, Pamela; Seyedkazemi, Star; Goodman, Zachary; Wong, Vincent Wai-Sun; Loomba, Rohit; Tacke, Frank; Sanyal, Arun; Lefebvre, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1754-1767</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C-C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis (LF).  A randomized, double-blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fatty liver disease activity score (NAS) â¥4, and LF (stages 1-3, NASH Clin. Research Network) at 81 clin. sites.  Subjects (N = 289) were randomly assigned CVC 150 mg or placebo.  Primary outcome was â¥2-point improvement in NAS and no worsening of fibrosis at year 1.  Key secondary outcomes were: resoln. of steatohepatitis (SH) and no worsening of fibrosis; improvement in fibrosis by â¥1 stage and no worsening of SH.  Biomarkers of inflammation and adverse events were assessed.  Full study recruitment was achieved.  The primary endpoint of NAS improvement in the intent-to-treat population and resoln. of SH was achieved in a similar proportion of subjects on CVC (N = 145) and placebo (N = 144; 16% vs. 19%, P = 0.52 and 8% vs. 6%, P = 0.49, resp.).  However, the fibrosis endpoint was met in significantly more subjects on CVC than placebo (20% vs. 10%; P = 0.02).  Treatment benefits were greater in those with higher disease activity and fibrosis stage at baseline.  Biomarkers of systemic inflammation were reduced with CVC.  Safety and tolerability of CVC were comparable to placebo.  Conclusion: After 1 yr of CVC treatment, twice as many subjects achieved improvement in fibrosis and no worsening of SH compared with placebo.  Given the urgent need to develop antifibrotic therapies in NASH, these findings warrant phase 3 evaluation. (Hepatol. 2018;67:1754-1767).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg_4ETuDf9irVg90H21EOLACvtfcHk0lgsrn77lJFxYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlCms7g%253D&md5=a712985806b627b992895637d9f59b58</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fhep.29477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.29477%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DS.%2BL.%26aulast%3DRatziu%26aufirst%3DV.%26aulast%3DHarrison%26aufirst%3DS.%2BA.%26aulast%3DAbdelmalek%26aufirst%3DM.%2BF.%26aulast%3DAithal%26aufirst%3DG.%2BP.%26aulast%3DCaballeria%26aufirst%3DJ.%26aulast%3DFrancque%26aufirst%3DS.%26aulast%3DFarrell%26aufirst%3DG.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DCraxi%26aufirst%3DA.%26aulast%3DSimon%26aufirst%3DK.%26aulast%3DFischer%26aufirst%3DL.%26aulast%3DMelchor-Khan%26aufirst%3DL.%26aulast%3DVest%26aufirst%3DJ.%26aulast%3DWiens%26aufirst%3DB.%2BL.%26aulast%3DVig%26aufirst%3DP.%26aulast%3DSeyedkazemi%26aufirst%3DS.%26aulast%3DGoodman%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DV.%2BW.%26aulast%3DLoomba%26aufirst%3DR.%26aulast%3DTacke%26aufirst%3DF.%26aulast%3DSanyal%26aufirst%3DA.%26aulast%3DLefebvre%26aufirst%3DE.%26atitle%3DA%2520randomized%252C%2520placebo-controlled%2520trial%2520of%2520cenicriviroc%2520for%2520treatment%2520of%2520nonalcoholic%2520steatohepatitis%2520with%2520fibrosis%26jtitle%3DHepatology%26date%3D2018%26volume%3D67%26spage%3D1754%26epage%3D1767%26doi%3D10.1002%2Fhep.29477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swendeman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christoffersen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafii, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span> <span> </span><span class="NLM_article-title">HDL activation of endothelial sphingosine-1-phosphate receptor-1 (S1P<sub>1</sub>) promotes regeneration and suppresses fibrosis in the liver</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e87058</span>, <span class="refDoi">Â DOI: 10.1172/jci.insight.87058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2Fjci.insight.87058" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=e87058&author=B.+S.+Dingauthor=C.+H.+Liuauthor=Y.+Sunauthor=Y.+Chenauthor=S.+L.+Swendemanauthor=B.+Jungauthor=D.+Chavezauthor=Z.+Caoauthor=C.+Christoffersenauthor=L.+B.+Nielsenauthor=S.+R.+Schwabauthor=S.+Rafiiauthor=T.+Hla&title=HDL+activation+of+endothelial+sphingosine-1-phosphate+receptor-1+%28S1P1%29+promotes+regeneration+and+suppresses+fibrosis+in+the+liver&doi=10.1172%2Fjci.insight.87058"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.87058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.87058%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DB.%2BS.%26aulast%3DLiu%26aufirst%3DC.%2BH.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSwendeman%26aufirst%3DS.%2BL.%26aulast%3DJung%26aufirst%3DB.%26aulast%3DChavez%26aufirst%3DD.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DChristoffersen%26aufirst%3DC.%26aulast%3DNielsen%26aufirst%3DL.%2BB.%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26aulast%3DRafii%26aufirst%3DS.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DHDL%2520activation%2520of%2520endothelial%2520sphingosine-1-phosphate%2520receptor-1%2520%2528S1P1%2529%2520promotes%2520regeneration%2520and%2520suppresses%2520fibrosis%2520in%2520the%2520liver%26jtitle%3DJCI%2520Insight%26date%3D2016%26volume%3D1%26spage%3De87058%26doi%3D10.1172%2Fjci.insight.87058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vestri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierucci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monaco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meacci, E.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate receptors: do they have a therapeutic potential in cardiac fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">298</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28588497" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=298&author=A.+Vestriauthor=F.+Pierucciauthor=A.+Fratiauthor=L.+Monacoauthor=E.+Meacci&title=Sphingosine-1-phosphate+receptors%3A+do+they+have+a+therapeutic+potential+in+cardiac+fibrosis&doi=10.3389%2Ffphar.2017.00296"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00296%26sid%3Dliteratum%253Aachs%26aulast%3DVestri%26aufirst%3DA.%26aulast%3DPierucci%26aufirst%3DF.%26aulast%3DFrati%26aufirst%3DA.%26aulast%3DMonaco%26aufirst%3DL.%26aulast%3DMeacci%26aufirst%3DE.%26atitle%3DSphingosine-1-phosphate%2520receptors%253A%2520do%2520they%2520have%2520a%2520therapeutic%2520potential%2520in%2520cardiac%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D298%26doi%3D10.3389%2Ffphar.2017.00296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Fernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Gallego, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunon, M. J.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate signaling as a target in hepatic fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">579</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28890699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2nsLrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=579&author=B.+Gonzalez-Fernandezauthor=D.+I.+Sanchezauthor=J.+Gonzalez-Gallegoauthor=M.+J.+Tunon&title=Sphingosine-1-phosphate+signaling+as+a+target+in+hepatic+fibrosis&doi=10.3389%2Ffphar.2017.00579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate signaling as a target in hepatic fibrosis therapy</span></div><div class="casAuthors">Gonzalez-Fernandez, Barbara; Sanchez, Diana I.; Gonzalez-Gallego, Javier; Tunon, Maria J.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">579/1-579/15</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Liver fibrosis is an excess prodn. of extracellular matrix proteins as a result of chronic liver disease which leads to cell death and organ dysfunction.  The key cells involved in fibrogenesis are resident hepatic stellate cells (HSCs) which are termed myofibroblasts after activation, acquiring contractile, proliferative, migratory and secretory capability.  Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid with well-established effects on angiogenesis, carcinogenesis and immunity.  Accumulating evidence demonstrates that this metabolite is involved in the profibrotic inflammatory process through the regulation of pleiotropic cell responses, such as vascular permeability, leukocyte infiltration, cell survival, migration, proliferation and HSCs differentiation to myofibroblasts.  S1P is synthesized by sphingosine kinases (SphKs) and many of its actions are mediated by S1P specific cell surface receptors (S1P1-5), although different intracellular targets of S1P have been identified.  Modulation of SphKs/S1P/S1P receptors signaling is known to result in beneficial effects on various in vivo and in vitro models of liver fibrosis.  Thus, a better knowledge of the mol. mechanisms involved in the modulation of the S1P pathway could help to improve liver fibrosis therapy.  In this review, we analyze the effects of the S1P axis on the fibrogenic process, and the involvement of a range of inhibitors or approaches targeting enzymes related to S1P in the abrogation of pathol. fibrogenesis.  All in all, targeting this pathway offers therapeutic potential in the treatment of hepatic fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2MtTJWyqUCLVg90H21EOLACvtfcHk0lgtLQ5HkI2faQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2nsLrN&md5=e18ac82c856baa9a1b2c40e19afbfaaa</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00579%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Fernandez%26aufirst%3DB.%26aulast%3DSanchez%26aufirst%3DD.%2BI.%26aulast%3DGonzalez-Gallego%26aufirst%3DJ.%26aulast%3DTunon%26aufirst%3DM.%2BJ.%26atitle%3DSphingosine-1-phosphate%2520signaling%2520as%2520a%2520target%2520in%2520hepatic%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D579%26doi%3D10.3389%2Ffphar.2017.00579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minasyan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, E. L.</span></span> <span> </span><span class="NLM_article-title">The role of immune and inflammatory cells in idiopathic pulmonary fibrosis</span>. <i>Front. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">43</span>, <span class="refDoi">Â DOI: 10.3389/fmed.2018.00043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffmed.2018.00043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1Mnosl2ksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=43&author=O.+Desaiauthor=J.+Winklerauthor=M.+Minasyanauthor=E.+L.+Herzog&title=The+role+of+immune+and+inflammatory+cells+in+idiopathic+pulmonary+fibrosis&doi=10.3389%2Ffmed.2018.00043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis</span></div><div class="casAuthors">Desai Omkar; Winkler Julia; Minasyan Maksym; Herzog Erica L</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43</span>
        ISSN:<span class="NLM_cas:issn">2296-858X</span>.
    </div><div class="casAbstract">The contribution of the immune system to idiopathic pulmonary fibrosis (IPF) remains poorly understood.  While most sources agree that IPF does not result from a primary immunopathogenic mechanism, evidence gleaned from animal modeling and human studies suggests that innate and adaptive immune processes can orchestrate existing fibrotic responses.  This review will synthesize the available data regarding the complex role of professional immune cells in IPF.  The role of innate immune populations such as monocytes, macrophages, myeloid suppressor cells, and innate lymphoid cells will be discussed, as will the activation of these cells via pathogen-associated molecular patterns derived from invading or commensural microbes, and danger-associated molecular patterns derived from injured cells and tissues.  The contribution of adaptive immune responses driven by T-helper cells and B cells will be reviewed as well.  Each form of immune activation will be discussed in the context of its relationship to environmental and genetic factors, disease outcomes, and potential therapies.  We conclude with discussion of unanswered questions and opportunities for future study in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTp_tzP210nszK395ZObgVfW6udTcc2eZ0P1p5iPDv2Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mnosl2ksg%253D%253D&md5=82ee170bfe6a824071c52b618faec2b9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.3389%2Ffmed.2018.00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmed.2018.00043%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DO.%26aulast%3DWinkler%26aufirst%3DJ.%26aulast%3DMinasyan%26aufirst%3DM.%26aulast%3DHerzog%26aufirst%3DE.%2BL.%26atitle%3DThe%2520role%2520of%2520immune%2520and%2520inflammatory%2520cells%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DFront.%2520Med.%26date%3D2018%26volume%3D5%26spage%3D43%26doi%3D10.3389%2Ffmed.2018.00043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: current status, recent progress, and emerging targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">527</span>â <span class="NLM_lpage">553</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00935</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00935" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCjsLjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=527-553&author=Y.+M.+Liuauthor=K.+Nepaliauthor=J.+P.+Liou&title=Idiopathic+pulmonary+fibrosis%3A+current+status%2C+recent+progress%2C+and+emerging+targets&doi=10.1021%2Facs.jmedchem.6b00935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets</span></div><div class="casAuthors">Liu, Yi-Min; Nepali, Kunal; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">527-553</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial pneumonia is a fatal lung disease with a median survival time of 3-5 years.  Problems in accurate diagnosis, poor prognosis, limited clin. therapy and high mortality rate together demonstrate that the development of efficient therapeutic strategies for IPF is an important future endeavor.  Deeper understanding of pathogenesis and identification of biomarkers and pathways involved might lead in the future to the emergence of some agents as novel therapeutics for IPF.  This review article presents the pathogenesis, therapeutic interventions, treatment approaches, and strategies employed for the design of antifibrotic agents for the treatment of IPF along with the patent literature from the last 10 years.  With a dozen antifibrotic agents with exciting preclin. potential in the armory, it seems certain that some of them will advance to clin. stage investigations.  The results of clin. trials for some of the new agents are also awaited, to assess their benefits in terms of efficacy and survival benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqizofQCxRDlrVg90H21EOLACvtfcHk0lhIHZNKx3T6qQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCjsLjK&md5=9c6f4f3ebde53b7d2afa625b8de4cf4d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00935%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BM.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520current%2520status%252C%2520recent%2520progress%252C%2520and%2520emerging%2520targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D527%26epage%3D553%26doi%3D10.1021%2Facs.jmedchem.6b00935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Araya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, S. L.</span></span> <span> </span><span class="NLM_article-title">Fibrogenic reactions in lung disease</span>. <i>Annu. Rev. Pathol.: Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">77</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1146/annurev.pathol.4.110807.092217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1146%2Fannurev.pathol.4.110807.092217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=20078216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFekt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=77-98&author=J.+Arayaauthor=S.+L.+Nishimura&title=Fibrogenic+reactions+in+lung+disease&doi=10.1146%2Fannurev.pathol.4.110807.092217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Fibrogenic reactions in lung disease</span></div><div class="casAuthors">Araya, Jun; Nishimura, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77-98</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Fibrogenic lung reactions occur as a common phenotype shared among disorders of heterogeneous etiologies.  Even with a common etiol., the extent and pattern of fibrosis vary greatly among individuals, even within families, suggesting complex gene-environment interactions.  The search for mechanisms shared among all fibrotic lung diseases would represent a major advance in the identification of therapeutic targets that could have a broad impact on lung health.  Although it is difficult to grasp all of the complexities of the varied cell types and cytokine networks involved in lung fibrogenic responses, and to predict the biol. responses to the overexpression or deficiency of individual cytokines, a large body of evidence converges on a single common theme: the central importance of the transforming growth factor beÎ²ta (TGF-Î²) pathway.  Therapies that act upstream or downstream of TGF-Î² activation have the therapeutic potential to treat all fibrogenic responses in the lung.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9JN7xNQMZt7Vg90H21EOLACvtfcHk0lhhprJ8Hy5sFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFekt7w%253D&md5=1883ae9d3a397d4768750cdf9249f978</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathol.4.110807.092217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathol.4.110807.092217%26sid%3Dliteratum%253Aachs%26aulast%3DAraya%26aufirst%3DJ.%26aulast%3DNishimura%26aufirst%3DS.%2BL.%26atitle%3DFibrogenic%2520reactions%2520in%2520lung%2520disease%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2010%26volume%3D5%26spage%3D77%26epage%3D98%26doi%3D10.1146%2Fannurev.pathol.4.110807.092217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aubert, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span> <span> </span><span class="NLM_article-title">Endothelin-receptor antagonists beyond pulmonary arterial hypertension: cancer and fibrosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8168</span>â <span class="NLM_lpage">8188</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01781</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01781" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVClsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8168-8188&author=J.+D.+Aubertauthor=L.+Juillerat-Jeanneret&title=Endothelin-receptor+antagonists+beyond+pulmonary+arterial+hypertension%3A+cancer+and+fibrosis&doi=10.1021%2Facs.jmedchem.5b01781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis</span></div><div class="casAuthors">Aubert, John-David; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8168-8188</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for therapeutic intervention in human diseases.  Endothelin-receptor antagonists are in clin. use to treat pulmonary arterial hypertension and have been under clin. investigation for the treatment of several other diseases, such as systemic hypertension, cancer, vasospasm, and fibrogenic diseases.  In this Perspective, we review the mols. that have been evaluated in human clin. trials for the treatment of pulmonary arterial hypertension, as well as other cardiovascular diseases, cancer, and fibrosis.  We will also discuss the therapeutic consequences of receptor selectivity with regard to ETA-selective, ETB-selective, or dual ETA/ETB antagonists.  We will also consider which chem. characteristics are relevant to clin. use and the properties of mols. necessary for efficacy in treating diseases against which known mols. displayed suboptimal efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKfhFfiImWNbVg90H21EOLACvtfcHk0lhhprJ8Hy5sFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVClsrs%253D&md5=b6f008d678c7e4ff5ded1db5f4a940c5</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01781%26sid%3Dliteratum%253Aachs%26aulast%3DAubert%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DEndothelin-receptor%2520antagonists%2520beyond%2520pulmonary%2520arterial%2520hypertension%253A%2520cancer%2520and%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8168%26epage%3D8188%26doi%3D10.1021%2Facs.jmedchem.5b01781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garneau-Tsodikova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thannickal, V. J.</span></span> <span> </span><span class="NLM_article-title">Protein kinase inhibitors in the treatment of pulmonary fibrosis</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2632</span>â <span class="NLM_lpage">2640</span>, <span class="refDoi">Â DOI: 10.2174/092986708785908969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2174%2F092986708785908969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18855683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1SgtbfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=2632-2640&author=S.+Garneau-Tsodikovaauthor=V.+J.+Thannickal&title=Protein+kinase+inhibitors+in+the+treatment+of+pulmonary+fibrosis&doi=10.2174%2F092986708785908969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase inhibitors in the treatment of pulmonary fibrosis</span></div><div class="casAuthors">Garneau-Tsodikova, Sylvie; Thannickal, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2632-2640</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Fibrosis of the lung and other organ systems is an increasing cause of morbidity and mortality worldwide.  Effective anti-fibrotic agents for such disorders are currently lacking.  Injury to epithelium-lined tissues in mammals is typically assocd. with a mesenchymal response, including the activation of myofibroblasts.  Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease that results from effacement of the normal alveolar architecture of the lung.  Loss of lung capacity for gas-exchange and increased work of breathing eventually leads to respiratory failure and death.  In cutaneous wound models, apoptosis of myofibroblasts are essential to scar-less wound healing.  Recent studies indicate that acquisition of an apoptosis-resistant myofibroblast phenotype in the injured lung is assocd. with non-resolving and persistent fibrosis.  The acquired resistance to apoptosis in myofibroblasts is mediated, at least in part, by the sustained activation of two crit. pro-survival protein kinases, focal adhesion kinase (FAK) and protein kinase B (PKB/AKT).  Therapeutic interventions that modulate the activity of these protein kinases with resultant alterations in the phenotype of myofibroblasts may prove to be effective anti-fibrotic therapeutic strategies.  We discuss the potential roles for protein kinase inhibitors as novel drugs for fibrotic disorders.  Progress in pre-clin. and clin. development of small mol. inhibitors targeting pro-survival protein kinases is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriAW2A7_uv37Vg90H21EOLACvtfcHk0ljDb0B9PnrGFw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1SgtbfN&md5=030118de5dbd67f6ba3cedb95b872d52</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F092986708785908969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785908969%26sid%3Dliteratum%253Aachs%26aulast%3DGarneau-Tsodikova%26aufirst%3DS.%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26atitle%3DProtein%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520pulmonary%2520fibrosis%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D2632%26epage%3D2640%26doi%3D10.2174%2F092986708785908969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, W. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, R. Y.</span></span> <span> </span><span class="NLM_article-title">Repurposing pentoxifylline for the treatment of fibrosis: an overview</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1245</span>â <span class="NLM_lpage">1269</span>, <span class="refDoi">Â DOI: 10.1007/s12325-017-0547-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1007%2Fs12325-017-0547-2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=1245-1269&author=W.+X.+Wenauthor=S.+Y.+Leeauthor=R.+Siangauthor=R.+Y.+Koh&title=Repurposing+pentoxifylline+for+the+treatment+of+fibrosis%3A+an+overview&doi=10.1007%2Fs12325-017-0547-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs12325-017-0547-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-017-0547-2%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DW.%2BX.%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DSiang%26aufirst%3DR.%26aulast%3DKoh%26aufirst%3DR.%2BY.%26atitle%3DRepurposing%2520pentoxifylline%2520for%2520the%2520treatment%2520of%2520fibrosis%253A%2520an%2520overview%26jtitle%3DAdv.%2520Ther.%26date%3D2017%26volume%3D34%26spage%3D1245%26epage%3D1269%26doi%3D10.1007%2Fs12325-017-0547-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, C. H.</span></span> <span> </span><span class="NLM_article-title">ERK5 regulates basic fibroblast growth factor-induced type 1 plasminogen activator inhibitor expression and cell proliferation in lung fibroblasts</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">8</span>, <span class="refDoi">Â DOI: 10.1016/j.lfs.2015.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.lfs.2015.05.006" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=1-8&author=J.+H.+Hanauthor=A.+R.+Hwangauthor=D.+H.+Namauthor=S.+Kimauthor=H.+C.+Choiauthor=J.+H.+Limauthor=C.+H.+Woo&title=ERK5+regulates+basic+fibroblast+growth+factor-induced+type+1+plasminogen+activator+inhibitor+expression+and+cell+proliferation+in+lung+fibroblasts&doi=10.1016%2Fj.lfs.2015.05.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2015.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2015.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%2BH.%26aulast%3DHwang%26aufirst%3DA.%2BR.%26aulast%3DNam%26aufirst%3DD.%2BH.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DH.%2BC.%26aulast%3DLim%26aufirst%3DJ.%2BH.%26aulast%3DWoo%26aufirst%3DC.%2BH.%26atitle%3DERK5%2520regulates%2520basic%2520fibroblast%2520growth%2520factor-induced%2520type%25201%2520plasminogen%2520activator%2520inhibitor%2520expression%2520and%2520cell%2520proliferation%2520in%2520lung%2520fibroblasts%26jtitle%3DLife%2520Sci.%26date%3D2015%26volume%3D135%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.lfs.2015.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonella, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stowasser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollin, L.</span></span> <span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">6407</span>â <span class="NLM_lpage">6419</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S76648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S76648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26715838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVekur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=6407-6419&author=F.+Bonellaauthor=S.+Stowasserauthor=L.+Wollin&title=Idiopathic+pulmonary+fibrosis%3A+current+treatment+options+and+critical+appraisal+of+nintedanib&doi=10.2147%2FDDDT.S76648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Idiopathic pulmonary fibrosis: Current treatment options and critical appraisal of nintedanib</span></div><div class="casAuthors">Bonella, Francesco; Stowasser, Susanne; Wollin, Lutz</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6407-6419</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial pneumonia and is characterized by a poor prognosis, with an estd. 5-yr survival of approx. 20%.  Progressive and irreversible lung functional impairment leads to chronic respiratory insufficiency with a severely impaired quality of life.  In the last 2 decades, novel treatments for IPF have been developed as a consequence of an increasing understanding of disease pathogenesis and pathobiol.  In IPF, injured dysfunctional alveolar epithelial cells promote fibroblast recruitment and proliferation, resulting in scarring of the lung tissue.  Recently, pirfenidone and nintedanib have been approved for the treatment of IPF, having shown efficacy to slow functional decline and disease progression.  This article focuses on the pharmacol. characteristics and clin. evidence supporting the use of nintedanib, a potent small-mol. tyrosine kinase inhibitor, as therapy for IPF.  After introducing the mechanism of action and pharmacokinetics, an overview of the safety and efficacy results from the most recent clin. trials of nintedanib in IPF is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfjUsaFPn0erVg90H21EOLACvtfcHk0lgU2j5Doj-jBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVekur8%253D&md5=ad6fa39dba483ae329daf63d5e38cc5a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S76648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S76648%26sid%3Dliteratum%253Aachs%26aulast%3DBonella%26aufirst%3DF.%26aulast%3DStowasser%26aufirst%3DS.%26aulast%3DWollin%26aufirst%3DL.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520current%2520treatment%2520options%2520and%2520critical%2520appraisal%2520of%2520nintedanib%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D6407%26epage%3D6419%26doi%3D10.2147%2FDDDT.S76648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ra, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulick, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerome, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofidou-Solomidou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speicher, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachovchin, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feghali-Bostwick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PurÃ©, E.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein (FAP) accelerates collagen degradation and clearance from lungs in mice</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">8070</span>â <span class="NLM_lpage">8089</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M115.701433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1074%2Fjbc.M115.701433" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=8070-8089&author=M.+H.+Fanauthor=Q.+Zhuauthor=H.+H.+Liauthor=H.+J.+Raauthor=S.+Majumdarauthor=D.+L.+Gulickauthor=J.+A.+Jeromeauthor=D.+H.+Madsenauthor=M.+Christofidou-Solomidouauthor=D.+W.+Speicherauthor=W.+W.+Bachovchinauthor=C.+Feghali-Bostwickauthor=E.+Pur%C3%A9&title=Fibroblast+activation+protein+%28FAP%29+accelerates+collagen+degradation+and+clearance+from+lungs+in+mice&doi=10.1074%2Fjbc.M115.701433"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.701433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.701433%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DM.%2BH.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DH.%2BH.%26aulast%3DRa%26aufirst%3DH.%2BJ.%26aulast%3DMajumdar%26aufirst%3DS.%26aulast%3DGulick%26aufirst%3DD.%2BL.%26aulast%3DJerome%26aufirst%3DJ.%2BA.%26aulast%3DMadsen%26aufirst%3DD.%2BH.%26aulast%3DChristofidou-Solomidou%26aufirst%3DM.%26aulast%3DSpeicher%26aufirst%3DD.%2BW.%26aulast%3DBachovchin%26aufirst%3DW.%2BW.%26aulast%3DFeghali-Bostwick%26aufirst%3DC.%26aulast%3DPur%25C3%25A9%26aufirst%3DE.%26atitle%3DFibroblast%2520activation%2520protein%2520%2528FAP%2529%2520accelerates%2520collagen%2520degradation%2520and%2520clearance%2520from%2520lungs%2520in%2520mice%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D8070%26epage%3D8089%26doi%3D10.1074%2Fjbc.M115.701433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sobel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menyhart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Killer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renault, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolli, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatfield, J.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate (S1P) receptor agonists mediate pro-fibrotic response in normal human lung fibroblasts via S1P<sub>2</sub> and S1P<sub>3</sub> receptors and Smad-independent mechanisms</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">14839</span>â <span class="NLM_lpage">14851</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M112.426726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1074%2Fjbc.M112.426726" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=14839-14851&author=K.+Sobelauthor=K.+Menyhartauthor=N.+Killerauthor=B.+Renaultauthor=Y.+Bauerauthor=R.+Studerauthor=B.+Steinerauthor=M.+H.+Bolliauthor=O.+Naylerauthor=J.+Gatfield&title=Sphingosine-1-phosphate+%28S1P%29+receptor+agonists+mediate+pro-fibrotic+response+in+normal+human+lung+fibroblasts+via+S1P2+and+S1P3+receptors+and+Smad-independent+mechanisms&doi=10.1074%2Fjbc.M112.426726"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.426726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.426726%26sid%3Dliteratum%253Aachs%26aulast%3DSobel%26aufirst%3DK.%26aulast%3DMenyhart%26aufirst%3DK.%26aulast%3DKiller%26aufirst%3DN.%26aulast%3DRenault%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DY.%26aulast%3DStuder%26aufirst%3DR.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DGatfield%26aufirst%3DJ.%26atitle%3DSphingosine-1-phosphate%2520%2528S1P%2529%2520receptor%2520agonists%2520mediate%2520pro-fibrotic%2520response%2520in%2520normal%2520human%2520lung%2520fibroblasts%2520via%2520S1P2%2520and%2520S1P3%2520receptors%2520and%2520Smad-independent%2520mechanisms%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D14839%26epage%3D14851%26doi%3D10.1074%2Fjbc.M112.426726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tager, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCamera, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shea, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campanella, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polosukhin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karimi-Shah, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackwell, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luster, A. D.</span></span> <span> </span><span class="NLM_article-title">The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">45</span>â <span class="NLM_lpage">54</span>, <span class="refDoi">Â DOI: 10.1038/nm1685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm1685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18066075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVWisQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=45-54&author=A.+M.+Tagerauthor=P.+LaCameraauthor=B.+S.+Sheaauthor=G.+S.+Campanellaauthor=M.+Selmanauthor=Z.+Zhaoauthor=V.+Polosukhinauthor=J.+Wainauthor=B.+A.+Karimi-Shahauthor=N.+D.+Kimauthor=W.+K.+Hartauthor=A.+Pardoauthor=T.+S.+Blackwellauthor=Y.+Xuauthor=J.+Chunauthor=A.+D.+Luster&title=The+lysophosphatidic+acid+receptor+LPA1+links+pulmonary+fibrosis+to+lung+injury+by+mediating+fibroblast+recruitment+and+vascular+leak&doi=10.1038%2Fnm1685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak</span></div><div class="casAuthors">Tager, Andrew M.; LaCamera, Peter; Shea, Barry S.; Campanella, Gabriele S.; Selman, Moises; Zhao, Zhenwen; Polosukhin, Vasiliy; Wain, John; Karimi-Shah, Banu A.; Kim, Nancy D.; Hart, William K.; Pardo, Annie; Blackwell, Timothy S.; Xu, Yan; Chun, Jerold; Luster, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-54</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathol. responses have yet to be fully identified.  We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model.  The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury.  In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid.  LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8pk5JY4qBbLVg90H21EOLACvtfcHk0lh1fGqN_nUOXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVWisQ%253D%253D&md5=1a7e86264154df8960699d18a7ef2407</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnm1685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1685%26sid%3Dliteratum%253Aachs%26aulast%3DTager%26aufirst%3DA.%2BM.%26aulast%3DLaCamera%26aufirst%3DP.%26aulast%3DShea%26aufirst%3DB.%2BS.%26aulast%3DCampanella%26aufirst%3DG.%2BS.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DPolosukhin%26aufirst%3DV.%26aulast%3DWain%26aufirst%3DJ.%26aulast%3DKarimi-Shah%26aufirst%3DB.%2BA.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DHart%26aufirst%3DW.%2BK.%26aulast%3DPardo%26aufirst%3DA.%26aulast%3DBlackwell%26aufirst%3DT.%2BS.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26atitle%3DThe%2520lysophosphatidic%2520acid%2520receptor%2520LPA1%2520links%2520pulmonary%2520fibrosis%2520to%2520lung%2520injury%2520by%2520mediating%2520fibroblast%2520recruitment%2520and%2520vascular%2520leak%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D45%26epage%3D54%26doi%3D10.1038%2Fnm1685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidduri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truitt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fretland, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenfeld, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budd, D. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7920</span>â <span class="NLM_lpage">7939</span>, <span class="refDoi">Â DOI: 10.1021/jm301022v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301022v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7920-7939&author=Y.+Qianauthor=M.+Hamiltonauthor=A.+Sidduriauthor=S.+Gabrielauthor=Y.+Renauthor=R.+Pengauthor=R.+Kondruauthor=A.+Narayananauthor=T.+Truittauthor=R.+Hamidauthor=Y.+Chenauthor=L.+Zhangauthor=A.+J.+Fretlandauthor=R.+Alvarez+Sanchezauthor=K.+C.+Changauthor=M.+Lucasauthor=R.+C.+Schoenfeldauthor=D.+Laineauthor=M.+E.+Fuentesauthor=C.+S.+Stevensonauthor=D.+C.+Budd&title=Discovery+of+highly+selective+and+orally+active+lysophosphatidic+acid+receptor-1+antagonists+with+potent+activity+on+human+lung+fibroblasts&doi=10.1021%2Fjm301022v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm301022v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301022v%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DY.%26aulast%3DHamilton%26aufirst%3DM.%26aulast%3DSidduri%26aufirst%3DA.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DNarayanan%26aufirst%3DA.%26aulast%3DTruitt%26aufirst%3DT.%26aulast%3DHamid%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFretland%26aufirst%3DA.%2BJ.%26aulast%3DAlvarez%2BSanchez%26aufirst%3DR.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DLucas%26aufirst%3DM.%26aulast%3DSchoenfeld%26aufirst%3DR.%2BC.%26aulast%3DLaine%26aufirst%3DD.%26aulast%3DFuentes%26aufirst%3DM.%2BE.%26aulast%3DStevenson%26aufirst%3DC.%2BS.%26aulast%3DBudd%26aufirst%3DD.%2BC.%26atitle%3DDiscovery%2520of%2520highly%2520selective%2520and%2520orally%2520active%2520lysophosphatidic%2520acid%2520receptor-1%2520antagonists%2520with%2520potent%2520activity%2520on%2520human%2520lung%2520fibroblasts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7920%26epage%3D7939%26doi%3D10.1021%2Fjm301022v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richeldi, L.</span></span> <span> </span><span class="NLM_article-title">Current approaches to the management of idiopathic pulmonary fibrosis</span>. <i>Resp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">24</span>â <span class="NLM_lpage">30</span>, <span class="refDoi">Â DOI: 10.1016/j.rmed.2017.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.rmed.2017.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28732832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1cfgtVGmtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=24-30&author=G.+Raghuauthor=L.+Richeldi&title=Current+approaches+to+the+management+of+idiopathic+pulmonary+fibrosis&doi=10.1016%2Fj.rmed.2017.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Current approaches to the management of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Raghu Ganesh; Richeldi Luca</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease associated with dyspnoea, cough and impaired quality of life.  Currently, the aims of patient care are to improve outcomes for patients by slowing the progression of the disease, extending life, and improving quality of life.  A prompt, accurate diagnosis is important to enable patients to receive treatment early in the course of the disease and to be considered for lung transplantation.  Two anti-fibrotic drugs, nintedanib and pirfenidone, have been shown to reduce decline in lung function in patients with IPF.  In addition to pharmacological therapy, optimal management of IPF includes treatment of comorbidities, symptom relief, pulmonary rehabilitation, and palliative care.  Patient education is important to enable patients to make decisions about their care and to help them manage their disease and the side-effects of anti-fibrotic drugs.  Research continues into new treatments and combinations of treatments that may improve outcomes for patients with this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDPrPp1yCsHpSWdIdmEou5fW6udTcc2ebqMScbCt38rbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfgtVGmtw%253D%253D&md5=4e0d042f92f1c57f906dd1fe61f73224</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2017.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2017.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DRicheldi%26aufirst%3DL.%26atitle%3DCurrent%2520approaches%2520to%2520the%2520management%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DResp.%2520Med.%26date%3D2017%26volume%3D129%26spage%3D24%26epage%3D30%26doi%3D10.1016%2Fj.rmed.2017.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, J. S.</span></span> <span> </span><span class="NLM_article-title">Cellular and molecular mechanisms in kidney fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2299</span>â <span class="NLM_lpage">2306</span>, <span class="refDoi">Â DOI: 10.1172/JCI72267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI72267" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=2299-2306&author=J.+S.+Duffield&title=Cellular+and+molecular+mechanisms+in+kidney+fibrosis&doi=10.1172%2FJCI72267"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1172%2FJCI72267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI72267%26sid%3Dliteratum%253Aachs%26aulast%3DDuffield%26aufirst%3DJ.%2BS.%26atitle%3DCellular%2520and%2520molecular%2520mechanisms%2520in%2520kidney%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D2299%26epage%3D2306%26doi%3D10.1172%2FJCI72267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffield, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violette, S.</span></span> <span> </span><span class="NLM_article-title">Therapy for fibrotic diseases: nearing the starting line</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">167sr1</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3004700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1126%2Fscitranslmed.3004700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23303606" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=167sr1&author=S.+L.+Friedmanauthor=D.+Sheppardauthor=J.+S.+Duffieldauthor=S.+Violette&title=Therapy+for+fibrotic+diseases%3A+nearing+the+starting+line&doi=10.1126%2Fscitranslmed.3004700"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3004700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3004700%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DS.%2BL.%26aulast%3DSheppard%26aufirst%3DD.%26aulast%3DDuffield%26aufirst%3DJ.%2BS.%26aulast%3DViolette%26aufirst%3DS.%26atitle%3DTherapy%2520for%2520fibrotic%2520diseases%253A%2520nearing%2520the%2520starting%2520line%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26spage%3D167sr1%26doi%3D10.1126%2Fscitranslmed.3004700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plieth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Threadgill, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neilson, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R. C.</span></span> <span> </span><span class="NLM_article-title">EGFR signaling promotes TGFÎ²-dependent renal fibrosis</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">215</span>â <span class="NLM_lpage">224</span>, <span class="refDoi">Â DOI: 10.1681/ASN.2011070645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1681%2FASN.2011070645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22095949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjslamtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=215-224&author=J.+Chenauthor=J.+K.+Chenauthor=K.+Nagaiauthor=D.+Pliethauthor=M.+Tanauthor=T.+C.+Leeauthor=D.+W.+Threadgillauthor=E.+G.+Neilsonauthor=R.+C.+Harris&title=EGFR+signaling+promotes+TGF%CE%B2-dependent+renal+fibrosis&doi=10.1681%2FASN.2011070645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR signaling promotes TGFÎ²-dependent renal fibrosis</span></div><div class="casAuthors">Chen, Jianchun; Chen, Jian-Kang; Nagai, Kojiro; Plieth, David; Tan, Mingqi; Lee, Tang-Cheng; Threadgill, David W.; Neilson, Eric G.; Harris, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-224</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">The mechanisms by which angiotensin II (Ang II) promotes renal fibrosis remain incompletely understood.  Ang II both stimulates TGFÎ² signaling and activates the EGF receptor (EGFR), but the relative contribution of these pathways to renal fibrogenesis is unknown.  Using a murine model with EGFR-deficient proximal tubules, we demonstrate that upstream activation of EGFR-dependent ERK signaling is crit. for mediating sustained TGFÎ² expression in renal fibrosis.  Persistent activation of the Ang II receptor stimulated ROS-dependent phosphorylation of Src, leading to sustained EGFR-dependent signaling for TGFÎ² expression.  Either genetic or pharmacol. inhibition of EGFR significantly decreased TGFÎ²-mediated fibrogenesis.  We conclude that TGFÎ²-mediated tissue fibrosis relies on a persistent feed-forward mechanism of EGFR/ERK activation through an unexpected signaling pathway, highlighting EGFR as a potential therapeutic target for modulating tissue fibrogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3mTaG1FkGTrVg90H21EOLACvtfcHk0lhVZ6Y28Mt0qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjslamtb8%253D&md5=bd4a76b4371d21ae732b07925e43b077</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1681%2FASN.2011070645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2011070645%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%2BK.%26aulast%3DNagai%26aufirst%3DK.%26aulast%3DPlieth%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DT.%2BC.%26aulast%3DThreadgill%26aufirst%3DD.%2BW.%26aulast%3DNeilson%26aufirst%3DE.%2BG.%26aulast%3DHarris%26aufirst%3DR.%2BC.%26atitle%3DEGFR%2520signaling%2520promotes%2520TGF%25CE%25B2-dependent%2520renal%2520fibrosis%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2012%26volume%3D23%26spage%3D215%26epage%3D224%26doi%3D10.1681%2FASN.2011070645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span> <span> </span><span class="NLM_article-title">Renal interstitial fibrosis induced by high doses mesoporous silica nanoparticles via the NF-ÎºB signaling pathway</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">22</span>, <span class="refDoi">Â DOI: 10.2147/IJN.S73538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FIJN.S73538" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1-22&author=C.+Xiauthor=Z.+Wangauthor=J.+Zhouauthor=X.+Fuauthor=J.+Liangauthor=Y.+Qiuauthor=Z.+Huang&title=Renal+interstitial+fibrosis+induced+by+high+doses+mesoporous+silica+nanoparticles+via+the+NF-%CE%BAB+signaling+pathway&doi=10.2147%2FIJN.S73538"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2147%2FIJN.S73538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S73538%26sid%3Dliteratum%253Aachs%26aulast%3DXi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26atitle%3DRenal%2520interstitial%2520fibrosis%2520induced%2520by%2520high%2520doses%2520mesoporous%2520silica%2520nanoparticles%2520via%2520the%2520NF-%25CE%25BAB%2520signaling%2520pathway%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2015%26volume%3D10%26spage%3D1%26epage%3D22%26doi%3D10.2147%2FIJN.S73538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovisa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBleu, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tampe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vadnagara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carstens, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagos, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burckhardt, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pentcheva-Hoang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nischal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeisberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalluri, R.</span></span> <span> </span><span class="NLM_article-title">Epithelial to mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">998</span>â <span class="NLM_lpage">1009</span>, <span class="refDoi">Â DOI: 10.1038/nm.3902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm.3902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26236991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCksL7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=998-1009&author=S.+Lovisaauthor=V.+S.+LeBleuauthor=B.+Tampeauthor=H.+Sugimotoauthor=K.+Vadnagaraauthor=J.+L.+Carstensauthor=C.+C.+Wuauthor=Y.+Hagosauthor=B.+C.+Burckhardtauthor=T.+Pentcheva-Hoangauthor=H.+Nischalauthor=J.+P.+Allisonauthor=M.+Zeisbergauthor=R.+Kalluri&title=Epithelial+to+mesenchymal+transition+induces+cell+cycle+arrest+and+parenchymal+damage+in+renal+fibrosis&doi=10.1038%2Fnm.3902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis</span></div><div class="casAuthors">Lovisa, Sara; Le Bleu, Valerie S.; Tampe, Bjorn; Sugimoto, Hikaru; Vadnagara, Komal; Carstens, Julienne L.; Wu, Chia-Chin; Hagos, Yohannes; Burckhardt, Birgitta C.; Pentcheva-Hoang, Tsvetelina; Nischal, Hersharan; Allison, James P.; Zeisberg, Michael; Kalluri, Raghu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">998-1009</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kidney fibrosis is marked by an epithelial-to-mesenchymal transition (EMT) of tubular epithelial cells (TECs).  Here we find that, during renal fibrosis, TECs acquire a partial EMT program during which they remain assocd. with their basement membrane and express markers of both epithelial and mesenchymal cells.  The functional consequence of the EMT program during fibrotic injury is an arrest in the G2 phase of the cell cycle and lower expression of several solute and solvent transporters in TECs.  We also found that transgenic expression of either Twist1 (encoding twist family bHLH transcription factor 1, known as Twist) or Snai1 (encoding snail family zinc finger 1, known as Snail) expression is sufficient to promote prolonged TGF-Î²1-induced G2 arrest of TECs, limiting the cells' potential for repair and regeneration.  In mouse models of exptl. induced renal fibrosis, conditional deletion of Twist1 or Snai1 in proximal TECs resulted in inhibition of the EMT program and the maintenance of TEC integrity, while also restoring cell proliferation, dedifferentiation-assocd. repair and regeneration of the kidney parenchyma and attenuating interstitial fibrosis.  Thus, inhibition of the EMT program in TECs during chronic renal injury represents a potential anti-fibrosis therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIWzh92Cy4rbVg90H21EOLACvtfcHk0liJs6p495t2hQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCksL7N&md5=54a4949f76e6f9fcc845f262c4c50344</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnm.3902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3902%26sid%3Dliteratum%253Aachs%26aulast%3DLovisa%26aufirst%3DS.%26aulast%3DLeBleu%26aufirst%3DV.%2BS.%26aulast%3DTampe%26aufirst%3DB.%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DVadnagara%26aufirst%3DK.%26aulast%3DCarstens%26aufirst%3DJ.%2BL.%26aulast%3DWu%26aufirst%3DC.%2BC.%26aulast%3DHagos%26aufirst%3DY.%26aulast%3DBurckhardt%26aufirst%3DB.%2BC.%26aulast%3DPentcheva-Hoang%26aufirst%3DT.%26aulast%3DNischal%26aufirst%3DH.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DZeisberg%26aufirst%3DM.%26aulast%3DKalluri%26aufirst%3DR.%26atitle%3DEpithelial%2520to%2520mesenchymal%2520transition%2520induces%2520cell%2520cycle%2520arrest%2520and%2520parenchymal%2520damage%2520in%2520renal%2520fibrosis%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D998%26epage%3D1009%26doi%3D10.1038%2Fnm.3902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eddy, A. A.</span></span> <span> </span><span class="NLM_article-title">Overview of the cellular and molecular basis of kidney fibrosis</span>. <i>Kidney Int. Suppl.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2</span>â <span class="NLM_lpage">8</span>, <span class="refDoi">Â DOI: 10.1038/kisup.2014.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fkisup.2014.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVKmtb3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=2-8&author=A.+A.+Eddy&title=Overview+of+the+cellular+and+molecular+basis+of+kidney+fibrosis&doi=10.1038%2Fkisup.2014.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the cellular and molecular basis of kidney fibrosis</span></div><div class="casAuthors">Eddy, Allison A.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International Supplements</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-8</span>CODEN:
                <span class="NLM_cas:coden">KISIAA</span>;
        ISSN:<span class="NLM_cas:issn">2157-1716</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The common pathogenetic pathway of progressive injury in patients with chronic kidney disease (CKD) is epitomized as normal kidney parenchymal destruction due to scarring (fibrosis).  Understanding the fundamental pathways that lead to renal fibrosis is essential in order to develop better therapeutic options for human CKD.  Although complex, four cellular responses are pivotal. (1) An interstitial inflammatory response that has multiple consequences-some harmful and others healing. (2) The appearance of a unique interstitial cell population of myofibroblasts, primarily derived from kidney stromal cells (fibroblasts and pericytes), that are the primary source of the various extracellular matrix proteins that form interstitial scars. (3) Tubular epithelial cells that have variable and time-dependent roles as early responders to injury and later as victims of fibrosis due to the loss of their regenerative abilities. (4) Loss of interstitial capillary integrity that compromises oxygen delivery and leads to a vicious cascade of hypoxia-oxidant stress that accentuates injury and fibrosis.  In the absence of adequate angiogenic responses, a healthy interstitial capillary network is not maintained.  The fibrotic 'scar' that typifies CKD is an interesting consortium of multifunctional macromols. that not only change in compn. and structure over time, but can be degraded via extracellular and intracellular proteases.  Although transforming growth factor beta appears to be the primary driver of kidney fibrosis, a vast array of addnl. mols. may have modulating roles.  The importance of genetic and epigenetic factors is increasingly appreciated.  An intriguing but incompletely understood cardiorenal syndrome underlies the high morbidity and mortality rates that develop in assocn. with progressive kidney fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQbMRehR4jqrVg90H21EOLACvtfcHk0liKsABSckkayQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVKmtb3J&md5=dc65f7c53ed78530c8f2e76a9da8716a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fkisup.2014.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fkisup.2014.2%26sid%3Dliteratum%253Aachs%26aulast%3DEddy%26aufirst%3DA.%2BA.%26atitle%3DOverview%2520of%2520the%2520cellular%2520and%2520molecular%2520basis%2520of%2520kidney%2520fibrosis%26jtitle%3DKidney%2520Int.%2520Suppl.%26date%3D2014%26volume%3D4%26spage%3D2%26epage%3D8%26doi%3D10.1038%2Fkisup.2014.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanasaki, K.</span></span> <span> </span><span class="NLM_article-title">Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease</span>. <i>Clin. Exp. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">488</span>â <span class="NLM_lpage">497</span>, <span class="refDoi">Â DOI: 10.1007/s10157-013-0781-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1007%2Fs10157-013-0781-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23430391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGmt7rI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=488-497&author=J.+Heauthor=Y.+Xuauthor=D.+Koyaauthor=K.+Kanasaki&title=Role+of+the+endothelial-to-mesenchymal+transition+in+renal+fibrosis+of+chronic+kidney+disease&doi=10.1007%2Fs10157-013-0781-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease</span></div><div class="casAuthors">He, Jianhua; Xu, Yong; Koya, Daisuke; Kanasaki, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Nephrology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">488-497</span>CODEN:
                <span class="NLM_cas:coden">CENPFV</span>;
        ISSN:<span class="NLM_cas:issn">1342-1751</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">A review.  All types of progressive chronic kidney disease (CKD) inevitably induce renal fibrosis, the hallmark of which is the activation and accumulation of a large no. of matrix-producing fibroblasts or myofibroblasts.  The activated fibroblasts or myofibroblasts are derived from diverse origins, such as residential fibroblasts, vascular pericytes, epithelial-to-mesenchymal transition (EMT), and bone marrow (circulating fibrocytes).  Recently, endothelial-to-mesenchymal transition (EndMT) or endothelial-to-myofibroblast transition has also been suggested to promote fibrosis and is recognized as a novel mechanism for the generation of myofibroblasts.  Similar to EMT, during EndMT, endothelial cells lose their adhesion and apical-basal polarity to form highly invasive, migratory, spindle-shaped, elongated mesenchymal cells.  More importantly, biochem. changes accompany these distinct changes in cell polarity and morphol., including the decreased expression of endothelial markers and the acquisition of mesenchymal markers.  This review highlights evidence supporting the important role of EndMT in the development of renal fibrosis in CKD and its underlying mechanisms, including novel biol. significance of microRNA regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrByO0uthLHtrVg90H21EOLACvtfcHk0liKsABSckkayQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGmt7rI&md5=7c758f89478cc01cff93db82bf2025f5</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1007%2Fs10157-013-0781-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10157-013-0781-0%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DKoya%26aufirst%3DD.%26aulast%3DKanasaki%26aufirst%3DK.%26atitle%3DRole%2520of%2520the%2520endothelial-to-mesenchymal%2520transition%2520in%2520renal%2520fibrosis%2520of%2520chronic%2520kidney%2520disease%26jtitle%3DClin.%2520Exp.%2520Nephrol.%26date%3D2013%26volume%3D17%26spage%3D488%26epage%3D497%26doi%3D10.1007%2Fs10157-013-0781-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grande, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¡nchez-Laorden, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ³pez-Blau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Frutos, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ArÃ©valo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ³pez-Novoa, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, M. A.</span></span> <span> </span><span class="NLM_article-title">Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">989</span>â <span class="NLM_lpage">997</span>, <span class="refDoi">Â DOI: 10.1038/nm.3901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm.3901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26236989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCksL7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=989-997&author=T.+M.+Grandeauthor=B.+S%C3%A1nchez-Laordenauthor=C.+L%C3%B3pez-Blauauthor=C.+A.+De+Frutosauthor=A.+Boutetauthor=M.+Ar%C3%A9valoauthor=R.+G.+Roweauthor=S.+J.+Weissauthor=J.+M.+L%C3%B3pez-Novoaauthor=M.+A.+Nieto&title=Snail1-induced+partial+epithelial-to-mesenchymal+transition+drives+renal+fibrosis+in+mice+and+can+be+targeted+to+reverse+established+disease&doi=10.1038%2Fnm.3901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease</span></div><div class="casAuthors">Grande, M. Teresa; Sanchez-Laorden, Berta; Lopez-Blau, Cristina; De Frutos, Cristina A.; Boutet, Agnes; Arevalo, Miguel; Rowe, R. Grant; Weiss, Stephen J.; Lopez-Novoa, Jose M.; Nieto, M. Angela</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">989-997</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Progressive kidney fibrosis contributes greatly to end-stage renal failure, and no specific treatment is available to preserve organ function.  During renal fibrosis, myofibroblasts accumulate in the interstitium of the kidney, leading to massive deposition of extracellular matrix and organ dysfunction.  The origin of myofibroblasts is manifold, but the contribution of an epithelial-to-mesenchymal transition (EMT) undergone by renal epithelial cells during kidney fibrosis is still debated.  We show that the reactivation of Snai1 (encoding snail family zinc finger 1, known as Snail1) in mouse renal epithelial cells is required for the development of fibrosis in the kidney.  Damage-mediated Snail1 reactivation induces a partial EMT in tubular epithelial cells that, without directly contributing to the myofibroblast population, relays signals to the interstitium to promote myofibroblast differentiation and fibrogenesis and to sustain inflammation.  We also show that Snail1-induced fibrosis can be reversed in vivo and that obstructive nephropathy can be therapeutically ameliorated in mice by genetically targeting Snail1 expression.  These results reconcile conflicting data on the role of the EMT in renal fibrosis and provide avenues for the design of novel anti-fibrotic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0A_c4no3Q27Vg90H21EOLACvtfcHk0liJpOTZv5M-zQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCksL7I&md5=691983f25e28ebf2a325dd59d6680c44</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fnm.3901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3901%26sid%3Dliteratum%253Aachs%26aulast%3DGrande%26aufirst%3DT.%2BM.%26aulast%3DS%25C3%25A1nchez-Laorden%26aufirst%3DB.%26aulast%3DL%25C3%25B3pez-Blau%26aufirst%3DC.%26aulast%3DDe%2BFrutos%26aufirst%3DC.%2BA.%26aulast%3DBoutet%26aufirst%3DA.%26aulast%3DAr%25C3%25A9valo%26aufirst%3DM.%26aulast%3DRowe%26aufirst%3DR.%2BG.%26aulast%3DWeiss%26aufirst%3DS.%2BJ.%26aulast%3DL%25C3%25B3pez-Novoa%26aufirst%3DJ.%2BM.%26aulast%3DNieto%26aufirst%3DM.%2BA.%26atitle%3DSnail1-induced%2520partial%2520epithelial-to-mesenchymal%2520transition%2520drives%2520renal%2520fibrosis%2520in%2520mice%2520and%2520can%2520be%2520targeted%2520to%2520reverse%2520established%2520disease%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D989%26epage%3D997%26doi%3D10.1038%2Fnm.3901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ovadya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krizhanovsky, V.</span></span> <span> </span><span class="NLM_article-title">A new Twist in kidney fibrosis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">975</span>â <span class="NLM_lpage">977</span>, <span class="refDoi">Â DOI: 10.1038/nm.3938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm.3938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26340117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7vF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=975-977&author=Y.+Ovadyaauthor=V.+Krizhanovsky&title=A+new+Twist+in+kidney+fibrosis&doi=10.1038%2Fnm.3938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">A new Twist in kidney fibrosis</span></div><div class="casAuthors">Ovadya, Yossi; Krizhanovsky, Valery</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">975-977</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kidney fibrosis is a main pathol. component of chronic kidney disease.  Two new studies pinpoint a partial epithelial-to-mesenchymal transition as a mechanism driving the development of kidney fibrosis, thus paving the way for novel treatments of fibrosis-assocd. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0BqbbOvScsrVg90H21EOLACvtfcHk0ljBivbId9LmXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7vF&md5=dc56e8509c6b6ac385d6e742dad414da</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnm.3938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3938%26sid%3Dliteratum%253Aachs%26aulast%3DOvadya%26aufirst%3DY.%26aulast%3DKrizhanovsky%26aufirst%3DV.%26atitle%3DA%2520new%2520Twist%2520in%2520kidney%2520fibrosis%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D975%26epage%3D977%26doi%3D10.1038%2Fnm.3938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VÃ¶lzke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ¼nsche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer zu Heringdorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwiler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeilschifter, J.</span></span> <span> </span><span class="NLM_article-title">Thiazolidinedione-dependent activation of sphingosine kinase 1 causes an anti-fibrotic effect in renal mesangial cells</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">1018</span>â <span class="NLM_lpage">1032</span>, <span class="refDoi">Â DOI: 10.1111/j.1476-5381.2012.01824.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1111%2Fj.1476-5381.2012.01824.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22221312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlWmsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2012&pages=1018-1032&author=A.+Kochauthor=A.+V%C3%B6lzkeauthor=C.+W%C3%BCnscheauthor=D.+Meyer+zu+Heringdorfauthor=A.+Huwilerauthor=J.+Pfeilschifter&title=Thiazolidinedione-dependent+activation+of+sphingosine+kinase+1+causes+an+anti-fibrotic+effect+in+renal+mesangial+cells&doi=10.1111%2Fj.1476-5381.2012.01824.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazolidinedione-dependent activation of sphingosine kinase 1 causes an anti-fibrotic effect in renal mesangial cells</span></div><div class="casAuthors">Koch, A.; Voelzke, A.; Wuensche, C.; Meyer zu Heringdorf, D.; Huwiler, A.; Pfeilschifter, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1018-1032</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose PPARÎ³ agonists [thiazolidinediones (TZDs)] are known to exert anti-fibrotic effects in the kidney.  In addn., we previously demonstrated that sphingosine kinase 1 (SK-1) and intracellular sphingosine-1-phosphate (S1P), by reducing the expression of connective tissue growth factor (CTGF), have a protective role in the fibrotic process.  Exptl. Approach Here, we investigated the effect of TZDs on intracellular sphingolipid levels and the transcriptional regulation of SK-1 in mesangial cells to evaluate potential novel aspects of the anti-fibrotic capacity of TZDs.  Key Results Stimulation with the TZDs, troglitazone and rosiglitazone, led to increased S1P levels in rat mesangial cells.  This was paralleled by increased SK-1 activity as a consequence of direct effects of the TZDs on SK-1 expression.  GW-9662, a PPARÎ³ antagonist, inhibited the stimulating effect of TZDs on SK-1 mRNA and activity levels and intracellular S1P concns.  Furthermore, SK-1 up-regulation by TZDs was functionally coupled with lower amts. of pro-fibrotic CTGF.  SK-1 inhibition with SKI II almost completely abolished this effect in a dose-dependent manner.  Moreover, the CTGF lowering effect of TZDs was fully blocked in MC isolated from SK-1 deficient mice (SK-1-/-) as well as in glomeruli of SK-1-/- mice compared with wild-type mice treated with TRO and RSG.  Conclusion and Implications These data show that TZD-induced SK-1 up-regulation results in lower amts. of CTGF, demonstrating novel facets for the anti-fibrotic effects of this class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXiojwdx-qZbVg90H21EOLACvtfcHk0ljBivbId9LmXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlWmsbo%253D&md5=2acbeb8f8b093a837cf96b15b69186bc</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.01824.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.01824.x%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%26aulast%3DV%25C3%25B6lzke%26aufirst%3DA.%26aulast%3DW%25C3%25BCnsche%26aufirst%3DC.%26aulast%3DMeyer%2Bzu%2BHeringdorf%26aufirst%3DD.%26aulast%3DHuwiler%26aufirst%3DA.%26aulast%3DPfeilschifter%26aufirst%3DJ.%26atitle%3DThiazolidinedione-dependent%2520activation%2520of%2520sphingosine%2520kinase%25201%2520causes%2520an%2520anti-fibrotic%2520effect%2520in%2520renal%2520mesangial%2520cells%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D166%26spage%3D1018%26epage%3D1032%26doi%3D10.1111%2Fj.1476-5381.2012.01824.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span> <span> </span><span class="NLM_article-title">Pioglitazone improves mitochondrial function in the remnant kidney and protects against renal fibrosis in 5/6 nephrectomized rats</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">545</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28860994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2gurbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=545&author=L.+Sunauthor=Q.+Yuanauthor=T.+Xuauthor=L.+Yaoauthor=J.+Fengauthor=J.+Maauthor=L.+Wangauthor=C.+Luauthor=D.+Wang&title=Pioglitazone+improves+mitochondrial+function+in+the+remnant+kidney+and+protects+against+renal+fibrosis+in+5%2F6+nephrectomized+rats&doi=10.3389%2Ffphar.2017.00545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Pioglitazone improves mitochondrial function in the remnant kidney and protects against renal fibrosis in 5/6 nephrectomized rats</span></div><div class="casAuthors">Sun, Li; Yuan, Quan; Xu, Tianhua; Yao, Li; Feng, Jiangmin; Ma, Jianfei; Wang, Lining; Lu, Changlong; Wang, Danan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">545/1-545/10</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Pioglitazone is a type of peroxisome proliferator-activated receptor Î³ (PPARÎ³) agonist and has been demonstrated to be effective in chronic kidney diseases (CKD) treatment.  However, the underlying mechanism involved in the renoprotection of pioglitazone has not been fully revealed.  In the present study, the renoprotective mechanism of pioglitazone was investigated in 5/6 nephrectomized (Nx) rats and TGF-Î²1-exposed HK- 2 cells.  Pioglitazone attenuated renal injury and improved renal function, as examd. by 24 h urinary protein, blood urea nitrogen and plasma creatinine in Nx rats.  Renal fibrosis and enhanced expressions of profibrotic proteins TGF-Î²1, fibronectin and collagen I caused by Nx were significantly alleviated by pioglitazone.  In addn., pioglitazone protected mitochondrial functions by stabilizing the mitochondrial membrane potential, inhibiting ROS generation, maintaining ATP prodn. and the activities of complexes I and III, and preventing cytochrome C leakage from mitochondria.  Pioglitazone also upregulated the expression levels of ATP synthase Î², COX I and NDUFB8, which were downregulated in the kidney of Nx rats and TGF-Î²1-exposed HK-2 cells.  Furthermore, pioglitazone increased fusion proteins Opa-1 and Mfn2 expressions and decreased fission protein Drp1 expression.  The results imply that pioglitazone may exert the renoprotective effects through modulating mitochondrial electron transport chain and mitochondrial dynamics in CKD.  Finally, these recoveries were completely or partly inhibited by GW9662, which suggests that these effects at least partly PPARg dependent.  This study provides evidence for the pharmacol. mechanism of pioglitazone in the treatment of CKD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4c61AWf-jbbVg90H21EOLACvtfcHk0lhUZiZUWtFpOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2gurbI&md5=9cacf04e6d432a1bf1c7c41c28379c8a</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00545%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DD.%26atitle%3DPioglitazone%2520improves%2520mitochondrial%2520function%2520in%2520the%2520remnant%2520kidney%2520and%2520protects%2520against%2520renal%2520fibrosis%2520in%25205%252F6%2520nephrectomized%2520rats%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D545%26doi%3D10.3389%2Ffphar.2017.00545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, M. E.</span></span> <span> </span><span class="NLM_article-title">Therapeutic targets for treating fibrotic kidney diseases</span>. <i>Translat. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">512</span>â <span class="NLM_lpage">530</span>, <span class="refDoi">Â DOI: 10.1016/j.trsl.2014.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.trsl.2014.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25176603" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2015&pages=512-530&author=S.+Y.+Leeauthor=S.+I.+Kimauthor=M.+E.+Choi&title=Therapeutic+targets+for+treating+fibrotic+kidney+diseases&doi=10.1016%2Fj.trsl.2014.07.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.trsl.2014.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trsl.2014.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DS.%2BI.%26aulast%3DChoi%26aufirst%3DM.%2BE.%26atitle%3DTherapeutic%2520targets%2520for%2520treating%2520fibrotic%2520kidney%2520diseases%26jtitle%3DTranslat.%2520Res.%26date%3D2015%26volume%3D165%26spage%3D512%26epage%3D530%26doi%3D10.1016%2Fj.trsl.2014.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolbert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponnusamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworkin, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, S.</span></span> <span> </span><span class="NLM_article-title">Genetic and pharmacologic blockade of EGFR inhibits renal fibrosis</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">854</span>â <span class="NLM_lpage">867</span>, <span class="refDoi">Â DOI: 10.1681/ASN.2011050493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1681%2FASN.2011050493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22362908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns12isbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=854-867&author=N.+Liuauthor=J.+K.+Guoauthor=M.+Pangauthor=E.+Tolbertauthor=M.+Ponnusamyauthor=R.+Gongauthor=G.+Baylissauthor=L.+D.+Dworkinauthor=H.+Yanauthor=S.+Zhuang&title=Genetic+and+pharmacologic+blockade+of+EGFR+inhibits+renal+fibrosis&doi=10.1681%2FASN.2011050493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis</span></div><div class="casAuthors">Liu, Na; Guo, Jian-Kan; Pang, Maoyin; Tolbert, Evelyn; Ponnusamy, Murugavel; Gong, Rujun; Bayliss, George; Dworkin, Lance D.; Yan, Haidong; Zhuang, Shougang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">854-867</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">Although enhanced activation of the EGF receptor (EGFR) assocs. with the development and progression of renal fibrosis, the mechanisms linking these observations are not completely understood.  Here, after unilateral ureteral obstruction (UUO), wild-type mice exhibited sustained EGFR phosphorylation in the kidney and developed renal fibrosis that was more severe than the renal fibrosis obsd. in waved-2 mice, which have reduced EGFR tyrosine kinase activity.  Waved-2 mice also showed fewer renal tubular cells arrested at G2/M, reduced expression of Î±-smooth muscle actin (Î±-SMA), downregulation of multiple genes encoding profibrogenic cytokines, including TGF-Î²1, and dephosphorylation of Smad3, STAT3, and ERK1/2.  Administration of the specific EGFR inhibitor gefitinib recapitulated this phenotype in wild-type mice after UUO.  Furthermore, inactivation of either EGFR or STAT3 reduced UUO-induced expression of lipocalin-2, a mol. assocd. with the pathogenesis of CKD.  In cultured renal interstitial fibroblasts, inhibition of EGFR also abrogated TGF-Î²1- or serum-induced phosphorylation of EGFR, STAT3, ERK1/2, and Smad3 as well as expression of Î±-SMA and extracelluar matrix proteins.  Taken together, these data suggest that EGFR may mediate renal fibrogenesis by promoting transition of renal epithelial cells to a profibrotic phenotype, increased prodn. of inflammatory factors, and activation of renal interstitial fibroblasts.  Inhibition of EGFR may have therapeutic potential for fibrotic kidney disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN8RUUw0GKybVg90H21EOLACvtfcHk0lhUZiZUWtFpOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns12isbo%253D&md5=012740de2ce38f4ed7c317173147d2ce</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1681%2FASN.2011050493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2011050493%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DJ.%2BK.%26aulast%3DPang%26aufirst%3DM.%26aulast%3DTolbert%26aufirst%3DE.%26aulast%3DPonnusamy%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DR.%26aulast%3DBayliss%26aufirst%3DG.%26aulast%3DDworkin%26aufirst%3DL.%2BD.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhuang%26aufirst%3DS.%26atitle%3DGenetic%2520and%2520pharmacologic%2520blockade%2520of%2520EGFR%2520inhibits%2520renal%2520fibrosis%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2012%26volume%3D23%26spage%3D854%26epage%3D867%26doi%3D10.1681%2FASN.2011050493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walton, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. A.</span></span> <span> </span><span class="NLM_article-title">Targeting TGF-Î² mediated SMAD signaling for the prevention of fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">461</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28769795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2nsr3M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=461&author=K.+L.+Waltonauthor=K.+E.+Johnsonauthor=C.+A.+Harrison&title=Targeting+TGF-%CE%B2+mediated+SMAD+signaling+for+the+prevention+of+fibrosis&doi=10.3389%2Ffphar.2017.00461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting TGF-Î² mediated SMAD signaling for the prevention of fibrosis</span></div><div class="casAuthors">Walton, Kelly L.; Johnson, Katharine E.; Harrison, Craig A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">461/1-461/11</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Fibrosis occurs when there is an imbalance in extracellular matrix (ECM) deposition and degrdn.  Excessive ECM deposition results in scarring and thickening of the affected tissue, and interferes with tissue and organ homeostasis - mimicking an exaggerated "wound healing" response.  Many transforming growth factor-Î² (TGF-Î²) ligands are potent drivers of ECM deposition, and addnl., have a natural affinity for the ECM, creating a concd. pool of pro-fibrotic factors at the site of injury.  Consequently, TGF-Î² ligands are upregulated in many human fibrotic conditions and, as such, are attractive targets for fibrosis therapy.  Here, we will discuss the contribution of TGF-Î² proteins in the pathogenesis of fibrosis, and promising anti-fibrotic approaches that target TGF-Î² ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5ECKO8MIXQrVg90H21EOLACvtfcHk0lhUZiZUWtFpOw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2nsr3M&md5=313823330d5d45a7a2aee6d67c90b640</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00461%26sid%3Dliteratum%253Aachs%26aulast%3DWalton%26aufirst%3DK.%2BL.%26aulast%3DJohnson%26aufirst%3DK.%2BE.%26aulast%3DHarrison%26aufirst%3DC.%2BA.%26atitle%3DTargeting%2520TGF-%25CE%25B2%2520mediated%2520SMAD%2520signaling%2520for%2520the%2520prevention%2520of%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D461%26doi%3D10.3389%2Ffphar.2017.00461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBleu, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosukonda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taduri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechtel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusckowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tampe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tampe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeisberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalluri, P.</span></span> <span> </span><span class="NLM_article-title">Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">396</span>â <span class="NLM_lpage">404</span>, <span class="refDoi">Â DOI: 10.1038/nm.2629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm.2629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22306733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslGktLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=396-404&author=H.+Sugimotoauthor=V.+S.+LeBleuauthor=D.+Bosukondaauthor=P.+Keckauthor=G.+Taduriauthor=W.+Bechtelauthor=H.+Okadaauthor=W.+Carlsonauthor=P.+Beyauthor=M.+Rusckowskiauthor=B.+Tampeauthor=D.+Tampeauthor=K.+Kanasakiauthor=M.+Zeisbergauthor=P.+Kalluri&title=Activin-like+kinase+3+is+important+for+kidney+regeneration+and+reversal+of+fibrosis&doi=10.1038%2Fnm.2629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis</span></div><div class="casAuthors">Sugimoto, Hikaru; LeBleu, Valerie S.; Bosukonda, Dattatreyamurty; Keck, Peter; Taduri, Gangadhar; Bechtel, Wibke; Okada, Hirokazu; Carlson, William; Bey, Philippe; Rusckowski, Mary; Tampe, Bjoern; Tampe, Desiree; Kanasaki, Keizo; Zeisberg, Michael; Kalluri, Raghu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">396-404</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mols. assocd. with the transforming growth factor Î² (TGF-Î²) superfamily, such as bone morphogenic proteins (BMPs) and TGF-Î², are key regulators of inflammation, apoptosis, and cellular transitions.  Here we show that the BMP receptor activin-like kinase 3 (Alk3) is elevated early in diseased kidneys after injury.  We also found that its deletion in the tubular epithelium leads to enhanced TGF-Î²1-Smad family member 3 (Smad3) signaling, epithelial damage, and fibrosis, suggesting a protective role for Alk3-mediated signaling in the kidney.  A structure-function anal. of the BMP-Alk3-BMP receptor, type 2 (BMPR2) ligand-receptor complex, along with synthetic org. chem., led us to construct a library of small peptide agonists of BMP signaling that function through the Alk3 receptor.  One such peptide agonist, THR-123, suppressed inflammation, apoptosis and the epithelial-to-mesenchymal transition program and reversed established fibrosis in 5 mouse models of acute and chronic renal injury.  THR-123 acts specifically through Alk3 signaling, as mice with a targeted deletion for Alk3 in their tubular epithelium did not respond to therapy with THR-123.  Combining THR-123 and the angiotensin-converting enzyme inhibitor captopril had an additive therapeutic benefit in controlling renal fibrosis.  Our studies show that BMP signaling agonists constitute a new line of therapeutic agents with potential utility in the clinic to induce regeneration, repair and reverse established fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXFd239-5fm7Vg90H21EOLACvtfcHk0lh2dbh3Y1vnpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslGktLs%253D&md5=db8ecebab61dc74ca3411b1d628b8203</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fnm.2629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2629%26sid%3Dliteratum%253Aachs%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DLeBleu%26aufirst%3DV.%2BS.%26aulast%3DBosukonda%26aufirst%3DD.%26aulast%3DKeck%26aufirst%3DP.%26aulast%3DTaduri%26aufirst%3DG.%26aulast%3DBechtel%26aufirst%3DW.%26aulast%3DOkada%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DW.%26aulast%3DBey%26aufirst%3DP.%26aulast%3DRusckowski%26aufirst%3DM.%26aulast%3DTampe%26aufirst%3DB.%26aulast%3DTampe%26aufirst%3DD.%26aulast%3DKanasaki%26aufirst%3DK.%26aulast%3DZeisberg%26aufirst%3DM.%26aulast%3DKalluri%26aufirst%3DP.%26atitle%3DActivin-like%2520kinase%25203%2520is%2520important%2520for%2520kidney%2520regeneration%2520and%2520reversal%2520of%2520fibrosis%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D396%26epage%3D404%26doi%3D10.1038%2Fnm.2629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, R.
E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zammit, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stapleton, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, D. J.</span></span> <span> </span><span class="NLM_article-title">A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e47160</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0047160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1371%2Fjournal.pone.0047160" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e47160&author=R.%0AE.+Gilbertauthor=Y.+Zhangauthor=S.+J.+Williamsauthor=S.+C.+Zammitauthor=D.+I.+Stapletonauthor=A.+J.+Coxauthor=H.+Krumauthor=R.+Langhamauthor=D.+J.+Kelly&title=A+purpose-synthesised+anti-fibrotic+agent+attenuates+experimental+kidney+diseases+in+the+rat&doi=10.1371%2Fjournal.pone.0047160"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0047160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0047160%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DR.%2BE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWilliams%26aufirst%3DS.%2BJ.%26aulast%3DZammit%26aufirst%3DS.%2BC.%26aulast%3DStapleton%26aufirst%3DD.%2BI.%26aulast%3DCox%26aufirst%3DA.%2BJ.%26aulast%3DKrum%26aufirst%3DH.%26aulast%3DLangham%26aufirst%3DR.%26aulast%3DKelly%26aufirst%3DD.%2BJ.%26atitle%3DA%2520purpose-synthesised%2520anti-fibrotic%2520agent%2520attenuates%2520experimental%2520kidney%2520diseases%2520in%2520the%2520rat%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De47160%26doi%3D10.1371%2Fjournal.pone.0047160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Renal fibrosis in 2015: Understanding the mechanisms of kidney fibrosis</span>. <i>Nat. Rev. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">68</span>â <span class="NLM_lpage">70</span>, <span class="refDoi">Â DOI: 10.1038/nrneph.2015.215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnrneph.2015.215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26714578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs12qtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=68-70&author=D.+Zhouauthor=Y.+Liu&title=Renal+fibrosis+in+2015%3A+Understanding+the+mechanisms+of+kidney+fibrosis&doi=10.1038%2Fnrneph.2015.215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Renal fibrosis in 2015 understanding the mechanisms of kidney fibrosis</span></div><div class="casAuthors">Zhou, Dong; Liu, Youhua</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Nephrology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">68-70</span>CODEN:
                <span class="NLM_cas:coden">NRNABO</span>;
        ISSN:<span class="NLM_cas:issn">1759-5061</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The year 2015 has seen great progress in the renal fibrosis field, as key studies began to build a consensus on the importance of epithelial-to-mesenchymal transition, cell cycle arrest, and defective metab. in the pathogenesis of kidney fibrosis.  New findings also point to a role of developmental signalling in renal fibrogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkJ8zl1sTVc7Vg90H21EOLACvtfcHk0lh2dbh3Y1vnpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs12qtw%253D%253D&md5=f6cf020b7c94e29f2e71ca8d4ececbc1</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnrneph.2015.215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneph.2015.215%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DRenal%2520fibrosis%2520in%25202015%253A%2520Understanding%2520the%2520mechanisms%2520of%2520kidney%2520fibrosis%26jtitle%3DNat.%2520Rev.%2520Nephrol.%26date%3D2016%26volume%3D12%26spage%3D68%26epage%3D70%26doi%3D10.1038%2Fnrneph.2015.215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. M.</span></span> <span> </span><span class="NLM_article-title">KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis</span>. <i>Nephrol., Dial., Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">313</span>â <span class="NLM_lpage">324</span>, <span class="refDoi">Â DOI: 10.1093/ndt/gft431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1093%2Fndt%2Fgft431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24166472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslyguro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=313-324&author=C.+Huangauthor=S.+Shenauthor=Q.+Maauthor=A.+Gillauthor=C.+A.+Pollockauthor=X.+M.+Chen&title=KCa3.1+mediates+activation+of+fibroblasts+in+diabetic+renal+interstitial+fibrosis&doi=10.1093%2Fndt%2Fgft431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis</span></div><div class="casAuthors">Huang, Chunling; Shen, Sylvie; Ma, Qing; Gill, Anthony; Pollock, Carol A.; Chen, Xin-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology, Dialysis, Transplantation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">313-324</span>CODEN:
                <span class="NLM_cas:coden">NDTREA</span>;
        ISSN:<span class="NLM_cas:issn">0931-0509</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background Fibroblast activation plays a crit. role in diabetic nephropathy (DN).  The Ca2+-activated K+ channel KCa3.1 mediates cellular proliferation of many cell types including fibroblasts.  KCa3.1 has been reported to be a potential mol. target for pharmacol. intervention in a diverse array of clin. conditions.  However, the role of KCa3.1 in the activation of myofibroblasts in DN is unknown.  These studies assessed the effect of KCa3.1 blockade on renal injury in exptl. diabetes.  Methods As TGF-Î²1 plays a central role in the activation of fibroblasts to myofibroblasts in renal interstitial fibrosis, human primary renal interstitial fibroblasts were incubated with TGF-Î²1 +/- the selective inhibitor of KCa3.1, TRAM34, for 48 h.  Two streptozotocin-induced diabetic mouse models were used in this study: wild-type KCa3.1+/+ and KCa3.1-/- mice, and secondly eNOS-/- mice treated with or without a selective inhibitor of KCa3.1 (TRAM34).  Then, markers of fibroblast activation and fibrosis were detd.  Results Blockade of KCa3.1 inhibited the upregulation of type I collagen, fibronectin, Î±-smooth muscle actin, vimentin and fibroblast-specific protein-1 in renal fibroblasts exposed to TGF-Î²1 and in kidneys from diabetic mice.  TRAM34 reduced TGF-Î²1-induced phosphorylation of Smad2/3 and ERK1/2 but not P38 and JNK MAPK in interstitial fibroblasts.  Conclusions These results suggest that blockade of KCa3.1 attenuates diabetic renal interstitial fibrogenesis through inhibiting activation of fibroblasts and phosphorylation of Smad2/3 and ERK1/2.  Therefore, therapeutic interventions to prevent or ameliorate DN through targeted inhibition of KCa3.1 deserve further consideration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyjWbmiONuerVg90H21EOLACvtfcHk0lj_cihaPLdodQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslyguro%253D&md5=d7b7a5d23d0d4dbb97406cfdd7d9aac2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgft431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgft431%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DGill%26aufirst%3DA.%26aulast%3DPollock%26aufirst%3DC.%2BA.%26aulast%3DChen%26aufirst%3DX.%2BM.%26atitle%3DKCa3.1%2520mediates%2520activation%2520of%2520fibroblasts%2520in%2520diabetic%2520renal%2520interstitial%2520fibrosis%26jtitle%3DNephrol.%252C%2520Dial.%252C%2520Transplant.%26date%3D2014%26volume%3D29%26spage%3D313%26epage%3D324%26doi%3D10.1093%2Fndt%2Fgft431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitch, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">JAK3/STAT6 stimulates bone-marrow-derived fibroblast activation in renal fibrosis</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3060</span>â <span class="NLM_lpage">3071</span>, <span class="refDoi">Â DOI: 10.1681/ASN.2014070717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1681%2FASN.2014070717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26032813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFGnsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=3060-3071&author=J.+Yanauthor=Z.+Zhangauthor=J.+Yangauthor=W.+E.+Mitchauthor=Y.+Wang&title=JAK3%2FSTAT6+stimulates+bone-marrow-derived+fibroblast+activation+in+renal+fibrosis&doi=10.1681%2FASN.2014070717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">JAK3/STAT6 stimulates bone marrow-derived fibroblast activation in renal fibrosis</span></div><div class="casAuthors">Yan, Jingyin; Zhang, Zhengmao; Yang, Jun; Mitch, William E.; Wang, Yanlin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3060-3071</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">Renal fibrosis is a final common manifestation of CKD resulting in progressive loss of kidney function.  Bone marrow-derived fibroblast precursors contribute significantly to the pathogenesis of renal fibrosis.  However, the signaling mechanisms underlying the activation of bone marrow-derived fibroblast precursors in the kidney are not fully understood.  In this study, we investigated the role of the Janus kinase 3 (JAK3)/signal transducer and activator of transcription (STAT6) signaling pathway in the activation of bone marrow-derived fibroblasts.  In cultured mouse monocytes, IL-4 or IL-13 activated STAT6 and induced expression of Î±-smooth muscle actin and extracellular matrix proteins (fibronectin and collagen I), which was abolished by a JAK3 inhibitor (CP690,550) in a dose-dependent manner or blocked in the absence of STAT6.  In vivo, STAT6 was activated in interstitial cells of the obstructed kidney, an effect that was abolished by CP690,550.  Mice treated with CP690,550 accumulated fewer bone marrow-derived fibroblasts in the obstructed kidneys compared with vehicle-treated mice.  Treatment with CP690,550 also significantly reduced myofibroblast transformation, matrix protein expression, fibrosis development, and apoptosis in obstructed kidneys.  Furthermore, STAT6-deficient mice accumulated fewer bone marrow-derived fibroblasts in the obstructed kidneys, produced less extracellular matrix protein, and developed much less fibrosis.  Finally, wild-type mice engrafted with STAT6-/- bone marrow cells displayed fewer bone marrow-derived fibroblasts in the obstructed kidneys and showed less severe renal fibrosis compared with wild-type mice engrafted with STAT6+/+ bone marrow cells.  Our results demonstrate that JAK3/STAT6 has an important role in bone marrow-derived fibroblast activation, extracellular matrix prodn., and interstitial fibrosis development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLBszkirUxgrVg90H21EOLACvtfcHk0lj_cihaPLdodQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFGnsro%253D&md5=7c55c38e56ac3744db0935656aff38f6</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1681%2FASN.2014070717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2014070717%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMitch%26aufirst%3DW.%2BE.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DJAK3%252FSTAT6%2520stimulates%2520bone-marrow-derived%2520fibroblast%2520activation%2520in%2520renal%2520fibrosis%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2015%26volume%3D26%26spage%3D3060%26epage%3D3071%26doi%3D10.1681%2FASN.2014070717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Zeeuw, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasslacher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouni-Berthold, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potarca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerspink, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schall, T. J.</span></span> <span> </span><span class="NLM_article-title">CCX140-B Diabetic Nephropathy Study Group. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial</span>. <i>Lancet Diabetes Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">687</span>â <span class="NLM_lpage">696</span>, <span class="refDoi">Â DOI: 10.1016/S2213-8587(15)00261-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2FS2213-8587%2815%2900261-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26268910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCisbrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=687-696&author=D.+de%0AZeeuwauthor=P.+Bekkerauthor=E.+Henkelauthor=C.+Hasslacherauthor=I.+Gouni-Bertholdauthor=H.+Mehlingauthor=A.+Potarcaauthor=V.+Tesarauthor=H.+J.+Heerspinkauthor=T.+J.+Schall&title=CCX140-B+Diabetic+Nephropathy+Study+Group.+The+effect+of+CCR2+inhibitor+CCX140-B+on+residual+albuminuria+in+patients+with+type+2+diabetes+and+nephropathy%3A+a+randomised+trial&doi=10.1016%2FS2213-8587%2815%2900261-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial</span></div><div class="casAuthors">de Zeeuw, Dick; Bekker, Pirow; Henkel, Elena; Hasslacher, Christopher; Gouni-Berthold, Ioanna; Mehling, Heidrun; Potarca, Antonia; Tesar, Vladimir; Heerspink, Hiddo J. Lambers; Schall, Thomas J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Diabetes & Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">687-696</span>CODEN:
                <span class="NLM_cas:coden">LDEAAS</span>;
        ISSN:<span class="NLM_cas:issn">2213-8587</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with type 2 diabetes and nephropathy have high cardiorenal morbidity and mortality despite optimum treatment including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).  Residual risk is related to residual albuminuria.  We assessed whether CCX140-B, a selective inhibitor of C-C chemokine receptor type 2 (CCR2), could further reduce albuminuria when given in addn. to std. care, including ACE inhibitors or ARBs.  In this randomised, double-blind, placebo-controlled clin. trial, we recruited patients from 78 research centers in Belgium, Czech Republic, Germany, Hungary, Poland, and the UK.  We enrolled patients with type 2 diabetes aged 18-75 years with proteinuria (first morning void urinary albumin to creatinine ratio [UACR] 100-3000 mg/g), estd. glomerular filtration rate of 25 mL/min per 1Â·73 m2 or higher, and taking stable antidiabetic treatment and ACE inhibitors or ARBs, for at least 8 wk before study entry.  Patients were stratified based on baseline UACR and renal function (estd. glomerular filtration rate), and then randomly assigned (1:1:1) via an interactive web response system with a minimisation algorithm to oral placebo, 5 mg CCX140-B, or 10 mg CCX140-B once a day.  The 12-wk dosing period in the initial protocol was extended to 52 wk by protocol amendment.  The primary efficacy measure was change from baseline in UACR during 52 wk in the modified intention-to-treat population (all patients with uninterrupted dosing, excluding patients who stopped dosing at week 12 either permanently under the original protocol, or temporarily because of delay in approval of the protocol amendment).  We did safety analyses on all randomly assigned patients who received at least one dose of study drug.  According to a prespecified anal. plan, we analyzed the primary endpoint with one-sided statistical testing with calcn. of upper 95% confidence limits of the differences between active and control.  This trial is registered with ClinicalTrials.gov, no. NCT01447147.  The study ran from Dec 7, 2011 (first patient enrolled), until Aug 4, 2014.  We enrolled 332 patients: 111 were assigned to receive placebo, 110 to 5 mg CCX140-B, and 111 to 10 mg CCX140-B.  Of these, 192 were included in the modified intention-to-treat population.  UACR changes from baseline during 52 wk were -2% for placebo (95% CI -11% to 9%), -18% for 5 mg CCX140-B (-26% to -8%), and -11% for 10 mg CCX140-B (-20% to -1%).  We recorded a -16% difference between 5 mg CCX140-B and placebo (one-sided upper 95% confidence limit -5%; p=0Â·01) and a -10% difference between 10 mg CCX140-B and placebo (upper 95% confidence limit 2%; p=0Â·08).  Adverse events occurred in 81 (73%) of 111 patients in the placebo group vs. 71 (65%) of 110 patients in the CCX140-B 5 mg group and 68 (61%) of 111 patients in the CCX140-B 10 mg group; there were no renal events during the study.  Our data suggest that CCR2 inhibition with CCX140-B has renoprotective effects on top of current std. of care in patients with type 2 diabetes and nephropathy.ChemoCentryx.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqarqWvXCzPfLVg90H21EOLACvtfcHk0lj_cihaPLdodQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCisbrF&md5=6eb7cea04fe6b0312c360a487b6cffbf</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS2213-8587%2815%2900261-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-8587%252815%252900261-2%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BZeeuw%26aufirst%3DD.%26aulast%3DBekker%26aufirst%3DP.%26aulast%3DHenkel%26aufirst%3DE.%26aulast%3DHasslacher%26aufirst%3DC.%26aulast%3DGouni-Berthold%26aufirst%3DI.%26aulast%3DMehling%26aufirst%3DH.%26aulast%3DPotarca%26aufirst%3DA.%26aulast%3DTesar%26aufirst%3DV.%26aulast%3DHeerspink%26aufirst%3DH.%2BJ.%26aulast%3DSchall%26aufirst%3DT.%2BJ.%26atitle%3DCCX140-B%2520Diabetic%2520Nephropathy%2520Study%2520Group.%2520The%2520effect%2520of%2520CCR2%2520inhibitor%2520CCX140-B%2520on%2520residual%2520albuminuria%2520in%2520patients%2520with%2520type%25202%2520diabetes%2520and%2520nephropathy%253A%2520a%2520randomised%2520trial%26jtitle%3DLancet%2520Diabetes%2520Endocrinol.%26date%3D2015%26volume%3D3%26spage%3D687%26epage%3D696%26doi%3D10.1016%2FS2213-8587%2815%2900261-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span> <span> </span><span class="NLM_article-title">Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2197</span>â <span class="NLM_lpage">2212</span>, <span class="refDoi">Â DOI: 10.1021/jm400658e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400658e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFynsrvK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2197-2212&author=L.+Juillerat-Jeanneret&title=Dipeptidyl+peptidase+IV+and+its+inhibitors%3A+therapeutics+for+type+2+diabetes+and+what+else%3F&doi=10.1021%2Fjm400658e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Dipeptidyl Peptidase IV and Its Inhibitors: Therapeutics for Type 2 Diabetes and What Else?</span></div><div class="casAuthors">Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2197-2212</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The proline-specific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26), widely expressed in mammalians, releases X-Pro/Ala dipeptides from the N-terminus of peptides.  DPP IV is responsible of the degrdn. of the incretin peptide hormones regulating blood glucose levels.  Several families of DPP IV inhibitors have been synthesized and evaluated.  Their pos. effects on the degrdn. of the incretins and the control of blood glucose levels have been demonstrated in biol. models and in clin. trials.  Presently, several DPP IV inhibitors, the "gliptins", are approved for type 2 diabetes or are under clin. evaluation.  However, the gliptins may also be of therapeutic interest for other diseases beyond the inhibition of incretin degrdn.  In this Perspective, the biol. functions and potential substrates of DPP IV enzymes are reviewed and the characteristics of the DPP IV inhibitors are discussed in view of type 2 diabetes and further therapeutic interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWd_YPU84lhrVg90H21EOLACvtfcHk0lj3pPQNrV2N_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFynsrvK&md5=f7ff160773940e307ddc3dc1495053b6</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm400658e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400658e%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DDipeptidyl%2520peptidase%2520IV%2520and%2520its%2520inhibitors%253A%2520therapeutics%2520for%2520type%25202%2520diabetes%2520and%2520what%2520else%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2197%26epage%3D2212%26doi%3D10.1021%2Fjm400658e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, D.</span></span> <span> </span><span class="NLM_article-title">N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">70</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24782774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvVeqtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=70&author=K.+Kanasakiauthor=T.+Nagaiauthor=K.+Nittaauthor=M.+Kitadaauthor=D.+Koya&title=N-acetyl-seryl-aspartyl-lysyl-proline%3A+a+valuable+endogenous+anti-fibrotic+peptide+for+combating+kidney+fibrosis+in+diabetes&doi=10.3389%2Ffphar.2014.00070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes</span></div><div class="casAuthors">Kanasaki Keizo; Nagai Takako; Nitta Kyoko; Kitada Munehiro; Koya Daisuke</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">70</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Fibroproliferative diseases are responsible for 45% of deaths in the developed world.  Curing organ fibrosis is essential for fibroproliferative diseases.  Diabetic nephropathy is a common fibroproliferative disease of the kidney and is associated with multiorgan dysfunction.  However, therapy to combat diabetic nephropathy has not yet been established.  In this review, we discuss the novel therapeutic possibilities for kidney fibrosis in diabetes focusing on the endogenous anti-fibrotic peptide, N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), which is the substrate for angiotensin-converting enzyme and exhibits meaningful anti-fibrotic effects in various experimental models of fibrotic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZfmq9ctleGs25P7XSLhESfW6udTcc2eYZG22UO-WEhrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvVeqtQ%253D%253D&md5=910d0627fe05257c118d9f528d9a5333</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00070%26sid%3Dliteratum%253Aachs%26aulast%3DKanasaki%26aufirst%3DK.%26aulast%3DNagai%26aufirst%3DT.%26aulast%3DNitta%26aufirst%3DK.%26aulast%3DKitada%26aufirst%3DM.%26aulast%3DKoya%26aufirst%3DD.%26atitle%3DN-acetyl-seryl-aspartyl-lysyl-proline%253A%2520a%2520valuable%2520endogenous%2520anti-fibrotic%2520peptide%2520for%2520combating%2520kidney%2520fibrosis%2520in%2520diabetes%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D70%26doi%3D10.3389%2Ffphar.2014.00070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boutet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Frutos, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayol, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieto, M. A.</span></span> <span> </span><span class="NLM_article-title">Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5603</span>â <span class="NLM_lpage">5613</span>, <span class="refDoi">Â DOI: 10.1038/sj.emboj.7601421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fsj.emboj.7601421" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=5603-5613&author=A.+Boutetauthor=C.+A.+De+Frutosauthor=P.+H.+Maxwellauthor=M.+J.+Mayolauthor=J.+Romeroauthor=M.+A.+Nieto&title=Snail+activation+disrupts+tissue+homeostasis+and+induces+fibrosis+in+the+adult+kidney&doi=10.1038%2Fsj.emboj.7601421"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601421%26sid%3Dliteratum%253Aachs%26aulast%3DBoutet%26aufirst%3DA.%26aulast%3DDe%2BFrutos%26aufirst%3DC.%2BA.%26aulast%3DMaxwell%26aufirst%3DP.%2BH.%26aulast%3DMayol%26aufirst%3DM.%2BJ.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DNieto%26aufirst%3DM.%2BA.%26atitle%3DSnail%2520activation%2520disrupts%2520tissue%2520homeostasis%2520and%2520induces%2520fibrosis%2520in%2520the%2520adult%2520kidney%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26spage%3D5603%26epage%3D5613%26doi%3D10.1038%2Fsj.emboj.7601421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span> <span> </span><span class="NLM_article-title">Lovastatin alleviates endothelial-to-mesenchymal transition in glomeruli via suppression of oxidative stress and TGF-Î²1 signaling</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">473</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28769803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2ns7bK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=473&author=Z.+Maauthor=L.+Zhuauthor=Y.+Liuauthor=Z.+Wangauthor=Y.+Yangauthor=L.+Chenauthor=Q.+Lu&title=Lovastatin+alleviates+endothelial-to-mesenchymal+transition+in+glomeruli+via+suppression+of+oxidative+stress+and+TGF-%CE%B21+signaling&doi=10.3389%2Ffphar.2017.00473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Lovastatin alleviates endothelial-to-mesenchymal transition in glomeruli via suppression of oxidative stress and TGF-Î²1 signaling</span></div><div class="casAuthors">Ma, Zejun; Zhu, Lili; Liu, Yan; Wang, Zhida; Yang, Yang; Chen, Liming; Lu, Qiulun</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">473/1-473/10</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Statins may decrease chronic kidney diseases (CKDs) risk, but their underlying mol. mechanisms are not completely understood.  Recent studies indicate Endothelial-to-mesenchymal transition (EndMT) plays an important role contributing to renal interstitial fibrosis.  In the present study, we first investigated whether lovastatin could ameliorate renal fibrosis via suppression of EndMT and its possible mechanism.  In vitro expts., lovastatin significantly ameliorated microalbuminuria and pathol. changes in diabetic rats.  Double labeling immunofluorescence showed lovastatin could inhibit EndMT in glomeruli.  Furthermore, lovastatin could inhibit oxidative stress and down-regulate TGF-Î²1-Smad signaling.  Consistent alterations were obsd. in vivo that lovastatin substantially suppressed EndMT and TGF-Î²1 signaling induced by high glucose in glomerular endothelial cells (GEnCs).  These data indicated that lovastatin could ameliorate EndMT in glomeruli in diabetic nephropathy, the mechanism of which might be at least partly through suppression of oxidative stress and TGF-Î²1/Smad signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoeubp74PzJLVg90H21EOLACvtfcHk0lgQvBgRDQDe8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2ns7bK&md5=e17d2579fe481902e60a43c322d6d2b9</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00473%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DQ.%26atitle%3DLovastatin%2520alleviates%2520endothelial-to-mesenchymal%2520transition%2520in%2520glomeruli%2520via%2520suppression%2520of%2520oxidative%2520stress%2520and%2520TGF-%25CE%25B21%2520signaling%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D473%26doi%3D10.3389%2Ffphar.2017.00473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheele, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clerin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamimi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grover-PÃ¡ez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros-Huguet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolph, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Nahas, M.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy</span>. <i>J. Am. Soc. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3459</span>â <span class="NLM_lpage">3468</span>, <span class="refDoi">Â DOI: 10.1681/ASN.2015050473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1681%2FASN.2015050473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=27113485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOru7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=3459-3468&author=W.+Scheeleauthor=S.+Diamondauthor=J.+Galeauthor=V.+Clerinauthor=N.+Tamimiauthor=V.+Leauthor=R.+Walleyauthor=F.+Grover-P%C3%A1ezauthor=C.+Perros-Huguetauthor=T.+Rolphauthor=M.+El+Nahas&title=Phosphodiesterase+type+5+inhibition+reduces+albuminuria+in+subjects+with+overt+diabetic+nephropathy&doi=10.1681%2FASN.2015050473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy</span></div><div class="casAuthors">Scheele, Wim; Diamond, Susan; Gale, Jeremy; Clerin, Valerie; Tamimi, Nihad; Le, Vu; Walley, Rosalind; Grover-Paez, Fernando; Perros-Huguet, Christelle; Rolph, Timothy; El Nahas, Meguid</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Society of Nephrology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3459-3468</span>CODEN:
                <span class="NLM_cas:coden">JASNEU</span>;
        ISSN:<span class="NLM_cas:issn">1046-6673</span>.
    
            (<span class="NLM_cas:orgname">American Society of Nephrology</span>)
        </div><div class="casAbstract">Diabetic nephropathy (DN) is the leading cause of ESRD worldwide.  Reduced bioavailability or uncoupling of nitric oxide in the kidney, leading to decreased intracellular levels of the nitric oxide pathway effector mol. cyclic guanosine monophosphate (cGMP), has been implicated in the progression of DN.  Preclin. studies suggest that elevating the cGMP intracellular pool through inhibition of the cGMP-hydrolyzing enzyme phosphodiesterase type 5 (PDE5) might exert renoprotective effects in DN.  To test this hypothesis, the novel, highly specific, and long-acting PDE5 inhibitor, PF-00489791, was assessed in a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group trial of subjects with type 2 diabetes mellitus and overt nephropathy receiving angiotensin converting enzyme inhibitor or angiotensin receptor blocker background therapy.  In total, 256 subjects with an eGFR between 25 and 60 mL/min per 1.73 m2 and macroalbuminuria defined by a urinary albumin-to-creatinine ratio >300 mg/g, were randomly assigned 3:1, resp., to receive PF-00489791 (20 mg) or placebo orally, once daily for 12 wk.  Using the predefined primary assessment of efficacy (Bayesian anal. with informative prior), we obsd. a significant redn. in urinary albumin-to-creatinine ratio of 15.7% (ratio 0.843; 95% credible interval 0.73 to 0.98) in response to the 12-wk treatment with PF-00489791 compared with placebo.  PF-00489791 was safe and generally well tolerated in this patient population.  Most common adverse events were mild in severity and included headache and upper gastrointestinal events.  In conclusion, the safety and efficacy profile of PDE5 inhibitor PF-00489791 supports further investigation as a novel therapy to improve renal outcomes in DN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuWrAOhY1Dj7Vg90H21EOLACvtfcHk0lgQvBgRDQDe8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOru7o%253D&md5=386d1c840e15e0184c7b5f64f1fb9894</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1681%2FASN.2015050473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1681%252FASN.2015050473%26sid%3Dliteratum%253Aachs%26aulast%3DScheele%26aufirst%3DW.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DGale%26aufirst%3DJ.%26aulast%3DClerin%26aufirst%3DV.%26aulast%3DTamimi%26aufirst%3DN.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DWalley%26aufirst%3DR.%26aulast%3DGrover-P%25C3%25A1ez%26aufirst%3DF.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DRolph%26aufirst%3DT.%26aulast%3DEl%2BNahas%26aufirst%3DM.%26atitle%3DPhosphodiesterase%2520type%25205%2520inhibition%2520reduces%2520albuminuria%2520in%2520subjects%2520with%2520overt%2520diabetic%2520nephropathy%26jtitle%3DJ.%2520Am.%2520Soc.%2520Nephrol.%26date%3D2016%26volume%3D27%26spage%3D3459%26epage%3D3468%26doi%3D10.1681%2FASN.2015050473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thannickal, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, S. R.</span></span> <span> </span><span class="NLM_article-title">Fibrosis: ultimate and proximate causes</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">4673</span>â <span class="NLM_lpage">4677</span>, <span class="refDoi">Â DOI: 10.1172/JCI74368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI74368" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=4673-4677&author=V.+J.+Thannickalauthor=Y.+Zhouauthor=A.+Gaggarauthor=S.+R.+Duncan&title=Fibrosis%3A+ultimate+and+proximate+causes&doi=10.1172%2FJCI74368"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1172%2FJCI74368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI74368%26sid%3Dliteratum%253Aachs%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DGaggar%26aufirst%3DA.%26aulast%3DDuncan%26aufirst%3DS.%2BR.%26atitle%3DFibrosis%253A%2520ultimate%2520and%2520proximate%2520causes%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D4673%26epage%3D4677%26doi%3D10.1172%2FJCI74368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranghino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussolati, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moggio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimuccio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapparo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biancone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gontero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frea, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camussi, G.</span></span> <span> </span><span class="NLM_article-title">The effects of glomerular and tubular renal progenitors and derived extracellular vesicles on recovery from acute kidney injury</span>. <i>Stem Cell Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">24</span>, <span class="refDoi">Â DOI: 10.1186/s13287-017-0478-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1186%2Fs13287-017-0478-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28173878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVahurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=24&author=A.+Ranghinoauthor=S.+Brunoauthor=B.+Bussolatiauthor=A.+Moggioauthor=V.+Dimuccioauthor=M.+Tapparoauthor=L.+Bianconeauthor=P.+Gonteroauthor=B.+Freaauthor=G.+Camussi&title=The+effects+of+glomerular+and+tubular+renal+progenitors+and+derived+extracellular+vesicles+on+recovery+from+acute+kidney+injury&doi=10.1186%2Fs13287-017-0478-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of glomerular and tubular renal progenitors and derived extracellular vesicles on recovery from acute kidney injury</span></div><div class="casAuthors">Ranghino, Andrea; Bruno, Stefania; Bussolati, Benedetta; Moggio, Aldo; Dimuccio, Veronica; Tapparo, Marta; Biancone, Luigi; Gontero, Paolo; Frea, Bruno; Camussi, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Research & Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24/1-24/15</span>CODEN:
                <span class="NLM_cas:coden">SCRTEK</span>;
        ISSN:<span class="NLM_cas:issn">1757-6512</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Mesenchymal stromal cells (MSCs) and renal stem/progenitors improve the recovery of acute kidney injury (AKI) mainly through the release of paracrine mediators including the extracellular vesicles (EVs).  Several studies have reported the existence of a resident population of MSCs within the glomeruli (Gl-MSCs).  However, their contribution towards kidney repair still remains to be elucidated.  The aimof the present study was to evaluate whether Gl-MSCs and Gl-MSC-EVs promote the recovery of AKI induced by ischemia-reperfusion injury (IRI) in SCID mice.  Moreover, the effects of Gl-MSCs and Gl-MSC-EVs were compared with those of CD133+ progenitor cells isolated from human tubules of the renal cortical tissue (T-CD133+ cells) and their EVs (T-CD133+-EVs).  Methods: IRI was performed in mice by clamping the left renal pedicle for 35 min together with a right nephrectomy.  Immediately after reperfusion, the animals were divided in different groups to be treated with: Gl-MSCs, T-CD133+ cells, Gl-MSC-EVs, T-CD133+-EVs or vehicle.  To assess the role of vesicular RNA, EVs were either isolated by floating to avoid contamination of non-vesicles-assocd. RNA or treated with a high dose of RNase.  Mice were sacrificed 48 h after surgery.  Results: Gl-MSCs, and Gl-MSC-EVs both ameliorate kidney function and reduce the ischemic damage post IRI by activating tubular epithelial cell proliferation.  Furthermore, T-CD133+ cells, but not their EVs, also significantly contributed to the renal recovery after IRI compared to the controls.  Floating EVs were effective while RNase-inactivated EVs were ineffective.  Anal. of the EV miRnome revealed that Gl-MSC-EVs selectively expressed a group of miRNAs, compared to EVs derived from fibroblasts, which were biol. ineffective in IRI.  Conclusions: In this study, we demonstrate that Gl-MSCs may contribute in the recovery of mice with AKI induced by IRI primarily through the release of EVs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1TgkCExYuDLVg90H21EOLACvtfcHk0lj1d8JJQLZ9Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVahurw%253D&md5=5878116d772b15c228cef4727135c6d2</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1186%2Fs13287-017-0478-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13287-017-0478-5%26sid%3Dliteratum%253Aachs%26aulast%3DRanghino%26aufirst%3DA.%26aulast%3DBruno%26aufirst%3DS.%26aulast%3DBussolati%26aufirst%3DB.%26aulast%3DMoggio%26aufirst%3DA.%26aulast%3DDimuccio%26aufirst%3DV.%26aulast%3DTapparo%26aufirst%3DM.%26aulast%3DBiancone%26aufirst%3DL.%26aulast%3DGontero%26aufirst%3DP.%26aulast%3DFrea%26aufirst%3DB.%26aulast%3DCamussi%26aufirst%3DG.%26atitle%3DThe%2520effects%2520of%2520glomerular%2520and%2520tubular%2520renal%2520progenitors%2520and%2520derived%2520extracellular%2520vesicles%2520on%2520recovery%2520from%2520acute%2520kidney%2520injury%26jtitle%3DStem%2520Cell%2520Res.%2520Ther.%26date%3D2017%26volume%3D8%26spage%3D24%26doi%3D10.1186%2Fs13287-017-0478-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahokas, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerling, I. C.</span></span> <span> </span><span class="NLM_article-title">Myofibroblast-mediated mechanisms of pathological remodeling of the heart</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">15</span>â <span class="NLM_lpage">26</span>, <span class="refDoi">Â DOI: 10.1038/nrcardio.2012.158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnrcardio.2012.158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23207731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvV2gtrfO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=15-26&author=K.+T.+Weberauthor=Y.+Sunauthor=S.+K.+Bhattacharyaauthor=R.+A.+Ahokasauthor=I.+C.+Gerling&title=Myofibroblast-mediated+mechanisms+of+pathological+remodeling+of+the+heart&doi=10.1038%2Fnrcardio.2012.158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Myofibroblast-mediated mechanisms of pathological remodelling of the heart</span></div><div class="casAuthors">Weber, Karl T.; Sun, Yao; Bhattacharya, Syamal K.; Ahokas, Robert A.; Gerling, Ivan C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-26</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The syncytium of cardiomyocytes in the heart is tethered within a matrix composed principally of type I fibrillar collagen.  The matrix has diverse mech. functions that ensure the optimal contractile efficiency of this muscular pump.  In the diseased heart, cardiomyocytes are lost to necrotic cell death, and phenotypically transformed fibroblast-like cells-termed 'myofibroblasts'-are activated to initiate a 'reparative' fibrosis.  The structural integrity of the myocardium is preserved by this scar tissue, although at the expense of its remodelled architecture, which has increased tissue stiffness and propensity to arrhythmias.  A persisting population of activated myofibroblasts turns this fibrous tissue into a living 'secretome' that generates angiotensin II and its type 1 receptor, and fibrogenic growth factors (such as transforming growth factor-Î²), all of which collectively act as a signal-transducer-effector signalling pathway to type I collagen synthesis and, therefore, fibrosis.  Persistent myofibroblasts, and the resultant fibrous tissue they produce, cause progressive adverse myocardial remodelling, a pathol. hallmark of the failing heart irresp. of its etiol. origin.  Herein, we review relevant cellular, subcellular, and mol. mechanisms integral to cardiac fibrosis and consequent remodelling of atria and ventricles with a heterogeneity in cardiomyocyte size.  Signalling pathways that antagonize collagen fibrillogenesis provide novel strategies for cardioprotection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVeP8kxRg0zrVg90H21EOLACvtfcHk0lj1d8JJQLZ9Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvV2gtrfO&md5=61bbe8d33f74ca318772709b734408fd</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2012.158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2012.158%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DK.%2BT.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26aulast%3DAhokas%26aufirst%3DR.%2BA.%26aulast%3DGerling%26aufirst%3DI.%2BC.%26atitle%3DMyofibroblast-mediated%2520mechanisms%2520of%2520pathological%2520remodeling%2520of%2520the%2520heart%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2013%26volume%3D10%26spage%3D15%26epage%3D26%26doi%3D10.1038%2Fnrcardio.2012.158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tillmanns, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habbaba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitto, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedding, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraccarollo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galuppo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauersachs, J.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardiac infarction</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">194</span>â <span class="NLM_lpage">203</span>, <span class="refDoi">Â DOI: 10.1016/j.yjmcc.2015.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.yjmcc.2015.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26319660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFeht7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=194-203&author=J.+Tillmannsauthor=D.+Hoffmannauthor=Y.+Habbabaauthor=J.+D.+Schmittoauthor=D.+Seddingauthor=D.+Fraccarolloauthor=P.+Galuppoauthor=J.+Bauersachs&title=Fibroblast+activation+protein+alpha+expression+identifies+activated+fibroblasts+after+myocardiac+infarction&doi=10.1016%2Fj.yjmcc.2015.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction</span></div><div class="casAuthors">Tillmanns, Jochen; Hoffmann, Daniel; Habbaba, Yasmin; Schmitto, Jan D.; Sedding, Daniel; Fraccarollo, Daniela; Galuppo, Paolo; Bauersachs, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">194-203</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fibroblast activation protein Î± (FAP) is a membrane-bound serine protease expressed by activated fibroblasts during wound healing in the skin.  Expression of FAP after myocardial infarction (MI) and potential effects on cardiac wound healing are largely unknown.  MI was induced in rats and FAP expression was analyzed at 3, 7 and 28 days post-MI by microarray, Western blot and immunohistochem.  In human hearts after MI, a FAP+ fibroblast population was identified, and characterized by immunohistochem. for prolyl-4-hydroxylase Î², Î±-smooth muscle actin, Thy-1 and vimentin.  Signaling pathways leading to FAP expression were studied in human cardiac fibroblasts by Western blot and ELISA using TGFÎ²1, TGF-beta type I-receptor (TGFbR1)-inhibitor SB431542 or the MAPK-inhibitor U0126 as well as siRNA targeting SMAD2 and SMAD3.  Finally, fibroblasts were assayed for FAP-dependent migration (modified Boyden-chamber), proliferation (BrdU-assay) and gelatinolytic activity by gelatin zymog.  In rats, FAP expression was increased after MI esp. in the peri-infarct area peaking at 7 days post-MI.  Co-localization anal. identified the majority of FAP+ cells as activated proto-myofibroblasts and myofibroblasts.  Concordantly, FAP+ fibroblasts were abundant in ischemic tissue of human hearts after MI, but not in healthy control hearts.  In vitro, FAP was induced by TGFÎ²1 via the canonical SMAD2/SMAD3 pathway.  Depletion of FAP in fibroblasts reduced migratory capacity, while proliferation was not affected.  Gelatin zymog. revealed gelatinase activity by fibroblast-derived FAP.  In this study, we show for the first time the expression of FAP in activated fibroblasts after MI and its activation by TGFÎ²1.  Effects of FAP on fibroblast migration and gelatinolytic activity indicate a potential role in cardiac wound healing and remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkduzibIcGTLVg90H21EOLACvtfcHk0lj1d8JJQLZ9Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFeht7zP&md5=979deaf019af45915ad8192b352a7b88</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2015.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2015.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DTillmanns%26aufirst%3DJ.%26aulast%3DHoffmann%26aufirst%3DD.%26aulast%3DHabbaba%26aufirst%3DY.%26aulast%3DSchmitto%26aufirst%3DJ.%2BD.%26aulast%3DSedding%26aufirst%3DD.%26aulast%3DFraccarollo%26aufirst%3DD.%26aulast%3DGaluppo%26aufirst%3DP.%26aulast%3DBauersachs%26aufirst%3DJ.%26atitle%3DFibroblast%2520activation%2520protein%2520alpha%2520expression%2520identifies%2520activated%2520fibroblasts%2520after%2520myocardiac%2520infarction%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2015%26volume%3D87%26spage%3D194%26epage%3D203%26doi%3D10.1016%2Fj.yjmcc.2015.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. S.</span></span> <span> </span><span class="NLM_article-title">Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e35007</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0035007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1371%2Fjournal.pone.0035007" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e35007&author=S.+Limauthor=S.+H.+Choiauthor=H.+Shinauthor=B.+J.+Choauthor=H.+S.+Parkauthor=B.+Y.+Ahnauthor=S.+M.+Kangauthor=J.+W.+Yoonauthor=H.+C.+Jangauthor=Y.+B.+Kimauthor=K.+S.+Park&title=Effect+of+a+dipeptidyl+peptidase-IV+inhibitor%2C+des-fluoro-sitagliptin%2C+on+neointimal+formation+after+balloon+injury+in+rats&doi=10.1371%2Fjournal.pone.0035007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0035007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0035007%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DShin%26aufirst%3DH.%26aulast%3DCho%26aufirst%3DB.%2BJ.%26aulast%3DPark%26aufirst%3DH.%2BS.%26aulast%3DAhn%26aufirst%3DB.%2BY.%26aulast%3DKang%26aufirst%3DS.%2BM.%26aulast%3DYoon%26aufirst%3DJ.%2BW.%26aulast%3DJang%26aufirst%3DH.%2BC.%26aulast%3DKim%26aufirst%3DY.%2BB.%26aulast%3DPark%26aufirst%3DK.%2BS.%26atitle%3DEffect%2520of%2520a%2520dipeptidyl%2520peptidase-IV%2520inhibitor%252C%2520des-fluoro-sitagliptin%252C%2520on%2520neointimal%2520formation%2520after%2520balloon%2520injury%2520in%2520rats%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De35007%26doi%3D10.1371%2Fjournal.pone.0035007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, A. M.</span></span> <span> </span><span class="NLM_article-title">A clinical perspective of anti-fibrotic therapies for cardiovascular diseases</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">186</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28428753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvFWjtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=186&author=L.+Fangauthor=A.+J.+Murphyauthor=A.+M.+Dart&title=A+clinical+perspective+of+anti-fibrotic+therapies+for+cardiovascular+diseases&doi=10.3389%2Ffphar.2017.00186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">A clinical perspective of anti-fibrotic therapies for cardiovascular disease</span></div><div class="casAuthors">Fang, Lu; Murphy, Andrew J.; Dart, Anthony M.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">186/1-186/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Cardiac fibrosis are central to various cardiovascular diseases.  Research on the mechanisms and therapeutic targets for cardiac fibrosis has advanced greatly in recent years.  However, while many anti-fibrotic treatments have been studied in animal models and seem promising, translation of exptl. findings into human patients has been rather limited.  Thus, several potential new treatments which have shown to reduce cardiac fibrosis in animal models have either not been tested in humans or proved to be disappointing in clin. trials.  A majority of clin. studies are of small size or have not been maintained for long enough periods.  In addn., although some conventional therapies, such as renin-angiotensin-aldosterone system (RAAS) inhibitors, have been shown to reduce cardiac fibrosis in humans, cardiac fibrosis persists in patients with heart failure even when treated with these conventional therapies, indicating a need to develop novel and effective anti-fibrotic therapies in cardiovascular disease.  In this review article, we summarize anti-fibrotic therapies for cardiovascular disease in humans, discuss the limitations of currently used therapies, along with possible reasons for the failure of so many anti-fibrotic drugs at the clin. level.  We will then explore the future directions of anti-fibrotic therapies on cardiovascular disease, and this will include emerging anti-fibrotics that show promise, such as relaxin.  A better understanding of the differences between animal models and human pathol., and improved insight into carefully designed trials on appropriate end-points and appropriate dosing need to be considered to identify more effective anti-fibrotics for treating cardiovascular fibrosis in human patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn2yH71JqfzLVg90H21EOLACvtfcHk0lg7fJbibgD69w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvFWjtrY%253D&md5=0296828eb268e985bf2d6acedfab457d</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00186%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DL.%26aulast%3DMurphy%26aufirst%3DA.%2BJ.%26aulast%3DDart%26aufirst%3DA.%2BM.%26atitle%3DA%2520clinical%2520perspective%2520of%2520anti-fibrotic%2520therapies%2520for%2520cardiovascular%2520diseases%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D186%26doi%3D10.3389%2Ffphar.2017.00186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brokopp, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmert, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aikawa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ¼scher, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoerstrup, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, C. M.</span></span> <span> </span><span class="NLM_article-title">Fibroblasts activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2713</span>â <span class="NLM_lpage">2722</span>, <span class="refDoi">Â DOI: 10.1093/eurheartj/ehq519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1093%2Feurheartj%2Fehq519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=21292680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGnu7nO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=2713-2722&author=C.+E.+Brokoppauthor=R.+Schoenauerauthor=P.+Richardsauthor=S.+Bauerauthor=C.+Lohmannauthor=M.+Y.+Emmertauthor=B.+Weberauthor=S.+Winnikauthor=E.+Aikawaauthor=K.+Gravesauthor=M.+Genoniauthor=P.+Vogtauthor=T.+F.+L%C3%BCscherauthor=C.+Rennerauthor=S.+P.+Hoerstrupauthor=C.+M.+Matter&title=Fibroblasts+activation+protein+is+induced+by+inflammation+and+degrades+type+I+collagen+in+thin-cap+fibroatheromata&doi=10.1093%2Feurheartj%2Fehq519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata</span></div><div class="casAuthors">Brokopp, Chad E.; Schoenauer, Roman; Richards, Peter; Bauer, Stefan; Lohmann, Christine; Emmert, Maximilian Y.; Weber, Benedikt; Winnik, Stephan; Aikawa, Elena; Graves, Kirk; Genoni, Michele; Vogt, Peter; Luescher, Thomas F.; Renner, Christoph; Hoerstrup, Simon P.; Matter, Christian M.</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2713-2722</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims Collagen degrdn. in atherosclerotic plaques with thin fibrous caps renders them more prone to rupture.  Fibroblast activation protein (FAP) plays a role in arthritis and tumor formation through its collagenase activity.  However, the significance of FAP in thin-cap human fibroatheromata remains unknown.  Methods and results We detected enhanced FAP expression in type IV-V human aortic atheromata (n = 12), compared with type II-III lesions (n = 9; P < 0.01) and healthy aortae (n = 8; P < 0.01) by immunostaining and western blot analyses.  Fibroblast activation protein was also increased in thin-cap (<65 Î¼m) vs. thick-cap (â¥65 Î¼m) human coronary fibroatheromata (n = 12; P < 0.01).  Fibroblast activation protein was expressed by human aortic smooth muscle cells (HASMC) as shown by colocalization on immunofluorescent aortic plaque stainings (n = 10; P < 0.01) and by flow cytometry in cell culture.  Although macrophages did not express FAP, macrophage burden in human aortic plaques correlated with FAP expression (n = 12; R2= 0.763; P < 0.05).  Enzyme-linked immunosorbent assays showed a time- and dose-dependent up-regulation of FAP in response to human tumor necrosis factor Î± (TNFÎ±) in HASMC (n = 6; P < 0.01).  Moreover, supernatants from peripheral blood-derived macrophages induced FAP expression in cultured HASMC (n = 6; P < 0.01), an effect abolished by blocking TNFÎ± (n = 6; P < 0.01).  Fibroblast activation protein assocd. with collagen-poor regions in human coronary fibrous caps and digested type I collagen and gelatin in vitro (n = 6; P < 0.01).  Zymog. revealed that FAP-mediated collagenase activity was neutralized by an antibody directed against the FAP catalytic domain both in HASMC (n = 6; P < 0.01) and in fibrous caps of atherosclerotic plaques (n = 10; P < 0.01).  Conclusion Fibroblast activation protein expression in HASMC is induced by macrophage-derived TNFÎ±.  Fibroblast activation protein assocs. with thin-cap human coronary fibroatheromata and contributes to type I collagen breakdown in fibrous caps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4eDr7Cnj1c7Vg90H21EOLACvtfcHk0lg7fJbibgD69w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGnu7nO&md5=585eb7eb395d15ac6c5bb83f625da5b6</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehq519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehq519%26sid%3Dliteratum%253Aachs%26aulast%3DBrokopp%26aufirst%3DC.%2BE.%26aulast%3DSchoenauer%26aufirst%3DR.%26aulast%3DRichards%26aufirst%3DP.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DLohmann%26aufirst%3DC.%26aulast%3DEmmert%26aufirst%3DM.%2BY.%26aulast%3DWeber%26aufirst%3DB.%26aulast%3DWinnik%26aufirst%3DS.%26aulast%3DAikawa%26aufirst%3DE.%26aulast%3DGraves%26aufirst%3DK.%26aulast%3DGenoni%26aufirst%3DM.%26aulast%3DVogt%26aufirst%3DP.%26aulast%3DL%25C3%25BCscher%26aufirst%3DT.%2BF.%26aulast%3DRenner%26aufirst%3DC.%26aulast%3DHoerstrup%26aufirst%3DS.%2BP.%26aulast%3DMatter%26aufirst%3DC.%2BM.%26atitle%3DFibroblasts%2520activation%2520protein%2520is%2520induced%2520by%2520inflammation%2520and%2520degrades%2520type%2520I%2520collagen%2520in%2520thin-cap%2520fibroatheromata%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2011%26volume%3D32%26spage%3D2713%26epage%3D2722%26doi%3D10.1093%2Feurheartj%2Fehq519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horlock, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jandeleit-Dahm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, D. M.</span></span> <span> </span><span class="NLM_article-title">CXCR4 antagonism attenuates the development of diabetic cardiac fibrosis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0133616</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0133616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1371%2Fjournal.pone.0133616" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0133616&author=P.+Y.+Chuauthor=K.+Walderauthor=D.+Horlockauthor=D.+Williamsauthor=E.+Nelsonauthor=M.+Byrneauthor=K.+Jandeleit-Dahmauthor=P.+Zimmetauthor=D.+M.+Kaye&title=CXCR4+antagonism+attenuates+the+development+of+diabetic+cardiac+fibrosis&doi=10.1371%2Fjournal.pone.0133616"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0133616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0133616%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DP.%2BY.%26aulast%3DWalder%26aufirst%3DK.%26aulast%3DHorlock%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%26aulast%3DNelson%26aufirst%3DE.%26aulast%3DByrne%26aufirst%3DM.%26aulast%3DJandeleit-Dahm%26aufirst%3DK.%26aulast%3DZimmet%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DD.%2BM.%26atitle%3DCXCR4%2520antagonism%2520attenuates%2520the%2520development%2520of%2520diabetic%2520cardiac%2520fibrosis%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0133616%26doi%3D10.1371%2Fjournal.pone.0133616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span> <span> </span><span class="NLM_article-title">Notch antagonists: potential modulators of cancer and inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7719</span>â <span class="NLM_lpage">7737</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01516</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01516" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7719-7737&author=R.+Kumarauthor=L.+Juillerat-Jeanneretauthor=D.+Golshayan&title=Notch+antagonists%3A+potential+modulators+of+cancer+and+inflammatory+diseases&doi=10.1021%2Facs.jmedchem.5b01516"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01516%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DGolshayan%26aufirst%3DD.%26atitle%3DNotch%2520antagonists%253A%2520potential%2520modulators%2520of%2520cancer%2520and%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7719%26epage%3D7737%26doi%3D10.1021%2Facs.jmedchem.5b01516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nistri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bani, D.</span></span> <span> </span><span class="NLM_article-title">Notch signaling in ischemic damage and fibrosis: evidence and clues from the heart</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">187</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28424623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVKmsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=187&author=S.+Nistriauthor=C.+Sassoliauthor=D.+Bani&title=Notch+signaling+in+ischemic+damage+and+fibrosis%3A+evidence+and+clues+from+the+heart&doi=10.3389%2Ffphar.2017.00187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Notch signaling in ischemic damage and fibrosis: evidence and clues from the heart</span></div><div class="casAuthors">Nistri, Silvia; Sassoli, Chiara; Bani, Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">187/1-187/6</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Notch signaling is a major intercellular coordination mechanism highly conserved throughout evolution.  In vertebrates, Notch signaling is physiol. involved in embryo development, including mesenchymal cell commitment, formation of heart tissues and angiogenesis.  In post-natal life, Notch signaling is maintained as a key mechanism of cell-cell communication and its dysregulations have been found in pathol. conditions such as ischemic and fibrotic diseases.  In the heart, Notch takes part in the protective response to ischemia, being involved in pre- and post-conditioning, redn. of reperfusion-induced oxidative stress and myocardial damage, and cardiomyogenesis.  Conceivably, the cardioprotective effects of Notch may depend on neo-angiogenesis, thus blunting lethal myocardial ischemia, as well as on direct stimulation of cardiac cells to increase their resistance to injury.  Another post-developmental adaptation of Notch signaling is fibrosis: being involved in the orientation of mesenchymal cell fate, Notch can modulate the differentiation of profibrotic myofibroblasts, e.g., by reducing the effects of the profibrotic cytokine TGF-Î².  In conclusion, Notch can regulate the interactions between heart muscle and stromal cells and switch cardiac repair from a pro-fibrotic default pathway to a pro-cardiogenic one.  These features make Notch signaling a suitable target for new cardiotropic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Pma0PnG-jrVg90H21EOLACvtfcHk0lghY2ASQ71Tug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVKmsrY%253D&md5=ea35dd67d811b4f1055e9638bb742cda</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00187%26sid%3Dliteratum%253Aachs%26aulast%3DNistri%26aufirst%3DS.%26aulast%3DSassoli%26aufirst%3DC.%26aulast%3DBani%26aufirst%3DD.%26atitle%3DNotch%2520signaling%2520in%2520ischemic%2520damage%2520and%2520fibrosis%253A%2520evidence%2520and%2520clues%2520from%2520the%2520heart%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D187%26doi%3D10.3389%2Ffphar.2017.00187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span> <span> </span><span class="NLM_article-title">Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4599</span>â <span class="NLM_lpage">4611</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S85399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S85399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26316699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVOgsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=4599-4611&author=X.+Zhouauthor=X.+Chenauthor=J.+J.+Caiauthor=L.+Z.+Chenauthor=Y.+S.+Gongauthor=L.+X.+Wangauthor=Z.+Gaoauthor=H.+Q.+Zhangauthor=W.+J.+Huangauthor=H.+Zhou&title=Relaxin+inhibits+cardiac+fibrosis+and+endothelial-mesenchymal+transition+via+the+Notch+pathway&doi=10.2147%2FDDDT.S85399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway</span></div><div class="casAuthors">Zhou, X.; Chen, X.; Cai, J. J.; Chen, L. Z.; Gong, Y. S.; Wang, L. X.; Gao, Z.; Zhang, H. Q.; Huang, W. J.; Zhou, H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4599-4611</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Relaxin (RLX) can prevent cardiac fibrosis.  We aimed to investigate the possible mechanism and signal transduction pathway of RLX inhibiting cardiac fibrosis Methods: Isoproterenol (5 mgÂ·kg-1Â·d-1) was used to establish the cardiac fibrosis model in rats, which were administered RLX.  The cardiac function, related targets of cardiac fibrosis, and endothelial-mesenchymal transition (EndMT) were measured.  Transforming growth factor Î² (TGF-Î²) was used to induce EndMT in human umbilical vein endothelial cells, which were pretreated with RLX, 200 ngÂ·mL-1, then with the inhibitor of Notch.  Transwell cell migration was used to evaluate cell migration.  CD31 and vimentin content was detd. by immunofluorescence staining and Western blot anal.  Notch protein level was examd. by Western blot anal. Results: RLX improved cardiac function in rats with cardiac fibrosis;it reduced the content of collagen I and III, increased the microvascular d. of the myocardium,and suppressed the EndMT in heart tissue.  In vitro,RLX decreased the mobility of human umbilical vein endothelial cells induced by TGF-Î²,increased the expression of endothelial CD31, and decreased vimentin content.  Compared to TGF-Î² and RLX co-culture alone,TGF-Î² + RLX + Notch inhibitor increased cell mobility and the EndMT, but decreased the levels of Notch-1, HES-1, and Jagged-1 proteins Conclusion: RLX may inhibit the cardiac fibrosis via EndMT by Notch-mediated signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYPR5yurBlHrVg90H21EOLACvtfcHk0lhfO4dvBwQOhg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVOgsbw%253D&md5=240a8b1bf3c18e6844de3ca06adfb60d</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S85399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S85399%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DJ.%2BJ.%26aulast%3DChen%26aufirst%3DL.%2BZ.%26aulast%3DGong%26aufirst%3DY.%2BS.%26aulast%3DWang%26aufirst%3DL.%2BX.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%2BQ.%26aulast%3DHuang%26aufirst%3DW.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26atitle%3DRelaxin%2520inhibits%2520cardiac%2520fibrosis%2520and%2520endothelial-mesenchymal%2520transition%2520via%2520the%2520Notch%2520pathway%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D4599%26epage%3D4611%26doi%3D10.2147%2FDDDT.S85399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vecchio, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, L. T.</span></span> <span> </span><span class="NLM_article-title">Targeting adenosine receptors for the treatment of cardiac fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">243</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28529484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFentbrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=243&author=E.+A.+Vecchioauthor=P.+J.+Whiteauthor=L.+T.+May&title=Targeting+adenosine+receptors+for+the+treatment+of+cardiac+fibrosis&doi=10.3389%2Ffphar.2017.00243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting adenosine receptors for the treatment of cardiac fibrosis</span></div><div class="casAuthors">Vecchio, Elizabeth A.; White, Paul J.; May, Lauren T.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">243/1-243/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Adenosine is a ubiquitous mol. with key regulatory and cytoprotective mechanisms at times of metabolic imbalance in the body.  Among a plethora of physiol. actions, adenosine has an important role in attenuating ischemia-reperfusion injury and modulating the ensuing fibrosis and tissue remodeling following myocardial damage.  Adenosine exerts these actions through interaction with four adenosine G protein-coupled receptors expressed in the heart.  The adenosine A2B receptor (A2BAR) is the most abundant adenosine receptor (AR) in cardiac fibroblasts and is largely responsible for the influence of adenosine on cardiac fibrosis.  In vitroand in vivo studies demonstrate that acute A2BAR stimulation can decrease fibrosis through the inhibition of fibroblast proliferation and redn. in collagen synthesis.  However, in contrast, there is also evidence that chronic A2BAR antagonism reduces tissue fibrosis.  This review explores the opposing pro- and anti-fibrotic activity attributed to the activation of cardiac ARs and investigates the therapeutic potential of targeting ARs for the treatment of cardiac fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3KFPvl-g-rrVg90H21EOLACvtfcHk0lhmdIwZ5xKtfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFentbrN&md5=d196d5cc0362cc0ee2cf728503cbd761</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00243%26sid%3Dliteratum%253Aachs%26aulast%3DVecchio%26aufirst%3DE.%2BA.%26aulast%3DWhite%26aufirst%3DP.%2BJ.%26aulast%3DMay%26aufirst%3DL.%2BT.%26atitle%3DTargeting%2520adenosine%2520receptors%2520for%2520the%2520treatment%2520of%2520cardiac%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D243%26doi%3D10.3389%2Ffphar.2017.00243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dulauroy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Carlo, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peduto, L.</span></span> <span> </span><span class="NLM_article-title">Lineage tracing and genetic ablation of ADAM12+ perivascular cells identify a major source of profibrotic cells during acute tissue injury</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1262</span>â <span class="NLM_lpage">1270</span>, <span class="refDoi">Â DOI: 10.1038/nm.2848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm.2848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22842476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1262-1270&author=S.+Dulauroyauthor=S.+E.+Di+Carloauthor=F.+Langaauthor=G.+Eberlauthor=L.+Peduto&title=Lineage+tracing+and+genetic+ablation+of+ADAM12%2B+perivascular+cells+identify+a+major+source+of+profibrotic+cells+during+acute+tissue+injury&doi=10.1038%2Fnm.2848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Lineage tracing and genetic ablation of ADAM12+ perivascular cells identify a major source of profibrotic cells during acute tissue injury</span></div><div class="casAuthors">Dulauroy, Sophie; Di Carlo, Selene E.; Langa, Francina; Eberl, Gerard; Peduto, Lucie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1262-1270</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Profibrotic cells that develop upon injury generate permanent scar tissue and impair organ recovery, though their origin and fate are unclear.  Here we show that transient expression of ADAM12 (a disintegrin and metalloprotease 12) identifies a distinct proinflammatory subset of platelet-derived growth factor receptor-Î±-pos. stromal cells that are activated upon acute injury in the muscle and dermis.  By inducible genetic fate mapping, we demonstrate in vivo that injury-induced ADAM12+ cells are specific progenitors of a major fraction of collagen-overproducing cells generated during scarring, which are progressively eliminated during healing.  Genetic ablation of ADAM12+ cells, or knockdown of ADAM12, is sufficient to limit generation of profibrotic cells and interstitial collagen accumulation.  ADAM12+ cells induced upon injury are developmentally distinct from muscle and skin lineage cells and are derived from fetal ADAM12+ cells programmed during vascular wall development.  Thus, our data identify injury-activated profibrotic progenitors residing in the perivascular space that can be targeted through ADAM12 to limit tissue scarring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo32-rtcfFTSrVg90H21EOLACvtfcHk0lhj3086slW-3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmt73I&md5=28b13b4d88a2e9c43e9ffc0b1b5a0766</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fnm.2848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2848%26sid%3Dliteratum%253Aachs%26aulast%3DDulauroy%26aufirst%3DS.%26aulast%3DDi%2BCarlo%26aufirst%3DS.%2BE.%26aulast%3DLanga%26aufirst%3DF.%26aulast%3DEberl%26aufirst%3DG.%26aulast%3DPeduto%26aufirst%3DL.%26atitle%3DLineage%2520tracing%2520and%2520genetic%2520ablation%2520of%2520ADAM12%252B%2520perivascular%2520cells%2520identify%2520a%2520major%2520source%2520of%2520profibrotic%2520cells%2520during%2520acute%2520tissue%2520injury%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D1262%26epage%3D1270%26doi%3D10.1038%2Fnm.2848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzerini, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamberucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlÃ¬, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taddeucci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del-Ry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabiati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della-Latta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulceri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laghi-Pasini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capecchi, P. L.</span></span> <span> </span><span class="NLM_article-title">Searching novel therapeutic targets for scleroderma: P2 Ã 7-receptor is up-regulated and promotes a fibrogenic phenotype in systemic sclerosis fibroblasts</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">638</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28955239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegs7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=638&author=D.+Gentileauthor=P.+E.+Lazzeriniauthor=A.+Gamberucciauthor=M.+Nataleauthor=E.+Selviauthor=F.+Vanniauthor=A.+Al%C3%ACauthor=P.+Taddeucciauthor=S.+Del-Ryauthor=M.+Cabiatiauthor=V.+Della-Lattaauthor=D.+J.+Abrahamauthor=M.+A.+Moralesauthor=R.+Fulceriauthor=F.+Laghi-Pasiniauthor=P.+L.+Capecchi&title=Searching+novel+therapeutic+targets+for+scleroderma%3A+P2+%C3%97+7-receptor+is+up-regulated+and+promotes+a+fibrogenic+phenotype+in+systemic+sclerosis+fibroblasts&doi=10.3389%2Ffphar.2017.00638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Searching novel therapeutic targets for scleroderma: P2X7-receptor is up-regulated and promotes a fibrogenic phenotype in systemic sclerosis fibroblasts</span></div><div class="casAuthors">Gentile, Daniela; Lazzerini, Pietro E.; Gamberucci, Alessandra; Natale, Mariarita; Selvi, Enrico; Vanni, Francesca; Ali, Alessandra; Taddeucci, Paolo; Del-Ry, Silvia; Cabiati, Manuela; Della-Latta, Veronica; Abraham, David J.; Morales, Maria A.; Fulceri, Rosella; Laghi-Pasini, Franco; Capecchi, Pier L.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">638/1-638/13</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Objectives: Systemic sclerosis (SSc) is a connective tissue disorder presenting fibrosis of the skin and internal organs, for which no effective treatments are currently available.  Increasing evidence indicates that the P2X7 receptor (P2X7R), a nucleotide-gated ionotropic channel primarily involved in the inflammatory response, may also have a key role in the development of tissue fibrosis in different body districts.  This study was aimed at investigating P2X7R expression and function in promoting a fibrogenic phenotype in dermal fibroblasts from SSc patients, also analyzing putative underlying mechanistic pathways.  Methods: Fibroblasts were isolated by skin biopsy from 9 SSc patients and 8 healthy controls.  P2X7R expression, and function (cytosolic free Ca2+ fluxes, Î±-smooth muscle actin [Î±-SMA] expression, cell migration, and collagen release) were studied.  Moreover, the role of cytokine (interleukin-1Î², interleukin-6) and connective tissue growth factor (CTGF) prodn., and extracellular signal-regulated kinases (ERK) activation in mediating P2X7R-dependent pro-fibrotic effects in SSc fibroblasts was evaluated.  Results: P2X7R expression and Ca2+ permeability induced by the selective P2X7R agonist 2'-3'-O-(4-benzoylbenzoyl)ATP (BzATP) weremarkedly higher in SSc than control fibroblasts.  Moreover, increased Î±SMA expression, cell migration, CTGF, and collagen release were obsd. in lipopolysaccharides-primed SSc fibroblasts after BzATP stimulation.  While P2X7-induced cytokine changes did not affect collagen prodn., it was completely abrogated by inhibition of the ERK pathway.  Conclusion: In SSc fibroblasts, P2X7R is overexpressed and its stimulation induces Ca2+-signaling activation and a fibrogenic phenotype characterized by increased migration and collagen prodn.  These data point to the P2X7R as a potential, novel therapeutic target for controlling exaggerated collagen deposition and tissue fibrosis in patients with SSc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1qa9_QLCuprVg90H21EOLACvtfcHk0ljc-k33L-iPDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegs7rN&md5=734dd4a1baaf01b6dfdcc81c76c18143</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00638%26sid%3Dliteratum%253Aachs%26aulast%3DGentile%26aufirst%3DD.%26aulast%3DLazzerini%26aufirst%3DP.%2BE.%26aulast%3DGamberucci%26aufirst%3DA.%26aulast%3DNatale%26aufirst%3DM.%26aulast%3DSelvi%26aufirst%3DE.%26aulast%3DVanni%26aufirst%3DF.%26aulast%3DAl%25C3%25AC%26aufirst%3DA.%26aulast%3DTaddeucci%26aufirst%3DP.%26aulast%3DDel-Ry%26aufirst%3DS.%26aulast%3DCabiati%26aufirst%3DM.%26aulast%3DDella-Latta%26aufirst%3DV.%26aulast%3DAbraham%26aufirst%3DD.%2BJ.%26aulast%3DMorales%26aufirst%3DM.%2BA.%26aulast%3DFulceri%26aufirst%3DR.%26aulast%3DLaghi-Pasini%26aufirst%3DF.%26aulast%3DCapecchi%26aufirst%3DP.%2BL.%26atitle%3DSearching%2520novel%2520therapeutic%2520targets%2520for%2520scleroderma%253A%2520P2%2520%25C3%2597%25207-receptor%2520is%2520up-regulated%2520and%2520promotes%2520a%2520fibrogenic%2520phenotype%2520in%2520systemic%2520sclerosis%2520fibroblasts%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D638%26doi%3D10.3389%2Ffphar.2017.00638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leask, A.</span></span> <span> </span><span class="NLM_article-title">Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment</span>. <i>Fibrog. Tissue Repair</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi">Â DOI: 10.1186/1755-1536-3-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1186%2F1755-1536-3-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=20507556" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=8&author=A.+Leask&title=Towards+an+anti-fibrotic+therapy+for+scleroderma%3A+targeting+myofibroblast+differentiation+and+recruitment&doi=10.1186%2F1755-1536-3-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-3-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-3-8%26sid%3Dliteratum%253Aachs%26aulast%3DLeask%26aufirst%3DA.%26atitle%3DTowards%2520an%2520anti-fibrotic%2520therapy%2520for%2520scleroderma%253A%2520targeting%2520myofibroblast%2520differentiation%2520and%2520recruitment%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2010%26volume%3D3%26spage%3D8%26doi%3D10.1186%2F1755-1536-3-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distler, J. H. W.</span></span> <span> </span><span class="NLM_article-title">Canonical Wnt signaling in systemic sclerosis</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">151</span>â <span class="NLM_lpage">155</span>, <span class="refDoi">Â DOI: 10.1038/labinvest.2015.154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Flabinvest.2015.154" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2016&pages=151-155&author=C.+Bergmannauthor=J.+H.+W.+Distler&title=Canonical+Wnt+signaling+in+systemic+sclerosis&doi=10.1038%2Flabinvest.2015.154"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2015.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2015.154%26sid%3Dliteratum%253Aachs%26aulast%3DBergmann%26aufirst%3DC.%26aulast%3DDistler%26aufirst%3DJ.%2BH.%2BW.%26atitle%3DCanonical%2520Wnt%2520signaling%2520in%2520systemic%2520sclerosis%26jtitle%3DLab.%2520Invest.%26date%3D2016%26volume%3D96%26spage%3D151%26epage%3D155%26doi%3D10.1038%2Flabinvest.2015.154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamdan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drakulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikici, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomic-Canic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daunert, S.</span></span> <span> </span><span class="NLM_article-title">Nanotechnology-driven therapeutic interventions in wound healing: potential uses and applications</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">163</span>â <span class="NLM_lpage">175</span>, <span class="refDoi">Â DOI: 10.1021/acscentsci.6b00371</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.6b00371" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtlCjt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=163-175&author=S.+Hamdanauthor=I.+Pastarauthor=S.+Drakulichauthor=E.+Dikiciauthor=M.+Tomic-Canicauthor=S.+Deoauthor=S.+Daunert&title=Nanotechnology-driven+therapeutic+interventions+in+wound+healing%3A+potential+uses+and+applications&doi=10.1021%2Facscentsci.6b00371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Nanotechnology-Driven Therapeutic Interventions in Wound Healing: Potential Uses and Applications</span></div><div class="casAuthors">Hamdan, Suzana; Pastar, Irena; Drakulich, Stefan; Dikici, Emre; Tomic-Canic, Marjana; Deo, Sapna; Daunert, Sylvia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">163-175</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The chronic nature and assocd. complications of nonhealing wounds have led to the emergence of nanotechnol.-based therapies that aim at facilitating the healing process and ultimately repairing the injured tissue.  A no. of engineered nanotechnologies have been proposed demonstrating unique properties and multiple functions that address specific problems assocd. with wound repair mechanisms.  In this outlook, we highlight the most recently developed nanotechnol.-based therapeutic agents and assess the viability and efficacy of each treatment, with emphasis on chronic cutaneous wounds.  Herein we explore the unmet needs and future directions of current technologies, while discussing promising strategies that can advance the wound healing field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1UHLlQ5pa0LVg90H21EOLACvtfcHk0lg9BYqJQKkF3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtlCjt78%253D&md5=8d062dc44d44c7b028f9ebdd8d44e5c3</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.6b00371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.6b00371%26sid%3Dliteratum%253Aachs%26aulast%3DHamdan%26aufirst%3DS.%26aulast%3DPastar%26aufirst%3DI.%26aulast%3DDrakulich%26aufirst%3DS.%26aulast%3DDikici%26aufirst%3DE.%26aulast%3DTomic-Canic%26aufirst%3DM.%26aulast%3DDeo%26aufirst%3DS.%26aulast%3DDaunert%26aufirst%3DS.%26atitle%3DNanotechnology-driven%2520therapeutic%2520interventions%2520in%2520wound%2520healing%253A%2520potential%2520uses%2520and%2520applications%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2017%26volume%3D3%26spage%3D163%26epage%3D175%26doi%3D10.1021%2Facscentsci.6b00371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajanayake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olariu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeclÃ¨re, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhayani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bongoni, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banz, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantinescu, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar Vemula, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieben, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VÃ¶gelin, E.</span></span> <span> </span><span class="NLM_article-title">A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">249ra110</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.3008778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1126%2Fscitranslmed.3008778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25122638" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=249ra110&author=T.+Gajanayakeauthor=R.+Olariuauthor=F.+M.+Lecl%C3%A8reauthor=A.+Dhayaniauthor=Z.+Yangauthor=A.+K.+Bongoniauthor=Y.+Banzauthor=M.+A.+Constantinescuauthor=J.+M.+Karpauthor=P.+Kumar+Vemulaauthor=R.+Riebenauthor=E.+V%C3%B6gelin&title=A+single+localized+dose+of+enzyme-responsive+hydrogel+improves+long-term+survival+of+a+vascularized+composite+allograft&doi=10.1126%2Fscitranslmed.3008778"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3008778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3008778%26sid%3Dliteratum%253Aachs%26aulast%3DGajanayake%26aufirst%3DT.%26aulast%3DOlariu%26aufirst%3DR.%26aulast%3DLecl%25C3%25A8re%26aufirst%3DF.%2BM.%26aulast%3DDhayani%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DBongoni%26aufirst%3DA.%2BK.%26aulast%3DBanz%26aufirst%3DY.%26aulast%3DConstantinescu%26aufirst%3DM.%2BA.%26aulast%3DKarp%26aufirst%3DJ.%2BM.%26aulast%3DKumar%2BVemula%26aufirst%3DP.%26aulast%3DRieben%26aufirst%3DR.%26aulast%3DV%25C3%25B6gelin%26aufirst%3DE.%26atitle%3DA%2520single%2520localized%2520dose%2520of%2520enzyme-responsive%2520hydrogel%2520improves%2520long-term%2520survival%2520of%2520a%2520vascularized%2520composite%2520allograft%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D249ra110%26doi%3D10.1126%2Fscitranslmed.3008778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatayama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsutahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichimaru, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaimori, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomura, N.</span></span> <span> </span><span class="NLM_article-title">High-pressure carbon monoxide preserves rat kidney grafts from apoptosis and inflammation</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">468</span>â <span class="NLM_lpage">477</span>, <span class="refDoi">Â DOI: 10.1038/labinvest.2016.157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Flabinvest.2016.157" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2017&pages=468-477&author=T.+Abeauthor=K.+Yazawaauthor=M.+Fujinoauthor=R.+Imamuraauthor=N.+Hatayamaauthor=Y.+Kakutaauthor=K.+Tsutaharaauthor=M.+Okumiauthor=N.+Ichimaruauthor=J.+Y.+Kaimoriauthor=Y.+Isakaauthor=K.+Sekiauthor=S.+Takaharaauthor=X.+K.+Liauthor=N.+Nonomura&title=High-pressure+carbon+monoxide+preserves+rat+kidney+grafts+from+apoptosis+and+inflammation&doi=10.1038%2Flabinvest.2016.157"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2016.157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2016.157%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DT.%26aulast%3DYazawa%26aufirst%3DK.%26aulast%3DFujino%26aufirst%3DM.%26aulast%3DImamura%26aufirst%3DR.%26aulast%3DHatayama%26aufirst%3DN.%26aulast%3DKakuta%26aufirst%3DY.%26aulast%3DTsutahara%26aufirst%3DK.%26aulast%3DOkumi%26aufirst%3DM.%26aulast%3DIchimaru%26aufirst%3DN.%26aulast%3DKaimori%26aufirst%3DJ.%2BY.%26aulast%3DIsaka%26aufirst%3DY.%26aulast%3DSeki%26aufirst%3DK.%26aulast%3DTakahara%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%2BK.%26aulast%3DNonomura%26aufirst%3DN.%26atitle%3DHigh-pressure%2520carbon%2520monoxide%2520preserves%2520rat%2520kidney%2520grafts%2520from%2520apoptosis%2520and%2520inflammation%26jtitle%3DLab.%2520Invest.%26date%3D2017%26volume%3D97%26spage%3D468%26epage%3D477%26doi%3D10.1038%2Flabinvest.2016.157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linardi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiamulera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumagalli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Biagio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebrie, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luciani, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faggian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rungatscher, A.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate receptor modulator fingolimod (FTY720) attenuates myocardial fibrosis in post-heterotropic heart transplantation</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">645</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28966593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegsb7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=645&author=N.+Ahmedauthor=D.+Linardiauthor=N.+Muhammadauthor=C.+Chiamuleraauthor=G.+Fumagalliauthor=L.+San+Biagioauthor=M.+A.+Gebrieauthor=M.+Aslamauthor=G.+B.+Lucianiauthor=G.+Faggianauthor=A.+Rungatscher&title=Sphingosine-1-phosphate+receptor+modulator+fingolimod+%28FTY720%29+attenuates+myocardial+fibrosis+in+post-heterotropic+heart+transplantation&doi=10.3389%2Ffphar.2017.00645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) attenuates myocardial fibrosis in post-heterotopic heart transplantation</span></div><div class="casAuthors">Ahmed, Naseer; Linardi, Daniele; Muhammad, Nazeer; Chiamulera, Cristiano; Fumagalli, Guido; San Biagio, Livio; Gebrie, Mebratu A.; Aslam, Muhammad; Luciani, Giovanni Battista; Faggian, Giuseppe; Rungatscher, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">645/1-645/10</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Background and Objective: Sphingosine 1-phosphate (S1P), and S1P receptor modulator fingolimod have been suggested to play important cardioprotective role in animal models of myocardial ischemia/reperfusion injuries.  To understand the cardioprotective function of S1P and its mechanism in vivo, we analyzed apoptotic, inflammatory biomarkers, and myocardial fibrosis in an in vivo heterotopic rat heart transplantation model.  Methods: Heterotopic heart transplantation is performed in 60 Sprague-Dawley (SD) rats (350-400 g).  The heart transplant recipients (n = 60) are categorized into Group A (control) and Group B (fingolimod treated 1 mg/kg i.v.).  At baseline with 24 h after heart transplantation, blood and myocardial tissue are collected for anal. of myocardial biomarkers, apoptosis, inflammatory markers, oxidative stress, and phosphorylation of Akt/Erk/STAT-3 signaling pathways.  Myocardial fibrosis was investigated using Masson's trichrome staining and L-hydroxyline.  Results: Fingolimod treatment activates both Reperfusion Injury Salvage Kinase (RISK) and Survivor Activating Factor Enhancement (SAFE) pathways as evident from activation of anti-apoptotic and anti-inflammatory pathways.  Fingolimod treatment caused a redn. in myocardial oxidative stress and hence cardiomyocyte apoptosis resulting in a decrease in myocardial reperfusion injury.  Moreover, a significant (p < 0.001) redn. in collagen staining and hydroxyproline content was obsd. in fingolimod treated animals 30 days after transplantation demonstrating a redn. in cardiac fibrosis.  Conclusion: S1P receptor activation with fingolimod activates anti-apoptotic and antiinflammatory pathways, leading to improved myocardial salvage causing a redn. in cardiac fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGongOy-7Mf4RbVg90H21EOLACvtfcHk0ljizo5KJVo0gw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegsb7O&md5=aa78e1a5c883558d2f969e7225092c20</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00645%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DN.%26aulast%3DLinardi%26aufirst%3DD.%26aulast%3DMuhammad%26aufirst%3DN.%26aulast%3DChiamulera%26aufirst%3DC.%26aulast%3DFumagalli%26aufirst%3DG.%26aulast%3DSan%2BBiagio%26aufirst%3DL.%26aulast%3DGebrie%26aufirst%3DM.%2BA.%26aulast%3DAslam%26aufirst%3DM.%26aulast%3DLuciani%26aufirst%3DG.%2BB.%26aulast%3DFaggian%26aufirst%3DG.%26aulast%3DRungatscher%26aufirst%3DA.%26atitle%3DSphingosine-1-phosphate%2520receptor%2520modulator%2520fingolimod%2520%2528FTY720%2529%2520attenuates%2520myocardial%2520fibrosis%2520in%2520post-heterotropic%2520heart%2520transplantation%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D645%26doi%3D10.3389%2Ffphar.2017.00645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cernoch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viklicky, O.</span></span> <span> </span><span class="NLM_article-title">Complement in kidney transplantation</span>. <i>Front. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">66</span>, <span class="refDoi">Â DOI: 10.3389/fmed.2017.00066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffmed.2017.00066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1cnotVGisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=66&author=M.+Cernochauthor=O.+Viklicky&title=Complement+in+kidney+transplantation&doi=10.3389%2Ffmed.2017.00066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Complement in Kidney Transplantation</span></div><div class="casAuthors">Cernoch Marek; Viklicky Ondrej; Viklicky Ondrej</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">66</span>
        ISSN:<span class="NLM_cas:issn">2296-858X</span>.
    </div><div class="casAbstract">The complement system is considered to be an important part of innate immune system with a significant role in inflammation processes.  The activation can occur through classical, alternative, or lectin pathway, resulting in the creation of anaphylatoxins C3a and C5a, possessing a vast spectrum of immune functions, and the assembly of terminal complement cascade, capable of direct cell lysis.  The activation processes are tightly regulated; inappropriate activation of the complement cascade plays a significant role in many renal diseases including organ transplantation.  Moreover, complement cascade is activated during ischemia/reperfusion injury processes and influences delayed graft function of kidney allografts.  Interestingly, complement system has been found to play a role in both acute cellular and antibody-mediated rejections and thrombotic microangiopathy.  Therefore, complement system may represent an interesting therapeutical target in kidney transplant pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3msm3K93O7BBrI9DTGjC0fW6udTcc2eYwFiwIsmjwaLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnotVGisA%253D%253D&md5=d65996d8dd178c8ee5e483481efefc53</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.3389%2Ffmed.2017.00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmed.2017.00066%26sid%3Dliteratum%253Aachs%26aulast%3DCernoch%26aufirst%3DM.%26aulast%3DViklicky%26aufirst%3DO.%26atitle%3DComplement%2520in%2520kidney%2520transplantation%26jtitle%3DFront.%2520Med.%26date%3D2017%26volume%3D4%26spage%3D66%26doi%3D10.3389%2Ffmed.2017.00066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gueler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmschrott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeing, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankenstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleissner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruhparwar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlermann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katus, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doesch, A. O.</span></span> <span> </span><span class="NLM_article-title">Effects of vildagliptin (Galvus<sup>R</sup>) therapy in patients with type 2 diabetes mellitus after heart transplantation</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">297</span>â <span class="NLM_lpage">303</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S43092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S43092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23630415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosVSntLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=297-303&author=I.+Guelerauthor=S.+Muellerauthor=M.+Helmschrottauthor=C.+U.+Oeingauthor=C.+Erbelauthor=L.+Frankensteinauthor=C.+Gleissnerauthor=A.+Ruhparwarauthor=P.+Ehlermannauthor=T.+J.+Denglerauthor=H.+A.+Katusauthor=A.+O.+Doesch&title=Effects+of+vildagliptin+%28GalvusR%29+therapy+in+patients+with+type+2+diabetes+mellitus+after+heart+transplantation&doi=10.2147%2FDDDT.S43092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of vildagliptin (Galvus) therapy in patients with type 2 diabetes mellitus after heart transplantation</span></div><div class="casAuthors">Gueler, Ibrahim; Mueller, Susanne; Helmschrott, Matthias; Oeing, Christian U.; Erbel, Christian; Frankenstein, Lutz; Gleissner, Christian; Ruhparwar, Arjang; Ehlermann, Philipp; Dengler, Thomas J.; Katus, Hugo A.; Doesch, Andreas O.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">297-303</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Type 2 Diabetes mellitus (T2DM) is a common comorbidity in patients after heart transplantation (HTx) and is assocd. with adverse long-term outcomes.  Methods: The retrospective study reported here analyzed the effects of vildagliptin therapy in stable patients post-HTx with T2DM and compared these with control patients for matched-pairs anal.  A total of 30 stable patients post-HTx with T2DM were included in the study.  Fifteen patients (mean age 58.6 Â± 6.0 years, mean time post-HTx 4.9 Â± 5.3 years, twelve male and three female) were included in the vildagliptin group (VG) and 15 patients were included in the control group (CG) (mean age 61.2 Â± 8.3 years, mean time post-HTx 7.2 Â± 6.6 years, all male).  Results: Mean glycated Hb (HbA1c) in the VG was 7.4% Â± 0.7% before vs. 6.8% Â± 0.8% after 8 mo of vildagliptin therapy (P = 0.002 vs. baseline).  In the CG, HbA1c was 7.0% Â± 0.7% vs. 7.3% Â± 1.2% at follow-up (P = 0.21).  Addnl., there was a significant redn. in mean blood glucose in the VG, from 165.0 Â± 18.8 mg/dL to 147.9 Â± 22.7 mg/dL (P = 0.002 vs. baseline), whereas mean blood glucose increased slightly in the CG from 154.7 Â± 19.7 mg/dL to 162.6 Â± 35.0 mg/dL (P = 0.21).  No statistically significant changes in body wt. (from 83.3 Â± 10.8 kg to 82.0 Â± 10.9 kg, P = 0.20), total cholesterol (1.5%, P = 0.68), or triglyceride levels (8.0%, P = 0.65) were seen in the VG.  No significant changes in immunosuppressive drug levels or dosages were obsd. in either group.  Conclusion: Vildagliptin therapy significantly reduced HbA1c and mean blood glucose levels in post-HTx patients in this study with T2DM and did not have any neg. effects on lipid profile or body wt.  Thus, vildagliptin therapy presented an interesting therapeutic approach for this selected patient cohort.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAIk48pts7FLVg90H21EOLACvtfcHk0lguBBqcWkgkHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosVSntLo%253D&md5=b0a4aa610c5d9cad1aaa897a5f4d7e4e</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S43092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S43092%26sid%3Dliteratum%253Aachs%26aulast%3DGueler%26aufirst%3DI.%26aulast%3DMueller%26aufirst%3DS.%26aulast%3DHelmschrott%26aufirst%3DM.%26aulast%3DOeing%26aufirst%3DC.%2BU.%26aulast%3DErbel%26aufirst%3DC.%26aulast%3DFrankenstein%26aufirst%3DL.%26aulast%3DGleissner%26aufirst%3DC.%26aulast%3DRuhparwar%26aufirst%3DA.%26aulast%3DEhlermann%26aufirst%3DP.%26aulast%3DDengler%26aufirst%3DT.%2BJ.%26aulast%3DKatus%26aufirst%3DH.%2BA.%26aulast%3DDoesch%26aufirst%3DA.%2BO.%26atitle%3DEffects%2520of%2520vildagliptin%2520%2528GalvusR%2529%2520therapy%2520in%2520patients%2520with%2520type%25202%2520diabetes%2520mellitus%2520after%2520heart%2520transplantation%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2013%26volume%3D7%26spage%3D297%26epage%3D303%26doi%3D10.2147%2FDDDT.S43092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Meester, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baerts, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vliegen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inci, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weder, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jungraithmayr, W.</span></span> <span> </span><span class="NLM_article-title">CD26 costimulation blockade improves lung allograft rejection and is associated with enhanced interleukin-10 expression</span>. <i>J. Heart Lung Transl.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">508</span>â <span class="NLM_lpage">517</span>, <span class="refDoi">Â DOI: 10.1016/j.healun.2015.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.healun.2015.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26755203" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=508-517&author=Y.+Yamadaauthor=J.+H.+Jangauthor=I.+De+Meesterauthor=L.+Baertsauthor=G.+Vliegenauthor=I.+Inciauthor=I.+Yoshinoauthor=W.+Wederauthor=W.+Jungraithmayr&title=CD26+costimulation+blockade+improves+lung+allograft+rejection+and+is+associated+with+enhanced+interleukin-10+expression&doi=10.1016%2Fj.healun.2015.11.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.healun.2015.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.healun.2015.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DJang%26aufirst%3DJ.%2BH.%26aulast%3DDe%2BMeester%26aufirst%3DI.%26aulast%3DBaerts%26aufirst%3DL.%26aulast%3DVliegen%26aufirst%3DG.%26aulast%3DInci%26aufirst%3DI.%26aulast%3DYoshino%26aufirst%3DI.%26aulast%3DWeder%26aufirst%3DW.%26aulast%3DJungraithmayr%26aufirst%3DW.%26atitle%3DCD26%2520costimulation%2520blockade%2520improves%2520lung%2520allograft%2520rejection%2520and%2520is%2520associated%2520with%2520enhanced%2520interleukin-10%2520expression%26jtitle%3DJ.%2520Heart%2520Lung%2520Transl.%26date%3D2016%26volume%3D35%26spage%3D508%26epage%3D517%26doi%3D10.1016%2Fj.healun.2015.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, S.</span></span> <span> </span><span class="NLM_article-title">Recent advances in renal interstitial fibrosis and tubular atrophy after kidney transplantation</span>. <i>Fibrog. Tissue Repair</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">15</span>, <span class="refDoi">Â DOI: 10.1186/1755-1536-7-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1186%2F1755-1536-7-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25285155" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=15&author=X.+Liauthor=S.+Zhuang&title=Recent+advances+in+renal+interstitial+fibrosis+and+tubular+atrophy+after+kidney+transplantation&doi=10.1186%2F1755-1536-7-15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-7-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-7-15%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhuang%26aufirst%3DS.%26atitle%3DRecent%2520advances%2520in%2520renal%2520interstitial%2520fibrosis%2520and%2520tubular%2520atrophy%2520after%2520kidney%2520transplantation%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2014%26volume%3D7%26spage%3D15%26doi%3D10.1186%2F1755-1536-7-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievert, W.</span></span> <span> </span><span class="NLM_article-title">A pilot study evaluating the safety of intravenously administrated human amnion epithelial cells for the treatment of hepatic fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">549</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28878671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2ns7jL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=549&author=R.+Limauthor=A.+Hodgeauthor=G.+Mooreauthor=E.+M.+Wallaceauthor=W.+Sievert&title=A+pilot+study+evaluating+the+safety+of+intravenously+administrated+human+amnion+epithelial+cells+for+the+treatment+of+hepatic+fibrosis&doi=10.3389%2Ffphar.2017.00549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">A pilot study evaluating the safety of intravenously administered human amnion epithelial cells for the treatment of hepatic fibrosis</span></div><div class="casAuthors">Lim, Rebecca; Hodge, Alexander; Moore, Gregory; Wallace, Euan M.; Sievert, William</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">549/1-549/9</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Liver cirrhosis is the 6th leading cause of death in adults aged 15-59 years in high-income countries.  For many who progress to cirrhosis, the only prospect for survival is liver transplantation.  While there is some indication that mesenchymal stem cells may be useful in reversing established liver fibrosis, there are limitations to their widespread use - namely their rarity, the need for extensive serial passaging and the assocd. potential for genomic instability and cellular senescence.  To this end, we propose the use of allogeneic amnion epithelial cells.  This clin. trial will assess the safety of i.v. delivered allogeneic human amnion epithelial cells (hAECs) in patients with compensated liver cirrhosis.  This will also provide clin. data that will inform phases 2 and 3 clin. trials with the ultimate goal of developing hAECs as a therapeutic option for patients with cirrhosis who are at significant risk of disease progression.  We will recruit 12 patients with compensated cirrhosis, based on their hepatic venous pressure gradient, for a dose escalation study.  Patients will be closely monitored in the first 24 h post-infusion, then via daily telephone interviews until clin. assessment on day 5.  Long term follow up will include std. liver tests, transient elastog. and hepatic ultrasound.  Ethics approval was obtained from Monash Health for this trial 16052A, "A Pilot Study Evaluating the Safety of I.v. Administered Human Amnion Epithelial Cells for the Treatment of Liver Fibrosis, A First in Adult Human Study." The trial will be conducted in accordance to Monash Health Human Ethics guidelines.  Outcomes from this study will be disseminated in the form of conference presentations and submission to a peer reviewed journal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMgemCyYmmWLVg90H21EOLACvtfcHk0lguBBqcWkgkHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2ns7jL&md5=98eb6eea483f6508b0461f67fa44cb01</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00549%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DR.%26aulast%3DHodge%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DG.%26aulast%3DWallace%26aufirst%3DE.%2BM.%26aulast%3DSievert%26aufirst%3DW.%26atitle%3DA%2520pilot%2520study%2520evaluating%2520the%2520safety%2520of%2520intravenously%2520administrated%2520human%2520amnion%2520epithelial%2520cells%2520for%2520the%2520treatment%2520of%2520hepatic%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D549%26doi%3D10.3389%2Ffphar.2017.00549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricardo, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievert, W.</span></span> <span> </span><span class="NLM_article-title">Cell-based therapies for tissue fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">633</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29033833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegs7fJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=633&author=R.+Limauthor=S.+D.+Ricardoauthor=W.+Sievert&title=Cell-based+therapies+for+tissue+fibrosis&doi=10.3389%2Ffphar.2017.00633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-based therapies for tissue fibrosis</span></div><div class="casAuthors">Lim, Rebecca; Ricardo, Sharon D.; Sievert, William</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">633/1-633/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The development of tissue fibrosis in the context of a wound-healing response to injury is common to many chronic diseases.  Unregulated or persistent fibrogenesis may lead to structural and functional changes in organs that increase the risk of significant morbidity and mortality.  We will explore the natural history, epidemiol., and pathogenesis of fibrotic disease affecting the lungs, kidneys, and liver as dysfunction of these organs is responsible for a substantial proportion of global mortality.  For many patients with end-stage disease, organ transplantation is the only effective therapy to prolong life.  However, not all patients are candidates for the major surgical interventions and life-long immunosuppression required for a successful outcome and donor organs may not be available to meet the clin. need.  We will provide an overview of the latest treatment strategies for these conditions and will focus on stem or progenitor cell-based therapies for which there is substantial pre-clin. evidence based on animal models as well as early phase clin. trials of cell-based therapy in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBNGfSdTptErVg90H21EOLACvtfcHk0lgMxDZ1nE1DUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegs7fJ&md5=5686439cda982717c1c765dd3ad0828c</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00633%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DR.%26aulast%3DRicardo%26aufirst%3DS.%2BD.%26aulast%3DSievert%26aufirst%3DW.%26atitle%3DCell-based%2520therapies%2520for%2520tissue%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D633%26doi%3D10.3389%2Ffphar.2017.00633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russell, A. J.</span></span> <span> </span><span class="NLM_article-title">Regenerative medicinal chemistry: the in situ control of stem cells</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">365</span>â <span class="NLM_lpage">368</span>, <span class="refDoi">Â DOI: 10.1021/ml400110b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400110b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkslahu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=365-368&author=A.+J.+Russell&title=Regenerative+medicinal+chemistry%3A+the+in+situ+control+of+stem+cells&doi=10.1021%2Fml400110b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Regenerative Medicinal Chemistry: The in Situ Control of Stem Cells</span></div><div class="casAuthors">Russell, Angela J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">365-368</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In recent years, there has been mounting evidence to support the presence of stem and progenitor cells within many adult tissues that retain the capacity to proliferate and differentiate, thereby contributing to tissue homeostasis and repair.  In line with these discoveries, there have been increasing efforts to develop new agents that target these resident stem and progenitor cell populations in situ to augment or to stimulate repair and regeneration processes.  Two such agents are approved drugs, and several more are currently in clin. and preclin. development.  Through this emerging therapeutic paradigm there is enormous scope for medicinal chem. to play a pivotal role in regenerative medicine.  The potential impact of regenerative medicinal chem. is profound, and future studies will reveal which tissue types or disease states will prove most readily tractable through this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcSsyW6-vi6LVg90H21EOLACvtfcHk0lgMxDZ1nE1DUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkslahu7g%253D&md5=b47be3ceb0d356268f8972a380323e72</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fml400110b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400110b%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DA.%2BJ.%26atitle%3DRegenerative%2520medicinal%2520chemistry%253A%2520the%2520in%2520situ%2520control%2520of%2520stem%2520cells%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D365%26epage%3D368%26doi%3D10.1021%2Fml400110b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thevenot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span> <span> </span><span class="NLM_article-title">Surface chemistry influences implant biocompatibility</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">270</span>â <span class="NLM_lpage">280</span>, <span class="refDoi">Â DOI: 10.2174/156802608783790901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2174%2F156802608783790901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18393890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsFyjtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=270-280&author=L.+Tangauthor=P.+Thevenotauthor=W.+Hu&title=Surface+chemistry+influences+implant+biocompatibility&doi=10.2174%2F156802608783790901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Surface chemistry influences implant biocompatibility</span></div><div class="casAuthors">Thevenot, Paul; Hu, Wenjing; Tang, Liping</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">270-280</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Implantable medical devices are increasingly important in the practice of modern medicine.  Unfortunately, almost all medical devices suffer to a different extent from adverse reactions, including inflammation, fibrosis, thrombosis and infection.  To improve the safety and function of many types of medical implants, a major need exists for development of materials that evoked desired tissue responses.  Because implant-assocd. protein adsorption and conformational changes thereafter have been shown to promote immune reactions, rigorous research efforts have been emphasized on the engineering of surface property (phys. and chem. characteristics) to reduce protein adsorption and cell interactions and subsequently improve implant biocompatibility.  This brief review is aimed to summarize the past efforts and our recent knowledge about the influence of surface functionality on protein:cell:biomaterial interactions.  It is our belief that detailed understandings of bioactivity of surface functionality provide an easy, economic, and specific approach for the future rational design of implantable medical devices with desired tissue reactivity and, hopefully, wound healing capability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0qBMRoM-27Vg90H21EOLACvtfcHk0lgMxDZ1nE1DUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsFyjtbw%253D&md5=214eb8c68652a06868b190192f8d0287</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.2174%2F156802608783790901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608783790901%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DL.%26aulast%3DThevenot%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DW.%26atitle%3DSurface%2520chemistry%2520influences%2520implant%2520biocompatibility%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D270%26epage%3D280%26doi%3D10.2174%2F156802608783790901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nerem, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambanis, A.</span></span> <span> </span><span class="NLM_article-title">Tissue engineering: from biology to biological substitutes</span>. <i>Tissue Eng.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">13</span>, <span class="refDoi">Â DOI: 10.1089/ten.1995.1.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1089%2Ften.1995.1.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=19877911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BD1MjjtVegtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1995&pages=3-13&author=R.+M.+Neremauthor=A.+Sambanis&title=Tissue+engineering%3A+from+biology+to+biological+substitutes&doi=10.1089%2Ften.1995.1.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue engineering: from biology to biological substitutes</span></div><div class="casAuthors">Nerem R M; Sambanis A</div><div class="citationInfo"><span class="NLM_cas:title">Tissue engineering</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-13</span>
        ISSN:<span class="NLM_cas:issn">1076-3279</span>.
    </div><div class="casAbstract">Tissue engineering is an emerging multidisciplinary and interdisciplinary field involving the development of bioartificial implants and/or the fostering of tissue remodeling with the purpose of repairing or enhancing tissue or organ function.  Bioartificial constructs generally consist of cells and biomaterials, so tissue engineering draws from both cell and biomaterials science and technology.  Successful applications require a thorough understanding of the environment experienced by cells in normal tissues and by cells in bioartificial devices before and after implantation.  This paper reviews these topics, as well as the current status and future possibilities in the development of different bioartificial constructs, including bioartificial skin, cardiovascular implants, bioartificial pancreas, and encapsulated secretory cells.  Issues that need to be addressed in the future are also discussed.  These include, but are not limited to, the development of new cell lines and biomaterials, the evaluation of the optimal construct architecture, and the reproducible manufacture and preservation of bioartificial devices until ready for use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmwWIRoKhvqa69lAbTj9rGfW6udTcc2eaP3-Luy1cN5bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjjtVegtQ%253D%253D&md5=755262ffccfc3b7c519d5b931ded7c97</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1089%2Ften.1995.1.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Ften.1995.1.3%26sid%3Dliteratum%253Aachs%26aulast%3DNerem%26aufirst%3DR.%2BM.%26aulast%3DSambanis%26aufirst%3DA.%26atitle%3DTissue%2520engineering%253A%2520from%2520biology%2520to%2520biological%2520substitutes%26jtitle%3DTissue%2520Eng.%26date%3D1995%26volume%3D1%26spage%3D3%26epage%3D13%26doi%3D10.1089%2Ften.1995.1.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadtler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrellas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Housseau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elisseeff, J. H.</span></span> <span> </span><span class="NLM_article-title">Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">366</span>â <span class="NLM_lpage">370</span>, <span class="refDoi">Â DOI: 10.1126/science.aad9272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1126%2Fscience.aad9272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=27081073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2isbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2016&pages=366-370&author=K.+Sadtlerauthor=K.+Estrellasauthor=B.+W.+Allenauthor=M.+T.+Wolfauthor=H.+Fanauthor=A.+J.+Tamauthor=C.+H.+Patelauthor=B.+Luberauthor=H.+Wangauthor=K.+R.+Wagnerauthor=J.+D.+Powellauthor=F.+Housseauauthor=D.+M.+Pardollauthor=J.+H.+Elisseeff&title=Developing+a+pro-regenerative+biomaterial+scaffold+microenvironment+requires+T+helper+2+cells&doi=10.1126%2Fscience.aad9272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells</span></div><div class="casAuthors">Sadtler, Kaitlyn; Estrellas, Kenneth; Allen, Brian W.; Wolf, Matthew T.; Fan, Hongni; Tam, Ada J.; Patel, Chirag H.; Luber, Brandon S.; Wang, Hao; Wagner, Kathryn R.; Powell, Jonathan D.; Housseau, Franck; Pardoll, Drew M.; Elisseeff, Jennifer H.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">6283</span>),
    <span class="NLM_cas:pages">366-370</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Immune-mediated tissue regeneration driven by a biomaterial scaffold is emerging as an innovative regenerative strategy to repair damaged tissues.  The authors investigated how biomaterial scaffolds shape the immune microenvironment in traumatic muscle wounds to improve tissue regeneration.  The scaffolds induced a pro-regenerative response, characterized by an mTOR/Rictor-dependent T helper 2 pathway that guides interleukin-4-dependent macrophage polarization, which is crit. for functional muscle recovery.  Manipulating the adaptive immune system using biomaterials engineering may support the development of therapies that promote both systemic and local pro-regenerative immune responses, ultimately stimulating tissue repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKgZIM1DC6HLVg90H21EOLACvtfcHk0lgaVkS7VPjQJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2isbs%253D&md5=190e9c20fc5c18d91ff4570c4d980e5c</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad9272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad9272%26sid%3Dliteratum%253Aachs%26aulast%3DSadtler%26aufirst%3DK.%26aulast%3DEstrellas%26aufirst%3DK.%26aulast%3DAllen%26aufirst%3DB.%2BW.%26aulast%3DWolf%26aufirst%3DM.%2BT.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DTam%26aufirst%3DA.%2BJ.%26aulast%3DPatel%26aufirst%3DC.%2BH.%26aulast%3DLuber%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWagner%26aufirst%3DK.%2BR.%26aulast%3DPowell%26aufirst%3DJ.%2BD.%26aulast%3DHousseau%26aufirst%3DF.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DElisseeff%26aufirst%3DJ.%2BH.%26atitle%3DDeveloping%2520a%2520pro-regenerative%2520biomaterial%2520scaffold%2520microenvironment%2520requires%2520T%2520helper%25202%2520cells%26jtitle%3DScience%26date%3D2016%26volume%3D352%26spage%3D366%26epage%3D370%26doi%3D10.1126%2Fscience.aad9272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadtler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elisseeff, J. H.</span></span> <span> </span><span class="NLM_article-title">Design, clinical translation and immunological response of biomaterials in regenerative medicine</span>. <i>Nat. Rev. Materials</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">16040</span>, <span class="refDoi">Â DOI: 10.1038/natrevmats.2016.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnatrevmats.2016.40" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVeru70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=16040&author=K.+Sadtlerauthor=A.+Singhauthor=M.+T.+Wolfauthor=X.+Wangauthor=D.+M.+Pardollauthor=J.+H.+Elisseeff&title=Design%2C+clinical+translation+and+immunological+response+of+biomaterials+in+regenerative+medicine&doi=10.1038%2Fnatrevmats.2016.40"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Design, clinical translation and immunological response of biomaterials in regenerative medicine</span></div><div class="casAuthors">Sadtler, Kaitlyn; Singh, Anirudha; Wolf, Matthew T.; Wang, Xiaokun; Pardoll, Drew M.; Elisseeff, Jennifer H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Materials</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">16040</span>CODEN:
                <span class="NLM_cas:coden">NRMADL</span>;
        ISSN:<span class="NLM_cas:issn">2058-8437</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The field of regenerative medicine aims to replace tissues lost as a consequence of disease, trauma or congenital abnormalities.  Biomaterials serve as scaffolds for regenerative medicine to deliver cells, provide biol. signals and phys. support, and mobilize endogenous cells to repair tissues.  Sophisticated chemistries are used to synthesize materials that mimic and modulate native tissue microenvironments, to replace form and to elucidate structure-function relationships of cell-material interactions.  The therapeutic relevance of these biomaterial properties can only be studied after clin. translation, whereby key parameters for efficacy can be defined and then used for future design.  In this Review, we present the development and translation of biomaterials for two tissue engineering targets, cartilage and cornea, both of which lack the ability to self-repair.  Finally, looking to the future, we discuss the role of the immune system in regeneration and the potential for biomaterial scaffolds to modulate immune signalling to create a pro-regenerative environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWEUcW7pDiArVg90H21EOLACvtfcHk0lgaVkS7VPjQJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVeru70%253D&md5=31da0789b8d8931cb8d7cbfa44a9bc2b</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fnatrevmats.2016.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnatrevmats.2016.40%26sid%3Dliteratum%253Aachs%26aulast%3DSadtler%26aufirst%3DK.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DWolf%26aufirst%3DM.%2BT.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DElisseeff%26aufirst%3DJ.%2BH.%26atitle%3DDesign%252C%2520clinical%2520translation%2520and%2520immunological%2520response%2520of%2520biomaterials%2520in%2520regenerative%2520medicine%26jtitle%3DNat.%2520Rev.%2520Materials%26date%3D2016%26volume%3D1%26spage%3D16040%26doi%3D10.1038%2Fnatrevmats.2016.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eming, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, J. M.</span></span> <span> </span><span class="NLM_article-title">Inflammation in wound repair: molecular and cellular mechanisms</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">514</span>â <span class="NLM_lpage">525</span>, <span class="refDoi">Â DOI: 10.1038/sj.jid.5700701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fsj.jid.5700701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17299434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhs1CrtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2007&pages=514-525&author=S.+A.+Emingauthor=T.+Kriegauthor=J.+M.+Davidson&title=Inflammation+in+wound+repair%3A+molecular+and+cellular+mechanisms&doi=10.1038%2Fsj.jid.5700701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation in Wound Repair: Molecular and Cellular Mechanisms</span></div><div class="casAuthors">Eming, Sabine A.; Krieg, Thomas; Davidson, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">514-525</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In post-natal life the inflammatory response is an inevitable consequence of tissue injury.  Exptl. studies established the dogma that inflammation is essential to the establishment of cutaneous homeostasis following injury, and in recent years information about specific subsets of inflammatory cell lineages and the cytokine network orchestrating inflammation assocd. with tissue repair has increased.  Recently, this dogma has been challenged, and reports have raised questions on the validity of the essential prerequisite of inflammation for efficient tissue repair.  Indeed, in exptl. models of repair, inflammation has been shown to delay healing and to result in increased scarring.  Furthermore, chronic inflammation, a hallmark of the non-healing wound, predisposes tissue to cancer development.  Thus, a more detailed understanding in mechanisms controlling the inflammatory response during repair and how inflammation directs the outcome of the healing process will serve as a significant milestone in the therapy of pathol. tissue repair.  Here, the authors review cellular and mol. mechanisms controlling inflammation in cutaneous tissue repair and provide a rationale for targeting the inflammatory phase to modulate the outcome of the healing response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Hbzwd2DTdbVg90H21EOLACvtfcHk0lgTsyo-Bo-k1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhs1CrtL0%253D&md5=4e5422d628b2d71d755ea6138052cf5c</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fsj.jid.5700701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.jid.5700701%26sid%3Dliteratum%253Aachs%26aulast%3DEming%26aufirst%3DS.%2BA.%26aulast%3DKrieg%26aufirst%3DT.%26aulast%3DDavidson%26aufirst%3DJ.%2BM.%26atitle%3DInflammation%2520in%2520wound%2520repair%253A%2520molecular%2520and%2520cellular%2520mechanisms%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2007%26volume%3D127%26spage%3D514%26epage%3D525%26doi%3D10.1038%2Fsj.jid.5700701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermette, P.</span></span> <span> </span><span class="NLM_article-title">Endothelial cell response towards low-fouling surfaces bearing RGD in a three-dimensional environment</span>. <i>Exp. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">1994</span>â <span class="NLM_lpage">2006</span>, <span class="refDoi">Â DOI: 10.1016/j.yexcr.2011.05.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.yexcr.2011.05.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=21679704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1ykt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2011&pages=1994-2006&author=G.+Sabraauthor=P.+Vermette&title=Endothelial+cell+response+towards+low-fouling+surfaces+bearing+RGD+in+a+three-dimensional+environment&doi=10.1016%2Fj.yexcr.2011.05.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelial cell responses towards low-fouling surfaces bearing RGD in a three-dimensional environment</span></div><div class="casAuthors">Sabra, Georges; Vermette, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1994-2006</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study reveals that it is possible to obtain a specific cell response towards low-fouling carboxymethyl dextran (CMD) surfaces bearing the RGD adhesive peptide in fibrin.  To avoid cell sedimentation on surfaces obsd. in traditional cell culture systems, CMD surfaces bearing RGD were vertically embedded in fibrin contg. human umbilical vein endothelial cells (HUVEC) and their effect over cells was investigated.  Compared to the CMD surfaces and to CMD layers bearing the neg. control RGE, RGD coatings promoted cell adhesion, induced focal contact formation indicated by co-localization of vinculin and actin fibers, and presented a significant effect over HUVEC net growth during the first 24 h of the culture, as revealed by Ki67 staining and cell counting.  The intracellular localization of caveolin-1 combined with the expression of beta 1 integrins was investigated and the orientation of HUVEC towards and on the RGD surfaces was studied.  When compared to the neg. controls, HUVEC responded to the RGD surface in fibrin resulting in acceleration of morphol. changes.  RGD surfaces supported fibrin degrdn. by HUVEC as revealed by fluorescent fibrin expts. as well as multi-cellular structure formation, vacuolation and lumen formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhO-MKiI74TLVg90H21EOLACvtfcHk0lgTsyo-Bo-k1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1ykt74%253D&md5=46886ab9246c8d6238ea6dee2b75e325</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2011.05.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2011.05.029%26sid%3Dliteratum%253Aachs%26aulast%3DSabra%26aufirst%3DG.%26aulast%3DVermette%26aufirst%3DP.%26atitle%3DEndothelial%2520cell%2520response%2520towards%2520low-fouling%2520surfaces%2520bearing%2520RGD%2520in%2520a%2520three-dimensional%2520environment%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2011%26volume%3D317%26spage%3D1994%26epage%3D2006%26doi%3D10.1016%2Fj.yexcr.2011.05.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nih, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimatteo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segura, T.</span></span> <span> </span><span class="NLM_article-title">Hydrogels with precisely controlled integrin activation dictate vascular patterning and permeability</span>. <i>Nat. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">953</span>â <span class="NLM_lpage">961</span>, <span class="refDoi">Â DOI: 10.1038/nmat4954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnmat4954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28783156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ylsb3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=953-961&author=S.+Liauthor=L.+R.+Nihauthor=H.+Bachmanauthor=P.+Feiauthor=Y.+Liauthor=E.+Namauthor=R.+Dimatteoauthor=S.+T.+Carmichaelauthor=T.+H.+Barkerauthor=T.+Segura&title=Hydrogels+with+precisely+controlled+integrin+activation+dictate+vascular+patterning+and+permeability&doi=10.1038%2Fnmat4954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrogels with precisely controlled integrin activation dictate vascular patterning and permeability</span></div><div class="casAuthors">Li, Shuoran; Nih, Lina R.; Bachman, Haylee; Fei, Peng; Li, Yilei; Nam, Eunwoo; Dimatteo, Robert; Carmichael, S. Thomas; Barker, Thomas H.; Segura, Tatiana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Materials</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">953-961</span>CODEN:
                <span class="NLM_cas:coden">NMAACR</span>;
        ISSN:<span class="NLM_cas:issn">1476-1122</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Integrin binding to bioengineered hydrogel scaffolds is essential for tissue regrowth and regeneration, yet not all integrin binding can lead to tissue repair.  Here, we show that through engineering hydrogel materials to promote Î±3/Î±5Î²1 integrin binding, we can promote the formation of a space-filling and mature vasculature compared with hydrogel materials that promote Î±vÎ²3 integrin binding.  In vitro, Î±3/Î±5Î²1 scaffolds promoted endothelial cells to sprout and branch, forming organized extensive networks that eventually reached and anastomosed with neighboring branches.  In vivo, Î±3/Î±5Î²1 scaffolds delivering vascular endothelial growth factor (VEGF) promoted non-tortuous blood vessel formation and non-leaky blood vessels by 10 days post-stroke.  In contrast, materials that promote Î±vÎ²3 integrin binding promoted endothelial sprout clumping in vitro and leaky vessels in vivo.  This work shows that precisely controlled integrin activation from a biomaterial can be harnessed to direct therapeutic vessel regeneration and reduce VEGF-induced vascular permeability in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeGpYdULzN47Vg90H21EOLACvtfcHk0lgTsyo-Bo-k1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ylsb3J&md5=cda5518a4fdceb95686f0a9521f670a3</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fnmat4954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmat4954%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DNih%26aufirst%3DL.%2BR.%26aulast%3DBachman%26aufirst%3DH.%26aulast%3DFei%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DNam%26aufirst%3DE.%26aulast%3DDimatteo%26aufirst%3DR.%26aulast%3DCarmichael%26aufirst%3DS.%2BT.%26aulast%3DBarker%26aufirst%3DT.%2BH.%26aulast%3DSegura%26aufirst%3DT.%26atitle%3DHydrogels%2520with%2520precisely%2520controlled%2520integrin%2520activation%2520dictate%2520vascular%2520patterning%2520and%2520permeability%26jtitle%3DNat.%2520Mater.%26date%3D2017%26volume%3D16%26spage%3D953%26epage%3D961%26doi%3D10.1038%2Fnmat4954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Washington, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashur, C. A.</span></span> <span> </span><span class="NLM_article-title">Delivery of anti-oxidant and anti-inflammatory agents for tissue engineered vascular grafts</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">659</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29033836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegs7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=659&author=K.+S.+Washingtonauthor=C.+A.+Bashur&title=Delivery+of+anti-oxidant+and+anti-inflammatory+agents+for+tissue+engineered+vascular+grafts&doi=10.3389%2Ffphar.2017.00659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Delivery of antioxidant and anti-inflammatory agents for tissue engineered vascular grafts</span></div><div class="casAuthors">Washington, Kenyatta S.; Bashur, Chris A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">659/1-659/18</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The treatment of patients with severe coronary and peripheral artery disease represents a significant clin. need, esp. for those patients that require a bypass graft and do not have viable veins for autologous grafting.  Tissue engineering is being investigated to generate an alternative graft.  While tissue engineering requires surgical intervention, the release of pharmacol. agents is also an important part of many tissue engineering strategies.  Delivery of these agents offers the potential to overcome the major concerns for graft patency and viability.  These concerns are related to an extended inflammatory response and its impact on vascular cells such as endothelial cells.  This review discusses the drugs that have been released from vascular tissue engineering scaffolds and some of the non-traditional ways that the drugs are presented to the cells.  The impact of antioxidant compds. and gasotransmitters, such as nitric oxide and carbon monoxide, are discussed in detail.  The application of tissue engineering and drug delivery principles to biodegradable stents is also briefly discussed.  Overall, there are scaffold-based drug delivery techniques that have shown promise for vascular tissue engineering, but much of this work is in the early stages and there are still opportunities to incorporate addnl. drugs to modulate the inflammatory process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI6U3dDFud67Vg90H21EOLACvtfcHk0lh7WwuuB9pNUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegs7zP&md5=037861f5e933a61120b39f6485287325</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00659%26sid%3Dliteratum%253Aachs%26aulast%3DWashington%26aufirst%3DK.%2BS.%26aulast%3DBashur%26aufirst%3DC.%2BA.%26atitle%3DDelivery%2520of%2520anti-oxidant%2520and%2520anti-inflammatory%2520agents%2520for%2520tissue%2520engineered%2520vascular%2520grafts%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D659%26doi%3D10.3389%2Ffphar.2017.00659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorrello, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenthart, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biscotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swayne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wobma, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchetta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vunjak-Novakovic, G.</span></span> <span> </span><span class="NLM_article-title">Functional vascularized lung grafts for lung bioengineering</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e1700521</span>, <span class="refDoi">Â DOI: 10.1126/sciadv.1700521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1126%2Fsciadv.1700521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28875163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls1Gmtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=e1700521&author=N.+V.+Dorrelloauthor=B.+A.+Guenthartauthor=J.+D.+O%E2%80%99Neillauthor=J.+Kimauthor=K.+Cunninghamauthor=Y.+W.+Chenauthor=M.+Biscottiauthor=T.+Swayneauthor=H.+M.+Wobmaauthor=S.+X.+L.+Huangauthor=H.+W.+Snoeckauthor=M.+Bacchettaauthor=G.+Vunjak-Novakovic&title=Functional+vascularized+lung+grafts+for+lung+bioengineering&doi=10.1126%2Fsciadv.1700521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Functional vascularized lung grafts for lung bioengineering</span></div><div class="casAuthors">Dorrello, N. Valerio; Guenthart, Brandon A.; O'Neill, John D.; Kim, Jinho; Cunningham, Katherine; Chen, Ya-Wen; Biscotti, Mauer; Swayne, Theresa; Wobma, Holly M.; Huang, Sarah X. L.; Snoeck, Hans-Willem; Bacchetta, Matthew; Vunjak-Novakovic, Gordana</div><div class="citationInfo"><span class="NLM_cas:title">Science Advances</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1700521/1-e1700521/14</span>CODEN:
                <span class="NLM_cas:coden">SACDAF</span>;
        ISSN:<span class="NLM_cas:issn">2375-2548</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">End-stage lung disease is the third leading cause of death worldwide, accounting for 400,000 deaths per yr in the United States alone.  To reduce the morbidity and mortality assocd. with lung disease, new therapeutic strategies aimed at promoting lung repair and increasing the no. of donor lungs available for transplantation are being explored.  Because of the extreme complexity of this organ, previous attempts at bioengineering functional lungs from fully decellularized or synthetic scaffolds lacking functional vasculature have been largely unsuccessful.  An intact vascular network is crit. not only for maintaining the blood-gas barrier and allowing for proper graft function but also for supporting the regenerative cells.  We therefore developed an airway-specific approach to removing the pulmonary epithelium, while maintaining the viability and function of the vascular endothelium, using a rat model.  The resulting vascularized lung grafts supported the attachment and growth of human adult pulmonary cells and stem cell-derived lung-specified epithelial cells.  We propose that de-epithelialization of the lung with preservation of intact vasculature could facilitate cell therapy of pulmonary epithelium and enable bioengineering of functional lungs for transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ZUT3lWVYEbVg90H21EOLACvtfcHk0lh7WwuuB9pNUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls1Gmtbc%253D&md5=c835f710667dca537f9d20bb32d4758c</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.1700521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.1700521%26sid%3Dliteratum%253Aachs%26aulast%3DDorrello%26aufirst%3DN.%2BV.%26aulast%3DGuenthart%26aufirst%3DB.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DJ.%2BD.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DY.%2BW.%26aulast%3DBiscotti%26aufirst%3DM.%26aulast%3DSwayne%26aufirst%3DT.%26aulast%3DWobma%26aufirst%3DH.%2BM.%26aulast%3DHuang%26aufirst%3DS.%2BX.%2BL.%26aulast%3DSnoeck%26aufirst%3DH.%2BW.%26aulast%3DBacchetta%26aufirst%3DM.%26aulast%3DVunjak-Novakovic%26aufirst%3DG.%26atitle%3DFunctional%2520vascularized%2520lung%2520grafts%2520for%2520lung%2520bioengineering%26jtitle%3DSci.%2520Adv.%26date%3D2017%26volume%3D3%26spage%3De1700521%26doi%3D10.1126%2Fsciadv.1700521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthiesen, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kren, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netoff, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. A.</span></span> <span> </span><span class="NLM_article-title">Perfusion-decellularized matrix: using natureâs platform to engineer a bioartificial heart</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">213</span>â <span class="NLM_lpage">221</span>, <span class="refDoi">Â DOI: 10.1038/nm1684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm1684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18193059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1Khsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=213-221&author=H.+C.+Ottauthor=T.+S.+Matthiesenauthor=S.+K.+Gohauthor=L.+D.+Blackauthor=S.+M.+Krenauthor=T.+I.+Netoffauthor=D.+A.+Taylor&title=Perfusion-decellularized+matrix%3A+using+nature%E2%80%99s+platform+to+engineer+a+bioartificial+heart&doi=10.1038%2Fnm1684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart</span></div><div class="casAuthors">Ott, Harald C.; Matthiesen, Thomas S.; Goh, Saik-Kia; Black, Lauren D.; Kren, Stefan M.; Netoff, Theoden I.; Taylor, Doris A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">About 3,000 individuals in the United States are awaiting a donor heart; worldwide, 22 million individuals are living with heart failure.  A bioartificial heart is a theor. alternative to transplantation or mech. left ventricular support.  Generating a bioartificial heart requires engineering of cardiac architecture, appropriate cellular constituents and pump function.  We decellularized hearts by coronary perfusion with detergents, preserved the underlying extracellular matrix, and produced an acellular, perfusable vascular architecture, competent acellular valves and intact chamber geometry.  To mimic cardiac cell compn., we reseeded these constructs with cardiac or endothelial cells.  To establish function, we maintained eight constructs for up to 28 d by coronary perfusion in a bioreactor that simulated cardiac physiol.  By day 4, we obsd. macroscopic contractions.  By day 8, under physiol. load and elec. stimulation, constructs could generate pump function (equiv. to about 2% of adult or 25% of 16-wk fetal heart function) in a modified working heart prepn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDxMjft9JY6bVg90H21EOLACvtfcHk0lh7WwuuB9pNUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1Khsb0%253D&md5=a7e728c7751a88a9b13d1d96364ea8e8</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fnm1684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1684%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DH.%2BC.%26aulast%3DMatthiesen%26aufirst%3DT.%2BS.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DBlack%26aufirst%3DL.%2BD.%26aulast%3DKren%26aufirst%3DS.%2BM.%26aulast%3DNetoff%26aufirst%3DT.%2BI.%26aulast%3DTaylor%26aufirst%3DD.%2BA.%26atitle%3DPerfusion-decellularized%2520matrix%253A%2520using%2520nature%25E2%2580%2599s%2520platform%2520to%2520engineer%2520a%2520bioartificial%2520heart%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D213%26epage%3D221%26doi%3D10.1038%2Fnm1684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vishwakarma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhise, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelista, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouwkema, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokmeci, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghaemmaghami, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrana, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khademhosseini, A.</span></span> <span> </span><span class="NLM_article-title">Engineering immunomodulatory biomaterials to tune the inflammatory response</span>. <i>Trends Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">470</span>â <span class="NLM_lpage">482</span>, <span class="refDoi">Â DOI: 10.1016/j.tibtech.2016.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.tibtech.2016.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=27138899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtValtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=470-482&author=A.+Vishwakarmaauthor=N.+S.+Bhiseauthor=M.+B.+Evangelistaauthor=J.+Rouwkemaauthor=M.+R.+Dokmeciauthor=A.+M.+Ghaemmaghamiauthor=N.+E.+Vranaauthor=A.+Khademhosseini&title=Engineering+immunomodulatory+biomaterials+to+tune+the+inflammatory+response&doi=10.1016%2Fj.tibtech.2016.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering Immunomodulatory Biomaterials To Tune the Inflammatory Response</span></div><div class="casAuthors">Vishwakarma, Ajaykumar; Bhise, Nupura S.; Evangelista, Marta B.; Rouwkema, Jeroen; Dokmeci, Mehmet R.; Ghaemmaghami, Amir M.; Vrana, Nihal Engin; Khademhosseini, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biotechnology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">470-482</span>CODEN:
                <span class="NLM_cas:coden">TRBIDM</span>;
        ISSN:<span class="NLM_cas:issn">0167-7799</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Current state-of-the-art biomedical implants and tissue engineering methods promise technologies to improve or even restore the function of diseased organs.  However, one of the biggest challenges to clin. success is the lack of functional integration.  A series of cellular and mol. events following biomaterial implantation poses an important bottleneck for developing breakthrough solns.  With inflammation increasingly recognized as a crucial component influencing regeneration, immunomodulation or immuno-engineering has emerged as a potential soln. to overcome this key challenge in regenerative medicine.  We postulate possibilities to utilize biomaterial physicochem. modifications to modulate the host inflammatory response and develop strategies for effective biomaterial integration.  Biomaterial-based immunomodulation strategies can significantly ameliorate the outcomes of medical implants and tissue engineering therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOZPzYj8mSZLVg90H21EOLACvtfcHk0lj_1SETtNx13A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtValtbY%253D&md5=dafb6701a987b7cbfcd7fc675ff9e1bc</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.tibtech.2016.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibtech.2016.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DVishwakarma%26aufirst%3DA.%26aulast%3DBhise%26aufirst%3DN.%2BS.%26aulast%3DEvangelista%26aufirst%3DM.%2BB.%26aulast%3DRouwkema%26aufirst%3DJ.%26aulast%3DDokmeci%26aufirst%3DM.%2BR.%26aulast%3DGhaemmaghami%26aufirst%3DA.%2BM.%26aulast%3DVrana%26aufirst%3DN.%2BE.%26aulast%3DKhademhosseini%26aufirst%3DA.%26atitle%3DEngineering%2520immunomodulatory%2520biomaterials%2520to%2520tune%2520the%2520inflammatory%2520response%26jtitle%3DTrends%2520Biotechnol.%26date%3D2016%26volume%3D34%26spage%3D470%26epage%3D482%26doi%3D10.1016%2Fj.tibtech.2016.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. K.</span></span> <span> </span><span class="NLM_article-title">Pirfenidone inhibits fibrosis in foreign body reaction after glaucoma drainage device</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1477</span>â <span class="NLM_lpage">1488</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S99957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S99957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=27143855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtFOltLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=1477-1488&author=K.+I.+Jungauthor=C.+K.+Park&title=Pirfenidone+inhibits+fibrosis+in+foreign+body+reaction+after+glaucoma+drainage+device&doi=10.2147%2FDDDT.S99957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone inhibits fibrosis in foreign body reaction after glaucoma drainage device implantation</span></div><div class="casAuthors">Jung, Kyoung In; Park, Chan Kee</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1477-1488</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: The aim of this study was to investigate the antiscarring effects of pirfenidone on foreign body reaction in a rabbit model of glaucoma drainage implant surgery.  Methods: Adult New Zealand White rabbits had glaucoma drainage device implantation using Model FP8 Ahmed glaucoma valves.  One eye was randomly assigned to receive postoperative intrableb injection of pirfenidone followed by topical treatment.  The other eye underwent the same procedure but without the addn. of pirfenidone.  Histochem. staining and immuno histochem. for blebs were performed.  Results: The degree of cellularity was smaller in the pirfenidone group than in the control group at 2 wk post operation (P=0.005).  A few foreign body giant cells were detected in the inner border of the capsule, and their nos. were similar in the control and pirfenidone groups (P >0.05).  Using Masson's trichrome stain, the inner collagen-rich layer was found to be thinner in the pirfenidone group than the control group at 4 wk (P=0.031) and 8 wk (P=0.022) post operation.  The percentage of proliferating cell nuclear antigen-pos. cells was lower in the pirfenidone group than in the control group at 2 wk post operation (total bleb, P=0.022; inner bleb, P=0.036).  Pirfenidone treatment decreased the immunoreactiv ity of connective tissue growth factor at 2 wk post operation (total bleb, P=0.029; inner bleb, P=0.018).  The height and area of Î±-smooth muscle actin expression were lower in the pirfenidone group than the control group at 2 wk, 4 wk, and 8 wk post operation (all P <0.05).  Conclusion: Postoperative intrableb injection of pirfenidone followed by topical administra tion reduced fibrosis following glaucoma drainage device implantation.  These findings sug gest that pirfenidone may function as an antiscarring treatment in foreign body reaction after tube-shunt surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_VXroKAd5cLVg90H21EOLACvtfcHk0lj_1SETtNx13A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtFOltLc%253D&md5=26f30e5d68013049914820a86f1e7a99</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S99957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S99957%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DK.%2BI.%26aulast%3DPark%26aufirst%3DC.%2BK.%26atitle%3DPirfenidone%2520inhibits%2520fibrosis%2520in%2520foreign%2520body%2520reaction%2520after%2520glaucoma%2520drainage%2520device%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D1477%26epage%3D1488%26doi%3D10.2147%2FDDDT.S99957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tlsty, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coussens, L. M.</span></span> <span> </span><span class="NLM_article-title">Tumor stroma and regulation of cancer development</span>. <i>Annu. Rev. Pathol.: Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">119</span>â <span class="NLM_lpage">150</span>, <span class="refDoi">Â DOI: 10.1146/annurev.pathol.1.110304.100224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1146%2Fannurev.pathol.1.110304.100224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18039110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVOitb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=119-150&author=T.+D.+Tlstyauthor=L.+M.+Coussens&title=Tumor+stroma+and+regulation+of+cancer+development&doi=10.1146%2Fannurev.pathol.1.110304.100224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor stroma and regulation of cancer development</span></div><div class="casAuthors">Tlsty, Thea D.; Coussens, Lisa M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">119-150</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  In the past 25 years, a majority of cancer studies have focused on examg. functional consequences of activating and/or inactivating mutations in crit. genes implicated in cell cycle control.  These studies have taught us a great deal about the functions of oncogenes and tumor suppressor genes and the signaling pathways regulating cell proliferation and/or cell death.  However, such studies have largely ignored the fact that cancers are heterogeneous cellular entities whose growth is dependent upon reciprocal interactions between genetically altered "initiated" cells and the dynamic microenvironment in which they live.  This review highlights the aspects of cancer development that, like organogenesis during embryonic development and tissue repair in adult mammals, are regulated by interactions between epithelial cells, activated stromal cells, and sol. and insol. components of the extracellular matrix.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZHCYEcFMcsrVg90H21EOLACvtfcHk0lh90Ct0dGVYYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVOitb0%253D&md5=6140a30a9a1b09ad067ebdb0b6ae0eff</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathol.1.110304.100224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathol.1.110304.100224%26sid%3Dliteratum%253Aachs%26aulast%3DTlsty%26aufirst%3DT.%2BD.%26aulast%3DCoussens%26aufirst%3DL.%2BM.%26atitle%3DTumor%2520stroma%2520and%2520regulation%2520of%2520cancer%2520development%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2006%26volume%3D1%26spage%3D119%26epage%3D150%26doi%3D10.1146%2Fannurev.pathol.1.110304.100224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orimo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Stromal fibroblasts in cancer. A novel tumor-promoting cell type</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1597</span>â <span class="NLM_lpage">1601</span>, <span class="refDoi">Â DOI: 10.4161/cc.5.15.3112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.4161%2Fcc.5.15.3112" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1597-1601&author=A.+Orimoauthor=R.+A.+Weinberg&title=Stromal+fibroblasts+in+cancer.+A+novel+tumor-promoting+cell+type&doi=10.4161%2Fcc.5.15.3112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.4161%2Fcc.5.15.3112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.5.15.3112%26sid%3Dliteratum%253Aachs%26aulast%3DOrimo%26aufirst%3DA.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DStromal%2520fibroblasts%2520in%2520cancer.%2520A%2520novel%2520tumor-promoting%2520cell%2520type%26jtitle%3DCell%2520Cycle%26date%3D2006%26volume%3D5%26spage%3D1597%26epage%3D1601%26doi%3D10.4161%2Fcc.5.15.3112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamauchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurie, J. M.</span></span> <span> </span><span class="NLM_article-title">The fibrotic tumor stroma</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">16</span>â <span class="NLM_lpage">25</span>, <span class="refDoi">Â DOI: 10.1172/JCI93554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2FJCI93554" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=16-25&author=M.+Yamauchiauthor=T.+H.+Barkerauthor=D.+L.+Gibbonsauthor=J.+M.+Kurie&title=The+fibrotic+tumor+stroma&doi=10.1172%2FJCI93554"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1172%2FJCI93554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI93554%26sid%3Dliteratum%253Aachs%26aulast%3DYamauchi%26aufirst%3DM.%26aulast%3DBarker%26aufirst%3DT.%2BH.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DKurie%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520fibrotic%2520tumor%2520stroma%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D16%26epage%3D25%26doi%3D10.1172%2FJCI93554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Augsten, M.</span></span> <span> </span><span class="NLM_article-title">Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">62</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2014.00062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffonc.2014.00062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24734219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsl2mtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=62&author=M.+Augsten&title=Cancer-associated+fibroblasts+as+another+polarized+cell+type+of+the+tumor+microenvironment&doi=10.3389%2Ffonc.2014.00062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment</span></div><div class="casAuthors">Augsten Martin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">62</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Tumor- or cancer-associated fibroblasts (CAFs) are one of the most abundant stromal cell types in different carcinomas and comprise a heterogeneous cell population.  Classically, CAFs are assigned with pro-tumorigenic effects stimulating tumor growth and progression.  More recent studies demonstrated also tumor-inhibitory effects of CAFs suggesting that tumor-residing fibroblasts exhibit a similar degree of plasticity as other stromal cell types.  Reciprocal interactions with the tumor milieu and different sources of origin are emerging as two important factors underlying CAF heterogeneity.  This review highlights recent advances in our understanding of CAF biology and proposes to expand the term of cellular "polarization," previously introduced to describe different activation states of various immune cells, onto CAFs to reflect their phenotypic diversity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYoMsMF_spOohLSh9fo81bfW6udTcc2eZ2eqz4cXzqEbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsl2mtQ%253D%253D&md5=f9f948b6990677005a727651ef53654b</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2014.00062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2014.00062%26sid%3Dliteratum%253Aachs%26aulast%3DAugsten%26aufirst%3DM.%26atitle%3DCancer-associated%2520fibroblasts%2520as%2520another%2520polarized%2520cell%2520type%2520of%2520the%2520tumor%2520microenvironment%26jtitle%3DFront.%2520Oncol.%26date%3D2014%26volume%3D4%26spage%3D62%26doi%3D10.3389%2Ffonc.2014.00062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamauchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurie, J.</span></span> <span> </span><span class="NLM_article-title">MFKBP65-dependent peptidyl-prolyl isomerase activity potentiates the lysyl hydroxylase 2-driven collagen cross-link switch</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">46021</span>, <span class="refDoi">Â DOI: 10.1038/srep46021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fsrep46021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28378777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVeksrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=46021&author=Y.+Chenauthor=M.+Terajimaauthor=P.+Banerjeeauthor=H.+Guoauthor=X.+Liuauthor=J.+Yuauthor=M.+Yamauchiauthor=J.+Kurie&title=MFKBP65-dependent+peptidyl-prolyl+isomerase+activity+potentiates+the+lysyl+hydroxylase+2-driven+collagen+cross-link+switch&doi=10.1038%2Fsrep46021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">FKBP65-dependent peptidyl-prolyl isomerase activity potentiates the lysyl hydroxylase 2-driven collagen cross-link switch</span></div><div class="casAuthors">Chen, Yulong; Terajima, Masahiko; Banerjee, Priyam; Guo, Houfu; Liu, Xin; Yu, Jiang; Yamauchi, Mitsuo; Kurie, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46021</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruck Syndrome is a connective tissue disease assocd. with inactivating mutations in lysyl hydroxylase 2 (LH2/PLOD2) or FK506 binding protein 65 (FKBP65/FKBP10).  However, the functional relationship between LH2 and FKBP65 remains unclear.  Here, we postulated that peptidyl prolyl isomerase (PPIase) activity of FKBP65 pos. modulates LH2 enzymic activity and is crit. for the formation of hydroxylysine-aldehyde derived intermol. collagen cross-links (HLCCs).  To test this hypothesis, we analyzed collagen cross-links in Fkbp10-null and -wild-type murine embryonic fibroblasts.  Although LH2 protein levels did not change, FKBP65 deficiency significantly diminished HLCCs and increased the non-hydroxylated lysine-aldehyde-derived collagen cross-links (LCCs), a pattern consistent with loss of LH2 enzymic activity.  The HLCC-to-LCC ratio was rescued in FKBP65-deficient murine embryonic fibroblasts by reconstitution with wild-type but not mutant FKBP65 that lacks intact PPIase domains.  Findings from co-immunopptn., protein-fragment complementation, and co-immunofluorescence assays showed that LH2 and FKBP65 are part of a common protein complex.  We conclude that FKBP65 regulates LH2-mediated collagen crosslinking.  Because LH2 promotes fibrosis and cancer metastasis, our findings suggest that pharmacol. strategies to target FKBP65 and LH2 may have complementary therapeutic activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrojTNo3vnJkbVg90H21EOLACvtfcHk0liUMMyCO64zpw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVeksrk%253D&md5=01e4ccef57b455d6803fd6b6f5018181</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fsrep46021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep46021%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTerajima%26aufirst%3DM.%26aulast%3DBanerjee%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYamauchi%26aufirst%3DM.%26aulast%3DKurie%26aufirst%3DJ.%26atitle%3DMFKBP65-dependent%2520peptidyl-prolyl%2520isomerase%2520activity%2520potentiates%2520the%2520lysyl%2520hydroxylase%25202-driven%2520collagen%2520cross-link%2520switch%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D46021%26doi%3D10.1038%2Fsrep46021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tommelein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verset, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boterberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wever, O.</span></span> <span> </span><span class="NLM_article-title">Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">63</span>, <span class="refDoi">Â DOI: 10.3389/fonc.2015.00063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffonc.2015.00063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25853091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjit1WrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=63&author=J.+Tommeleinauthor=L.+Versetauthor=T.+Boterbergauthor=P.+Demetterauthor=M.+Brackeauthor=O.+De+Wever&title=Cancer-associated+fibroblasts+connect+metastasis-promoting+communication+in+colorectal+cancer&doi=10.3389%2Ffonc.2015.00063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer</span></div><div class="casAuthors">Tommelein Joke; Boterberg Tom; Bracke Marc; De Wever Olivier; Verset Laurine; Demetter Pieter</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Colorectal cancer (CRC) progression and eventually metastasis is directed in many aspects by a circuitous ecosystem consisting of an extracellular matrix scaffold populated by cancer-associated fibroblasts (CAFs), endothelial cells, and diverse immune cells.  CAFs are recruited from local tissue-resident fibroblasts or pericryptal fibroblasts and distant fibroblast precursors.  CAFs are highly abundant in CRC.  In this review, we apply the metastasis-promoting communication of colorectal CAFs to 10 cancer hallmarks described by Hanahan and Weinberg.  CAFs influence innate and adaptive tumor immune responses.  Using datasets from previously published work, we re-explore the potential messages implicated in this process.  Fibroblasts present in metastasis (metastasis-associated fibroblasts) from CRC may have other characteristics and functional roles than CAFs in the primary tumor.  Since CAFs connect metastasis-promoting communication, CAF markers are potential prognostic biomarkers.  CAFs and their products are possible targets for novel therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZvHVQAn27d5cXNb62YGmbfW6udTcc2eaPxmZS8u-2BLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjit1WrtA%253D%253D&md5=38d11271526ef0ba95352cb5ad8f1349</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2015.00063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2015.00063%26sid%3Dliteratum%253Aachs%26aulast%3DTommelein%26aufirst%3DJ.%26aulast%3DVerset%26aufirst%3DL.%26aulast%3DBoterberg%26aufirst%3DT.%26aulast%3DDemetter%26aufirst%3DP.%26aulast%3DBracke%26aufirst%3DM.%26aulast%3DDe%2BWever%26aufirst%3DO.%26atitle%3DCancer-associated%2520fibroblasts%2520connect%2520metastasis-promoting%2520communication%2520in%2520colorectal%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2015%26volume%3D5%26spage%3D63%26doi%3D10.3389%2Ffonc.2015.00063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scherz-Shouval, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santagata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendillo, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sholl, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Aharon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias-Santagata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span> <span> </span><span class="NLM_article-title">The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">564</span>â <span class="NLM_lpage">578</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2014.05.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.cell.2014.05.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25083868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ymtLrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2014&pages=564-578&author=R.+Scherz-Shouvalauthor=S.+Santagataauthor=M.+L.+Mendilloauthor=L.+M.+Shollauthor=I.+Ben-Aharonauthor=A.+H.+Beckauthor=D.+Dias-Santagataauthor=M.+Koevaauthor=S.+M.+Stemmerauthor=L.+Whitesellauthor=S.+Lindquist&title=The+reprogramming+of+tumor+stroma+by+HSF1+is+a+potent+enabler+of+malignancy&doi=10.1016%2Fj.cell.2014.05.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy</span></div><div class="casAuthors">Scherz-Shouval, Ruth; Santagata, Sandro; Mendillo, Marc L.; Sholl, Lynette M.; Ben-Aharon, Irit; Beck, Andrew H.; Dias-Santagata, Dora; Koeva, Martina; Stemmer, Salomon M.; Whitesell, Luke; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">564-578</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Stromal cells within the tumor microenvironment are essential for tumor progression and metastasis.  Surprisingly little is known about the factors that drive the transcriptional reprogramming of stromal cells within tumors.  We report that the transcriptional regulator heat shock factor 1 (HSF1) is frequently activated in cancer-assocd. fibroblasts (CAFs), where it is a potent enabler of malignancy.  HSF1 drives a transcriptional program in CAFs that complements, yet is completely different from, the program it drives in adjacent cancer cells.  This CAF program is uniquely structured to support malignancy in a non-cell-autonomous way.  Two central stromal signaling mols.-TGF-Î² and SDF1-play a crit. role.  In early-stage breast and lung cancer, high stromal HSF1 activation is strongly assocd. with poor patient outcome.  Thus, tumors co-opt the ancient survival functions of HSF1 to orchestrate malignancy in both cell-autonomous and non-cell-autonomous ways, with far-reaching therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCiHlbkoEibVg90H21EOLACvtfcHk0lj8tnlQDUwLgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ymtLrE&md5=a01f61fa9ef05c97681dc52386741332</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.05.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.05.045%26sid%3Dliteratum%253Aachs%26aulast%3DScherz-Shouval%26aufirst%3DR.%26aulast%3DSantagata%26aufirst%3DS.%26aulast%3DMendillo%26aufirst%3DM.%2BL.%26aulast%3DSholl%26aufirst%3DL.%2BM.%26aulast%3DBen-Aharon%26aufirst%3DI.%26aulast%3DBeck%26aufirst%3DA.%2BH.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DKoeva%26aufirst%3DM.%26aulast%3DStemmer%26aufirst%3DS.%2BM.%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DThe%2520reprogramming%2520of%2520tumor%2520stroma%2520by%2520HSF1%2520is%2520a%2520potent%2520enabler%2520of%2520malignancy%26jtitle%3DCell%26date%3D2014%26volume%3D158%26spage%3D564%26epage%3D578%26doi%3D10.1016%2Fj.cell.2014.05.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, H. Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. C.</span></span> <span> </span><span class="NLM_article-title">Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signaling</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3472</span>, <span class="refDoi">Â DOI: 10.1038/ncomms4472</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fncomms4472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24668028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2crnt12rsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3472&author=W.+J.+Chenauthor=C.+C.+Hoauthor=Y.+L.+Changauthor=H.+Y.+Chenauthor=C.+A.+Linauthor=T.+Y.+Lingauthor=S.+L.+Yuauthor=S.+S.+Yuanauthor=Y.+J.+L.+Chenauthor=C.+Y.+Linauthor=S.+H.+Panauthor=H.+Y.+E.+Chouauthor=Y.+J.+Chenauthor=G.+C.+Changauthor=W.+C.+Chuauthor=Y.+M.+Leeauthor=J.+Y.+Leeauthor=P.+J.+Leeauthor=K.+C.+Liauthor=H.+W.+Chenauthor=P.+C.+Yang&title=Cancer-associated+fibroblasts+regulate+the+plasticity+of+lung+cancer+stemness+via+paracrine+signaling&doi=10.1038%2Fncomms4472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling</span></div><div class="casAuthors">Chen Wan-Jiun; Ho Chao-Chi; Chang Yih-Leong; Chen Hsuan-Yu; Yuan Shin-Sheng; Chen Yu-Ju Louisa; Lin Chien-Yu; Lin Chih-An; Yu Sung-Liang; Ling Thai-Yen; Pan Szu-Hua; Chou Han-Yi Elizabeth; Chen Yu-Ju; Chang Gee-Chen; Chu Wen-Cheng; Lee Yee-Ming; Lee Jen-Yi; Lee Pei-Jung; Li Ker-Chau; Chen Huei-Wen; Yang Pan-Chyr</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3472</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer stem cells (CSCs) are a promising target for treating cancer, yet how CSC plasticity is maintained in vivo is unclear and is difficult to study in vitro.  Here we establish a sustainable primary culture of Oct3/4(+)/Nanog(+) lung CSCs fed with CD90(+) cancer-associated fibroblasts (CAFs) to further advance our knowledge of preserving stem cells in the tumour microenvironment.  Using transcriptomics we identify the paracrine network by which CAFs enrich CSCs through de-differentiation and reacquisition of stem cell-like properties.  Specifically, we find that IGF1R signalling activation in cancer cells in the presence of CAFs expressing IGF-II can induce Nanog expression and promote stemness.  Moreover, this paracrine signalling predicts overall and relapse-free survival in stage I non-small cell lung cancer (NSCLC) patients.  IGF-II/IGF1R signalling blockade inhibits Nanog expression and attenuates cancer stem cell features.  Our data demonstrate that CAFs constitute a supporting niche for cancer stemness, and targeting this paracrine signalling may present a new therapeutic strategy for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTm3hC1BFRecNy3lHz94U-GfW6udTcc2eb67OlmRXJkxrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crnt12rsQ%253D%253D&md5=361b9cb8eee2a5a5b521f2d8a7ae7992</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fncomms4472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4472%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%2BJ.%26aulast%3DHo%26aufirst%3DC.%2BC.%26aulast%3DChang%26aufirst%3DY.%2BL.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DLin%26aufirst%3DC.%2BA.%26aulast%3DLing%26aufirst%3DT.%2BY.%26aulast%3DYu%26aufirst%3DS.%2BL.%26aulast%3DYuan%26aufirst%3DS.%2BS.%26aulast%3DChen%26aufirst%3DY.%2BJ.%2BL.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DPan%26aufirst%3DS.%2BH.%26aulast%3DChou%26aufirst%3DH.%2BY.%2BE.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26aulast%3DChang%26aufirst%3DG.%2BC.%26aulast%3DChu%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DY.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DP.%2BJ.%26aulast%3DLi%26aufirst%3DK.%2BC.%26aulast%3DChen%26aufirst%3DH.%2BW.%26aulast%3DYang%26aufirst%3DP.%2BC.%26atitle%3DCancer-associated%2520fibroblasts%2520regulate%2520the%2520plasticity%2520of%2520lung%2520cancer%2520stemness%2520via%2520paracrine%2520signaling%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3472%26doi%3D10.1038%2Fncomms4472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tafelmeyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span> <span> </span><span class="NLM_article-title">Fibroblast activation protein-Î± in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">977</span>â <span class="NLM_lpage">991</span>, <span class="refDoi">Â DOI: 10.1080/14728222.2017.1370455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1080%2F14728222.2017.1370455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28829211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVarsLvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=977-991&author=L.+Juillerat-Jeanneretauthor=P.+Tafelmeyerauthor=D.+Golshayan&title=Fibroblast+activation+protein-%CE%B1+in+fibrogenic+disorders+and+cancer%3A+more+than+a+prolyl-specific+peptidase%3F&doi=10.1080%2F14728222.2017.1370455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast activation protein-Î± in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?</span></div><div class="casAuthors">Juillerat-Jeanneret, Lucienne; Tafelmeyer, Petra; Golshayan, Dela</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">977-991</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Fibroblast activation protein-Î± (FAP-Î±) belongs to the family of prolyl-specific serine proteases.  FAP-Î± displays both exopeptidase and endopeptidase/gelatinase/collagenase activities.  FAP-Î± protein and/or activity have been assocd. with fibrosis, inflammation and cancer, but the protein is undetectable in most normal tissues.  FAP-Î± is selectively expressed at sites of tissue remodeling and repair and enhances tumor progression, suggesting that this protease may be a therapeutic target to treat human disorders assocd. with fibrotic dysregulation.  In this review, we summarize the mechanisms driving tissue fibrosis and describe some of the enzymes involved in fibrosis, concg. on FAP-Î±.  We describe its enzymic properties, discuss the tools developed to control its activity and the problem of selectivity toward the other proteases of the family and outline its potential biol. substrates.  We also consider non-enzymic functions of this protein and suggest that repression of FAP-Î± expression may represent therapeutic options.  Questions remain regarding the biol. functions of FAP-Î±, either dependent or independent of its enzyme activity.  However, as progress is underway to develop FAP-Î±-specific inhibitors and therapeutic antibodies, its role in diseases assocd. with fibrosis is starting to emerge, ultimately leading to novel therapeutic options for inflammatory and oncol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcbPSAqAMjn7Vg90H21EOLACvtfcHk0lipShK2145pbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVarsLvJ&md5=596669985733b4eb79e68a66031f7e7a</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1080%2F14728222.2017.1370455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728222.2017.1370455%26sid%3Dliteratum%253Aachs%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DTafelmeyer%26aufirst%3DP.%26aulast%3DGolshayan%26aufirst%3DD.%26atitle%3DFibroblast%2520activation%2520protein-%25CE%25B1%2520in%2520fibrogenic%2520disorders%2520and%2520cancer%253A%2520more%2520than%2520a%2520prolyl-specific%2520peptidase%253F%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2017%26volume%3D21%26spage%3D977%26epage%3D991%26doi%3D10.1080%2F14728222.2017.1370455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ota, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutomi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torigoe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morimoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uede, T.</span></span> <span> </span><span class="NLM_article-title">Tumor-Î±9Î²1 integrin-mediated signaling induces breast cancer growth and lymphatic metastasis via the recruitment of cancer-associated fibroblasts</span>. <i>J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1271</span>â <span class="NLM_lpage">1281</span>, <span class="refDoi">Â DOI: 10.1007/s00109-014-1183-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1007%2Fs00109-014-1183-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25099519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlanu7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2014&pages=1271-1281&author=D.+Otaauthor=M.+Kanayamaauthor=Y.+Matsuiauthor=K.+Itoauthor=N.+Maedaauthor=G.+Kutomiauthor=K.+Hirataauthor=T.+Torigoeauthor=N.+Satoauthor=A.+Takaokaauthor=A.+F.+Chambersauthor=J.+Morimotoauthor=T.+Uede&title=Tumor-%CE%B19%CE%B21+integrin-mediated+signaling+induces+breast+cancer+growth+and+lymphatic+metastasis+via+the+recruitment+of+cancer-associated+fibroblasts&doi=10.1007%2Fs00109-014-1183-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-Î±9Î²1 integrin-mediated signaling induces breast cancer growth and lymphatic metastasis via the recruitment of cancer-associated fibroblasts</span></div><div class="casAuthors">Ota, Daichi; Kanayama, Masashi; Matsui, Yutaka; Ito, Koyu; Maeda, Naoyoshi; Kutomi, Goro; Hirata, Koichi; Torigoe, Toshihiko; Sato, Noriyuki; Takaoka, Akinori; Chambers, Ann F.; Morimoto, Junko; Uede, Toshimitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1271-1281</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: Tumor-derived matricellular proteins such as osteopontin (OPN) and tenascin-C (TN-C) have been implicated in tumor growth and metastasis.  However, the mol. basis of how these proteins contribute to tumor progression remains to be elucidated.  Importantly, these matricellular proteins are known to interact with Î±9Î²1 integrin.  Therefore, we hypothesized that tumor-derived Î±9Î²1 integrin may contribute to tumor progression.  To clarify the roles of Î±9Î²1 integrin in tumor growth and lymphatic metastasis, we used an inhibitory anti-human Î±9Î²1 integrin antibody (anti-hÎ±9Î²1 antibody) and a Î±9Î²1 integrin-pos. human breast cancer cell line, MDA-MB-231 luc-D3H2LN (D3H2LN), in vitro functional assays, and an in vivo orthotopic xenotransplantation model.  In this study, we demonstrated that tumor, but not host Î±9Î²1 integrin, contributes to tumor growth, lymphatic metastasis, recruitment of cancer-assocd. fibroblasts (CAFs), and host-derived OPN prodn.  We also found that CAFs contributed to tumor growth, lymphatic metastasis, and host-derived OPN levels.  Consistent with those findings, tumor vol. was well-correlated with nos. of CAFs and levels of host-derived OPN.  Furthermore, it was shown that the inoculation of D3H2LN cells into mammary fat pads with mouse embryonic fibroblasts (MEFs), obtained from wild type, but not OPN knock-out mice, resulted in enhancement of tumor growth, thus indicating that CAF-derived OPN enhanced tumor growth.  These results suggested that tumor Î±9Î²1-mediated signaling plays a pivotal role in generating unique primary tumor tissue microenvironments, which favor lymphatic metastasis and tumor growth.  Key messages: Tumor Î±9Î²1 integrin promotes lymphatic metastasis through enhancing invasion.  Tumor Î±9Î²1 integrin promotes tumor growth through CAFs.  Tumor Î±9Î²1 integrin enhances the recruitment of CAFs into the primary tumor.  Tumor cells induce the prodn. of OPN by CAFs in the primary tumor.  CAF-derived OPN promotes tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOoyL5xlQxNLVg90H21EOLACvtfcHk0lipShK2145pbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlanu7rN&md5=614df7c0e6a9e25620d8486acc618dc4</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1007%2Fs00109-014-1183-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-014-1183-9%26sid%3Dliteratum%253Aachs%26aulast%3DOta%26aufirst%3DD.%26aulast%3DKanayama%26aufirst%3DM.%26aulast%3DMatsui%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DMaeda%26aufirst%3DN.%26aulast%3DKutomi%26aufirst%3DG.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DTorigoe%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DN.%26aulast%3DTakaoka%26aufirst%3DA.%26aulast%3DChambers%26aufirst%3DA.%2BF.%26aulast%3DMorimoto%26aufirst%3DJ.%26aulast%3DUede%26aufirst%3DT.%26atitle%3DTumor-%25CE%25B19%25CE%25B21%2520integrin-mediated%2520signaling%2520induces%2520breast%2520cancer%2520growth%2520and%2520lymphatic%2520metastasis%2520via%2520the%2520recruitment%2520of%2520cancer-associated%2520fibroblasts%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2014%26volume%3D92%26spage%3D1271%26epage%3D1281%26doi%3D10.1007%2Fs00109-014-1183-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco-Barraza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valianou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cukierman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span> <span> </span><span class="NLM_article-title">FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">245</span>, <span class="refDoi">Â DOI: 10.1186/1471-2407-11-245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1186%2F1471-2407-11-245" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=245&author=H.+O.+Leeauthor=S.+R.+Mullinsauthor=J.+Franco-Barrazaauthor=M.+Valianouauthor=E.+Cukiermanauthor=J.+D.+Cheng&title=FAP-overexpressing+fibroblasts+produce+an+extracellular+matrix+that+enhances+invasive+velocity+and+directionality+of+pancreatic+cancer+cells&doi=10.1186%2F1471-2407-11-245"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-11-245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-11-245%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BO.%26aulast%3DMullins%26aufirst%3DS.%2BR.%26aulast%3DFranco-Barraza%26aufirst%3DJ.%26aulast%3DValianou%26aufirst%3DM.%26aulast%3DCukierman%26aufirst%3DE.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26atitle%3DFAP-overexpressing%2520fibroblasts%2520produce%2520an%2520extracellular%2520matrix%2520that%2520enhances%2520invasive%2520velocity%2520and%2520directionality%2520of%2520pancreatic%2520cancer%2520cells%26jtitle%3DBMC%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D245%26doi%3D10.1186%2F1471-2407-11-245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine kinas 1 enables communication between melanoma cells and fibroblasts that provides a new link to metastasis</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">3361</span>â <span class="NLM_lpage">3363</span>, <span class="refDoi">Â DOI: 10.1038/onc.2013.292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fonc.2013.292" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=3361-3363&author=N.+J.+Pyneauthor=S.+Pyne&title=Sphingosine+kinas+1+enables+communication+between+melanoma+cells+and+fibroblasts+that+provides+a+new+link+to+metastasis&doi=10.1038%2Fonc.2013.292"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.292%26sid%3Dliteratum%253Aachs%26aulast%3DPyne%26aufirst%3DN.%2BJ.%26aulast%3DPyne%26aufirst%3DS.%26atitle%3DSphingosine%2520kinas%25201%2520enables%2520communication%2520between%2520melanoma%2520cells%2520and%2520fibroblasts%2520that%2520provides%2520a%2520new%2520link%2520to%2520metastasis%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D3361%26epage%3D3363%26doi%3D10.1038%2Fonc.2013.292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, H.</span></span> <span> </span><span class="NLM_article-title">Strategies targeting angiogenesis in advanced non-small cell lung cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">53854</span>â <span class="NLM_lpage">53872</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.17957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.18632%2Foncotarget.17957" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=53854-53872&author=J.+Wangauthor=J.+Chenauthor=Y.+Guoauthor=B.+Wangauthor=H.+Chu&title=Strategies+targeting+angiogenesis+in+advanced+non-small+cell+lung+cancer&doi=10.18632%2Foncotarget.17957"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17957%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DH.%26atitle%3DStrategies%2520targeting%2520angiogenesis%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D53854%26epage%3D53872%26doi%3D10.18632%2Foncotarget.17957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic-Paterson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, H. Y.</span></span> <span> </span><span class="NLM_article-title">TGFbeta: the master regulator of fibrosis</span>. <i>Nat. Rev. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">325</span>â <span class="NLM_lpage">338</span>, <span class="refDoi">Â DOI: 10.1038/nrneph.2016.48</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnrneph.2016.48" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=27108839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFChu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=325-338&author=X.+M.+Mengauthor=D.+J.+Nikolic-Patersonauthor=H.+Y.+Lan&title=TGFbeta%3A+the+master+regulator+of+fibrosis&doi=10.1038%2Fnrneph.2016.48"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">TGF-Î²: the master regulator of fibrosis</span></div><div class="casAuthors">Meng, Xiao-ming; Nikolic-Paterson, David J.; Lan, Hui Yao</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Nephrology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">325-338</span>CODEN:
                <span class="NLM_cas:coden">NRNABO</span>;
        ISSN:<span class="NLM_cas:issn">1759-5061</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Transforming growth factor-Î² (TGF-Î²) is the primary factor that drives fibrosis in most, if not all, forms of chronic kidney disease (CKD).  Inhibition of the TGF-Î² isoform, TGF-Î²1, or its downstream signalling pathways substantially limits renal fibrosis in a wide range of disease models whereas overexpression of TGF-Î²1 induces renal fibrosis.  TGF-Î²1 can induce renal fibrosis via activation of both canonical (Smad-based) and non-canonical (non-Smad-based) signalling pathways, which result in activation of myofibroblasts, excessive prodn. of extracellular matrix (ECM) and inhibition of ECM degrdn.  The role of Smad proteins in the regulation of fibrosis is complex, with competing profibrotic and antifibrotic actions (including in the regulation of mesenchymal transitioning), and with complex interplay between TGF-Î²/Smads and other signalling pathways.  Studies over the past 5 years have identified addnl. mechanisms that regulate the action of TGF-Î²1/Smad signalling in fibrosis, including short and long noncoding RNA mols. and epigenetic modifications of DNA and histone proteins.  Although direct targeting of TGF-Î²1 is unlikely to yield a viable antifibrotic therapy due to the involvement of TGF-Î²1 in other processes, greater understanding of the various pathways by which TGF-Î²1 controls fibrosis has identified alternative targets for the development of novel therapeutics to halt this most damaging process in CKD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEipbykM1nFLVg90H21EOLACvtfcHk0lgvUCP2zFoWgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFChu70%253D&md5=7df4db39b64b6137ec52b744d34b9c12</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fnrneph.2016.48&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrneph.2016.48%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DX.%2BM.%26aulast%3DNikolic-Paterson%26aufirst%3DD.%2BJ.%26aulast%3DLan%26aufirst%3DH.%2BY.%26atitle%3DTGFbeta%253A%2520the%2520master%2520regulator%2520of%2520fibrosis%26jtitle%3DNat.%2520Rev.%2520Nephrol.%26date%3D2016%26volume%3D12%26spage%3D325%26epage%3D338%26doi%3D10.1038%2Fnrneph.2016.48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Transforming growth factor beta (TGF-beta) mediates cardiac fibrosis and induces diabetic cardiomyopathy</span>. <i>Diabetes Res. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">124</span>â <span class="NLM_lpage">130</span>, <span class="refDoi">Â DOI: 10.1016/j.diabres.2017.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.diabres.2017.08.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28934669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVeqsrrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2017&pages=124-130&author=Y.+Yueauthor=K.+Mengauthor=Y.+Puauthor=X.+Zhang&title=Transforming+growth+factor+beta+%28TGF-beta%29+mediates+cardiac+fibrosis+and+induces+diabetic+cardiomyopathy&doi=10.1016%2Fj.diabres.2017.08.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Transforming growth factor beta (TGF-Î²) mediates cardiac fibrosis and induces diabetic cardiomyopathy</span></div><div class="casAuthors">Yue, Yiyang; Meng, Ke; Pu, Yuejie; Zhang, Xiaoming</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Research and Clinical Practice</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">124-130</span>CODEN:
                <span class="NLM_cas:coden">DRCPE9</span>;
        ISSN:<span class="NLM_cas:issn">0168-8227</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Cardiovascular diseases account for the major cause of morbidity and mortality among individuals with diabetes.  The diabetic cardiomyopathy (DCM) is a type of diabetic cardiovascular disease, which further directs to the heart failure.  The researchers found that diabetes induced cardiac fibrosis plays a vital role in several of the pathol. changes that assocd. with DCM, causing left ventricular hypertrophy (LVH), diastolic dysfunction and systolic dysfunction.  However, the mechanisms involved in the pathogenesis of DCM are still elusive.  Many studies have demonstrated that the transforming growth factor beta (TGF-Î²) is one of the mol. mediators implicated in the progression of fibrogenesis.  In diabetes, hyperglycemia causes the expression changes of microRNAs (miRNAs), long non-coding RNAs (lncRNAs), TGF-Î² genes, TGF-Î² proteins and their receptors.  Activated TGF-Î² further leads to cardiac fibrosis, which in turn inducing DCM through the SMAD-dependent and independent pathways.  Here, we reviewed the the mol. pathways that activate TGF-Î² then leading to cardiac fibrosis, which induced the pathol. changes of DCM.  Illustrating the pathways of TGF-ss would propose an efficient way for the management of diabetic cardiomyopathy (see Fig. 1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7RQaoyUnOKLVg90H21EOLACvtfcHk0lhs4t_BpYe34A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVeqsrrI&md5=88b8a72ac881b38ef898f6d39805dbcf</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1016%2Fj.diabres.2017.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.diabres.2017.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DK.%26aulast%3DPu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DTransforming%2520growth%2520factor%2520beta%2520%2528TGF-beta%2529%2520mediates%2520cardiac%2520fibrosis%2520and%2520induces%2520diabetic%2520cardiomyopathy%26jtitle%3DDiabetes%2520Res.%2520Clin.%2520Pract.%26date%3D2017%26volume%3D133%26spage%3D124%26epage%3D130%26doi%3D10.1016%2Fj.diabres.2017.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shihata, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putra, M. R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin-Dusting, J. P. F.</span></span> <span> </span><span class="NLM_article-title">Is there a potential therapeutic role for caveolin-1 in fibrosis?</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">587</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28900397" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=587&author=W.+A.+Shihataauthor=M.+R.+A.+Putraauthor=J.+P.+F.+Chin-Dusting&title=Is+there+a+potential+therapeutic+role+for+caveolin-1+in+fibrosis%3F&doi=10.3389%2Ffphar.2017.00567"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00567%26sid%3Dliteratum%253Aachs%26aulast%3DShihata%26aufirst%3DW.%2BA.%26aulast%3DPutra%26aufirst%3DM.%2BR.%2BA.%26aulast%3DChin-Dusting%26aufirst%3DJ.%2BP.%2BF.%26atitle%3DIs%2520there%2520a%2520potential%2520therapeutic%2520role%2520for%2520caveolin-1%2520in%2520fibrosis%253F%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D587%26doi%3D10.3389%2Ffphar.2017.00567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Borgo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirmiz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspari, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span> <span> </span><span class="NLM_article-title">Anti-fibrotic potential of AT<sub>2</sub> receptor agonists</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">564</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28912715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2nsrfP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=564&author=Y.+Wangauthor=M.+Del+Borgoauthor=H.+W.+Leeauthor=D.+Baraldiauthor=B.+Hirmizauthor=T.+A.+Gaspariauthor=K.+M.+Dentonauthor=M.+I.+Aguilarauthor=C.+S.+Samuelauthor=R.+E.+Widdop&title=Anti-fibrotic+potential+of+AT2+receptor+agonists&doi=10.3389%2Ffphar.2017.00564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-fibrotic potential of AT2 receptor agonists</span></div><div class="casAuthors">Wang, Yan; Del Borgo, Mark; Lee, Huey W.; Baraldi, Dhaniel; Hirmiz, Baydaa; Gaspari, Tracey A.; Denton, Kate M.; Aguilar, Marie-Isabel; Samuel, Chrishan S.; Widdop, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">564/1-564/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">There are a no. of therapeutic targets to treat organ fibrosis that are under investigation in preclin. models.  There is increasing evidence that stimulation of the angiotensin II type 2 receptor (AT2R) is a novel anti-fibrotic strategy and we have reviewed the published in vivo preclin. data relating to the effects of compd. 21 (C21), which is the only nonpeptide AT2R agonist that is currently available for use in chronic preclin. studies.  In particular, the differential influence of AT2R on extracellular matrix status in various preclin. fibrotic models is discussed.  Collectively, these studies demonstrate that pharmacol. AT2R stimulation using C21 decreases organ fibrosis, which has been most studied in the setting of cardiovascular and renal disease.  In addn., AT2R-mediated anti-inflammatory effects may contribute to the beneficial AT2R-mediated anti-fibrotic effects seen in preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXQrEmlGvVi7Vg90H21EOLACvtfcHk0lg56D0pjpOKcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2nsrfP&md5=616e2c23a2a6d046dd5bb0cd2c3733ed</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00564%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDel%2BBorgo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DBaraldi%26aufirst%3DD.%26aulast%3DHirmiz%26aufirst%3DB.%26aulast%3DGaspari%26aufirst%3DT.%2BA.%26aulast%3DDenton%26aufirst%3DK.%2BM.%26aulast%3DAguilar%26aufirst%3DM.%2BI.%26aulast%3DSamuel%26aufirst%3DC.%2BS.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26atitle%3DAnti-fibrotic%2520potential%2520of%2520AT2%2520receptor%2520agonists%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D564%26doi%3D10.3389%2Ffphar.2017.00564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alhomrani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zavou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leaw, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greening, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievert, W.</span></span> <span> </span><span class="NLM_article-title">The human amnion epithelial cell secretome decreases hepatic fibrosis in mice with chronic liver ibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">748</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29114223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFegs7%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=748&author=M.+Alhomraniauthor=J.+Correiaauthor=M.+Zavouauthor=B.+Leawauthor=N.+Kukauthor=R.+Xuauthor=M.+I.+Saadauthor=A.+Hodgeauthor=D.+W.+Greeningauthor=R.+Limauthor=W.+Sievert&title=The+human+amnion+epithelial+cell+secretome+decreases+hepatic+fibrosis+in+mice+with+chronic+liver+ibrosis&doi=10.3389%2Ffphar.2017.00748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">The human amnion epithelial cell secretome decreases hepatic fibrosis in mice with chronic liver fibrosis</span></div><div class="casAuthors">Alhomrani, Majid; Correia, Jeanne; Zavou, Marcus; Leaw, Bryan; Kuk, Nathan; Xu, Rong; Saad, Mohamed I.; Hodge, Alexander; Greening, David W.; Lim, Rebecca; Sievert, William</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">748/1-748/13</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Background: Hepatic stellate cells (HSCs) are the primary collagen-secreting cells in the liver.  While HSCs are the major cell type involved in the pathogenesis of liver fibrosis, hepatic macrophages also play an important role in mediating fibrogenesis and fibrosis resoln.  Previously, we obsd. a redn. in HSC activation, proliferation, and collagen synthesis following exposure to human amnion epithelial cells (hAEC) and hAEC-conditioned media (hAEC-CM).  This suggested that specific factors secreted by hAEC might be effective in ameliorating liver fibrosis. hAEC-derived extracellular vesicles (hAEC-EVs), which are nanosized (40-100 nm) membrane bound vesicles, may act as novel cell-cell communicators.  Accordingly, we evaluated the efficacy of hAEC-EV in modulating liver fibrosis in a mouse model of chronic liver fibrosis and in human HSC.  Methods: The hAEC-EVs were isolated and characterized.  C57BL/6 mice with CCl4-induced liver fibrosis were administered hAEC-EV, hAEC-CM, or hAEC-EV depleted medium (hAEC-EVDM).  LX2 cells, a human HSC line, and bone marrow-derived mouse macrophages were exposed to hAEC-EV, hAEC-CM, and hAEC-EVDM.  Mass spectrometry was used to examine the proteome profile of each prepn.  Results: The extent of liver fibrosis and no. of activated HSCs were reduced significantly in CCl4-treated mice given hAEC-EVs, hAEC-CM, and hAEC EVDM compared to untreated controls.  Hepatic macrophages were significantly decreased in all treatment groups, where a predominant M2 phenotype was obsd.  Human HSCs cultured with hAEC-EV and hAEC-CM displayed a significant redn. in collagen synthesis and hAEC-EV, hAEC-CM, and hAEC-EVDM altered macrophage polarization in bone marrow-derived mouse macrophages.  Proteome anal. showed that 164 proteins were unique to hAEC-EV in comparison to hAEC-CM and hAEC-EVDM, and 51 proteins were co-identified components with the hAEC-EV fraction.  Conclusion: This study provides novel data showing that hAEC-derived EVs significantly reduced liver fibrosis and macrophage infiltration to an extent similar to hAEC-EVDM and hAEC-CM. hAEC-EV-based therapy may be a potential therapeutic option for liver fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO-RyBjuNS0LVg90H21EOLACvtfcHk0liP8kxhG0HzSA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFegs7%252FP&md5=2c75fa4216ac03827cf754930609ab31</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00748%26sid%3Dliteratum%253Aachs%26aulast%3DAlhomrani%26aufirst%3DM.%26aulast%3DCorreia%26aufirst%3DJ.%26aulast%3DZavou%26aufirst%3DM.%26aulast%3DLeaw%26aufirst%3DB.%26aulast%3DKuk%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DSaad%26aufirst%3DM.%2BI.%26aulast%3DHodge%26aufirst%3DA.%26aulast%3DGreening%26aufirst%3DD.%2BW.%26aulast%3DLim%26aufirst%3DR.%26aulast%3DSievert%26aufirst%3DW.%26atitle%3DThe%2520human%2520amnion%2520epithelial%2520cell%2520secretome%2520decreases%2520hepatic%2520fibrosis%2520in%2520mice%2520with%2520chronic%2520liver%2520ibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D748%26doi%3D10.3389%2Ffphar.2017.00748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nanthakumar, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatley, R. J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauldie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">Dissecting fibrosis: therapeutic insights from the small-molecule toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">693</span>â <span class="NLM_lpage">720</span>, <span class="refDoi">Â DOI: 10.1038/nrd4592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnrd4592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26338155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7rJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=693-720&author=C.+B.+Nanthakumarauthor=R.+J.+D.+Hatleyauthor=S.+Lemmaauthor=J.+Gauldieauthor=R.+P.+Marshallauthor=S.+J.+F.+Macdonald&title=Dissecting+fibrosis%3A+therapeutic+insights+from+the+small-molecule+toolbox&doi=10.1038%2Fnrd4592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting fibrosis: therapeutic insights from the small-molecule toolbox</span></div><div class="casAuthors">Nanthakumar, Carmel B.; Hatley, Richard J. D.; Lemma, Seble; Gauldie, Jack; Marshall, Richard P.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">693-720</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibrosis, which leads to progressive loss of tissue function and eventual organ failure, has been estd. to contribute to â¼45% of deaths in the developed world, and so new therapeutics to modulate fibrosis are urgently needed.  Major advances in our understanding of the mechanisms underlying pathol. fibrosis are supporting the search for such therapeutics, and the recent approval of two anti-fibrotic drugs for idiopathic pulmonary fibrosis has demonstrated the tractability of this area for drug discovery.  This Review examines the pharmacol. and structural information for small mols. being evaluated for lung, liver, kidney and skin fibrosis.  In particular, we discuss the insights gained from the use of these pharmacol. tools, and how these entities can inform, and probe, emerging insights into disease mechanisms, including the potential for future drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk6pfSk3gsCrVg90H21EOLACvtfcHk0lic94ckiuLX2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrt7rJ&md5=b05a37db6ede2acc0f5c65826aa344f3</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnrd4592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4592%26sid%3Dliteratum%253Aachs%26aulast%3DNanthakumar%26aufirst%3DC.%2BB.%26aulast%3DHatley%26aufirst%3DR.%2BJ.%2BD.%26aulast%3DLemma%26aufirst%3DS.%26aulast%3DGauldie%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DR.%2BP.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DDissecting%2520fibrosis%253A%2520therapeutic%2520insights%2520from%2520the%2520small-molecule%2520toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D693%26epage%3D720%26doi%3D10.1038%2Fnrd4592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mora, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selman, M.</span></span> <span> </span><span class="NLM_article-title">Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">755</span>â <span class="NLM_lpage">772</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2017.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnrd.2017.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28983101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7nM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=755-772&author=A.+L.+Moraauthor=M.+Rojasauthor=A.+Pardoauthor=M.+Selman&title=Emerging+therapies+for+idiopathic+pulmonary+fibrosis%2C+a+progressive+age-related+disease&doi=10.1038%2Fnrd.2017.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease</span></div><div class="casAuthors">Mora, Ana L.; Rojas, Mauricio; Pardo, Annie; Selman, Moises</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">755-772</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a fatal age-assocd. disease that is characterized by progressive and irreversible scarring of the lung.  The pathogenesis of IPF is not completely understood and current therapies are limited to those that reduce the rate of functional decline in patients with mild-to-moderate disease.  In this context, new therapeutic approaches that substantially improve the survival time and quality of life of these patients are urgently needed.  Our incomplete understanding of the pathogenic mechanisms of IPF and the lack of appropriate exptl. models that reproduce the key characteristics of the human disease are major challenges.  As ageing is a major risk factor for IPF, age-related cell perturbations such as telomere attrition, senescence, epigenetic drift, stem cell exhaustion, loss of proteostasis and mitochondrial dysfunction are becoming targets of interest for IPF therapy.  In this Review, we discuss current and emerging therapies for IPF, particularly those targeting age-related mechanisms, and discuss future therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhctsz_uEsn7Vg90H21EOLACvtfcHk0lic94ckiuLX2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7nM&md5=47cc6f5e332c9cfe77271cf6d351d233</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.170%26sid%3Dliteratum%253Aachs%26aulast%3DMora%26aufirst%3DA.%2BL.%26aulast%3DRojas%26aufirst%3DM.%26aulast%3DPardo%26aufirst%3DA.%26aulast%3DSelman%26aufirst%3DM.%26atitle%3DEmerging%2520therapies%2520for%2520idiopathic%2520pulmonary%2520fibrosis%252C%2520a%2520progressive%2520age-related%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D755%26epage%3D772%26doi%3D10.1038%2Fnrd.2017.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varone, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montemurro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iovene, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mari, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richeldi, L.</span></span> <span> </span><span class="NLM_article-title">Investigational drugs for idiopathic pulmonary fibrosis</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1019</span>â <span class="NLM_lpage">1031</span>, <span class="refDoi">Â DOI: 10.1080/13543784.2017.1364361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1080%2F13543784.2017.1364361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28777013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSlt7rO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=1019-1031&author=F.+Varoneauthor=G.+Montemurroauthor=F.+Macagnoauthor=M.+Calvelloauthor=E.+Conteauthor=E.+Intiniauthor=B.+Ioveneauthor=P.+M.+Leoneauthor=P.+V.+Mariauthor=L.+Richeldi&title=Investigational+drugs+for+idiopathic+pulmonary+fibrosis&doi=10.1080%2F13543784.2017.1364361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational drugs for idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Varone, Francesco; Montemurro, Giuliano; Macagno, Francesco; Calvello, Mariarosaria; Conte, Emanuele; Intini, Enrica; Iovene, Bruno; Leone, Paolo Maria; Mari, Pier-Valerio; Richeldi, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1019-1031</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">IPF is a specific form of chronic fibrosing interstitial pneumonia of unknown cause, characterized by progressive worsening in lung function and an unfavorable prognosis.  Current concepts on IPF pathogenesis are based on a dysregulated wound healing response, leading to an over prodn. of extracellular matrix.  Based on recent research however, several other mechanisms are now proposed as potential targets for novel therapeutic strategies.: This review analyzes the current investigational strategies targeting extracellular matrix deposition, tyrosine-kinase antagonism, immune and autoimmune response, and cell-based therapy.  A description of the pathogenic rationale implied in each novel therapeutic approach is summarized.: New IPF drugs are being evaluated in the context of phase 1 and 2 clin. trials.  Nevertheless, many drugs that have shown efficacy in preclin. studies, failed to exhibit the same pos. effect when translated to humans.  A possible explanation for these failures might be related to the known limitations of animal models of the disease.  The recent development of 3D systems composed of cells from individual patients that recreate an ex-vivo model of IPF, could lead to significant improvements in disease pathogenesis and treatment.  New drugs could be tested on more genuine models and clinicians could tailor therapy based on patient's response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlsdftkwJpvrVg90H21EOLACvtfcHk0lgHK2wBFTjl5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSlt7rO&md5=928cc7b97e53659c8e4e2e61289afed5</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1364361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1364361%26sid%3Dliteratum%253Aachs%26aulast%3DVarone%26aufirst%3DF.%26aulast%3DMontemurro%26aufirst%3DG.%26aulast%3DMacagno%26aufirst%3DF.%26aulast%3DCalvello%26aufirst%3DM.%26aulast%3DConte%26aufirst%3DE.%26aulast%3DIntini%26aufirst%3DE.%26aulast%3DIovene%26aufirst%3DB.%26aulast%3DLeone%26aufirst%3DP.%2BM.%26aulast%3DMari%26aufirst%3DP.%2BV.%26aulast%3DRicheldi%26aufirst%3DL.%26atitle%3DInvestigational%2520drugs%2520for%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D1019%26epage%3D1031%26doi%3D10.1080%2F13543784.2017.1364361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghu, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential</span>. <i>Eur. Resp. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">170071</span>, <span class="refDoi">Â DOI: 10.1183/16000617.0071-2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1183%2F16000617.0071-2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28954769" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=170071&author=G.+Raghu&title=Pharmacotherapy+for+idiopathic+pulmonary+fibrosis%3A+current+landscape+and+future+potential&doi=10.1183%2F16000617.0071-2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1183%2F16000617.0071-2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F16000617.0071-2017%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26atitle%3DPharmacotherapy%2520for%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520current%2520landscape%2520and%2520future%2520potential%26jtitle%3DEur.%2520Resp.%2520Rev.%26date%3D2017%26volume%3D26%26spage%3D170071%26doi%3D10.1183%2F16000617.0071-2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hewitson, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelynack, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tait, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, G. J.</span></span> <span> </span><span class="NLM_article-title">Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis</span>. <i>J. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">453</span>â <span class="NLM_lpage">460</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=11783601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BD38%252FlvVGisQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2001&pages=453-460&author=T.+D.+Hewitsonauthor=K.+J.+Kelynackauthor=M.+G.+Taitauthor=M.+Marticauthor=C.+L.+Jonesauthor=S.+B.+Margolinauthor=G.+J.+Becker&title=Pirfenidone+reduces+in+vitro+rat+renal+fibroblast+activation+and+mitogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis</span></div><div class="casAuthors">Hewitson T D; Kelynack K J; Tait M G; Martic M; Jones C L; Margolin S B; Becker G J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nephrology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">453-60</span>
        ISSN:<span class="NLM_cas:issn">1121-8428</span>.
    </div><div class="casAbstract">BACKGROUND:  Fibroblasts have been universally recognised in tubulointerstitial injury, where their presence has been shown to be a marker of disease progression.  Recently, pirfenidone (PF) has been shown to both ameliorate progressive fibrosis and reduce established scarring after ureteric obstruction (UUO) in the rat, suggesting that it is a novel anti-fibrotic agent.  The objective of this study was therefore to determine if these effects include down-regulation of fibroblast function.  METHODS:  Cortical fibroblasts were obtained from outgrowth cultures of renal tissue isolated from kidneys 3 days after UUO and constituted 100% of cells studied.  Functional studies examined the effects of 20 and 200 microg/ml PF on basal serum stimulated activity.  Activation was examined by western blotting for alpha smooth muscle actin (alphaSMA) and connective tissue growth factor (CTGF).  Cell proliferation, collagenase activity and collagen production were determined from kinetic studies, zymography for MMP2 and [3H] proline incorporation in collagenous proteins respectively.  RESULTS:  Proliferation, as measured by [3H] thymidine incorporation, was reduced in dose dependent manner by 20 and 200 microg/ml PF (p<0.05; 200 vs 0 microg/ml).  Likewise, 200 microg/ml PF reduced cell population growth over 5 days of culture (p<0.05 vs 0 microg/ml).  PF (200 microg/ml) decreased alphaSMA and CTGF protein expression to 66+/-13 and 37+/-26% of basal levels respectively (both p<0.05 vs 0 microg/ml).  Synthesis of collagen was unaffected by PF.  Maximal dose of PF produced a modest reduction in MMP2 lytic activity (p=0.05).  Effects of PF were independent of cell toxicity.  CONCLUSIONS:  Down-regulation of renal fibroblast activation and proliferation are specific actions of PF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS5amtT9efKZJ6KlWarZTAzfW6udTcc2ea3-VDyPJmzT7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38%252FlvVGisQ%253D%253D&md5=afd776d80b9b75917caada6b4792c4db</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHewitson%26aufirst%3DT.%2BD.%26aulast%3DKelynack%26aufirst%3DK.%2BJ.%26aulast%3DTait%26aufirst%3DM.%2BG.%26aulast%3DMartic%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DC.%2BL.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26aulast%3DBecker%26aufirst%3DG.%2BJ.%26atitle%3DPirfenidone%2520reduces%2520in%2520vitro%2520rat%2520renal%2520fibroblast%2520activation%2520and%2520mitogenesis%26jtitle%3DJ.%2520Nephrol.%26date%3D2001%26volume%3D14%26spage%3D453%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grattendick, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giri, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolin, S. B.</span></span> <span> </span><span class="NLM_article-title">Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro</span>. <i>Int. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">679</span>â <span class="NLM_lpage">687</span>, <span class="refDoi">Â DOI: 10.1016/j.intimp.2008.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.intimp.2008.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18387510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlCqurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=679-687&author=K.+J.+Grattendickauthor=J.+M.+Nakashimaauthor=L.+Fengauthor=S.+N.+Giriauthor=S.+B.+Margolin&title=Effects+of+three+anti-TNF-alpha+drugs%3A+etanercept%2C+infliximab+and+pirfenidone+on+release+of+TNF-alpha+in+medium+and+TNF-alpha+associated+with+the+cell+in+vitro&doi=10.1016%2Fj.intimp.2008.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of three anti-TNF-Î± drugs: Etanercept, infliximab and pirfenidone on release of TNF-Î± in medium and TNF-Î± associated with the cell in vitro</span></div><div class="casAuthors">Grattendick, K. J.; Nakashima, J. M.; Feng, L.; Giri, S. N.; Margolin, S. B.</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-687</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Tumor necrosis factor-alpha (TNF-Î±) is a vital component of the inflammatory process and its aberrant over-expression has been linked to numerous disease states.  New treatment strategies have sought to reduce circulating TNF-Î±, either with neutralizing anti-TNF-Î± binding proteins such as etanercept or via drugs that inhibit de novo TNF-Î± synthesis like pirfenidone.  In the present study, we examd. the effects of both classes of drugs on secreted and cell-assocd. TNF-Î± produced by THP-1 cells.  All of the tested drugs significantly reduced secreted levels of bioactive TNF-Î± following stimulation with LPS as measured by bioassay.  However, etanercept-treated cells had approx. six-fold higher levels of cell-assocd. TNF-Î± compared with that of the LPS-alone treatment group.  Surprisingly, LPS + infliximab treated cells did not increase cell-assocd. TNF-Î± relative to the LPS-alone treatment.  Pirfenidone significantly reduced both secreted and cell-assocd. TNF-Î± levels.  These drug-related differences in cell-assocd. TNF-Î± may have broad implications in the future for the therapeutic uses of anti-TNF-Î± drugs in the management of TNF-Î± diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFjtVozp1Ru7Vg90H21EOLACvtfcHk0ljvcGCePeFmbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlCqurs%253D&md5=091be3ebb4b611acde0c97fad6d2e9f4</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2008.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2008.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DGrattendick%26aufirst%3DK.%2BJ.%26aulast%3DNakashima%26aufirst%3DJ.%2BM.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DGiri%26aufirst%3DS.%2BN.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26atitle%3DEffects%2520of%2520three%2520anti-TNF-alpha%2520drugs%253A%2520etanercept%252C%2520infliximab%2520and%2520pirfenidone%2520on%2520release%2520of%2520TNF-alpha%2520in%2520medium%2520and%2520TNF-alpha%2520associated%2520with%2520the%2520cell%2520in%2520vitro%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2008%26volume%3D8%26spage%3D679%26epage%3D687%26doi%3D10.1016%2Fj.intimp.2008.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurokawa, K.</span></span> <span> </span><span class="NLM_article-title">Pirfenidone improves renal function and fibrosis in the post-obstructed kidney</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">99</span>â <span class="NLM_lpage">109</span>, <span class="refDoi">Â DOI: 10.1046/j.1523-1755.1998.00962.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1046%2Fj.1523-1755.1998.00962.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=9648068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADyaK1cXksVyhs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=99-109&author=T.+Shimizuauthor=T.+Kurodaauthor=S.+Hataauthor=M.+Fukagawaauthor=S.+B.+Margolinauthor=K.+Kurokawa&title=Pirfenidone+improves+renal+function+and+fibrosis+in+the+post-obstructed+kidney&doi=10.1046%2Fj.1523-1755.1998.00962.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone improves renal function and fibrosis in the post-obstructed kidney</span></div><div class="casAuthors">Shimizu, Toshikatsu; Kuroda, Takayuki; Hata, Satoshi; Fukagawa, Masafumi; Margolin, Solomon B.; Kurokawa, Kiyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-109</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">Pirfenidone (PFD) is a novel anti-fibrotic agent that can prevent and even reverse extracellular matrix accumulation in several organs, as shown by exptl. and clin. studies.  Unilateral ureteral obstruction (UUO) is a well-characterized model of exptl. renal disease culminating in tubulointerstitial fibrosis.  UUO or sham-operated rats were administered PFD (500 mg/kg/day) in their food for 21 days to examine the effect on collagen prodn.  The renal function was measured in the kidney after release of obstruction which had been maintained for one week to examine the effects of PFD on restoration after renal dysfunction.  The collagen content detected by hydroxyproline progressively increased in kidney with UUO for 21 days.  These increases were significantly suppressed by administration of PFD.  PFD had no effect on collagen prodn. in sham-operated rats.  Expression of mRNA for type IV and I collagen and matrix metalloproteinase-2 in the cortex increased with UUO, but was inhibited by PFD treatment.  The levels of cortical transforming growth factor-Î² (TGF-Î²) mRNA progressively rose with UUO for 21 days, but this increase also could be suppressed by PFD.  Inulin clearance of the obstructed kidney was markedly depressed and remained low at five weeks after release.  A progressive increase in hydroxyproline content was also obsd. in the post-obstructed kidney despite the release of obstruction.  Administration of PFD following the release not only attenuated collagen accumulation, but also induced recovery of the impaired renal function.  These results demonstrate that PFD can attenuate both renal fibrosis and renal damage in this model, and suggest that PFD can be clin. useful for preventing progressive, irreversible renal failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr01Lihr_mS2bVg90H21EOLACvtfcHk0ljqcfMwAphJ1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksVyhs7s%253D&md5=6d2c506191da06ef8af90d3021464139</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1046%2Fj.1523-1755.1998.00962.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1523-1755.1998.00962.x%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DKuroda%26aufirst%3DT.%26aulast%3DHata%26aufirst%3DS.%26aulast%3DFukagawa%26aufirst%3DM.%26aulast%3DMargolin%26aufirst%3DS.%2BB.%26aulast%3DKurokawa%26aufirst%3DK.%26atitle%3DPirfenidone%2520improves%2520renal%2520function%2520and%2520fibrosis%2520in%2520the%2520post-obstructed%2520kidney%26jtitle%3DKidney%2520Int.%26date%3D1998%26volume%3D54%26spage%3D99%26epage%3D109%26doi%3D10.1046%2Fj.1523-1755.1998.00962.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costabel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glassberg, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kardatzke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancaster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szwarcberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeyre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">du Bois, R. M.</span></span> <span> </span><span class="NLM_article-title">Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1760</span>â <span class="NLM_lpage">1769</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(11)60405-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2FS0140-6736%2811%2960405-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=21571362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtl2ktrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2011&pages=1760-1769&author=P.+W.+Nobleauthor=C.+Alberaauthor=W.+Z.+Bradfordauthor=U.+Costabelauthor=M.+K.+Glassbergauthor=D.+Kardatzkeauthor=T.+E.+Kingauthor=L.+Lancasterauthor=S.+A.+Sahnauthor=J.+Szwarcbergauthor=D.+Valeyreauthor=R.+M.+du+Bois&title=Pirfenidone+in+patients+with+idiopathic+pulmonary+fibrosis+%28CAPACITY%29%3A+two+randomised+trials&doi=10.1016%2FS0140-6736%2811%2960405-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials</span></div><div class="casAuthors">Noble, Paul W.; Albera, Carlo; Bradford, Williamson Z.; Costabel, Ulrich; Glassberg, Marilyn K.; Kardatzke, David; King, Talmadge E., Jr.; Lancaster, Lisa; Sahn, Steven A.; Szwarcberg, Javier; Valeyre, Dominique; du Bois, Roland M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9779</span>),
    <span class="NLM_cas:pages">1760-1769</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function.  The CAPACITY program (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis.  In two concurrent trials (004 and 006), patients (aged 40-80 years) with idiopathic pulmonary fibrosis were randomly assigned to oral pirfenidone or placebo for a min. of 72 wk in 110 centers in Australia, Europe, and North America.  In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo.  The randomization code (permuted block design) was computer generated and stratified by region.  All study personnel were masked to treatment group assignment until after final database lock.  Treatments were administered orally, 801 mg or 399 mg three times a day.  The primary endpoint was change in percentage predicted forced vital capacity (FVC) at week 72.  Anal. was by intention to treat.  The studies are registered with ClinicalTrials.gov, nos. NCT00287729 and NCT00287716.  In study 004, 174 of 435 patients were assigned to pirfenidone 2403 mg/day, 87 to pirfenidone 1197 mg/day, and 174 to placebo.  In study 006, 171 of 344 patients were assigned to pirfenidone 2403 mg/day, and 173 to placebo.  All patients in both studies were analyzed.  In study 004, pirfenidone reduced decline in FVC (p = 0.001).  Mean FVC change at week 72 was -8.0% (SD 16.5) in the pirfenidone 2403 mg/day group and -12.4% (18.5) in the placebo group (difference 4.4%, 95% CI 0.7 to 9.1); 35 (20%) of 174 vs. 60 (35%) of 174 patients, resp., had a decline of at least 10%.  A significant treatment effect was noted at all timepoints from week 24 and in an anal. over all study timepoints (p = 0.0007).  Mean change in percentage FVC in the pirfenidone 1197 mg/day group was intermediate to that in the pirfenidone 2403 mg/day and placebo groups.  In study 006, the difference between groups in FVC change at week 72 was not significant (p = 0.501).  Mean change in FVC at week 72 was -9.0% (SD 19.6) in the pirfenidone group and -9.6% (19.1) in the placebo group, and the difference between groups in predicted FVC change at week 72 was not significant (0.6%, -3.5 to 4.7); however, a consistent pirfenidone effect was apparent until week 48 (p = 0.005) and in an anal. of all study timepoints (p = 0.007).  Patients in the pirfenidone 2403 mg/day group had higher incidences of nausea (125 [36%] of 345 vs 60 [17%] of 347), dyspepsia (66 [19%] vs 26 [7%]), vomiting (47 [14%] vs 15 [4%]), anorexia (37 [11%] vs 13 [4%]), photosensitivity (42 [12%] vs 6 [2%]), rash (111 [32%] vs 40 [12%]), and dizziness (63 [18%] vs 35 [10%]) than did those in the placebo group.  Fewer overall deaths (19 [6%] vs 29 [8%]) and fewer deaths related to idiopathic pulmonary fibrosis (12 [3%] vs 25 [7%]) occurred in the pirfenidone 2403 mg/day groups than in the placebo groups.  The data show pirfenidone has a favorable benefit risk profile and represents an appropriate treatment option for patients with idiopathic pulmonary fibrosis.  Funding: InterMune.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKu0rjQ2oNaLVg90H21EOLACvtfcHk0ljVzAxl_JuSBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtl2ktrg%253D&md5=b32d8b1f0b3b1f8401d3744fc18c662a</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960405-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960405-4%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DAlbera%26aufirst%3DC.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DKardatzke%26aufirst%3DD.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DSahn%26aufirst%3DS.%2BA.%26aulast%3DSzwarcberg%26aufirst%3DJ.%26aulast%3DValeyre%26aufirst%3DD.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26atitle%3DPirfenidone%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%2520%2528CAPACITY%2529%253A%2520two%2520randomised%2520trials%26jtitle%3DLancet%26date%3D2011%26volume%3D377%26spage%3D1760%26epage%3D1769%26doi%3D10.1016%2FS0140-6736%2811%2960405-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohshio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanaoka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teramoto, K.</span></span> <span> </span><span class="NLM_article-title">Tranilast inhibits the function of cancer-associated fibroblasts responsible for the induction of immune suppressor cell types</span>. <i>Scand. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">408</span>â <span class="NLM_lpage">416</span>, <span class="refDoi">Â DOI: 10.1111/sji.12242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1111%2Fsji.12242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25224016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCjtLnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=408-416&author=Y.+Ohshioauthor=J.+Hanaokaauthor=K.+Kontaniauthor=K.+Teramoto&title=Tranilast+inhibits+the+function+of+cancer-associated+fibroblasts+responsible+for+the+induction+of+immune+suppressor+cell+types&doi=10.1111%2Fsji.12242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Tranilast Inhibits the Function of Cancer-Associated Fibroblasts Responsible for the Induction of Immune Suppressor Cell Types</span></div><div class="casAuthors">Ohshio, Y.; Hanaoka, J.; Kontani, K.; Teramoto, K.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">408-416</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cancer-assocd. fibroblasts (CAFs) are the dominant stromal component in the tumor microenvironment (TME), playing crit. roles in generation of pro-tumorigenic TME; however, their contribution to suppression of antitumor immune responses has not been fully understood.  To elucidate the interaction between CAFs and immune suppressor cells, we examd. whether inhibition of CAFs function would impair the induction of immune suppressor cell types in vitro.  In this study, we applied an anti-allergic and antifibrotic agent tranilast, which is used clin., and evaluated a potential of tranilast to serve as a CAFs inhibitor.  CAFs that had been isolated from E.G7 or LLC1 tumor-bearing mice were cultured in the presence of tranilast, and thereafter, CAFs functions on the secretion of some sol. factors as well as the induction of immune suppressor cells were evaluated.  As a result, tranilast inhibited the proliferation of CAFs and reduced the levels of stromal cell-derived factor-1, prostaglandin E2 and transforming growth factor-Î²1 from CAFs in a dose-dependent manner.  On the other hand, tranilast exerted no inhibitory effects on immune cells at doses under 100 Î¼m.  The induction of regulatory T cells and myeloid-derived suppressor cells from their progenitor cells was suppressed in the medium that CAFs had been cultured in the presence of tranilast; however, these findings were not obsd. when those progenitor cells were cultured in the medium contg. tranilast alone.  These data demonstrate that tranilast inhibits CAFs function, which is responsible for the induction of immune suppressor cells, and possesses a potential to serve as a specific CAFs inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaTutpezSASbVg90H21EOLACvtfcHk0ljVzAxl_JuSBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCjtLnJ&md5=c2b90bd44a4b07a1a49db0c53ae91516</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1111%2Fsji.12242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fsji.12242%26sid%3Dliteratum%253Aachs%26aulast%3DOhshio%26aufirst%3DY.%26aulast%3DHanaoka%26aufirst%3DJ.%26aulast%3DKontani%26aufirst%3DK.%26aulast%3DTeramoto%26aufirst%3DK.%26atitle%3DTranilast%2520inhibits%2520the%2520function%2520of%2520cancer-associated%2520fibroblasts%2520responsible%2520for%2520the%2520induction%2520of%2520immune%2520suppressor%2520cell%2520types%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D2014%26volume%3D80%26spage%3D408%26epage%3D416%26doi%3D10.1111%2Fsji.12242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaBlanche, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grip, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serruys, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinker, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willerson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lincoff, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tcheng, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poland, M.</span></span> <span> </span><span class="NLM_article-title">Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1243</span>â <span class="NLM_lpage">1250</span>, <span class="refDoi">Â DOI: 10.1161/01.CIR.0000028335.31300.DA</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2F01.CIR.0000028335.31300.DA" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2002&pages=1243-1250&author=D.+R.+Holmesauthor=M.+Savageauthor=J.+M.+LaBlancheauthor=L.+Gripauthor=P.+W.+Serruysauthor=P.+Fitzgeraldauthor=D.+Fischmanauthor=S.+Goldbergauthor=J.+A.+Brinkerauthor=A.+M.+Zeiherauthor=L.+M.+Shapiroauthor=J.+Willersonauthor=B.+R.+Davisauthor=J.+J.+Fergusonauthor=J.+Popmaauthor=S.+B.+Kingauthor=A.+M.+Lincoffauthor=J.+E.+Tchengauthor=R.+Chanauthor=J.+R.+Granettauthor=M.+Poland&title=Results+of+Prevention+of+REStenosis+with+Tranilast+and+its+Outcomes+%28PRESTO%29+trial&doi=10.1161%2F01.CIR.0000028335.31300.DA"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000028335.31300.DA&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000028335.31300.DA%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DD.%2BR.%26aulast%3DSavage%26aufirst%3DM.%26aulast%3DLaBlanche%26aufirst%3DJ.%2BM.%26aulast%3DGrip%26aufirst%3DL.%26aulast%3DSerruys%26aufirst%3DP.%2BW.%26aulast%3DFitzgerald%26aufirst%3DP.%26aulast%3DFischman%26aufirst%3DD.%26aulast%3DGoldberg%26aufirst%3DS.%26aulast%3DBrinker%26aufirst%3DJ.%2BA.%26aulast%3DZeiher%26aufirst%3DA.%2BM.%26aulast%3DShapiro%26aufirst%3DL.%2BM.%26aulast%3DWillerson%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DB.%2BR.%26aulast%3DFerguson%26aufirst%3DJ.%2BJ.%26aulast%3DPopma%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DS.%2BB.%26aulast%3DLincoff%26aufirst%3DA.%2BM.%26aulast%3DTcheng%26aufirst%3DJ.%2BE.%26aulast%3DChan%26aufirst%3DR.%26aulast%3DGranett%26aufirst%3DJ.%2BR.%26aulast%3DPoland%26aufirst%3DM.%26atitle%3DResults%2520of%2520Prevention%2520of%2520REStenosis%2520with%2520Tranilast%2520and%2520its%2520Outcomes%2520%2528PRESTO%2529%2520trial%26jtitle%3DCirculation%26date%3D2002%26volume%3D106%26spage%3D1243%26epage%3D1250%26doi%3D10.1161%2F01.CIR.0000028335.31300.DA" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, S. K.</span></span> <span> </span><span class="NLM_article-title">Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">811</span>â <span class="NLM_lpage">818</span>, <span class="refDoi">Â DOI: 10.1517/13543784.17.5.811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1517%2F13543784.17.5.811" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=811-818&author=S.+K.+Field&title=Roflumilast%3A+an+oral%2C+once-daily+selective+PDE-4+inhibitor+for+the+management+of+COPD+and+asthma&doi=10.1517%2F13543784.17.5.811"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1517%2F13543784.17.5.811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.17.5.811%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DS.%2BK.%26atitle%3DRoflumilast%253A%2520an%2520oral%252C%2520once-daily%2520selective%2520PDE-4%2520inhibitor%2520for%2520the%2520management%2520of%2520COPD%2520and%2520asthma%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D811%26epage%3D818%26doi%3D10.1517%2F13543784.17.5.811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span> <span> </span><span class="NLM_article-title">C3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-Î²/smad3 and IKBÎ± pathway</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e113639</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0113639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1371%2Fjournal.pone.0113639" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e113639&author=J.+Liauthor=Q.+Yinauthor=X.+Tangauthor=L.+Baiauthor=J.+Zhangauthor=S.+Gouauthor=H.+Zhuauthor=J.+Chengauthor=P.+Fuauthor=F.+Liu&title=C3a+receptor+antagonist+ameliorates+inflammatory+and+fibrotic+signals+in+type+2+diabetic+nephropathy+by+suppressing+the+activation+of+TGF-%CE%B2%2Fsmad3+and+IKB%CE%B1+pathway&doi=10.1371%2Fjournal.pone.0113639"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0113639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0113639%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DQ.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DF.%26atitle%3DC3a%2520receptor%2520antagonist%2520ameliorates%2520inflammatory%2520and%2520fibrotic%2520signals%2520in%2520type%25202%2520diabetic%2520nephropathy%2520by%2520suppressing%2520the%2520activation%2520of%2520TGF-%25CE%25B2%252Fsmad3%2520and%2520IKB%25CE%25B1%2520pathway%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De113639%26doi%3D10.1371%2Fjournal.pone.0113639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giannetta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isidori, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galea, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandosi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizza, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenzi, A.</span></span> <span> </span><span class="NLM_article-title">Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2323</span>â <span class="NLM_lpage">2333</span>, <span class="refDoi">Â DOI: 10.1161/CIRCULATIONAHA.111.063412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2FCIRCULATIONAHA.111.063412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22496161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1arsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=2323-2333&author=E.+Giannettaauthor=A.+M.+Isidoriauthor=N.+Galeaauthor=I.+Carboneauthor=E.+Mandosiauthor=C.+D.+Vizzaauthor=F.+Naroauthor=S.+Moranoauthor=F.+Fedeleauthor=A.+Lenzi&title=Chronic+Inhibition+of+cGMP+phosphodiesterase+5A+improves+diabetic+cardiomyopathy%3A+a+randomized%2C+controlled+clinical+trial+using+magnetic+resonance+imaging+with+myocardial+tagging&doi=10.1161%2FCIRCULATIONAHA.111.063412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy: A Randomized, Controlled Clinical Trial Using Magnetic Resonance Imaging With Myocardial Tagging</span></div><div class="casAuthors">Giannetta, Elisa; Isidori, Andrea M.; Galea, Nicola; Carbone, Iacopo; Mandosi, Elisabetta; Vizza, Carmine D.; Naro, Fabio; Morano, Susanna; Fedele, Francesco; Lenzi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2323-2333</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND-: cGMP phosphodiesterase type 5 protein is upregulated in myocardial hypertrophy.  However, it has never been ascertained whether phosphodiesterase type 5 inhibition exerts an antiremodeling effect in nonischemic heart disease in humans.  We explored the cardioreparative properties of a selective phosphodiesterase type 5 inhibitor, sildenafil, in a model of diabetic cardiomyopathy.  METHODS AND RESULTS-: Fifty-nine diabetic men (60.3Â±7.4 years) with cardiac magnetic resonance imaging consistent with nonischemic, nonfailing diabetic cardiomyopathy (reduced circumferential strain [Ï], -12.6Â±3.1; increased left ventricular [LV] torsion [Î¸], 18.4Â±4.6Â°; and increased ratio of LV mass to vol., 2.1Â±0.5 g/mL) were randomized to receive sildenafil or placebo (100 mg/d).  At baseline, the metabolic indexes were correlated with torsion, strain, N-terminal pro-B-type natriuretic peptide, vascular endothelial growth factor, monocyte chemotactic protein-1, and blood pressure.  After 3 mo, sildenafil produced a significant improvement compared with placebo in LV torsion (ÎÎ¸: sildenafil, -3.89Â±3.11Â° vs. placebo, 2.13Â±2.35Â°; P<0.001) and strain (ÎÏ: sildenafil, -3.30Â±1.86 vs. placebo, 1.22Â±1.84; P<0.001).  Sildenafil-induced improvement of LV contraction was accompanied by consistent changes in chamber geometry and performance, with a 6.5Â±11 improvement in mass-to-vol. ratio over placebo (P=0.021).  Monocyte chemotactic protein-1 and transforming growth factor-Î² were the only markers affected by active treatment (Îmonocyte chemotactic protein-1: -75.30Â±159.28 pg/mL, P=0.032; Îtransforming growth factor-Î²: 5.26Â±9.67 ng/mL, P=0.009).  No changes were found in endothelial function, afterload, or metab.  CONCLUSIONS-: The early features of diabetic cardiomyopathy are LV concentric hypertrophy assocd. with altered myocardial contraction dynamics.  Chronic phosphodiesterase type 5 inhibition, at this stage, has an antiremodeling effect, resulting in improved cardiac kinetics and circulating markers.  This effect is independent of any other vasodilatory or endothelial effects and is apparently exerted through a direct intramyocardial action.  Clin. TRIAL REGISTRATION-: URL: http://www.clinicaltrials.gov.  Unique identifier: NCT00692237.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5mdsU_dHU7LVg90H21EOLACvtfcHk0lgX17S06kaecw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1arsrY%253D&md5=7b9bccb98c10f0a024d8c2713792b3bd</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.063412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.063412%26sid%3Dliteratum%253Aachs%26aulast%3DGiannetta%26aufirst%3DE.%26aulast%3DIsidori%26aufirst%3DA.%2BM.%26aulast%3DGalea%26aufirst%3DN.%26aulast%3DCarbone%26aufirst%3DI.%26aulast%3DMandosi%26aufirst%3DE.%26aulast%3DVizza%26aufirst%3DC.%2BD.%26aulast%3DNaro%26aufirst%3DF.%26aulast%3DMorano%26aufirst%3DS.%26aulast%3DFedele%26aufirst%3DF.%26aulast%3DLenzi%26aufirst%3DA.%26atitle%3DChronic%2520Inhibition%2520of%2520cGMP%2520phosphodiesterase%25205A%2520improves%2520diabetic%2520cardiomyopathy%253A%2520a%2520randomized%252C%2520controlled%2520clinical%2520trial%2520using%2520magnetic%2520resonance%2520imaging%2520with%2520myocardial%2520tagging%26jtitle%3DCirculation%26date%3D2012%26volume%3D125%26spage%3D2323%26epage%3D2333%26doi%3D10.1161%2FCIRCULATIONAHA.111.063412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodaragama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chew, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdop, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royce, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitson, T. D.</span></span> <span> </span><span class="NLM_article-title">Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">315</span>â <span class="NLM_lpage">322</span>, <span class="refDoi">Â DOI: 10.1161/HYPERTENSIONAHA.114.03594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2FHYPERTENSIONAHA.114.03594" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2014&pages=315-322&author=C.+S.+Samuelauthor=H.+Bodaragamaauthor=J.+Y.+Chewauthor=R.+E.+Widdopauthor=S.+G.+Royceauthor=T.+D.+Hewitson&title=Serelaxin+is+a+more+efficacious+antifibrotic+than+enalapril+in+an+experimental+model+of+heart+disease&doi=10.1161%2FHYPERTENSIONAHA.114.03594"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.114.03594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.114.03594%26sid%3Dliteratum%253Aachs%26aulast%3DSamuel%26aufirst%3DC.%2BS.%26aulast%3DBodaragama%26aufirst%3DH.%26aulast%3DChew%26aufirst%3DJ.%2BY.%26aulast%3DWiddop%26aufirst%3DR.%2BE.%26aulast%3DRoyce%26aufirst%3DS.%2BG.%26aulast%3DHewitson%26aufirst%3DT.%2BD.%26atitle%3DSerelaxin%2520is%2520a%2520more%2520efficacious%2520antifibrotic%2520than%2520enalapril%2520in%2520an%2520experimental%2520model%2520of%2520heart%2520disease%26jtitle%3DHypertension%26date%3D2014%26volume%3D64%26spage%3D315%26epage%3D322%26doi%3D10.1161%2FHYPERTENSIONAHA.114.03594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lekgabe, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiriazis, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathgate, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, C. S.</span></span> <span> </span><span class="NLM_article-title">Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">412</span>â <span class="NLM_lpage">418</span>, <span class="refDoi">Â DOI: 10.1161/01.HYP.0000171930.00697.2f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2F01.HYP.0000171930.00697.2f" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2005&pages=412-418&author=E.+D.+Lekgabeauthor=H.+Kiriazisauthor=C.+Zhaoauthor=Q.+Xuauthor=X.+L.+Mooreauthor=Y.+Suauthor=R.+A.+D.+Bathgateauthor=X.+J.+Duauthor=C.+S.+Samuel&title=Relaxin+reverses+cardiac+and+renal+fibrosis+in+spontaneously+hypertensive+rats&doi=10.1161%2F01.HYP.0000171930.00697.2f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000171930.00697.2f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000171930.00697.2f%26sid%3Dliteratum%253Aachs%26aulast%3DLekgabe%26aufirst%3DE.%2BD.%26aulast%3DKiriazis%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMoore%26aufirst%3DX.%2BL.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DBathgate%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDu%26aufirst%3DX.%2BJ.%26aulast%3DSamuel%26aufirst%3DC.%2BS.%26atitle%3DRelaxin%2520reverses%2520cardiac%2520and%2520renal%2520fibrosis%2520in%2520spontaneously%2520hypertensive%2520rats%26jtitle%3DHypertension%26date%3D2005%26volume%3D46%26spage%3D412%26epage%3D418%26doi%3D10.1161%2F01.HYP.0000171930.00697.2f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henry, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabris, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shroff, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salama, G.</span></span> <span> </span><span class="NLM_article-title">Relaxin suppresses atrial fibrillation in aged rats by reversing fibrosis and upregulating Na+ channels</span>. <i>Heart Rhythm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">983</span>â <span class="NLM_lpage">991</span>, <span class="refDoi">Â DOI: 10.1016/j.hrthm.2015.12.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.hrthm.2015.12.030" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=983-991&author=B.+L.+Henryauthor=B.+Gabrisauthor=Q.+Liauthor=B.+Martinauthor=M.+Gianniniauthor=A.+Parikhauthor=D.+Patelauthor=J.+Haneyauthor=D.+S.+Schwartzmanauthor=S.+G.+Shroffauthor=G.+Salama&title=Relaxin+suppresses+atrial+fibrillation+in+aged+rats+by+reversing+fibrosis+and+upregulating+Na%2B+channels&doi=10.1016%2Fj.hrthm.2015.12.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.hrthm.2015.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hrthm.2015.12.030%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DB.%2BL.%26aulast%3DGabris%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMartin%26aufirst%3DB.%26aulast%3DGiannini%26aufirst%3DM.%26aulast%3DParikh%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DHaney%26aufirst%3DJ.%26aulast%3DSchwartzman%26aufirst%3DD.%2BS.%26aulast%3DShroff%26aufirst%3DS.%2BG.%26aulast%3DSalama%26aufirst%3DG.%26atitle%3DRelaxin%2520suppresses%2520atrial%2520fibrillation%2520in%2520aged%2520rats%2520by%2520reversing%2520fibrosis%2520and%2520upregulating%2520Na%252B%2520channels%26jtitle%3DHeart%2520Rhythm%26date%3D2016%26volume%3D13%26spage%3D983%26epage%3D991%26doi%3D10.1016%2Fj.hrthm.2015.12.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekgabe, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tregear, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bathgate, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X. J.</span></span> <span> </span><span class="NLM_article-title">Endogenous relaxin does not affect chronic pressure overload-induced cardiac hypertrophy and fibrosis</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">476</span>â <span class="NLM_lpage">482</span>, <span class="refDoi">Â DOI: 10.1210/en.2007-1220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1210%2Fen.2007-1220" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2008&pages=476-482&author=Q.+Xuauthor=E.+D.+Lekgabeauthor=X.+M.+Gaoauthor=Z.+Mingauthor=G.+W.+Tregearauthor=A.+M.+Dartauthor=R.+A.+D.+Bathgateauthor=C.+S.+Samuelauthor=X.+J.+Du&title=Endogenous+relaxin+does+not+affect+chronic+pressure+overload-induced+cardiac+hypertrophy+and+fibrosis&doi=10.1210%2Fen.2007-1220"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1210%2Fen.2007-1220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2007-1220%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLekgabe%26aufirst%3DE.%2BD.%26aulast%3DGao%26aufirst%3DX.%2BM.%26aulast%3DMing%26aufirst%3DZ.%26aulast%3DTregear%26aufirst%3DG.%2BW.%26aulast%3DDart%26aufirst%3DA.%2BM.%26aulast%3DBathgate%26aufirst%3DR.%2BA.%2BD.%26aulast%3DSamuel%26aufirst%3DC.%2BS.%26aulast%3DDu%26aufirst%3DX.%2BJ.%26atitle%3DEndogenous%2520relaxin%2520does%2520not%2520affect%2520chronic%2520pressure%2520overload-induced%2520cardiac%2520hypertrophy%2520and%2520fibrosis%26jtitle%3DEndocrinology%26date%3D2008%26volume%3D149%26spage%3D476%26epage%3D482%26doi%3D10.1210%2Fen.2007-1220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westermann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutschow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Linthout, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linderer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¼cker-GÃ¤rtner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobirey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauschinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultheiss, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TschÃ¶pe, G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2507</span>â <span class="NLM_lpage">2513</span>, <span class="refDoi">Â DOI: 10.1007/s00125-006-0385-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1007%2Fs00125-006-0385-2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2507-2513&author=D.+Westermannauthor=S.+Rutschowauthor=S.+Van+Linthoutauthor=A.+Lindererauthor=C.+B%C3%BCcker-G%C3%A4rtnerauthor=M.+Sobireyauthor=A.+Riadauthor=M.+Pauschingerauthor=H.+P.+Schultheissauthor=G.+Tsch%C3%B6pe&title=Inhibition+of+p38+mitogen-activated+protein+kinase+attenuates+left+ventricular+dysfunction+by+mediating+pro-inflammatory+cardiac+cytokine+levels+in+a+mouse+model+of+diabetes+mellitus&doi=10.1007%2Fs00125-006-0385-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1007%2Fs00125-006-0385-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-006-0385-2%26sid%3Dliteratum%253Aachs%26aulast%3DWestermann%26aufirst%3DD.%26aulast%3DRutschow%26aufirst%3DS.%26aulast%3DVan%2BLinthout%26aufirst%3DS.%26aulast%3DLinderer%26aufirst%3DA.%26aulast%3DB%25C3%25BCcker-G%25C3%25A4rtner%26aufirst%3DC.%26aulast%3DSobirey%26aufirst%3DM.%26aulast%3DRiad%26aufirst%3DA.%26aulast%3DPauschinger%26aufirst%3DM.%26aulast%3DSchultheiss%26aufirst%3DH.%2BP.%26aulast%3DTsch%25C3%25B6pe%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520attenuates%2520left%2520ventricular%2520dysfunction%2520by%2520mediating%2520pro-inflammatory%2520cardiac%2520cytokine%2520levels%2520in%2520a%2520mouse%2520model%2520of%2520diabetes%2520mellitus%26jtitle%3DDiabetologia%26date%3D2006%26volume%3D49%26spage%3D2507%26epage%3D2513%26doi%3D10.1007%2Fs00125-006-0385-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mann, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swedberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borer, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kober, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieminen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavazzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veldhuisen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldenstrom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westheim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zannad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, T.</span></span> <span> </span><span class="NLM_article-title">Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1594</span>â <span class="NLM_lpage">1602</span>, <span class="refDoi">Â DOI: 10.1161/01.CIR.0000124490.27666.B2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2F01.CIR.0000124490.27666.B2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2004&pages=1594-1602&author=D.+L.+Mannauthor=J.+J.+McMurrayauthor=M.+Packerauthor=K.+Swedbergauthor=J.+S.+Borerauthor=W.+S.+Colucciauthor=J.+Djianauthor=H.+Drexlerauthor=A.+Feldmanauthor=L.+Koberauthor=H.+Krumauthor=P.+Liuauthor=M.+Nieminenauthor=L.+Tavazziauthor=D.+J.+van+Veldhuisenauthor=A.+Waldenstromauthor=M.+Warrenauthor=A.+Westheimauthor=F.+Zannadauthor=T.+Fleming&title=Targeted+anticytokine+therapy+in+patients+with+chronic+heart+failure%3A+results+of+the+Randomized+Etanercept+Worldwide+Evaluation+%28RENEWAL%29&doi=10.1161%2F01.CIR.0000124490.27666.B2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000124490.27666.B2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000124490.27666.B2%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DD.%2BL.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26aulast%3DPacker%26aufirst%3DM.%26aulast%3DSwedberg%26aufirst%3DK.%26aulast%3DBorer%26aufirst%3DJ.%2BS.%26aulast%3DColucci%26aufirst%3DW.%2BS.%26aulast%3DDjian%26aufirst%3DJ.%26aulast%3DDrexler%26aufirst%3DH.%26aulast%3DFeldman%26aufirst%3DA.%26aulast%3DKober%26aufirst%3DL.%26aulast%3DKrum%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DNieminen%26aufirst%3DM.%26aulast%3DTavazzi%26aufirst%3DL.%26aulast%3Dvan%2BVeldhuisen%26aufirst%3DD.%2BJ.%26aulast%3DWaldenstrom%26aufirst%3DA.%26aulast%3DWarren%26aufirst%3DM.%26aulast%3DWestheim%26aufirst%3DA.%26aulast%3DZannad%26aufirst%3DF.%26aulast%3DFleming%26aufirst%3DT.%26atitle%3DTargeted%2520anticytokine%2520therapy%2520in%2520patients%2520with%2520chronic%2520heart%2520failure%253A%2520results%2520of%2520the%2520Randomized%2520Etanercept%2520Worldwide%2520Evaluation%2520%2528RENEWAL%2529%26jtitle%3DCirculation%26date%3D2004%26volume%3D109%26spage%3D1594%26epage%3D1602%26doi%3D10.1161%2F01.CIR.0000124490.27666.B2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasanmade, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willerson, J. T.</span></span> <span> </span><span class="NLM_article-title">and the anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">3133</span>â <span class="NLM_lpage">3140</span>, <span class="refDoi">Â DOI: 10.1161/01.CIR.0000077913.60364.D2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2F01.CIR.0000077913.60364.D2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2003&pages=3133-3140&author=E.+S.+Chungauthor=M.+Packerauthor=K.+H.+Loauthor=A.+A.+Fasanmadeauthor=J.+T.+Willerson&title=and+the+anti-TNF+therapy+against+congestive+heart+failure+investigators.+Randomized%2C+double-blind%2C+placebo-controlled%2C+pilot+trial+of+infliximab%2C+a+chimeric+monoclonal+antibody+to+tumor+necrosis+factor-alpha%2C+in+patients+with+moderate-to-severe+heart+failure%3A+results+of+the+anti-TNF+therapy+against+congestive+heart+failure+%28ATTACH%29+trial&doi=10.1161%2F01.CIR.0000077913.60364.D2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000077913.60364.D2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000077913.60364.D2%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DE.%2BS.%26aulast%3DPacker%26aufirst%3DM.%26aulast%3DLo%26aufirst%3DK.%2BH.%26aulast%3DFasanmade%26aufirst%3DA.%2BA.%26aulast%3DWillerson%26aufirst%3DJ.%2BT.%26atitle%3Dand%2520the%2520anti-TNF%2520therapy%2520against%2520congestive%2520heart%2520failure%2520investigators.%2520Randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520pilot%2520trial%2520of%2520infliximab%252C%2520a%2520chimeric%2520monoclonal%2520antibody%2520to%2520tumor%2520necrosis%2520factor-alpha%252C%2520in%2520patients%2520with%2520moderate-to-severe%2520heart%2520failure%253A%2520results%2520of%2520the%2520anti-TNF%2520therapy%2520against%2520congestive%2520heart%2520failure%2520%2528ATTACH%2529%2520trial%26jtitle%3DCirculation%26date%3D2003%26volume%3D107%26spage%3D3133%26epage%3D3140%26doi%3D10.1161%2F01.CIR.0000077913.60364.D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. B.</span></span> <span> </span><span class="NLM_article-title">Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">591</span>â <span class="NLM_lpage">597</span>, <span class="refDoi">Â DOI: 10.1161/HYPERTENSIONAHA.109.131243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1161%2FHYPERTENSIONAHA.109.131243" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=591-597&author=S.+A.+Changauthor=Y.+J.+Kimauthor=H.+W.+Leeauthor=D.+H.+Kimauthor=H.+K.+Kimauthor=H.+J.+Changauthor=D.+W.+Sohnauthor=B.+H.+Ohauthor=Y.+B.+Park&title=Effect+of+rosuvastatin+on+cardiac+remodeling%2C+function%2C+and+progression+to+heart+failure+in+hypertensive+heart+with+established+left+ventricular+hypertrophy&doi=10.1161%2FHYPERTENSIONAHA.109.131243"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.109.131243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.109.131243%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%2BA.%26aulast%3DKim%26aufirst%3DY.%2BJ.%26aulast%3DLee%26aufirst%3DH.%2BW.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BK.%26aulast%3DChang%26aufirst%3DH.%2BJ.%26aulast%3DSohn%26aufirst%3DD.%2BW.%26aulast%3DOh%26aufirst%3DB.%2BH.%26aulast%3DPark%26aufirst%3DY.%2BB.%26atitle%3DEffect%2520of%2520rosuvastatin%2520on%2520cardiac%2520remodeling%252C%2520function%252C%2520and%2520progression%2520to%2520heart%2520failure%2520in%2520hypertensive%2520heart%2520with%2520established%2520left%2520ventricular%2520hypertrophy%26jtitle%3DHypertension%26date%3D2009%26volume%3D54%26spage%3D591%26epage%3D597%26doi%3D10.1161%2FHYPERTENSIONAHA.109.131243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kjekshus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apetrei, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¶hm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleland, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunselman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grande, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullestad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjalmarson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hradec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">JÃ¡nosi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KamenskÃ½, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komajda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korewicki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuusi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mareev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranjith, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaufelberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaecke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veldhuisen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waagstein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrand, J.</span></span> <span> </span><span class="NLM_article-title">Rosuvastatin in older patients with systolic heart failure</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">2248</span>â <span class="NLM_lpage">2261</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa0706201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1056%2FNEJMoa0706201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17984166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVSlsLvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=2248-2261&author=J.+Kjekshusauthor=E.+Apetreiauthor=V.+Barriosauthor=M.+B%C3%B6hmauthor=J.+G.+Clelandauthor=J.+H.+Cornelauthor=P.+Dunselmanauthor=C.+Fonsecaauthor=A.+Goudevauthor=P.+Grandeauthor=L.+Gullestadauthor=A.+Hjalmarsonauthor=J.+Hradecauthor=A.+J%C3%A1nosiauthor=G.+Kamensk%C3%BDauthor=M.+Komajdaauthor=J.+Korewickiauthor=T.+Kuusiauthor=F.+Machauthor=V.+Mareevauthor=J.+J.+V.+McMurrayauthor=N.+Ranjithauthor=M.+Schaufelbergerauthor=J.+Vanhaeckeauthor=D.+J.+van+Veldhuisenauthor=F.+Waagsteinauthor=H.+Wedelauthor=J.+Wikstrand&title=Rosuvastatin+in+older+patients+with+systolic+heart+failure&doi=10.1056%2FNEJMoa0706201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Rosuvastatin in older patients with systolic heart failure</span></div><div class="casAuthors">Kjekshus, John; Apetrei, Eduard; Barrios, Vivencio; Bohm, Michael; Cleland, John G. F.; Cornel, Jan H.; Dunselman, Peter; Fonseca, Candida; Goudev, Assen; Grande, Peer; Gullestad, Lars; Hjalmarson, Ake; Hradec, Jaromir; Janosi, Andras; Kamensky, Gabriel; Komajda, Michel; Korewicki, Jerzy; Kuusi, Timo; Mach, Francois; Mareev, Vycheslav; McMurray, John J. V.; Ranjith, Naresh; Schaufelberger, Maria; Vanhaecke, Johan; van Veldhuisen, Dirk J.; Waagstein, Finn; Wedel, Hans; Wikstrand, John; Aires, N.; Janson, L.; Dunselman, P.; Hjalmarson, A.; Waagstein, F.; Kjekshus, J.; McMurray, J.; Wedel, H.; Wikstrand, J.; Dargie, H.; DeMets, D.; Collins, R.; Feyzi, J.; Massie, B.; Fredlund, B.-O.; Holmberg, M.; Saldeen, K.; Swedberg, K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2248-2261</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Patients with systolic heart failure have generally been excluded from statin trials.  Acute coronary events are uncommon in this population, and statins have theor. risks in these patients.  A total of 5011 patients at least 60 years of age with New York Heart Assocn. class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day.  The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.  Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the no. of hospitalizations.  As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-d. lipoprotein cholesterol (difference between groups, 45.0%; P < 0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P < 0.001).  During a median follow-up of 32.8 mo, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P = 0.12), and 728 patients and 759 patients, resp., died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P = 0.31).  There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes.  In a prespecified secondary anal., there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P < 0.001).  No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group.  Rosuvastatin did not reduce the primary outcome or the no. of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the no. of cardiovascular hospitalizations.  The drug did not cause safety problems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXVo6yWc5QT7Vg90H21EOLACvtfcHk0lg1JjNBnIU83w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVSlsLvI&md5=4f72e238de430c30369ab3ea8548096c</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0706201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0706201%26sid%3Dliteratum%253Aachs%26aulast%3DKjekshus%26aufirst%3DJ.%26aulast%3DApetrei%26aufirst%3DE.%26aulast%3DBarrios%26aufirst%3DV.%26aulast%3DB%25C3%25B6hm%26aufirst%3DM.%26aulast%3DCleland%26aufirst%3DJ.%2BG.%26aulast%3DCornel%26aufirst%3DJ.%2BH.%26aulast%3DDunselman%26aufirst%3DP.%26aulast%3DFonseca%26aufirst%3DC.%26aulast%3DGoudev%26aufirst%3DA.%26aulast%3DGrande%26aufirst%3DP.%26aulast%3DGullestad%26aufirst%3DL.%26aulast%3DHjalmarson%26aufirst%3DA.%26aulast%3DHradec%26aufirst%3DJ.%26aulast%3DJ%25C3%25A1nosi%26aufirst%3DA.%26aulast%3DKamensk%25C3%25BD%26aufirst%3DG.%26aulast%3DKomajda%26aufirst%3DM.%26aulast%3DKorewicki%26aufirst%3DJ.%26aulast%3DKuusi%26aufirst%3DT.%26aulast%3DMach%26aufirst%3DF.%26aulast%3DMareev%26aufirst%3DV.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%2BV.%26aulast%3DRanjith%26aufirst%3DN.%26aulast%3DSchaufelberger%26aufirst%3DM.%26aulast%3DVanhaecke%26aufirst%3DJ.%26aulast%3Dvan%2BVeldhuisen%26aufirst%3DD.%2BJ.%26aulast%3DWaagstein%26aufirst%3DF.%26aulast%3DWedel%26aufirst%3DH.%26aulast%3DWikstrand%26aufirst%3DJ.%26atitle%3DRosuvastatin%2520in%2520older%2520patients%2520with%2520systolic%2520heart%2520failure%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D2248%26epage%3D2261%26doi%3D10.1056%2FNEJMoa0706201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavazzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggioni, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchioli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzosi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolosi, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognoni, G.</span></span>; <span class="NLM_contrib-group">GISSI-HF Investigators</span> <span> </span><span class="NLM_article-title">Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1231</span>â <span class="NLM_lpage">1239</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(08)61240-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2FS0140-6736%2808%2961240-4" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2008&pages=1231-1239&author=L.+Tavazziauthor=A.+P.+Maggioniauthor=R.+Marchioliauthor=S.+Barleraauthor=M.+G.+Franzosiauthor=R.+Latiniauthor=D.+Lucciauthor=G.+L.+Nicolosiauthor=M.+Porcuauthor=G.+Tognoniauthor=GISSI-HF+Investigators&title=Effect+of+rosuvastatin+in+patients+with+chronic+heart+failure+%28the+GISSI-HF+trial%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2FS0140-6736%2808%2961240-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2961240-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252961240-4%26sid%3Dliteratum%253Aachs%26aulast%3DTavazzi%26aufirst%3DL.%26aulast%3DMaggioni%26aufirst%3DA.%2BP.%26aulast%3DMarchioli%26aufirst%3DR.%26aulast%3DBarlera%26aufirst%3DS.%26aulast%3DFranzosi%26aufirst%3DM.%2BG.%26aulast%3DLatini%26aufirst%3DR.%26aulast%3DLucci%26aufirst%3DD.%26aulast%3DNicolosi%26aufirst%3DG.%2BL.%26aulast%3DPorcu%26aufirst%3DM.%26aulast%3DTognoni%26aufirst%3DG.%26aulast%3D%26atitle%3DEffect%2520of%2520rosuvastatin%2520in%2520patients%2520with%2520chronic%2520heart%2520failure%2520%2528the%2520GISSI-HF%2520trial%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%26date%3D2008%26volume%3D372%26spage%3D1231%26epage%3D1239%26doi%3D10.1016%2FS0140-6736%2808%2961240-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalff, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amarena, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonkin, A.</span></span> <span> </span><span class="NLM_article-title">Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure</span>. <i>J. Card. Failure</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">7</span>, <span class="refDoi">Â DOI: 10.1016/j.cardfail.2006.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.cardfail.2006.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17338996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitl2jtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1-7&author=H.+Krumauthor=E.+Ashtonauthor=C.+Reidauthor=V.+Kalffauthor=J.+Rogersauthor=J.+Amarenaauthor=B.+Singhauthor=A.+Tonkin&title=Double-blind%2C+randomized%2C+placebo-controlled+study+of+high-dose+HMG+CoA+reductase+inhibitor+therapy+on+ventricular+remodeling%2C+pro-inflammatory+cytokines+and+neurohormonal+parameters+in+patients+with+chronic+systolic+heart+failure&doi=10.1016%2Fj.cardfail.2006.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Double-Blind, Randomized, Placebo-Controlled Study of High-Dose HMG CoA Reductase Inhibitor Therapy on Ventricular Remodeling, Pro-Inflammatory Cytokines and Neurohormonal Parameters in Patients With Chronic Systolic Heart Failure</span></div><div class="casAuthors">Krum, Henry; Ashton, Emma; Reid, Christopher; Kalff, Victor; Rogers, Jim; Amarena, John; Singh, Bhuwan; Tonkin, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiac Failure</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">JCFAF9</span>;
        ISSN:<span class="NLM_cas:issn">1071-9164</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: Statins decrease mortality in patients with coronary artery disease.  However, chronic heart failure (CHF) patients were often excluded in such trials.  Statins possess pharmacol. properties (independent of cholesterol lowering) that may be beneficial on ventricular remodeling in such patients.  Methods and Results: We conducted a 6-mo randomized placebo (PBO)-controlled study of rosuvastatin (ROS) in patients with systolic (left ventricular ejection fraction [LVEF] <40%) CHF of ischemic or nonischemic etiol.  The primary end point was change in LVEF by radionuclide ventriculogram.  Secondary end points included change in echocardiog. parameters, neurohormonal and inflammatory markers, Packer composite score, death, and heart failure hospitalization.  Patients were well matched for baseline values.  Compared with PBO (n = 46), ROS patients (n = 40) had a decrease in low-d. lipoprotein cholesterol (PBO +3, ROS -54%, P < .001).  There was no significant change in LVEF by radionuclide ventriculogram (PBO +5.3, ROS +3.2%), fractional shortening by echocardiog. (PBO +2.7, ROS +1.8%), left ventricular end-diastolic diam. (PBO -1.7, ROS +0.8 mm), left ventricular end-systolic diam. (PBO -1.9, ROS +0.1 mm).  Plasma norepinephrine, endothelin-1, brain natriuretic peptide, hsCRP, tumor necrosis factor-Î± and interleukin-6, patient global assessment, Packer composite, death/heart failure hospitalization, and adverse events were similar between PBO and ROS.  Conclusions: Despite being safe and effective at decreasing plasma cholesterol, high-dose ROS did not beneficially alter parameters of LV remodeling.  Reasons for absence of benefit are uncertain, but may include patient population studied, high dose of ROS used or high use of effective background CHF medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbh9jEbKtaEbVg90H21EOLACvtfcHk0lgk3aGnqNSp4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitl2jtbw%253D&md5=786f1803c3291366fd8a39e3abefe85b</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.cardfail.2006.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardfail.2006.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DKrum%26aufirst%3DH.%26aulast%3DAshton%26aufirst%3DE.%26aulast%3DReid%26aufirst%3DC.%26aulast%3DKalff%26aufirst%3DV.%26aulast%3DRogers%26aufirst%3DJ.%26aulast%3DAmarena%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DTonkin%26aufirst%3DA.%26atitle%3DDouble-blind%252C%2520randomized%252C%2520placebo-controlled%2520study%2520of%2520high-dose%2520HMG%2520CoA%2520reductase%2520inhibitor%2520therapy%2520on%2520ventricular%2520remodeling%252C%2520pro-inflammatory%2520cytokines%2520and%2520neurohormonal%2520parameters%2520in%2520patients%2520with%2520chronic%2520systolic%2520heart%2520failure%26jtitle%3DJ.%2520Card.%2520Failure%26date%3D2007%26volume%3D13%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.cardfail.2006.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salomone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeber, C.</span></span> <span> </span><span class="NLM_article-title">Selectivity and specificity of sphingosine-1-phosphate receptor ligands: cavats and critical thinking in characterizing receptor-mediated effects</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">9</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2011.00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2011.00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=21687504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC3MnhvV2qsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=9&author=S.+Salomoneauthor=C.+Waeber&title=Selectivity+and+specificity+of+sphingosine-1-phosphate+receptor+ligands%3A+cavats+and+critical+thinking+in+characterizing+receptor-mediated+effects&doi=10.3389%2Ffphar.2011.00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects</span></div><div class="casAuthors">Salomone Salvatore; Waeber Christian</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Receptors for sphingosine-1-phosphate (S1P) have been identified only recently.  Their medicinal chemistry is therefore still in its infancy, and few selective agonists or antagonists are available.  Furthermore, the selectivity of S1P receptor agonists or antagonists is not well established.  JTE-013 and BML-241 (also known as CAY10444), used extensively as specific S1P(2) and S1P(3) receptors antagonists respectively, are cases in point.  When analyzing S1P-induced vasoconstriction in mouse basilar artery, we observed that JTE-013 inhibited not only the effect of S1P, but also the effect of U46619, endothelin-1 or high KCl; JTE-013 strongly inhibited responses to S1P in S1P(2) receptor knockout mice.  Similarly, BML-241 has been shown to inhibit increases in intracellular Ca(2+) concentration via P(2) receptor or Î±(1A)-adrenoceptor stimulation and Î±(1A)-adrenoceptor-mediated contraction of rat mesenteric artery, while it did not affect S1P(3)-mediated decrease of forskolin-induced cyclic AMP accumulation.  Another putative S1P(1/3) receptor antagonist, VPC23019, does not inhibit S1P(3)-mediated vasoconstriction.  With these examples in mind, we discuss caveats about relying on available pharmacological tools to characterize receptor subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStGLeNXz9auf9pSBfyDvp7fW6udTcc2eaBFkjj0OLPpbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnhvV2qsg%253D%253D&md5=287e62b7cf54d8bc5a73b2ca0abd79a1</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2011.00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2011.00009%26sid%3Dliteratum%253Aachs%26aulast%3DSalomone%26aufirst%3DS.%26aulast%3DWaeber%26aufirst%3DC.%26atitle%3DSelectivity%2520and%2520specificity%2520of%2520sphingosine-1-phosphate%2520receptor%2520ligands%253A%2520cavats%2520and%2520critical%2520thinking%2520in%2520characterizing%2520receptor-mediated%2520effects%26jtitle%3DFront.%2520Pharmacol.%26date%3D2011%26volume%3D2%26spage%3D9%26doi%3D10.3389%2Ffphar.2011.00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezuhly, M.</span></span> <span> </span><span class="NLM_article-title">Modulation of angiotensin II signaling in the prevention of fibrosis</span>. <i>Fibrog. Tissue Repair</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">7</span>, <span class="refDoi">Â DOI: 10.1186/s13069-015-0023-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1186%2Fs13069-015-0023-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25949522" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=7&author=A.+M.+Murphyauthor=A.+L.+Wongauthor=M.+Bezuhly&title=Modulation+of+angiotensin+II+signaling+in+the+prevention+of+fibrosis&doi=10.1186%2Fs13069-015-0023-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1186%2Fs13069-015-0023-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13069-015-0023-z%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DA.%2BM.%26aulast%3DWong%26aufirst%3DA.%2BL.%26aulast%3DBezuhly%26aufirst%3DM.%26atitle%3DModulation%2520of%2520angiotensin%2520II%2520signaling%2520in%2520the%2520prevention%2520of%2520fibrosis%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2015%26volume%3D8%26spage%3D7%26doi%3D10.1186%2Fs13069-015-0023-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alzayadneh, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, M. C.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-(1â7) abolishes AGE-induced cellular hypertrophy and myofibroblasts transformation via inhibition of ERK1/2</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3027</span>â <span class="NLM_lpage">3035</span>, <span class="refDoi">Â DOI: 10.1016/j.cellsig.2014.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.cellsig.2014.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25246357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2gsr7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=3027-3035&author=E.+M.+Alzayadnehauthor=M.+C.+Chappell&title=Angiotensin-%281%E2%80%937%29+abolishes+AGE-induced+cellular+hypertrophy+and+myofibroblasts+transformation+via+inhibition+of+ERK1%2F2&doi=10.1016%2Fj.cellsig.2014.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-(1-7) abolishes AGE-induced cellular hypertrophy and myofibroblast transformation via inhibition of ERK1/2</span></div><div class="casAuthors">Alzayadneh, Ebaa M.; Chappell, Mark C.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3027-3035</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Angiotensin-(1-7) (Ang-(1-7))/AT7-Mas receptor axis is an alternative pathway within the renin-angiotensin system (RAS) that generally opposes the actions of Ang II/AT1 receptor pathway.  Advanced glycated end product (AGEs) including glucose- and methylglyoxal-modified albumin (MGA) may contribute to the development and progression of diabetic nephropathy in part through activation of the Ang II/AT1 receptor system; however, the influence of AGE on the Ang-(1-7) arm of the RAS within the kidney is unclear.  The present study assessed the impact of AGE on the Ang-(1-7) axis in NRK-52E renal epithelial cells.  MGA exposure for 48 h significantly reduced the intracellular levels of Ang-(1-7) approx. 50%; however, Ang I or Ang II expression was not altered.  The reduced cellular content of Ang-(1-7) was assocd. with increased metab. of the peptide to the inactive metabolite Ang-(1-4) [MGA: 175 Â± 9 vs. Control: 115 Â± 11 fmol/min/mg protein, p < 0.05, n = 3] but no change in the processing of Ang I to Ang-(1-7).  Treatment with Ang-(1-7) reversed MGA-induced cellular hypertrophy and myofibroblast transition evidenced by reduced immunostaining and protein expression of Î±-smooth muscle actin (Î±-SMA) [0.4 Â± 0.1 vs. 1.0 Â± 0.1, resp., n = 3, p < 0.05].  Ang-(1-7) abolished AGE-induced activation of the MAP kinase ERK1/2 to a similar extent as the TGF-Î² receptor kinase inhibitor SB58059; however, Ang-(1-7) did not attenuate the MGA-stimulated release of TGF-Î².  The AT7-Mas receptor antagonist D-Ala7-Ang-(1-7) abolished the inhibitory actions of Ang-(1-7).  In contrast, AT1 receptor antagonist losartan did not attenuate the MGA-induced effects.  We conclude that Ang-(1-7) may provide an addnl. therapeutic approach to the conventional RAS blockade regimen to attenuate AGE-dependent renal injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyQEG6vwy6GLVg90H21EOLACvtfcHk0lg0ckoYLvuv1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2gsr7O&md5=f8bd3ee5b505c236324ed75757b6f554</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2014.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2014.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DAlzayadneh%26aufirst%3DE.%2BM.%26aulast%3DChappell%26aufirst%3DM.%2BC.%26atitle%3DAngiotensin-%25281%25E2%2580%25937%2529%2520abolishes%2520AGE-induced%2520cellular%2520hypertrophy%2520and%2520myofibroblasts%2520transformation%2520via%2520inhibition%2520of%2520ERK1%252F2%26jtitle%3DCell.%2520Signalling%26date%3D2014%26volume%3D26%26spage%3D3027%26epage%3D3035%26doi%3D10.1016%2Fj.cellsig.2014.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacorre, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozin, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stylianopoulos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adstamongkonkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PopoviÄ, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bawendi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span> <span> </span><span class="NLM_article-title">Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2516</span>, <span class="refDoi">Â DOI: 10.1038/ncomms3516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fncomms3516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24084631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252Fls1amsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=2516&author=V.+P.+Chauhanauthor=J.+D.+Martinauthor=H.+Liuauthor=D.+A.+Lacorreauthor=S.+R.+Jainauthor=S.+V.+Kozinauthor=T.+Stylianopoulosauthor=A.+S.+Mousaauthor=X.+Hanauthor=P.+Adstamongkonkulauthor=Z.+Popovi%C4%87author=P.+Huangauthor=M.+G.+Bawendiauthor=Y.+Boucherauthor=R.+K.+Jain&title=Angiotensin+inhibition+enhances+drug+delivery+and+potentiates+chemotherapy+by+decompressing+tumour+blood+vessels&doi=10.1038%2Fncomms3516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels</span></div><div class="casAuthors">Chauhan Vikash P; Martin John D; Liu Hao; Lacorre Delphine A; Jain Saloni R; Kozin Sergey V; Stylianopoulos Triantafyllos; Mousa Ahmed S; Han Xiaoxing; Adstamongkonkul Pichet; Popovic Zoran; Huang Peigen; Bawendi Moungi G; Boucher Yves; Jain Rakesh K</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2516</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion.  Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour.  Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels.  We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-Î²1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition.  Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion.  Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models.  Thus, angiotensin inhibitors -inexpensive drugs with decades of safe use - could be rapidly repurposed as cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCTkmoIT3ohZotVjB3IRIyfW6udTcc2eYET3DbzkWtRbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252Fls1amsw%253D%253D&md5=c2a7c9d6615a44bd06ab6201a3bc57a2</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fncomms3516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms3516%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DV.%2BP.%26aulast%3DMartin%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLacorre%26aufirst%3DD.%2BA.%26aulast%3DJain%26aufirst%3DS.%2BR.%26aulast%3DKozin%26aufirst%3DS.%2BV.%26aulast%3DStylianopoulos%26aufirst%3DT.%26aulast%3DMousa%26aufirst%3DA.%2BS.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DAdstamongkonkul%26aufirst%3DP.%26aulast%3DPopovi%25C4%2587%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DBawendi%26aufirst%3DM.%2BG.%26aulast%3DBoucher%26aufirst%3DY.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DAngiotensin%2520inhibition%2520enhances%2520drug%2520delivery%2520and%2520potentiates%2520chemotherapy%2520by%2520decompressing%2520tumour%2520blood%2520vessels%26jtitle%3DNat.%2520Commun.%26date%3D2013%26volume%3D4%26spage%3D2516%26doi%3D10.1038%2Fncomms3516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clozel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloukh, H.</span></span> <span> </span><span class="NLM_article-title">Role of endothelin in fibrosis and anti-fibrotic potential of bosentan</span>. <i>Ann. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2</span>â <span class="NLM_lpage">12</span>, <span class="refDoi">Â DOI: 10.1080/07853890410018925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1080%2F07853890410018925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=15902842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslenurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2005&pages=2-12&author=M.+Clozelauthor=H.+Salloukh&title=Role+of+endothelin+in+fibrosis+and+anti-fibrotic+potential+of+bosentan&doi=10.1080%2F07853890410018925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Role of endothelin in fibrosis and anti-fibrotic potential of bosentan</span></div><div class="casAuthors">Clozel, Martine; Salloukh, Hashem</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Medicine (Basingstoke, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">ANMDEU</span>;
        ISSN:<span class="NLM_cas:issn">0785-3890</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent data demonstrate the fundamental role of endothelin in the pathogenesis of fibrosis, and the anti-fibrotic potential of dual endothelin receptor antagonists such as bosentan.  Although transforming growth factor-beta, aldosterone and connective tissue growth factor, have already been established as contributors to the process of fibrosis, endothelin now emerges as a key player, which may have a role both in the initiation and in maintenance of fibrosis, and may mediate the pro-fibrotic effects of the other agents.  Bosentan is an orally active, dual endothelin receptor antagonist, which competitively antagonizes the binding of endothelin to both endothelin receptors ETA and ETB.  Bosentan prevents endothelin-induced fibroblast proliferation and extracellular matrix deposition and contraction, and reduces cardiac, hepatic, pulmonary and renal fibrosis in different disease models characterized by the activation of the endothelin system.  Bosentan even reverses existing fibrosis, possibly by its effect of stimulating matrix metalloproteinase type 1 (collagenase) expression.  The anti-fibrotic effects of bosentan extend to fibrosis induced by mediators other than endothelin such as transforming growth factor-beta, angiotensin II and aldosterone, indicating a central role of endothelin and endothelin receptors in fibrotic processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOmwjYBPr9mbVg90H21EOLACvtfcHk0ljYiCNVXvyiVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslenurk%253D&md5=76966435b0243748c07b0cc8fd77960c</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1080%2F07853890410018925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07853890410018925%26sid%3Dliteratum%253Aachs%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DSalloukh%26aufirst%3DH.%26atitle%3DRole%2520of%2520endothelin%2520in%2520fibrosis%2520and%2520anti-fibrotic%2520potential%2520of%2520bosentan%26jtitle%3DAnn.%2520Med.%26date%3D2005%26volume%3D37%26spage%3D2%26epage%3D12%26doi%3D10.1080%2F07853890410018925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Pascual, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busnadiego, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Santamaria, J.</span></span> <span> </span><span class="NLM_article-title">The profibrotic role of endothelin-1: is the door still open for the treatment od fibrotic diseases</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">156</span>â <span class="NLM_lpage">164</span>, <span class="refDoi">Â DOI: 10.1016/j.lfs.2013.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.lfs.2013.12.024" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2014&pages=156-164&author=F.+Rodriguez-Pascualauthor=O.+Busnadiegoauthor=J.+Gonzalez-Santamaria&title=The+profibrotic+role+of+endothelin-1%3A+is+the+door+still+open+for+the+treatment+od+fibrotic+diseases&doi=10.1016%2Fj.lfs.2013.12.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2013.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2013.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez-Pascual%26aufirst%3DF.%26aulast%3DBusnadiego%26aufirst%3DO.%26aulast%3DGonzalez-Santamaria%26aufirst%3DJ.%26atitle%3DThe%2520profibrotic%2520role%2520of%2520endothelin-1%253A%2520is%2520the%2520door%2520still%2520open%2520for%2520the%2520treatment%2520od%2520fibrotic%2520diseases%26jtitle%3DLife%2520Sci.%26date%3D2014%26volume%3D118%26spage%3D156%26epage%3D164%26doi%3D10.1016%2Fj.lfs.2013.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yong, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabad, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves
Dasilva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, L. M.</span></span> <span> </span><span class="NLM_article-title">Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators</span>. <i>J. Neurol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>259</i></span>,  <span class="NLM_fpage">79</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1016/j.jns.2006.11.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.jns.2006.11.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17382965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWrsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=259&publication_year=2007&pages=79-84&author=V.+W.+Yongauthor=R.+K.+Zabadauthor=S.+Agrawalauthor=A.+Goncalves%0ADasilvaauthor=L.+M.+Metz&title=Elevation+of+matrix+metalloproteinases+%28MMPs%29+in+multiple+sclerosis+and+impact+of+immunomodulators&doi=10.1016%2Fj.jns.2006.11.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators</span></div><div class="casAuthors">Yong, V. Wee; Zabad, Rana K.; Agrawal, Smriti; Goncalves Da Silva, Angelika; Metz, Luanne M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Neurological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">259</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">79-84</span>CODEN:
                <span class="NLM_cas:coden">JNSCAG</span>;
        ISSN:<span class="NLM_cas:issn">0022-510X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The matrix metalloproteinases (MMPs) are implicated in the pathol. of multiple sclerosis (MS).  This review summarizes the consequences of upregulation of MMP members in MS as well as in an animal model of the disease, exptl. autoimmune encephalomyelitis (EAE).  The pathogenic roles of MMPs are considered, esp. in the transmigration of leukocytes into the CNS.  We review the evidence that interferon-beta, an immunomodulator that is commonly used in MS, affects MMP expression in the disease.  The potential of minocycline as a therapy in MS, based on its activity as an MMP inhibitor, is discussed.  Besides affecting MMPs, minocycline may have other actions that help account for its possible utility in MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph1mzvbhnbD7Vg90H21EOLACvtfcHk0lgsBpyocoMOEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWrsLc%253D&md5=5b87d04cd4c62500f9d9a084962e0cc9</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.jns.2006.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jns.2006.11.021%26sid%3Dliteratum%253Aachs%26aulast%3DYong%26aufirst%3DV.%2BW.%26aulast%3DZabad%26aufirst%3DR.%2BK.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DGoncalves%2BDasilva%26aufirst%3DA.%26aulast%3DMetz%26aufirst%3DL.%2BM.%26atitle%3DElevation%2520of%2520matrix%2520metalloproteinases%2520%2528MMPs%2529%2520in%2520multiple%2520sclerosis%2520and%2520impact%2520of%2520immunomodulators%26jtitle%3DJ.%2520Neurol.%2520Sci.%26date%3D2007%26volume%3D259%26spage%3D79%26epage%3D84%26doi%3D10.1016%2Fj.jns.2006.11.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Lint, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libert, C.</span></span> <span> </span><span class="NLM_article-title">Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">1375</span>â <span class="NLM_lpage">1381</span>, <span class="refDoi">Â DOI: 10.1189/jlb.0607338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1189%2Fjlb.0607338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17709402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsValtbfN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2007&pages=1375-1381&author=P.+Van+Lintauthor=C.+Libert&title=Chemokine+and+cytokine+processing+by+matrix+metalloproteinases+and+its+effect+on+leukocyte+migration+and+inflammation&doi=10.1189%2Fjlb.0607338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation</span></div><div class="casAuthors">Van Lint, Philippe; Libert, Claude</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1375-1381</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review.  The action of matrix metalloproteinases (MMPs) was originally believed to be restricted to degrdn. of the extracellular matrix; however, in recent years, it has become evident that these proteases can modify many nonmatrix substrates, such as cytokines and chemokines.  The use of MMP-deficient animals has revealed that these proteases can indeed influence the progression of various inflammatory processes.  This review aims to provide the reader with a concise overview of these novel MMP functions in relation to leukocyte migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT2xGqSmyTQbVg90H21EOLACvtfcHk0ljKKkNR_Mwxig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsValtbfN&md5=65c34da9f3dc5ba1d4ddcdde2a70f0b7</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1189%2Fjlb.0607338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.0607338%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BLint%26aufirst%3DP.%26aulast%3DLibert%26aufirst%3DC.%26atitle%3DChemokine%2520and%2520cytokine%2520processing%2520by%2520matrix%2520metalloproteinases%2520and%2520its%2520effect%2520on%2520leukocyte%2520migration%2520and%2520inflammation%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2007%26volume%3D82%26spage%3D1375%26epage%3D1381%26doi%3D10.1189%2Fjlb.0607338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kefaloyianni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthu, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaeppler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbisetti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalaris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose-John, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waikar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rennke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonventre, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrlich, A.</span></span> <span> </span><span class="NLM_article-title">ADAM17 substrate release in proximal tubule drives kidney fibrosis</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e87023</span>, <span class="refDoi">Â DOI: 10.1172/jci.insight.87023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1172%2Fjci.insight.87023" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=e87023&author=E.+Kefaloyianniauthor=M.+L.+Muthuauthor=K.+Kaepplerauthor=X.+Sunauthor=V.+Sabbisettiauthor=A.+Chalarisauthor=S.+Rose-Johnauthor=E.+Wongauthor=I.+Sagiauthor=S.+S.+Waikarauthor=H.+Rennkeauthor=B.+D.+Humphreysauthor=J.+V.+Bonventreauthor=A.+Herrlich&title=ADAM17+substrate+release+in+proximal+tubule+drives+kidney+fibrosis&doi=10.1172%2Fjci.insight.87023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.87023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.87023%26sid%3Dliteratum%253Aachs%26aulast%3DKefaloyianni%26aufirst%3DE.%26aulast%3DMuthu%26aufirst%3DM.%2BL.%26aulast%3DKaeppler%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DSabbisetti%26aufirst%3DV.%26aulast%3DChalaris%26aufirst%3DA.%26aulast%3DRose-John%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DSagi%26aufirst%3DI.%26aulast%3DWaikar%26aufirst%3DS.%2BS.%26aulast%3DRennke%26aufirst%3DH.%26aulast%3DHumphreys%26aufirst%3DB.%2BD.%26aulast%3DBonventre%26aufirst%3DJ.%2BV.%26aulast%3DHerrlich%26aufirst%3DA.%26atitle%3DADAM17%2520substrate%2520release%2520in%2520proximal%2520tubule%2520drives%2520kidney%2520fibrosis%26jtitle%3DJCI%2520Insight%26date%3D2016%26volume%3D1%26spage%3De87023%26doi%3D10.1172%2Fjci.insight.87023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giannandrea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parks, W. C.</span></span> <span> </span><span class="NLM_article-title">Diverse functions of matrix metalloproteinases during fibrosis</span>. <i>Disease Models Mech.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">193</span>â <span class="NLM_lpage">203</span>, <span class="refDoi">Â DOI: 10.1242/dmm.012062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1242%2Fdmm.012062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24713275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlGqsLjL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=193-203&author=M.+Giannandreaauthor=W.+C.+Parks&title=Diverse+functions+of+matrix+metalloproteinases+during+fibrosis&doi=10.1242%2Fdmm.012062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Diverse functions of matrix metalloproteinases during fibrosis</span></div><div class="casAuthors">Giannandrea, Matthew; Parks, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Disease Models & Mechanisms</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">193-203, 11</span>CODEN:
                <span class="NLM_cas:coden">DMMIAX</span>;
        ISSN:<span class="NLM_cas:issn">1754-8403</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Fibrosis - a debilitating condition that can occur in most organs - is characterized by excess deposition of a collagen-rich extracellular matrix (ECM).  At first sight, the activities of proteinases that can degrade matrix, such as matrix metalloproteinases (MMPs), might be expected to be under-expressed in fibrosis or, if present, could function to resolve the excess matrix.  However, as we review here, some MMPs are indeed anti-fibrotic, whereas others can have profibrotic functions.  MMPs modulate a range of biol. processes, esp. processes related to immunity and tissue repair and/or remodeling.  Although we do not yet know precisely how MMPs function during fibrosis - i.e., the protein substrate or substrates that an individual MMP acts on to effect a specific process - expts. in mouse models demonstrate that MMP-dependent functions during fibrosis are not limited to effects on ECM turnover.  Rather, data from diverse models indicate that these proteinases influence cellular activities as varied as proliferation and survival, gene expression, and multiple aspects of inflammation that, in turn, impact outcomes related to fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGrxTCIFB0KrVg90H21EOLACvtfcHk0lgXK86seLPeMg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlGqsLjL&md5=88d15b1adbf7047a564eebb999463769</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1242%2Fdmm.012062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdmm.012062%26sid%3Dliteratum%253Aachs%26aulast%3DGiannandrea%26aufirst%3DM.%26aulast%3DParks%26aufirst%3DW.%2BC.%26atitle%3DDiverse%2520functions%2520of%2520matrix%2520metalloproteinases%2520during%2520fibrosis%26jtitle%3DDisease%2520Models%2520Mech.%26date%3D2014%26volume%3D7%26spage%3D193%26epage%3D203%26doi%3D10.1242%2Fdmm.012062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzyllo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusmano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzeski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theroux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydlowski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaber, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, W. D.</span></span> <span> </span><span class="NLM_article-title">Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">15</span>â <span class="NLM_lpage">20</span>, <span class="refDoi">Â DOI: 10.1016/j.jacc.2006.02.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.jacc.2006.02.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=16814643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtlGms70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2006&pages=15-20&author=M.+P.+Hudsonauthor=P.+W.+Armstrongauthor=W.+Ruzylloauthor=J.+Brumauthor=L.+Cusmanoauthor=P.+Krzeskiauthor=R.+Lyonauthor=M.+Quinonesauthor=P.+Therouxauthor=D.+Sydlowskiauthor=H.+E.+Kimauthor=M.+J.+Garciaauthor=W.+A.+Jaberauthor=W.+D.+Weaver&title=Effects+of+selective+matrix+metalloproteinase+inhibitor+%28PG-116800%29+to+prevent+ventricular+remodeling+after+myocardial+infarction%3A+results+of+the+PREMIER+%28Prevention+of+Myocardial+Infarction+Early+Remodeling%29+trial&doi=10.1016%2Fj.jacc.2006.02.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial Infarction</span></div><div class="casAuthors">Hudson, Michael P.; Armstrong, Paul W.; Ruzyllo, Witold; Brum, Jose; Cusmano, Lisa; Krzeski, Piotr; Lyon, Robert; Quinones, Miguel; Theroux, Pierre; Sydlowski, Diana; Kim, Henry E.; Garcia, Mario J.; Jaber, Wael A.; Weaver, W. Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-20</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objectives: We sought to det. whether matrix metalloproteinase (MMP) inhibitor, PG-116800, reduced left ventricular (LV) remodeling after myocardial infarction (MI).  Background: PG-116800 is an oral MMP inhibitor with significant antiremodeling effects in animal models of MI and ischemic heart failure.  Methods: In an international, randomized, double-blind, placebo-controlled study, 253 patients with first ST-segment elevation MI and ejection fraction between 15% and 40% were enrolled 48 Â± 24 h after MI and treated with placebo or PG-116800 for 90 days.  Major efficacy end points were changes in LV vols. as detd. by serial echocardiog., and clin. and safety outcomes were also collected.  Results: In total, 203 patients (80%) completed 90 days of treatment and had evaluable baseline and 90-day echo cardiograms.  The proportion of patients with anterior MI (78% vs. 81%) and primary percutaneous coronary intervention (90% vs. 91%) along with baseline LV ejection fraction (35.5% vs. 36.8%) did not differ between PG-116800-treated and placebo-treated patients.  There was no difference in the change in LV end-diastolic vol. index from days 0 to 90 with PG-116800 vs. placebo (5.09 Â± 1.45 mL/m2 vs. 5.48 Â± 1.41 mL/m2, p = 0.42).  Changes in LV diastolic vol., LV systolic vol., LV ejection fraction, sphericity index, plus rates of death or reinfarction were not significantly improved with PG-116800.  PG-116800 was well tolerated; however, there was increased incidence of arthralgia and joint stiffness without significant increase in overall musculoskeletal adverse events (21% vs. 15%, p = 0.33).  Conclusions: Matrix metalloproteinase inhibition with PG-116800 failed to reduce LV remodeling or improve clin. outcomes after MI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqceUkFd2YuhLVg90H21EOLACvtfcHk0liXIKUpO0kMeA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtlGms70%253D&md5=ed973718f404cbd7207321dec8f1b4b6</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2006.02.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2006.02.055%26sid%3Dliteratum%253Aachs%26aulast%3DHudson%26aufirst%3DM.%2BP.%26aulast%3DArmstrong%26aufirst%3DP.%2BW.%26aulast%3DRuzyllo%26aufirst%3DW.%26aulast%3DBrum%26aufirst%3DJ.%26aulast%3DCusmano%26aufirst%3DL.%26aulast%3DKrzeski%26aufirst%3DP.%26aulast%3DLyon%26aufirst%3DR.%26aulast%3DQuinones%26aufirst%3DM.%26aulast%3DTheroux%26aufirst%3DP.%26aulast%3DSydlowski%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DH.%2BE.%26aulast%3DGarcia%26aufirst%3DM.%2BJ.%26aulast%3DJaber%26aufirst%3DW.%2BA.%26aulast%3DWeaver%26aufirst%3DW.%2BD.%26atitle%3DEffects%2520of%2520selective%2520matrix%2520metalloproteinase%2520inhibitor%2520%2528PG-116800%2529%2520to%2520prevent%2520ventricular%2520remodeling%2520after%2520myocardial%2520infarction%253A%2520results%2520of%2520the%2520PREMIER%2520%2528Prevention%2520of%2520Myocardial%2520Infarction%2520Early%2520Remodeling%2529%2520trial%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2006%26volume%3D48%26spage%3D15%26epage%3D20%26doi%3D10.1016%2Fj.jacc.2006.02.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Migita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abiru, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatsuhashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibashi, H.</span></span> <span> </span><span class="NLM_article-title">Immunosuppressant FK506 inhibits matrix metalloproteinase-9 induction in TNF-Î±-stimulated human hepatic stellate cells</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">2510</span>â <span class="NLM_lpage">2515</span>, <span class="refDoi">Â DOI: 10.1016/j.lfs.2005.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.lfs.2005.10.003" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2006&pages=2510-2515&author=K.+Migitaauthor=Y.+Maedaauthor=S.+Abiruauthor=M.+Nakamuraauthor=A.+Komoriauthor=T.+Yokoyamaauthor=Y.+Takiiauthor=T.+Moriauthor=H.+Yatsuhashiauthor=K.+Eguchiauthor=H.+Ishibashi&title=Immunosuppressant+FK506+inhibits+matrix+metalloproteinase-9+induction+in+TNF-%CE%B1-stimulated+human+hepatic+stellate+cells&doi=10.1016%2Fj.lfs.2005.10.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2005.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2005.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMigita%26aufirst%3DK.%26aulast%3DMaeda%26aufirst%3DY.%26aulast%3DAbiru%26aufirst%3DS.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DKomori%26aufirst%3DA.%26aulast%3DYokoyama%26aufirst%3DT.%26aulast%3DTakii%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DYatsuhashi%26aufirst%3DH.%26aulast%3DEguchi%26aufirst%3DK.%26aulast%3DIshibashi%26aufirst%3DH.%26atitle%3DImmunosuppressant%2520FK506%2520inhibits%2520matrix%2520metalloproteinase-9%2520induction%2520in%2520TNF-%25CE%25B1-stimulated%2520human%2520hepatic%2520stellate%2520cells%26jtitle%3DLife%2520Sci.%26date%3D2006%26volume%3D78%26spage%3D2510%26epage%3D2515%26doi%3D10.1016%2Fj.lfs.2005.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Donato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiggeri, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Duca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jivotenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acinni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginevri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusmano, R.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase expression and collagen cross-linking during chronic Adriamycin nephropathy</span>. <i>Nephron</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">192</span>â <span class="NLM_lpage">200</span>, <span class="refDoi">Â DOI: 10.1159/000190168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1159%2F000190168" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1997&pages=192-200&author=A.+Di+Donatoauthor=G.+M.+Ghiggeriauthor=M.+Di+Ducaauthor=E.+Jivotenkoauthor=R.+Acinniauthor=J.+Campoloauthor=F.+Ginevriauthor=R.+Gusmano&title=Lysyl+oxidase+expression+and+collagen+cross-linking+during+chronic+Adriamycin+nephropathy&doi=10.1159%2F000190168"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1159%2F000190168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000190168%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BDonato%26aufirst%3DA.%26aulast%3DGhiggeri%26aufirst%3DG.%2BM.%26aulast%3DDi%2BDuca%26aufirst%3DM.%26aulast%3DJivotenko%26aufirst%3DE.%26aulast%3DAcinni%26aufirst%3DR.%26aulast%3DCampolo%26aufirst%3DJ.%26aulast%3DGinevri%26aufirst%3DF.%26aulast%3DGusmano%26aufirst%3DR.%26atitle%3DLysyl%2520oxidase%2520expression%2520and%2520collagen%2520cross-linking%2520during%2520chronic%2520Adriamycin%2520nephropathy%26jtitle%3DNephron%26date%3D1997%26volume%3D76%26spage%3D192%26epage%3D200%26doi%3D10.1159%2F000190168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barker, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erler, J. T.</span></span> <span> </span><span class="NLM_article-title">The rationale for targeting the LOX family in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">540</span>â <span class="NLM_lpage">552</span>, <span class="refDoi">Â DOI: 10.1038/nrc3319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnrc3319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22810810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCltLfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=540-552&author=H.+E.+Barkerauthor=T.+R.+Coxauthor=J.+T.+Erler&title=The+rationale+for+targeting+the+LOX+family+in+cancer&doi=10.1038%2Fnrc3319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">The rationale for targeting the LOX family in cancer</span></div><div class="casAuthors">Barker, Holly E.; Cox, Thomas R.; Erler, Janine T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">540-552</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The therapeutic targeting of extracellular proteins is becoming hugely attractive in light of evidence implicating the tumor microenvironment as pivotal in all aspects of tumor initiation and progression.  Members of the lysyl oxidase (LOX) family of proteins are secreted by tumors and are the subject of much effort to understand their roles in cancer.  In this Review we discuss the roles of members of this family in the remodelling of the tumor microenvironment and their paradoxical roles in tumorigenesis and metastasis.  We also discuss how targeting this family of proteins might lead to a new avenue of cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZcLr3Y7rPKLVg90H21EOLACvtfcHk0liXIKUpO0kMeA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCltLfE&md5=455064ea8d5332b43fa6490a1aaa0c8f</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1038%2Fnrc3319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3319%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DH.%2BE.%26aulast%3DCox%26aufirst%3DT.%2BR.%26aulast%3DErler%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520rationale%2520for%2520targeting%2520the%2520LOX%2520family%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D540%26epage%3D552%26doi%3D10.1038%2Fnrc3319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Georges, P.
C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gombos, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janmey, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furth, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, R. G.</span></span> <span> </span><span class="NLM_article-title">Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis</span>. <i>Am. J. Physiol., Gastrointest. Liver Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">G1147</span>â <span class="NLM_lpage">1154</span>, <span class="refDoi">Â DOI: 10.1152/ajpgi.00032.2007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1152%2Fajpgi.00032.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=17932231" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2007&pages=G1147-1154&author=P.%0AC.+Georgesauthor=J.+J.+Huiauthor=Z.+Gombosauthor=M.+E.+McCormickauthor=A.+Y.+Wangauthor=M.+Uemuraauthor=R.+Mickauthor=P.+A.+Janmeyauthor=E.+E.+Furthauthor=R.+G.+Wells&title=Increased+stiffness+of+the+rat+liver+precedes+matrix+deposition%3A+implications+for+fibrosis&doi=10.1152%2Fajpgi.00032.2007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.00032.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.00032.2007%26sid%3Dliteratum%253Aachs%26aulast%3DGeorges%26aufirst%3DP.%2BC.%26aulast%3DHui%26aufirst%3DJ.%2BJ.%26aulast%3DGombos%26aufirst%3DZ.%26aulast%3DMcCormick%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DA.%2BY.%26aulast%3DUemura%26aufirst%3DM.%26aulast%3DMick%26aufirst%3DR.%26aulast%3DJanmey%26aufirst%3DP.%2BA.%26aulast%3DFurth%26aufirst%3DE.%2BE.%26aulast%3DWells%26aufirst%3DR.%2BG.%26atitle%3DIncreased%2520stiffness%2520of%2520the%2520rat%2520liver%2520precedes%2520matrix%2520deposition%253A%2520implications%2520for%2520fibrosis%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Gastrointest.%2520Liver%2520Physiol.%26date%3D2007%26volume%3D293%26spage%3DG1147%26epage%3D1154%26doi%3D10.1152%2Fajpgi.00032.2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchio-Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manabe, N.</span></span> <span> </span><span class="NLM_article-title">Transforming growth factor-beta1 mediated up-regulation of lysyl oxidase in the kidneys of hereditary nephrotic mouse with chronic renal fibrosis</span>. <i>Virchows Arch.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>447</i></span>,  <span class="NLM_fpage">859</span>â <span class="NLM_lpage">868</span>, <span class="refDoi">Â DOI: 10.1007/s00428-005-0001-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1007%2Fs00428-005-0001-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=16086153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1KnsLbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2005&pages=859-868&author=Y.+Gotoauthor=K.+Uchio-Yamadaauthor=S.+Ananauthor=Y.+Yamamotoauthor=A.+Oguraauthor=N.+Manabe&title=Transforming+growth+factor-beta1+mediated+up-regulation+of+lysyl+oxidase+in+the+kidneys+of+hereditary+nephrotic+mouse+with+chronic+renal+fibrosis&doi=10.1007%2Fs00428-005-0001-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Transforming growth factor-Î²1 mediated up-regulation of lysyl oxidase in the kidneys of hereditary nephrotic mouse with chronic renal fibrosis</span></div><div class="casAuthors">Goto, Yasufumi; Uchio-Yamada, Kozue; Anan, Sayuri; Yamamoto, Yoshie; Ogura, Atsuo; Manabe, Noboru</div><div class="citationInfo"><span class="NLM_cas:title">Virchows Archiv</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">859-868</span>CODEN:
                <span class="NLM_cas:coden">VARCEM</span>;
        ISSN:<span class="NLM_cas:issn">0945-6317</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Lysyl oxidase (LOX), an extracellular enzyme, plays a key role in the post-translational modification of collagens and elastin, catalyzing inter- and intra-crosslinking reactions.  Because the crosslinked extracellular matrixes (ECMs) are highly resistant to degradative enzymes, it is considered that the over-expression of LOX may cause severe fibrotic degeneration.  In the present study, we addressed the role of LOX-mediated crosslinking in chronic renal tubulointerstitial fibrosis using an animal model of hereditary nephrotic syndrome, the Institute of Cancer Research (ICR)-derived glomerulonephritis (ICGN) mouse.  RNase protection assay (RPA) revealed that LOX mRNA expression was up-regulated in the kidneys of ICGN mice as compared with control ICR mice.  High-level expression of LOX and transforming growth factor (TGF)-Î²1 (an up-regulator of LOX) mRNA was detected in tubular epithelial cells of ICGN mouse kidneys by in situ hybridization.  Type-I and -III collagens, major substrates for LOX, were accumulated in tubulointerstitium of ICGN mouse kidneys.  The present findings imply that TGF-Î²1 up-regulates the prodn. of LOX in tubular epithelial cells of ICGN mouse kidneys, and the excessive LOX acts on interstitial collagens and catalyzes crosslinking reactions.  As a result, the highly crosslinked collagens induce an irreversible progression of chronic renal tubulointerstitial fibrosis in the kidneys of ICGN mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWwjlWxHOJfbVg90H21EOLACvtfcHk0ljnQxvBXl0Tcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1KnsLbF&md5=a61ad20761ecd209a8fdd0cf2b38c9cc</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1007%2Fs00428-005-0001-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00428-005-0001-8%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DY.%26aulast%3DUchio-Yamada%26aufirst%3DK.%26aulast%3DAnan%26aufirst%3DS.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DOgura%26aufirst%3DA.%26aulast%3DManabe%26aufirst%3DN.%26atitle%3DTransforming%2520growth%2520factor-beta1%2520mediated%2520up-regulation%2520of%2520lysyl%2520oxidase%2520in%2520the%2520kidneys%2520of%2520hereditary%2520nephrotic%2520mouse%2520with%2520chronic%2520renal%2520fibrosis%26jtitle%3DVirchows%2520Arch.%26date%3D2005%26volume%3D447%26spage%3D859%26epage%3D868%26doi%3D10.1007%2Fs00428-005-0001-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barry-Hamilton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyasu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikels, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaysberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghermazien, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velayo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biermann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaffryar-Eilot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neufeld, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Vlasselaer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1009</span>â <span class="NLM_lpage">1017</span>, <span class="refDoi">Â DOI: 10.1038/nm.2208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fnm.2208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=20818376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFWksrvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1009-1017&author=V.+Barry-Hamiltonauthor=R.+Spanglerauthor=D.+Marshallauthor=S.+McCauleyauthor=H.+M.+Rodriguezauthor=M.+Oyasuauthor=A.+Mikelsauthor=M.+Vaysbergauthor=H.+Ghermazienauthor=C.+Waiauthor=C.+A.+Garciaauthor=A.+C.+Velayoauthor=B.+Jorgensenauthor=D.+Biermannauthor=D.+Tsaiauthor=J.+Greenauthor=S.+Zaffryar-Eilotauthor=A.+Holzerauthor=S.+Oggauthor=D.+Thaiauthor=G.+Neufeldauthor=P.+Van+Vlasselaerauthor=V.+Smith&title=Allosteric+inhibition+of+lysyl+oxidase-like-2+impedes+the+development+of+a+pathologic+microenvironment&doi=10.1038%2Fnm.2208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment</span></div><div class="casAuthors">Barry-Hamilton, Vivian; Spangler, Rhyannon; Marshall, Derek; McCauley, Scott; Rodriguez, Hector M.; Oyasu, Miho; Mikels, Amanda; Vaysberg, Maria; Ghermazien, Haben; Wai, Carol; Garcia, Carlos A.; Velayo, Arleene C.; Jorgensen, Brett; Biermann, Donna; Tsai, Daniel; Green, Jennifer; Zaffryar-Eilot, Shelly; Holzer, Alison; Ogg, Scott; Thai, Dung; Neufeld, Gera; Van Vlasselaer, Peter; Smith, Victoria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1009-1017</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have identified a new role for the matrix enzyme lysyl oxidase-like-2 (LOXL2) in the creation and maintenance of the pathol. microenvironment of cancer and fibrotic disease.  Our anal. of biopsies from human tumors and fibrotic lung and liver tissues revealed an increase in LOXL2 in disease-assocd. stroma and limited expression in healthy tissues.  Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models.  Inhibition of LOXL2 resulted in a marked redn. in activated fibroblasts, desmoplasia and endothelial cells, decreased prodn. of growth factors and cytokines and decreased transforming growth factor-Î² (TGF-Î²) pathway signaling.  AB0023 outperformed the small-mol. lysyl oxidase inhibitor Î²-aminopropionitrile.  The efficacy and safety of LOXL2-specific AB0023 represents a new therapeutic approach with broad applicability in oncol. and fibrotic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkE52VQCvcZrVg90H21EOLACvtfcHk0ljnQxvBXl0Tcg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFWksrvF&md5=7e69cbf26c2985ad03fbb620538a5f04</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fnm.2208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2208%26sid%3Dliteratum%253Aachs%26aulast%3DBarry-Hamilton%26aufirst%3DV.%26aulast%3DSpangler%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DD.%26aulast%3DMcCauley%26aufirst%3DS.%26aulast%3DRodriguez%26aufirst%3DH.%2BM.%26aulast%3DOyasu%26aufirst%3DM.%26aulast%3DMikels%26aufirst%3DA.%26aulast%3DVaysberg%26aufirst%3DM.%26aulast%3DGhermazien%26aufirst%3DH.%26aulast%3DWai%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DC.%2BA.%26aulast%3DVelayo%26aufirst%3DA.%2BC.%26aulast%3DJorgensen%26aufirst%3DB.%26aulast%3DBiermann%26aufirst%3DD.%26aulast%3DTsai%26aufirst%3DD.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DZaffryar-Eilot%26aufirst%3DS.%26aulast%3DHolzer%26aufirst%3DA.%26aulast%3DOgg%26aufirst%3DS.%26aulast%3DThai%26aufirst%3DD.%26aulast%3DNeufeld%26aufirst%3DG.%26aulast%3DVan%2BVlasselaer%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DV.%26atitle%3DAllosteric%2520inhibition%2520of%2520lysyl%2520oxidase-like-2%2520impedes%2520the%2520development%2520of%2520a%2520pathologic%2520microenvironment%26jtitle%3DNat.%2520Med.%26date%3D2010%26volume%3D16%26spage%3D1009%26epage%3D1017%26doi%3D10.1038%2Fnm.2208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikenaga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sverdlov, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenstein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuppan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, Y.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1599</span>â <span class="NLM_lpage">1609</span>, <span class="refDoi">Â DOI: 10.1096/fj.14-268425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1096%2Ffj.14-268425" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1599-1609&author=S.+B.+Liuauthor=N.+Ikenagaauthor=Z.+W.+Pengauthor=D.+Y.+Sverdlovauthor=A.+Greensteinauthor=V.+Smithauthor=D.+Schuppanauthor=Y.+Popov&title=Lysyl+oxidase+activity+contributes+to+collagen+stabilization+during+liver+fibrosis+progression+and+limits+spontaneous+fibrosis+reversal+in+mice&doi=10.1096%2Ffj.14-268425"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1096%2Ffj.14-268425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.14-268425%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%2BB.%26aulast%3DIkenaga%26aufirst%3DN.%26aulast%3DPeng%26aufirst%3DZ.%2BW.%26aulast%3DSverdlov%26aufirst%3DD.%2BY.%26aulast%3DGreenstein%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DSchuppan%26aufirst%3DD.%26aulast%3DPopov%26aufirst%3DY.%26atitle%3DLysyl%2520oxidase%2520activity%2520contributes%2520to%2520collagen%2520stabilization%2520during%2520liver%2520fibrosis%2520progression%2520and%2520limits%2520spontaneous%2520fibrosis%2520reversal%2520in%2520mice%26jtitle%3DFASEB%2520J.%26date%3D2016%26volume%3D30%26spage%3D1599%26epage%3D1609%26doi%3D10.1096%2Ffj.14-268425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keene, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazono, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasumura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism responsible for fibronectin-controlled alterations in matrix stiffness in advanced chronic liver fibrogenesis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">72</span>â <span class="NLM_lpage">88</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M115.691519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1074%2Fjbc.M115.691519" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=72-88&author=A.+Iwasakiauthor=K.+Sakaiauthor=K.+Moriyaauthor=T.+Sasakiauthor=D.+R.+Keeneauthor=R.+Akhtarauthor=T.+Miyazonoauthor=S.+Yasumuraauthor=M.+Watanabeauthor=S.+Morishitaauthor=T.+Sakai&title=Molecular+mechanism+responsible+for+fibronectin-controlled+alterations+in+matrix+stiffness+in+advanced+chronic+liver+fibrogenesis&doi=10.1074%2Fjbc.M115.691519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.691519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.691519%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DA.%26aulast%3DSakai%26aufirst%3DK.%26aulast%3DMoriya%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DKeene%26aufirst%3DD.%2BR.%26aulast%3DAkhtar%26aufirst%3DR.%26aulast%3DMiyazono%26aufirst%3DT.%26aulast%3DYasumura%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DMorishita%26aufirst%3DS.%26aulast%3DSakai%26aufirst%3DT.%26atitle%3DMolecular%2520mechanism%2520responsible%2520for%2520fibronectin-controlled%2520alterations%2520in%2520matrix%2520stiffness%2520in%2520advanced%2520chronic%2520liver%2520fibrogenesis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D72%26epage%3D88%26doi%3D10.1074%2Fjbc.M115.691519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14909</span>, <span class="refDoi">Â DOI: 10.1038/ncomms14909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1038%2Fncomms14909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28416796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFKgtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14909&author=H.+Tangauthor=L.+Leungauthor=G.+Saturnoauthor=A.+Virosauthor=D.+Smithauthor=G.+Di+Levaauthor=E.+Morrisonauthor=D.+Niculescu-Duvazauthor=F.+Lopesauthor=L.+Johnsonauthor=N.+Dhomenauthor=C.+Springerauthor=R.+Marais&title=Lysyl+oxidase+drives+tumour+progression+by+trapping+EGF+receptors+at+the+cell+surface&doi=10.1038%2Fncomms14909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface</span></div><div class="casAuthors">Tang, Hao Ran; Leung, Leo; Saturno, Grazia; Viros, Amaya; Smith, Duncan; Di Leva, Gianpiero; Morrison, Eamonn; Niculescu-Duvaz, Dan; Lopes, Filipa; Johnson, Louise; Dhomen, Nathalie; Springer, Caroline; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14909</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lysyl oxidase (LOX) remodels the tumor microenvironment by crosslinking the extracellular matrix.  LOX overexpression is assocd. with poor cancer outcomes.  Here, we find that LOX regulates the epidermal growth factor receptor (EGFR) to drive tumor progression.  We show that LOX regulates EGFR by suppressing TGFÎ²1 signalling through the secreted protease HTRA1.  This increases the expression of Matrilin2 (MATN2), an EGF-like domain-contg. protein that traps EGFR at the cell surface to facilitate its activation by EGF.  We describe a pharmacol. inhibitor of LOX, CCT365623, which disrupts EGFR cell surface retention and delays the growth of primary and metastatic tumor cells in vivo.  Thus, we show that LOX regulates EGFR cell surface retention to drive tumor progression, and we validate the therapeutic potential of inhibiting this pathway with the small mol. inhibitor CCT365623.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjI8odBCa4OLVg90H21EOLACvtfcHk0lihkHdZh76qlA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFKgtbw%253D&md5=d0db599dc8344c8685196f6d289fd3cf</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1038%2Fncomms14909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14909%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DDi%2BLeva%26aufirst%3DG.%26aulast%3DMorrison%26aufirst%3DE.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DLysyl%2520oxidase%2520drives%2520tumour%2520progression%2520by%2520trapping%2520EGF%2520receptors%2520at%2520the%2520cell%2520surface%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14909%26doi%3D10.1038%2Fncomms14909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonte, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Montolio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deodhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timpson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erler, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, T. R.</span></span> <span> </span><span class="NLM_article-title">Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">26066</span>â <span class="NLM_lpage">26078</span>, <span class="refDoi">Â DOI: 10.18632/oncotarget.15257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.18632%2Foncotarget.15257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28199967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1c3mvFOnsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=26066-26078&author=J.+Changauthor=M.+C.+Lucasauthor=L.+E.+Leonteauthor=M.+Garcia-Montolioauthor=L.+B.+Singhauthor=A.+D.+Findlayauthor=M.+Deodharauthor=J.+S.+Footauthor=W.+Jarolimekauthor=P.+Timpsonauthor=J.+T.+Erlerauthor=T.+R.+Cox&title=Pre-clinical+evaluation+of+small+molecule+LOXL2+inhibitors+in+breast+cancer&doi=10.18632%2Foncotarget.15257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer</span></div><div class="casAuthors">Chang Joan; Leonte Lidia E; Garcia-Montolio Marc; Singh Lukram Babloo; Erler Janine T; Cox Thomas R; Lucas Morghan C; Timpson Paul; Cox Thomas R; Findlay Alison D; Deodhar Mandar; Foot Jonathan S; Jarolimek Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">26066-26078</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lysyl Oxidase-like 2 (LOXL2), a member of the lysyl oxidase family of amine oxidases is known to be important in normal tissue development and homeostasis, as well as the onset and progression of solid tumors.  Here we tested the anti-tumor properties of two generations of novel small molecule LOXL2 inhibitor in the MDA-MB-231 human model of breast cancer.  We confirmed a functional role for LOXL2 activity in the progression of primary breast cancer.  Inhibition of LOXL2 activity inhibited the growth of primary tumors and reduced primary tumor angiogenesis.  Dual inhibition of LOXL2 and LOX showed a greater effect and also led to a lower overall metastatic burden in the lung and liver.  Our data provides the first evidence to support a role for LOXL2 specific small molecule inhibitors as a potential therapy in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOpqvFkfAy6suCWE5mhx1RfW6udTcc2ea-tBsGBqBmVLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3mvFOnsQ%253D%253D&md5=eda7044a327ae1746d7ae3ab2c2386fc</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.15257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.15257%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLeonte%26aufirst%3DL.%2BE.%26aulast%3DGarcia-Montolio%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DL.%2BB.%26aulast%3DFindlay%26aufirst%3DA.%2BD.%26aulast%3DDeodhar%26aufirst%3DM.%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DTimpson%26aufirst%3DP.%26aulast%3DErler%26aufirst%3DJ.%2BT.%26aulast%3DCox%26aufirst%3DT.%2BR.%26atitle%3DPre-clinical%2520evaluation%2520of%2520small%2520molecule%2520LOXL2%2520inhibitors%2520in%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D26066%26epage%3D26078%26doi%3D10.18632%2Foncotarget.15257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolman, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, E. H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparidans, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szokol, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ãrfi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storm, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennink, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, R. C.</span></span> <span> </span><span class="NLM_article-title">Targeting of a oral platinum-bound sunitinib analog to renal proximal tubular cells</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">417</span>â <span class="NLM_lpage">433</span>, <span class="refDoi">Â DOI: 10.2147/IJN.S26485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FIJN.S26485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22334775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFaksbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=417-433&author=E.+M.+Dolmanauthor=S.+Harmsenauthor=E.+H.+E.+Pietersauthor=R.+W.+Sparidansauthor=M.+Lacombeauthor=B.+Szokolauthor=L.+%C3%96rfiauthor=G.+Keriauthor=G.+Stormauthor=W.+E.+Henninkauthor=R.+C.+Kok&title=Targeting+of+a+oral+platinum-bound+sunitinib+analog+to+renal+proximal+tubular+cells&doi=10.2147%2FIJN.S26485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells</span></div><div class="casAuthors">Dolman, M. E. M.; Harmsen, Stefan; Pieters, Ebel H. E.; Sparidans, Rolf W.; Lacombe, Marie; Szokol, Balint; Orfi, Laszlo; Keri, Gyorgy; Storm, Gert; Hennink, Wim E.; Kok, Robbert J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">417-433</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Activated proximal tubular cells play an important role in renal fibrosis.  We investigated whether sunitinib and a kidney-targeted conjugate of sunitinib were capable of attenuating fibrogenic events in tubulointerstitial fibrosis.  Methods: A kidney-targeted conjugate was prepd. by linkage of a sunitinib analog (named 17864) via a platinum-based linker to the kidney-specific carrier lysozyme.  Pharmacol. activity of 17864-lysozyme was evaluated in human kidney proximal tubular cells (HK-2); the capability of the kidney-directed conjugate to accumulate in the kidneys was studied in mice.  Potential antifibrotic effects of a single-dose treatment were evaluated in the unilateral ureteral obstruction (UUO) model in mice.  Results: The 17864-lysozyme conjugate and its metabolites strongly inhibited tyrosine kinase activity.  Upon i.v. injection, 17864-lysozyme rapidly accumulated in the kidneys and provided sustained renal drug levels for up to 3 days after a single dose.  Renal drug level area under the curve was increased 28-fold vs. an equimolar dose of sunitinib malate.  Daily treatment of UUO mice with a high dose of sunitinib malate (50 mg/kg) resulted in antifibrotic responses, but also induced drug-related toxicity.  A single dose of 17864-lysozyme (equiv. to 1.8 mg/kg sunitinib) was safe but showed no antifibrotic effects.  Conclusion: Multikinase inhibitors like sunitinib can be of benefit in the treatment of fibrotic diseases, provided that their safety can be improved by strategies as presented in this paper, and sustained renal levels can be achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDvQxFI8JqnbVg90H21EOLACvtfcHk0lhjGUgNAIwSfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFaksbg%253D&md5=5c1e9dc5bb759c3b4478d1f0885943dd</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.2147%2FIJN.S26485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S26485%26sid%3Dliteratum%253Aachs%26aulast%3DDolman%26aufirst%3DE.%2BM.%26aulast%3DHarmsen%26aufirst%3DS.%26aulast%3DPieters%26aufirst%3DE.%2BH.%2BE.%26aulast%3DSparidans%26aufirst%3DR.%2BW.%26aulast%3DLacombe%26aufirst%3DM.%26aulast%3DSzokol%26aufirst%3DB.%26aulast%3D%25C3%2596rfi%26aufirst%3DL.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DStorm%26aufirst%3DG.%26aulast%3DHennink%26aufirst%3DW.%2BE.%26aulast%3DKok%26aufirst%3DR.%2BC.%26atitle%3DTargeting%2520of%2520a%2520oral%2520platinum-bound%2520sunitinib%2520analog%2520to%2520renal%2520proximal%2520tubular%2520cells%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2012%26volume%3D7%26spage%3D417%26epage%3D433%26doi%3D10.2147%2FIJN.S26485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blease, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azaryan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez-Valle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceres, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Velden, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen-Heininger, Y.
M. W.</span></span> <span> </span><span class="NLM_article-title">CC-90001, a second generation Jun N-terminal kinase (JNK) inhibitor for the treatment of idiopathic pulmonary fibrosis</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">A5409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2017&pages=A5409&author=B.+Bennettauthor=K.+Bleaseauthor=Y.+Yeauthor=A.+Azaryanauthor=F.+Ramirez-Valleauthor=R.+Ceresauthor=G.+Horanauthor=P.+Schaferauthor=J.+L.+Van+Der+Veldenauthor=Y.%0AM.+W.+Janssen-Heininger&title=CC-90001%2C+a+second+generation+Jun+N-terminal+kinase+%28JNK%29+inhibitor+for+the+treatment+of+idiopathic+pulmonary+fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DB.%26aulast%3DBlease%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DAzaryan%26aufirst%3DA.%26aulast%3DRamirez-Valle%26aufirst%3DF.%26aulast%3DCeres%26aufirst%3DR.%26aulast%3DHoran%26aufirst%3DG.%26aulast%3DSchafer%26aufirst%3DP.%26aulast%3DVan%2BDer%2BVelden%26aufirst%3DJ.%2BL.%26aulast%3DJanssen-Heininger%26aufirst%3DY.%2BM.%2BW.%26atitle%3DCC-90001%252C%2520a%2520second%2520generation%2520Jun%2520N-terminal%2520kinase%2520%2528JNK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2017%26volume%3D195%26spage%3DA5409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.
K.</span></span> <span> </span><span class="NLM_article-title">Integrins and cadherins as therapeutic targets in fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">131</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2014.00131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2014.00131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=24917820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC2cflvFygsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=131&author=S.%0AK.+Agarwal&title=Integrins+and+cadherins+as+therapeutic+targets+in+fibrosis&doi=10.3389%2Ffphar.2014.00131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Integrins and cadherins as therapeutic targets in fibrosis</span></div><div class="casAuthors">Agarwal Sandeep K</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">131</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Fibrosis is the excessive deposition of extracellular matrix proteins into tissues leading to scar formation, disruption of normal tissue architecture and organ failure.  Despite the large clinical impact of fibrosis, treatment options are limited.  Adhesion molecules, in particular Î±vÎ²6 and Î±3Î²1 integrins and cadherin-11, have been demonstrated to be important mediators of tissue fibrosis.  These data are reviewed here and provide the foundation for these molecules to be potential therapeutic targets for patients with fibrotic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQeWflPetSDUHdcurJClFcfW6udTcc2eZrtUlY_D-XHLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflvFygsA%253D%253D&md5=74ef04f4406ee98ba1eead9bbeb266c1</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00131%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DS.%2BK.%26atitle%3DIntegrins%2520and%2520cadherins%2520as%2520therapeutic%2520targets%2520in%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D131%26doi%3D10.3389%2Ffphar.2014.00131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mazo, D. F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, I. V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogliati, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefano, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, G. F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabelo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira Alves, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrilho, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, C. P. M.
S.</span></span> <span> </span><span class="NLM_article-title">S-nitroso, N acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">553</span>â <span class="NLM_lpage">563</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S43930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S43930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23843692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCntrrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=553-563&author=D.+F.+C.+Mazoauthor=M.+G.+de+Oliveiraauthor=I.+V.+A.+Pereiraauthor=B.+Cogliatiauthor=J.+T.+Stefanoauthor=G.+F.+P.+de+Souzaauthor=F.+Rabeloauthor=F.+R.+Limaauthor=V.+A.+Ferreira+Alvesauthor=F.+J.+Carrilhoauthor=C.+P.+M.%0AS.+de+Oliveira&title=S-nitroso%2C+N+acetylcysteine+attenuates+liver+fibrosis+in+experimental+nonalcoholic+steatohepatitis&doi=10.2147%2FDDDT.S43930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis</span></div><div class="casAuthors">Mazo, Daniel F. C.; de Oliveira, Marcelo G.; Pereira, Isabel V. A.; Cogliati, Bruno; Stefano, Jose T.; de Souza, Gabriela F. P.; Rabelo, Fabiola; Lima, Fabiana R.; Alves Ferreira, Venancio A.; Carrilho, Flair J.; de Oliveira, Claudia P. M. S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">553-563</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">S-nitroso-N-acetylcysteine (SNAC) is a water sol. primary S-nitrosothiol capable of transferring and releasing nitric oxide and inducing several biochem. activities, including modulation of hepatic stellate cell activation.  In this study, we evaluated the antifibrotic activity of SNAC in an animal model of nonalcoholic steatohepatitis (NASH) induced in Sprague-Dawley rats fed with a choline-deficient, high trans fat diet and exposed to diethylnitrosamine for 8 wk.  The rats were divided into three groups: SNAC, which received oral SNAC soln. daily; NASH, which received the vehicle; and control, which received std. diet and vehicle.  Genes related to fibrosis (matrix metalloproteinases [MMP]-13, -9, and -2), transforming growth factor Î²-1 [TGFÎ²-1], collagen-1Î±, and tissue inhibitors of metalloproteinase [TIMP-1 and -2] and oxidative stress (heat-shock proteins [HSP]-60 and -90) were evaluated.  SNAC led to a 34.4% redn. in the collagen occupied area assocd. with upregulation of MMP-13 and -9 and downregulation of HSP-60, TIMP-2, TGFÎ²-1, and collagen-1Î±.  These results indicate that oral SNAC administration may represent a potential antifibrotic treatment for NASH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZfIstyEKqr7Vg90H21EOLACvtfcHk0ljTG4BRTblSdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCntrrP&md5=23b53e42317a5b8d3d11992f7f77a2d7</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S43930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S43930%26sid%3Dliteratum%253Aachs%26aulast%3DMazo%26aufirst%3DD.%2BF.%2BC.%26aulast%3Dde%2BOliveira%26aufirst%3DM.%2BG.%26aulast%3DPereira%26aufirst%3DI.%2BV.%2BA.%26aulast%3DCogliati%26aufirst%3DB.%26aulast%3DStefano%26aufirst%3DJ.%2BT.%26aulast%3Dde%2BSouza%26aufirst%3DG.%2BF.%2BP.%26aulast%3DRabelo%26aufirst%3DF.%26aulast%3DLima%26aufirst%3DF.%2BR.%26aulast%3DFerreira%2BAlves%26aufirst%3DV.%2BA.%26aulast%3DCarrilho%26aufirst%3DF.%2BJ.%26aulast%3Dde%2BOliveira%26aufirst%3DC.%2BP.%2BM.%2BS.%26atitle%3DS-nitroso%252C%2520N%2520acetylcysteine%2520attenuates%2520liver%2520fibrosis%2520in%2520experimental%2520nonalcoholic%2520steatohepatitis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2013%26volume%3D7%26spage%3D553%26epage%3D563%26doi%3D10.2147%2FDDDT.S43930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. Q.</span></span> <span> </span><span class="NLM_article-title">Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3019</span>â <span class="NLM_lpage">3033</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S144807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S144807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29081650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSkt7nE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=3019-3033&author=W.+W.+Zhangauthor=F.+Baiauthor=J.+Wangauthor=R.+H.+Zhengauthor=L.+W.+Yangauthor=E.+Jamesauthor=Z.+Q.+Zhao&title=Edaravone+inhibits+pressure+overload-induced+cardiac+fibrosis+and+dysfunction+by+reducing+expression+of+angiotensin+II+AT1+receptor&doi=10.2147%2FDDDT.S144807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor</span></div><div class="casAuthors">Zhang, Wei-Wei; Bai, Feng; Wang, Jin; Zheng, Rong-Hua; Yang, Li-Wang; James, Erskine A.; Zhao, Zhi-Qing</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3019-3033</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Angiotensin II (Ang II) is known to be involved in the progression of ventricular dysfunction and heart failure by eliciting cardiac fibrosis.  The purpose of this study was to demonstrate whether treatment with an antioxidant compd., edaravone, reduces cardiac fibrosis and improves ventricular function by inhibiting Ang II AT1 receptor.  The study was conducted in a rat model of transverse aortic constriction (TAC).  In control, rats were subjected to 8 wk of TAC.  In treated rats, edaravone (10 mg/kg/day) or Ang II AT1 receptor blocker, telmisartan (10 mg/kg/day) was administered by i.p. injection or gastric gavage, resp., during TAC.  Relative to the animals with TAC, edaravone reduced myocardial malonaldehyde level and increased superoxide dismutase activity.  Protein level of the AT1 receptor was reduced and the AT2 receptor was upregulated, as evidenced by the reduced ratio of AT1 over AT2 receptor (0.57Â±0.2 vs 3.16Â±0.39, p<0.05) and less locally expressed AT1 receptor in the myocardium.  Furthermore, the protein level of angiotensin converting enzyme 2 was upregulated.  In coincidence with these changes, edaravone significantly decreased the populations of macrophages and myofibroblasts in the myocardium, which were accompanied by reduced levels of transforming growth factor beta 1 and Smad2/3.  Collagen I synthesis was inhibited and collagen-rich fibrosis was attenuated.  Relative to the TAC group, cardiac systolic function was preserved, as shown by increased left ventricular systolic pressure (204Â±51 vs 110Â±19 mmHg, p<0.05) and ejection fraction (82%Â±3% vs 60%Â±5%, p<0.05).  Treatment with telmisartan provided a comparable level of protection as compared with edaravone in all the parameters measured.  Taken together, edaravone treatment ameliorates cardiac fibrosis and improves left ventricular function in the pressure overload rat model, potentially via suppressing the AT1 receptor-mediated signaling pathways.  These data indicate that edaravone might be selected in combination with other existing drugs in preventing progression of cardiac dysfunction in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdgiWC1QUkDLVg90H21EOLACvtfcHk0lhj_6Y3CBbhow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSkt7nE&md5=b869850a0f306239e13dcc3ae3991cb9</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S144807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S144807%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%2BW.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DR.%2BH.%26aulast%3DYang%26aufirst%3DL.%2BW.%26aulast%3DJames%26aufirst%3DE.%26aulast%3DZhao%26aufirst%3DZ.%2BQ.%26atitle%3DEdaravone%2520inhibits%2520pressure%2520overload-induced%2520cardiac%2520fibrosis%2520and%2520dysfunction%2520by%2520reducing%2520expression%2520of%2520angiotensin%2520II%2520AT1%2520receptor%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D3019%26epage%3D3033%26doi%3D10.2147%2FDDDT.S144807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKallip, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z. Q.</span></span> <span> </span><span class="NLM_article-title">Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT<sub>1</sub>/AT<sub>2</sub> receptors and ACE2 in rats</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">6043</span>â <span class="NLM_lpage">6054</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S95333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S95333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=26648693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXls1Sjtr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=6043-6054&author=X.+F.+Pangauthor=L.+H.+Zhangauthor=F.+Baiauthor=N.+P.+Wangauthor=R.+E.+Garnerauthor=R.+J.+McKallipauthor=Z.+Q.+Zhao&title=Attenuation+of+myocardial+fibrosis+with+curcumin+is+mediated+by+modulating+expression+of+angiotensin+II+AT1%2FAT2+receptors+and+ACE2+in+rats&doi=10.2147%2FDDDT.S95333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats</span></div><div class="casAuthors">Pang, Xue-Fen; Zhang, Li-Hui; Bai, Feng; Wang, Ning-Ping; Garner, Ron E.; McKallip, Robert J.; Zhao, Zhi-Qing</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6043-6054</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Curcumin is known to improve cardiac function by balancing degrdn. and synthesis of collagens after myocardial infarction.  This study tested the hypothesis that inhibition of myocardial fibrosis by curcumin is assocd. with modulating expression of angiotensin II (Ang II) receptors and angiotensin-converting enzyme 2 (ACE2).  Male Sprague Dawley rats were subjected to Ang II infusion (500 ng/kg/min) using osmotic minipumps for 2 and 4 wk, resp., and curcumin (150 mg/kg/day) was fed by gastric gavage during Ang II infusion.  Compared to the animals with Ang II infusion, curcumin significantly decreased the mean arterial blood pressure during the course of the observation.  The protein level of the Ang II type 1 (AT1) receptor was reduced, and the Ang II type 2 (AT2) receptor was up-regulated, evidenced by an increased ratio of the AT2 receptor over the AT1 receptor in the curcumin group (1.2Â±0.02%) vs in the Ang II group (0.7Â±0.03%, P<0.05).  These changes were coincident with less locally expressed AT1 receptor and enhanced AT2 receptor in the intracardiac vessels and intermyocardium.  Along with these modulations, curcumin significantly decreased the populations of macrophages and alpha smooth muscle actin-expressing myofibroblasts, which were accompanied by reduced expression of transforming growth factor beta 1 and phosphorylated-Smad2/3.  Collagen I synthesis was inhibited, and tissue fibrosis was attenuated, as demonstrated by less extensive collagen-rich fibrosis.  Furthermore, curcumin increased protein level of ACE2 and enhanced its expression in the intermyocardium relative to the Ang II group.  These results suggest that curcumin could be considered as an add-on therapeutic agent in the treatment of fibrosis-derived heart failure patient who is intolerant of ACE inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhKyEygGyjVLVg90H21EOLACvtfcHk0lixH1--fNpAAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXls1Sjtr4%253D&md5=87d58358354203eb8ebb40422a86fb5f</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S95333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S95333%26sid%3Dliteratum%253Aachs%26aulast%3DPang%26aufirst%3DX.%2BF.%26aulast%3DZhang%26aufirst%3DL.%2BH.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DN.%2BP.%26aulast%3DGarner%26aufirst%3DR.%2BE.%26aulast%3DMcKallip%26aufirst%3DR.%2BJ.%26aulast%3DZhao%26aufirst%3DZ.%2BQ.%26atitle%3DAttenuation%2520of%2520myocardial%2520fibrosis%2520with%2520curcumin%2520is%2520mediated%2520by%2520modulating%2520expression%2520of%2520angiotensin%2520II%2520AT1%252FAT2%2520receptors%2520and%2520ACE2%2520in%2520rats%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D6043%26epage%3D6054%26doi%3D10.2147%2FDDDT.S95333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deguzman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apparsundaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogaboam, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budd, D. C.</span></span> <span> </span><span class="NLM_article-title">Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis in lung fibroblasts and in vivo models of lung fibrosis</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">470</span>â <span class="NLM_lpage">479</span>, <span class="refDoi">Â DOI: 10.1016/j.ajpath.2013.04.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.ajpath.2013.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23759512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFynur7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2013&pages=470-479&author=X.+Tangauthor=R.+Pengauthor=J.+E.+Phillipsauthor=J.+Deguzmanauthor=Y.+Renauthor=S.+Apparsundaramauthor=Q.+Luoauthor=C.+M.+Bauerauthor=M.+E.+Fuentesauthor=J.+A.+DeMartinoauthor=G.+Tyagiauthor=R.+Garridoauthor=C.+M.+Hogaboamauthor=C.+P.+Dentonauthor=A.+M.+Holmesauthor=C.+Kitsonauthor=C.+S.+Stevensonauthor=D.+C.+Budd&title=Assessment+of+Brd4+inhibition+in+idiopathic+pulmonary+fibrosis+in+lung+fibroblasts+and+in+vivo+models+of+lung+fibrosis&doi=10.1016%2Fj.ajpath.2013.04.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Brd4 Inhibition in Idiopathic Pulmonary Fibrosis Lung Fibroblasts and in Vivo Models of Lung Fibrosis</span></div><div class="casAuthors">Tang, Xiaoyan; Peng, Ruoqi; Phillips, Jonathan E.; Deguzman, Jeremy; Ren, Yonglin; Apparsundaram, Subramanium; Luo, Qi; Bauer, Carla M.; Fuentes, Maria E.; DeMartino, Julie A.; Tyagi, Gaurav; Garrido, Rosario; Hogaboam, Cory M.; Denton, Christopher P.; Holmes, Alan M.; Kitson, Christopher; Stevenson, Christopher S.; Budd, David C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">470-479</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of high unmet medical need.  Although bromodomain (Brd) and extra terminal domain isoforms have recently been implicated in mediating inflammatory and oncol. indications, their roles in lung fibrosis have not been comprehensively assessed.  We investigated the role of Brd on the profibrotic responses of lung fibroblasts (LFs) in patients with rapidly progressing IPF and a mouse bleomycin model of lung fibrosis.  The enhanced migration, proliferation, and IL-6 release obsd. in LFs from patients with rapidly progressing IPF are attenuated by pharmacol. inhibition of Brd4.  These changes are accompanied by enhanced histone H4 lysine5 acetylation and assocn. of Brd4 with genes involved in the profibrotic responses in IPF LFs as demonstrated using chromatin immunopptn. and quant. PCR.  Oral administration of 200 mg/kg per day Brd4 inhibitor JQ1 in a therapeutic dosing regimen substantially attenuated lung fibrosis induced by bleomycin in C57BL/6 mice.  In conclusion, this study shows that the Brd4 inhibitor JQ1, administered in a therapeutic dosage, is capable of inhibiting the profibrotic effects of IPF LFs and attenuates bleomycin-induced lung fibrosis in mice.  These results suggest that Brd4 inhibitors may represent a novel therapy for the treatment of rapidly progressing IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeyA6Tfi6PObVg90H21EOLACvtfcHk0ljc1cf1yhC95A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFynur7I&md5=8a7b094630ce44df6cd1b2b9de6cc6ec</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2013.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2013.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DX.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DDeguzman%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DApparsundaram%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DBauer%26aufirst%3DC.%2BM.%26aulast%3DFuentes%26aufirst%3DM.%2BE.%26aulast%3DDeMartino%26aufirst%3DJ.%2BA.%26aulast%3DTyagi%26aufirst%3DG.%26aulast%3DGarrido%26aufirst%3DR.%26aulast%3DHogaboam%26aufirst%3DC.%2BM.%26aulast%3DDenton%26aufirst%3DC.%2BP.%26aulast%3DHolmes%26aufirst%3DA.%2BM.%26aulast%3DKitson%26aufirst%3DC.%26aulast%3DStevenson%26aufirst%3DC.%2BS.%26aulast%3DBudd%26aufirst%3DD.%2BC.%26atitle%3DAssessment%2520of%2520Brd4%2520inhibition%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520in%2520lung%2520fibroblasts%2520and%2520in%2520vivo%2520models%2520of%2520lung%2520fibrosis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2013%26volume%3D183%26spage%3D470%26epage%3D479%26doi%3D10.1016%2Fj.ajpath.2013.04.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tesch, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. J.</span></span> <span> </span><span class="NLM_article-title">Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">313</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28611666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFentbrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=313&author=G.+H.+Teschauthor=M.+J.+Young&title=Mineralocorticoid+receptor+signaling+as+a+therapeutic+target+for+renal+and+cardiac+fibrosis&doi=10.3389%2Ffphar.2017.00313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis</span></div><div class="casAuthors">Tesch, Greg H.; Young, Morag J.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">313/1-313/9</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Activation of the mineralocorticoid receptor (MR) plays important roles in both physiol. and pathol. events.  Blockade of MR signaling with MR antagonists (MRAs) has been used clin. to treat kidney and cardiac disease assocd. with hypertension and other chronic diseases, resulting in suppression of fibrosis in these organs.  However, the current use of steroidal MRAs has been limited by off target effects on other hormone receptors or adverse effects on kidney tubular function.  In this review, we summarize recent insights into the profibrotic roles of MR signaling in kidney and cardiovascular disease.  We review exptl. in vitro data identifying the pathol. mechanisms assocd. with MR signaling in cell types found in the kidney (mesangial cells, podocytes, tubular cells, macrophages, interstitial fibroblasts) and heart (cardiomyocytes, endothelial cells, vascular smooth muscle cells, macrophages).  In addn., we demonstrate the in vivo importance of MR signaling in specific kidney and cardiac cell types by reporting the outcomes of cell type selective MR gene deletion in animal models of kidney and cardiac disease and comparing these findings to those obtained with MRAs treatment.  This review also includes a discussion of the potential benefits of novel non-steroidal MRAs for targeting kidney and cardiac fibrosis compared to existing steroidal MRAs, as well as the possibility of novel combination therapies and cell selective delivery of MRAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIN6hW9Qou5rVg90H21EOLACvtfcHk0lhsak2x8xYp4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFentbrO&md5=612c08613391192e75b704a32470abe7</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00313%26sid%3Dliteratum%253Aachs%26aulast%3DTesch%26aufirst%3DG.%2BH.%26aulast%3DYoung%26aufirst%3DM.%2BJ.%26atitle%3DMineralocorticoid%2520receptor%2520signaling%2520as%2520a%2520therapeutic%2520target%2520for%2520renal%2520and%2520cardiac%2520fibrosis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D313%26doi%3D10.3389%2Ffphar.2017.00313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phosri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arieyawong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunrukchai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parichatikanond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangmool, S.</span></span> <span> </span><span class="NLM_article-title">Stimulation of adenosine A<sub>2B</sub> receptor inhibits endothelin-1-induced cardiac fibroblast proliferation and Î±-smooth muscle actin synthesis through the Camp/Epac/PI3K/Akt signaling pathway</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">428</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28713274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2nsL3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=428&author=S.+Phosriauthor=A.+Arieyawongauthor=K.+Bunrukchaiauthor=W.+Parichatikanondauthor=A.+Nishimuraauthor=M.+Nishidaauthor=S.+Mangmool&title=Stimulation+of+adenosine+A2B+receptor+inhibits+endothelin-1-induced+cardiac+fibroblast+proliferation+and+%CE%B1-smooth+muscle+actin+synthesis+through+the+Camp%2FEpac%2FPI3K%2FAkt+signaling+pathway&doi=10.3389%2Ffphar.2017.00428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of adenosine A2B receptor inhibits endothelin-1-Induced cardiac fibroblast proliferation and Î±-smooth muscle actin synthesis through the cAMP/Epac/PI3K/Akt-signaling pathway</span></div><div class="casAuthors">Phosri, Sarawuth; Arieyawong, Ajaree; Bunrukchai, Kwanchai; Parichatikanond, Warisara; Nishimura, Akiyuki; Nishida, Motohiro; Mangmool, Supachoke</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">428/1-428/15</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Background and Purpose: Cardiac fibrosis is characterized by an increase in fibroblast proliferation, overprodn. of extracellular matrix proteins, and the formation of myofibroblast that express a-smooth muscle actin (Î±-SMA).  Endothelin-1 (ET-1) is involved in the pathogenesis of cardiac fibrosis.  Overstimulation of endothelin receptors induced cell proliferation, collagen synthesis, and Î±-SMA expression in cardiac fibroblasts.  Although adenosine was shown to have cardioprotective effects, the mol. mechanisms by which adenosine A2 receptor inhibit ET-1-induced fibroblast proliferation and Î±-SMA expression in cardiac fibroblasts are not clearly identified.  Exptl. Approach: This study aimed at evaluating the mechanisms of cardioprotective effects of adenosine receptor agonist in rat cardiac fibroblast by measurement of cell proliferation, and mRNA and protein levels of a-SMA.  Key results: Stimulation of adenosine subtype 2B (A2B) receptor resulted in the inhibition of ET-1-induced fibroblast proliferation, and a redn. of ET-1-induced a-SMA expression that is dependent on cAMP/Epac/PI3K/Akt signaling pathways in cardiac fibroblasts.  The data in this study confirm a crit. role for Epac signaling on A2B receptor-mediated inhibition of ET-1-induced cardiac fibrosis via PI3K and Akt activation.  Conclusion and Implications: This is the first work reporting a novel signaling pathway for the inhibition of ET-1-induced cardiac fibrosis mediated through the A2B receptor.  Thus, A2B receptor agonists represent a promising perspective as therapeutic targets for the prevention of cardiac fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrepPFsvzd3trVg90H21EOLACvtfcHk0liPMqzUxKEf_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2nsL3I&md5=f4a525a71a833f009775a00ef95e80bc</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00428%26sid%3Dliteratum%253Aachs%26aulast%3DPhosri%26aufirst%3DS.%26aulast%3DArieyawong%26aufirst%3DA.%26aulast%3DBunrukchai%26aufirst%3DK.%26aulast%3DParichatikanond%26aufirst%3DW.%26aulast%3DNishimura%26aufirst%3DA.%26aulast%3DNishida%26aufirst%3DM.%26aulast%3DMangmool%26aufirst%3DS.%26atitle%3DStimulation%2520of%2520adenosine%2520A2B%2520receptor%2520inhibits%2520endothelin-1-induced%2520cardiac%2520fibroblast%2520proliferation%2520and%2520%25CE%25B1-smooth%2520muscle%2520actin%2520synthesis%2520through%2520the%2520Camp%252FEpac%252FPI3K%252FAkt%2520signaling%2520pathway%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D428%26doi%3D10.3389%2Ffphar.2017.00428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Schisandrin B atteneuates CCl4-induced liver fibrosis in rats by regulation of Nrf2-ARE and TGF-Î²/Smad signaling pathways</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2179</span>â <span class="NLM_lpage">2191</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S137507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S137507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28794616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1cfmt1aluw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=2179-2191&author=Q.+Chenauthor=H.+Zhangauthor=Y.+Caoauthor=Y.+Liauthor=S.+Sunauthor=I.+Zhangauthor=G.+Zhang&title=Schisandrin+B+atteneuates+CCl4-induced+liver+fibrosis+in+rats+by+regulation+of+Nrf2-ARE+and+TGF-%CE%B2%2FSmad+signaling+pathways&doi=10.2147%2FDDDT.S137507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Schisandrin B attenuates CCl4-induced liver fibrosis in rats by regulation of Nrf2-ARE and TGF-Î²/Smad signaling pathways</span></div><div class="casAuthors">Chen Qingshan; Li Ying; Sun Sen; Zhang Guoqing; Zhang Hai; Cao Yan; Zhang Junping</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2179-2191</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Liver fibrosis is a major pathological feature of chronic liver diseases and there is no effective therapy program at present.  Schisandrin B (Sch B) is the major bioactive ingredient of Schisandra chinensis, with antioxidative, anti-inflammatory, antitumor, and hepatoprotective properties.  This study aimed to investigate the protective effect and related molecular mechanism of Sch B against carbon tetrachloride (CCl4)-induced liver fibrosis in rats.  The in vivo therapeutic effect of Sch B on liver fibrosis induced by CCl4 was examined in rats.  In vitro, rat hepatic stellate cells (HSC-T6) were used to assess the effect of Sch B on the activation of HSCs.  Sch B effectively attenuated liver damage and progression of liver fibrosis in rats, as evidenced by improved liver function and decreased collagen deposition.  The effects of Sch B were associated with attenuating oxidative stress by activating nuclear factor-erythroid 2-related factor 2 (Nrf2)-mediated antioxidant signaling and suppressing HSC activation by inhibiting the transforming growth factor-Î² (TGF-Î²)/Smad signaling pathway.  In an in vitro study, it was shown that Sch B inhibited TGF-Î²-induced HSC activation.  Finally, Sch B significantly inhibited TGF-Î²1-stimulated phosphorylation of Smad and signaling of mitogen-activated protein kinases.  This study demonstrates that Sch B prevents the progression of liver fibrosis by the regulation of Nrf2-ARE and TGF-Î²/Smad signaling pathways, and indicates that Sch B can be used for the treatment of liver fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVahJUex_0f8ScOqQTSkOffW6udTcc2eY_DbG96UDbHLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfmt1aluw%253D%253D&md5=12677f2fe533b05b1570fad64b1fc1f2</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S137507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S137507%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DSchisandrin%2520B%2520atteneuates%2520CCl4-induced%2520liver%2520fibrosis%2520in%2520rats%2520by%2520regulation%2520of%2520Nrf2-ARE%2520and%2520TGF-%25CE%25B2%252FSmad%2520signaling%2520pathways%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D2179%26epage%3D2191%26doi%3D10.2147%2FDDDT.S137507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, L. D.</span></span> <span> </span><span class="NLM_article-title">Astragaloside IV improves bleomycin-induced pulmonary fibrosis in rats by attenuating extracellular matrix deposition</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">513</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2017.00513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.3389%2Ffphar.2017.00513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28848434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2ns7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=513&author=L.+C.+Liauthor=L.+Xuauthor=Y.+Huauthor=W.+J.+Cuiauthor=W.+H.+Cuiauthor=W.+C.+Zhouauthor=L.+D.+Kan&title=Astragaloside+IV+improves+bleomycin-induced+pulmonary+fibrosis+in+rats+by+attenuating+extracellular+matrix+deposition&doi=10.3389%2Ffphar.2017.00513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Astragaloside IV improves bleomycin-induced pulmonary fibrosis in rats by attenuating extracellular matrix deposition</span></div><div class="casAuthors">Li, Liu-Cheng; Xu, Liang; Hu, Yan; Cui, Wen-Jie; Cui, Wen-Hui; Zhou, Wen-Cheng; Kan, Lian-Di</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">513/1-513/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Pulmonary fibrosis is a devastating lung disorder with mysterious pathogenesis and limited treatment options.  It is well-recognized that the uncontrolled proliferation of lung fibroblasts and differentiation of fibroblasts into myofibroblasts excessively produce extracellular matrix (ECM) proteins which contribute to the fibrosis change of the lungs.  Thus, blocking ECM accumulation would delay fibrosis progression.  In this study, we obsd. the effects of astragaloside IV (ASV) (10 mg/kg/d) on ECM proteins in bleomycin (BLM, 5 mg/kg)-treated rats.  Our results showed that ASV not only ameliorated BLM-induced body wt. loss, lung coeff. increase, histol. changes and collagen secretion, but also reduced the levels of type III collagen (Col-III) in lung homogenate, laminin (LN) and hyaluronic acid (HA) in serum, as well as hydroxyproline (HYP) in lung tissue.  Besides, ASV significantly down-regulated the levels of high-mobility group box1 (HMGB1) in serum and lung tissue, and inhibited the up-regulated expression of Î±-SMA (marker of myofibroblasts) in the lungs.  Taken together, these findings indicate that ASV attenuates BLM-induced ECM deposition, supporting its use as a promising candidate to treat lung fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCoGCZUWiux7Vg90H21EOLACvtfcHk0lizngh2-QjteA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2ns7nI&md5=f420d79e2304bde70029d6ca0584ea8c</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00513%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%2BC.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DW.%2BJ.%26aulast%3DCui%26aufirst%3DW.%2BH.%26aulast%3DZhou%26aufirst%3DW.%2BC.%26aulast%3DKan%26aufirst%3DL.%2BD.%26atitle%3DAstragaloside%2520IV%2520improves%2520bleomycin-induced%2520pulmonary%2520fibrosis%2520in%2520rats%2520by%2520attenuating%2520extracellular%2520matrix%2520deposition%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D513%26doi%3D10.3389%2Ffphar.2017.00513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span> <span> </span><span class="NLM_article-title">Effect of echinacoside on kidney fibrosis by inhibition of TGFÎ²1/Smads signaling pathway in the db/db mice model of diabetic nephropathy</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2813</span>â <span class="NLM_lpage">2826</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S143805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FDDDT.S143805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=29033543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A280%3ADC%252BC1M7gvVCruw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=2813-2826&author=F.+Tangauthor=Y.+Haoauthor=X.+Zhangauthor=J.+Qin&title=Effect+of+echinacoside+on+kidney+fibrosis+by+inhibition+of+TGF%CE%B21%2FSmads+signaling+pathway+in+the+db%2Fdb+mice+model+of+diabetic+nephropathy&doi=10.2147%2FDDDT.S143805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of echinacoside on kidney fibrosis by inhibition of TGF-Î²1/Smads signaling pathway in the db/db mice model of diabetic nephropathy</span></div><div class="casAuthors">Tang Fengjuan; Hao Yarong; Zhang Xue; Qin Jian</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2813-2826</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Kidney fibrosis and renal tubular epithelial-to-mesenchymal transition (EMT) are the main pathological changes of diabetic nephropathy (DN), which eventually leads to end-stage renal disease.  Previous studies have suggested that echinacoside (ECH) is antifibrotic in the liver.  However, the effect of ECH on kidney fibrosis in DN and its mechanisms are unknown.  This study was performed to explore the effect of ECH on kidney fibrosis and also the molecular mechanisms of ECH in a db/db mice model of DN.  Our results showed that, relative to db/db mice, the mice in the ECH group had an improved general state and reduced blood glucose and 24-hour urinary protein levels.  The deterioration of renal function was delayed due to treatment with ECH.  We also observed that ECH can improve histopathological findings in the kidneys of db/db mice, including collagen deposition, mesangial cell and mesangial matrix hyperplasia, basement membrane thickening, and podocyte reduction.  Moreover, ECH inhibited the TGF-Î²1/Smads signaling pathway, downregulated fibronectin (FN), collagen IV, and alpha-smooth muscle actin (Î±-SMA) levels, and upregulated E-cadherin level in the db/db mice model of DN.  Our findings indicate that ECH has a therapeutic effect on DN, including the inhibition of renal tubular EMT and kidney fibrosis.  Furthermore, ECH inhibits kidney fibrosis through regulation of the TGF-Î²1/Smads signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8dgSWTE02UJagfuraLLzSfW6udTcc2eYNpzfV0XO5krntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7gvVCruw%253D%253D&md5=ef72ed99d7e258df9bc11c82a3a18b29</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S143805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S143805%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DF.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DQin%26aufirst%3DJ.%26atitle%3DEffect%2520of%2520echinacoside%2520on%2520kidney%2520fibrosis%2520by%2520inhibition%2520of%2520TGF%25CE%25B21%252FSmads%2520signaling%2520pathway%2520in%2520the%2520db%252Fdb%2520mice%2520model%2520of%2520diabetic%2520nephropathy%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D2813%26epage%3D2826%26doi%3D10.2147%2FDDDT.S143805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sallam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, S. K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonning, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauersachs, J.</span></span> <span> </span><span class="NLM_article-title">Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction</span>. <i>Basic Res. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">485</span>â <span class="NLM_lpage">492</span>, <span class="refDoi">Â DOI: 10.1007/s00395-008-0739-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1007%2Fs00395-008-0739-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=18651091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOgu7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2008&pages=485-492&author=S.+Frantzauthor=K.+Huauthor=A.+Adamekauthor=J.+Wolfauthor=A.+Sallamauthor=S.+K.+G.+Maierauthor=S.+Lonningauthor=H.+Lingauthor=G.+Ertlauthor=J.+Bauersachs&title=Transforming+growth+factor+beta+inhibition+increases+mortality+and+left+ventricular+dilatation+after+myocardial+infarction&doi=10.1007%2Fs00395-008-0739-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction</span></div><div class="casAuthors">Frantz, Stefan; Hu, Kai; Adamek, Anna; Wolf, Juergen; Sallam, Abed; Maier, Sebastian K. G.; Lonning, Scott; Ling, Hong; Ertl, Georg; Bauersachs, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Basic Research in Cardiology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-492</span>CODEN:
                <span class="NLM_cas:coden">BRCAB7</span>;
        ISSN:<span class="NLM_cas:issn">0300-8428</span>.
    
            (<span class="NLM_cas:orgname">Steinkopff Verlag</span>)
        </div><div class="casAbstract">Transforming growth factor (TGF)-Î² is a locally generated cytokine involved in healing processes and tissue fibrosis, all relevant for cardiac remodeling and the development of heart failure after myocardial infarction (MI).  However, data regarding the function of TGF-Î² after ischemic injury are inconclusive.  We tested the effect of TGF-Î² inhibition by application of a blocking antibody in mice with MI.  Starting 1 wk before or 5 days after coronary artery ligation mice were treated with i.p. injections of an anti-TGF-Î² (5 mg/kg bodyweight 1D11, Genzyme) or control antibody.  Mortality over 8 wk was significantly higher in the groups treated with the anti-TGF-Î² antibody.  Both, pre or post MI treatments were assocd. with increased left ventricular dilatation after MI as detd. by serial echocardiog.  In anti-TGF-Î² treated mice collagen prodn. decreased and matrix-metalloproteinase expression increased.  However, the expression of TGF pro-inflammatory cytokine TNF-Î± was not altered by the treatment.  Anti-TGF-Î² treatment before or after coronary artery ligation increases mortality and worsens left ventricular remodeling in mice with non-reperfused MI.  The detrimental effects of TGF-Î² inhibition may be mediated by alterations in extracellular matrix remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4J94onD-yV7Vg90H21EOLACvtfcHk0li5uD3ql-KiuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOgu7jM&md5=d010e346d1b277d104fa0daa0cb06026</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1007%2Fs00395-008-0739-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00395-008-0739-7%26sid%3Dliteratum%253Aachs%26aulast%3DFrantz%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DAdamek%26aufirst%3DA.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DSallam%26aufirst%3DA.%26aulast%3DMaier%26aufirst%3DS.%2BK.%2BG.%26aulast%3DLonning%26aufirst%3DS.%26aulast%3DLing%26aufirst%3DH.%26aulast%3DErtl%26aufirst%3DG.%26aulast%3DBauersachs%26aufirst%3DJ.%26atitle%3DTransforming%2520growth%2520factor%2520beta%2520inhibition%2520increases%2520mortality%2520and%2520left%2520ventricular%2520dilatation%2520after%2520myocardial%2520infarction%26jtitle%3DBasic%2520Res.%2520Cardiol.%26date%3D2008%26volume%3D103%26spage%3D485%26epage%3D492%26doi%3D10.1007%2Fs00395-008-0739-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engebretsen, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SkÃ¥rdal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BjÃ¸rnstad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marstein, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrbic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjaastad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BjÃ¸rnstad, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TÃ¸nnessen, T.</span></span> <span> </span><span class="NLM_article-title">Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">148</span>â <span class="NLM_lpage">157</span>, <span class="refDoi">Â DOI: 10.1016/j.yjmcc.2014.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.yjmcc.2014.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=25169971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOhsbzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2014&pages=148-157&author=K.+V.+Engebretsenauthor=K.+Sk%C3%A5rdalauthor=S.+Bj%C3%B8rnstadauthor=H.+S.+Marsteinauthor=B.+Skrbicauthor=I.+Sjaastadauthor=G.+Christensenauthor=J.+J.+Bj%C3%B8rnstadauthor=T.+T%C3%B8nnessen&title=Attenuated+development+of+cardiac+fibrosis+in+left+ventricular+pressure+overload+by+SM16%2C+an+orally+active+inhibitor+of+ALK5&doi=10.1016%2Fj.yjmcc.2014.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5</span></div><div class="casAuthors">Engebretsen, Kristin V. T.; Skaardal, Kristine; Bjoernstad, Sigrid; Marstein, Henriette S.; Skrbic, Biljana; Sjaastad, Ivar; Christensen, Geir; Bjoernstad, Johannes L.; Toennessen, Theis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">148-157</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Pressure overload-induced TGF-Î² signaling activates cardiac fibroblasts (CFB) and leads to increased extracellular matrix (ECM) protein synthesis including fibrosis.  Excessive ECM accumulation may in turn affect cardiac function contributing to development of heart failure.  The aim of this study was to examine the effects of SM16, an orally active small mol. inhibitor of ALK5, on pressure overload-induced cardiac fibrosis.  One week after aortic banding (AB), C57Bl/6J mice were randomized to std. chow or chow with SM16.  Sham operated animals served as controls.  Following 4 wk AB, mice were characterized by echocardiog. and cardiovascular magnetic resonance before sacrifice.  SM16 abolished phosphorylation of SMAD2 induced by AB in vivo and by TGF-Î² in CFB in vitro.  Interestingly, Masson Trichrome and Picrosirius Red stained myocardial left ventricular tissue revealed reduced development of fibrosis and collagen crosslinking following AB in the SM16 treated group, which was confirmed by reduced hydroxyproline incorporation.  Furthermore, treatment with SM16 attenuated mRNA expression following induction of AB in vivo and stimulation with TGF-Î² in CFB in vitro of Col1a2, the crosslinking enzyme LOX, and the pro-fibrotic glycoproteins SPARC and osteopontin.  Reduced ECM synthesis by CFB and a redn. in myocardial stiffness due to attenuated development of fibrosis and collagen crosslinking might have contributed to the improved diastolic function and cardiac output seen in vivo, in combination with reduced lung wt. and ANP expression by treatment with SM16.  Despite these beneficial effects on cardiac function and development of heart failure, mice treated with SM16 exhibited increased mortality, increased LV dilatation and inflammatory heart valve lesions that may limit the use of SM16 and possibly also other small mol. inhibitors of ALK5, as future therapeutic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMNwlO3Nci2LVg90H21EOLACvtfcHk0lgGxUykea_IGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOhsbzK&md5=8b1362da806694f28ca846437ba1b1b8</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2014.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2014.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DEngebretsen%26aufirst%3DK.%2BV.%26aulast%3DSk%25C3%25A5rdal%26aufirst%3DK.%26aulast%3DBj%25C3%25B8rnstad%26aufirst%3DS.%26aulast%3DMarstein%26aufirst%3DH.%2BS.%26aulast%3DSkrbic%26aufirst%3DB.%26aulast%3DSjaastad%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DG.%26aulast%3DBj%25C3%25B8rnstad%26aufirst%3DJ.%2BJ.%26aulast%3DT%25C3%25B8nnessen%26aufirst%3DT.%26atitle%3DAttenuated%2520development%2520of%2520cardiac%2520fibrosis%2520in%2520left%2520ventricular%2520pressure%2520overload%2520by%2520SM16%252C%2520an%2520orally%2520active%2520inhibitor%2520of%2520ALK5%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2014%26volume%3D76%26spage%3D148%26epage%3D157%26doi%3D10.1016%2Fj.yjmcc.2014.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, S.</span></span> <span> </span><span class="NLM_article-title">Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits?</span>. <i>Curr. Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">255</span>â <span class="NLM_lpage">263</span>, <span class="refDoi">Â DOI: 10.2174/1874467211205020255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2174%2F1874467211205020255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=22122455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVeqsLzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=255-263&author=S.+Sarma&title=Use+of+clinically+available+PPAR+agonists+for+heart+failure%3B+do+the+risks+outweigh+the+potential+benefits%3F&doi=10.2174%2F1874467211205020255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits?</span></div><div class="casAuthors">Sarma, Satyam</div><div class="citationInfo"><span class="NLM_cas:title">Current Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255-263</span>CODEN:
                <span class="NLM_cas:coden">CMPUB6</span>;
        ISSN:<span class="NLM_cas:issn">1874-4672</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  PPAR agonists represent a heterogeneous group of compds. that were used in the treatment of cardiovascular and metabolic diseases for over thirty years.  While the primary indications for PPAR agonist therapy focus on hyperlipidemia and diabetes, there is a growing body of pre-clin. data that suggests they may be beneficial in the treatment of heart failure; a disease marked by abnormal myocardial metab., fibrosis and insulin insensitivity.  PPAR agonist treatment in numerous animal models of systolic heart failure have demonstrated improvement in cardiac function with decreased fibrosis, improved contractility and endothelial function.  However, considerable controversy exists on the cardiac safety profile of PPAR agonists, particularly concern for inducing lipotoxicity and pptg. or worsening heart failure.  In addn. during pre-clin. testing, many compds. have been assocd. with increased death and adverse cardiovascular outcomes casting a pall over their future use for treating disorders of myocardial function.  This article will review cardiac pathways involved in PPAR activation and their potential regulation of maladaptive pathways involved in heart failure and highlight mol. mechanisms that may contribute to adverse events and raise safety concerns.  Specific attention will be focused on PPAR alpha and gamma, subtypes for which com. available PPAR agonists are currently available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoAtL0tkza-7Vg90H21EOLACvtfcHk0ljnC6DfWbkDdQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVeqsLzL&md5=ac89552ac28bbe582b34285357a0fb43</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.2174%2F1874467211205020255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874467211205020255%26sid%3Dliteratum%253Aachs%26aulast%3DSarma%26aufirst%3DS.%26atitle%3DUse%2520of%2520clinically%2520available%2520PPAR%2520agonists%2520for%2520heart%2520failure%253B%2520do%2520the%2520risks%2520outweigh%2520the%2520potential%2520benefits%253F%26jtitle%3DCurr.%2520Mol.%2520Pharmacol.%26date%3D2012%26volume%3D5%26spage%3D255%26epage%3D263%26doi%3D10.2174%2F1874467211205020255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poelstra, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beljaars, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melgert, B. N.</span></span> <span> </span><span class="NLM_article-title">Cell-specific delivery of biologicals; problems, pitfals and possibilities of antifibrotic compounds in the liver</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1237</span>â <span class="NLM_lpage">1242</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2013.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1016%2Fj.drudis.2013.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=23732178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslGjsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=1237-1242&author=K.+Poelstraauthor=L.+Beljaarsauthor=B.+N.+Melgert&title=Cell-specific+delivery+of+biologicals%3B+problems%2C+pitfals+and+possibilities+of+antifibrotic+compounds+in+the+liver&doi=10.1016%2Fj.drudis.2013.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-specific delivery of biologicals: problems, pitfalls and possibilities of antifibrotic compounds in the liver</span></div><div class="casAuthors">Poelstra, Klaas; Beljaars, Leonie; Melgert, Barbro N.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">1237-1242</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Liver fibrosis is a complex disease affecting millions of people world-wide.  It involves the activation of several cell types whose activities are tightly controlled by endogenous mediators.  No pharmacotherapy is available for this disease, despite the fact that many exptl. drugs are very effective in vitro and the liver is easily accessible for most drugs.  Our review provides arguments showing that cell-selectivity is essential for most antifibrotics.  Several cell-specific drug carriers targeting the key pathogenic liver cells are discussed with special focus on hepatic stellate cells and fibroblast-like cells.  Since endogenous mediators represent a powerful set of tools to modify the pathogenic process, this review focuses on these mediators as therapeutics and the problems and pitfalls assocd. with the use of such biologicals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6U6QdUnfw6LVg90H21EOLACvtfcHk0lgMaPIwxZAOug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslGjsro%253D&md5=483b1ffdb897c6e9aebe213233aee286</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DPoelstra%26aufirst%3DK.%26aulast%3DBeljaars%26aufirst%3DL.%26aulast%3DMelgert%26aufirst%3DB.%2BN.%26atitle%3DCell-specific%2520delivery%2520of%2520biologicals%253B%2520problems%252C%2520pitfals%2520and%2520possibilities%2520of%2520antifibrotic%2520compounds%2520in%2520the%2520liver%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D1237%26epage%3D1242%26doi%3D10.1016%2Fj.drudis.2013.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, j. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshayan, D.</span></span> <span> </span><span class="NLM_article-title">Targeted gamma-secretase inhibition of Notch signaling activation in acute renal injury</span>. <i>Am. J. Physiol., Renal Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">F736</span>â <span class="NLM_lpage">F746</span>, <span class="refDoi">Â DOI: 10.1152/ajprenal.00414.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.1152%2Fajprenal.00414.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28971991" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2018&pages=F736-F746&author=J.+C.+Wyssauthor=R.+Kumarauthor=J.+Mikulicauthor=M.+Schneiderauthor=j.+D.+Aebiauthor=L.+Juillerat-Jeanneretauthor=D.+Golshayan&title=Targeted+gamma-secretase+inhibition+of+Notch+signaling+activation+in+acute+renal+injury&doi=10.1152%2Fajprenal.00414.2016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.00414.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.00414.2016%26sid%3Dliteratum%253Aachs%26aulast%3DWyss%26aufirst%3DJ.%2BC.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DMikulic%26aufirst%3DJ.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DAebi%26aufirst%3Dj.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DGolshayan%26aufirst%3DD.%26atitle%3DTargeted%2520gamma-secretase%2520inhibition%2520of%2520Notch%2520signaling%2520activation%2520in%2520acute%2520renal%2520injury%26jtitle%3DAm.%2520J.%2520Physiol.%252C%2520Renal%2520Physiol.%26date%3D2018%26volume%3D314%26spage%3DF736%26epage%3DF746%26doi%3D10.1152%2Fajprenal.00414.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span> <span> </span><span class="NLM_article-title">Spermidine-mediated poly(laxtic-co-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">6687</span>â <span class="NLM_lpage">6704</span>, <span class="refDoi">Â DOI: 10.2147/IJN.S140569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=10.2147%2FIJN.S140569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=28932114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2gtrzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=6687-6704&author=J.+Tangauthor=J.+Liauthor=G.+Liauthor=H.+Zhangauthor=L.+Wangauthor=D.+Liauthor=J.+Ding&title=Spermidine-mediated+poly%28laxtic-co-glycolic+acid%29+nanoparticles+containing+fluorofenidone+for+the+treatment+of+idiopathic+pulmonary+fibrosis&doi=10.2147%2FIJN.S140569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Spermidine-mediated poly(lactic-co-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Tang, Jing; Li, Jianming; Li, Guo; Zhang, Haitao; Wang, Ling; Li, Dai; Ding, Jinsong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6687/1-6687/18</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive, fatal lung disease with poor survival.  The advances made in deciphering this disease have led to the approval of different antifibrotic mols., such as pirfenidone and nintedanib.  An increasing no. of studies with particles (liposomes, nanoparticles [NPs], microspheres, nanopolymersomes, and nanoliposomes) modified with different functional groups have demonstrated improvement in lung-targeted drug delivery.  In the present study, we prepd., characterized, and evaluated spermidine (Spd)-modified poly(lactic-co-glycolic acid) (PLGA) NPs as carriers for fluorofenidone (AKF) to improve the antifibrotic efficacy of this drug in the lung.  Spd-AKF-PLGA NPs were prepd. and functionalized by modified solvent evapn. with Spd and polyethylene glycol (PEG)-PLGA groups.  The size of Spd-AKF-PLGA NPs was 172.5 Â± 4.3 nm.  AKF release from NPs was shown to fit the Higuchi model.  A549 cellular uptake of an Spd-coumarin (Cou)-6-PLGA NP group was found to be almost twice as high as that of the Cou-6-PLGA NP group.  Free Spd and difluoromethylornithine (DFMO) were preincubated in A549 cells to prove uptake of Spd-Cou-6-PLGA NPs via a polyamine-transport system.  As a result, the uptake of Spd-Cou-6-PLGA NPs significantly decreased with increased Spd concns. in incubation.  At higher Spd concns. of 50 and 500 Î¼M, uptake of Spd-Cou-6-PLGA NPs reduced 0.34- and 0.49-fold from that without Spd pretreatment.  After pretreatment with DFMO for 36 h, cellular uptake of Spd-Cou-6-PLGA NPs reached 1.26-fold compared to the untreated DFMO group.  In a biodistribution study, the drug-targeting index of Spd-AKF-PLGA NPs in the lung was 3.62- and 4.66-fold that of AKF-PLGA NPs and AKF soln., resp.  This suggested that Spd-AKF-PLGA NPs accumulated effectively in the lung.  Lung-histopathol. changes and collagen deposition were obsd. by H&E staining and Masson staining in an efficacy study.  In the Spd-AKF-PLGA NP group, damage was further improved compared to the AKF-PLGA NP group and AKF-soln. group.  The results indicated that Spd-AKF-PLGA NPs are able to be effective nanocarriers for anti-pulmonary fibrosis therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP5HsGu54A3LVg90H21EOLACvtfcHk0lhiMbIIGT5QHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2gtrzF&md5=68cb89c65f5557a2cffe6fa28a8a5e3e</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.2147%2FIJN.S140569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S140569%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DJ.%26atitle%3DSpermidine-mediated%2520poly%2528laxtic-co-glycolic%2520acid%2529%2520nanoparticles%2520containing%2520fluorofenidone%2520for%2520the%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2017%26volume%3D12%26spage%3D6687%26epage%3D6704%26doi%3D10.2147%2FIJN.S140569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00294&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-22%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00294%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00294" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e11c2f3e63d93a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
